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PLEN01.01 Lung Cancer Screening Christine Berg Radiation Oncology, Johns 
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Screening of high risk individuals for lung cancer was shown to reduce lung cancer 
mortality by 20% in the National Lung Screening Trial (NLST) comparing low-dose helical 
computerized tomography (LDCT) to chest x-ray [1]. Implementation of lung cancer 
screening will be a serious challenge. Since the time of the IASLC meeting in Sydney 
in 2013 additional information from the NLST has provided guidance on many aspects 
of screening and informed public health policy in the United States. The United States 
Preventive Services Task Force (USPSTF) in December 2013 and the Centers for Medicare 
and Medicaid Services in February 2015 released decisions favorable to lung cancer 
screening [2, 3]. The USPSTF recommended it at a Grade B level which means under 
the terms of the Affordable Care Act (ACA), many insurance companies must reimburse 
without a deductible. The recommendations followed the NLST criteria but extended 
the age for screening to cover 55 to 80. CMS also followed NLST extending screening 
to age 77. The coverage includes a counseling and shared decision making visit with 
a written order for the procedure. Requirements also included radiologist credentials, 
image acquisition standards and participation in a CMS registry. The American College 
of Radiology Lung Cancer Screening Registry has been approved. Coverage decisions 
acknowledged the known drawbacks of high false-positive rates, overdiagnosis potential, 
radiation risk, psychosocial consequences, effect on smoking behavior and incidental 
findings. More efficient screening strategies may use different criteria than the NLST 
excluding those at lower risk while including those outside NLST criteria that are at 
identifiable high risk. Several risk prediction models exist. The PLCOm2012 model is the 
best-validated. Selected risk factors included age, race, ethnicity, education, body mass 
index, self-reported chronic obstructive pulmonary disease, personal and family history 
of lung cancer, and smoking variables. A risk threshold of 1.5% over 6 years was chosen 
as below this threshold there was no reliable evidence of screening benefit and much 
higher numbers needed to screen. Comparing this risk model threshold to the USPSTF 
criteria in the PLCO CXR arm demonstrates that the PLCOm2012 risk model approach is 
more efficient [4]. Table The American College of Radiology developed the Lung-RADS 
nodule classification system [5]. When applied retrospectively to NLST data (26,455 
baseline scans and 48,671 incidence scans), Lung-RADS 1.0 substantially reduced the 
false-positive rate (12.8% versus 26.6% at baseline and 5.3% versus 21.8% at incidence 
scans respectively). However, the trade-off was reduced sensitivity compared to NLST 
criteria: 84.9% vs. 93.5% at baseline and 78.6% versus 93.8% for incidence scans [6]. 
Retrospective subset analyses while imperfect are useful, providing some information 
about potential variations in effectiveness in subgroups. Analysis of performance within 
the NLST was conducted by age, gender and smoking status with additional detail 
comparing those less than 65 and ≥ 65 [7]. The mortality risk ratios by age, < 65 and 
≥ 65, were 0.82 and 0.87; gender, males and females, 0.92 and 0.73, and by smoking 
status, current versus former, 0.81 and 0.91. Reassuringly, ninety day postsurgical 
mortality rates in those less than and ≥ 65 were 1.8% and 1.0% respectively. An estimate 
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responsible for 85% of all types of this cancer. The major risk factors and risk modifiers 
for lung cancer include:
• Cigarette Smoking
• Secondhand Smoke (SHS)
• Air Pollution
• Radon
• Occupational Exposures (e.g., asbestos, silica, Chromium, radon)
• Lung Cancer Susceptibility Genes
• Aspirin/NSAIDs Use (protective)
• Dietary vitamin D (protective)
• HRT – possibly protective.
I will cover updates on our understanding of the major risk factors for lung cancer in the 
USA and globally. Smoking Smoking causes an estimated 170,000 cancer deaths in the 
U.S. every year (American Cancer Society) and the incidence among women is rising. 
Lung cancer now surpasses breast cancer as the number one cause of death among 
women. Globally, cigarette consumption has changed over the decades, with China now 
the number one consumer (44%) of cigarettes in the world, while the USA is consumes 
about 5%. In the USA, “Second Hand Smoke” is the third leading cause of lung cancer 
and responsible for an estimated 3,000 lung cancer deaths every year. Globally, the 
number of SHS related cancer deaths is unknown, but surely rising. SHS is also referred 
as ‘environmental tobacco smoke (ETS)’, ‘passive smoking’ or ‘involuntary smoking’. IARC 
has deemed SHS is “carcinogenic to humans”, with an increased risk of 20% for women 
and of 30% for men among never smokers who are exposed to SHS (i.e., environmental 
tobacco smoke) from their spouse. Ambient Air Pollution IARC has classified outdoor 
air pollution - as a whole - as “carcinogenic to humans (Group 1)”. Outdoor air pollution 
has been shown to cause lung cancer and bladder cancer, pointing to the role of 
overlapping carcinogen exposure to compounds such as polycylic aromatic compounds 
(PAC). The most recent data from the Global Burden of Disease (GBD) Project indicate 
that in 2010, 3.2 million deaths worldwide resulted from air pollution alone, including 
223,000 from lung cancer. Radon Radon is an odorless, colorless, radioactive gas that 
causes lung cancer. IARC classifies radon and its progeny as “carcinogenic to humans” 
(Class I), and the US EPA lists radon as the second leading cause of lung cancer in the 
US and the number one cause of lung cancer among non-smokers. Originally described 
as a risk factor in underground miners (among both smokers and non-smokers, with 
synergistic interaction with smoking), the U.S. EPA estimates that 1 of 15 homes in the 
US (as many as 1 of 3 homes in some states) -about 7 million homes-have high radon 
levels. Occupational Exposures: Asbestos In North America, and most other high 
income countries, asbestos has been the most prevalent occupational lung carcinogen 
exposure. All forms of asbestos have been classified as a known human carcinogen (by 
the U.S. Department of Health and Human Services, EPA, and the IARC). About 125 
million people in the world are exposed to asbestos at the workplace. According to 
WHO estimates, more than 107,000 deaths each year are attributable to occupational 
exposure to asbestos. Exposure to asbestos, including chrysotile, causes cancer of 
the lung, larynx and ovaries, and also mesothelioma. Co-exposure to tobacco smoke 
and asbestos fibers substantially increases the risk for lung cancer (multiplicative 
interaction). Heritable Factors: Common Genetic Variants GWAS provide novel 
insights into the development of LC. Genetic factors are increasingly recognized to be 
important in the etiology of LC:
• 15q25.1 (CHRNA5-CHRNA3-CHRNB4)
• 5p15.33 (TERT-CLPTM1)
• 6p21.33 (BAT3-MSH5)
Follow up studies that pool data international as part of a large consortium (International 
Lung Cancer Consortium - ILCCO) have identified other common variants at multiple loci 
influencing LC risk, and these include BRACA1. Studies of pleiotropy are well underway. 
Additionally, GWAS studies globally, such as one from China, have identified unique, 
population-specific, risk loci. COPD and Lung Cancer risk COPD and LC are the 4the and 
7th leading causes of death worldwide. The coexistence of COPD is an important marker 
of future risk of LC among smokers. Epidemiologic studies have shown that 50-70% of 
LC patients have co-existing impaired lung function or COPD. And, not surprisingly, 90% 
of combined LC and COPD cases are attributable to cigarette smoking. Recently, we 
have found that the co-existence of COPD with lung cancer also negatively influences 
survival among patients with all stages. Conclusion Lung cancer remains the number 
one cancer threat to the world’s populations. Lung cancer epidemiology continues 
to evolve and as we understand more about the origins and behavior of lung cancer, 
the more opportunities we will have for prevention and control of this deadly disease. 
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Charleston/SC/United States of America
Smoking is the largest preventable risk factor for the development of lung cancer. 
Continued smoking by cancer patients and survivors causes adverse outcomes including 
an increase in overall mortality, cancer specific mortality, risk for second primary cancer, 
and associated increases in cancer treatment toxicity. Significant evidence demonstrates 
the biologic mechanisms of cancer initiation and progression caused by cigarette smoke, 
but relatively few studies have evaluated the effects of smoking on cancer biology and 
therapeutic response to cytotoxic agents. Most oncologists believe smoking causes 
of overdiagnosis within the NLST has been done [8]. Using follow-up data extended from 
that in the primary manuscript, a total of 1089 lung cancers occurred in the LDCT arm 
compared with 969 in the CXR arm, resulting in 120 additional lung cancer cases in the 
LDCT arm. Two estimates of the upper bound of overdiagnosis were calculated, 18.5% of 
the cases detected during screening and 11% of the cases overall. More follow-up would 
be helpful to determine the extent of continued catch-up in cases in the CXR arm. Current 
smokers in the Lung Screening Study portion of the NLST were evaluated for smoking 
cessation and results also analyzed by findings on LDCT [9]. Those with normal scans did 
show a decline in smoking prevalence that continued for the seven years of assessment. 
Those with abnormal scans had higher cessations rates; the more abnormal the scan the 
higher the rates. All lung cancer screening programs should incorporate proven smoking 
cessation strategies. The cost-effectiveness analysis from the NLST utilized data from 
medical record abstraction covering in exhaustive detail medical interventions delivered 
as a consequence of screening [10]. As compared with no screening, screening with 
low-dose CT cost an additional $1,631 per person and provided an additional 0.0316 
life-years per person and 0.0201 Quality Adjusted Live Years (QALY) per person. The 
corresponding Incremental Cost Effectiveness Ratios were $52,000 per life-year gained 
and $81,000 per QALY gained but varied widely by underlying risk group. Information 
from the NLST continues to refine our understanding of lung cancer screening. This 
should prove invaluable in ensuring that screening is done at a high level to achieve 
optimal mortality reductions as programs are expanded. References 1. The National 
Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-Dose 
Computed Tomographic Screening. N Engl J Med 2011; 365: 395-409. 2. Moyer VA. 
Screening for lung cancer: U.S. Preventive Services Task Force recommendation 
statement. Ann Int Med 2014; 160: 330-338. 3. Centers for Medicare and Medicaid 
Services. Decision Memo for Screening for Lung Cancer with Low Dose Computed 
Tomography (LDCT) (CAG-00439N). http://www.cms.gov/medicare-coverage-
database/details/nca-decision-memo.aspx?NCAId=274 (accessed February 22, 2015). 
4.Tammemagi MC, Church TR, Hocking WG et al. Evaluation of the Lung Cancer Risks 
at Which to Screen Ever- and Never-Smokers: Screening Rules Applied to the PLCO and 
NLST Cohorts. PLoS Medicine 2014; 11: e10001764. 5. American College of Radiology 
ACR-STR Practice Guideline for the Performance and Reporting of Lung Cancer Screening 
Thoracic Computed Tomography http://www.acr.org/~/media/ACR/Documents/PGTS/
guidelines/LungScreening.pdf (accessed February 22, 2015). 6. Pinsky PF, Gierada DS, 
Black W et al. Performance of Lung-RADS in the National Lung Screening Trial. Ann Intern 
Med [Epub ahead of print 10 February 2015] doi:10.7326/M14-2086. 7. Pinsky PF, Gierada 
DS, Hocking W et al. National Lung Screening Trial Findings by Age: Medicare-Eligible 
Versus Under-65 Population. Ann Intern Med 2014; 161: 627-633. 8. Patz EF, Pinsky 
P, Gatsonis CG et al. Overdiagnosis in Low-Dose Computed Tomography Screening for 
Lung Cancer. JAMA Intern Med 2014: 174: 269-274. 9. Tammemagi MC, Berg CD, Riley 
TL et al. Impact of Lung Cancer Screening Results on Smoking Cessation. J Natl Cancer 
Inst 2014;106: dju084. 10. Black WC, Gareen IF, Soneji SS et al. Cost-Effectiveness 
of CT Screening in the National Lung Screening Trial. N Engl J Med 2014; 371: 1793-
1802. TABLE Comparison of PLCOM2012, NLST and USPSTF [4]
PLCOM2012 vs. 
NLST
PLCOM2012 vs. 
USPTF
PLCOM2012 NLST PLCOM2012 USPSTF
Selection 
criteria >1.3455%[1]
Age 55-74, 
current/former 
smoker ≥30 PY
≥ 1.51%1
Age 55-80, 
current/former 
smoker ≥30 PY
Validation 
cohort
14,144 PLCO trial 
screening arm 
smokers
14,144 PLCO trial 
screening arm 
smokers who met 
NLST criteria
37,327 PLCO trial 
screening arm 
smokers
37,327 PLCO trial 
screening arm 
smokers who met 
USPSTF criteria
Sensitivity, 
% (95% CI) 83.0 71.1 80.1 (76.8–83.0) 71.2 (67.6–74.6)
Specificity, 
% (95% CI) 62.9 62.7 66.2 (65.7–66.7) 62.7 (62.2–63.1)
Positive 
Predictive 
Value, % 
(95% CI)
4.0 3.4 4.2 (3.9–4.6) 3.4 (3.1–3.7)
[1] Estimated lung cancer risk over six years 
Keywords: lung cancer screening; computerized tomography; risk assessment; false-
positives
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Environmental and Occupational Medicine and Epidemiology Program, Harvard School of 
Public Health, Boston/MA/United States of America
Lung cancer remains the most common cancer in the world. Worldwide, the leading cause 
of cancer mortality in men and the second leading cause in women. 1.8 million new cases 
were diagnosed in 2012. About 58% of lung cancer cases occurred in low and middle 
income countries. Although by far not the only known or suspected lung carcinogen, 
cigarette smoking remains the principal cause of lung cancer and is estimated to be 
S68 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
genetic data supports previous clinical, epidemiologic and pathologic data 
showing that low and intermediate grade typical (TC) and atypical carcinoids 
(AC) are distinct from the high grade small cell carcinoma (SCLC) and large cell 
neuroendocrine carcinoma (LCNEC). Ki-67 is useful to distinguish carcinoids from 
SCLC and LCNEC especially in small crushed biopsies. However, published data do 
not support incorporation into the classification, particularly in separating TC from AC. 
Spread through air spaces (STAS) is a newly recognized pattern of invasion 
which consists of micropapillary clusters, solid nests or single cells beyond 
the edge of the tumor into air spaces in the surrounding lung parenchyma, It 
probably contributes to the significantly increased recurrence rate for patients 
with small stage 1 adenocarcinomas who undergo limited resections.10 
Future clinical trials and large scale genetic studies such as The Cancer Genome 
Atlas (TCGA) need to incorporate the new pathologic criteria for both small biopsies 
and resection specimens which now require immunohistochemistry to precisely 
classify poorly differentiated tumors such as solid adenocarcinoma or nonkeratinizing 
squamous cell carcinoma. Despite promising preliminary data, additional work is needed 
to develop a histological grading system for lung cancer. Acknowledgement: This 
abstract is presented with gratitude on behalf of the WHO Panel and the IASLC Pathology 
Committee. References: 1. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. 
WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: International 
Agency for Research on Cancer; 2015. 2. Travis WD, Brambilla E, Noguchi M, et al. The 
New IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. 
JThoracic Oncol 2011;6:244-85. 3. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla 
E, in collaboration with LHS, Countries pf. Histological Typing of Lung and Pleural 
Tumors. Berlin: Springer; 1999. 4. Travis WD, Brambilla E, Mller-Hermelink HK, Harris CC. 
Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC; 
2004. 5. Tsao MS, Travis WD, Brambilla E, Nicholson AG, Noguchi M, Hirsch FR. Forty 
years of the international association for study of lung cancer pathology committee. J 
Thorac Oncol 2014;9:1740-9. 6. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic 
S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi 
M. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and
ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists,
International Association for the Study of Lung Cancer, and Association for Molecular
Pathology. J ThoracOncol 2013. 7. Nicholson AG, Gonzalez D, Shah P, Pynegar MJ,
Deshmukh M, Rice A, Popat S. Refining the Diagnosis and EGFR Status of Non-small Cell
Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, 
Cytokeratin 5/6, and P63, and EGFR Mutation Analysis. JThoracOncol 2010;5:436-41.
8. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of Undifferentiated
Non-small Cell Carcinomas in Bronchial Biopsy Specimens. JThoracOncol 2010;5:442-
7. 9. Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, Kratzke
R, Graziano SL, Popper HH, Rosell R, Douillard JY, Le-Chevalier T, Pignon JP, Soria JC, 
Brambilla EM. Subtype Classification of Lung Adenocarcinoma Predicts Benefit From 
Adjuvant Chemotherapy in Patients Undergoing Complete Resection. J Clin Oncol 2015. 
10. Kadota K, Nitadori JI, Sima CS, Ujiie H, Rizk NP, Jones DR, Adusumilli PS, Travis WD.
Tumor Spread Through Air Spaces is an Important Pattern of Invasion and Impacts the
Frequency and Location of Recurrences Following Limited Resection for Small Stage I
Lung Adenocarcinomas. J Thorac Oncol 2015;10:806-14.
WHO CLASSIFICATION
Adenocarcinoma
Lepidic adenocarcinoma
Acinar adenocarcinoma
Papillary adenocarcinoma
Micropapillary adenocarcinoma
Solid adenocarcinoma
Invasive mucinous adenocarcinoma Mixed invasive mucinous and non-mucinous 
adenocarcinoma
Colloid adenocarcinoma
Fetal adenocarcinoma
Enteric adenocarcinoma
Minimally invasive adenocarcinoma Non-mucinous Mucinous
Preinvasive lesions Atypical adenomatous hyperplasia Adenocarcinoma in 
situ Nonmucinous Mucinous
Squamous cell carcinoma
Keratinizing squamous cell carcinoma
Non-keratinizing squamous cell carcinoma
Basaloid squamous cell carcinoma
Preinvasive lesion Squamous cell carcinoma in situ
Neuroendocrine tumors
Small cell carcinoma Combined small cell carcinoma
Large cell neuroendocrine carcinoma Combined large cell neuroendocrine carcinoma
Carcinoid tumors Typical carcinoid Atypical carcinoid
Preinvasive lesion Diffuse idiopathic pulmpnary neuroendocrine cell hyperplasia
Large cell carcinoma
Keywords: lung cancer, Pathology, genetics, WHO Classification
adverse outcomes and that smoking cessation treatment should be a standard part of 
cancer care. However, most oncologists do not regularly provide cessation support to 
cancer patients. Moreover, tobacco assessments and cessation support are not regularly 
incorporated into clinical trials design or analysis. Recently released guidelines from 
several national and international organizations advocate for addressing tobacco use by 
cancer patients. This session will discuss the clinical and biologic effects of smoking on 
cancer, present the current state of tobacco assessments and cessation in clinical practice 
and research, and discuss methods to improve access to cessation support for cancer 
patients. Discussion will further detail deficits in the current understanding of the effects 
of smoking on cancer treatment outcomes and highlight areas of needed improvement. 
Keywords: smoking, tobacco, Cancer, cessation
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PLEN02.01 2015 WHO Classification of the Pathology and Genetics of Tumors 
of the Lung William D. Travis Dept of Pathology, Memorial Sloan Kettering Cancer Center, 
New York/NY/United States of America
The 2015 WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart has just 
been published with numerous important changes from the 2004 WHO classification, 
due in part to remarkable advances in lung cancer genetics and therapy.1 Multiple major 
changes for the common lung cancers mostly follow the 2011 lung adenocarcinoma 
classification sponsored by the International Association for the Study of Lung Cancer 
(IASLC), American Thoracic Society (ATS) and European Respiratory Society (ERS).2 This 
2015 edition follows previous WHO Classifications of Lung Tumors in 1967 and 1981, of 
Lung and Pleural Tumors in 1999 and Tumors of the Lung, Pleura, Thymus and Heart in 
2004.3, 4 Through support of its Pathology Committee, the IASLC has played a key role in 
the last three WHO Classifications.5 With each subsequent classification, new techniques 
were introduced resulting in increased complexity, but greater ability to personalize 
therapeutic strategies that are now frequently dependent on histology and genetics. 
The most significant changes in the 2015 Classification involve: 
1) Use of immunohistochemistry throughout the classification, when possible,
not only for small biopsies/cytology, but also for resected specimens in certain
settings such as solid adenocarcinoma, nonkeratinizing squamous cell carcinoma,
large cell carcinoma, neuroendocrine tumors and sarcomatoid carcinomas.
2) A new emphasis on genetic studies, in particular integration of molecular testing
to help personalize treatment strategies for advanced lung cancer patients. Due
to the therapeutic implications, molecular testing for EGFR mutation and ALK
rearrangement is today recommended in tumors classified as adenocarcinoma
and in cases where an adenocarcinoma component cannot be excluded.2, 6
3) A new classification for small biopsies and cytology similar to that proposed in the
2011 IASLC/ATS/ERS Classification2 proposes that tumors that have clear morphologic 
patterns of adenocarcinoma or squamous cell can be diagnosed as adenocarcinoma 
or squamous cell carcinoma, respectively, without immuhistochemistry, unless a 
pneumocyte marker such as TTF-1 is desired to address primary versus metastatic 
adenocarcinoma. However, in the setting of poorly differentiated tumors that do not 
show clear differentiation by routine microscopy, a limited immunohistochemical workup 
is recommended to allow for an accurate diagnosis and also to preserve as much 
tissue for molecular testing as possible. Most tumors can be classified using a single 
adenocarcinoma marker (e.g. TTF-1) and a single squamous marker (e.g. p40 or p63). 
Nonsmall cell carcinomas (NSCC) that show no clear adenocarcinoma or squamous 
cell carcinoma morphology or immunohistochemical markers are regarded as NSCC 
not otherwise specified (NOS). If a tumor with this morphology stains with pneumocyte 
markers (i.e. TTF-1), it is classified as NSCC, favor adenocarcinoma and if it stains only 
with squamous markers (i.e. p40) it is classified as NSCC, favor squamous cell carcinoma. 
Using this approach, a diagnosis of NSCC-NOS can be avoided in up to 90% of cases.7, 8 
4) According to the 2011 IASLC/ATS/ERS Classification of lung adenocarcinoma,
adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) were 
defined as entities to have 100% or near 100% disease free survival if completely 
resected, respectively. Also, invasive adenocarcinomas are classified according to the 
predominant pattern using comprehensive histologic subtyping (CHS). Multiple studies 
have shown prognostic significance to this approach with favorable outcome for lepidic 
adenocarcinomas and poor outcome for solid and micropapillary adenocarcinomas. CHS 
can be helpful in staging as well: 1) along with other morphologic features, it can be useful in 
comparing multiple lung adenocarcinomas in a single patient in order to distinguish multiple 
primary tumors from intrapulmonary metastases and 2) it can also help in measuring 
invasive size in lepidic adenocarcinomas. Micropapillary or solid predominant subtyping 
also appears to predict improved responsiveness to adjuvant chemotherapy compared 
to acinar or papillary predominant tumors in surgically resected lug adenocarcinoma 
patients when analyzed by disease free survival and specific disease free survival.9 
5) The diagnosis of large cell carcinoma is restricted only to resected tumors that lack
any clear morphologic or immunohistochemical differentiation with reclassification
of the remaining former large cell carcinoma subtypes into different categories.
6) Squamous cell carcinomas are reclassified into keratinizing, 
nonkeratinizing and basaloid subtypes with the non-keratinizing tumors 
requiring immunohistochemistry proof of squamous differentiation. 
7) Neuroendocrine tumors are grouped together in one category, although new
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Platinum-based doublet chemotherapy is the standard first-line treatment for non-
selected patients with advanced non-small cell lung cancer (NSCLC) who have a good 
performance status. However, some tumors are highly dependent on the function of 
specific oncogenes for proliferation and survival. This “oncogenic addiction” has 
leaded the development of targeted anticancer therapies and their ad hoc biomarkers 
as predictors of their efficacy. This fact has changed the diagnostic and treatment 
approach in NSCLC. Moreover, this ‘‘personalized medicine’’ approach, in which tumors 
might potentially benefit from a biology-guided treatment, has an impact in patients’ 
outcome. Personalized medicine is also feasible in other malignancies such as 
metastatic breast cancer, even for patients with rare genomic alterations (SAFIR01 trial), 
and in other refractory malignancies (SHIVA trial) , reinforcing that the establishment of a 
comprehensive tumour molecular profile is feasible and compatible with clinical practice. 
Unlike “basket trials”, where researchers test the effect of a single drug on a single 
mutation in a variety of cancer types, “umbrella” trials are designed to test the impact 
of personalized medicine with different drugs on different mutations in a single type of 
cancer on the basis of a centralized molecular portrait . The phase II BATTLE (Biomarker-
integrated Approaches of Targeted Therapy for lung Cancer) trial was the first prospective, 
biopsy-mandated, biomarker-based study that adaptively randomised 255 pre-treated 
NSCLC patients to erlotinib, sorafenib, erlotinib plus bexarotene, or vandetanib, based 
on molecular biomarker analysed in fresh core needle biopsy specimens. Overall results 
included a 46% 8-week disease control rate (primary endpoint). This trial established 
the feasibility of “real-time” biopsies and personalized treatment in lung cancer. 
BATTLE-2 (NCT01248247), a phase II, randomised, multi-arm study in advanced pre-
treated EGFR wild type and ALK non-rearranged NSCLC patients is currently ongoing. 
The SPECTA-lung (NCT02214134), included within the SPECTA-platform, is a 
program aiming at Screening Patients with thoracic tumors (lung cancer, malignant 
pleural mesothelioma, thymoma or thymic carcinoma at any stage) to identify 
the molecular characteristics of their disease for Efficient Clinical Trial Access. 
Second-generation trials encompass within the trial design to access 
to targeted therapies and usually incorporate a randomization process. 
SAFIR02-Lung (NCT02117167) is an open-label, multicentric randomised, phase II 
trial. Advanced no EGFR-activating mutation or ALK translocation NSCLC patients are 
biopsied during the two initial platinum-based chemotherapy cycles. A comparative 
genomic hybridisation (CGH) array and a next-generation sequencing are performed 
and analysed during the two subsequent cycles as a therapeutic decision tool. 
Only patients with a molecular alteration are randomized to maintenance targeted 
drug arm (AZD8931, Vandetanib, Selemutinib, AZD5363, AZD4547, AZD2014); or 
standard maintenance treatment (pemetrexed or erlotinib) after completion of four 
cycles of chemotherapy to test an improvement in progression free survival (PFS). 
Lung-MAP (NCT02154490) trial is a phase II/III multidrug, multi-sub-study, and 
biomarker-driven clinical trial in advanced second-line squamous lung cancer 
patients. Patients are randomized to standard second-line treatment (docetaxel 
/ erlotinib) or five experimental drugs (four targeted therapies according NGS 
results and an anti-PDL1 immunotherapy based on immunochemistry results). The 
primary end-point of the trial is PFS. Approximately 500 and 1000 patients will 
be screened per year for over 200 cancer-related genes for genomic alterations. 
ALChEMIST trial (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing 
Trials) is designed to assess whether adjuvant therapy with erlotinib (ALCHEMIST-
erlotinib, NCT02193282) or crizotinib (ALCHEMIST-crizotinib, NCT02201992) for 2 
years will improve survival over placebo for patients with completely resected stage 
IB-IIIA EGFR-mutant or ALK-rearranged NSCLC tumors following standard post-
operative therapy. ALCHEMIST-screening trial (NCT02194738) will screen about 
6,000 to 8,000 participants over 5 to 6 years, with 400 patients enrolled per arm. 
The RTOG1306 is a phase II trial in EGFR-mutant or ALK-rearranged unresectable 
stage IIIA (pN2) or IIIB (pN3) NSCLC patients. The aim of the study is to assess 
whether induction therapy with erlotinib or crizotinib for 12 weeks prior to chemo-
radiotherapy improves PFS compared to those treated with standard care therapy alone. 
Molecular screening is also tested across prospective trials in different malignancies. 
The MOSCATO trial (NCT01566019) includes metastatic solid tumors and the primary 
LUNG CANCER: IASLC GLOBAL INITIATIVES  
TUESDAY, SEPTEMBER 8, 2015 - 08:15-09:45
PLEN02.02 Revised (8th) Edition of TNM Staging System for Lung Cancer 
Ramon Rami-Porta Thoracic Surgery, Hospital Universitari Mutua Terrassa, Terrassa/Spain
The changes introduced in the 7th edition of the tumour, node and metastasis (TNM) 
classification for lung cancer derived from the analyses of the International Association 
for the Study of Lung Cancer (IASLC) database. These analyses were conducted by 
the members of the IASLC Staging and Prognostic Factors Committee (SPFC) and the 
biostatisticians of Cancer Research And Biostatistics (CRAB). For the first time in the 
history of the TNM classification for lung cancer, the 7th edition was based on a truly 
international database of more than 80,000 evaluable patients collected in 45 different 
sources in 20 countries and treated with all treatment modalities from 1990 to 2000. (1) 
The changes recommended by the IASLC were accepted by the Union for International 
Cancer Control (UICC) and by the American Joint Committee on Cancer (AJCC) and were 
eventually published in their staging manuals. With this involvement of the IASLC in the 
revision of the TNM classification for lung cancer, the IASLC became the most important 
provider of data to the UICC and the AJCC for future editions of the classification. A 
similar process was used for the revision of the 7th edition into the 8th edition. The IASLC 
made an international call for submission of more data to the IASLC database. (2) The 
resulting international contribution amounted to more than 77,000 evaluable patients 
diagnosed with either non-small cell lung cancer (70,967 patients) or small cell lung 
cancer (6,189 patients) from 1990 to 2010. They were submitted from 35 different 
databases located in 16 countries in Europe, Asia, North and South America, and 
Australia. (3) The different subcommittees of the Lung Cancer Domain of the IASLC SPFC 
were in charge of analysing the data pertaining to the T, the N and the M component of the 
classification, as well as the stages and the small cell lung cancer. For the T component, 
the prognostic impact of the T descriptors was analysed in five different populations: 
pT1-4N0M0R0, pT1-4anyNM0R0, pT1-4anyNM0anyR, i.e., including incomplete 
resections, either microscopically incomplete, R1, or macroscopically incomplete, R2; 
and cT1-4N0M0 and cT1-4anyNM0. Survival analyses were completed with univariate 
and multivariate analyses adjusted by histological type, gender, region and age. The 
main results showed that the capacity of tumour size to separate tumours of different 
prognosis was greater than that shown in previous analyses, and that its influence could 
be spread to all T categories; the role of visceral pleura invasion as a T2 descriptor 
was confirmed; the prognostic impact of endobronchial location less than 2 cm from 
the carina (T3 in 7th edition) and of total atelectasis/pneumonitis (T3 in 7th edition) was 
found to be similar to that of their T2 counterparts; diaphragm invasion was found to 
have worse prognosis than that of other T3 descriptors; and mediastinal pleura invasion 
was found to be scarcely used as a T descriptor. (4) For the N component, the present N 
descriptors (N0, N1, N2 and N3) were found to separate tumours of different prognosis 
in clinically and pathologically (both in the R0 and any R populations) staged tumours. 
The impact of tumour burden in the lymph nodes could also be assessed when survival 
was analysed according to the number of nodal stations, but this could only be analysed 
in the population of patients who had undergone tumour resection and systematic nodal 
dissection, and could not be validated at clinical staging. (5) For the M component, the 
7th edition M1a descriptors were validated, as all showed similar survival. However, 
when the M1b descriptors were analysed in detail, single metastasis (one metastasis 
in one organ) had better prognosis than multiple metastases in one or several organs. 
(6) Table 1 shows the changes recommended by the IASLC SPFC based on the analyses 
of the new IASLC database. The described changes implied some modifications in the 
stage grouping, creating more stages for early and advanced disease, (7) and were 
also applicable to small-cell lung cancer. (8) The IASLC recommendations emphasize the 
prognostic impact of tumour size; simplify the T descriptors by combining some of them; 
maintain the current N descriptors; separate tumours with single metastasis in a distinct 
group; and establish more stage groupings to refine prognosis based on anatomic 
extent of disease. They improve our capacity to indicate prognosis, which is one of the 
objectives of the TNM classification, and, therefore, they should be implemented in the 
8th edition of the TNM classification. Table 1
Descriptor 7th edition
8th edition 
(recommended 
classification)
T component
</=1cm T1a T1a
>1-2cm T1a T1b
>2-3cm T1b T1c
>3-4cm T2a T2a
>4-5cm T2a T2b
>5-7cm T2b T3
>7cm T3 T4
Bronchus <2cm from carina T3 T2
Total atelectasis/pneumonitis T3 T2
Invasion of diaphragm T3 T4
Invasion of mediastinal pleura T3 -
N component
No involvement or involvement of 
regional lymph nodes N0, N1, N2, N3 N0, N1, N2, N3
M component
Metastases within the thoracic cavity M1a M1a
Single extrathoracic metastasis M1b M1b
Multiple extrathoracic metastases M1b M1c
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objective is to use high throughput molecular analysis (CGH Array and sequencing) to 
guide treatment of patients with targeted therapeutics in order to improve the PFS 
compared to the previous treatment line. IMPACT trial (Initiative for Molecular Profiling 
in Advanced Cancer Therapy Trial, NCT00851032), is an umbrella protocol in 5,000 
patients with advanced malignancies. The goal is to correlate the molecular profile with 
response to phase I therapies. The NCI-MATCH trial (Molecular Analysis for Therapy 
CHoice) trial is an umbrella protocol for multiple single-arm, phase II trials. Biopsies 
from as many as 3,000 patients will be screened by next-generation DNA sequencing 
to identify 100 actionable mutations, with 1000 participants being enrolled (25% of 
whom will have rare cancers). Co-primary end-points are overall response rate and 
PFS rate at 6 months. Finally, for advanced and refractory cancer patients who do not 
have recognised genetic abnormalities WINTHER trial (NCT01856296) aims at selecting 
rational therapeutics based on the analysis of matched tumors and normal biopsies 
according to micro arrays and gene expression profiling results. The main objective is to 
compare the PFS of the current treatment versus the previously prescribed treatment. 
Models of personalized medicine implementation (no organized compared with 
organized framework), optimal technology for molecular profile, and the optimal 
patients’ selection are some of challenges to be overcome in personalized medicine. 
Moreover, the actual model of personalized medicine does not take in account 
secondary events, which will be involved in cancer resistance. A major challenge in 
molecular medicine will be to target these secondary events early enough, in order to 
avoid treatment resistance. Intratumoral heterogeneity plays a critical role in tumor 
evolution. However, molecular characterization of the tumor is provided from a single 
biopsy and at single time point. Multiregional evaluations to determine geographical 
heterogeneity and molecular characterization of different samples collected over space 
and time to ascertain clonal evolution are not routinely carried out. The prospective 
TRACERx trial (TRAcking non-small cell lung Cancer Evolution through therapy [Rx], 
NCT01888601) in NSCLC patients, aims to define the evolutionary trajectories of lung 
cancer in both space and time through multi-region and longitudinal tumor sampling 
and genetic analysis by following cancer from diagnosis to relapse. The study aims 
to recruit 842 patients. Incorporating an analysis of the tumor immune contexture 
is also a key challenge and need for the design of new precision medicine trials. 
In the near future most patients with metastatic tumors will receive targeted 
therapies or immune modulators delineated by tumor genotyping and 
analysis of immune contexture and all of these trials will help to validate 
current biomarkers facilitating rapid access to innovative therapies. 
Keywords: personalized, medicine, lung, Cancer
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Lung cancer and mesotheliomas belong to the most lethal human malignancies with 
poor prognosis. The majority of these tumors is associated with carcinogen exposure 
(smoking and asbestos). Small cell lung cancer (SCLC) and mesothelioma patients 
show very poor survival statistics due to their late detection, invasive and high 
metastatic potential, and chemo-resistance. Using the Rbf/f;p53f/f mouse model 
for SCLC, we found that the tumors are often composed of phenotypically different 
cells, characterized by mesenchymal and neuroendocrine markers. These cells often 
share a common origin. Crosstalk between these cells can endow the neuroendocrine 
component with metastatic capacity, illustrating the potential relevance of tumor cell 
heterogeneity in dictating functional tumor properties. Also specific genetic lesions 
appear to be associated with metastatic potential. We have studied the nature of this 
crosstalk and identified the components responsible for paracrine signaling and the 
downstream effector pathway critical for promoting metastatic spread. We have also 
evaluated the relevance of additional lesions that were frequently acquired in the mouse 
SCLC, such as amplification of Myc and Nfib. Therefore, we have derived ES cells from 
Rbf/f;p53f/f, equipped these cells with an exchange cassette in the ColA1 locus, and 
shuttled a conditional L-Myc and Nfib under a strong promoter into this locus. This 
accelerated tumorigenesis and resulted also in a shift in the metastatic phenotype. To 
investigate the cell-of-origin of thoracic tumors, we have inactivated a number of tumor 
suppressor/oncogene combinations (Trp53, Rb1, Nf2, Cdkn2ab-p19Arf, mutant Kras) in 
distinct cell types by targeting Cre-recombinase expression specifically to Clara cells, 
to neuroendocrine cells, alveolar type II cells and cells of the mesothelial lining (origin 
of malignant mesothelioma) using adenoviral or lentiviral vectors with Cre recombinase 
driven from specific promoters. Dependent on the induced lesions and the cell-type 
specific targeting, SCLC, NSCLC, or mesothelioma could be induced. We show that 
multiple cell types can give rise to these tumors but that the cell-of-origin is an important 
factor in determining tumor phenotype. Our data indicate that both cell type specific 
features and the nature of the oncogenic lesion(s) are critical factors in determining the 
tumor initiating capacity of lung (progenitor) cells. Furthermore, the cell-of-origin appears 
to influence the malignant properties of the resulting tumors. Sutherland, K., Song, J-Y., 
Kwon, M-C, Prooost and Berns A. (2014). Multiple cells-of-origin in K-RasG12D induced 
mous lung adenocarcinoma. Proc. Natl. Acad. SCi. USA, 111, 4952-4957. Kwon, M-C, 
and Berns, A. (2013) mouse models of Lung Cancer. Mol. Oncol. 7, 65-177. Sutherland, 
K.D., Proost, N., Brouns, I., Adriaensen, D., Song, J-Y., and Berns, A. (2011). Cell of Origin 
of Small Cell Lung Cancer: Inactivation of Trp53 and Rb1 in Distinct Cell Types of Adult 
Mouse Lung. Cancer Cell 19, 754-64. Calbo, J., van Montfort, E., Proost, N., van Drunen, 
E., Beverloo, H., Meuwissen, R., and Berns, A. (2011) A functional role for tumor cell 
heterogeneity in a mouse model of Small Cell Lung Cancer. Cancer Cell, 19, 244-56. 
Keywords: SCLC, NSCLC, Mesothelioma, Mouse model
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on Cancer of the American College of Surgeons and the American Cancer Society, has 
been queried to study the impact of modern PORT in the setting of standard-of-care 
adjuvant chemotherapy for pathologic stage IIIA (N2) NSCLC (6). Data of 1850 patients 
who received PORT between 1998 and 2010 were obtained. Use of PORT, compared 
with no PORT, was associated with a significant increase in median OS (45.2 v 40.7 
months, respectively), 3-year OS (59.3% v 55.2% , respectively), and 5-year OS (39.3% 
v 34.8%, respectively; P=.014. This analysis of the NCDB for patients with pathologic 
N2 disease, receiving adjuvant chemotherapy, shows that PORT seems to confer an 
additional improvement in OS. In conclusion, modern radiotherapy techniques should 
be evaluated in stage III patients, as already stated in the initial individual-patient-data 
meta-analysis. This new evaluation is justified for several reasons: (a) the N2 population 
has changed because of a better selection with pre-treatment PET-CT scan and brain 
imaging; (b) adjuvant chemotherapy has become a standard of care in these patients; 
(c) technical advances of radiotherapy may enhance the ability of PORT to improve 
local relapse-free survival and possibly overall survival. Thus, based on the previous 
studies, the underlying hypotheses remain to be proven, with sufficiently powered new 
randomised trials. A prospective randomized phase III trial, LungART (Lung Adjuvant 
Radiotherapy Trial), designed with the primary aim of investigating the benefits of 
conformal radiotherapy in completely resected pN2 NSCLC, together with adjuvant 
chemotherapy, is currently ongoing in Europe, and should help answering definitely this 
question, investigators are strongly encouraged to enroll patients on this randomized 
trial. 1 : PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-
cell lung cancer: systematic review and meta-analysis of individual patient data from 
nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 
352:257-63. 2 : PORT Meta-analysis Trialists Group: Postoperative radiotherapy for non-
small cell lung cancer. Cochrane Database Syst Rev 2:CD002142, 2005 3 : Kepka L, 
Bujko K, Orlowski TM, et al. Cardiopulmonary morbidity and quality of life in non-small 
cell lung cancer patients treated with or without postoperative radiotherapy. Radiother 
Oncol 2011;98:238–43. 4 : Lally BE, Zelterman D, Colasanto JM, et al. Postoperative 
radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, 
epidemiology, and end results database. J Clin Oncol 2006; 24:2998-3006. 5 : Douillard 
JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation 
in patients with completely resected stage IB-IIIA non-small-cell lung cancer. Adjuvant 
Navelbine International Trialist Association ANITA: a randomised controlled trial. Lancet 
Oncol 2006;7: 719-27. 6 : Robinson CG, Patel AP, Bradley JD et al. Postoperative 
radiotherapy for pathologic N2 Non small Cell lung cancer treated with adjuvant 
chemotherapy : A review of the National Cancer Data Base. J Clin Oncol 2015 ; 33 :870-77 
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The key objectives of this presentation are to review the fundamental biology underlying 
metastatic disease, understand the definition and clinical evidence for oligo- (or limited) 
metastatic disease, analyze key clinical trials showing the potential role of stereotactic 
body radiation therapy (SBRT) for oligometastases and address challenges regarding 
this “high-tech” strategy. In the early 1900s, Halsted suggested that breast cancer 
spread via the local regional lymphatic vessels in a stepwise manner. Thus, once there 
are metastases, local therapy had no clear role. Later in the 20th century, an opposing 
theory (the “Fisher” theory) suggested that cancer is a systemic disease that, if 
it will ever metastasize, will already have done so early in the disease course. Local 
therapies are therefore less important than systemic therapies. A counterpoint to these 
approaches was proposed by Hellman and Weichselbaum, postulating that cancer is 
a spectrum from localized to wide-spread disease at the time of diagnosis, with many 
intermediate states (Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995 
Jan;13(1):8-10). “Oligometastases” are essentially early metastases which are limited in 
number and location and based on a state of limited metastatic capacity. The hypothesis 
based on this approach is that there may be a subset of patients with oligometastatic 
disease for whom aggressive local treatment (such as surgery or SBRT) could change 
their outcome. Clinical evidence for oligometastasis includes the surgical experience for 
lung or liver metastases showing long-term survivals of approximately 20%. Studies are 
now emerging suggesting similar results utilizing SBRT. In an individual patient data meta-
analysis of outcomes after surgery or SBRT, Ashworth et al. reported a 5-year survival 
rate of approximately 30% in patients with oligometastatic non-small cell lung cancer 
(Ashworth AB, et al. An individual patient data metaanalysis of outcomes and prognostic 
factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 
2014 Sep;15(5):346-55). They developed a risk classification schema showing a better 
prognosis for metachronous vs. synchronous oligometastases (of which node-negative 
was favorable to node-positive). Other studies have shown that, among patients treated 
with SBRT for 1-5 oligometastases, those with ≤3 metastases had better outcomes 
compared to those with 4-5 metastases. The size of the metastases also appears to 
be important, as well as the biological equivalent dose (BED) of the SBRT. Studies have 
begun to explore the role of SBRT for oligometastases involving the lung, liver, adrenal, 
and other sites. It is likely that host-related factors (for example, immune mediated anti-
cancer activity) and tumor related factors (such as genomics and proteomics) also affect 
the spectrum of disease aggressiveness. Challenges to this new “high-tech” approach 
will also be addressed, including issues related to patient selection, the level of evidence, 
and the cost effectiveness of this approach. Other approaches for improving the outcome 
for patients with metastatic disease will also be discussed, including the role of early 
palliative interventions. In summary, emerging (albeit non-randomized) data suggests 
that SBRT appears to be a promising strategy in selected patients with oligometastases. 
The patients most likely to benefit from SBRT have metachronous (vs. synchronous) 
metastases, N0 (vs. N+) disease, 1-3 metastases (vs. more), small metastases, and the 
ability to receive a higher radiation dose (BED >100Gy). Randomized trials are needed to 
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ED01.01 Current Status of Proton and Heavy Particle Therapy Hak Choy 
Radiation Oncology, UTSW, Dallas/TX/United States of America
Proton therapy, in particular, and ion therapy, just beginning, are becoming an increasing 
focus of attention in clinical radiation oncology. Proton therapy is a type of radiation 
treatment that uses protons rather than x-rays to treat cancer. Protons, however, can 
target the tumor with lower radiation doses to surrounding normal tissues. Proton 
therapy is particularly useful for treating cancer in children because it lessens the chance 
of harming healthy, developing tissue. In addition, proton therapy may be used to treat 
Lung cancer. Compared with standard radiation treatment, proton therapy has several 
benefits. It reduces the risk of radiation damage to healthy tissues; may allow a higher 
radiation dose to be directed at some types of tumors, which may keep the tumor from 
growing or spreading; and may result in fewer and less severe side effects (such as low 
blood counts, fatigue, and nausea) during and after treatment. However, there are some 
drawbacks such as higher cost and lack of convincing evidence from randomized trials 
proving their efficacy, justifying the higher costs involved in these therapies. Carbon ion 
therapy is another type of radiotherapies that can deliver high-dose radiation to a tumor 
while minimizing the dose delivered to the organs at risk; this profile differs from that of 
photon radiotherapy. Moreover, carbon ions are classified as high-linear energy transfer 
radiation and are expected to be effective for even photon-resistant tumors. There are 
several centers in Asia and Europe using carbon beam to treat lung cancer patients. In 
this session, we will provide an overview of the current status of clinical trials in proton 
therapy, including recent developments in ion therapy for lung cancer. We will also 
attempt to highlight some of the challenges that surround clinical trials in particle therapy. 
Keywords: proton, Carbon, particle, therapy
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Radiation Oncology, Centre Hospitalier Lyon-Sud, Lyon/France
Despite advances in treatment, lung cancer remains the leading cause of cancer 
mortality in most countries. About one third of patients with non-small cell lung cancer 
(NSCLC) presents with locally advanced non-metastatic disease (stages IIIA and B). 
Although 5-year overall survival (OS) ranges from 60 to 73% for completely resected 
pathologic stage I disease, OS decreases to less than 25% for pathological stage III 
disease. Patients with potentially resectable stage IIIA-N2 can be treated with induction 
chemotherapy followed by radical surgery. Prospective studies report 5-year OS rates 
from 20% to 30%, with about 30% of the patients reporting local recurrence (LR). When 
surgery is performed first, for patients presenting with node-positive disease at the time of 
resection, meta-analysis data demonstrate that adjuvant platinum-based chemotherapy 
has been shown to decrease distant metastases and locoregional recurrence (LRR), 
resulting in an approximately 5% OS advantage, and is now considered standard of care 
for patients with resected node-positive NSCLC. However, these patients have a 20% to 
40% risk of LRR, and LRR correlates independently with worse OS. Thus, postoperative 
radiotherapy (PORT) holds great appeal as a means to reduce LRR and improve OS. 
Several phase III trials investigated the role of PORT after surgical resection in NSCLC. 
In 1998, the PORT Meta-analysis Trialists Group undertook an individual participant data 
(IPD) meta-analysis (of both published and unpublished trial data) of PORT versus surgery 
alone in NSCLC [1]. The original meta-analysis, based on 9 randomised controlled trials 
and 2128 patients, concluded that PORT was detrimental with a 7% absolute reduction in 
2-year OS and a 4% reduction in recurrence-free survival. Subgroup analyses suggested 
that PORT was increasingly detrimental with decreasing stage (p = 0.0003) and lower 
nodal status (p = 0.016). The updated results for OS, and for local, distant and overall 
recurrence-free survival are unchanged, continuing to show a detrimental effect of 
PORT(2) : For the whole patient group, PORT decreased the OS at two years by 6% 
(52% vs. 58%). This deleterious effect was detected in patients with pN0–1 disease. No 
effect was detected in patients with pN2 disease. The PORT meta-analysis raised a lot 
of criticism for the following reasons: significant heterogeneity between trials, inclusion 
of trials with old radiotherapy techniques (notably, most of these trials, conducted 
principally in the 1960s to 1970s, included outmoded RT techniques and doses). The 
deleterious effect of PORT has been attributed to an excess of intercurrent deaths, with 
a high incidence of cardiac and respiratory complications due to poor radiotherapy 
techniques. In support of this hypothesis, several more recent trials with contemporary 
radiation techniques did not report an increase of death from intercurrent disease. Kepka 
et al. did not detect a difference in QoL scores, cardiopulmonary morbidity or non-cancer 
related deaths between patients receiving PORT and those treated with surgery alone 
(3). Two Surveillance, Epidemiology, and End Results (SEER) analyses and a secondary 
analysis of data from the Adjuvant Navelbine International Trialist Association (ANITA) trial 
suggest that PORT may be safely delivered in a modern cohort of patients with a potential 
OS benefit for stage IIIA (N2) disease (4, 5). In addition, being now established that the 
use of adjuvant chemotherapy in stage III disease prolongs OS, it is then hypothesised 
that with the reduction of distant metastases with chemotherapy, the survival benefit 
by improved local control after three-dimensional conformal (3D-CRT) PORT will occur. 
Then, recently, the National Cancer Data Base (NCDB), joint program of the Commission 
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trials were registered on ClinicalTrials.gov and some trials used a local pharmaceutical 
company TKI, icotinib. Phase II studies of crizotinib in East Asian patients with ROS1-
positive NSCLC are ongoing in China, Japan, South Korea and Taiwan. Anaplastic 
lymphoma kinase (ALK) rearrangement accounts for about 2–13% of unselected Asian 
patients with NSCLC, and occurs predominantly in younger individuals with 
adenocarcinoma who never smoked or light smokers (< 40 pack years). There is no 
strong evidence to suggest an ethnic difference of translocations among patients with 
NSCLC. The CAP/IASLC/AMP guideline recommended ALK FISH assay using FDA-
approved specific companion test (Vysis ALK Break-Apart FISH Probe Kit, Abbott 
Molecular, Des Plaines, IL) for selecting patients for ALK tyrosine kinase inhibitor therapy. 
ALK immunohistochemistry (IHC) may be considered as a screening methodology to 
select specimens for ALK FISH testing. The ALK rearrangements have been shown to be 
4.3% in men and 7.5% in women in Asian NSCLC by meta-analysis. Most Asia countries 
use FISH to detect ALK rearrangement, in Japan, reverse transcription–PCR (RT–PCR) is 
commonly used. In China, the Chinese Food and Drug Administration (CFDA) had 
approved VENTANA ALK IHC assay to aid the identification of patients for crizotinib 
treatment. The price of FISH detection range from US$415-800, and IHC range from 
US$14-220, most of which is funded by the patients.9 Recently, two additional oncogenes, 
RET and ROS1, were added to the list of driver oncogenes that are targetable with 
existing TKIs, and several clinical trials investigating the efficacy of such TKIs in Asia have 
been conducted. FISH and IHC are suitable for the diagnosis of ROS1 fusion, but some 
studies showed IHC is not suitable for the diagnosis of RET fusion.10 Over the past 
decades, we have witnessed rapid advances in molecular and cellular biology of lung 
cancer biology, and new data are upcoming which should facilitate personalized 
biomarker-based therapy in lung cancer, including characterization of driver mutations, 
genomic abnormalities and epigenetic changes. Individual centers should develop a 
multidisciplinary approach to integrate a molecular testing algorithm. Next generation 
sequencing should be able to resolve much of the complexity of molecular testing, 
especially in situations where there is only a small amount of tissue available. 
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ED02.04 Central/South America Mercedes L. Dalurzo Pathology, Hospital Italiano, 
Buenos Aires/Argentina
This presentation comprises data from Central and South America, as well as Mexico 
since all of us, as Latin American countries share similar characteristics. The countries 
included in this group are considered “developing countries” and are characterized by 
their racial, geographic, cultural, political and economic heterogeneity. In order to obtain 
data about the current situation in the region, I have sent a survey to the institutions that 
perform molecular tests in these countries for which I could get contact information. 
The survey has been sent to 34 laboratories in 12 countries. I tried to be as inclusive 
as possible, although in some cases it was rather difficult to get adequate contact 
information. My apologies to those who did not received the survey and would have 
liked to participate. Nineteen laboratories answered the survey ¹. Although not updated, 
I also added information from 5 other laboratories presented at LALCA 2014². Despite 
these results do not represent every country nor all molecular laboratories in the region, 
many common factors can be identified which allow for a relatively accurate analysis. 
The results show: Molecular tests are run by a small group of laboratories concentrated 
in the main cities of these countries. Most frequently, molecular testing is financed by 
pharmaceutical companies or private health care programs; however, in some cases the 
government, through the public healthcare system, supports the cost of the tests, and 
occasionally the patient pays for it. The pharmaceutical companies centralize molecular 
testing in a few laboratories in each country. Although frequency is generally low, some 
specimens are analyzed abroad, mainly in the USA. Some regional laboratories perform 
the tests for those countries that do not have adequate technology for molecular testing. 
The general opinion was that sending specimens to molecular center did not pose major 
complications, except in big countries where the geographic distance tends to delay 
the transport. Pharmaceutical companies provide the logistic structure to aid in the 
transfer of specimens, thus, accelerating the process. Specimen rejection rate can be 
establish whether SBRT improves progression free and/or over survival in this setting. 
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National University College of Medicine, Seoul/Korea
Substantial progress has been made toward understanding the tumor biology of non-
small cell lung cancer (NSCLC) during the last few years, and major discoveries in the 
molecular pathogenesis of lung cancer have led to successful applications of targeted 
therapeutic strategies. One representative of these successes is the subset of lung 
cancer patients with epidermal growth factor receptor (EGFR) mutations who have shown 
improved clinical response to tyrosine kinase inhibitors (TKIs).1 The prevalence of EGFR 
mutation is higher in the East Asian population than in Western populations. Asian NSCLC 
patients were reported to show a higher response rate and a longer survival to EGFR 
tyrosine kinase inhibitors (EGFR TKIs) as well as traditional chemotherapy. Therefore, 
genetic testing prior to treatment is becoming increasingly important and considered 
essential to select appropriate treatment strategies for NSCLC patients, especially in 
Asia. The exact mechanisms underlying these differences are not clear. However, 
approximately 45% of patients with NSCLC in the US are women whereas only 25% to 
30% of patients with lung cancer are women in Eastern Asia. In addition, In the US, 
approximately 10% of patients with lung cancer are neversmokers (<100 lifetime 
cigarettes). In Asia, more than 30% of patients with lung cancer are neversmokers.2 
Some international studies and global surveys have been conducted during the past few 
years to establish the current status of EGFR mutation testing and to establish the 
standard testing protocols.3-5EGFR mutation test is not yet available in many East Asian 
medical institutions. In the medical facilities which do perform EGFR mutation test, the 
overall testing rate of newly diagnosed NSCLC is 31.8%, varying from 18.3% - 64.8%, the 
highest EGFR mutation testing rate was observed in Japan and the lowest in China. Sex, 
smoking status and histological subtype are the main determining factors for EGFR 
mutation tests.5 However, the College of American Pathologists (CAP), International 
Association for the Study of Lung Cancer (IASLC), and Association for Molecular 
Pathology (AMP) guidelines recommended that patients with lung adenocarcinoma 
should not be excluded from testing on the basis of clinical characteristics that include 
ethnicity, smoking history, and sex. Factors associated with EGFR mutation status were 
country, sex, ethnicity, smoking status, smoking pack-years, disease stage and histology 
type. 4 In most countries, EGFR mutation rate and clinical pathologic factors are in line 
with previous reports in Asia, and the variations of EGFR mutation prevalence between 
countries are due to the selection of the tested populations. The majority of Asian 
institutions use PCR-based DNA direct sequencing methods to detect EGFR mutation. 
Other predictive biomarkers for EGFR TKI therapy are also available, including EGFR gene 
copy number, single-nucleotide polymorphisms of the EGFR gene, EGFR protein 
expression. 3 Next Generation Sequencing (NGS) and multiplex assays have made 
feasible the widespread adoption of molecular diagnostics for clinical use. According to 
our survey, the NGS is not available in clinics in most Asian medical institutions, and can 
be used for diagnosis of rare diseases and/or research. In China, sequencing based 
methods are the most commonly used, followed by the amplification mutation refractory 
system (ARMS).6 In Korea, the PNA clamp method is the most commonly used testing 
method, followed by direct sequencing methods.7 PCR-INVADER is the most commonly 
used test in Japan, followed by PNA-LNA PCR clamp.5 The materials for EGFR mutation 
analysis are usually from diagnostic samples, thus in most countries, small biopsy and 
cytology specimens are the most commonly used, followed by surgically resected 
tissues. Cytological specimens including smear slides and/or cell blocks have been 
shown to be suitable for EGFR mutation test.3, 5At present, the potential barriers to EGFR 
mutation testing in Asia include the cost, the number of laboratories capable of 
performing the test, communications between the clinicians and pathologists, and the 
predefined criteria for the type of patients who should be tested.3 The cost for EGFR 
mutation tests vary from U.S.$170 to 500. In most countries the costs are funded by the 
patients, but in a few countries are funded by pharmaceutical companies, while the 
insurance does not cover the cost of molecular testing in most Asian countries. Currently, 
National Comprehensive Cancer Network (NCCN)’s guidelines recommend EGFR-TKI as 
the first line treatment for patients with NSCLC harboring EGFR sensitizing mutations. 
Randomized first-line trials have demonstrated consistent improvement in tumor 
response rate and progression-free survival, but failed to prove overall survival benefit. 
These finding make TKI the second-line or third-line treatment options for NSCLC. Current 
data on treatment outcomes of second- and/or third-line EGFR therapy are still 
inconsistent.8 Patients treated with EGFR-TKI inevitably experience acquired resistance 
by various molecular mechanisms. Many clinical trials are ongoing to explore the novel 
agents and strategies for better response and overcoming TKI resistance. In our 
questionnaire-based survey, four of seven Asia countries have ongoing clinical trials. The 
clinical trials include the first line and second line and maintenance therapy using first 
generation and new generation EGFR TKIs. In 2013, more than 1000 studies with Chinese 
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ED03.01 Global Lung Cancer E-Atlas - How Can This Be Used as a Tool to 
Advocate for Change? Sarah Winstone Incisive Health, London/United Kingdom
Background: The Global Lung Cancer Coalition (GLCC) is a unique partnership dedicated 
to improving disease outcomes for all lung cancer patients worldwide. The GLCC has 
a clear objective to place lung cancer on the global agenda. There are known to be 
signifi cant variations both between and within countries in terms of: lung cancer 
incidence, mortality and survival; access to the latest treatments and to high quality 
specialist healthcare professionals; and investment in research and clinical trials. 
Evidence of variations can be a powerful tool for advocates – both clinicians and patient 
advocacy groups – to use to engage with policymakers about the ways in which legislative 
or regulatory policies can be shaped to optimise treatment and care for people living with 
lung cancer. However, there was no single statistical resource for the global lung cancer 
community to use in comparing countries, benchmarking progress, and campaigning. In 
2014, therefore, the GLCC created the Global Lung Cancer E-Atlas, making accessible 
in one place the latest published information about lung cancer’s global impact and 
outcomes, in an interactive format. Creating the E-Atlas: Potential data sources were 
mapped to identify the most current and comparable available. Incidence and mortality 
data were drawn from GLOBOCAN 2012[i], which provides contemporary estimates of 
the incidence, mortality and prevalence from major types of cancer, at national level, 
for 184 countries. The estimates are based on the most recent data available at the 
International Agency for Research on Cancer (IARC) though more recent fi gures may be 
available directly from local sources. Survival data were drawn from a variety of sources, 
where available. These included: CONCORD-2[ii], which includes data provided by 279 
cancer registries in 67 countries; the EUROCARE-5 study[iii], which provides the most 
up-to-date survival analysis for patients diagnosed with cancer across 29 European 
countries; and the International Cancer Benchmarking Partnership (ICBP)[iv], which 
includes data from population-based cancer registries in 6 countries – Australia, Canada, 
Denmark, Norway, Sweden and the United Kingdom. The E-Atlas also details whether 
each country operates a cancer plan or has implemented the World Health Organization 
Framework Convention on Tobacco Control with data drawn from responses to the World 
Health Organization Noncommunicable Diseases Country profi les[v], covering 184 
countries. GLCC members were invited to validate data for their country and identify any 
more recent national data. If more recent data were found then these were added. Using 
the E-Atlas: The E-Atlas allows anyone to compare statistics for lung cancer across the 
world. It is publically accessible on the GLCC’s website: http://www.lungcancercoalition.
org/atlas/(Figure1):
Figure 1: GLCC Global Lung Cancer E-Atlas home page By clicking on individual countries, 
or using the search function, users can ‘zoom in’ on different areas to see the fi gures for 
that nation. The E-Atlas also has a comparison tool, enabling the user to select up to four 
countries and directly compare the fi gures for them (Figure2).
divided into two groups: insuffi cient tissue or inadequate specimen quality by poor tissue 
preservation. The average rejection rate was 5 to 22%, more frequently around 15%. As 
for quantity, some institutions improved the amount of tissue obtained and specimen 
handling over time. When consulted on the possibility to perform molecular tests for 
treatment and/or research, the answer were: 2 laboratories only make test for research, 
10 only run them for treatment purposes and 9 perform tests both for treatment and 
research. In most of the countries research is more frequently economically supported 
by the government than by other sources. When oncologists participate in clinical 
trials the tests are usually run abroad, mainly in the USA. Table 1 shows the available 
test platforms in the laboratories that participated in the survey and their access to 
quality control (QC) programs. For sequencing, all the laboratories began with Sanger 
sequencing, but many of them have changed to PCR-allele specifi c real-time platform. 
Some countries are introducing NGS. Most countries do not have local regulations for 
quality control of molecular tests. A half of the laboratories included in the survey have a 
kind of international QC, represented by participation in CAP or European QC programs 
or sending material to reference laboratories for interobserver concordance of results. 
Table1
Country Argentina Brazil Chile Colombia
Costa 
Rica
Ecuador Mexico Peru Uruguay
Labora-
tories 6 2/2* 2/1* 2/1* 1 1* 2 1 2
EGFR 6 3 3 3 1 1 2 1 2
ALK 6 4 3 3 1 1 2 1
Other 
tests 5 3 2 3 1 2 1 2
Sanger 
Seq. 5 2 1 2 2
PCR 
allele 
specif-
ic-real 
time
4 2 2 2 1 1 2 1 1
NGS 3 1 1
FISH 4 3 3 2 1 1 2 1
IHQ 5 2 1 2 1 1 1
Exter-
nal QC 3 1 1 1 1 1 1
* LALCA surveys information not updated Information on the total tests performed in 
the region is still incomplete and the number varies from country to country. In spite of 
this, the main reference laboratories are included in the survey and the data obtained 
reveals an insuffi cient number of tests related to the frequency of advanced lung 
cancer cases in the region. I did not include in this survey the test results but published 
Latin American data³ 4¯¯5 shown regional/country variability in the frequency of EGFR 
mutation and sometimes in ALK fusion test, probably related to genetic variability in 
the Latin American population. What are the challenges of molecular testing in Latin 
America? One of them is the quality and quantity of tissue available for molecular 
tests. In the region we still struggle against badly-fi xed or inadequately processed 
specimens. In this fi eld, probably, there is much education and interdisciplinary work to 
do yet. Reimbursement is another challenge. In most of the countries, pharmaceutical 
companies have fi nanced so far the cost of molecular tests, but if this were not the 
case in the future when the need for many other tests arises, health care systems will 
have to bear testing and treatment costs. A careful evaluation will be required in each 
country to organize the most balanced use of the available resources. A particularly 
important challenge for the region is molecular testing quality certifi cation. The access 
to international quality control programs is very expensive for the majority of the regional 
laboratories but quality control must be ensured. A group of us is trying to organize a 
stratifi ed system that allows for a more affordable program to all laboratories. It is still 
a project in development. 1-Survey participants: Argentina: Esteban Mocetti: Hospital 
Italiano. Buenos Aires. Marina Gutierrez: Laboratorio Stamboulian. Buenos Aires. 
Erica Rojas Bilbao:Hospital Roffo. Buenos Aires. Guillermo Bramuglia: Argenomics. 
Fundacion Investigar. Buenos Aires. Valeria Denninghoff: Instituto CEMIC. Buenos 
Aires. Jorge Palazzi: IICT Labs. Rosario. Brasil:Fernando Soarez. Isabela Werneck da 
Cunha: AC Camargo Cancer Center. Sao Pablo. Fabio Tabora:Argos Lab / Messejana 
Hospital. Fortaleza. Chile: Cristina Fernández Ferradás: Instituto Nacional del 
Tórax. Santiago de Chile. Antonio Piottante Becker: Clínica Las Condes. Santiago de 
Chile. Colombia: Andres Felipe Cardona. July Rodriguez: Foundation for Clinical and 
Applied Cancer Research Bogotá. Ruby E. Ríos Quintana-Roberto Jaramillo: Unidad de 
Diagnostico Hemto-Oncologico. Cali.Costa Rica: Luis Corrales Rodriguez: Centro de 
Investigación y Manejo del Cancer.(CIMCA y CCSS). San José. Mexico: Graciela Cruz 
Rico: Instituto Nacional de Cancerología. Distrito Federal. Erica Sagrario Peña Mirabal: 
Instituto de Enfermedades Respiratorias. Distrito Federal. Perú: Juan Carlos Gomez 
de La Torre Petrell: Laboratorios ROE. Lima. Uruguay: Alejandra Torres: Laboratorio 
Genia. Montevideo.Gonzalo Manrique, María Noel Zubillaga. Asociación Española. 
Montevideo. 2. LALCA 2014 surveys, not updated: Cintya Sternberg. INCA. Rio de 
Janeiro.Brasil, Vinicius Duval Da Silva Pontifi cia Universidade Catolica do Rio Grande 
do Sul. Brasil. Yumay Pires. Clinica Alemana. Santiago de Chile. Ana Margarita Baldión 
Elorza. Hospital Universitario Fundación Santafé de Bogota. Colombia. Nicolas Vivar 
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individuals advocating for improvements in this disease. All organisations engaging in 
lung cancer advocacy are different and respond to the particular cultures and needs of 
their regions or countries. However, there are a number of common campaign themes:
Integrated Tobacco Control programs.
Increased funding for lung cancer research
Increase in the number of patients enrolled in Clinical Trials
Earlier diagnosis
Equitable access to best practice treatment and care
The Need for High Quality Data Underpinning advocacy in all of the above, is the need 
for advocates to access high quality, timely data on survival, quality of life and patient 
experience. Such data, not only provides a benchmark for the quality and outcomes of lung 
cancer services, but also provides advocates with a tool to campaign for improvement 
and showcase good practice. A good example is the work of the International Cancer 
Benchmarking Partnership [1], which has shown huge variation in one year and fi ve year 
survival in lung cancer across the study countries, prompting health policy makers to 
investigate differences. The publication of the recent CONCORD- 2 data [2] has had a 
similar effect, with advocates highlighting 5 years survival inequalities. In November 
2014, the Global Lung Cancer Coalition launched it’s online e-atlas [3 ], bringing together 
international lung cancer data sets and information, where available, in every WHO 
country. An important national initiative is the UK’s National Lung Cancer Audit [4], which 
is examined in further detail The UK’s National Lung Cancer Audit (NLCA) – Example 
of a tool for advocates The NLCA has taken around 20 years from conception to its 
establishment as a gold standard national clinical audit. The fi rst discussions around 
the need to audit services and patient outcomes took place among a small group of UK 
lung cancer clinicians, in 1994. Since then, the NLCA has developed into a national audit 
which captures information on almost every case of lung cancer and mesothelioma that 
reaches hospital in the UK. It captures data on a range of demographics, clinical features 
and key process measures in treatment and care, spanning the patient journey. The NLCA 
is used by a wide variety of stakeholders within the lung cancer community to understand 
how care is being delivered across the country and to drive improvements to services. It 
includes data which are as close to real-time as possible. As contained in the Roy Castle 
Lung Cancer Foundation’s 2014 report on the NLCA [5], this audit has been vital to lung 
cancer advocates in driving improvements in lung cancer service provision. Findings of 
this Report highlight the NLCA’s vital contribution to:
Improving clinical practice – average rates of active treatment, surgery, histological 
diagnosis and access to lung cancer nurse specialists have all improved during the 
lifetime of the audit
Creating further advocacy tools - this audit data has been extensively used by UK 
advocacy groups, as in the web based ‘Smart Map’ [6], displaying the data in a patient 
friendly, easily accessible format.
Supporting clinical research –The 2014 RCLCF Report [5] notes that there were at least 
13 clinical research projects ongoing across the UK which were making use of NLCA 
data. Also, 175 key clinical journal articles published between 2006 and 2013 referenced 
the NLCA.
Informing cancer policy and guidelines – the NLCA has been cited in much policy 
documentation.. The 2014 RCLCF Report [5] notes that the National Institute for Health 
and Care Excellence (NICE) references the NLCA at least 36 times in documents ranging 
from guidance, implementation guides, and audit tools to briefi ngs. Also. the National 
Cancer Intelligence Network (NCIN) references the NLCA 32 times in the documents 
currently available on its website and uses most of the NLCA’s ‘headline indicators’ in its 
on-line lung cancer service profi les
Raising awareness of lung cancer issues - the annual NLCA report helps to raise 
awareness of lung cancer issues among national and local decision-makers and the 
general public. It has been used almost exclusively to positively evaluate the major 
clinical impact of the 2011 and 2012 national public awareness campaigns (the Be Clear 
on Cancer campaign for lung cancer [7]), relating to persistent cough as an early warning 
symptom of lung cancer. Roy Castle Lung Cancer Foundation has used data from the 
NLCA to raise awareness of lung cancer, and variations in lung cancer care and outcomes 
across England and Scotland, through the publication of two reports[i] on variations in 
lung cancer care across the country [8,9].
Learnings for all lung cancer advocates
There is a need for high quality, timely, lung cancer data on incidence, mortality, survival. 
Also, a need for high quality, timely data to assess health services – on diagnostics, 
treatment availability and support/care provision.
If the above is not available – advocates need to ask why not and campaign for data 
collection
Quality data provides lung cancer advocates with a key tool to highlight good practice, 
variation and inadequacies. Thus, advocating for change and improvement.
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Figure 2: the comparator tool GLCC campaigners have been using the E-Atlas to support 
engagement with national policy-makers and infl uencers. To support this, the project 
team produced a campaigning toolkit, giving headline fi gures, tips for engagement 
and template materials (press releases, briefi ng documents and a presentation for 
adaptation). Conclusions: Feedback from GLCC members confi rms that the E-Atlas 
is a helpful resource in their campaigning and advocacy. The GLCC is continuing to 
develop the E-Atlas, and it will be updated with breakdowns by age and gender. The 
GLCC is also keen for the E-Atlas to be shared and to receive feedback (via http://
www.lungcancercoalition.org/atlas/contact.php) on additional national data for 
inclusion or suggestions for further development. References: [i] GLOBOCAN 2012 
v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11, Ferlay J, 
Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman 
D, Bray, F. Lyon, 2013, France: International Agency for Research on Cancer. Available 
at: http://globocan.iarc.fr/Default.aspx [ii] Global surveillance of cancer survival 1995–
2009: analysis of individual data for 25 676 887 patients from 279 population-based 
registries in 67 countries (CONCORD-2), C Allemani, H Weir, H Carreira, R Harewood, 
D Spika, X Wang, et al. The Lancet, Volume 385, No. 9972, p977–1010, 14 March 
2015. [iii] EUROCARE-5-a population-based study of cancer survival in Europe 1999-
2007 by country and age. Available at: https://w3.iss.it/site/EU5Results/ [iv] Cancer 
survival in Australia, Canada, Denmark, Norway, Sweden and the UK, 1995-2007 (the 
International Cancer Benchmarking Partnership): an analysis of population-based cancer 
registry data, MP Coleman, D Forman, H Bryan, J Butler, B Rachet, C Maringe, et al. 
The Lancet Volume 377, No. 9760, p127–138, 8 January 2011. [v] Noncommunicable 
Diseases Country Profi les 2011, World Health Organization (WHO), 2011. Available 
at:http://whqlibdoc.who.int/publications/2011/9789241502283_eng.pdf 
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ED03.03 The Value of National Lung Cancer Audit Data - The UK Experience
Jesme Fox Medical Director, Roy Castle Lung Cancer Foundation, Liverpool/United Kingdom
Background Despite recent advances, lung cancer remains a disease characterised 
by negativity, late diagnosis and poor outcomes. The need for advocacy in lung cancer 
is obvious. Recent years have seen an increase in the number of organisations and 
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political parties. Although major parties have eschewed tobacco company donations 
by law or choice in recent years, influence is still peddled. To counter interference, the 
case for tobacco control was made politically impelling. That is, the community was 
perceived by political decision takers to have a desire to be rid of the harms of smoking 
that exceeds any concerns about restrictions that need to be imposed to achieve this. 
A lesson from Australia is that health professionals interested in tobacco control must 
educate communities at the same time as they seek to alter public policy.  
Keywords: Tobacco Control, Mandatory plain packaging, Tobacco price regulation, 
Tobacco counter-advertising
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ED04.02 How Can We Strengthen MD Care in Large Hospital Systems? Kathryn 
Mileham Hematology - Oncology, Levine Cancer Institute, Charlotte/NC/United States of 
America
Lung cancer remains the leading cause of cancer-related mortality in men and women. 
Since about 85% of all lung cancer care in the United States is provided in the community 
setting (1), it is imperative to optimize the delivery of accessible, high-quality lung 
cancer care in this environment. Implementation of a multidisciplinary clinic is not 
enough to strengthen physician care across large hospital systems. Many systems have 
an established weekly tumor board to review patient cases. These multidisciplinary 
conferences are a venue for involved specialties including thoracic surgery, medical 
oncology, pulmonary medicine, radiology, radiation oncology, and pathology to provide 
an opinion regarding the management of each presented case. This forum for open 
dialogue results in reinforced recommendations and streamlines patient care (2). It can 
be challenging for physicians in a community setting who are managing multiple tumor 
types to remain abreast of evolving information regarding each subgroup. Expanding 
multidisciplinary care beyond the case conference provides a more robust collaboration 
for physicians managing these patients. For physicians, journal club, continuing medical 
education programs, and standardized guidelines provide direction regarding the 
latest advances in diagnosis and management. Specifically in lung cancer, launching a 
screening program builds partnerships with radiologists pursuing early detection and 
expands relationships with other practitioners monitoring abnormal chest imaging. For 
patients, access to smoking cessation directives, chemotherapy teaching, palliative 
medicine, and survivorship programs enhances the care delivered in community lung 
cancer programs. A nurse navigator is an invaluable resource providing the patient and 
family support and education to improve the cancer experience. The navigator also 
serves as a liaison to ensure interdisciplinary coordination of cancer management. 
Clinical trials, genetic counselors, interpreters and geriatric oncologists should 
supplement well-integrated lung cancer networks. Even when all of these components 
are implemented into a community lung cancer program with the goal to provide the best 
care, if the core physician care is not strengthened as a part of this process, in a large 
hospital system, the program will fall short. Thus it is just not what should be executed 
but how. In large hospital systems, clinicians can become engaged through regional 
councils, designed to establish the aims of a cohesive lung cancer program and to create 
a model that will service these recommendations (3). Allowing system-wide participation 
in customizing the organizational structure of a lung cancer program will result in team 
development. If team is defined as “a group of people with complementary skills who are 
committed to a common purpose, performance goals, and approach, for which they hold 
themselves mutually accountable” (4), then it seems that strengthened care is inevitable. 
In a large health system, physician teams need to have shared goals and values, need to 
understand and recognize the competencies of other team members, and need to learn 
from other disciplines and respect their different views and perspectives. Individual team 
members may need to reassess exclusive claims to specialist knowledge and authority 
in order to form effective multidisciplinary teams which can provide the best care. By 
establishing a one-tiered system, physicians of various expertise find a comfortable 
niche that is not rewarded by self-promotion. Some physicians may maintain a more 
traditional generalized oncology clinic. Other physicians may adopt a more academic 
practice with subspecialty care, clinical trial participation, and literature publications. 
Collegiate collaborations between these two models strengthen physician care 
because the gap between private practice and academics is bridged within the same 
system. Because tumor boards provide multidisciplinary meetings but not necessarily 
multidisciplinary care, tumor boards may validate physician care but not necessarily 
strengthen it. A physical multidisciplinary clinic is not required to achieve this success. 
Instead, a solid team of engaged members focused on a specific disease will enrich the 
program. Routine meetings of a disease-specific section open to all interested provide 
a forum to review comprehensive needs for lung cancer patients. When a consistent 
message is issued from the group, physician care is strengthened. Telephone, video, 
and internet access to all disease-specific section meetings encourage participation. 
Communication facilitated by technology is the backbone to the success of this linked 
enterprise. The format of routine section meetings provides the venue to shift the “what” 
into the “how.” Announcements for lung cancer events are widely distributed. Consensus-
driven standard algorithms of care are reviewed and updated. Finally, research options 
are reassessed. Integration of clinical trials in the community setting is necessary to 
1010 3. GLCC website – Global Lung Cancer e-Atlas. http://www.lungcancercoalition.org 
4. Health and Social Care Information Centre, National Lung Cancer Audit annual reports, 
via: http://www.hscic.gov.uk/lung 5. Roy Castle Lung Cancer Foundation, Leading 
the information revolution in lung cancer intelligence: why the National Lung Cancer 
Audit is the key to transforming lung cancer outcomes, January 2014. 6. Roy Castle 
Lung Cancer Foundation’s Smart Map. http://roycastle.org/news-and-campaigning/
campaigns/interactive-map 7. Be Clear on Cancer – Lung Cancer campaign, via 
http://www.campaigns.dh.gov.uk/category/beclearoncancer/ 8. Roy Castle Lung 
Cancer Foundation, Explaining variations in lung cancer in England, July 2011 9.Roy 
Castle Lung Cancer Foundation, Explaining variations in lung cancer in Scotland, 2011 
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ED03.04 Advocating for Tobacco Control - The Australia Experience Matthew 
Peters Respiratory Medicine, Concord Hospital, Concord/NSW/Australia
Lung cancer was a rarity a century ago. A dramatic increase in the use of tobacco, in 
the form of cigarettes, and the science-based reformulation of tobacco that renders 
the modern cigarette so addictive, the world would not be in the grip of the current lung 
cancer epidemic. Several other critical factors contributed. These include ready access 
for sale and purchase, few limitations on time and place of tobacco use and highly skilled 
promotion and marketing. This combination of corporate success and health tragedy 
was supported by carefully orchestrated public disinformation and the achievement and 
maintenance of political influence. It follows from these observations that reversing the 
course of this epidemic requires that each of these be addressed. Now that legislation 
for the introduction of mandatory plain packaging of tobacco products has been passed 
in Ireland and the United Kingdom, Australia is not unique in any single tobacco control 
action. However, it has been innovative and the extent and breadth of activity is world-
leading. A non-exhaustive list of innovations includes 
Pack warnings and regulation 
Simple text messages(1972) 
Rotating text messages 
Graphic health warnings(2004) 
Mandatory plain packaging(2012) 
Product and sale restrictions  
Public information on tar content 
Restrictions on sales to minors 
Prohibition of “kiddy-packs” with <20 cigarettes 
Smoke-free indoors policy - non smoking in  
Workplaces (Federal Government initially in 1985) 
Domestic aircraft(1987) 
Public transport vehicles (bus/train/tram) 
Large shopping centres 
Motor vehicles carrying cars 
Indoor restaurants/bars 
Hospitals and health centres 
Smoke-free outdoors policy  
Al fresco dining 
Sports stadiums 
Children’s play areas 
Beaches and parks 
Railway stations and bus/tram stops 
Counter-advertising  
First TV campaign in late 1970’s. Several innovative TV and radio campaigns since 
including “Every cigarette is doing you damage”. Aims were to broaden knowledge of 
harms and bring risk into the present 
Tobacco Advertising and Promotion Restriction  
Voluntary banning of tobacco advertising by the Medical Journal of Australia 
Banning TV and radio and later print advertising 
Elimination of sports and arts sponsorships
Price and taxation  
Introduction of hypothecated tax to replace tobacco sponsorship income 
Removal of tobacco from consumer price (inflation) index calculation 
Aggressive tax increases (current Marlbro 20’s > $US25) From time to time, 
opportunistic targeting a single state or local government entity, aimed at a specific 
innovation, has established a policy precedent. This has been achieved with a relatively 
small group of tobacco control advocates and effective health NGOs. Effective use 
of media has been critical in the process. The tobacco industry, in tactics used to 
oppose effective interventions, is quite predictable. Separate from simplistic themes 
of civil liberties, crystallised in the absurdist “nanny-state” concept. Common themes 
used to oppose evidence-based actions, include the threat of large legal penalties, 
spectre of illicit tobacco sales and the harm potentially caused to Australia more 
generally as a place to do business. Effective lobbying campaigns can be transplanted. 
For example, promoting the right of workers to work long hours in safe workplaces 
can aid arguments in favour of smoke-free dining and other public places. All of the 
policy victories achieved are within the scope of aims of the Framework Convention on 
Tobacco Control. This remains the international template and its objects are proven 
able to be implemented. These policy innovations have been achieved despite tobacco 
industry interference via the political process and well-documented donations to major 
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to those with language concordant providers. This effect was mitigated with the use of 
a clinic interpreter4. This language barrier includes key signage and patient information 
documents. The Joint Commission has published guidance in establishing effective 
communication, both written and verbal, for diverse patient populations5. Finally the 
clinical (patient- provider encounter) level must be addressed. When cultural differences 
between provider and patient are not fully understood it becomes a barrier to effective 
care. Diverse patient populations have specific health beliefs; such as use of home 
remedies, attitude toward medical care and medical practices, level of trust in doctors 
and the health system. Each of these differences, if not understood, can interfere with 
effective care. The Witness Program is an example of a successful, culturally competent 
approach to health care delivery6. Although African-American (AA) women have high 
rates of breast cancer, screening with mammography was low in this population. To 
better understand the cultural barriers associated with breast cancer screening among 
this group, investigators performed multiple focus groups. By directly interviewing 
AA women in the community barriers to breast cancer screening were identified. The 
Witness Program® turned cultural barriers into culturally based interventions. Key to 
this project are Witness Role Models – African American breast and cervical cancer 
survivors who talk about their experiences with other AA women in a community setting. 
This approach has led to improved rates of breast cancer screening among the women 
who participated in this educational program. Training of medical providers in cultural 
competency is necessary to effectively treat diverse patient communities. Efforts to 
improve the care of diverse patient populations will increase the lung cancer cure rate. 
This begins by having a clear understanding of the community that is served, including 
health care values and beliefs, predominate language used, and any barriers to health 
care that are present. Training for staff in cultural competency and the ability to evaluate 
the perceived quality of health care of diverse populations is needed to provide the 
best care. References 1. Li et al. Journal of Thoracic Oncology, 2015; 10:256-263. 2. 
Bach PB et al. N Engl J Med. 1999; 341:1198-1205. 3. Koshy et al. Journal of Thoracic 
Oncology. 2015; 10:264-271. 4. Ngo-Metzger et al. J Gen Intern Med. 22(suppl 2):324-
30. 5. The Joint Commission: Advancing Effective Communication, Cultural Competence, 
and Patient- and Family-Centered Care: A Roadmap for Hospitals. Oakbrook Terrace, 
IL: The Joint Commission, 2010. 6. Bailey et al. J Natl Med Assoc. 2000; 92:136-142. 
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ED04.04 Differences in Rural/Urban Care Craig H. Reynolds Medical Director, 
Lung Cancer, Us Oncology Research/McKesson Specialty Health, Ocala/FL/United States of 
America
The rapid changes in lung cancer treatment with the development of new treatment 
modalities such as immunotherapy, coupled with the emergence of low-dose CT screening 
for lung cancer have made mutli-modality thoracic oncology programs even more vital 
than previously. However, almost all of these programs are in urban areas, despite a 
great need in rural communities. Epidemiologic studies show that rural areas have higher 
lung cancer and all cancer mortality than urban areas (Singh et al J Ca Epidemiol 2011) 
with even greater disparity in minority and socio-economically disadvantaged rural 
populations. An analysis of the SEER database found that rural residence had no impact 
on stage-specific lung cancer survival with the exception of Stage I (Atkins et al, Am J Crit 
Care Med 191:2015;A3595). Tobacco use is more prevalent in rural communities and 
may account for much of the higher lung cancer mortality seen in these communities 
(ALS monograph, Cutting Tobacco’s Rural Roots: Tobacco Use in Rural Communities, 
2014). It does appear that rural residents are more likely to be diagnosed with an 
advanced stage of lung cancer than their urban peers (Wen et al, Ann Pub Health and 
Res 2015 2:1011 ; Johnson et al, Lung Cancer 2014 83:401-7). Survival was lower in 
rural areas with greater poverty and less educated residents. In addition, rural residents 
were less likely to receive radiotherapy and chemotherapy, and those in less educated 
areas were less likely to undergo surgery or chemotherapy (Johnson et al). Another study 
found poorer outcomes in Stage I lung cancer in rural areas, perhaps due to less access 
to surgical care (Atkins, op cit). Kim et al compared barriers to clinical trial participation 
in rural and urban areas of South Carolina (Kim et al, J Comm Health 2013). They found 
no significant difference between rural and urban residents in willingness to participate 
in clinical trials but found that rural residents perceived less access to less access to, 
and awareness and knowledge of, clinical trials. A study funded by the Rand Corporation 
found that physicians who participated in tumor boards weekly were more likely to enroll 
lung cancer patients in clinical trials (Kiehl et al, J Onc Practice 2015 11:E267-78). 
This suggests that rural thoracic oncology programs are likely to improve clinical trial 
participation by rural residents by improving access and physician particiapation. It is not 
just access to therapeutic modalities in lung cancer that differs between rural and urban 
areas; supportive/ palliative care is also different. An analysis of the SEER database 
found disparities in end of life care as well. Medicare beneficiaries in rural areas had more 
ER visits in the last 90 days of life than urban residents. Urban residents had more ICU 
days in the last 90 days of life and were more likely to be enrolled in hospice programs. 
Minority and lower socioeconomic patients were less likely to use hospice and had more 
ICU days, inpatient days, and ER visits in the last 90 days of life (Nayar et al, J Comm 
Health 2014 39:1012-9). These disparities are of particular note since several studies 
have shown that early palliative care improves survival in lung and other cancers. Greater 
prevalence of rural thoracic oncology programs may improve access to potentially 
curative modalities, particularly for early stage disease. Given the higher prevalence 
of tobacco use in rural populations, these programs should ideally include smoking 
cessation efforts. Since rural residents are more likely to be diagnosed with advanced 
lung cancer, the implementation of low-dose CT screening is likely to be particularly 
beneficial in these communities. It seems likely that rural areas with thoracic oncology 
programs will have better rates of clinical trial access and participation. Incorparation of 
strengthen care even in larger systems that may otherwise feel that care is already 
comprehensive. The best academic programs are often built on a reputation of offering 
research and clinical trial opportunities. Because the majority of patients with lung 
cancer are never seen in major academic centers, it is imperative that community 
programs become involved in clinical trials. Common protocol review (again maximizing 
participation with technology access) broadens interest. A centralized trials unit blends 
the team with appropriate system-wide delegation of resources. Utilization of a common 
internal review board allows for trials to open efficiently as well as simultaneously at 
multiple sites within the larger system. Local access obviates the need for travel, 
enhances program visibility, and provides ongoing relationships with the larger worldwide 
research community. Ultimately, a larger hospital system will benefit from restructuring 
the community. Physician care can be effectively strengthened not under the traditional 
hub-and-spoke model but instead as a cancer institute “without walls” (5). Regional 
councils, subspecialty sections, and multi-site clinical trial options under common review 
are all successful when system-wide participation is encouraged and when access is 
easily provided via advanced technology. Consider the large hospital organization as a 
system not a center. Aim to decentralize cancer care facilities by providing as many of the 
programs of a tertiary referral center throughout the region, limiting patient travel and 
lost time while still maintaining balanced quality (6). In order strengthen physician care 
in large hospital systems, growth measured as patient encounters is not as productive 
as reorganizing the care team. You can have “many” but still be “One.” 1. American 
College of Surgeons: Commission on cancer national cancer data base. Benchmark 
Reports v1.1 2. Fischel RJ, Dillman RO: Developing an effective lung cancer program in 
a community hospital setting. Clin Lung Cancer 10: 239-243, 2009 3. Dahele M, Ung Y, 
Meharchand J, et al: Integrating regional and community lung cancer services to improve 
patient care. Curr Oncol 14: 234-237, 2007 4. Carrier JM, Kendall I: Professionalism 
and interprofessionalism in health and community care; some theoretical issues. 
Interprofessional Issues in Community and Primary Health Care, 1995 5. Goldberg P: 
The Raghavan experiment. The Cancer Letter 39: 1-9, 2013 6. Raghavan D: Costs of 
cancer care: rhetoric, value, and steps forward. Semin in Oncol 40: 659-661, 2013 
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ED04.03 Treating Diverse Communities Laurie Carr Medicine, National Jewish 
Health, Denver/CO/United States of America
Minority populations often suffer disproportionately from lung cancer due to 1) lower 
levels of education 2) jobs with higher occupational hazards 3) housing in areas with higher 
environmental hazards and 4) economic disadvantage. Lower socioeconomic status 
leads to higher rates of uninsured or underinsured populations living in neighborhoods 
with less access to quality health care. The recently published “Neighborhood 
Deprivation Study of Lung Cancer”, demonstrated living in a social-economic depressed 
environment, defined as high rates of low education status (< 10 years formal education), 
low income (less than 50% of individual median income), high unemployment and high 
rates of social welfare assistance, leads to higher incidence and mortality from lung 
cancer1. The lung cancer mortality was 13 per 1000 in high deprivation neighborhoods 
vs 8 per 1000 (OR 1.6) in low deprivation neighborhoods. Minority communities also 
have more barriers to effective cancer care. Barriers include differences in culturally 
related health beliefs, (values and preferences that are not understood by health care 
providers and lead to decreased compliance with medical recommendations), language 
discordance, provider stereotypes that lead to health care disparities, limited clinic hours 
of service that do not account for community work patterns, etc. Health care disparities 
in lung cancer have been studied in treatment decisions for early-stage disease. Bach et 
al. studied the differences in survival of Medicare beneficiaries with stage I or II NSCLC 
based on race2. The five year survival of black patients was significantly less than white 
patients, 26 % vs. 34.1% (p < 0.001). The difference in survival could be accounted for 
by the lower number of black patients treated with surgery, 64.0 % vs. 76.7 % for white 
patients. Although the difference in treatment had an impact on survival, the authors 
could not determine if this was due to patient held health beliefs regarding surgery and/
or black patients being offered surgical resection less often. A similar outcome was 
seen by Koshy et al. when examining the National Cancer Database for differences in 
radiation treatment modalities offered for early stage disease3. Socioeconomic factors, 
including insurance type and race/ ethnicity, were significant variables in determining if a 
patient received no radiation therapy, conventional radiation therapy or stereotactic body 
radiation therapy. Each of these barriers is important to study and overcome as efforts 
to improve the treatment of diverse patient populations will increase the lung cancer 
cure rate. Applying cultural competence to cancer care delivery will improve adherence 
to screening and prevention measures, improve compliance to medical treatment and 
necessary follow-up, and reduce health care disparities. Effectively treating diverse 
populations of lung cancer patients requires change on multiple levels within healthcare 
delivery. On an organizational level, the leadership and workforce must allow for 
greater minority representation, to remain connected to the communities they serve. 
For minority patients, racial concordance between patient and physician is associated 
with greater patient satisfaction and higher self-reported quality of care. Specific quality 
measures for diverse patient populations must be developed. For example, patient-
reported health care quality surveys can be adapted to better evaluate culturally diverse 
populations. Ultimately, health care organizations benefit from establishing ongoing links 
for consultation with representatives from diverse communities. On a structural level, 
work-processes can be adapted to aid diverse patient populations. Often the intake 
process is difficult or cumbersome for minority patients to navigate. Lack of interpreter 
services or inappropriate health care education materials can limit the effectiveness of 
the clinic visit. Ngo-Metzger et al. studied the effects of language discordance between 
patient and provider within a Chinese and Vietnamese population in the US. Patients 
with language discordant providers reported receiving less health education compared 
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Via Oncology is affiliated with the University of Pittsburgh Medical Center (UPMC) and 
University of Pittsburgh Cancer Institute (UPCI). The Via Oncology Pathways were 
developed in 2005 to ensure high quality and standardized care in medical and radiation 
oncology across UPMC/UPCI facilities and now has grown to include practices from 20 
states. Disease committees, consisting of physicians from all participating practices, 
have developed guidelines covering more than 90% of cancers to demonstrate value 
to patients, payers and referring physicians. Guidelines are available to participating 
providers only. 
Overcoming Barriers and Resistance Many reasons for why physicians do not follow 
guidelines have been noted in the literature, including: lack of clarity; length of guidelines; 
guideline format; lack of awareness; lack of familiarity; lack of agreement with the 
evidence; lack of outcome expectancy; lack of self-efficacy; inertia of previous practice; 
organizational constraints; excessive frequency of revision; and external barriers5-8. 
Kaster et al recently published data on key domains (stakeholder involvement, evidence 
synthesis, considered judgment, implementation feasibility, message, and format) 
related to positive implementation of pathways5. These domains largely are nested within 
two, broad categories: content creation and communication of content5. 
Clinical Trials One aspect that is not as inclusive in all clinical pathways is access 
or information to clinical trials. This content is an entirely different aspect to clinical 
pathways as different groups value clinical trials access differently. National accrual 
rates to clinical trials are low9,10. Barriers to clinical trial participation are noted on the 
patient, physician and system level. Clinical pathways that incorporate clinical trials 
may benefit the patient by increasing physician knowledge of available trials and may 
benefit the overall clinical trial by increasing accrual rates. EAPathways, Levine Cancer 
Institute, Carolinas HealthCare System We have developed in-house clinical pathways 
which include not only treatment pathways to assist clinicians, but also have a number of 
additional features. These include access to documents, educational resources, clinical 
trials information and communication to colleagues. The pathways on this proprietary 
system are developed by our disease-specific sections and housed on our system 
intranet. 
Conclusions Clinical pathways are an integral part of patient management. Their 
utilization is increasing and additional groups are developing these. Functionality and 
adaptability will be key, especially in the oncology realm, as changes in molecular 
testing and treatment options are occurring at a faster than ever rate. Educating our 
practitioners and empowering their ability to accurately assess and treat patients with 
cancer will enable consistent and efficient care. 
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of America, 3Mesothelioma Applied Research Foundation, Alexandria/VA/United States of 
America, 4NYU Langone Medical Center; Perlmutter Comprehensive Cancer Center, New 
York/AL/United States of America
Background: From the moment of diagnosis, malignant mesothelioma (MM), decreases 
health-related quality-of-life (QOL) in patients and their caregivers. In addition to the 
symptoms of the disease itself, aggressive treatments options such as surgery, radiation, 
and chemotherapy can cause side effects which border on the intolerable. Specifically, 
early effective palliative care into these programs may improve outcomes and help reduce 
the disparities seen in end of life care and survival in rural areas. However, resources are 
often limited in small rural hospitals, so it may be difficult to provide all of these services. 
Keywords: rural thoracic access disparities
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Introduction and Rationale Assessment and treatment of the cancer patient 
continues to increase in complexity. Some oncologists have subspecialized in their 
disease discipline, allowing for a greater depth of knowledge in that particular cancer 
but not having the breadth of expertise over numerous cancers. The majority of 
cancer treatment is delivered in the community-based setting where most oncologists 
practice general oncology. This has created a need for treatment guidelines which 
help oncologists manage patients in a standard approach. The evolution of treatment 
guidelines or pathways has several purposes. There has been much research in justifying 
the implementation of treatment pathways as they lead to consistent care, tend to lower 
healthcare costs overall, and influence outcomes of care1-3. However, each individual 
system, hospital, or physician will have their own purpose for utilizing pathways, ranging 
from education of assessment and treatment recommendations to providing evidence 
to payers for treatment. The development of clinical pathways requires a predetermined 
strategy. Reports have stressed the need for transparency, inclusiveness, disclosure 
and frequency of meetings4,5. This then requires a team to translate the results of these 
meetings into disseminated information for the clinical teams. The Institute of Medicine 
published recommendations in 2011 on how to develop these clinical pathways4. Various 
other organizations have published guidelines, such as the National Comprehensive 
Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), European 
Society of Medical Oncology (ESMO), Cancer Care Ontario, Cancer Council Australia, 
and Via Oncology. 
National Comprehensive Cancer Network (http://www.nccn.org/about/default.aspx)  
Clinical Practice Guidelines in Oncology
The NCCN is the most comprehensive set of guidelines in the United States, covering 
97% of all cancers. Guidelines cover the entire cancer spectrum, from prevention to 
survivorship issues, and are evidence-based and continually updated. Guideline content 
is consensus based and developed by one of 47 panels consisting of multidisciplinary 
and disease-specific oncologists and researchers. Within the guidelines, a variety of 
content can be utilized, including algorithms or decision pathways and discussion text 
summarizing historical and current data. 
American Society of Clinical Oncology (http://www.instituteforquality.org/practice-guidelines) 
Clinical Practice Guidelines
ASCO currently has 11 topic areas in which clinical practice guidelines are available for 
both solid and hematologic malignancies (e.g. use of diagnostic testing and predictive 
assays, disease-specific treatment, supportive care and survivorship). Each year, ASCO 
solicits guideline proposals from its members. Expert panels, consisting of oncologists, 
nurses, pharmacists, and practice managers approve proposal topics and develop the 
guidelines. Anyone has the opportunity to comment on or provide new evidence for use in 
the guidelines through the ASCO Guideline Wiki page (https://pilotguidelines.atlassian.
net/wiki/display/GW/ASCO+Guidelines). 
European Society of Medical Oncology (http://www.esmo.org/Guidelines)  
Clinical Practice Guidelines 
The ESMO Clinical Practice Guidelines consist of 60 guidelines on cancers of the breast, 
lung, gastrointestinal tract, head and neck, and more, as well as supportive care and 
bone health. The ESMO Guidelines Committee is comprised of a Subject Editor and other 
leading experts and they are charged with authoring, publishing, and disseminating the 
full clinical practices guidelines and Pocket Guides. 
Cancer Care Ontario (https://www.cancercare.on.ca/cms/One.
aspx?portalId=1377&pageId=7582)  
Program in Evidence-Based Care (PEBC) 
The Cancer Care Ontario’s PEBC is a program of the Ontario provincial cancer system, 
with support from the Ontario Ministry of Health and Long Term Care. Guidelines focus on 
all stages of cancer, including prevention, screening, diagnostic assessment, treatment, 
palliative care and survivorship. The PEBC consists of multidiscipline panels (disease-
specific and modality-specific guideline development groups) consisting of 200+ 
physicians, other healthcare providers, and methodologists. 
Cancer Council Australia (http://www.cancer.org.au/health-professionals/clinical-guidelines/) 
Clinical Guidelines Network 
Cancer Council Australia (CCA) is Australia’s national non-government cancer 
organizations. CCA has published full and condensed guidelines on cancer screening and 
treatment of lung, esophageal, endometrial, sarcoma, and prostate cancers. The CCA is 
currently working to transform these guidelines in to a web-based format 
Via Oncology, LLC (http://viaoncology.com/)  
Via Oncology Pathways
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severe rates of adverse events than their younger counterparts, yet many derive 
benefit from therapy. The challenges of treating older patients remain notable largely 
because enrollment in cancer clinical trials tends to show an underrepresentation of 
older patients. In this context, this talk with discuss 1) the ongoing challenges faced 
in treating older patients with lung cancer; 2) the relevant and instructive data derived 
to date from clinical trials; 3) the role of the comprehensive geriatric assessment; and 
4) general recommendations on approaches to treating elderly lung cancer patients. 
Keywords: lung cancer, comprehensive geriatric assessment, elderly
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Non-small cell lung cancer is a disease of the elderly. In Australia in 2010, 84% of new 
lung cancers in men and 81% in women were diagnosed in people aged 60 years and 
older. The definition of “elderly” in the lung cancer radiotherapy literature varies with 
the lower limit ranging from 65 years (1) up to 85 (2). Older patients are not only more 
likely to develop toxicities of intensive treatment, but also to have less physiologic 
reserve to tolerate these toxicities. They include fatigue, pneumonitis, esophagitis and 
myelosuppression. Although older patients may have good performance status (ECOG 
0-1), and be judged suitable for radical treatment, they may become deconditioned 
and harmed by treatment. Identification of these patients pre-treatment is challenging. 
An instrument to measure “frailty”, such as that devised by Fried et al (3) to predict 
post surgery complications would be useful in the radiotherapy setting. Frailty should 
be distinguished from performance status, which is only one measure of physiologic 
reserve; Fried’s frailty score includes measures of weight loss, grip strength and walking 
speed as well. Given the above, it is not surprising that older patients have worse survival 
than younger patients (4). Partly this may be due to a higher likelihood of suboptimal 
treatment (radiotherapy alone rather than concomitant chemoradiotherapy), and partly 
to the competing risks of non-neoplastic comorbidities. Once survival is adjusted for 
these effects, age is no longer associated with increased risk of death (4). It is generally 
agreed that functional rather than chronological age is a more important consideration 
in patient selection for radical treatment (2, 5). Age is certainly not a contraindication 
to treatment with SABR for stage I disease (6). The choice of chemotherapy to 
accompany radiotherapy in pateints with locally advanced disease is unclear because 
of a lack of trials performed specifically in a geriatric population. Carboplatin is usually 
preferred to cisplatin in patients over 70 because of its more favorable toxicity profile. 
The evidence for two drugs rather than one is limited. In a study of the Japan Clinical 
Oncology Group limited to patients 70 years and older, daily carboplatin added to 60 Gy 
of radiotherapy improved median survival from 16.9 to 22.4 months (p=0.02) compared 
with radiotherapy alone (7). Performance status, in the absence of a validated frailty 
score, remains a critical determinant of suitability for (chemo)radiotherapy. Patients with 
performance status ECOG 2 or worse seem not to benefit from treatment intensification, 
including when the intent of treatment is palliation (8). Comorbidity scores (Charlson, 
Colinet) appear to be closely linked to performance status, but there is insufficient 
evidence to support their use in clinical decision making. Diminished pulmonary function 
is sometimes thought to be a contraindication to radical radiotherapy - yet patients 
who are unfit for surgery, usually because of diminished cardiopulmonary reserve, are 
the very patients most likely to be referred for stereotactic ablative body radiotherapy 
(SABR). In fact, some studies suggest that patients developing symptomatic radiation 
induced lung injury were more likely to have a higher FEV1(9). However caution should 
be exercised in treating patients with pre-existing interstitial lung disease, including 
with SABR (10). Our approach is to judge a patient’s suitability for treatment based on 
their biological age. In older patients with locoregional disease and performance status 
ECOG 0-1 who are suitable for radical treatment, we would recommend full dose SABR 
for patients with peripheral stage I disease, and chemoradiation for locally advanced 
disease, 60 Gy with concomitant carboplatin and paclitaxel. Patients who are not fit 
for chemotherapy are treated with radiotherapy alone. If there is concern regarding the 
patient’s capacity to undergo a six week course, we either review the patient at 40 Gy , 
and if there is evidence of diminished tolerance, cease at that point. If there is concern 
that a patient will not tolerate a risk of grade 3 esophagitis, but the aim is improved local 
control rather than paliiation, we would offer a split course to allow for mucosal recovery 
(20 Gy in 5 fractions, followed by a 4 week break, then another 20 Gy). Although thought 
to be suboptimal because of the risk of repopulation, a split course schedule is less 
likely to produce high grade esophagitis than 36 Gy in 12 continuous fractions. For older 
patients with diminished performance status (ECOG 2 or greater) and for whom palliation 
is the objective, 20 Gy in five fractions is a reasonable option, and little more demanding 
on resources and patient inconvenience than a large single dose. References 1. Sigel 
K, Lurslurchachai L, Bonomi M, Mhango G, Bergamo C, Kale M, et al. Effectiveness of 
radiation therapy alone for elderly patients with unresected stage III non-small cell lung 
cancer. Lung Cancer. 2013;82(2):266-70. 2. Khor RC, Bressel M, Tedesco J, Tai KH, Ball 
DL, Duchesne GM, et al. Tolerability and outcomes of curative radiotherapy in patients 
aged 85 or more years. Med J Aust. 2015;202(3):153-5. 3. Makary MA, Segev DL, 
Pronovost PJ, Syin D, Bandeen-Roche K, Patel P, et al. Frailty as a predictor of surgical 
outcomes in older patients. J Am Coll Surg. 2010;210(6):901-8. 4. Aridgides PD, Janik 
A, Bogart JA, Duffy S, Rosenbaum P, Gajra A. Radiotherapy for stage III non-small-cell 
lung carcinoma in the elderly (age >/= 70 years). Clin Lung Cancer. 2013;14(6):674-9. 5. 
Wanders R, Steevens J, Botterweck A, Dingemans A-MC, Reymen B, Baardwijk Av, et al. 
Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: 
A prospective population-based study. European Journal of Cancer. 2011;47(18):2691-7. 
6. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman B, Senan S. Treatment of stage 
I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic 
radiotherapy versus surgery. Radiother Oncol. 2011;101(2):240-4. 7. Atagi S, Kawahara 
M, Yokoyama A, Okamoto H, Yamamoto N, Ohe Y, et al. Thoracic radiotherapy with or 
without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a 
chemotherapy is associated with side effects such as fatigue, nausea, vomiting, and 
systemic pain which has been described as unpleasant and stressful. The side effects of 
treatments can be burdensome enough to lead to noncompliance or outright refusal of 
continuation of care. Data from 13 frequently cited QOL studies conducted in the United 
States and Europe between 1990 and 2009 focus on chest pain and shortness of breath 
as the two chief symptoms of pleural mesothelioma. The largest QOL study to date, 
conducted across five continents, enrolled 495 patients in a multicenter study evaluating 
MM using the LCSS (lung cancer symptom scale). Investigators reported the most 
common symptoms as: fatigue (94%), dyspnea (89%), loss of appetite (86%), Chest pain 
(85%), cough (75%), and hemoptysis (24%). Ninety-two percent of patients experienced 
three or more above symptoms. Research on the psychological aspects of patients living 
with mesothelioma has shown their disregard for their exposure to asbestos in respect to 
their diagnosis. One such study investigated the reactions of 38 patients upon diagnoses 
with mesothelioma. Interestingly, although most patients had exposure to asbestos, 
only 17% of patients reported being concerned about their health prior to diagnosis, 
and, perhaps most interestingly, 65% of those with asbestos exposure denied anger 
towards the asbestos industry. Such studies’ preliminary findings suggest the need for 
better information about asbestos and mesothelioma, especially for high-risk individuals. 
Mesothelioma has a number of emotional consequences as well. A study conducted by the 
British Lung Foundation (BLF) reported significant impairment of emotional function and/
or emotional state in patients with mesothelioma and their family members. The BLF’s 
study further reported a more positive response amongst patients versus caregivers in 
regards to supportive treatment to their emotional functioning. However, the authors did 
not provide a definition for significantly impaired emotional functioning, opacifying the 
results of such support. Recent psychological studies have demonstrated health benefits 
in cancer patients when sharing their illness experiences through online blogs. It has 
been suggested that blogging creates a survivor identity and facilitates a social support 
network for patients. Further, studies suggest that expressive writing increases self-
management of chronic pain and lowers depressive symptoms. Methods: The platform 
for the support group was remote, consisting of both online and telephone domains. 
Each participant received an email a week prior to support sessions with an access code 
to the online and phone conference systems. Participants would utilize both online and 
phone systems during sessions, which were held once a week during evenings for a total 
of 6 weeks. Sessions were guided (by a team of healthcare professionals consisting 
of: a social worker, nurse, and community group leader) and kept closed, available 
only to those affected by mesothelioma – confidentiality was kept strong to encourage 
dialogue. The only non-patient participants were the group’s facilitators. The platform 
facilitated anonymity, should a patient have wished to remain so. Session summaries 
and follow-up information were provided online after support meetings. Conclusions: 
Active participation in a guided support group allowed participants to share their feelings 
and concerns about their diagnosis without feeling judged by their peers or healthcare 
providers while getting the emotional, mental, and post-active treatment support they 
needed facilitating the transition to follow-p care. The online portion of the platform 
was particularly helpful in assuaging common negative concerns like: fear of healthcare 
provider judgment, confidentiality, self-editing, emotional backlash from loved ones, and 
disapproval of lifestyle post-active treatment. Analysis of support session dialogue allowed 
facilitators to gauge information available to patients as well as to provide information 
about life after active treatment. Online space (on our blogs) gave participants a place to 
provide more communicative responses outside the main dialogue of support sessions. 
Keywords: quality-of-life (QOL), Mesothelioma, Survivor
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ED05.06 Nurse Practitioner Michelle Turner Medical Oncology, University of Maryland 
Medical Center, Baltimore/MD/United States of America
Multi-disciplinary care has become an essential part of medicine, especially 
in oncology. This care is not limited to the disciplines of medical, surgical and 
radiation oncology. We as providers must start, if we haven’t already, expanding 
our thinking to involving other disciplines such as nutrition, social work, respiratory 
therapy, palliative care, physical therapy, psychiatry etc. Even though medicine 
is becoming more personalized with targeted therapies, we cannot allow this to 
narrow our focus of treating the patient as a whole. Our panel of experts from 
different disciplines will review and discuss lung cancer and mesothelioma cases 
highlighting the importance of a multi-disciplinary approach to patient care. 
Keywords: lung cancer, Mesothelioma, Allied health care, Multi-disciplinary
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ED06.01 Medical Oncology Aminah Jatoi Oncology, Mayo Clinic, Rochester/MN/United 
States of America
In the United States, almost 50% of lung cancer patients are 70 years of age or older. 
Moreover, shifting demographics in the United States -- indeed, across the world 
-- suggest that oncologists will be seeing many more older patients with lung cancer 
in years to come. With cancer therapy, older patients often suffer higher and more 
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features which drive these cancers and make them distinct from lung adenocarcinomas. 
I will discuss specific subtypes of squamous cancers, animal models of the disease and 
associations among genomic features and patient outcomes. I will discuss therapeutically 
relevant genetic alterations and efforts aimed at exploring these targets both pre-clinically 
and clinically with an emphasis on FGFR pathway genes. I will discuss heterogeneity and 
adaptive responses to therapy in squamous cell carcinomas as potential challenges to 
the treatment paradigms which have been successful in adenocarcinomas and these 
concepts in the context of the recent introduction of immunotherapeutic approaches. 
Keywords: Genomics, Squamous cancers, Targeted Therapies
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Oncology, The Ottawa Hospital Cancer Centre, Ottawa/ON/Canada, 2Medical Oncology, The 
Ottawa Hospital Cancer Centre, Ottawa/Canada
Squamous cell carcinoma of the lung accounts for 20-30% of all non-small cell lung 
cancer (NSCLC). Until recently, treatment options for advanced squamous NSCLC 
(sqNSCLC) were limited. Compared to non-squamous NSCLC, standard care of sqNSCLC 
was restricted to first-line platinum-based doublet chemotherapy and second-line 
docetaxel or the epidermal-growth factor receptor (EGFR) inhibitor, erlotinib, and did not 
include pemetrexed because of inferior efficacy1, bevacizumab because of increased risk 
of pulmonary hemorrhage2 or agents active against known oncogenic driver mutations. 
Prompted by the high levels of EGFR overexpression in sqNSCLC and encouraging 
activity of EGFR-targeted therapies in patients with squamous histology 3,4 EGFR-inhibition 
trials limited to patients with sqNSCLC were initiated, the results of which are redefining 
the treatment of sqNSCLC. In the first-line setting, the addition of the second-generation 
recombinant human IgG1 EGFR monoclonal antibody (Mab), necitumumab, to gemcitabine 
and cisplatin has been shown to improve overall survival (OS) 11.5m vs 9.9 m (HR: 0.84, 
95%CI: 0.74-0.96) in the phase III open-label SQUIRE trial, with comparable adverse 
events (AE) leading to treatment discontinuation in both treatment arms.5 The better 
tolerability of necitumumab over the first-generation chimeric EGFR Mab, cetuximab, is 
supported by the similar OS efficacy in patients with good (PS: 0-1) (HR: 0.85, 95%CI: 
0.74-0.98) and poor performance status (PS=2) (HR: 0.78, 95%CI: 0.51-1.21), in the 
absence of additional safety risk.6 In fact, in SQUIRE, necitumumab was notably more 
effective at higher levels of baseline symptom severity7 , which is contrary to the belief 
that patients with sqNSCLC deteriorate too quickly to benefit from combination 
approaches. In the second-line setting, the newer second-generation EGFR small 
molecule inhibitor, afatinib, has also been shown to improve OS. Most recently, the 
results of the phase III LUX-Lung 8 trial of afatinib vs erlotinib in patients with sqNSCLC 
progressing after four cycles of platinum-based chemotherapy have been published, 
demonstrating improved OS with afatinib 7.9m vs 6.8m (HR: 0.81, 95%CI: 0.69-0.95), 
with similar adverse events profiles noted between groups.8 Based on these results, 
afatinib is clearly a treatment option for patients in the second-line management of 
sqNSCLC. Together, the recent results of these small molecule and MAb anti-EGFR 
studies support the continued relevance of EGFR as a target in the treatment of sqNSCLC 
and are shaping management strategies. Despite being a hallmark of cancer, the 
inhibition of angiogenesis has historically proven challenging in the treatment of patients 
with sqNSCLC due to the central location of these tumors and their close proximity to 
large blood vessels in the chest wall, and has been associated with an increased risk of 
bleeding. Findings from newer second-generation angiogenesis inhibitors, however, show 
comparable levels of gastrointestinal and respiratory tract bleeding events across all 
NSCLC histologies. 9 Compared to placebo, the anti-VEGFR-2 IgG MAb, ramucirumab, has 
recently been shown to improve progression-free survival (PFS) 4.5m vs 3.0 m (HR: 0.76, 
95%CI: 0.68-0.86) and OS 10.5m vs 9.1m (HR: 0.86, 95%CI:0.75-0.98) in patients with 
advanced NSCLC progressing after first-line platinum-based chemotherapy, with 
significant improvements in patients with squamous histology in terms of overall objective 
response (ORR) (26.8% vs 10.5%, p=0.001), disease control rate (59.9% vs 45%, 
p=0.015) and PFS 4.2m vs 2.7m (HR 0.78, 95%CI0.61-0.96) and a numerically superior 
OS benefit 9.5m vs 8.2m (HR: 0.88, 95%CI: 0.69-1.13). 9 In Dec 2014, ramucirumab 
received FDA approval for use with docetaxel in the second-line management of advanced 
NSCLC, including patients with squamous histology. Finally, the inhibition of T-cell 
activation through programmed death (PD-1) receptor interaction with the tumor 
expressing PD-L1 ligand (immune checkpoint) is a noted mechanism of tumor immune 
surveillance escape in NSCLC. From early clinical trials immune checkpoint blockade is 
an attractive therapeutic strategy in NSCLC, given its ability to activate the immune 
system and produce long-term response. In the management of sqNSCLC, the fully 
human IgG4 anti-PD-1 monoclonal antibody, nivolumab, has recently replaced docetaxel 
as the preferred second-line therapy based on the results of CHECKMATE 017 10, a phase 
III study of nivolumab versus docetaxel. Findings in CHECKMATE 017 demonstrated 
improved median OS 9.2m vs 6.0m (HR: 0.59, 95%CI: 0.44-0.79) and improved 1-year 
survival over docetaxel (42% vs 24%), with a more favorable safety profile and fewer 
treatment related grade 3/4 AE (7% vs 55%).10 With the recent FDA approval of nivolumab 
in the second-line setting in March 2015, docetaxel will likely be relegated to third-line 
therapy in the management of sqNSCLC. However, additional studies are required to 
confirm the results of CHECKMATE 017 given the lower than expected median survival 
observed in the docetaxel arm, to identify biomarkers of response, and to better define 
the unique toxicities associated with these immune-modulating agents. The last year has 
seen an unprecedented evolution in the management of sqNSCLC, with survival gains 
noted in both the first and second-line setting in randomized clinical trials. Unfortunately, 
to date the identification of oncogenic driver mutations in sqNSCLC have yet to yield the 
significant improvements seen in non-squamous histology, however it is likely that the 
relevant biomarkers of efficacy will soon be identified. Regardless, with the current 
regulatory approvals and the numerous novel agents in development, improved outcomes 
in patients with squamous cell carcinoma of the lung are anticipated. The immediate task, 
with the expanded treatment options now available for sqNSCLC, is the interrogation of 
randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). 
Lancet Oncol. 2012;13(7):671-8. 8. Strom HH, Bremnes RM, Sundstrom SH, Helbekkmo 
N, Aasebo U. How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent 
Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset 
Analysis From a Clinical Phase III Trial. Clin Lung Cancer. 2015;16(3):183-92. 9. Kong 
FM, Wang S. Nondosimetric risk factors for radiation-induced lung toxicity. Semin Radiat 
Oncol. 2015;25(2):100-9. 10. Ueki N, Matsuo Y, Togashi Y, Kubo T, Shibuya K, Iizuka Y, et al. 
Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after 
stereotactic body radiation therapy for lung cancer. J Thorac Oncol. 2015;10(1):116-25. 
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It is difficult to define what an elderly or truly “high risk” patient is in regards to offering 
surgical treatment of lung cancer. The World Health organization defines an elderly 
patient as being over age 65 although most practitioners of thoracic surgery would 
likely define an elderly patient as someone over age 70 (1) . Likewise the definition of 
a truly high-risk patient is difficult to determine. These patients are often described as 
having significant cardiopulmonary or other organ dysfunction that could be potentially 
worsened by the surgical event. In developed countries the average population age 
is increasing and the incidence of lung cancer is also increasing in elderly patients. 
Combined with the natural decline in lung and cardiac function these data suggests 
that there will likely be a steady and significant increase in elderly and high-risk patients 
who present for consideration of resection for localized lung cancer. Clinical data in 
the elderly and high-risk patients is hard to come by, as many of these patients are 
not represented in clinical trials despite the high proportion of these patients in the 
lung cancer population. The data that is available is often retrospective in nature but it 
suggests that treatment decisions in these patient groups should not solely be based on 
chronological age but should take into account the patient’s life expectancy, quality of life 
desires, presence of comorbidities, and estimated risks and benefits of the procedure 
(2). Several studies have demonstrated the feasibility of surgically treating lung cancer 
in elderly patients including octogenarians. Likewise several studies evaluating patients 
with compromised lung function and other comorbidities have suggested that surgery 
is feasible in these patients (3,4). What is not clear is what the true limits of age and 
underlying organ dysfunction is that represent absolute contraindications to surgery. 
It is likely that improvements in anesthesia and surgical care have allowed older and 
more high-risk patients to be operated on safely. The use of video assisted thoracoscopy 
has greatly enhanced our ability to perform surgical resections on these elderly and 
high-risk patients. The gold standard operation of lobectomy for these patients can 
potentially be modified in high risk and elderly patients. Several retrospective studies 
suggest that in the elderly a lesser resection can be equivalent or superior to lobectomy 
in survival and perioperative morbidity (5). In addition the use of pneumonectomy in these 
patients should be avoided as the morbidity and mortality is increased significantly (6). 
It is clear that treatment with stereotactic radiotherapy will play an emerging role in the 
therapy if these patients. Long-term follow up is needed to truly understand the utility of 
radiotherapy in high risk and elderly patients. References 1) World Health Organization. 
Health statistics and health information systems. Available from URL http://www.who.
int/healthinfo/survey/ageingdefnolder/en/index.html. 2) Pallis AG, Gridelli C, Wedding 
U, Faivre-Finn C, Veronesi G, Jaklitsch M, Luciani A, O’Brien M. Management of elderly 
patients with NSCLC; updated expert’s opinion paper: EORTC Elderly Task Force, 
Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol. 2014 
Jul;25(7):1270-83. 3) Rivera C, Dahan M, Bernard A et al. Surgical treatment of lung 
cancer in the octogenarians: results of a nationwide audit. Eur J Cardiothorac Surg 
2011; 39: 981–986. 4) Zhang R, Ferguson MK. Video-Assisted versus Open Lobectomy 
in Patients with Compromised Lung Function: A Literature Review and Meta-Analysis. 
PLoS One. 2015 Jul 6;10(7) 5) Cheng YD, Duan CJ, Dong S et al. Clinical controlled 
comparison between lobectomy and segmental resection for patients over 70 years 
of age with clinical stage I non-small cell lung cancer. Eur J Surg Oncol 2012; 38: 
1149–1155. 6) Zuin A, Marulli G, Breda C et al. Pneumonectomy for lung cancer over the 
age of 75 years: is it worthwhile? Interact Cardiovasc Thorac Surg 2010; 10: 931–935. 
Keywords: elderly, high risk, lung cancer
SESSION ED 07:  
HOW TO TREAT ADVANCED SQUAMOUS CARCINOMA  
OF THE LUNG  
TUESDAY, SEPTEMBER 08, 2015
HOW TO TREAT ADVANCED SQUAMOUS CARCINOMA OF THE LUNG  
TUESDAY, SEPTEMBER 08, 2015 - 14:15-15:45
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Hammerman Medical Oncology, Dana-Farber Cancer Institute, Boston/MA/United States of 
America
While genomic studies of lung adenocarcinomas over the past decade have enabled 
substantial improvements in treatment and patient outcomes, advances in squamous 
cell carcinomas of the lung have been far more modest. At present there are no targeted 
agents approved for the treatment of squamous cell lung cancers and there has been 
limited success in the use of targeted kinase inhibition in this disease. Here, I will review 
the results of genomic studies of squamous cell carcinomas and highlight the molecular 
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Copy number alterations are common events in squamous cell lung cancers. A number 
of these play defined roles in tumorigenesis. Some are known to be oncogenic drivers 
in a subset of cases. Broad high-level amplification of the 3q26-28 cytoband occurs in 
about 30% of squamous cell lung cancers and was one of the first recurrent alterations 
characterized in this disease.(1) More focal amplification of 8p11 occurs between 10-20% 
of tumors.(2, 3) Specific genes in 3q26 that are recurrently amplified include SOX2, PIK3CA, 
and PRKCI. Other genes commonly amplified in 3q27-28 include BCL6, TP63, and EPHB3. 
Genes that are amplified at lower frequencies include EGFR, MYC, MCL1,RICTOR, CCND1, 
and CDK6. The table below summarizes these alterations.
Gene Chromosome Frequency
SOX2 3q26 35%
PIK3CA 3q26 30%
BCL6 3q27 20%
PRKCI 3q26 25%
TP63 3q28 21%
FGFR1 8p11 12%
MYC 8q24 8%
MCL1 1q21 6%
RICTOR 5p13 6%
EGFR 7p12 5%
CCND1 11q13 10%
CDK6 7q21-22 3%
Pharmacologic targeting of gene amplification events in squamous cell lung cancers has 
centered largely on 4 genes- FGFR1, PIK3CA, CCND1, and CDK6. The pre-clinical data and 
clinical trial work defining FGFR1 amplification as an oncogenic driver and drug target, 
respectively, are the most mature. Three abstracts summarizing the preliminary efficacy 
of the pan-FGFR inhibitors AZD4547, BGJ398, and JNJ42756493 were presented in 
2014.(4-6) The overall response rates were low, ranging from 8-15%. Some of these have 
continued on as phase 2 trials (NCT02154490, AD4547). Other studies using less-specific 
FGFR inhibitors are also ongoing (NCT01935336, ponatinib; NCT02109016, lucitanib). 
Upstream PI3K pathway alterations have been the therapeutic targets for a number of 
trials of PI3K inhibitors, though only a subset have included PIK3CA amplification as a 
biomarker of interest. These include two phase 1 trials of PI3K-α or PI3K/mTOR inhibitors 
that have added expansion arms for PIK3CA amplified squamous cell lung cancers 
(NCT01296555, GDC0032; NCT01655225, LY3023414). Data for these studies have not 
yet been presented. Finally, G1/S checkpoint inhibitors, whose efficacy has been best 
defined in breast cancer, are now being tested for CCDN1 and CDK4/6 amplified squamous 
cell lung cancers. Drugs include palbociclib (S1400, NCT02154490) and abemaciclib 
(NCT02450539). It is worth noting, however, that the pre-clinical rationale for targeting 
the G1/S checkpoint alone is substantially weaker than for other pathways. The clinical 
experience derived from targeting FGFR1 amplification in squamous cell lung cancers can 
serve as a framework to understand, in general, which targeted therapy strategies are 
likely to fail both now and in the future. Comprehensive genomic analyses of squamous 
cell lung cancers have shown that these tumors are complex, with overlapping alterations 
in more than one oncogene and/or tumor suppressor occurring in most cases. This 
is particularly problematic for gene amplification targets, which are also plagued by 
questions of functional relevance apropos degree of amplification and association with 
protein expression. As borne out in the phase 1 trials of the pan-FGFR inhibitors, single-
target inhibition is unlikely to generate the breadth and depth of responses seen with 
other drugs targeting other oncogenes. Issues surrounding pharmacodynamic efficacy 
and target inhibition may also play a role in limiting responses. Data from ongoing work 
will be presented identifying potential genomic and non-genomic modifiers of response 
to FGFR1 inhibition. References 1. Björkqvist A-M, Husgafvel-Pursiainen K, Anttila 
S, Karjalainen A, Tammilehto L, Mattson K, et al. DNA gains in 3q occur frequently in 
squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes, Chromosomes 
and Cancer. 1998;22:79-82. 2. Paik PK, Shen R, Won H, Rekhtman N, Wang L, Sima CS, 
et al. Next generation sequencing of stage IV squamous cell lung cancers reveals an 
association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain 
metastases. Cancer Discovery. 2015. 3. TCGA. Comprehensive genomic characterization 
of squamous cell lung cancers. Nature. 2012;489(7417):519-25. 4. Paik P, Shen R, Ferry 
D, Soria J-C, Mathewson A, Kilgour E, et al. A phase 1b open-label multicenter study of 
AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor 
activity and pharmacodynamic data. J Clin Oncol. 2014;32:suppl; abstr 8035. 5. Nogova 
L, Sequist L, Cassier P, Hidalgo M, Delord J-P, Schuler M, et al. Targeting FGFR1-amplified 
lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. J Clin Oncol. 
2014;32:suppl; abstr 8034. 6. Bahleda R, Dienstemann R, Adamo B, Gazzah A, Infante J, 
Zhong B. Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) 
inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014;32:abstr 2501. 
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new combinations and the sequencing of available therapies to maximize the benefit for 
this historically underserved subgroup of patients with NSCLC. References 1. Scagliotti 
G, Brodowicz T, Shepherd FA et al. Treatment-by-histology interaction analyses in three 
phase III trials show superiority of pemetrexed in non-squamous non-small cell lung 
cancer. J Thorac Oncol 2011; 6: 64-70. 2. Johnson DH, Fehrenbacher L, Novotny WF et 
al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with 
carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic 
non-small cell lung cancer. J Clin Oncol 2004; 22: 2184-91. 3. Pujol JL, Pirker R, Lynch TJ 
et al. Meta-analysis of individual patient data from randomized trials of chemotherapy 
plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung 
Cancer 2014; 83: 211-218. 4. Kim JH, Grossi F, De Marinis F et al. Afatinib monotherapy 
in patients with metastatic squamous cell carcinoma of the lung progressing after 
erlotinib/gefitinib (E/G) and chemotherapy : interim subset analysis from a phase III trial. 
Proc Am Soc Clin Oncol 2012; 30 (suppl 15): abstr 7558. 5. Thatcher N, Hirsch F, Luft A 
et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin 
alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer 
(SQUIRE): an open-label, randomized, controlled phase 3 trial. Lancet Oncol 2015; 16(7): 
763-774. 6. Socinski M, Luft A, Szczesna A et al. Subgroup analyses by performance 
status (PS) in the phase III SQUIRE study: First-line necitumumab (N) plus gemcitabine-
cisplatin (GC) vs. GC in squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 
33:suppl; abstr e19023. 7. Reck M, Gralla RJ, Bonomi P et al. Maximum severity score 
(MSS) of baseline patient-reported Lung Cancer Symptom Scale (LCSS) as a prognostic 
and predictive factor for overall survival (OS) in the Phase III SQUIRE study. ASCO Meeting 
2015 abst; 33: 8099. 8. Soria J-C, Felip E, Cobo M et al. Afatinib versus erlotinib as 
second-line treatment of patients with advanced squamous cell carcinoma of the lung 
(LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 2015; 
dx.doi.org/10.1016/s1470-2045(15)00006-6. 9. Garon EB, Ciuleanu TE, Arrieta O et al. 
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of 
stage IV non-small cell lung cancer after disease progression on platinum-based therapy 
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73. 10. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus Docetaxel in advanced 
squamous-cell non small cell lung cancer. NEJM 2015; doi: 10.1056/NEJMoa1504627. 
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ED07.03 Lung Master Protocol in Squamous Cell Lung Cancer (Lung-MAP, 
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Ellen Sigal5, Fred R. Hirsch6, Philip C. Mack7, Vassiliki Papadimitrakopoulou8 1Division of 
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of America, 4CTEP, NCI/NIH, Rockville/MD/United States of America, 5Friends of Cancer 
Research, Washington, DC/United States of America, 6Univ of Colorado Cancer Center, 
Aurora/CO/United States of America, 7Division of Hem-Oncology, UC Davis Comprehensive 
Cancer Center, Sacramento/United States of America, 8Thoracic/Head and Neck Medical 
Oncology, MD Anderson, Houston/TX/United States of America
In recent years, our understanding of non-small cell lung cancer (NSCLC) has evolved 
from thinking of this malignancy as a single disease, or a small number of histologic 
subtypes, to now a multitude of genomically-defined subsets, both in adenocarcinoma 
and squamous lung cancer. In development of new targeted therapies against these 
abnormalities, so-called Master Protocols offer a number of advantages over traditional 
single study designs for drug-biomarker approval, including a common infrastructure, 
homogeneous patient populations with consistent eligibility across multiple independent 
sub-studies, and the ability to screen large numbers of patients in rapid fashion. Thus, 
the Lung-MAP project was designed to facilitate approval of targeted therapy-predictive 
biomarker combinations in squamous lung cancer, a recognized area of unmet need. Lung-
MAP is constructed as a unique public-private partnership engaging the National Cancer 
Institute (NCI) and its Thoracic Malignancies Steering Committee (TMSC), the Foundation 
of the NIH (FNIH), the pharmaceutical industry and advocacy groups such as Friends of 
Cancer Research (FOCR), along with an advisory role by the Federal Drug Administration 
(FDA). The design is multiple simultaneously running Phase II/III trials, each capable of 
independently opening and/or closing without affecting the other sub-studies, in which 
patients eligible for 2nd line therapy for lung SCC have their cancers genomically screened 
through a next generation sequencing (NGS) platform (Foundation Medicine). Patients 
are then randomized into one of several sub-studies, each comparing an experimental 
targeted therapy with standard of care therapy, based on identification of candidate 
predictive biomarkers associated with each sub-study. At launch, drug targets under 
study consisted of “match sub-studies” for PI3K, FGFR, CDK 4/6 and HGF, and a non-match 
sub-study testing PD-L1-directed therapy, as described below. Rapid turn-around time of 
NGS screening results, within 2 weeks, allows real time assignment into the appropriate 
sub-study. For those patients with cancers that do not “match” into a biomarker-driven 
sub-study, there is a ‘non-match” sub-study, in which a predictive biomarker is not yet of 
sufficient validation to utilize it in a drug-biomarker registration strategy. Due to changes 
in the therapeutic landscape since the launch of Lung-MAP, a number of amendments and 
modifications have been implemented, which will be discussed during this presentation. 
Keywords: Master Protocol, squamous cell, Lung-MAP
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and anticipatory feelings of loss are all appropriate responses to advanced disease and 
dying, however, feelings of hopelessness, helplessness, worthlessness, guilt, lack of 
pleasure, and suicidal ideation are indicators of depressive syndromes in these patients. 
Although most used criteria for diagnosing major depression in non- oncology patients 
is the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the 
most widely used for cancer patients is the substitutive approach of Endicott. This scale 
replaces four of the DSM-IV somatic criteria thought most likely attributable to medical 
illness or its treatment (ie, change of weight/appetite, sleep disturbance, loss of energy/
fatigue, difficulty thinking or concentrating) with cognitive substitutes (depressed 
appearance, social withdrawal, brooding/self-pity/pessimism, and lack of reactivity in 
situations that would normally be pleasurable) Treatment: Unfortunately, some data 
suggest most cancer patients with depressive syndromes are undertreated. The first 
step in treating depression is to relieve uncontrolled symptoms, particularly pain and 
potentially reversible general medical cause of depressed mood. If depression persists 
once these are identified and controlled, specific therapy is warranted. Treatment should 
be tailored to the individual needs of the patient. In addition to drug therapy, effective 
psychosocial interventions include individual or group psychotherapy, cognitive-
behavioral therapy, existential therapy, and self-help groups. There are no randomized 
trials that specifically address the benefit of psychotherapy for palliative care patients 
with depression. As a result, therapy for depression in these patients is generally based 
upon the larger evidence on effective treatments in patients of primary care populations 
with either no physical illness or less severe medical conditions. The agents used most 
commonly in palliative care patients are psychostimulants, selective serotonin reuptake 
inhibitors (SSRIs), and tricyclic antidepressants (TCAs), these drugs are an important 
option for treatment of depression at the end of life because they take effect quicker than 
other classical drugs. Other advantages as their more favorable side effect profile and 
the markedly lower danger with overdose, led to the recommendation of the American 
College of Physicians in the 2008 clinical practice guidelines for initial treatment of 
depression in primary care patients, to initiate an SSRI, serotonin and norepinephrine 
reuptake inhibitors SNRI, or atypical antidepressant in this group of patients.
Meyer HA. et al. Palliat Med 2003; 17:604
Portenoy LK. et al. Qual Life Res 1994; 3:183
Wilson KG. et al. J Pain Symptom Manage 2007; 33:118
Akechi T. et al. J Clin Oncol 2004; 22:1957
DeFlorio ML. et al. Depression 1995; 3:66
Endicott J. Cancer 1984; 53:2243
Andersen B. et al. J Clin Oncol 2014; 32:1605
Qaseem et al. Ann Intern Med. 2008;149(10):725
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ln the UK, lung cancer has one of the lowest 5 year survival rates of all cancers (8.8% 
of men and 11.1% of women are alive 5 years after their diagnosis) whilst only 30% 
of people live for more than one year following their diagnosis (Macmillan, 2014). This 
poor outlook can have a profound impact on the quality of life of those affected by the 
disease (LCA, 2015). However, helping people and their families cope with the impact 
and consequences of the disease and its treatment can make a substantial difference 
to the quality of their lives. In this context coping might be regarded as a means of 
understanding and regulating the emotions in response to stress but it might also be 
viewed as solving problems and adapting lifestyles and behaviour through goal setting 
and seeking information and help. By adopting a structured and planned approach to 
care, the healthcare professional can enhance the coping capability of the person with 
cancer and their families and thereby directly contribute to their quality of life. This 
approach can be seen in the Recovery Package. Data from the London Cancer Alliance 
reveals that the top ten concerns for the person with lung cancer are a mix of physical and 
psychological issues including breathlessness, fatigue, anxiety, weight loss, sleeping, 
finances, walking, pain, eating and transport. People with lung cancer have the highest 
number of unmet needs out of all cancer patients, mainly due to higher psychological 
support and physical/daily living support needs (Li et al, 2006). Depression levels tend 
to be higher for people with lung cancer compared to cancer patients with other types 
of cancer (Fischer et al, 2010). Self reported sexual concerns are common in people 
with lung cancer and are related to shortness of breath and emotional distress (Reese 
et al, 2011) whilst people with lung cancer experience higher levels of pain compared 
with patients with other types of cancer (Fischer et al, 2010) Link et al (2005) discuss 
the work of Lazarus and Folkman, and their ‘Transactional model of distress and coping’ 
which suggests that people respond to stressful situations by a primary appraisal 
(where they evaluate the significance of the stressor) and a secondary appraisal (where 
they evaluate their ability to change the situation and manage their emotions). It is at 
these key junctures that effective interventions might be best employed. The Recovery 
Package allows the identification and selection of suitable interventions which can be 
tailored to meet the specific needs of people with cancer and their families. In the UK the 
report ‘Taking Action to Improve Outcomes (NCSI, 2013) envisaged that care should be 
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ED08.02 The Art of Taking Care of Patients, The Art of Giving Bad News Ana 
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For some health professionals, communicating bad news is one of the most frequent 
tasks of their daily work. Conversations on new diagnosis of a dismal disease, 
discontinuation of therapy due to disease progression or end-of-life care goals are 
some examples of discussions that oncologists and other health professionals are 
responsible for everyday with patients and caregivers. However, despite the frequency 
of these conversations, few health professionals are properly trained in how to conduct 
difficult conversations in an effective and yet compassionate manner. Navigating through 
these difficult conversations with thoughtfulness are crucial moments on the patient-
physician relationship. The way in how these conversations are delivered have a direct 
impact on how the patient will perceive and react to the situation and it might make 
the difference between failure and success of this relationship. Communicating bad 
news demonstrates personal courage and integrity and when conducted in the right 
way, increases patient’s confidence and trust on the oncologist and his ability to make 
the right decisions during the patient’s journey. In addition, empathic communication 
can influence patient’s satisfaction with care, quality of life and ultimately patient’s 
outcome. Some studies have reported that the most valued qualities in nurses and 
doctors communicating bad news –from the patient’s perspective, are: recognition (how 
the oncologist respond to the gravity of the news), guiding (what patient would like to 
get after news are delivered) and responsiveness (oncologist’s ability to sense patient’s 
need). Learning how to communicate bad news effectively with patients and family 
members is an essential requirement on becoming a successful and contemporary 
health professional. During this lecture we will review some communication strategies 
on how to efficiently lead these conversations with our patients. References: Baile 
WF, et al. Curr Opin Oncol 2005, Jul;17(4):331-5 Fujmori M, et al. J Clin Oncol 2014 
jul 10;32(20):2166-72 Back AL, et al. Oncologist 2011;16(3):342-50 Baile WF, et al. 
Oncologist 2000; 5(4):302-11 Girgis A, at al. Aust N Z J Surg 1997 Nov;67(11):775-80 
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TALKING WITH PATIENTS  
TUESDAY, SEPTEMBER 08, 2015 - 14:15-15:45
ED08.03 Depression, The Silent Killer Luis Ubillos Medical Oncology, Hospital de 
Clínicas, Montevideo/Uruguay
Background: Emotional reactions are natural and expected in individuals experiencing 
cancer and confronting the end of their lives, the differentiation between a normal and 
appropriate reaction to dying versus a psychiatric disorder such as major depression 
can be clinically difficult to differentiate. Depression is a common mental health 
problem in palliative cancer patients, unfortunately misunderstood, underdiagnosed, 
and undertreated. Depression is a major cause of suffering among patients with 
advanced disease or terminal illness like cancer. Depressive syndromes are correlated 
with a reduced quality of life, greater difficulty in managing the course of the patient’s 
illness, decreased adherence to treatment, and earlier admission to inpatient or hospice 
care. It amplifies pain and other symptoms, and causes worry in family members and 
friends. Patients with advanced illness who suffer from depressive syndromes are also 
at high risk of suicide and suicidal ideation, and they have an increased desire for a 
hastened death. The recognition and diagnosis of patient depression, is often delayed 
in the course of the disease. Prevalence and risk factors: The reported prevalence 
of major depression in individuals with cancer varies from 3 to 38 percent. This wide 
variability is explained by the lack of agreement as to appropriate diagnostic criteria 
to be used in the setting of advanced illness, differences in patient populations, and 
variation in assessment methods. In general, rates are higher in populations with 
advanced cancer, greater levels of disability, and/or unrelieved pain. In several studies, 
younger cancer patients have higher rates of depressive disorders and self-reported 
distress. While depression is twice as common in women as compared to men in the 
general population, gender is not consistently reported to be a risk factor for depression 
in cancer patients. A prior history of depression is a risk factor for major depression in 
cancer patients. The presence of uncontrolled symptoms, particularly pain, is a major 
risk factor for depression and suicide among patients with cancer. The incidence of 
depression also depends upon the patient’s particular illness. Among cancer patients, 
those with head and neck and pancreatic cancers are at a particularly high risk. Certain 
factors associated with the patient’s illness or its treatment may be associated with 
depression. Central nervous tumors or metastasis to the central nervous system 
can cause depression. Other causes of depression in cancer patients include toxins 
created by the tumor, autoimmune reactions, and nutritional deficiencies. Depression 
can also represent an adverse effect from certain treatments, including glucocorticoids, 
chemotherapy drugs (vincristine, vinblastine, interferon and tamoxifen) as well as 
radiotherapy to the brain or head and neck. Patients who have high levels of spiritual 
well-being tend to be less depressed. The beneficial aspects of religion related primarily 
to spiritual well-being rather than to formal religious practice. Screening and diagnosis: 
Screening for depression should be carried out in all palliative care patients given the 
high prevalence of symptoms. Expert recommendations state that every patient with 
cancer should be screened for depression at initial diagnosis and thereafter as clinically 
indicated, especially with changes in cancer status or treatment. There are many tools 
to identify vulnerable patients by screening, Patient Health Questionnaire (PHQ-2) and 
PHQ-9 can identify deserving cases a deeper interview. Depressed mood, sadness, grief, 
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sequencing. Each molecular laboratory should establish criteria for specimen adequacy 
for molecular studies taking into account the specific testing platforms, while surgical 
pathologists should assess the specimen adequacy. Although PCR-based methods can 
detect mutations from a single cell, a low copy number DNA template can generate 
sequence artifacts leading to false results. Therefore, the assessment of adequacy 
is essential to avoid assays failures and false positive/negative results. Estimates of 
tumor content from H&E stained sections vary between pathologists and there is no 
true standard. Acceptable specimens should have a sufficient amount of tumor cells, 
but also a small proportion of admixed non-neoplastic cells, and no necrosis.116 If 
the specimen is inadequate, a new specimen needs to be procured although in this 
situation decision regarding specimen type is often difficult and depends on many 
factors including the patient’s health. Alternate non-invasive highly sensitive methods 
so called “liquid biopsies” have been developed to detect the presence of cancer 
specific mutations in circulating DNA in blood samples. This approach may result in 
significant changes in the management of lung cancer patients and may replace invasive 
procedures. Until then, it is essential that each institution develops its own strategy 
that addresses the collection and processing of lung cancer samples. At the same 
time, pathology departments must implement the procedures that would precisely 
define how to spare the tumor tissue for molecular testing, and how to provide clinically 
acceptable turnaround time for molecular testing results. It is also essential to define 
how to integrate diagnostic interpretation and molecular results in a single pathology 
report. References: Travis WD et al. Diagnosis of lung cancer in small biopsies and 
cytology: implications of the 2011 International Association for the Study of Lung 
Cancer/American Thoracic Society/European Respiratory Society classification. Arch 
Pathol Lab Med 2013; 137(5):668-84. Lindeman NI. et al. Molecular testing guideline for 
selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline 
from CAP/IASLC/AMP. J Thorac Oncol 2013:8(7):823-59. Francis G, Stein S.Circulating 
cell-free tumor DNA in the management of cancer. Int J Mol Sci. 2015;1 (6):14122-42 
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Thoracic Oncology Program, Baptist Cancer Center, Memphis/TN/United States of America
With 1.6 million new diagnoses and 1.4 million annual deaths worldwide, 230,000 
annual cases and 160,000 deaths in the US, lung cancer is the oncologic scourge of 
the present age. It accounts for 23% of worldwide, and 28% of US, cancer deaths.1 
Four decades of advances in diagnostic and treatment modalities, including the current 
‘molecular’ decade of rapid-fire discovery of breakthrough therapeutics, have seen 
aggregate US 5-year survival improve from 12% to 17%.2 Although the deployment 
of effective population-based tobacco cessation and lung cancer screening programs 
can change these statistics, there remains the danger of blunted impact because of 
relatively little progress in the coordination of care, and major deficits in the use of 
curative-intent therapy. Lung cancer care is complicated. The disease is common 
and lethal; the primary at-risk population is ravaged by cumulative age- and tobacco-
related comorbidities; the lungs and mediastinum are relatively inaccessible; multiple 
approaches and techniques for diagnosis, staging, and treatment exist, each requires 
different, highly-trained specialists (radiologists, pulmonologists, surgeons, medical 
oncologists, radiation oncologists, pathologists, palliative care specialists), using high-
cost equipment, to perform high-risk procedures, any one of which may or may not be 
needed for specific patients. Determining which specific specialists and management 
approaches are needed for individual patients requires objective evaluation and careful 
coordination, in order to tailor management to patient needs. Prevailing nihilism about 
lung cancer care further complicates matters: ‘statistics suggest the patient will die 
anyway, so what’s the point? ’, ‘he brought this on himself by smoking, whose problem 
is this?’ Care delivery must be better coordinated before we can achieve meaningful 
improvement in population-level survival statistics. All lung cancer care begins 
with an abnormal chest x-ray or CT scan. From then, it flows through certain ‘nodal 
points’: histologic confirmation, radiologic staging, histologic staging, selection of 
treatment, and (ultimately) outcomes. Each nodal point includes a myriad of options. 
Diagnosis is usually made by percutaneous (interventional radiologist), bronchoscopic 
(pulmonologist), or surgical (thoracic surgeon) biopsy ; radiologic staging often involves 
a PET/CT scan (nuclear radiologist), and brain MRI scan (neuro-radiologist); histologic 
staging requires an invasive biopsy procedure, which can be transbronchial needle 
biopsy during conventional bronchoscopy, endobronchial ultrasound-guided (EBUS) 
biopsy (pulmonologist), endoscopic ultrasound-guided (EUS) biopsy (gastroenterologist), 
percutaneous image-guided biopsy of a distant stage-defining lesion (interventional 
radiologist), mediastinoscopy, or other approaches to various parts of the mediastinum 
(surgeon). Treatment increasingly requires combinations of surgery, radiation therapy, 
chemotherapy and palliative care. Therefore lung cancer care demands a high degree of 
coordination. Major, well-described geographic, socio-economic, racial, and age-based 
disparities in diagnosis, staging, treatment, and outcomes suggest that healthcare 
systems fail to provide the required level of care coordination. The proportion of patients 
who make it to surgery, the most important curative treatment modality, varies from 
9% in the UK, to 29% in the US.3 Use of invasive staging tests and surgical resection is 
significantly lower in African Americans than in Caucasians.4,5 Elderly patients are less 
likely to receive chemotherapy than younger patients.6 Although partly driven by patient 
choice, improvement in care coordination narrows or eliminates most disparities.7,8 
Beyond disparities, access to high-quality care is generally low. ‘Trimodality’ staging 
(CT, PET/CT scan and invasive staging in combination) although associated with a 2-fold 
survival improvement was used in only 5% of US patients.9 In a high lung cancer mortality 
zone of the US, only 17% of curative-intent resections were preceded by invasive staging, 
including only one-third of patients with clinical N1, N2 or N3 disease (Osarogiagbon, 
unpublished data). Low rate of histologic confirmation of stage-defining lesions raises 
designed with the following key aims:
• Providing information and support from the point of diagnosis
• Promoting recovery
• Sustaining recovery
• Managing the consequences of treatment
• Supporting people with active and advanced disease
These key aims underpin The Recovery Package which is a series of key interventions 
which, when delivered together, can greatly improve outcomes for people living with and 
beyond cancer. The Recovery Package is made up of
• an assessment of holistic needs and the development of a care plan to address 
these issues;
• a treatment summary that explains to the General Practitioner and individual what 
treatment has taken place;
• a cancer care review by the General Practitioner within 6 months of diagnosis;
• attendance at a health and wellbeing educational event.
The Recovery Package The success of the Recovery Package depends upon the 
creation of a partnership with the individual and the focus of care is on supporting self-
management after a cancer diagnosis. This is underpinned by effective assessment. 
Holistic needs assessment acknowledges that coping strategies are mediated by 
social context and that the quality and quantity of the person’s support can be quite 
variable. The assessment works by gathering and discussing information in order to 
develop an understanding of what the person living with and beyond cancer knows, 
understands and needs. It is focused on the whole person and the entirety of his/her 
needs including the physical, emotional, spiritual, mental, social, and environmental 
needs of the individual. The process culminates when the assessment results are used 
to inform a care plan. Holistic assessment tools offer front-line health service staff a 
structured yet collaborative way to elicit people’s concerns and, with adequate training 
and informational resources, respond to these concerns effectively, efficiently and 
humanely. By integrating the assessment of very understandable emotional concerns 
within a holistic treatment review there is less likelihood that psychological difficulties 
become pathologised by professionals or seen as a source of shame for those living with 
and beyond cancer (Brennan et al, 2012). Lung cancer is often characterised by rapid 
deterioration and a complex interplay of symptoms, concerns and worries and health 
care professionals can play a critical role in choice of coping strategy (which can be used 
to help people to more actively participate in their care) (Link et al, 2005). This can be 
helped by a structured and planned approach to care such as The Recovery Package. 
Keywords: coping, living with and beyond cancer, survivorship, recovery package
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The majority of patients with lung cancer present in advanced stages, and small biopsy 
and cytology specimens most frequently provide the only tumor material for diagnosis. 
Furthermore, the same sample is also needed for molecular studies that guide 
treatment and management. Lung carcinomas often are diagnosed by minimally invasive 
techniques and specimens are obtained by bronchoscopic or transthoracic approaches. 
The choice of the procedure depends on the location, accessibility of the mass and 
other clinical parameters. Since most adenocarcinomas are peripherally located, the 
transthoracic approach is often chosen to provide diagnostic samples. Squamous cell 
carcinoma is most frequently centrally located and the bronchoscopic approach is more 
common. If cytology specimens, including pleural fluids, are obtained, cell blocks should 
be prepared. Despite the best efforts, the lesional tissue or the most representative area 
of the tumor may not be obtained in some cases due to sampling issues. Even when the 
tumor is sampled, poor tumor differentiation or insufficient characteristic morphological 
features in the tumor sample will cause the difficulty in rendering a specific diagnosis and 
would prompt pathologists to use immunohistochemistry. Use of immunohistochemistry 
greatly reduced the number of lung carcinoma cases classified as non-small cell 
carcinoma, NOS to only 3%. .In addition to immunohistochemistry, cytology samples 
should be interpreted in conjunction with histology of small biopsies whenever possible. 
Immunohistochemistry should be limited only to cases when classification is uncertain 
and every effort should be made to preserve as much material as possible for molecular 
studies. There are few strategies besides limited immunohistochemistry panels how this 
could be accomplished. One approach is to cut unstained slides from a paraffin block 
after initial hematoxylin-eosin stain sections were obtained. It is essential that histology 
technicians limit facing of the block and place only one tissue section per slide. Another 
approach is to have each core biopsy tissue fragment placed into separate blocks during 
specimen processing so only one block can be used for immunohistochemistry and all 
of the blocks can be used for molecular studies. Same laboratories in order to avoid 
tumor microdissection from the unstained slides prefer to core paraffin blocks by 1-mm 
needles after diagnostic work up. Formalin-fixed, paraffin-embedded tissue samples and 
cytology aspirates can be used for various testing platforms including next generation 
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close to 100% disease-free survival. In contrast, invasive adenocarcinomas with solid 
and micropapillary predominant histological subtypes were associated with worse overall 
survival.[2, 4] Because most patients with lung cancer will be diagnosed with advanced-
stage disease, one of the most important distinctions between the 2011 IASLC/ATS/
ERS classification system and the previous 2004 World Health Association (WHO) 
classification is the establishment of diagnostic criteria for small biopsies and cytology. 
Although the focus was on adenocarcinoma, diagnostic criteria for other histologies 
were also included with the primary focus on distinguishing between squamous cell 
carcinoma and adenocarcinoma. A limited diagnostic work up was recommended to 
preserve as much tissue as possible for molecular testing. In cases where the diagnosis 
can be established based on light microscopy alone, the WHO classification criteria were 
maintained and no additional confirmatory testing was recommended. In tumors without 
definite squamous or adenocarcinoma morphology, limited immunohistochemistry 
may be used to refine the diagnosis. Most tumors can be classified using a single 
adenocarcinoma marker (i.e. TTF-1 or mucin) and a single squamous marker (i.e. p40 or 
p63.[5] The acknowledgement that one needs to “preserve as much tissue as possible” 
for biomarker testing reflects the changing uncertainty in which biomarkers need to 
be assessed and what techniques might be available for testing. With the identification 
and validation of actionable molecular targets that can guide therapy in patients with 
advanced adenocarcinoma, institutions are encouraged to develop consistent strategies 
for obtaining and managing tissue samples that are optimized for molecular testing. 
Because this approach has not been validated for squamous histology, tumors with 
equivocal morphology or IHC findings should be classified as NSCLC-NOS so as not to 
exclude patients from histology-specific chemotherapy or molecular testing. In 2013, the 
College of American Pathologists (CAP), IASLC and Association for Molecular Pathology 
(AMP) published a molecular testing guideline for selection of lung cancer patients for 
EGFR and ALK tyrosine kinase inhibitors that included 37 recommendations addressing 5 
principal questions, including: (1) When should molecular testing be performed? (2) How 
should EGFR testing be performed? (3) How should ALK testing be performed? (4) Should 
other genes be routinely tested in lung adenocarcinoma? And, (5) How should molecular 
testing be implemented and operationalized?[6, 7] In addition to EGFR and ALK, a number 
of other molecular alterations have been described that are potentially treatable with 
targeted agents. Because the data were insufficient to support routine testing of other 
targets when the CAP/IASLC/AMP guidelines were finalized, the recommendation was to 
prioritize EGFR and ALK testing over other molecular markers in order to reserve tissue 
for these analyses.[6] The type and number of molecular alterations being evaluated 
ultimately determine how a limited specimen should be used. Immununohistochemical 
(IHC) and Fluorescent In Situ Hybridization (FISH) are the standard approaches for the 
detection of protein expression and chromosomal rearrangements and amplifications. 
Specific single nucleotide polymorphisms (SNPs) that are recognized mutations 
influencing response to specific therapies demand nucleic acid based tests utilizing a 
PCR based approach or, in the extreme, DNA sequencing. Most of these assays are 
typically developed as singleton tests for one specific SNP. As the number of necessary 
biomarkers increases, efficiency demands multiplexing these 
singleton assays or adopting a different technology, e.g. Next Gen 
Sequencing (NGS).[8-10] However, the timeliness for reporting results 
vary depending on the platform and the number of genes. It needs to be 
understood that none of these technologies can detect all of the types of 
genomic alterations of interest and that all of these methodologies must remain 
in the armamentarium available for proper specimen evaluation. With this in mind, 
efficient use of limited tissue demands clear communication between oncologists, 
surgeons, interventional radiologists and pathologists with regard what is needed for 
patient care and an understanding of available resources, either in house or through an 
appropriate reference laboratory. A further complexity is the timeliness in obtaining a 
result. While good practice suggests establishment of institutional protocols, individual 
patient needs ultimately dictate how best to proceed, emphasizing the importance of 
good interdisciplinary communication 
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the danger of overuse and underuse of treatment modalities. At the extremes are 
primary surgical resection for patients with clinically evident mediastinal nodal disease, 
and palliative systemic chemotherapy for patients with false-positive radiologic staging 
tests or multiple primary cancers erroneously classified as stage IV. Avoiding misuse of 
diagnostic and staging modalities is equally difficult. The need to recognize and correctly 
act on non-diagnostic, false-negative and false-positive test results is great. Lung cancer 
care is often delayed when insufficient-quality diagnostic material or sampling error leads 
to erroneous reassurance that a high-risk radiologic lesion is benign. The problem is 
even greater in the use of invasive staging tests. More than half of US mediastinoscopy 
procedures fail to deliver lymph node tissue for pathology examination.10 This dismal 
statistic is probably worse with EBUS and EUS. The need for high-quality tissue rises 
as prognostic and response-predictive implications steadily increase our need for clear 
histologic categorization (and sub –categorization), and with the advent of molecular 
prognostication and treatment selection. The demand for high-quality tissue spans the 
stage spectrum. Therapeutic clinical trials now routinely demand tissue for molecular 
testing, surgical resection trials increasingly mandate a minimum quality of nodal 
staging. Patients’ eligibility for clinical trials and our ability to accelerate testing and 
deployment of novel treatments increasingly hinge on tissue procurement. Pathologists 
and interventionists who procure tissue must work collaboratively to increase tissue yield 
for the numerous purposes of treating clinicians. This must be achieved while maintaining 
patient safety and convenience. The countervailing forces of increasing adoption of 
minimally invasive diagnostic, staging and treatment modalities and ravenous hunger for 
high-quality tissue for prognostication and treatment selection collide within individual 
patients and healthcare systems. Only better coordination, involving all relevant 
clinicians in early strategic decision-making for each individual patient can prevent the 
delays, anxieties, exposure to harm, missed opportunity for better treatment outcomes, 
and looming medico-legal risk that the status quo in lung cancer care represents. Rising 
survival rates will only increase this conflict, as the need for re-characterization of 
disease rises, and lung cancer care evolves from a game of checkers to a chess match. 
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The personalized treatment of lung cancer begins with an accurate histologic diagnosis. 
Lung cancer is a heterogeneous disease and recent advances in understanding the 
genetic underpinnings of cancer coupled with the development of targeted therapeutics 
have added to the complexity of the diagnostic evaluation. The previous simple division 
of lung cancer into small cell and non-small cell histology is no longer adequate, and 
evaluation of tumors for specific genetic changes and their expression is essential for the 
precise and accurate diagnoses required for optimal treatment and patient management. 
In 2011, the International Association for the Study of Lung Cancer (IASLC), the American 
Thoracic Society (ATS), and the European Respiratory Society (ERS) published a new 
pathological classification of lung adenocarcinoma.[1] This new system established 
uniform terminology and diagnostic criteria for both resection specimens and small 
biopsies. Based on advances in the understanding of lung tumor biology, the correlation 
between specific tumor histology and outcomes with selected chemotherapy agents, as 
well as the successful development of novel targeted therapies, this new classification 
system emphasized the importance of a multidisciplinary approach to the diagnosis of 
lung cancer in order to best guide management decisions. In the IASLC/ATS/ERS system, 
several changes to pathological classification of adenocarcinoma were proposed.[1] 
The term “BAC” (bronchioloalveolar carcinoma) was discontinued and new pathological 
subtypes were added, including adenocarcinoma in situ (AIS) and minimally invasive 
adenocarcinoma. For patients with invasive adenocarcinoma, the new system proposed 
comprehensive histological subtyping with classification based on predominant 
histological pattern (lepidic, acinar, papillary, micropapillary and solid). Mucinous tumors 
were classified as mucinous AIS, mucinous MIA or invasive mucinous adenocarcinoma 
based on extent of invasion. In subsequent validation studies, pathological subtyping 
using the IASLC/ATS/ERS adenocarcinoma classification system has been demonstrated 
to have both prognostic and predictive significance.[2, 3] Patients with AIS and MIA have 
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that activate ROS1, RET, NTRK, and FGFR; mutations that activate KRAS, BRAF,HER2, 
and FGFR; and amplifications that activate MET, FGFR and HER2. It is also likely that 
some of these agents will approved in the near future. These developments bring 
into focus the most appropriate methods to test for molecular drivers in lung cancer. 
The techniques include direct sequencing, PCR testing for mutation hot spots, Next 
generation whole exome sequencing for mutations, translocations and amplifications, 
immunohistochemical testing for activated proteins or specific mutations, FISH testing 
for specific translocations, fusions, and amplifications. The sequential testing of one gene 
at a time is very inefficient especially with respect to the time it takes to complete testing, 
with the total cost and with respect to the amount of tissue necessary to complete the 
testing. Thus, multiplex testing is becoming far more common. However, in the US, the 
FDA’s companion diagnostic tests are one a time for specific tests for specific drugs. 
This one off policy is threatening the ability to perform one test for multiple analytes 
simultaneously. Hopefully, these issues can be resolved in the near future. What are the 
molecular changes that appear to be drivers for which there exist therapeutic TKIs? We 
can first discuss the development of resistance to 1st generation EGFR and ALK TKIs. 
About half of all patients who progress on a 1st generation EGFR TKI will have a secondary 
gatekeeper mutation, T790M that limits binding of 1st generation EGFR TKIs to the EGF 
receptor. 3rd generation EGFR TKIs such as AZD9291 and CO1686 (rocelitinib) have been 
shown to produce objective clinical responses in about 60% of patients with T790M who 
progress on a first generation EGFR TKI. These responses are associated with a median 
PFS of about 10 months. These drugs bind irreversibly to the T790M receptor and to 
activating mutations such as del19 and L858R but do not bind to the wildtype receptor. 
Therefore they have far less skin rash and diarrhea compared to the 1st generation 
inhibitors. Rocelitinb may cause hyperglycemia in up to a third of patients that is believed 
to be caused by a metabolite that inhibits IGFR. The use of oral anti-hyperglycemic agents 
such as metformin may be required for glucose control in these patients. Rocelitinib 
may also cause prolongation of the QTc on EKGs and thus monitoring is required. This 
side effect is rare but requires monitoring. AZD9291 may be associated with slightly 
more skin rash and diarrhea and uncommon reports of pneumonitis have been reported. 
The mechanism of resistance to these agents is under investigation but most often 
appears to be activation of alternative signaling pathways or phenotypic switching to a 
mesenchymal state. There are multiple tests available to detect the T790M mutation and 
many studies are evaluating its presence in circulating free DNA. Such analyses seem to 
be quite specific but less sensitive to analyses of tumor tissue. Testing for mutations in 
circulating free DNA is quite appealing because it does not require another tumor biopsy. 
Crizotinib which was the first agent approved for ALK positive cases, is also a potent 
ROS1 and MET inhibitor. ROS1 may be activated by fusion to other genes on the same 
chromosome and detected by FISH or Next generation sequencing. Crizotinib has been 
reported to produce objective response is about 60% of cases with ROS1 fusions with 
median progression free survival of about 16 months. Crizotinib has also been reported 
to produce objective responses in about 2/3 of patients with high MET amplification 
although the number of patients studied is very low. Additional studies are ongoing. 
Because MET amplification is frequent in patients who progress on 1st generation EGFR 
TKIs that do not have T790M, MET inhibitors are also being studied on this setting. 
Both ceritinb and alectinib have been approved for patients with ALK fusions who have 
progressed on crizotinib. It is clear that the two drugs have different activity among 
various resistance mutations for ALK. Thus, rebiopsy of tumor or testing of circulation 
free DNA may become standard in patients progressing on ALK TKIs as it is in patients 
progressing on EGFR TKIs. BRAF mutations occur in about 2% of advanced NSCLC 
patients and the V600E mutation is the most common. BRAF TKIs such as vemurafinib 
have been reported to produce frequent responses in NSCLC patients with V600E BRAF 
mutations. In melanoma the combination of BRAF inhibitors with MEK inhibitors has been 
more effective than BRAF inhibitors alone and this combination is being studied in NSCLC 
patient with BRAF mutations. HER 2 may be activated by either mutation or amplifications 
and the response to various HER inhibitors may vary by the method of activation. About 
2% of patients have activation by amplification and about 2% by mutation (usually exon 
20 insertions). The irreversible pan HER TKIs such as neratinib, afatinib and dacomitinib 
have not produced high response rates in these patients. However a phase 1 trial of the 
combination of niratinib with temsirolimus produced higher responses in both breast 
and lung cancers and a phase 2 study of the combination in lung cancers with HER2 
mutations/amplifications is in progress. Other HER2 inhibitors have been reported to 
produce occasional responses but we await formal study of such agents. RET and NTRK 
fusions have been reported I about 1% of patients and there are sporadic reports of 
responses to specific TKIS. Formal studies are in progress but may not be reported 
for some time due to the rarity of the abnormalities and the fact that multiple TKIs are 
available. FGFR may be activated by amplification, fusion and mutations and there are 
both quite specific FGFR TKIs and multi-TKIs that have been studied in small numbers 
of patients. It is fair to say that response rates to specific FGFR TKIs are low in patients 
with squamous cell carcinoma patients with FGFR amplification. Additional studies with 
other biomarkers and other agents are ongoing. The most frequent oncogenic driver in 
lung cancer is KRAS. No specific TKI has been developed. Downstream inhibitors such 
as MEK inhibitors and FAK inhibitors have the most study to date. Response rates as 
single agents are relatively low and combination studies are in progress. In summary, 
the increased numbers of TKIs specific for various molecular drivers in lung cancer is 
becoming far more important not only a diagnosis but also at the time of progression. 
Future studies will focus on multiplex testing and testing of circulating free DNA.
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Technologic and scientific development in medicine and the biomedical sciences has led 
to almost immediate transfer of knowledge and methodology applied initially in the 
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Introduction: Standard treatment of stage IIIA non-small-cell lung cancer consists of 
definitive concurrent chemoradiotherapy (CTx/RTx) protocols. Based on the broad 
heterogeneity of stage IIIA alone, there are selected patients (single mediastinal lymph 
node involvement, IIIA3 Robinson) where induction chemotherapy (CTx) followed by 
definitive surgery may be an alternative and valid approach preferably to test within 
prospective clinical trials with a close documentation of the toxicity/efficacy ratio. 
Patients and Methods: The medical literature (PUBMED) was reviewed looking for the 
search terms “induction chemotherapy“ and “stage III“ and “non-small cell lung cancer“. 
Furthermore large clinical trials were added that had been presented at important clinical 
conferences such as ASCO, WCLC and ESMO. Prospective phase-III clinical trials and 
prospective phase-II clinical trials were examined and categorized for efficacy and 
outcome parameters. We looked specifically for general patterns in the reporting of 
clinical trials results. Results: General outcome parameters for efficacy that have been 
reported were: 1) objective response rates 2) overall survival (median) 3) progression-
free survival rates 4) complete resection rates (R0-resection) 5) pathological complete 
response rates (pCR) in the primary tumor and 6) pathological complete response 
rates (pCR) in the mediastinum. On the other hand important benchmarks for toxicity 
were 1) grade 3 and grade 4 maximum toxicity rates during induction 2) perioperative 
toxicity rates grade 3 and 4 3) treatment related death rates. Very few investigations 
have looked at patient reported outcome parameters such as symptom improvement 
or quality of life evaluation during the complete treatment protocol. Several groups 
have tried to improve outcome data by the use of 1) three-drug regimen as induction 
treatment 2) second- and third-generation platinum-based combinations 3) introduction 
of new molecular targeted agents (VEGF, EGF-R etc) especially looking closely at the 
pathological complete response rates induced by induction therapy 4) inclusion of 
different radiation schemas within a concurrent or sequential preoperative application 
protocols. Several reported trials have also tried to alternatively give a definitive CTx/
RTx protocol with increased radiation doses and have not included a definitive surgical 
approach. These studies could not report data on pathological responses and some have 
alternatively looked at FDG-PET response to induction therapy as a surrogate marker 
for pathological response. Currently the treatment protocols with the highest reported 
pathological response (pCR) rates were based on cisplatinum and taxane (paclitaxel 
and docetaxel) combinations and induction protocols including concurrent cCTx/RTx 
regimen were those with the highest pathological efficacy in the mediatinum as well as 
in the primary tumor. Conclusions and Outlook: With the existing broad heterogeneity 
in patient selection within the different clinical studies performed it is currently difficult 
to give an overall recommendation about the most optimal treatment approach in this 
setting of stage IIIA NSCLC. Induction CTx could potentially serve as a backbone for 
including new treatment principles (eg. molecular targeted agents, immunotherapy, 
CTx/RTx protocols) into these multimodality treatment protocols and closely monitoring 
outcome by translational investigations and pathological response evaluations. 
Keywords: non-small cell lung cancer, Surgery, induction chemotherapy, 
Chemoradiotherapy
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The current IASLC/CAP/AMP guidelines indicate that testing for EGFR mutations and 
ALK fusions is recommended before instituting therapy in patients with advanced lung 
cancers with adenocarcinoma features. The guidelines indicate that the guidelines 
would be updated as other therapies become available for specific drivers. Since these 
guidelines were published, considerable information has become available on molecular 
changes that cause resistance to the first generation EGFR and ALK tyrosine kinase 
inhibitors (TKIs) and new 2nd and 3rd generation drugs to treat molecular resistance 
are in the clinic are likely to be approved in 2015. New drugs are also in development 
for other molecular drivers that have been reported in lung cancer including fusions 
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Cancer David R. Spigel Thoracic Oncology, Sarah Cannor Research Institute, Nashville/
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Remarkable progress has been made in the treatment of ALK-rearranged NSCLC 
with the initial approval of crizotinib. Multiple next-generation agents are impacting 
care as approved therapies in some regions of the world or in first- and second+-line 
clinical trials where early data are promising. Additional development of crizotinib 
and newer agents in ROS-1-positive NSCLC is quickly changing how patients are 
evaluated at diagnosis. Moreover, maturing data in BRAF-mutated NSCLC with 
BRAF and MEK inhibitors, along with early data in RET- and FGFR-positive NSCLC 
support broader and earlier testing in the care of patients with advanced NSCLC. 
The data for, and challenges of, selecting the best first-line (and beyond) options for 
patients with ALK, ROS-1, BRAF, RET, FGFR, or other altered NSCLC will be reviewed. 
Keywords: ALK, ROS-1, BRAF, RET, FGFR
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When more than one drug exists for the same target (e.g. erlotinib, icotinib, gefitinib 
and afatinib for EGFR mutant NSCLC), decisions in terms of which drug to commence 
targeted therapy with may be based on personal experience, side effects and 
cost. Until head-to-head trials in the same sensitive target population read out, any 
potential efficacy differences remain speculative. Other than to switch out drugs based 
on tolerability issues, the anti-cancer benefit from sequential use of different drugs in 
the same class/generation as a strategy separate from any benefit of ongoing target 
suppression post-progression with the same drug also remains largely unproven. 
However, as new generation drugs are developed, drugs directed against the same 
dominant driver now exist which have activity against both the initial form of the target 
and common acquired resistance forms (e.g. ceritinib and alectinib for ALK+ NSCLC, or 
rociletinib and AZD9291 for EGFR mutant NSCLC). While initial licensing strategies have 
focused on sequential use of such drugs after first generation drugs, studies are also 
underway looking to see if first line use of these next generation drugs could be more 
beneficial in the relevant molecularly selected population. As mechanisms of acquired 
resistance become better understood, specific actionable second drivers, co-existing 
with the initial sensitive form of the oncogenic driver, are now being identified (e.g. MET 
amplification with EGFR mutations). Preclinically, inhibition of both drivers is required to 
achieve cancer control in this setting. Clinically, trials of combination therapy are showing 
promise with determination of the exact predictive cutpoint in continuous variables such 
as MET emerging as a key issue. With more extensive molecular testing being deployed 
upfront, rather than in tiered testing strategies and separate from in the acquired 
resistance setting, multiple potential molecular drivers on each patient are now being 
reported to treating physicians. When some of these are known acquired mechanisms 
of resistance (e.g. MET or T790M in EGFR mutant), concern may arise re whether initial 
therapy will be effective. However, most diagnostic assays do not give information on the 
proportion of each molecular aberration. Consequently, a highly sensitive test can detect 
a small clonal fraction of a resistance mechanism that will later be selected out by use of 
the initial targeted therapy, but does not preclude an initial response. In contrast, germline 
abnormalities present in all cells, such as can occur with T790M, would preclude an initial 
response to the relevant targeted therapy. As such germline events are very rare, initial 
use of a targeted agent still makes most sense. While defined oncogenic drivers are often 
perceived to be mutually exclusive (e.g. EGFR and ALK), exceptions do occur. While there 
appears to be no specific growth advantage to having two oncogenic drivers in the same 
cell in the absence of a specific selection pressure, such examples of double drivers 
could reflect false positives, true positives where one of them is somehow non-functional 
(e.g. an ALK rearrangement detected by FISH, which is not transcribed), or true positives 
where each is present in a different cell population. Again, as proportional positivity is not 
a feature of most diagnostic assays, starting with monotherapy for the abnormality that 
is either easiest to target or has the lowest chance of being non-functional (e.g. a point 
mutation over a chromosomal abnormality), makes the most clinical sense. At acquired 
resistance, rebiopsy and reanalysis for changes in biology including the dominance of 
the other initial driver should be strongly considered. Perhaps the biggest challenge has 
been the proliferation of multiplex reports detailing a range of abnormalities in the same 
cancer, where the exact driver status and biological significance of the abnormalities 
remains unclear. Caution should be exercised in assuming that all changes are true drivers 
and extreme caution should be exercised if attempting to combine available targeted 
drugs that have not been combined before in the absence of a formal phase I study. 
Keywords: driver, egfr, alk, resistance
research lab to the clinic, producing a profound impact in screening, diagnosis and 
treatment. These enormous amount of information and specialized skills in the medical 
practice have made it necessary to integrate multidisciplinary teams to improve quality 
of cancer care. Lung cancer is the most common neoplasia worldwide as well as the 
leading cause of cancer-related death, with more than 50% of patients presenting with 
stage IV disease at diagnosis (1). Therefore, lung cancer management usually requires 
the collaboration of surgeons, medical oncologists, radiation oncologists, pathologists, 
nurses, and other health care professionals (2). Given the fact that many patients will 
present with locally advanced or metastatic disease, only small amounts of tissue or cell 
preparations will be available for morphologic analysis, immunohistochemistry and 
molecular testing. Recommendations from academic centers and agencies are in favor 
of limiting the amount of immunohistochemical stains in order to save tissue for molecular 
assays, stressing the need to integrate pathologist to multidisciplinary teams, where 
clinical information is exchanged, and specific differential diagnosis and objectives 
established in a case-to-case basis (3). The traditional role of pathologist in lung cancer 
has been to establish histological diagnosis of malignancy, as well as proper taxonomic 
allocation according to widely accepted classification schemes. (4) This approach sets 
pathologist within single moment interventions early in the course of patient management, 
aside from opportunities to collaborate during the rest of care. However, the advent of 
personalized medicine, characterized by the identification of biological features in cells 
that predict benefit from specific targeted drugs, opened up the way for pathologist to 
actively participate with the team in the selection of treatment and patient follow-up. 
Overall, from 60-70% of NSCLC have specific mutations of well characterized oncogenic 
drivers, some of them with 1st line treatment drugs and many with targeted therapies 
under development. Current guidelines of advance stage disease recommend initial 
characterization of EGFR mutation status and ALK rearrangement, although there is 
building evidence to support testing of a number of actionable genes such as HER2, 
BRAF, MET, RET, ROS1, or other biomarkers with predictive capacity such as microsatellite 
instability (5). Multiple methods and technological platforms have been developed to 
identify gene mutations, and although most of them have very high specificity values, the 
sensitivity to detect a mutant clone from a background of wild type DNA is wide. 
Conventional Sanger sequencing will identify a mutation if it is present in 10-20% of the 
sampled cells, pyrosequencing increases the level to 1%, mutant-enriched polymerase 
chain reaction (PNA-LNA PCR, ARMS, etc.) can detect a mutant gene among as many as 
103 wild-type alleles (0.1-1%) with comparative performance to next generation 
sequencing(6). These differences in analytical sensitivity do not only affect the number 
of EGFR mutated cases identified, but may also impact the clinical results obtained when 
using TKI therapy. For example, studies suggest that high EGFR mutation allele burden at 
diagnosis may be associated with increased progression-free survival and overall survival 
in patients treated with tyrosine kinase inhibitors, based in sensitivity differences 
between conventional sequencing and allele-specific PCR(7,8). In the light of these 
challenges, pathologist face the need to secure tissue availability and adequacy for 
testing in order to increase the diagnostic yield of molecular characterization. This 
demands the establishment of changes in sample management and processing, 
depending on the biological material to be tested. For example, rapid on-site evaluation 
may be performed in cytological specimens from fine needle aspirates. In the case of 
CT-guided transthoracic biopsies, one initial core may be submitted for frozen section or 
studied with cytological imprints to assess tumor viability. If proper cellular material is 
identified, this core may be entirely used for molecular testing and subsequent cores 
destined for histological processing. Once the tissue is paraffin-blocked, the tissue 
cuttings product of facing the block may be saved in a sterile, DNAase/RNAase-free tube 
for later use if necessary. It is established that patients will ultimately develop resistance 
to targeted therapies through different mechanisms, either the emergence of mutations 
in the target gene or the acquisition of mutations or over-expression of oncogenes that 
overcome this inhibition. Studies have proved that at tumor progression, a number of 
cases may have a morphological switch from adenocarcinoma to sarcomatoid carcinoma 
or small-cell carcinoma (9), requiring therapy adjustments. Re-biopsy allows molecular 
evaluation as well as morphologic analysis, however; it is an invasive procedure that not 
all patients may undergo. Alternative highly sensitive molecular methods may be used for 
patient follow-up without the need of invasive interventions. Blood sample-based PCR or 
NGS can detect circulating free DNA from the tumour (liquid biopsy), the concordance 
rate between tissue and plasma for EGFR mutation going from 58.3% to 93.1%, stressing 
the need of analytical improvement. Of especial interest is the fact that when examining 
the appearance of the T790M mutation in serial blood samples, this mutation could be 
detected in the plasma DNA before clinically evident disease progression. (10) NSCLC 
diagnostics is rapidly changing to combine a dual morphologic-molecular approach, 
where initial HE-slide examination is used to confirm malignancy and to allocate the tissue 
sample to a group of molecular test relevant to the cellular composition of the tumour. 
Continuous increase in the number of genes responsible of oncogenesis in lung 
carcinoma ensures the development of new targeted drugs as well as active 
communication from all the members of the multidisciplinary team. References 1) Aisner 
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Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) with:
• fluid restriction;
• chemotherapy (effective in 80% of SCLC cases);
• Demeclocycline;
• Vasopressin receptor antagonists (Conivaptan, Tolvaptan).
• direct inhibition of cortisol secretion to reduce circulating glucocorticoids (eg 
Ketoconazole);
• Octreotide (blocking the release of ACTH);
• bilateral adrenalectomy.
Cushing syndrome by:
Once the diagnosis of lung cancer has been established the optimal treatment for any 
PNS is to treat the disease. There is no randomised control trial data for treatment for 
PNS on which to base practice (Giometto 2012) but there is evidence that the anti-cancer 
treatments (surgery, radiotherapy, chemotherapy, biological therapies, immunotherapies, 
immunomodulation and immunosuppression including glucocorticoids) may be beneficial. 
One of the challenges is that irreversible neuronal damage may have already happened by 
the time the diagnosis has been established. 
Supportive Care The symptoms of PNS can have a major impact on the patient’s quality 
of life and on individual care requirements. It is recommended that a Health Needs 
Assessment (DoH 2011) is undertaken when symptoms first present, prior to starting 
any intervention and at the end of treatment. This assessment should take into account 
the patient’s physical, psychological, social, spiritual and practical needs and will enable 
interventions to be put in place to maximise the quality of daily life. When symptoms 
present the psychological and physical impact can be devastating as immobility, 
discomfort, cognitive dysfunction and loss of the ability to self-care can affect the patient 
and care providers. In the UK the role of the Lung Cancer Nurse Specialist (RCLCF 2014) 
is ideally placed to address these concerns not only when the diagnosis is first made 
but throughout treatment and beyond by providing psychological support and symptom 
management, home care coordination and referrals to other health professional such as 
Physiotherapists and Occupational Therapists. Once primary treatment has taken place 
the ongoing monitoring of response to treatment is required together with a comparison 
of presenting symptoms. Patients should know what to do if these reoccur and how they 
should access their clinical team. 
Conclusion The management of PNS is complex and in the absence of randomised trials 
there is available guidance to help with the management of Paraneoplastic Syndromes. 
The individual care of each patient should be tailored to the diagnosis, symptoms and 
holistic needs.
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Paraneoplastic Syndromes (PNS) are a group of clinical disorders that are associated 
with malignant diseases that are not directly related to the physical effects of the primary 
tumour (Spiro 2007). The mechanisms by which PNS occur is not fully understood 
(Dalmau 2014) but is related to the production of polypeptide hormones or cytokines 
by the cancer itself or an immune response to the cancer. PNS may occur in 10% of 
patients with lung cancer and with the type of cancer influencing the nature of syndrome 
(Kanaji 2014). A wide variety of PNS have been associated with lung cancer with the most 
common syndromes being endocrine and neurological syndromes. This paper will only 
address these two groups of syndromes. 
Paraneoplastic Endocrine Syndromes include:
Inappropriate Antidiuretic Hormone Secretion:
• hyponatremia is seen in 30-70% of patients with lung cancer with only 1-5% having 
symptoms and mostly associated with small cell lung cancer (SCLC);
• symptoms include confusion, seizure, reduced consciousness and coma (Spiro 
2007).
• Hypercalcaemia:
• the incidence ranges from 2-12% in lung cancer;
• symptoms include nausea, vomiting, abdominal pain, constipation, polyuria, thirst, 
dehydration, confusion and irritability (Spiro 2007).
• Cushing Syndrome:
• production of adrenocorticotropic hormone(ACTH) is the most common explanation 
with approximately 50% being neuroendocrine lung cancers with 36%-46% carcinoid 
tumours and 8%-20% SCLC of cases;
• symptoms include weakness, muscle wasting, drowsiness, confusion, psychosis, 
oedema, hypokalaemia alkalosis and hyperglycaemia.
• hypertrophic osteoarthropathy (HOA) and finger clubbing:
• 90% cases in lung cancer
• Prevalence of 5-15% in lung cancer
• most common with squamous cell and adenocarcinoma.
• occurs due to proliferation of connective tissue beneath the nail bed with HOA 
causing distal expansion of the long bones;
The Paraneoplastic Neurological Syndromes most commonly displayed are peripheral 
neuropathies and include Lambert-Eaton Myasthenic Syndrome, necrotizing myelopathy, 
cerebral encephalopathy, visual loss and visceral neuropathy. Symptoms include muscle 
weakness, cognitive and personality changes, ataxia, cranial nerve deficits or numbness. 
Classical and Non-Classical Symptoms have been defined (Graus 2004 Table 1) to 
aid in diagnosis. These syndromes are often associated with the presence of anti-Hu 
antibodies which are produced together with antigen-specific T lymphocytes and attack 
parts of the nervous system (Pelosof 2010). This syndrome is detected in 80% of cases 
before cancer is diagnosed (Honnorat 2007) and upto 20 per cent of those with SCLC 
have detectable antibodies although this syndrome will not necessarily develop (Darnell 
2003). There is a reported 4-5% incidence in SCLC. 
Diagnostic Pathway Patients with lung cancer usually present with multiple symptoms 
with a time delay between symptom recognition and the ultimate diagnosis of lung cancer. 
The presence of a PNS may not necessarily preclude treatment with a curative intent 
which may help in the improvement of symptoms. Pathways of care commence with 
clinical evaluation, CT scan, blood screen and rapid evaluation for the next diagnostic 
test. It is at this point where a PNS may become apparent and can aid in the diagnosis 
of lung cancer. Where there are concerning symptoms for Paraneoplastic Neurological 
Syndrome and there is difficulty in identifying the underlying cancer:
• antibody screening can be considered but require considered interpretation 
as patients without cancer can harbour paraneoplastic antibodies, variation in 
the consistency of the presence of antibodies can be associated with different 
syndromes and the absence of antibodies may not exclude a syndrome;
• PET may identify neurological syndrome activity;
• electrophysiology may confirm the syndrome but are not always associated with 
cancer;
• MRI can assist in the diagnosis of limbic encephalitis as atrophy can be detected.
Treatment As symptoms often present prior to the confirmed diagnosis it is important 
to treat the signs and symptoms of:
Hypercalcaemia with:
• an increase in fluid intake;
• Bisphosphonates.
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Occupational therapists are integral members of the lung cancer multidisciplinary team, 
working with lung cancer patients in the inpatient hospital setting, hospital outpatient 
clinics and in the community. The focus of the occupational therapist is on enabling 
an individual’s participation in chosen everyday activities (Morgan DD and White KM, 
2012). For people living with metastatic lung cancer, this focus is on enabling continued 
participation in the face of functional decline and increasing symptom burden. This focus 
can also encompass rehabilitation for people who have undergone curative treatment for 
their lung cancer, with the aim of facilitating a return to previous chosen and meaningful 
roles. Occupational therapists can assist people living with lung cancer prioritise their 
goals while managing the side effects of treatment. They also have a vital role in assisting 
the person living with lung cancer as their function changes with progressive disease. 
People living with lung cancer experience high symptom burden, which can include 
refractory breathlessness, fatigue and pain (Yang P et al., 2012). There is a growing 
body of evidence for occupational therapy interventions for people living with cancer 
to assist with symptom management and many of these interventions are applicable 
for people living with lung cancer (Morgan DD and White KM, 2012). Interventions 
utilised by occupational therapists when working with people living with lung cancer 
include task analysis, task modification, equipment prescription, priority setting 
and relaxation therapy. The occupational therapist is in a unique position to facilitate 
mastery of non-pharmacological interventions to assist in the management of refractory 
breathlessness and fatigue. It is important to teach techniques early in the lung cancer 
trajectory, to ensure mastery prior to the escalation of symptoms. This assists with 
preventing decreasing function and supports the engagement of the individual in valued 
activities (White KM, 2013). Occupational therapy management of breathlessness has 
been extensively researched in chronic lung conditions. The work of Migliore Norweg 
et al (Migliore Norweg A et al., 2005)focuses on interventions targeting improvement in 
everyday function for people living with COPD through mastery of breathing techniques 
and task modification. These interventions focus on managing breathlessness during 
activities that provoke breathlessness. Participation in pulmonary rehabilitation 
programmes is an established form of care for people with chronic lung disease. There 
is now a growing interest in the role of pulmonary rehabilitation to optimise function 
pre and post surgery for lung cancer (Pasqua F et al., 2013), as well as the role of 
exercise generally for people living with lung cancer (Bade BC et al., 2015, Lin Y et al., 
2014, Cheville AL et al., 2012). The use of rehabilitation programmes for people living 
with cancer are being reported more frequently in the literature, and the occupational 
therapist is identified as a key team member (Silver JK and Gilchrist LS, 2011). Energy 
conservation techniques are useful in managing both fatigue and breathlessness. The 
occupational therapist completes a detailed assessment, including task analysis of how 
the person completes their everyday activities. This then informs interventions which can 
include behaviour and task modification, relaxation techniques, biofeedback, prescription 
of adaptive techniques and environmental modifications (White, 2013). Those living with 
advanced lung cancer may not have the time, energy or function to achieve full mastery 
of fatigue and breathlessness management techniques. Using adaptive equipment can 
be an effective and immediate way of improving function and assisting with symptom 
management for people living with advanced lung cancer. 
Conclusion Occupational therapy interventions aim to improve and optimise a person’s 
participation in everyday activities (World Federation of Occupational Therapy, 2010). 
Internationally, there are few occupational therapists that specialise in the field of lung 
cancer. This has led to a paucity of evidence and research into occupational therapy 
interventions that may benefit people living with lung cancer. Many interventions utilised 
by occupational therapists have a research base in non-malignant conditions and nursing 
literature. It is critical that occupational therapists build on this evidence and continue 
to research the efficacy of interventions used to optimise function for people living with 
lung cancer. The focus of occupational therapy interventions for people living with lung 
cancer is on enabling continued participation in valued and chosen activities in the face 
of functional decline and increasing symptom burden. 
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There were 35,371 deaths from Lung cancer in the United Kingdom in 2012 and it remains 
the leading cause of United Kingdom cancer deaths (Cancer Research UK 2014). Many 
patients can carry a high burden of symptoms, so the nature and scale of the disease 
can present significant challenges for the patients, their carer’s and for those who care 
for them within the National Health Service. As health care professionals we have a 
responsibility to provide an excellent service including communication and support of the 
highest standard. Lung Cancer Nurse Specialists (LCNS) are involved across all stages 
of the patient journey and have a distinctive role in communicating information and 
enabling patients with lung cancer to take an inclusive role in decisions around their care. 
They are mostly known as the patient’s keyworker, although the identified keyworker 
may change throughout the pathway according to the patient’s needs. Effective face to 
face communication along with regular telephone contact between the LCNS and the 
patient and carers can aid the development and implementation of individualised care 
plans. The LCNS should be available at all stages to complement care and facilitate best 
practice, responsible for the provision of information to patients and their families in a 
timely manner, within a supportive environment (NICE 2011). With an average annual new 
caseload of 122 patients per LCNS (UKLCC, 2012) there can be an overstrain on the level 
of support provided by the LCNS which can lead to inequity of access and inconsistent 
support (Leary et al, 2008). Yet consistent specialist support and advice are essential 
as individuals care needs and treatment options can be complex. With this in mind we 
have restructured the lung cancer service at Aintree Hospitalwith the development of a 
support worker role. Implementation of the role is competency led and training needs 
structured around specific pathways (Brummell et al, 2014). With correct delegation, 
such as being an access point for patients and health care professionals, the support 
worker can release the LCNS to enable a more effective use of LCNS skills, improving 
patient experience. United Kingdom Lung Cancer Coalition (UKLCC, 2012) recommends 
that all lung cancer patients should be able to access LCNS support and advocacy when 
they need it throughout their whole journey to support their holistic needs. Holistic 
care is total patient care that considers the physical, psychological, social, economic 
and spiritual needs of the person with his or her response to illness. Holistic Needs 
Assessment (HNA) helps form a base on which to navigate care needs of the individual. 
It provides a framework to discuss individuals concerns and how they are feeling, to 
identify and understand individual needs, enable care that is personalised, sign post to 
appropriate agencies, and enables patients to access, identify, appraise and interpret 
information. HNA should be performed at or near diagnosis and at the end of treatment 
and whenever health and social needs change. Indeed, work undertaken by Tod et al 
(2013) ‘Opening Doors to treatment’ explored the impact of LCNS’s on access to anti-
cancer treatment. The report demonstrated why and how the LCNS has an impact in 
accessing treatment, with the communication and coordination aspects of the LCNS role 
being essential in realising the impact in increasing treatment access. This paper sets out 
to demonstrate as to why the LCNS in the UK is pivotal to navigating the care of the lung 
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training because it can strengthen weakened muscles. Fatigue can lead to sedentary 
behavior. Muscle mass will decrease if you sit or lie in bed a lot. By getting stronger 
it may be possible to return to work and take care of activities of daily living. Strength 
training can help you to improve balance, posture and increase bone strength. Patients 
with shortness of breath due to their cancer should perform stretching exercises daily 
to increase lung capacity. These can help to keep chest muscles loose and encourage 
deep breathing. Stretching can also help improve posture. Sitting down all day at a desk 
or driving can cause rounded shoulders and kyphosis, which can decrease lung capacity. 
It is also good to exercise prior to surgery and treatments and for those who are not 
surgical candidates. Exercise before surgery has multiple benefits such as improved 
quality of life, pulmonary capacity, endurance and strength coupled with reduced fatigue 
and surgical complications. Fitness level before surgery may predict risks of surgical 
complications and pre-surgery fitness levels may also predict how long lung patients may 
live beyond traditional markers of longevity. Despite limited lung capacity, exercise can 
help patients with lung cancer improve their quality of life by reducing fatigue, adverse 
symptoms and depression, while improving muscle strength, flexibility and mood. 
Keywords: exercise, physical activity, importance of exercise for lung cancer survivors, 
benefits of physical activity for lung cancer patients
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The ability to identify and therapeutically target specific mutations (typically exon 19 
deletions and L858R) in the Epidermal Growth Factor Receptor (EGFR) gene marked 
the beginning of personalized medicine for NSCLC. Phase III clinical trials with the EGFR 
tyrosine kinase inhibitors gefitinib, erlotinib and afatinib demonstrated superiority 
of these agents over chemotherapy establishing these agents as standard therapy 
for EGFR mutation positive NSCLC. However, resistance to therapy invariably occurs 
through multiple, heterogeneous mechanisms of which a secondary gatekeeper mutation 
in EGFR, T790M, is the most frequent, being identified in 50-60% of patients at the 
time ofprogression after initial EGFR TKI. EGFR T790M is thought to result in resistance 
by increasing the affinity for ATP rather than simple stearic hinderance. Recently novel 
irreversible inhibitors, structurally distinct to earlier generation compounds, have been 
developed that inhibit T790M while having relatively less potency against wildtype EGFR 
including rocelitnib (C01686) and AZD9291. Phase I/II studies have demonstrated 
responses to rocilitinib (CO1686) and AZD9291 in about 60% of patients with T790M 
positive disease. Preliminary data indicates the degree of response may correlate with 
the allelic frequency of T790, with greater degrees of responses in patients with higher 
proportions of T790M. Resistance to these compounds has been described clinically 
and includes loss of T790M, small cell transformation as well as development of tertiary 
mutations C7957 (resistance to AZD9291).
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Recent advances in targeted therapies and the molecular analysis of tumor samples have 
led to recommendations that EGFR mutation testing be implemented as standard of care in 
non-small cell lung cancer (NSCLC) of non-squamous type. This is in large part because of 
substantial benefits provided to patients treated with EGFR tyrosine kinase inhibitor (TKI) 
therapy, particularly those patients whose tumors are positive for activating, sensitizing 
mutations in EGFR. Despite these benefits, resistance to EGFR TKIs inevitably develops in 
all cases. The most common molecular mechanism of acquired resistance in this setting, 
occurring in approximately 50% of cases, is the evolution of a secondary ‘gatekeeper’ 
mutation which results in p.T790M (T790M). This acquired mutation results in a reduction 
in affinity of EGFR for the TKIs, while preserving catalytic function of the tyrosine kinase 
domain. The testing for T790M at the time of progression on TKI has emerged as an 
important clinical practice, as new-in-class EGFR TKIs demonstrate activity against this 
subset of resistant tumors. Because T790M initially emerges as a sub-clonal event, 
technical elements involved in its detection become paramount. Most importantly, 
achieving a high technical sensitivity to allow for detection of a sub-clonal (low alleleic 
frequency) phenomenon is critical for assays designed to detect this mutation. Sanger 
sequencing, for example, lacks the technical sensitivity to adequately identify low variant 
frequency events, and therefore alternate mechanisms of testing are required. Additional 
factors requiring major consideration in detection of T790M include potential sampling 
bias (particularly for the small biopsies or fine needle aspirates that are typically 
acquired), heterogeneity between multiple progressing lesions, cellular components of 
post-treatment biopsies, and technical ability to perform tumor enrichment to enhance 
detection. Genomic alterations resulting in T790M are uncommonly detected prior to TKI 
therapy, likely owing to the technical sensitivity of assays used to query for the presence 
of this alteration. Studies employing extraordinarily sensitive assays have demonstrated 
the presence of T790M as a subclonal event prior to TKI therapy in many tumors. Thus 
clonal selection under the pressure of TKI is a major mechanism allowing this alteration 
to be identified in the setting of progression on targeted therapy using less analytically 
sensitive assays. The secondary implication of this finding is that assays employed for 
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ED12.05 Overcoming the Challenges of Getting Patients Through Chemo and 
XRT Wilma Uyterlinde Thoracic Oncology, NKI-AVL, Amsterdam/Netherlands
Due to toxicity during chemoradiation, patients are at risk for discontinuation 
of treatment and might not benefit optimally from this treatment. Small 
intervention trials are a possible tool to reduce toxicity within limited time. 
Toxicity and discontinuation of treatment were scored in 188 NSCLC 
patients treated with concurrent chemoradiotherapy. Literature based 
small intervention studies were performed for the reduction of toxicity 
Severe toxicity was seen in 33% of the patients; discontinuation of treatment in 20%. 
Esophagitis, gastro-intestinal toxicity and renal impairment were the most prominent 
toxicities. Intervention studies led to a reduction of nausea, weight loss, nephro toxicity 
and dysphagia. CCRT for NSCLC is the treatment of choice at the cost of severe toxicity. 
Small intervention studies have shown to be beneficial in reducing severe toxicity, 
enabling patients to accomplish CCRT en thus benefit optimal from this treatment.
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ED12.06 Importance of Exercise in Lung Cancer Treatment Carol Michaels 
Cancer Exercise, Recovery Fitness LLC, Short Hills/NJ/United States of America
Lung cancer survivors may suffer difficulty breathing, coughing, fatigue, anxiety, 
depression, insomnia and pain. Lung cancer survivors often experience a reduced 
quality of life. The good news is that quality of life can be improved with exercise and it 
should be considered for every patient. Exercise reduces the risk of lung cancer and is 
associated with reduced mortality. Exercise also lessens adverse symptoms and may 
improve quality of life, by enhancing physical and social function and lessening fatigue. 
The following are three of the more recent studies that have examined the benefits of 
exercise for lung cancer patients: 
1. A 2012 study from Denmark looked at 25 patients with stage III/IV non-small cell cancer, 
and four patients with extensive disease small cell lung cancer. They participated in a 
6-week supervised structured exercise and relaxation-training program. The researchers 
found that of the 23 patients, who completed the program, the majority adhered to 
the program and there were significant improvements in VO2 peak and 6-minute 
walking distance, as well as in muscle strength. The patients also reported a significant 
improvement in emotional well being. 2. In 2014, a larger study in Germany, included 
40 patients with predominantly advanced NSCLC, who were receiving simultaneous 
or sequential radio chemotherapy or chemotherapy alone. The authors concluded, “ In 
this pilot study, endurance and strength capacity improved over time, indicating the 
rehabilitative importance of the applied intervention.” 3. In 2015, Dr. Gerard Silvestri, Dr. 
Brett Bade, David Thomas, and JoAnn Scott at the Medical University of South Carolina 
researched the benefit of physical activity and exercise for lung cancer patients. Their 
results were published in the Journal of Thoracic Oncology, June 2015. They found that 
physical activity should be considered as a therapeutic option for patients with lung 
cancer. They also concluded that exercise is safe, reduces symptoms, improves quality 
of life, increases exercise tolerance, and decreases length of hospitalization and post-
surgery complications for lung cancer. Additionally, health care professionals should 
recommend exercise and encourage physical activity in patients at any stage of lung 
cancer. We can conclude from these studies and from my experience of working with 
this population that lung cancer survivors benefit from cancer exercise programs. These 
programs teach survivors how to exercise properly, and provide an exercise schedule. 
They can also provide a social and educational forum. Lung cancer patients may see 
even the idea of exercising as overwhelming, particularly if they suffer from shortness 
of breath, coughing or fatigue. The Medical University of South Carolina study found 
that patients with lung cancer want advice about physical activity from a cancer center 
physician before, during and following cancer therapy. The researchers also found that, 
when patients received this type of advice, there was a greater likelihood that the patients 
would comply with an exercise program. Why exercise during and after treatment or 
surgery? Exercise is a safe and inexpensive cancer therapy that reduces symptoms 
and improves quality of life. It improves strength, endurance, pulmonary function and 
flexibility, decreases the side effects of treatment and post-operative complications. 
Inactivity in cancer patients is associated with poorer outcomes and can cause the heart 
and muscles to regress and become less efficient. Being physically active not only helps 
prevent lung cancer in the first place, but it appears to also improve survival and quality 
of life for those already diagnosed. How much and what type of exercise is needed? The 
goal is to be able to exercise every day with a total of 150 minutes a week, the same as 
a healthy person. Lung cancer survivors should progress slowly, set goals, and listen 
to their bodies. Exercises can be performed initially in small increments of 10 minutes 
at a time depending on the fatigue level. Aerobic exercise is a great way to improve 
fitness. It not only improves cardiac function, but also improves the oxygen capacity. 
Aerobic exercises include walking, dancing, or any activity that increase the heart rate. 
Participate in enjoyable low intensity activities. Low intensity exercise such as walking 
is a safe way to begin. Aerobic exercise can be performed at a time that is convenient 
and there is no need to belong to an expensive gym. You can start by walking around 
a room in the house and slowly increase the distance walked. This can be done several 
times a day. You can use a pedometer to measure your steps and to help you set and 
attain goals. When sedentary one loses strength and gets weaker. Try to add movement 
to your day. You can take the stairs, park far from your destination, dance or whatever 
you enjoy that involves movement. Lung cancer patients may also benefit from strength 
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Erlotinib & crizotinib – Hypothetical option for MET-mediated resistance but requires 
dose reduction of both (Ou et al, ASCO, 2012) Nivolumab – 82 patients with prior TKI 
and chemo treated on CheckMate 057, and there was no OS benefit seen compared to 
docetaxel (HR 1.18) (Paz-Arez, ASCO, 2015) · Erlotinib & nivolumab – 3 of 20 patients 
responded (15%) in the phase I study (Rizvi et al, ASCO, 2014) · Brain radiation – For 
CNS-only progression, radiation followed by restarting TKI can gain additional months 
of PFS (Weickhardt et al, JTO, 2012) · SBRT or surgical resection – An approach that 
is hypothesized to debulk a single resistant clone, thus delaying clinical resistance and 
prolonging the progression-free period (Weickhardt et al, JTO, 2012; Yu et al, JTO, 2013) 
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ED13.04 3rd Generation EGFR TKI Keunchil Park Div of Hem/ONC, Samsung Med Ctr, 
Sungkyunkwan Univ School of Med, Seoul/Korea
The introduction of EGFR TKIs has dramatically changed the natural history of advanced 
and/or metastatic NSCLC. The objective response rates of 50 to 70% are achieved 
and overall survival has improved from 4-5 months to over 30 months in EGFRm(+) 
NSCLC patients. However, unfortunately the patients are not cured of the disease and 
after a median PFS of 9 to 13 months, the disease comes back eventually with the 
emergence of acquired resistance (AR) to EGFR TKIs. Mechanisms of AR include target 
gene modification, activation of bypass tracks or histologic transformation, etc. In 
approximately 60% of patients, the mechanism of resistance is due to the acquisition 
of a gatekeeper T790M EGFR mutation. This T790M mutation leads to an enhanced 
affinity for ATP, thus reducing the ability of ATP-competitive reversible EGFR tyrosine 
kinase inhibitors, including gefitinib and erlotinib, to bind to the tyrosine kinase domain of 
EGFR. One strategy to overcome this mechanism of resistance mediated by target gene 
modification is through the use of more potent, novel, next-generation inhibitors. The 
‘2nd-generation’ irreversible EGFR inhibitors such as afatinib and dacomitinib, covalent 
inhibitors of HER family kinases, showed preclinical activity against T790M in vitro. Both 
agents demonstrated excellent clinical activities in EGFR TKI-naïve patients with EGFR-
mutant NSCLC in terms of response rate and progression-free survival as compared to 
cytotoxic chemotherapy. However, the results of treatment in patients with EGFR-mutant 
lung cancer who progress on an EGFR TKI are quite disappointing. Studies of afatinib 
monotherapy among patients with acquired resistance to erlotinib or gefitinib showed 
a response rate of only 7-8% and a progression-free survival of 3 to 4 months. This 
result may be due to the fact that physiologic doses of current generation irreversible 
EGFR TKIs do not fully inhibit EGFR T790M and dose escalation of 2nd-generation EGFR 
inhibitors is limited by on-target inhibition of wild-type EGFR, which leads to EGFR-
mediated toxicity (skin rash and diarrhea). The so-called ‘3rd-generation’ EGFR TKIs 
are pyrimidine-based irreversible inhibitors and has mutant-specific activity including 
T790M mutation while sparing wild-type EGFR. There are several 3rd-generation EGFR 
TKIs under development, e.g., AZD 9291, CO-1686(Rociletinib), HM61713, ASP8273, 
EGF816, to name a few. The early clinical trials of the 3rd-generation EGFR TKIs have 
demonstrated a promising efficacy in patients with advanced EGFR-mutated NSCLC who 
have progressed on prior EGFR TKI therapy, including cohorts of patients with EGFR 
T790M-mutated NSCLC. For CO-1686, the reported overall response rate in the phase 
1 study was 59%(27/46) in patients with centrally confirmed EGFR T790M-containing 
tumors. Median progression-free survival was 13.1 months. Likewise, initial results from 
the phase I trial of AZD9291 demonstrated a response rate of 61%(78/127) in patients 
with EGFR T790M positive tumors with median PFS of 9.6 months. Both AZD9291 and 
CO-1686 have recently been granted Breakthrough Therapy designation by the US FDA 
based upon results from early clinical studies. Early phase I/II results of HM61713 also 
showed encouraging anti-tumor activity with objective response rate of 55%(34/62) in 
T790M positive Korean NSCLC patients and global phase II trial is planned to launch. 
The early results of EGF816 and ASP8273, another irreversible 3rd-generation EGFR 
TKIs under clinical development, were recently reported and both agents demonstrated 
encouraging response rates of 50-60% in T790M(+) NSCLC patients after progression 
on a 1st or 2nd generation EGFR TKIs. Further studies are ongoing and mature results are 
awaited. In brief, many of the 3rd generation EGFR TKIs currently at various stages of 
development look so promising with encouraging clinical activities for T790M(+) NSCLC 
patients esp. in terms of response rate. In general these newer generation EGFR TKIs also 
have much better toxicity profiles as they spare the wild-type EGFR, e.g., less skin rash, 
diarrhea or paronychia compared with the 1st- or 2nd-generation EGFR TKIs though the 
toxicity profiles are slightly different one from another at some aspects. Since the follow-
up is rather short we need longer follow up to confirm survival benefits. We certainly have 
made a significant progress in the management of advanced NSCLC with AR to EGFR 
TKIs, however, there are still several issues to be investigated to further improve the 
treatment outcomes, e.g., optimal timing and/or sequence of the 3rd generation EGFR 
TKIs, how to delay or prevent the emergence of resistance to 3rd generation agents, CNS 
progression, management of non-T790M-dependent AR to EGFR TKIs, etc. 
References
Cong CR and Jänne PA. The quest to overcome esistance to EGFR-targeted therapies in 
cancer. Nat Med. 2013;19(11):1389-1400
Lovly CM and Shaw AT. Molecular Pathways: Resistance to Kinase Inhibitors and 
Implications for Therapeutic Strategies. Clin Cancer Res. 2014;20(9):2249–56.
Jänne PA et al. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer, N 
Engl J Med. 2015 Apr 30;372(18):1689-99.
Sequist LV et al. Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer, N Engl J Med. 
2015 Apr 30;372(18):1700-9.
detection of T790M must be adequately sensitive, but not over-sensitive to allow for 
the appropriate identification of what can best be considered the dominant mechanism 
of resistance. Others have postulated that highly sensitive detection of T790M prior to 
therapy could be used to determine a combination therapy approach which effectively 
prevents the evolutionary advantages of this sub-clone. In the uncommon instance 
that this alteration is identified at a high level pre-TKI therapy using standard assay 
approaches (<5% of cases), it can be associated with a germline alteration leading to 
a genetic predisposition for lung cancer. Recently, there has been great interest in the 
potential to monitor for the emergence of T790M alterations in the periphery, either 
via circulating tumor cells or circulating cell-free DNA. This approach is particularly 
attractive as it reduces requirements for invasive tissue sampling and can allow for a 
continuous monitoring approach. While the technical elements of liquid biopsy testing 
have been diversely applied, with very little in the way of consensus on methodology, 
numerous studies have demonstrated the promise of liquid biopsy approaches for both 
primary mutation detection as well as evaluation for T790M. In some cases, peripheral 
detection of T790M was demonstrated substantially before radiographic evidence 
of progression, a key proof-of-principle that such monitoring could be utilized as an 
effective approach for disease monitoring. Similar approaches for chimerism analysis 
or BCR-ABL1 transcript monitoring in the setting of bone marrow transplant or TKI 
therapy for chronic myelogenous leukemia, respectively, have been very successful. 
Major challenges still exist for both tissue-based and peripheral blood-based detection 
of T790M. Determination of the ideal level of assay technical sensitivity required for 
prediction of response to T790M-directed therapies will be a critical component to the 
implementation of these drugs in the clinic. In addition, for tissue biopsies, techniques 
to enhance the tumor cellularity of tested material and to avoid sample bias will need 
to be further refined. Liquid biopsy techniques, though demonstrating extraordinary 
promise, are widely divergent in terms of methodologies employed, and further study in 
this technological space is needed. 
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ED13.03 How to Make the Best Use Of “Old” Drugs Geoffrey R. Oxnard Lowe Center 
for Thoracic Oncology, Dana-Farber Cancer Institute, Boston/MA/United States of America
Acquired resistance to initial EGFR TKI invariably develops in patients with EGFR-mutant 
lung cancer after a median of 9-14 months. Though acquired EGFR resistance in NSCLC 
is a clinical condition that is treated and studied worldwide, there has until recently been a 
paucity of prospective data describing the best practices for managing these patients. In 
2014, the first phase III trial studying EGFR-mutant lung cancer with acquired resistance 
was reported. Presented at ESMO 2014, the IMPRESS trial established platinum doublet 
chemotherapy as the standard second-line therapy for these patients, with no benefit to 
additionally continuing EGFR TKI at progression. And yet, even with standard second-
line therapy established, there remain questions regarding how to manage patients 
with progressive disease (PD) on EGFR TKI, questions that will likely grow even more 
complex should newer agents reach the market. One way of framing this question is 
to consider the tools we have for managing acquired EGFR resistance, and then to 
consider how to best utilize them. The following outline provides a brief summary of 
therapeutic strategies that will be discussed further at WCLC 2015. Continued TKI after 
PD - Feasible for a median of 3 months, especially in those with slow or asymptomatic 
PD (Lo et al, Cancer, 2015; Park et al, ESMO, 2014) · Retreatment with TKI after PD on 
chemo - 25% RR on a prospective phase II study of 20 patients, but responses were brief 
with a 3.4 month median PFS (Oh et al, Lung Cancer, 2012) Afatinib – Limited activity 
in LUX-Lung 1 trial with 7% RR and 3 month median PFS (Miller et al, Lancet Oncol, 
2010) Afatinib / cetuximab – 29% RR and 4.7 month median PFS, with responses seen 
regardless of T790M status (Janjigian et al, Cancer Disc, 2014) Cytotoxic chemotherapy 
– Cisplatin /pemetrexed has a 34% RR and 5.4 month median PFS after PD on gefitinib 
(Mok et al, ESMO, 2014) Erlotinib & bevacizumab – May delay development of PD, 
but no prospective data for treatment of resistance (Seto et al, Lancet Oncol, 2014) 
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Park K et al. Updated safety and efficacy results from phase I/II study of HM61713 in 
patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed 
previous EGFR-tyrosine kinase inhibitor (TKI). PASCO 2015 #8084
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a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-
small cell lung cancer (NSCLC) harboring T790M. PASCO 2015 #8013
Goto Y et al. ASP8273, a mutant-selective irreversible 
EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: 
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from adenomatous hyperplasia (AAH) to invasive adenocarcinoma (AC). Histologic 
heterogeneity can be reflected in uncertain growth rates, making therapeutic decision 
making challenging. While historically GGOs have been managed surgically or with close 
surveillance, chemotherapeutic strategies have been employed. In addition, recent 
identification of relevant, driver mutations within GGOs has allowed for consideration of 
targeted therapies including tyrosine kinase inhibitors (TKIs). Given that GGOs frequently 
represent bronchioloaveolar carcinoma (BAC) (recently reclassified as adenocarcinoma 
in situ, lepidic predominant adenocarcinoma or mucinous adenocarcinoma), an overview 
of chemotherapeutic and targeted strategies for such lesions would require extrapolation 
from the BAC literature. Despite longstanding recognition of BAC as a distinct subclass of 
lung adenocarcinoma, few completed prospective trials are available to inform on therapy 
decisions. To date, only two, small phase II prospective studies evaluating cytotoxic 
chemotherapy for treatment naïve patients with multi-focal BAC have been published. 
Both trials evaluated single agent paclitaxel and resulted in disappointing response rates 
(RR) of 11% and 15%, respectively [4, 5]. Post hoc analysis from the sentinel ECOG 1594 
study demonstrated a response rate of only 6% to platinum chemotherapy in patients 
with BAC [6]. In contrast, the French IFCT-0401 trial demonstrated a RR of 21% and PFS of 
3 months in 43 patients with BAC who received chemotherapy (platinum doublet; N=38) 
after disease progression on first line gefitnib[7]. Experience with third-generation 
agents such as pemetrexed or gemcitabine has been described only in case reports or 
retrospective series; however, these agents have demonstrated acceptable outcomes 
and may be considered in systemic treatment plans Subgroup analysis of early studies 
evaluating the role of EGFR TKIs in NSCLC demonstrated disproportionate and often 
dramatic responses in those tumors formally classified as BAC. This observation led to 
several trials exploiting gefitinb or erlotinib as initial therapy for patients with BAC. While 
overall responses rates in these studies were similar to studies evaluating chemotherapy 
(RR: 15 to 25%) patients with EGFR mutations derived greater benefit. For example, in 
a study evaluating erlotinib as initial therapy for patients with advanced BAC, the RR for 
those with EGFR mutations was 87% compared to 7% for those without EGFR mutations 
[8]. The association of EGFR mutations with GGOs and the non-mucinous subtype of BAC 
is supported by multiple studies including a recent comprehensive analysis evaluating 
genetic alterations in 217 resected GGOs from 215 lung cancer patients[9]. In this 
study, EGFR mutations were detected in 119 (54.8%). Other relevant driver mutations, 
including ALK mutations (2.8% in the aforementioned study evaluating resected GGOs) 
and KRAS mutations in mucinous subtype of AIS, have also been identified. This allows 
for consideration of other targeted therapies including ALK directed therapies (crizotinib, 
certinib, alectinib) and those targeting KRAS (selumetinib). Despite the well-established 
paradigm of offering targeted therapy to molecularly characterized subgroups, the 
clinical scenarios for patients with multiple GGO’s can be unique in several ways. Should 
these patients, if confirmed to have EGFR mutations, be treated with TKIs if lesions are 
slow growing or not growing at all? Or, should the indolent biology of such lesions trump 
the actionable mutation when making a therapeutic decision? In addition, the notion that a 
mutation discovered on a biopsied or resected GGOs is representative of all GGOs within 
a patient may be incorrect. A recent analysis evaluating 72 resected GGO lesions from 35 
patients, all with more than one GGO, demonstrated a high rate of mutation discrepancy. 
In this study, 80% of patients (24/30) who harbored at least one genetic alteration had a 
driver mutation discrepancy within another GGO supporting the hypothesis that multiple 
GGOs seem to arise from different primary clones [10]. Given that patients with GGOs 
represent a spectrum of tumor biology and clinical behavior, an individualized approach 
that affords flexibility should be employed when implementing treatment strategies 
(Figure 1). Management decisions need to factor in the potential for indolent disease 
with consideration of a watch and wait approach for stable or slow growing lesions. 
If the clinician identifies progressive disease, systemic options should be entertained 
and include both chemotherapy and TKIs for patients who harbor actionable mutations. 
Further studies are needed to better define the clonal relationship of GGOs in an effort to 
optimize targeted approaches for such patients.
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MS01.02 What Is the Role of Surgical Resection in the Setting of Multiple 
GGO’s? Raja Flores Department of Thoracic Surgery, Icahn School of Medicine at Mount 
Sinai, New York/NY/United States of America
Main point: Given the nonspecific nature of a GGO or multiple GGOs, a conservative 
approach to GGOs without a solid component is suggested. Ground glass opacity 
is a localized nodular lesion which appears as an undetermined finding ‘of hazy lung 
opacification, without obscuration of the underlying vascular markings’ on a CT scan. 
Any condition that decreases the air content of the lungs without totally obliterating 
the alveoli can produce ground glass opacity. GGOs, also known as nonsolid nodules, 
have been known to decrease or increase in size and/or disappear. There are benign 
and malignant causes of GGOs. A GGO can be indicative of inflammation, infection and 
fibrosis that are usually not fatal: pulmonary edema, alveolar proteinosis, many causes of 
alveolitis or interstitial pneumonitis, including idiopathic pulmonary fibrosis, sarcoidosis, 
hypersensitivity pneumonitis, early radiation pneumonitis, aspergillus infection, 
pneumonia, and bronchiectasis. GGOs can also be an early finding of neoplasms such as 
bronchioalveolar carcinoma (BAC). A recent study has shown that lung cancers appearing 
as nonsolid nodules were Stage I adenocarcinomas. Analysis of 57,496 participants in 
the International Early Lung Cancer Action program has shown a 100% survival rate 
regardless of the time from diagnosis to treatment and tumor size. There are methods to 
indicate malignancy without surgery: marginal characteristics, the size and development 
of the solid component or the attenuation on the CT scan, patient’s medical history of 
cancer, and fine needle aspiration. These are not without some controversy. A solid 
component is concerning because they are areas of collapsed alveoli or fibroplastic 
proliferation which signifies more invasive lesions. However, nonsolid nodules can 
be followed safely by CT screening annually to see if they transition to a part-solid 
component. Lung cancers diagnosed among nonsolid nodules tend to be slow growing 
and indolent in nature. The recent I-ELCAP study shows that until the identification of 
molecular markers, CT imaging can differentiate among different levels of lung cancer 
sufficiently early so delay in treatment did not change prognosis. A surgeon has to weigh 
the risks inherent to surgery while leaving the patient with as much lung as possible. 
Note that a patient’s desire to have the nodule removed may factor in. If feasible, follow 
the patient and if the GGO’s morphologic characteristics begin to change dramatically, 
proceed with surgical intervention, preferably VATS. In most cases, with a conservative 
approach, the patient has enough pulmonary reserve for aggressive action if required. 
Location of the lesions may make surgical resection challenging. The decision to perform 
a lobar versus sublobar resection is based on multiple factors and varies from patient 
to patient. 
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MS01.03 Is There a Role for Targeted Therapy or Conventional Chemotherapy 
in Patients with Multiple GGO’s? Benjamin P. Levy Thoracic Oncology, Mount Sinai 
Hospital, New York/NY/United States of America
Recent advances in diagnostic imaging and the use of low dose screening CT scans for 
high risk individuals has increased detection of ground-glass opacities (GGOs). These 
lesions are defined as hazy lung opacities on CT with preservation of bronchial and 
vascular markings, and are typically classified as pure, without a solid component, or 
mixed, with a solid component[1, 2]. While GGOs have historically been characterized 
by slow growth and indolent tumor biology, their pathogenesis is poorly understood, 
and progression can be variable. It remains unclear whether these lesions represent 
dissemination of malignant cells from a single primary tumor (intrapulmonary spread) or 
synchronous development of multifocal independent clones [3]. In addition, depending on 
their size and solid component, GGOs can exist anywhere along the histological spectrum 
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may become partially filled by several ways, such as transudative fluid, blood, 
inflammatory cells or debris, or amorphous material as seen in cardiogenic pulmonary 
edema, diffuse alveolar hemorrhage, pneumonia, and pulmonary alveolar proteinosis. 
Alveolar walls and septal interstitium may become thickened secondary to edema, 
neoplastic proliferation, fibrosis, and noncaseating granulomatous deposition as seen in 
cardiogenic pulmonary edema, nonspecific interstitial pneumonia, and sarcoidosis. 
Partial alveolar filling and interstitial thickening coexist in many disease entities. Thus 
GGO is a non-specific finding that may be caused by various disorders, including 
inflammatory disease, pulmonary fibrosis, alveolar haemorrhage or neoplasms. GGO 
may be either (multi)focal (=localised GGO) or diffuse (present bilaterally in most of the 
lobes, nicely reviewed by El-Sherief et al.1), usually associated with inflammatory 
diseases. Localized GGO may be pure associated with a solid component (mixed GGO) or 
without (pure GGO). Localized GGO may contain benign3,4(organising pneumonia, non-
specific fibrosis, atypical adenomatous hyperplasia: AAH; aspergillosis) premalignant 
(adenocarcinoma in situ: AIS, formerly also called BAC)5and malignant diseases3((minimal) 
invasive adenocarcinoma with prominent lepidic component4,5). The clinical significance 
of localized GGO is its high incidence of malignancy compared with solid nodules. The 
reported range varies from 10-90%.6–8 CT-guided thoracic needle biopsy is a useful tool 
for tissue diagnosis and may support the patient management with GGO 
lesions.9Fluoroscopic or image guidance has been studied as well.10–12 The core biopsy 
procedure is preferred over aspiration.13As usual with biopsies underestimation/ 
underdiagnosis due to sampling variation is not excluded.11,14As GGO contains many 
diseases the term “Natural history of GGO” is a misnomer.15,16 Radiology To distinguish 
GGOs with growth from those without growth, a 3-year follow-up observation period is a 
reasonable benchmark based on the data that the volume-doubling time (VDT) of pure 
GGOs ranges from approximately 600 to 900 days and that of part-solid GGOs ranges 
from 300 to 450 days.7,8,17 AAH is often associated with malignancy and is shown on CT 
as persistent well-defined oval or round nodular GGOs without solid components, and it 
does not change on the follow-up CT.18 Clinicoradiological characteristics of a benign 
course are smaller size (< 10 mm.), round/oval shape, lack of consolidation18,19or 
scattered consolidation.20 Clinicoradiological characteristics of a progressive course are 
smoking history21and initial lesion diameter (> 1 cm) 5,19,22,23, lobulated or speculated 
margin,4growth16, increase in attenuation,24greater irregularity of pixel texture 
(entropy).5Growth of localised GGO may be slow: for one case progression was reported 
within 10 years.25 Biomarkers EGFR mutations may be present in pure and mixed GGO 
lesions, representing preinvasive and invasive cancer.26–28Interestingly, for p53 
immunohistochemistry positive staining was seen in a small group (n=6) associated with 
growth or a solid component.26MIB1 (ki67) is higher in mixed GGO than in pure GGO.29CEA 
not relevant for the distinction of the progressive GGO.30 Remarkably, with laborious 
cytogenetic analysis spontaneous metaphases appeared after 24-48 h. in 9 cases of 
pure GGO. Abnormal FISH was associated with poor outcome.15 In case of multiple GGO 
synchronous BAC and/or ADC can have different EGFR or K-ras mutational profiles 
suggesting these lesions arise as independent events rather than intrapulmonary spread 
or systemic metastasis.31 Management Surgical handling is hampered since AAH not or 
much less well easy palpable than AIS.30 Since GGO may contain only AIS or minimal 
invasive adenocarcinoma partial resection may be the method of choice.30and systematic 
lymph node dissection may be avoided.32 For multiple localized GGO wait and see is an 
option33 Prognosis of mixed GGO invasive adenocarcinomas better for solid size than 
size including the GGO.34,35A larger solid component is worse than less solid 
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Definition. Ground glass opacity (GGO) is a finding on thin-section CT that is defined as 
“hazy increased attenuation of the lung with preservation of bronchial and vascular 
margins”.1This is in contrast to consolidation that is defined as a “homogeneous increase 
in pulmonary parenchymal attenuation that obscures the margins of vessels and airway 
walls” (also called ‘solid´ component). Introduction The resolution of the CT differs few 
orders of magnitude from the resolution of the microscope. Therefore, GGO is not one 
disease: pathological examination reveals several different diseases. The radiological 
GGO change is actually due to a reduction of air, while a certain amount of air remains 
present. At the microscopic level this may be caused by either i) partial filling of the 
alveolar airspaces, ii) thickening of the parenchymal interstitium and alveolar walls, iii) 
relative increase in perfusion, or iv) any combination of these factors.1,2Alveolar spaces 
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Blood-based proteomics strategies for the early detection of lung cancer. Since the 
advent of the new proteomics era, large-scale studies of protein profiling have been 
exploited to identify the distinctive molecular signatures in a wide array of biological 
systems spanning areas of basic biological research, various disease states, and 
biomarker discovery directed toward diagnostic and therapeutic applications. Recent 
advances in protein separation and identification techniques have significantly improved 
proteomics approaches, leading to enhancement of the depth and breadth of proteome 
coverage. Proteomic signatures specific for invasive lung cancer and preinvasive lesions 
have begun to emerge. In this presentation, we will provide a critical assessment of the 
state of recent advances in proteomic approaches to the discovery and validation of blood 
based biomarker signatures for the early detection of lung cancer. Mass spectrometry 
and immuno-based detection methods will be reviewed including commercially available 
blood tests to aid the early detection of lung cancer. Much of this progress was driven by 
increasing knowledge of tumor-related aberrations that affect nucleic acids at genomic, 
transcriptional, and posttranscriptional levels. Proteins are the functional end product 
of genes that ultimately control vital biological processes via their expression level and 
posttranslational modifications. Moreover, the number of proteins produced by cells far 
exceeds the number of genes because proteins vary in their stability compared with 
mRNA and are subjected to many levels of posttranscriptional and posttranslational 
regulations, such as splicing variants, fusions, and posttranslational modifications. 
Therefore, to advance our understanding of the biology of lung cancer and to obtain a 
more integrated view of the disease biology, it is critical to capture the full spectrum of the 
variations in protein expression patterns, their posttranslational modifications, and their 
functions in cancer cells. Thus, we hope to take advantage of the molecular complexity of 
the proteome to improve early detection strategies for lung cancer. Proteomic analysis 
of blood represents an appealing choice to researchers addressing the discovery of 
biomarkers because it can be quickly and easily obtained noninvasively in large quantities 
over time. Several recent studies have investigated the extent to which proteomic 
technologies can unravel the complexity of the plasma proteome. In this regard, the 
Human Proteome Organization completed a comprehensive collaborative study to 
characterize the human serum and plasma proteomes. The rapid proteomic profiling of 
blood in particular has generated great enthusiasm but has been minimally successful at 
providing robust signatures to translate to the clinic. The major preanalytical challenges 
are related to the lack of standardized sample collection and preparation techniques, 
leading to the introduction of analytical bias and the lack of reproducibility. The extreme 
complexity of biofluids, such as blood, serum, or plasma, and the low abundance of most 
of the specific protein markers are among other factors that reduce the sensitivity of 
detection by proteomic technologies. After the discovery of new biomarkers, the next 
critical steps are to validate and evaluate their performance in clinically relevant patient 
populations. Multiple levels of validation have to take place before confirming the clinical 
utility of the biomarker. This includes confirmation of detected changes in protein level by 
different techniques and correlation with biological outcomes of lung cancer such as early 
detection, chemosensitivity, or survival. These phases of clinical validation will evaluate 
a biomarker’s performance in relevant clinical context and how it may affect clinical 
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MS02.02 Circulating Tumor Cells Tilak Sundaresan Division of Hematology/Oncology 
in the MGH Cancer Center, Massachusetts General Hospital, Boston/MA/United States of 
America
In EGFR-mutant lung cancer, acquired resistance to EGFR tyrosine kinase inhibitors 
(TKIs) develops after a median of 9-14 months. The T790M gatekeeper mutation is 
the most common mechanism of TKI resistance, detected in >50% of tissue biopsies 
done after the advent of resistance. The recent clinical development of third-generation, 
irreversible EGFR TKIs that have preliminarily demonstrated durable tumor responses 
in patients who have developed the EGFR T790M mutation has generated a need for 
novel methods of T790M detection. Repeating tumor biopsies at the time of acquired 
resistance to help select second-line therapies is recommended in the NCCN guidelines. 
However, tissue biopsies do not always supply sufficient material for current sequencing 
strategies and thus may require multiple invasive procedures for adequate genotyping. 
Blood-based methods are more readily repeated when necessary and avoid the risks 
and discomfort of invasive tissue biopsies. As there may be heterogenous mechanisms 
of acquired resistance, a tissue biopsy of a single site of disease also may not capture 
the full spectrum of resistance. Blood-based methods theoretically have the potential 
of more comprehensively illustrating the principal mechanisms of resistance within a 
patient. Although there are multiple non-invasive sources of tumor-derived genetic 
material, circulating tumor cells (CTCs) and plasma circulating tumor DNA (ctDNA) 
are two that have received particular attention for blood-based genotyping. CTCs 
are cells shed into the bloodstream from primary and metastatic tumors that can be 
captured through multiple microfluidic platforms. Despite their rarity in the blood there 
is ongoing development of increasingly sensitive methods of CTC isolation. ctDNA is 
also shed into the bloodstream from tumor deposits. While more abundant than CTCs, 
ctDNA analysis is complicated by a high background of plasma DNA shed from normal 
cells. Techniques for genotyping from these blood-based sources of tumor-derived 
genetic material have proliferated rapidly, but there have been few studies directly 
comparing them. In this presentation, I will describe an exploratory study comparing 
T790M genotyping, using either CTCs or ctDNA versus concurrent tumor biopsies 
in patients with non-small cell lung cancer progressing on first line EGFR inhibitors. 
Keywords: Circulating tumor cells, Circulating Tumor DNA, EGFR, T790M
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MS03.03 Where Are We with Defining Potential Biomarkers Geoffrey Liu 
Medical Oncology, Princess Margaret Cancer Centre, Toronto/ON/Canada
Angiogenesis-targeting drugs have been evaluated in a multitude of lung cancer 
settings, with variable results. Unlike other pathways, these drugs target host related 
pathways and host responses to lung tumors. Thus there is the potential for both 
host and tumor mechanisms to lead to variable responses to therapy. In the advent of 
precision medicine, there has been a concerted effort to evaluate whether there are 
known genetic and genomic, epigenomic, serologic, and tissue biomarkers of response 
or toxicity to both anti-angiogenesis monoclonal antibodies and small molecule inhibitors 
of the angiogenesis pathways. Such studies will be reviewed in detail. Nonetheless, the 
evaluation of such biomarkers has been challenging, as the relevant anti angiogenesis 
pathways are large, mechanisms of drug function are often incompletely understood, 
and tumor-stromal interactionsare particularly difficult to measure. There are currently 
no clear examples of biomarkers that can define the anti-angiogenesis drug responsive 
patient. However, this review will focus on both the key opportunities and challenges 
associated with defining potential biomarkers related to anti-angiogenesis drug therapy 
in lung cancer, and the current state of ths research. Biomarker development has 
mostly focused on the discovery of novel marekrs of the VEGF pathway. The roles of 
assessing magnitudes and directions of association must still be supplemented by 
the evaluation of test performance, namely biomarker discriminatory performance 
and calibration. The need to move biomaker association studies towards these other 
specific evaluations will help move the field of VEGF-related biomarker research forward. 
Keywords: pharmacogenomics, biomarker, anti angiogenesis
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Target in Advanced NSCLC? Heather A. Wakelee Medicine/Oncology, Stanford 
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When the results of E4599 were presented over a decade ago the era of anti-angiogenesis 
in the treatment of advanced stage NSCLC began. Though the overall survival benefit 
with the addition of the vascular endothelial growth factor (VEGF) antibody, bevacizumab, 
to carboplatin/ paclitaxel was only 2 months, it was not only the first randomized phase 
III trial to show a survival benefit with the addition of any agent to a first line platinum 
doublet, but also the first to break the 12 months overall survival barrier in a first-line 
advanced stage NSCLC trial.(Sandler 2006) The enthusiasm lessened with the results 
of AVAiL, which failed to show an overall survival benefit when bevacizumab was added 
to cisplatin/gemcitabine.(Reck 2010) However, significant response improvement 
has been seen in all trials with bevacizumab and many patients benefit from this anti-
angiogenesis approach. Recent data from China confirmed the overall survival data from 
E4599 with a carboplatin/ paclitaxel chemotherapy backbone.(Zhou 2015) The use of 
bevacizumab with multiple different chemotherapeutics has been explored, and many 
agents have been added to the E4599 backbone regimen, unfortunately with limited 
success to date. Ongoing trials continue to utilize this strategy including with everolimus, 
vorinostat, cixutumumab, GDC-0941, TG4010, and innumerable others. Of particular 
note, S0819 is a large randomized phase III study in the United States exploring the 
addition of cetuximab to carboplatin/paclitaxel +/- bevacizumab.(ClinicalTrials.gov 
Identifier: NCT00946712) A biosimilar bevacizumab (Pf 06439535) is under investigation 
in a randomized phase III trial of 798 patients in combination with carboplatin/paclitaxel, 
compared to the E4599 regimen.(ClinicalTrials.gov Identifier: NCT02364999) Key 
research questions about bevacizumab at this time focus on duration of therapy. 
E5508 (ClinicalTrials.gov Identifier: NCT01107626), which recently completed accrual, 
addresses the question of maintenance with bevacizumab. This trial builds on E4599 
SESSION MS 03: 
IS TUMOR ANGIOGENESIS STILL A VIABLE TARGET IN 
ADVANCED NSCLC? 
MONDAY, SEPTEMBER 07, 2015
IS TUMOR ANGIOGENESIS STILL A VIABLE TARGET IN ADVANCED NSCLC?  
MONDAY, SEPTEMBER 07, 2015 - 14:15-15:45
MS03.02 Anti-Angiogenic Therapy: Current and Future Agents 
Suresh S. Ramalingam Department of Hematology and Medical Oncology, Emory 
University, Atlanta/GA/United States of America
Neo-angiogenesis, critical for sustenance and growth of cancers, is regulated by 
a number of pro- and anti-angiogenic factors. The vascular endothelial growth factor 
(VEGF) is an important mediator of angiogenesis and has therefore been pursued as 
a target for cancer therapy. Bevacizumab, a monoclonal antibody against VEGF, was 
the first anti-angiogenic agent to be approved for the treatment of non-small cell lung 
cancer (NSCLC). It provides modest improvements in overall survival when given in 
combination with carboplatin and paclitaxel for patients with advanced non-squamous 
NSCLC (12.3 m vs. 10.3 m).1 A second phase 3 study of bevacizumab in combination with 
cisplatin and gemcitabine improved progression-free survival (PFS), but survival was not 
prolonged.2 Bevacizumab can also be safely combined with the combination of carboplatin 
and pemetrexed, though there was no survival benefit for this combination when 
compared to carboplatin-paclitaxel-bevacizumab. 3 In all of these studies, bevacizumab 
was also given as maintenance therapy following 4-6 cycles of combination therapy for 
patients that achieved stable disease or an objective response. An ongoing phase III 
study (E5508) compares the role of bevacizumab, pemetrexed or both as maintenance 
therapy following initial therapy with carboplatin-paclitaxel-bevacizumab for 4 cycles. 
 
Based on its therapeutic utility in advanced stage NSCLC, bevacizumab was studied 
in earlier stages of the disease. However, administration of bevacizumab with 
concurrent chemoradiotherapy in the treatment of stage III NSCLC was deemed 
unsafe by a study conducted by SWOG. The results of a phase III study that evaluated 
bevacizumab in combination with chemotherapy in the adjuvant setting for early 
stage NSCLC (E1505) will be reported at the 16th World Conference on Lung Cancer. 
 
In another encouraging development, the combination of bevacizumab and erlotinib 
was associated with improved progression-free survival (PFS) in patients with epidermal 
growth factor receptor (EGFR) mutations compared to erlotinib alone in a phase II study 
conducted in Japan.4 The median PFS was approximately 16 months for the combination 
compared to 9.7 months with erlotinib. This is the first study to show incremental 
efficacy over that of an EGFR tyrosine kinase inhibitor in this patient population. An 
ongoing study in the Western population will verify the results of the Japanese trial. 
Taken together, bevacizumab has proven to be a valuable addition to the therapeutic 
armamentarium against NSCLC. The use of bevacizumab is not recommended 
for patients with squamous cell histology due to the higher risk of hemoptysis. 
 
A number of small molecule VEGFR tyrosine kinase inhibitors were studied in patients with 
advanced NSCLC. Though many of these agents including sunitinib, sorafenib and axitinib 
were active as monotherapy, combination studies with chemotherapy or other targeted 
therapy failed to demonstrate survival benefit. Consequently, the development of nearly 
all of these agents has been discontinued in NSCLC. Recently, nintedanib, a small molecule 
tyrosine kinase inhibitor of VEGFR, fibroblast growth factor and platelet-derived growth 
factor, has been approved in Europe for the treatment of advanced lung adenocarcinoma 
in combination with docetaxel. Nintedanib has demonstrated single agent activity in 
advanced NSCLC and was subsequently studied in combination with docetaxel as salvage 
therapy in a large phase III study.5 There was a statistically significant improvement in 
overall survival for patients with adenocarcinoma histology that received the combination 
of docetaxel and nintedanib compared to docetaxel alone (12.6 m vs. 10.3 m, HR 0.83). 
A second confirmatory study is presently ongoing in patients with lung adenocarcinoma. 
 
Ramucirumab is a monoclonal antibody against the VEGF-R2 receptor. It has recently 
been approved for the treatment of advanced NSCLC in the salvage therapy setting 
in combination with docetaxel. This was prompted by the REVEL study that compared 
docetaxel given with ramucirumab or placebo in patients with advanced NSCLC 
following progression with a prior platinum-based regimen.6 There was an improvement 
in overall survival with the addition of ramucirumab to docetaxel (10.5 m vs. 9.1 m, 
HR 0.86). The median PFS was also improved for the combination (4.5 m vs. 3.0 m, 
HR 0.76). The incidence of grades 3/4 febrile neutropenia (16% vs. 10%), fatigue (14% 
vs. 10%) and hypertension (6% vs. 2%) were higher in the ramucirumab group. The 
overall results are noteworthy since this is the first study to demonstrate improvement 
in overall survival for a combination regimen in salvage therapy of advanced NSCLC. 
 
In summary, though the role of novel anti-angiogenic agents in NSCLC has been well 
established, their impact has been relatively modest in improving patient outcomes. The 
lack of predictive biomarkers has proven to be a major hurdle to identify patients that 
are likely to gain robust benefits. Efforts to identify combination strategies to improve 
the efficacy of anti-angiogenic agents have also been unsuccessful to date. Activation 
of alternate pathways that regulate angiogenesis could be an important reason for the 
limited success of anti-angiogenic therapy. The recent data on the combination of VEGF 
inhibition and EGFR inhibition in patients with an activating EGFR mutation warrant further 
evaluation, particularly to understand the mechanistic basis for the interaction. If confirmed, 
this approach is likely to be studied in patients with other ‘driver’ oncogenic events. 
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trial. Lancet. Lancet. 2014 Aug 23;384(9944):665-73.. Epub 2014 Jun 2. Reck M, Kaiser 
R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib 
versus docetaxel plus placebo in patients with previously treated non-small-cell lung 
cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 
2014 Feb;15(2):143-55.
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University Hospital KU Leuven, Leuven/Belgium
Cancer immunotherapy in a broad sense is any interaction with the immune system to 
treat cancer. One approach is non-antigen-specific modulation of the immune system. 
Historical examples with e.g. BCG, interferon, interleukins, were disappointing in lung 
cancer. More recently, specific antibodies against the Programmed Death 1 (PD-1) 
receptor or its ligands (PD-L1) have delivered exciting results, with major patient benefits 
in randomised controlled trials (RCTs) in relapsing NSCLC {Brahmer, 2015 19949 /
id}. Antigen-specific immunotherapy aims at specific priming of immune system to 
recognize the tumour as foreign, thereby generating specific antibodies and/or cytotoxic 
T cells. This is “therapeutic cancer vaccination (TCV)”. Conditions for optimal TCV are: 
1/ specificity (well-defined target antigen(s) in the tumour, not in other tissues); 2/ 
selectivity (use in the population expressing the target); 3/ immunogenicity (interaction 
with antigen leads to effective humoral and/or cellular response); 4/ tumour sensitive 
to immune kill in order to obtain improvement in patients’ outcome. Better knowledge 
of tumour immunity has led to encouraging data in phase II RCTs with several TCVs, 
which then have entered large phase III trials. Examples are the MAGE-A3 vaccine studied 
in resected early stage NSCLC, the BLP-25 vaccine in locally advanced NSCLC after 
chemoradiotherapy, and e.g. belagenpumatucel-L and the TG4010 vaccine in advanced 
stage NSCLC. The MAGE-A3 protein is totally tumour-specific and present in about 35% 
of early stage NSCLC. In the hypothesis generating double-blind, randomized, placebo-
controlled phase II study, 182 patients with completely resected MAGE-A3-positive stage 
IB-II NSCLC received recombinant MAGE-A3 protein combined with an immunostimulant 
(13 doses over 27 months) or placebo (2). No significant toxicity was observed. There 
was a 24% – non-significant – improvement in disease-free survival (DFS, HR 0.76; 95% 
CI 0.48 to 1.21). The ensuing large phase III study MAGRIT (MAGE-A3 as Adjuvant Non-
Small Cell LunG cancer ImmunoTherapy) was reported at the ESMO 2014 meeting (3). 
MAGE-A3 positive patients with completely resected stage IB-II-IIIA NSCLC and adjuvant 
chemotherapy as clinically indicated, were randomly 2:1 assigned to receive MAGE-A3 
vaccine or placebo. Almost 14,000 surgical patients were screened, 4210 patients were 
MAGE-A3 positive (33%), and 2312 patients were randomised. The median DFS (primary 
endpoint) was slightly better with MAGE-A3 (60.5 versus 57.9 months), but the difference 
was unfortunately not significant (Hazard Ratio, HR, 1.02, 95%CI: 0.89, 1.18, P=0.74). No 
subgroups with potential benefit could be identified. Based on this disappointing result, 
further development of the MAGE-A3 vaccine in NSCLC has been abandoned. Mucins 
like the MUC1 protein are present in many epithelia, but MUC1 expression is altered 
(mainly by aberrant glycosylation) in many cancer types, including NSCLC. The tandem 
repeat MUC1-peptide liposomal vaccine BLP-25 has been studied in patients with stage 
IIIB-IV NSCLC (4). While overall survival (OS) was not significantly different in the total 
group, a challenging effect was observed in stage IIIB patients (HR 0.524; 95%CI 0.261-
1.052). This led to START (Stimulating Targeted Antigenic Responses to NSCLC Trial), a 
phase III, double blind, RCT comparing maintenance therapy with Tecemotide (n=829) or 
placebo (n=410) in patients with unresectable stage III NSCLC who did not progress after 
sequential or concurrent chemo-radiotherapy (5). The primary endpoint – OS – was not 
significantly different between the vaccine and placebo group (25.6 and 22.3 months). 
However, pre-planned subgroup analysis showed that the patients treated with concurrent 
chemoradiotherapy (N=829) had a 10.2-month improvement in OS (30.8 versus 20.6 
months, adjusted HR 0.78, P=0.016). The consequential trial was START 2, a similar 
large RCT in patients who completed concurrent chemoradiotherapy for unresectable 
stage III NSCLC (NCT02049151). However, this RCT and further development of 
Tecemotide was abandoned after disappointing results of a smaller trial in Japanese 
patients with stage III NSCLC and concurrent chemoradiotherapy. Belagenpumatucel-L is 
a vaccine based on a mixture of allogeneic tumour cells with TGF-β2 antisense blockade 
as adjuvant. A phase III trial in patients with stage III-IV NSCLC in disease control after 
first-line therapy was reported at the 2013 ESMO meeting (STOP, NCT00676507) (6). 
Patients without progression after 1st line chemotherapy, were randomly assigned to 
intradermal belagenpumatucel-L (N=270) versus placebo (N=262)for 24 months. 
Median OS was 20.3 months with belagenpumatucel-L versus 17.8 months with placebo 
(HR 0.94, p=0.594). In subgroup analysis of patients randomized <12 weeks after the 
last chemotherapy, the HR of the median OS was 0.77 (P=0.092). For patients enrolled 
within 12 weeks and treated with previous radiotherapy, the HR was HR 0.45 (P=0.014). 
The vaccine was well tolerated with mainly mild local administration side-effects. TG4010 
is a vaccine based on a recombinant viral vector (attenuated strain of vaccinia virus) 
expressing both the tumour-associated antigen MUC1 and interleukin-2. This vaccine is 
explored in the phase IIB/III RCT TIME trial (NCT01383148). This double-blind, placebo-
controlled trial evaluates standard first-line chemotherapy with or without TG4010 in 
MUC1-positive stage IV NSCLC patients. In the phase IIB part, the predictive value of 
activated NKs (TrPAL: triple positive activated lymphocytes) was evaluated based on a 
PFS endpoint, and reported in an interim report at the 2014 ESMO meeting (7). Based on 
a Bayesian analysis, the predefined endpoint of a HR <1 in the patients with low level of 
such that all patients receive carboplatin/ paclitaxel/ bevacizumab for 4 cycles. Those 
without progression at that time then continue on bevacizumab alone until progression 
(as per E4599) or stop bevacizumab and start pemetrexed, or receive both agents. The 
results of this randomized phase III trial of over 1200 patients are eagerly awaited to 
determine an optimal maintenance approach. The results will also determine the benefit 
of prolonged bevacizumab use. Earlier work with bevacizumab in a maintenance setting 
included the AVAPERL trial which showed promising results with the combination of 
pemetrexed/bevacizumab maintenance compared to bevacziumab maintenance alone 
after a cisplatin/ pemetrexed/ bevacizumab first line regimen in advanced nonsquamous 
NSCLC.(Barlesi 2013) Based on positive data in colorectal and ovarian cancer, and 
retrospective data in lung cancer, demonstrating a survival benefit with continuation of 
bevacizumab beyond progression, the phase IIIb study AvaALL (MO22097) (ClinicalTrials.
gov Identifier:NCT01351415) randomizes patients to continuation of bevacizumab, or 
not, at the initiation of second line chemotherapy after progression on a bevacizumab 
containing first-line regimen.(Gridelli 2011) Overall survival is the primary endpoint and 
a clear survival benefit in this trial will significantly alter the treatment landscape for 
those patients with adenocarcinoma, without a driver mutation, who are treated with 
first line bevacizumab. Similar smaller studies are also ongoing. The use of bevacizmab 
with EGFR targeted therapy in patients with tumors harboring EGFR mutations is an 
area of particular interest after positive phase II trial results with the combination were 
published in 2014.(Seto 2014) This Japanese study showed a significant progression 
free survival advantage with the combination compared to single agent erlotinib as first 
line therapy in this patient population. Several ongoing trials seek to confirmation these 
results including a randomized phase II study in the United States (ClinicalTrials.gov 
Identifier: NCT01532089) and a non-randomized trial in Europe (BELIEF ClinicalTrials.
gov Identifier: NCT01562028). Trials looking at bevacizumab in combination with newer 
immune targeted drugs such as the checkpoint inhibitors targeting PD-1 and PD-L1 are 
ongoing. The largest is a 3-arm phase III study looking at carboplatin/ paclitaxel with or 
without bevacizumab PLUS the PD-L1 targeted atezolizumab (MPDL3280A) compared 
to a control arm of carboplatin/ paclitaxel/ bevacziumab.(ClinicalTrials.gov Identifier: 
NCT02366143) The study will enroll 1200 patients. Smaller phase I trials of other PD-1 
agents in combination with multiple different regimens include carboplatin/ paclitaxel/ 
bevacizumab arms. Examples include a multi-arm pembrolizumab study (ClinicalTrials.
gov Identifier: NCT02039674) and a trial with nivolumab which includes a bevacizumab 
maintenance with nivolumab arm.(ClinicalTrials.gov Identifier:NCT01454102) 
Bevacizumab is not the only anti-angiogenesis agent. The VEGFR-2 antibody ramucirumab 
had recent approval by the US FDA when given in combination with docetaxel in the 
2nd line setting.(Garon 2014) In contrast to bevacizumab, which is restricted to non-
squamous NSCLC, ramucirumab is approved for any histology of NSCLC. Ongoing 
trials with ramucirumab include a large (N=462) randomized double-blind study of 
erlotinib with ramucirumab or placebo in EGFR mutation positive NSCLC (ClinicalTrials.
gov Identifier: NCT02411448) and a phase 1 study of the agent in combination with 
pembrolizumab.(ClinicalTrials.gov Identifier: NCT02443324) The VEGFR TKIs continue to 
have unrealized potential in NSCLC. Combination studies with first-line chemotherapy 
have been universally negative for an overall survival benefit, though response rates 
and progression free survival were positive in many studies. Second line trials with 
docetaxel have also shown response and PFS benefit and subset overall survival benefits, 
particularly with nintedanib.(Reck 2014) Single agent activity of many is seen, but in 
a small percentage of patients. However, enthusiasm for these agents in NSCLC has 
waned and current trials with these drugs are limited. Bevacizumab remains an important 
component of first-line platinum combination therapy for many patients with advanced 
stage NSCLC. Ongoing trials are exploring duration of therapy questions with this drug 
and best ways to incorporate its use with newer immunotherapeutics. Combinations with 
molecularly targeted agents hold promise. Ramucirumab use may also be expanded to 
combinations with targeted agents pending results of ongoing trials. Resurrection of the 
VEGFR-TKIs in NSCLC will require further understanding of best combination therapies 
and better understanding of how to target them to the proper patients. The biggest 
challenge with anti-angiogenesis therapy remains a lack of reliable biomarkers. 
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cells It is highly expressed in the stroma of lung (and many other) cancers, but not in 
benign tumors or normal adult quiescent tissues (although it is upregulated in wounds 
and fibrotic tissues). We thus produced T cells expressing anti-mouse FAP CARs. The FAP 
CAR T cells selectively killed FAP-expressing cells. Immune-competent C57BL/6 mice 
bearing large established subcutaneous murine lung cancers and human A549 tumors 
in immune-deficient mice were treated. FAP-CAR T cells reduced the number of FAP+ 
cells, markedly reduced the amount of tumor matrix and limited tumor growth in all three 
lung cancer models (Wang et al., 2014; Lo et al., 2015). We hope to move this approach 
forward to clinical trials in lung cancer and mesothelioma. We will likely combine anti-
fibroblast therapy with chemotherapy, vaccines, or other types of immunotherapy. In 
summary, a new therapeutic paradigm is now emerging based on therapy aimed at the 
non-malignant host cells, NOT directly targeting the cancer cells. Examples include 
antibodies targeting endothelial cells and checkpoint inhibitors that target T cells. An 
advantage of this approach is that stromal cells are more genetically stable compared 
with tumor cells and they are unlikely to lose their antigen(s) and become invisible to T 
cells. Another advantage is the same targets could be used in multiple tumors. Future 
applications will likely include activation or elimination of TAMS, targeting fibroblasts, 
and deletion of T-regulatory cells. References: Corrales L, et al. Direct Activation of 
STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression 
and Immunity. Cell Reports 2015. 11:1-13. Jassar, A., et al. Activated Tumor-Associated 
Macrophages and CD8+ T-cells are the Key Mediators of Anti-tumor Effects of the 
Vascular Disrupting Agent DMXAA in Murine Models of Lung Cancer and Mesothelioma”. 
Cancer Research 2005. 65:11752-11761. Lo A, et al. Tumor-promoting desmoplasia is 
disrupted by depleting FAP-expressing stromal cells. Cancer Res. 2015 May 15. [Epub 
ahead of print] Wang LC, et al. Targeting Fibroblast Activation Protein in Tumor Stroma 
with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host 
Immunity Without Severe Toxicity. Cancer Immunology Research 2014. 2:154-166. 
Keywords: tumor-associated macrophages, chimeric antigen T cells, tumor 
microenvironment, fibroblasts
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Kingdom
Despite advances in genomic technologies, most advanced solid tumors remain 
incurable and drug resistance is almost inevitable with limited biomarkers available to 
personalize therapy. Two important lessons have emerged from the comprehensive 
genomic analyses of cancers, which may provide an explanation for difficulties that have 
been encountered in biomarker development. First, each tumor contains an individual 
assortment of multiple genomic aberrations, few of which are shared between patients 
with the same histopathological tumor subtype. Second, emerging evidence suggests that 
these anomalies appear to vary both spatially and temporally within the tumor, indicating 
substantial intratumor heterogeneity. Increasingly, molecular evidence suggests that 
intratumor heterogeneity may contribute to tumor growth through a branched (polytypic) 
rather than a linear pattern of tumor evolution. Branched evolutionary growth and 
intratumor heterogeneity results in coexisting cancer cell subclones with variegated 
genotypes and associated functional phenotypes that may be regionally separated within 
the same tumor or distinct within one biopsy and alter in dominance over time. Variegated 
phenotypes, resulting from intratumoral genetic heterogeneity and the emergence of 
new subclones at relapse, are likely to have important implications for developing novel 
targeted therapies and for preventing the emergence of drug resistance. Intratumor 
heterogeneity and tumour sampling bias, resulting from single biopsy-driven biomarker 
discovery and validation approaches, may also contribute to the recently reported failures 
in implementation of robust biomarkers in the clinical setting. Clinical trial efforts taking 
into account tumour heterogeneity and its relevance to lung cancer will be addressed. 
Keywords: Cancer evolution, drug resistance, Tumor heterogeneity
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MS05.02 How Does Tumor Heterogeneity Affect Molecular Testing on Biopsy 
Samples - Diagnostic vs. Rebiopsy (Resistance) Keith Kerr Pathology, Aberdeen 
University Medical School, Aberdeen/United Kingdom
There are many different manifestations of heterogeneity within lung tumours. The three 
main considerations are: Morphologically, all of the neoplastic cells in a tumour are not 
identical. These structural differences may be due to differential protein expression and 
cellular differentiation, in turn the result of either differential expression of wild type 
genes, post-transcriptional modification or expression of altered genes (mutation, fusion 
genes etc). Nuclear morphology varies at least in part due to alteration in chromosome 
structure and number. Genetically, tumour cell populations are heterogeneous, as 
mentioned above but also it can be demonstrated that there may be heterogeneity 
related to driver mutations and other functionally important changes which may not 
necessarily be deterministic of cell morphology. Compositely speaking, tumours are 
made up of more than just neoplastic cells; stromal cells, immune cells and vasculature 
for example may account for much of the tumour bulk. Potentially, all three of these 
may impact upon molecular testing practice in the initial diagnostic phase and at re-
NK cells was met. The PFS was not significantly different between vaccine and placebo 
(HR 0.78, 95%CI 0.55-1.10]. In subgroup analyses, the effect was more pronounced 
in patients with non-squamous NSCLC (HR 0.71, 95CI 0.51-0.97) than in squamous 
histology. Therefore, a decision was made to continue the phase III part of the trial in 
non-squamous NSCLC only, with OS a the primary endpoint. References 1. Brahmer 
J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous 
cell non-small cell lung cancer. N Engl J Med 2015; on-line May 31. 2. Vansteenkiste 
J, Zielinski M, Linder A et al. Adjuvant MAGE-A3 immunotherapy in resected non-small 
cell lung cancer: Phase II randomized study results. J Clin Oncol 2013;31:2396-2403. 
3. Vansteenkiste JF, Cho BC, Vanakesa T et al. MAGRIT, a double-blind, randomized, 
placebo-controlled phase III study to assess the efficacy of the recMAGE-A3 + AS15 
cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-
positive non-small cell lung cancer (NSCLC). Ann Oncol 2014; 25 Suppl 4: abstract 1173O. 
4. Butts C, Murray N, Maksymiuk A et al. Randomized phase IIB trial of BLP25 liposome 
vaccine in stage IIIB and IV non-small cell lung cancer. J Clin Oncol 2005;23:6674-6681. 
5. Butts C, Socinski MA, Mitchell PL et al. Tecemotide (L-BLP25) versus placebo after 
chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, 
double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68. 6. Giaccone G, Bazhenova 
L, Nemunaitis J et al. A phase III study of belagenpumatucel-L therapeutic tumor 
cell vaccine for non-small cell lung cancer (NSCLC). Eur J Cancer 2013; 47 Suppl 2: 
abstract LBA 7081. 7. Quoix E, Losonczy G, Forget F et al. TIME, a phase 2B/3 study 
evaluating TG4010 in combination with first-line therapy in advanced non-small lung 
cancer (NSCLC). Phase 2B results. Ann Oncol 2014; 25 Suppl 4: abstract 1055PD. 
Keywords: Therapeutic cancer vaccines, Immunotherapy, Randomised controlled trials, 
Lung cancer, non-small cell
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of Pennsylvania School of Medicine, Philadelphia/PA/United States of America
The traditional approaches to lung cancer therapy have focused on treating the malignant 
epithelial cancer cells within the tumor. However, it is now realized that in most cases, 
most of the tumor consists of “supporting cells” that include endothelium, pericytes, 
fibroblasts, and a variety of innate and acquired (B cells and T cells) immune cells. 
Thus, targeting these non-tumor cells could be an alternative therapeutic strategy. 
This concept is already being used in clinical practice. One example is targeting the 
endothelial cells within the tumor using an anti-VEGF antibody (bevacizumab). Another 
example are the checkpoint inhibitors (anti-CTLA4 and anti-PD1 antibodies) that target 
endogenous T cells. However, it may also be possible to attack other targets such as 
macrophages, Tregs, neutrophils or cancer-associated fibroblasts (CAFs). Tumor-
associated macrophages represent one target. These cells take on a tumor-supportive 
phenotype and produce anti-inflammatory cytokines/chemokines (i.e. TGFbeta, PGE2, 
IL10, VEGF), arginase (which inactivates T cells), and angiogenic factors. This has led to 
the hypothesis that changing the state of the macrophage to an anti-tumor phenotype 
in which immune-activating mediators would be made and antigen-presentation could 
be enhanced would have direct anti-tumor activities and would allow endogenous T 
cells to kill tumor cells. Macrophage activation has been attempted for many years 
using agents such as bacterial endotoxin, TNF, liposomal-encapsulated muramyl 
tripeptides, lipopeptides or oligonucleotides/agents that activate toll-like receptors. 
To date, however, this approach has not been very successful, primarily due to lack of 
specificity for tumor infiltrating macrophages resulting in intolerable systemic toxicity. 
Our group explored the use of a cell permeable flavonoid compound called DMXAA 
for this purpose. Administration of DMXAA causes activation of tumor-associated 
macrophages via multiple pathways with release of cytokines and chemokines resulting 
in hemorrhagic tumor necrosis, a subsequent inflammatory/immuno-permissive tumor 
environment, and ultimately attracts CD8 T cells into tumors (Jassar et al. 2005). 
Although intra-tumoral treatment of both large and small lung cancers in mouse 
models led to striking tumor regression, there was a major problem in translating this 
work- DMXAA does not react with human macrophages. Since we did not know how 
DMXAA was working (i.e. what was the DMXAA receptor that triggered macrophage 
activation) progress was stalled. This changed recently, when it was discovered that 
DMXAA worked by binding to a newly described intracellular sensor of cytosolic DNA 
(working through binding to cyclic dinucleotides) called STING (stimulator of Interferon 
Genes). STING activates innate immunity by signaling through the TBK/IRF3 axis, NF-
kB and STAT6 pathways. Interestingly, it was noted that DMXAA bound well to mouse 
STING but NOT to human STING (explaining its lack of efficacy in humans). A company 
(Aduro Biotech) has designed a compound that binds to human STING and thus activates 
human macrophages like DMXAA activates mouse macrophages. Their lead compound 
has strong in vivo anti-tumor activity (much like DMXAA) and clinical trials using intra-
tumoral injections are about to start (Corrales et al., 2015). Another potential target in 
the tumor microenvironment is the cancer-associated fibroblasts (CAFs). Fibroblasts and 
their associated stroma promote tumor growth through multiple mechanisms, including 
suppression of anti-tumor immunity, supporting angiogenesis, as a depot for growth 
factors/ cytokines/chemokines, modulating the inflammatory response, and shielding 
the tumor from infiltrating cells. Our group at Penn has been developing genetically 
altered T cells that can be targeted to any expressed surface antigen by transducing 
autologous T cells with a chimeric antigen receptor (CAR). A CAR is composed of a 
single chain antibody fused to the cytoplasmic sequences from the CD3zeta chain and a 
co-activating receptor (41BB/CD137). This construct combines antibody specificity with 
the ability to activate the killing machinery of T cells. Our lead CAR T cell target is CD19 
to treat B cell malignancies, however, we are also testing CARs targeted to mesothelin 
(mesothelioma, lung cancer, pancreas cancer, ovarian cancer) and other solid tumor 
cell targets. We hypothesized that we could use this approach to eliminate CAFs. To 
do so, we identified Fibroblast Activation Protein (FAP) as a target antigen for CAFs. 
In epithelial-derived tumors, FAP is selectively expressed by cancer-associated stromal 
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refinements in the histologic classification of lung adenocarcinomas provide greater 
resolution of the sequential steps of glandular lung neoplasia4. Atypical adenomatous 
hyperplasia (AAH) is a microscopic discrete focus of cytologically atypical type II 
pneumocytes and/or Clara cells5-6. Once dismissed as a reactive change, AAH is now 
regarded as the first histologic step in a morphologic continuum culminating in the 
fully malignant adenocarcinoma. The link between AAH and invasive adenocarcinoma 
is strong and compelling: 5-20% of lungs resected for primary adenocarcinomas also 
harbor AAH, and AAH harbors some of the same genetic and epigenetic alterations found 
in adenocarcinomas including KRAS mutations, EGFR mutations, loss of heterozygosity 
at 9q and 16p, TP53 mutations, and epigenetic alterations in the WNT pathway. Like 
AAH, adenocarcinoma in situ (AIS) (formerly known as bronchioloalveolar carcinoma, 
BAC) is recognized as a non-invasive form of glandular neoplasia, but one that exhibits 
increased size, cellularity and morphologic atypia. In effect, it represents a next step in 
the continuum towards malignant adenocarcinoma. Minimally-invasive adenocarcinoma 
(MIA) is defined as a small adenocarcinoma (≤ 3cm) with a predominantly lepidic pattern 
and invasion of 5 mm or less in any one focus4. Invasive growth is present, albeit so 
limited that these carcinomas have been associated with 100% disease free survival7,8. 
This enhanced delineation of early glandular neoplasia provides a rational histologic 
framework for studying the timing of genetic alterations driving the early stages of lung 
tumorigenesis. “Branched evolutionary tumor growth” is the concept that cancers evolve 
by a repetitive process of clonal expansion, genetic diversification and clonal selection 
within the adaptive landscapes of tissue ecosystems9. In this study, to determine whether 
this phenomenon is operational during early stages of tumor progression, we evaluated 
lung glandular neoplasms spanning the full spectrum of early histologic progression using 
next generation sequencing (NGS) of coding regions from 125 well-characterized cancer-
driving genes. We specifically targeted multifocal AAHs and advancing zones of histologic 
progression within individual AISs and MIAs. This multi-region sequencing revealed that 
clonal expansion is an early event that can be confirmed even in the earliest recognized 
step in glandular neoplasia. Moreover, the identification of significant genetic alterations 
such as KRAS mutations, loss of P53 activity and EGFR activation points to the presence 
of functionally relevant “drivers” that empower territorial expansion of subclones en 
route to malignancy. Importantly, these driver alterations are potentially measurable 
in clinical samples. Using ultra-sensitive droplet digital PCR (ddPCR), mutant DNA 
associated with early lesions was detected in a patient’s plasma and sputum providing 
proof of principle that even the earliest stages of glandular neoplasia can be detected 
via analysis of circulating DNA (circDNA). Our study provides the unique insight into the 
genetic alterations that initiate and drive the progression of lung glandular neoplasia and 
underlines the need for precise definition of these events to improve proper diagnosis and 
early detection of tumors. Identification of mutational features which characterize relevant 
lesions that actually progress to cancers will allow to better predict the fate of these early 
lesions and tailor the right therapy to prevent the progression. 1. Colby T. V., Koss M. N. 
& W., T. in Tumors of the Lower Respiratory Tract (eds Colby T. V., Koss M. N., & Travis W. 
D.) 91-106 (Armed Forces Institute of Pathology Washington DC, 1994). 2. Frost, J. K. et 
al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic 
screening in the Johns Hopkins study. The American review of respiratory disease 130, 
549-554 (1984). 3. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma 
with massively parallel sequencing. Cell 150, 1107-1120, doi:10.1016/j.cell.2012.08.029 
(2012). 4. Travis, W. D. et al. Diagnosis of lung adenocarcinoma in resected specimens: 
implications of the 2011 International Association for the Study of Lung Cancer/American 
Thoracic Society/European Respiratory Society classification. Archives of pathology & 
laboratory medicine 137, 685-705, doi:10.5858/arpa.2012-0264-RA (2013). 5. Weng, 
S. Y., Tsuchiya, E., Kasuga, T. & Sugano, H. Incidence of atypical bronchioloalveolar 
cell hyperplasia of the lung: relation to histological subtypes of lung cancer. Virchows 
Archiv. A, Pathological anatomy and histopathology 420, 463-471 (1992). 6. Chapman, 
A. D. & Kerr, K. M. The association between atypical adenomatous hyperplasia and 
primary lung cancer. British journal of cancer 83, 632-636, doi:10.1054/bjoc.2000.1317 
(2000). 7. Borczuk, A. C. et al. Invasive size is an independent predictor of survival in 
pulmonary adenocarcinoma. The American journal of surgical pathology 33, 462-469, 
doi:10.1097/PAS.0b013e318190157c (2009). 8. Yim, J. et al. Histologic features 
are important prognostic indicators in early stages lung adenocarcinomas. Modern 
pathology : an official journal of the United States and Canadian Academy of Pathology, 
Inc 20, 233-241, doi:10.1038/modpathol.3800734 (2007). 9. Greaves, M. & Maley, C. 
C. Clonal evolution in cancer. Nature 481, 306-313, doi:10.1038/nature10762 (2012). 
Keywords: droplet digital PCR, circulating DNA, lung glandular neoplasms, Next 
Generation Sequencing (NGS).
SESSION MS 06: 
REGULATION OF TOBACCO PRODUCTS 
MONDAY, SEPTEMBER 07, 2015
REGULATION OF TOBACCO PRODUCTS  
MONDAY, SEPTEMBER 07, 2015 - 14:15-15:45
MS06.01 Global Effects of Smoking, of Quitting, and of Taxing Tobacco 
Luk Joossens Advocacy, Association of European Cancer Leagues, Brussels/Belgium
Evidence from countries of all income levels shows that price increases on cigarettes 
are highly effective in reducing demand. Higher prices induce cessation and prevent 
initiation of tobacco use. Article 6 of the WHO Framework Convention on Tobacco Control, 
“Price and Tax Measures to Reduce the Demand for Tobacco”, recognizes the importance 
of this policy and calls on governments to implement tax and price policies to 
contribute to their national health objectives. Guidelines on Price and Tax Measures to 
reduce the demand for Tobacco, adopted by the 180 parties to the FCTC at the Sixth 
Conference of the Parties in October 2014, stipulate: “Any policy to increase tobacco 
taxes that effectively increases real prices reduces tobacco use. According to the 
biopsy. Molecular testing may be executed in many different ways and may seek many 
different molecular changes, such that the potential for heterogeneity making an impact 
on testing is considerable. Some molecular tests involve the morphological examination 
of a histological or cytological slide for the presence or absence of a particular factor. 
Proteins are normally assessed at a morphological level using immunohistochemistry. 
In situ hybridisation can be used to visualise and assess the presence of specific 
mRNAs. The same technique is used to assess DNA; specific gene copy numbers (gene 
amplification, polysomy), the creation of new ‘fusion genes’ during rearrangement using 
break-apart probes etc. These techniques require the molecular signal to be visualised in 
the cells of interest (usually the tumour cells); morphological and compositional tumour 
heterogeneity greatly impact the ease with which these techniques are executed. In lung 
cancer molecular testing, most current interest is in mutation testing. Compositional 
heterogeneity is a significant practical issue and drives recommendations that samples 
are pathologically assessed before extraction and mandates steps be taken to maximize 
the proportion of the sample for extraction that is tumour (macro- or microdissection 
techniques are often used). The dilution of mutant alleles by wild type alleles from 
non-neoplastic tissue may lower the mutation allele frequency below the threshold 
for detection. Are therapeutically important mutations such as those in exons 18-21 
of EGFR heterogeneously expressed in tumour cells? This remains a matter of some 
controversy. Some have argued that since these are addictive driver mutations, they 
are present from the start of tumourigenesis and therefore present in every tumour 
cell, as determined by clonal expansion of the neoplastic cell population. Studies 
which demonstrate mutations in some areas of extracted tumour but not in others, are 
criticized by failing to use sufficiently sensitive techniques to detect mutations which are 
over-diluted by non-neoplastic DNA. It is known that selective amplification of mutant 
alleles (MASI) is heterogeneous in tumours and this may lead to apparent heterogeneity 
of mutation (detectable in some areas and not in others) when the number of mutant 
alleles per tumour cell varies in different parts of the tumour, and those areas with fewer 
mutant alleles are not detected due to poor test sensitivity. This explanation for apparent 
mutational heterogeneity has been challenged by some studies, however, which have 
appeared to demonstrate heterogeneity, even when highly sensitive techniques are 
used. Heterogeneity appears to be associated with lower response rates to EGFR TKIs 
in EGFR mutant tumours. Discrepancy has been reported in mutational findings between 
synchronous primary tumour and metastatic deposits. These findings are not universal 
for EGFR mutations, but when present, tend to involve a mutated primary with wild 
type metastases more often than the reverse. Data are few but could influence biopsy 
strategies. More than one mutation may be present in a lung cancer. In the context of 
molecular aberrations commonly tested for (EGFR, KRAS mutation; ALK rearrangement), 
double mutations are described but are rare. It is rather more common, for example 
for double or even triple EGFR mutations to be found in the same tumour sample. For 
example, in the author’s laboratory, double EGFR mutations are found in 13.8% of EGFR-
mutated cases; triple mutations in 0.6%. KRAS double mutations are exceptionally 
rare (0.8%). The presence of more than one mutation, often at different allelic 
frequencies (such as can be estimated in many studies), implies different clones of 
cells bearing different mutations, and from this comes the concept of minor clones of 
therapeutically resistant cells which are responsible for some, though probably not all 
disease recurrences on TKI therapy. The best known scenario fitting this ‘minor clone’ 
hypothesis is the emergence of tumour bearing the EGFR T790M resistance mutation, 
as well as the original sensitizing mutation, for which an EGFR TKI was given. Resistant 
minor clones of MET amplified cells may be an alternative source of recurrent, EGFR 
TKI resistant disease. Similarly with ALK mutated or KRAS mutated recurrences during 
ALK TKI therapy for ALK rearranged tumours. This increasingly recognised outcome in 
patients treated with EGFR or ALK TKIs is now driving re-biopsy of recurrent disease 
into standard of care. Testing approaches and strategy for recurrent disease are still 
evolving and are driven by this concept of minor clone heterogeneity. Another finding 
in the re-biopsy setting is histological subtype transformation. Whilst the initial EGFR 
or ALK altered tumour is almost always adenocarcinoma, recurrent disease may be 
small cell, sarcomatoid or even squamous cell carcinoma. Little is known about the 
mechanism of this transformation; emergent clones of different histology or differential 
stem cell differentiation? There are also emergent data demonstrating that where 
recurrence occurs at multiple sites, detectable resistance mechanisms may vary. In 
a broader sense, heterogeneity of sensitivity to particular therapies, amongst tumour 
cells, is a major driver of treatment resistance and/or relapse, and effectively why there 
are so very few instances of true cure of lung cancer as a consequence of systemic 
therapy. The development of effective treatment strategies to overcome recurrence will 
require a better understanding of how tumour heterogeneity influences this process. 
Keywords: Heterogeneity, therapy resistance, T790M, minor clones
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Adenocarcinomas represent the most frequent subtype of lung cancer1, and they 
are usually discovered late in the course of the disease even in the setting of vigilant 
radiographic and cytologic screening2. Despite improvements in molecular diagnosis and 
targeted therapies, the average 5 year-survival rate for lung adenocarcinoma remains 
only 15%3. Novel strategies based on the detection of genetic markers offer new hope 
for improved risk assessment, early cancer detection, therapeutic intervention and 
tumor surveillance, but the impact of these strategies has been limited by an incomplete 
understanding of the biology of lung cancer, particularly in its early developmental 
stages. Disappointingly, relatively few genetic alterations critical to the development of 
lung adenocarcinomas are currently recognized, and the timing and manner by which 
these alterations initiate and drive glandular neoplasia remains to be delineated. Recent 
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currently use smokeless tobacco.3 Nearly 9 out of 10 daily adult smokers used their 
first cigarette before the age of 18.1 On a global level, tobacco use causes nearly 
six million deaths a year and at current rates could kill up to one billion people this 
century.4 Tobacco use is the most important risk factor for cancer causing around 
20% of global cancer deaths and around 70% of global lung cancer deaths.5 
 
Tobacco regulators around the globe seek to protect present and future 
generations from the devastating health, social, environmental and economic 
consequences of tobacco consumption and exposure to tobacco smoke. We 
share common priorities and face common challenges in the fight to improve 
global public health. It is imperative that all global stakeholders, including the 
medical and scientific community, learn from one another’s successes and failures. 
 
In the United States, FDA’s unique position as a regulatory agency allows for a framework 
of decisionmaking based on – and within the limits of – both the science and the law. 
CTP uses a comprehensive approach as the best way to end the negative health 
effects of tobacco use. This includes defining policy, issuing regulations, conducting 
research, educating Americans on regulated tobacco products, and making decisions 
on whether new products and claims can be marketed—including reviewing and 
evaluating applications and claims before the products are allowed on the market. 
 
CTP educates the public about the harms of tobacco products, working to reduce 
their appeal and keep them out of the hands of America’s youth. CTP is committed to 
protecting and improving public health by focusing on three top priorities:
• Reduce initiation rates and prevent youth from starting to use tobacco
• Encourage tobacco users to quit
• Decrease the harms of tobacco product use
 
This session will help the global medical, research, and public health communities 
understand the authority granted to the FDA to regulate tobacco and how science is used 
to make the most effective regulatory decisions. FDA staff will describe actions taken by 
the FDA in the first six years of regulating tobacco products and preview future regulatory 
priorities. Attendees will learn about specific ways in which they can collaborate with 
and inform FDA’s work. At the conclusion of this session, attendees will be able to 
describe the FDA’s role, its activities to date and priorities for the future. References: 
 
1. US Department of Health and Human Services. The Health Consequences of 
Smoking—50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: US Dept of 
Health and Human Services, Centers for Disease Control and Prevention, National Center 
for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014. 
 
2. Substance Abuse and Mental Health Services Administration (SAMHSA). Results 
from the 2012 National Survey on Drug Use and Health, NSDUH: Table 4.10A Past 
Year Initiation of Substance Use Among Persons Aged 12 or Older Who Initiated Use 
Prior to the Age of 18, by Gender: Numbers in Thousands, 2012 and 2013. Rockville 
(MD): US Dept of Health and Human Services, Substance Abuse and Mental Health 
Services Administration, Center for Behavioral Health Statistics and Quality, 2014. 
 
3. Centers for Disease Control and Prevention. Tobacco Product Use Among Middle and 
High School Students - United States, 2011-2014. Morbidity and Mortality Weekly Report 
2015; 64: 381-385.
4. http://www.who.int/mediacentre/factsheets/fs339/en/
5. http://www.who.int/mediacentre/factsheets/fs297/en/
The U.S. Food and Drug Administration (FDA) Center for Tobacco Products (CTP) 
oversees the implementation of the Family Smoking Prevention and Tobacco Control 
Act (TCA). This session will help the medical, research, and public health communities 
understand the authority granted to FDA to regulate tobacco and how science is used to 
make the most effective regulatory decisions. Mr. Zeller will describe actions taken by the 
FDA in the first six years of regulating tobacco products and provide an overview of CTP’s 
strategic priorities. Attendees will learn about specific ways in which they can collaborate 
with and inform FDA’s work. At the conclusion of this session, attendees will be able to 
describe the FDA’s role, its activities to date and priorities for the future and understand 
CTP’s strategic priorities and vision for the regulation of tobacco products to help reduce 
the death and disease toll caused by tobacco use.
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Product liability litigation has played a critical, if supporting, role in tobacco control. Most 
prominently, lawsuits brought by US state attorneys general in the mid-1990s seeking 
reimbursement for expenses incurred in treating residents for smoking-related diseases 
forced the industry to begin disgorging incriminating internal documents, with over 14 
million now available on the internet, detailing industry misbehavior around the world 
(http://legacy.library.ucsf.edu). Public exposure of these misdeeds made the tobacco 
industry politically toxic, easing the way for subsequent regulatory legislation. Under the 
Master Settlement Agreement resolving these cases, the industry agreed to eliminate 
various marketing techniques and promotional stratagems and pay the states about $10 
billion/year, resulting in dramatic cigarette price increases that greatly reduced teenage 
smoking. Some of that money went into effective tobacco control programs. Every 
studies referenced in the WHO technical manual on tobacco tax administration and IARC 
Handbooks of Cancer Prevention: Tobacco Control. Volume 14, the relationship between 
real prices and tobacco consumption is generally inelastic, meaning that the decline 
in consumption is less than proportional to the increase in real price. Most estimates 
of the price elasticity of demand lie between -0.2 and -0.8. In all settings, studies 
have shown that the price elasticity of demand is higher (in absolute terms) in the long 
term, meaning that consumption will fall even more in the long term. People with lower 
socioeconomic status are more responsive to tax and price changes because such 
changes have a greater impact on their disposable income. As regards the effect of 
higher taxes and prices on tobacco use by young people, it is estimated that young 
people are two to three times more responsive to tax and price changes than older 
people. Therefore, tobacco tax increases are likely to have a significant effect on 
reducing tobacco consumption, prevalence and initiation among young people, as well as 
on reducing the chances of young people moving from experimentation to addiction.”[1] 
[1] Conference of the Parties to the WHO Framework Convention on Tobacco Control, 
Sixth session, Guidelines for implementation of Article 6 of the WHO FCTC (Price and 
tax measures to reduce the demand for tobacco), Moscow, Russian Federation,13–18 
October 2014.
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Learning Objectives:
• Describe FDA’s authority under the Family Smoking Prevention and Tobacco Control 
Act and the steps FDA has taken to regulate tobacco products in the 6 years since 
enactment of the law. 
• Understand FDA’s Center for Tobacco Products’ (CTP) strategic priorities and CTP’s 
vision for the regulation of tobacco products to help reduce the death and disease 
toll caused by tobacco use. 
• Describe how the CTP Office of Science supports and evaluates research to ensure 
that CTP has the science base to make regulatory decisions. 
• Discuss the ways the public health community can engage with FDA to participate 
in tobacco product regulation. 
• Identify opportunities to inform FDA action on tobacco to promote public health.
Abstract: The landmark Family Smoking Prevention and Tobacco Control Act (TCA) 
gave the U.S. Food and Drug Administration (FDA) sweeping new authorities to create 
a healthier future for America’s families by regulating the manufacture, marketing, 
and distribution of tobacco products. The law, passed by Congress and signed by the 
President in 2009, gave FDA the authority to establish the Center for Tobacco Products 
(CTP), which drives powerful change to protect children and families from the dangers 
of tobacco products. The TCA takes a comprehensive approach—grounded in rigorous, 
timely science and the law—to improve public health, especially for the next generation. 
FDA uses its regulatory authority to take action to protect American families, charting a 
new course for comprehensive change. These actions include:
• Developing science-based regulations to safeguard the nation’s health.
• Publishing guidance to help the industry comply with regulations for tobacco 
products.
• Conducting retailer inspections to ensure compliance with laws restricting sales of 
tobacco products to youth, and issuing warning letters and monetary penalties for 
violations.
• Requiring tobacco manufacturers to report the ingredients in their products so FDA 
can evaluate the harm caused by the ingredients, take steps to reduce the harm, 
and educate the public about the toxic substances in tobacco products so public 
health can be improved.
• Reviewing proposed modified risk tobacco products before they can be sold.
• Restricting the access and attractiveness of cigarettes and smokeless tobacco to 
young people.
• Enforcing the ban on the manufacture and sale of fruit- or candy-flavored cigarettes. 
• Prohibiting the use of misleading claims such as “low,” “light,” and “mild” that 
falsely imply that some tobacco products are safer.
• Reviewing new tobacco products to determine whether they can be legally marketed.
• Launching public information and education campaigns, particularly targeted to 
youth, about the dangers of regulated tobacco products.
• Partnering with other public health agencies to conduct cutting-edge research 
on a range of topics such as smoking initiation and nicotine addiction. 
Currently, FDA regulates cigarettes, cigarette tobacco, roll-your-own tobacco, 
and smokeless tobacco. FDA has also published a proposed rule to bring other 
products that meet the definition of tobacco product under FDA’s regulatory 
authority, such e-cigarettes, waterpipes, some or all cigars, and pipe tobacco. 
 
Despite major progress over the past half-century tobacco use kills more than 
480,000 Americans each year, making it the leading cause of preventable death 
and disease in the United States.1 Every day in the United States, nearly 2,900 youth 
under the age of 18 smoke their first cigarette, and more than 700 youth under 
age 18 become daily smokers.2 Nationwide, 5.5 percent of high school students 
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as powerful pre-clinical tools for translational research. Inactivation of the tumour 
suppressor genes TRP53 and RB1 is almost universally found in human SCLC. Based 
on this observation, the Berns Laboratory generated a mouse model of sporadic 
SCLC whereby p53 and Rb1 loss was restricted to lung epithelial cells by intra-tracheal 
instillation of an Adeno-Cre virus (Cre expression is under the control of a ubiquitous CMV 
promoter). These mice develop NE lung tumours with striking morphological and genomic 
similarities to SCLC observed in human patients1. This model allows us to address 
questions that would not be possible using patient samples or cancer cell lines alone. In 
my presentation, I will provide an overview on the GEMMs for SCLC currently available. I 
will also touch upon the emergence of new gene editing technologies, such as CRISPR-
Cas9, and how these techniques can be used to further manipulate current models to 
address clinically relevant questions. Lung cancers exhibit a high level of intra-tumoral 
heterogeneity. The histopathology of individual tumour subtypes, suggests that these 
tumours have distinct cells-of-origin, but this has not been formally shown. I will present 
the work we carried out to address the cellular origins of lung cancer, with a focus on the 
research we performed using the GEMM of SCLC (p53f/f;Rb1f/f). Briefly, we generated a 
series of recombinant adenoviruses that target Cre-recombinase expression selectively 
in Club (Ad5-CC10-Cre), alveolar type 2 (Ad5-SPC-Cre) and neuroendocrine (Ad5-CGRP-
Cre) cells2. To address the cellular origins of SCLC, we infected p53f/f;Rb1f/f mice with our 
cell type-restricted Adeno-Cre viruses, listed above. Results from these studies show 
that inactivation of p53 and Rb1 can efficiently transform neuroendocrine (CGRP-positive) 
and to a lesser extent, alveolar type 2 (SPC-positive) cells leading to SCLC. In contrast, 
CC10-expressing cells were largely resistant to transformation. The results clearly 
indicate that neuroendocrine cells serve as the predominant cell-of-origin of SCLC. 
Interestingly genome-sequencing studies have revealed genetic aberrations that overlap 
with squamous cell carcinomas in a subset of SCLCs. Does this reflect a common cellular 
origin? I will present some recent data we have generated to address this question. 
References 1. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ 
and Berns A. Induction of small cell lung cancer by somatic inactivation of 
both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003 vol. 4(3) pp. 
181-189. 2. Sutherland KD, Proost N, Brouns I, Adriaesen D, Song J-Y and Berns 
A. Cell of origin in small cell lung cancer: inactivation of Trp53 and Rb1 in distinct 
cell types of the adult mouse lung. Cancer Cell 2011 vol. 19(6) pp. 754-764. 
Keywords: small cell lung cancer, Genetically modified mouse models, cell-of-origin, 
Adeno-Cre viruses
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Small cell lung cancer (SCLC) is a neuroendocrine subtype of lung cancer characterized 
by a fast growth rate, extensive dissemination, and rapid resistance to chemotherapy. 
Survival rates are dismal and have not significantly improved in the past few decades. 
The group of Roman Thomas and Martin Peifer sequenced the genomes of over 100 
human SCLC, which demonstrates universal inactivation of p53 and RB and identified 
inactivating mutations in NOTCH family genes in ~25% of tumors. Accordingly, we found 
that activation of Notch signaling in a pre-clinical SCLC mouse model dramatically 
reduces the number of tumors and extends the survival of the mutant mice. In addition 
to suppressing proliferation, active Notch inhibits neuroendocrine gene expression in 
SCLC cells. Thus, Notch plays a key tumor suppressive role in SCLC and strategies to 
re-activate Notch in SCLC tumors may be beneficial to patients (George, Lim, et al., in 
press). At the histological level, SCLC tumor cells are often viewed as homogeneous. 
These studies and previous studies (e.g. Calbo et al., Cancer Cell, 2011 – Berns lab) 
have identified several levels of intra-tumor heterogeneity in SCLC, which may contribute 
significantly to SCLC aggressive nature and resistance to therapy. We will also discuss 
the existence and the role of several subpopulations of SCLC tumor cells involved in the 
long-term propagation of this cancer type, the rapid acquisition of chemoresistance, 
and metastasis. A better understanding of the molecular underpinnings of these 
cellular heterogeneity may help identify novel therapeutic targets in SCLC. 
Keywords: SCLC, NOTCH, mouse models, therapeutic targets
stage of tobacco litigation (initial filings, motions, hearings, decisions, appeals) provides 
‘teachable moments’ for public education about the underlying issues: the health 
consequences of smoking, addictiveness, and tobacco industry misbehavior. The cases 
dramatize the impact of smoking on real people, not just statistics. Even the industry’s 
counter-spin, that smokers who contract lung cancer ‘assumed the risk’, implicitly 
acknowledges the reality of the causal link. Product liability litigation can take many 
forms. Most legal systems allow individuals, including smokers or their survivors, to seek 
compensation for their financial and emotional losses from product manufacturers that 
sell unreasonably dangerous products, fail to warn about the dangers of these products, 
and/or actually lie about these dangers. In the USA, multimillion-dollar punitive damages, 
designed to deter others from misbehaving like tobacco companies, are sometimes 
also available. Similar cases can be brought by victims of secondhand smoke, though 
establishing causation in cases against tobacco manufacturers has proven extremely 
difficult; obtaining workers compensation from employers, however, has become fairly 
routine. Injuries from cigarette-caused fires are compensable, since cigarettes with low 
ignition propensity can easily be manufactured. Injured smokers and non-smokers are 
not the only possible plaintiffs: as mentioned, many US states were permitted to sue 
tobacco companies in the 1990s for medical costs incurred in caring for smokers whose 
diseases could be attributed to tobacco industry misconduct. Similar cases are pending 
in Israel, and most Canadian provinces now have legislation facilitating such lawsuits. 
Finally, legal systems sometimes permit consumers with similar claims to proceed in 
a single class action, greatly reducing litigation costs. In May 2015 a judge in Quebec, 
Canada awarded more than US$100,000/smoker to a class of about 100,000 smokers 
with lung or throat cancer or emphysema, as well as about $100 million to another 
class of addicted smokers. U.S. courts have allowed class actions to go forward to 
fund medical monitoring programs for long-term smokers, and to compensate smokers 
who were fooled into thinking that “light” cigarettes were safer than regular cigarettes. 
Cases can be brought to stop tobacco industry misconduct brought by parties who were 
not themselves injured by that behavior. Thus, the US Department of Justice brought 
a successful case against the major tobacco companies to prevent their continued 
violations of the Racketeer Influenced and Corrupt Organizations Act. And cases can even 
be brought in some jurisdictions to force the government to protect the lives and health 
of their citizens. Thus, the Indian Supreme Court insisted upon legislation to protect 
nonsmokers from secondhand smoke. The efficacy of product liability litigation depends 
as much on procedural rules as on substantive legal doctrines (legal ‘rights’). In most 
countries other than the USA, the absence of contingency fees (where plaintiff’s lawyers 
are compensated with a portion of the plaintiff’s judgment or settlement, if any) means 
the lawyers must either provide their services for free or bill their ill, dying, or bereaved 
clients on an ongoing basis: hence, few such cases are brought. Worse, many legal 
systems require plaintiffs who lose their cases to pay the defendant’s legal costs, thus 
putting the plaintiff’s remaining assets at risk. These unfortunate procedural rules can, 
of course, be changed by court rule or statute. 
Going forward Article 4.5 of the WHO Framework Convention on Tobacco Control (FCTC) 
recognizes that ‘issues relating to liability… are an important part of comprehensive 
tobacco control’. Article 19, ‘Liability’, provides that ‘Parties shall consider taking 
legislative action… to deal with… civil liability, including compensation where 
appropriate’. Legislation correcting the procedural rules that prohibit contingency 
fees and shift litigation costs to the losing party, permitting consumer class actions, 
and facilitating healthcare cost recovery lawsuits, are examples of such highly 
desirable legislative action. Article 19 also encourages parties to assist each other 
in carrying out legal proceedings and to share relevant information with each other, 
and invites the Conference of the Parties (COP) to develop ‘appropriate international 
approaches to these issues’ as well as to support parties in their activities relating to 
liability. The COP has currently charged an expert group to design a mechanism for 
collecting, archiving and sharing litigation documents and for providing advice and 
assistance—electronically or in person—to attorneys bringing liability cases against 
the tobacco industry. For at least a decade tobacco company defendants in the US 
have admitted on their websites and ceased to deny in court that smoking is the major 
cause of lung cancer and chronic obstructive pulmonary disease (COPD), though they 
often contest the diagnosis or aetiology in particular cases. By contrast, and despite 
universal availability of the internet, tobacco defendants in Europe and Asia have 
been remarkably successful in confusing courts on the epidemiology of smoking 
and disease. The recent acceleration in the globalization of tobacco control efforts, 
inspired by the FCTC and supported by the Bloomberg and Gates Foundations, and 
the commitment of parties under Article 12 of the FCTC to conduct public education 
on tobacco control issues, can be expected to equalize around the world knowledge 
of basic tobacco epidemiology. Similarly, the presence of millions of easily accessible 
internal tobacco industry documents on the internet should simplify the process of 
establishing the liability of the major transnational tobacco companies and their affiliates. 
Keywords: tobacco, Litigation, prevention
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MS07.02 GEM Models (p53/Rb) Kate Sutherland Stem Cells and Cancer, The Walter 
and Eliza Hall Institute of Medical Research, Melbourne/VIC/Australia
Small cell lung cancer (SCLC) is an aggressive neuroendocrine (NE) tumour associated 
with poor 5-year survival rates. Given the difficulties associated with obtaining human 
material, genetically engineered mouse models (GEMMs) for SCLC have emerged 
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grade NE carcinomas and are also useful for the study of multistage pathogenesis and 
the metastatic properties of these tumors. Summary The major In vitro models for 
SCLC each have their individual strengths and weaknesses. Each has to be carefully 
evaluated for its suitability for the proposed experimental approach. Despite their 
limitations, In vitro models remain the single most important source of knowledge about 
the non-clinical aspects of SCLC and will likely remain so into the foreseeable future. 
1. Phelps RM, Johnson BE, Ihde DC, et al. NCI-Navy Medical Oncology Branch cell line 
data base. J Cell Biochem 1996;Suppl. 24:32-91. 2. Gazdar AF, Carney DN, Nau MM, 
et al. Characterization of variant subclasses of cell lines derived from small cell lung 
cancer having distinctive biochemical, morphological, and growth properties. Cancer 
Res 1985;45:2924-2930. 3. Gazdar AF, Girard L, Lockwood WW, et al. Lung cancer 
cell lines as tools for biomedical discovery and research. Journal of the National Cancer 
Institute2010;102:1310-1321. 4. Breslin S, O’Driscoll L. Three-dimensional cell culture: 
the missing link in drug discovery. Drug Discov Today 2013;18:240-249. 5. Hodgkinson 
CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells 
in small-cell lung cancer. Nat Med 2014;20:897-903. 6. Liu X, Ory V, Chapman S, et 
al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial 
cells. The American journal of pathology 2012;180:599-607. 7. Rosfjord E, Lucas J, Li 
G, et al. Advances in patient-derived tumor xenografts: from target identification to 
predicting clinical response rates in oncology. Biochem Pharmacol 2014;91:135-143. 8. 
Moro M, Bertolini G, Tortoreto M, et al. Patient-derived xenografts of non small cell lung 
cancer: resurgence of an old model for investigation of modern concepts of tailored 
therapy and cancer stem cells. J Biomed Biotechnol 2012;2012:568567. 9. Isobe T, 
Onn A, Morgensztern D, et al. Evaluation of novel orthotopic nude mouse models for 
human small-cell lung cancer. J Thorac Oncol 2013;8:140-146. 10. Gazdar AF, Carney 
DN, Sims HL, et al. Heterotransplantation of small-cell carcinoma of the lung into nude 
mice: comparison of intracranial and subcutaneous routes. Int J Cancer 1981;28:777-
783. 11. Zhang YA, Maitra A, Hsieh JT, et al. Frequent detection of infectious 
xenotropic murine leukemia virus (XMLV) in human cultures established from mouse 
xenografts. Cancer Biol Ther 2011;12:617-628. 12. Gazdar AF, Savage TK, Johnson 
JE, et al. The comparative pathology of genetically engineered mouse models for 
neuroendocrine carcinomas of the lung. J Thorac Oncol 2015;10:553-564. 13. McFadden 
DG, Papagiannakopoulos T, Taylor-Weiner A, et al. Genetic and clonal dissection of murine 
small cell lung carcinoma progression by genome sequencing. Cell 2014;156:1298-1311. 
Keywords: In vitro models, Cell lines, Patient Derived Xenografts, Genetically engineered 
mouse models
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1Institute of Cancer Sciences, Manchester University & Christie Hospital NHS Trust, 
Manchester/United Kingdom, 2Clinical & Experimental Pharmacology Group, CRUK 
Manchester Institute, Manchester/United Kingdom
Progress in understanding the molecular biology of small cell lung cancer has undoubtedly 
been hampered by lack of tissue resources suitable for comprehensive systems biology 
analysis. Tissue quantities sufficient for molecular analysis are more commonly from 
surgical resections and open biopsies from patients with very limited stage disease and 
therefore not representative of the majority of SCLC patients. Serial biopsies are even 
rarer to obtain. As an alternative to tumour tissue, circulating tumour cells (CTCs) are highly 
prevalent and abundant in patients with SCLC. These surrogate biomarkers, increasingly 
referred to as ‘virtual’ or ‘liquid’ biopsies, may be more relevant to understanding the 
biology of this disease that is hallmarked by early and widespread haematogenous 
dissemination. In our own series (Hou et al. JCO 2012) blood samples from 97 treatment 
naive patients, 31 with limited stage (LS) and 66 with extensive stage (ES), were assessed 
for CTCs using the EpCam-based immunomagnetic detection method, CellSearch. CTCs 
were detectable in the majority (85%) of patients and abundant. The mean ± standard 
deviation for CTC number(#) in a 7.5ml blood sample was 1,589 ± 5,565 and median 
CTC# was 24 (range 0 – 44, 896). CTC# was significantly associated (higher) with ES, 
lactate dehydrogenase, presence of liver metastases and number of sites of metastases. 
In multivariate analysis, adjusting for these clinical associations, pretreatment CTC# and 
change in CTC# after one cycle of chemotherapy were independent prognostic factors. 
A statistically derived cut off of 50 CTCs demonstrated most significant discrimination in 
survival estimation. The overall survival was 5.4 months for patients with ≥  50 CTCs/7.5 
mL of blood compared with 11.5 months (P < .0001) for patients with less than 50 
CTCs/7.5 mL of blood before chemotherapy (hazard ratio = 2.45; 95% CI, 1.39 to 
4.30; P =0 .002). In addition to prognostic information CTCs are pharmacodynamic 
and amenable to biomarker assay development (protein expression, omic profiling, FISH 
etc). CTCs ex vivo are also tumourigenic. We have established a series of CTC derived 
xenografts (CDX) in immune compromised (IC) mice (Hodgkinson et al. Nat Med 2014). 
Of 6 initial patients whose CTCs were implanted in IC mice, 4 gave rise to tumours in less 
than 5 months. Implantation and CDX tumour formation was associated with higher CTC# 
(>400 CTCs / 7.5mls of blood). The immunohistochemical characteristics of the CDX 
tumours were consistent with SCLC morphology and neuroendocrine marker expression. 
Whole genome sequencing demonstrated that the tumours had mutations (e.g. TP53 
and RB1) and copy number variation (e.g. loss of 3p and 13q) commonly observed in 
SCLC. Furthermore, the same genetic abnormalities as the CDX were present in single 
cells CTCs isolated from the corresponding patient. On exposure of the CDX to platinum 
and etoposide chemotherapy a remarkable correlation was observed for the tumour 
responses compared to the patients’ tumour responses and survival. For example the 
most chemoresistant CDX was established from CTCs of a patient who survived for only 
0.9 months and who had chemorefractory disease, whereas the most chemosensitive 
CDX was obtained from a patient who responded to platinum/etoposide chemotherapy 
and who survived for 9.7 months. A CDX of intermediate chemosensitivity was derived 
from a patient who survived for 3.5 months. Once the CDX tumours are established 
they can be harvested for passage, frozen and resurrected. Ongoing work aims to 
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MS07.04 From GEMs to ROCKs – An Assessment of In Vitro Models for the 
Study of SCLC Adi F. Gazdar Hamon Center for Therapeutic Oncology Research and 
Department of Pathology, UT Southwestern Medical Center, Dallas/TX/United States 
of America
Because SCLC tumors are seldom resected, in vitro models to study this “recalcitrant 
disease” are of crucial importance. The major strengths and limitations of the three basic 
preclinical model systems are summarized in Table 1. Table 1: Strengths and Limitations 
of Preclinical model systems for the study of SCLC
Preclinical Model Strengths Limitations
Tumor Cell lines 
(TCLs)
Spheroidal growth, cytological 
appearances and neuroendo-
crine (NE) cell properties.
May represent oligoclonal 
selection. Lacks stroma and 
vasculature.
Patient-derived 
xenografts (PDXs)
Histology and gene expression 
profile of tumors closely resem-
ble human counterpart.
Stroma and vasculature are of 
host mouse origin. Lacks intact 
immune system. Metastatic 
spread limited. Possible contam-
ination with murine xenotropic 
virus.
Genetically En-
gineered Mouse 
Models (GEMMs)
Reproduces pathology of NE car-
cinomas and similar metastatic 
pattern. Only model for studying 
multistage pathogenesis
Long latent time. Precise histolo-
gy mixture variable.
Tumor Cell Lines SCLC lines have been established since the early 1970s. A large series 
of cell lines was established by Drs. Gazdar, Desmond Carney and John Minna.1Most lines 
retained the cytological and NE cell features of SCLC tumors. We have confirmed that 
vast majority of the NCI series of lines have retained these features even after 4 decades 
in culture. Some of the lines, especially those established after prior therapy and which 
had amplification of a MYC family gene, had atypical morphology and lacked some of 
the NE cell program. These were termed variant SCLC cell lines.2They remain the major 
resource for most of the biology studies performed in SCLC.3 Constitutional sources 
of DNA are available for some of the lines. A major shortcoming is lack of cell lines 
established from the putative precursor cell, the NE cells of the respiratory epithelium. 
While most TCLs grow as two dimensional adherent monolayers, SCLC cultures naturally 
grow as three dimensional floating aggregates or spheroids. Several recent reports have 
suggested that three dimensional in vitro growth more closely resembles the natural 
growth characteristics of patient tumors, and may be more representative of drug 
response.4 While they are an estimated 150 SCLC TCLs established worldwide, recent 
reports have been scarce. Two recent developments offered innovative new approaches 
to the establishment of SCLC lines. The finding that the circulating tumor cell burden in 
SCLC cases were extremely high and could be used to establish PDXs5was promising 
and also suggested that the circulating cells could be used to establish new SCLC TCLs. 
Recently a method for the propagation of epithelial cells of non-malignant and malignant 
origin, termed “Conditionally Reprogrammed Cells” (CRC) was described. CRC cells have 
properties of epithelial stem cells.6This method was widely utilized to generate many 
new putative lung cancer TCLs, mainly of NSCLC origin. Our extensive characterization 
(led by Boning Gao and John Minna) of CRC cells from NSCLC specimens indicated 
robust growth of epithelial cells apparently free of fibroblast contamination. However, 
characterization of the cells indicated that they mostly had properties of stem cells 
derived from non-malignant cells, and were diploid and lacked mutations present in the 
corresponding tumors. These results suggest, at least for lung cancer specimens, that 
the CRC method preferentially grows the non malignant epithelial stem cell component 
present in all lung cancer resections. Patient Derived Xenografts (PDXs) PDX tumors 
are generated by direct transfer of human tumor fragments or cell isolates from patient 
tumors to immune-deficient mice (or other rodent species). At least during early serial 
passage, PDXs retain the genetic and morphological characteristics of the original 
human tumor, including histological features, gene expression profiles, copy number 
variations and chromosomal stability of PDX tumors.7 Thus, PDXs have been proposed as 
an advanced preclinical tool for therapy testing in a number of tumor types including lung 
cancers.8 Most PDXs are inoculated subcutaneously. Orthotopic models for SCLC may 
increase metastatic potential and relevance for chemotherapy evaluation.9 Intracranial 
heterotransplantation of SCLC into the brain provides a model to study intracranial and 
leptomeningeal meatastases.10 The mouse genome contains over 500,000 copies of 
integrated strains of mouse leukemia virus virus. Some strains are xenotropic and grow 
efficiently in human cells. Serial transplantation of PDXs, especially SCLC, is associated 
with a high frequency of xenotropic virus contamination,11which poses potential health 
risks and may influence genetic analyses.Genetically engineered mouse models 
(GEMMs) Berns developed the double knockout model (lacking p53 and Rb1 that 
closely recapitulated the histology and metastatic pattern of SCLC, but had a relatively 
long latent period.12Several triple knockout variants of the basic model have been 
developed, specifically to reduce the long latent period. However, these variations often 
have more complex histologies, reflecting the spectrum of high grade NE carcinoma 
of the lung. The resultant histological phenotypes were influenced by multiple factors. 
The lengthy latent time permitted observations of the preneoplastic and premalignant 
stages of SCLC development, which are seldom observed in human tumors because 
of the explosive growth of SCLC once it becomes invasive. The long latent period is 
caused by the development of secondary genetic changes required for tumor formation 
such as alterations of the PTEN and NFIB genes.13A recent review12concluded that 
GEMM models studied are representative for the entire spectrum of human high-
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20% of pleural malignant mesotheliomas (Zauderer MG, Bott M, McMillan R, Sima 
CS, Rusch V, Krug LM, Ladanyi M, 2013), with most studies reporting no significant 
differences in the histopathological features or survival of patients with BAP1 mutant 
compared to wild-type tumors. A recent study of Portuguese siblings discovered 
a germline BAP1 mutation as the possible cause of the only known familial clustering 
of well-differentiated papillary mesothelioma (WDPM), a rare subtype of epithelioid 
mesothelioma (Ribeiro et al., 2013), and there has since been another report of WDPM 
in a carrier of a germline BAP1 mutation (Pilarski et al., 2014). Previously, some patients 
with germline BAP1 mutations and malignant mesotheliomas have been reported as long-
term survivors, which is very rare for mesotheliomas, raising the possibility that such 
tumors may be associated with more favorable prognosis (Ribeiro et al., 2013; Wiesner 
T, Fried I, Ulz P, Stacher E, Popper H, Murali R, Kutzner H, Lax S, Smolle-Jüttner F, Geigl 
JB, 2014). In contrast, somatic BAP1 mutations or loss of BAP1 have been associated 
with high-grade tumors or disseminated disease in sporadic RCC and UM patients, which 
could indicate a worse prognosis for carriers of germline BAP1 mutations with these 
tumor types. Clearly, further studies are necessary to clarify whether BAP1 germline 
mutation carriers with various cancers have altered prognosis relative to individuals 
who acquire somatic mutations in BAP1. Here, we sought to determine the frequency of 
germline BAP1mutations in cancer prone families with accumulation of mesothelioma, 
UM, CM and RCC. Methods: Families were collected through the Danish melanoma 
registry and through Clinical Genetic Departments in Denmark. Families, who 
previously had received genetic counselling regarding mesothelioma, CM, UM, and 
RCC, were contacted. Results: In total we analysed 152 Danish families and found five 
with BAP1 mutations, which are described in Table 1. We analysed 127 CM patients, who 
were either young onset (<40 years), had multiple primary CM, or had a family history of 
melanoma, and found no BAP1 mutation. We analysed 22 sporadic cases of UM or familial 
cases of CM, with one case of UM in the family and found no BAP1 mutation. However, in 
6 melanoma families with two cases of UM, we found 4 families with BAP1 mutation, and 
2 of 3 families analysed with 2 or more cases of mesothelioma carried BAP1 mutations. 
We found that the strongest indicator of a germline BAP1 mutation, were families with 
two or more cases of mesotheliomas or UM. In 40% of families with the occurrence of 
mesothelioma and CM we also found BAP1 mutations but did not find BAP1 mutations in 
families with only CM or RCC, or families with CM and RCC. Table 1: Characterization of 
Danish BAP1 mutation-positive families
Family Mutation
Cases of 
UM/No. of 
mutation 
carriers
Cases of 
mesotheli-
oma/ No. 
of mutation 
carriers
Cases of 
CM/No. of 
mutation 
carriers
Other types of 
cancer in mutation 
carriers
A c.1708C>G p.L570V 3/14 2/14 1/14
Paraganglioma, 
Sarcoma
B c.581-2A>G Splice defect 7/9 0/9 1/9 Lung
C c.1209_1210dupT p.D404X 0/8 3/8 2/8
BCC, Breast, 
unknown primary
D c.178C>T p.R60X 3/10 0/10 2/10 BCC, ovary
E c.178C>T p.R60X 2/4 1/4 0/4 BCC
Total 15/45(33%) 6/45(13%) 6/45(13%)
 
13% of BAP1 mutation carries developed mesothelioma, 33% developed UM, and 13% 
developed CM. There were no cases of RCC in the 5 Danish BAP1 mutation-positive 
families. Conclusion: In the Danish BAP1 mutation carriers we observed rare tumor 
types (pericardial paraganglioma and malignant fibrous histiocytoma) and three cases 
of unknown primary tumors. At present there is no international consensus about 
a surveillance program for BAP1 mutation carriers. Since BAP1 contributes to a rare, 
recently discovered cancer syndrome, there is as yet no documented reduction of 
morbidity or mortality to persons following surveillance. To obtain such empirical data we 
offer persons carrying a pathogenic BAP1 mutation a surveillance program consisting of 
yearly ophthalmological and dermatological examination from the age of 15. In addition, 
from the age of 25, we offer ultrasound examination of the kidneys every second year. We 
inform the patient and their general practitioners of the increased cancer risk, and signs 
which should prompt further symptom-related investigations. At the moment, we have not 
established a surveillance program for mesothelioma. References: Carbone, M., Yang, 
H., Pass, H. I., Krausz, T., Testa, J. R., & Gaudino, G. (2013). BAP1 and cancer. Nature 
Reviews. Cancer, 13, 153–9. doi:10.1038/nrc3459 Murali, R., Wiesner, T., & Scolyer, R. a. 
(2013). Tumours associated with BAP1 mutations. Pathology, 45, 116–26. doi:10.1097/
PAT.0b013e32835d0efb Pilarski, R., Cebulla, C. M., Massengill, J. B., Rai, K., Rich, T., 
Strong, L., … Abdel-Rahman, M. H. (2014). Expanding the clinical phenotype of hereditary 
BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes 
and Cancer, 53, 177–182. doi:10.1002/gcc.22129 Ribeiro, C., Campelos, S., Moura, 
C. S., Machado, J. C., Justino, A., & Parente, B. (2013). Well-differentiated papillary 
mesothelioma: Clustering in a Portuguese family with a germline BAP1 mutation. Annals 
of Oncology, 24, 2147–2150. doi:10.1093/annonc/mdt135 Wadt, K. A. W., Aoude, L. G., 
Johansson, P., Solinas, A., Pritchard, A., Crainic, O., … Hayward, N. K. (2014). A recurrent 
germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to 
include basal cell carcinoma. Clinical Genetics. doi:10.1111/cge.12501 Wiesner T, Fried I, 
Ulz P, Stacher E, Popper H, Murali R, Kutzner H, Lax S, Smolle-Jüttner F, Geigl JB, S. M. 
(2014). J OURNAL OF C LINICAL O NCOLOGY Toward an Improved Definition of the Tumor 
Spectrum Associated With BAP1. Journal of Clinical Oncology, 30 (32), 2012–2015. Wiesner, 
T., Obenauf, A. C., Murali, R., Fried, I., Griewank, K. G., Ulz, P., … Speicher, M. R. (2011). 
Germline mutations in BAP1 predispose to melanocytic tumors. Nature Genetics, 43 (10), 
1018–21. doi:10.1038/ng.910 Yu, H., Pak, H., Hammond-Martel, I., Ghram, M., Rodrigue, 
establish serial CDX models from patients who have progressed after initial treatment 
for study of biology, particularly that of acquired chemoresistance, and for preclinical 
testing of novel therapeutics in treatment naïve and previously treated SCLC. There is 
also possibility to incorporate serial CTC analysis and CDX model generation into clinical 
trials as ‘co-clinical trials’ with interrogation of pharmacodynamic and putative predictive 
biomarkers in addition to discovering mechanisms of resistance to novel therapeutics. 
CTC analysis and CDX model generation are technically challenging and resource 
intensive, but essential tools to further develop if we are to end the impasse on a targeted 
therapy breakthrough for this disease. References Hou JM, Krebs MG, Lancashire 
L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, 
Blackhall FH, Dive C. Clinical significance and molecular characteristics of circulating 
tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. 
J Clin Oncol. 2012 Feb 10;30(5):525-32. Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, 
Rothwell DG, Trapani F, Polanski R, Burt DJ, Simpson KL, Morris K, Pepper SD, Nonaka D, 
Greystoke A, Kelly P, Bola B, Krebs MG, Antonello J, Ayub M, Faulkner S, Priest L, Carter 
L, Tate C, Miller CJ, Blackhall F, Brady G, Dive C. Tumorigenicity and genetic profiling 
of circulating tumor cells in small-cell lung cancer. Nat Med. 2014 Aug;20(8):897-903. 
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MS08.02 BAP1 and Ubiquitination El Bachir Affar Medicine, Université de Montréal, 
Montréal/Canada
The deubiquitinase (DUB) BAP1 recently emerged as a major tumor suppressor 
inactivated in several malignancies notably mesothelioma. With the aim of defining 
the BAP1 mechanism of action, we previously conducted a tandem affinity 
immunopurification of BAP1-associated proteins and found that most of the interacting 
partners are transcription factors and cofactors. Notably, BAP1 forms a complex with 
the Host Cell Factor (HCF-1), the O-linked N-acetyl-Glucosamine Transferase (OGT), the 
Lysine Specific Demethylase KDM1B, the Additional Sex Comb Like proteins ASXL1 and 
ASXL2 (ASXL1/2), the Forkhead Box transcription factors FOXK1 and FOXK2 as well as 
the zinc finger transcription factor Yin Yang 1 (YY1). We found that BAP1 regulates the 
expression of genes involved in cell proliferation and is recruited to gene regulatory 
regions to activate transcription. BAP1 is also recruited to the site of DNA double strand 
breaks to promote repair by homologous recombination. Moreover, this DUB appears 
to be also finely regulated by post-translational modifications including phosphorylation 
and ubiquitination. Interestingly, the ortholog of BAP1 in drosophila, named Calypso, 
deubiquitinates histone H2A on lysine 119 (H2Aub). H2Aub is a critical epigenomic 
modification involved in transcriptional and DNA repair, and is associated with stem 
cell function, development, cell proliferation and cancer. Calypso associates with 
Additional Sex Comb (ASX) and forms the Polycomb Repressive DUB (PR-DUB) complex. 
Recently, we provided insights into the importance of BAP1-interacting partners, ASXL1 
and ASXL2 (two orthologs of ASX) in promoting H2A deubiquitination. We found that 
BAP1 forms two mutually exclusive complexes with ASXL1 and ASXL2. ASXL1 and 
ASXL2 use their highly conserved ASXM domain to interact with the C-terminal domain 
(CTD) of BAP1, and these factors regulate each other’s protein stability. Significantly, 
through mutational analysis, we found that ASXM enhances BAP1 binding to ubiquitin 
and stimulates its DUB activity. Importantly, these functions require intramolecular 
interactions in BAP1 that generate a Composite Ubiquitin Binding Interface (CUBI). Gain 
and loss of function studies indicated that BAP1, ASXL1 and ASXL2 play critical roles in 
the coordination of cell cycle progression. Notably, overexpression of BAP1 or ASXL2 
trigger the p53/p21 DNA damage response and cellular senescence, and these effects 
are abolished by mutations of the CTD or ASXM interaction domains. Furthermore, we 
showed that cancer-associated inactivation of BAP1/ASXL1/2 DUB activity disrupts 
coordination of cell proliferation. Altogether, our results indicate that the mammalian 
BAP1 is an authentic DUB for H2A that regulates chromatin function and exerts a 
tight control on cell cycle progression. Moreover, our studies provide a mechanistic 
link between H2A deubiquitination, BAP1 interacting partners and tumor suppression. 
Keywords: Ubiquitin, BAP1, Chromatin, deubiquitination
BAP1 CANCER SYNDROME AND MESOTHELIOMA  
MONDAY, SEPTEMBER 07, 2015 - 14:15-15:45
MS08.03 Screening for BAP1 in Danish Families Karin Wadt1, Lauren Aoude2, 
NicholasK. Hayward3, Anne-Marie Gerdes1 1Department of Clinical Genetics, University 
Hospital of Copenhagen, Rigshospitalet, Copenhagen/Denmark, 2QIMR, Brisbane/ACT/
Australia, 3QIMR, Brisbane/Australia
Background: BRCA1 associated protein-1 (BAP1) is a tumor suppressor gene that 
encodes a deubiquitinase involved in cell cycle regulation, cellular differentiation, and 
cell death (Carbone et al., 2013; Murali, Wiesner, & Scolyer, 2013). BAP1 is recruited 
to double-stand DNA breaks and promotes error-free DNA-repair (Yu et al., 2014). 
GermlineBAP1 mutations have been identified in around 40 families with accumulation of 
mesothelioma, uveal melanoma (UM), cutaneous melanoma (CM), renal cell carcinoma 
(RCC), and basal cell carcinoma (BCC) (Carbone et al., 2013; Wadt et al., 2014; Wiesner 
et al., 2011). Speculation exists as to whether BAP1 germline mutation carriers with 
mesothelioma, UM or RCC have different prognosis compared to non-carriers with the 
same types of cancer. Somatic BAP1 mutations have been identified in approximately 
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personalized care, especially in terms of the Cachexia Clinic and the stages of cancer 
cachexia that will ultimately provide more specifi c and personalized care for those who 
are in the various stages of cancer cachexia (Vigano et al, 2012). The CRP and CC teams 
include a palliative care physician, a nurse clinician, a physiotherapist, an occupational 
therapist and a nutritionist. If patients present primarily with cancer related pain, they are 
referred to the Cancer Pain Clinic, whereas patients who have advanced disease and are 
no longer receiving treatment with a curative intent may be referred to the Palliative Care 
Clinic. Access to physiotherapy, occupational and nutritional services is available for all 
clinics which do not include these specialties in their teams.Patients assessed with 
psychosocial distress from all clinics are referred to the psychosocial oncology program 
and/or social services. CanSupport services (i.e. reimbursements for parking, 
transportation etc.) are also available upon request. Screening assessments for both 
malnutrition and symptom distress are available at the RIC. At the present time, there is 
ongoing research for using these screening to systematically identify frail elderly cancer 
patients prior to cancer treatment initiation. There is also a need to objectively determine 
if interventions targeted to decrease malnutrition and symptom burden will diminish 
frailty, may improve patient psychological and physiologic “readiness” for what are often 
aggressive treatments (chemotherapy, radiotherapy or surgery). There is a convincing 
body of research evidence including case reports (Carli et al., 2012, Carli et al., 2014), 
pilot studies (Li et al., 2013), and randomized clinical trials (Gillis et al., 2014) that 
supports geriatric patient engagement in multi-modal, cancer pre-habilitation programs 
designed to improve physical (physiological) and psychological (anxiety and depression) 
outcomes during a perioperative time period. We are therefore investigating ways to 
enhance access to supportive care services for elderly lung cancer patients, which 
include:
• Standardized screening for malnutrition and symptom burden.
• Standardized approaches to symptom control, psychological distress, as well as 
nutritional and functional problems
• Identifi cation of specifi c therapeutic targets and interventions to reduce frailty
Canadian Cancer Society’s Steering Committee on Cancer Statistics. Canadian 
Cancer Statistics 2012. Toronto, ON: Canadian Cancer Society; 2012. Carli F, Brown R, 
Kennepohl S. Prehabilitation to enhance postoperative recovery for an octogenarian 
following robotic-assisted hysterectomy with endometrial cancer. Can J Anaesth. 2012 
Aug;59(8):779-84. doi: 10.1007/s12630-012-9734-4. Epub 2012 May 26. Carli F, 
Awasthi R, Gillis C, Kassouf W Optimizing a frail elderly patient for radical cystectomy 
with a prehabilitation program. Can Urol Assoc J. 2014 Nov;8(11-12):E884-7. doi: 
10.5489/cuaj.2025. Dahele, M., R. J. Skipworth, L. Wall, A. Voss, T. Preston and K. C. 
Fearon (2007). “Objective physical activity and self-reported quality of life in patients 
receiving palliative chemotherapy.” J Pain Symptom Manage 33(6): 676-685. Dekhuijzen 
PN, Prins JB. Distress in suspected lung cancer patients following rapid and standard 
diagnostic programs: a prospective observational study. Psycho-oncology. 2014 
Sep 9. doi: 10.1002/pon.3660. [Epub ahead of print] Gillis C, Li C, Lee L, Awasthi 
R, Augustin B, Gamsa A, Liberman AS, Stein B, Charlebois P, Feldman LS, Carli F. 
Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing 
colorectal resection for cancer. Anesthesiology. 2014 Nov;121(5):937-47. doi: 10.1097/
ALN.0000000000000393. Greer JA, Jackson VA, Meier DE, Temel JS. Early integration 
of palliative care services with standard oncology care for patients with advanced cancer.
CA Cancer J Clin. 2013 Sep;63(5):349-63. doi: 10.3322/caac.21192. Epub 2013 Jul 
15. Iyer S, Roughley A, Rider A, Taylor-Stokes G. The symptom burden of non-small cell 
lung cancer in the USA: a real-world cross-sectional study Support Care Cancer. 2014 
Jan;22(1):181-7. doi: 10.1007/s00520-013-1959-4. Epub 2013 Sep 12. Li C, Carli F, Lee 
L, Charlebois P, Stein B, Liberman AS, Kaneva P, Augustin B, Wongyingsinn M, Gamsa 
A, Kim do J, Vassiliou MC, Feldman LS. Impact of a trimodal prehabilitation program 
on functional recovery after colorectal cancer surgery: a pilot study. Surg Endosc. 
2013 Apr;27(4):1072-82. doi: 10.1007/s00464-012-2560-5. Epub 2012 Oct 9. Vigano 
A, Morais JA. The elderly patient with cancer: a holistic view. Nutrition. Published on 
line January 8, 2015. http://dx.doi.org/10.1016/j.nut.2015.01.001 Vigano A, Del Fabbro 
E, Bruera E, Borod M. The cachexia clinic: from staging to managing nutritional and 
functional problems in advancer cancer patients. Critical Reviews in Oncogenesis 2012 
17(3), 293–304 Zabora J, Brintzenhofeszoc K, Curbow B, Hooker C and Piantadosi S. The 
prevalence of psychological distress by cancer site. Psycho-oncology 10 : 19–28 (2001) 
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Palliative care has been shown to improve outcomes for patients with life threatening 
illness and patients at the end of life, including decreasing symptom burden, improving 
quality of life, and working with patients and families to help ensure that the medical 
and nursing care provided is congruent with goals and preferences. Palliative care, 
focusing on assistance with advance care planning, decision-making, pain and symptom 
management, psycho-social support, and patient navigation, has the potential to improve 
care quality and reduce medical service utilization.1 In a randomized controlled trial (RCT) 
of a palliative care intervention, Temel and colleagues demonstrated that patients with 
advanced lung cancer who received early palliative care had better quality of life, less 
depression, and lived longer.2 The American Society of Clinical Oncology3 and other 
organizations have published position statements supporting the need for oncologists, 
nurses, and other clinicians to participate in diffi cult conversations with patients 
regarding prognosis, preferences, and palliative care options earlier in the course of 
illness. Patients and their caregivers (family and/or signifi cant others) need to be part of 
A., Daou, S., … Affar, E. B. (2014). Tumor suppressor and deubiquitinase BAP1 promotes 
DNA double-strand break repair. Proceedings of the National Academy of Sciences of the 
United States of America, 111, 285–90. doi:10.1073/pnas.1309085110 Zauderer MG, Bott 
M, McMillan R, Sima CS, Rusch V, Krug LM, Ladanyi M. (2013). Clinical Characteristics 
of Patients with Malignant Pleural. Journal of Thoracic Oncology, 8 (11), 1430–1433. 
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Lung cancer is the leading cause of cancer death in Canada, and is associated with the 
highest levels of distress among all cancers (Canadian Cancer Statistics 2012, Zabora J 
et al 2001). Over two-thirds of newly diagnosed lung cancer patients are over 65 years 
of age and have advanced-stage disease. Many of these patients experience malnutrition 
comprising a combination of starvation (inadequate nutrient intake), sarcopenia (loss of 
muscle mass associated with loss of strength and or function), and cachexia (presence of 
systemic infl ammation/altered metabolism). These factors are also major determinants 
of frailty in elderly lung cancer patients (ELCP), and are associated with reduced cancer 
treatment tolerance and response (Vigano and Morais, 2015). The addition of palliative 
care consultation initiated in parallel to treatment for lung cancer has been shown to 
improve both overall lung cancer mortality and patient symptom burden during cancer 
treatments (Greer et al, 2013). However, there is a paucity of information regarding 
the peri-diagnostic, pre-treatment phase. Most often, the pre-treatment phase of lung 
cancer care is defi ned as a prolonged period (mean = 6 weeks) of fragmented care that 
is associated with high levels of symptom burden and psychological distress (Dekhuijzen 
et al, 2014; Iyer et al 2013). The supportive care needs of patients during this period 
are often inadequately addressed. Thus, the potential for personalized interventions 
to reduce frailty in ELCP by targeting malnutrition and symptom burden have been 
largely unexplored during this critical phase. The Rapid Investigation Clinic (RIC) at the 
McGill University Health Centre (MUHC) currently investigates and stages patients with 
suspected lung cancer. The clinic operates on a bi-weekly basis and includes dedicated 
pulmonologists with a particular expertise in lung cancer, a dedicated nurse clinician, 
and a palliative care consultant. Once staged, patients’fi ndings are discussed at tumor 
board meetings and are evaluated at the multidisciplinary lung cancer clinic. The mean 
time from referral to lung cancer treatment is approximately 6 weeks. When patients 
are identifi ed at the RIC as requiring supportive care they are referred to one of seven 
interdisciplinary clinic/programs available at the Cancer Care Mission of the MUHC (see 
fi gure below).
For instance, if a patient presents primarily with signs and symptoms of cachexia or 
deconditioning, he/she is referred to the Cancer Rehabilitation Program (CRP) and 
Cachexia Clinic (CC) at the MUHC, which are fully integrated with the MUHC Nutrition and 
Performance Laboratory (MNUPAL, www.mnupal.mcgill.ca) . MNUPAL is a state-of-the-
art facility devoted to nutritional and functional assessment for patients with advanced 
cancer.. The primary goals of these assessments are: a) to identify presence and severity 
of cachexia and/or sarcopenia, b) to address reversible causes for these syndromes, 
such as inadequate symptom control, nutritional and hormonal defi cits (i.e. hypogonadism, 
hypothyroidism etc), and c) to identify personalized interventions (pharmacological, 
nutritional, and functional) that will be appropriate for patients’ conditions and wishes. 
The current research at MNUPAL is driving some of the future directions of specifi c and 
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course of their advanced illnesses.[2] Palliative care is a relatively new discipline in Africa, 
Initiatives in South Africa and Zimbabwe dated back to 1970s. There has been significant 
progress over the last ten years. From being significantly present in only five countries 
in 2004, palliative care services was established in nearly half of African countries in 
before the World Health Assembly in 2005.[4]These services usually confined to large 
cities, most of which are pain clinics driven by nongovernmental sector. The majority of 
health care professionals at palliative care clinics lack the appropriate training for pain 
assessment and management and they are relying on their own personal experience 
while practicing palliative care. Clark et al. [3]have conducted a multi-method survey to 
review services and experiences of palliative care development in 47 African countries. 
The 47 countries studied could be grouped into four categories of palliative care 
development: No identified hospice or palliative care activity (21 countries); Capacity-
building activity underway to promote hospices and palliative care delivery (11countries); 
localized provision of hospices and palliative care in place, often supported by external 
donors (11countries); and Hospices and palliative care services achieving some measure 
of integration with mainstream service providers and gaining wider policy recognition 
(4 countries) The Limitations to the development of multidisciplinary palliative care 
programs in Africa are that: high burden of HIV and cancer, extreme shortage of trained 
health care professionals in palliative care, insufficient facilities, weak referral systems 
and lack of access to opioid or the restriction of their use in many African countries.[5, 
6]Moreover, there is still a general lack of government policies that recognize palliative 
care as an essential component of health care along with great challenge to acquire 
funding for palliative care programs.[5] Despite these limitations, there has been some 
success so far. Uganda, Kenya, South Africa, and Zimbabwe developed successful 
models for the development of affordable, sustainable community- based hospices and 
palliative care services. [3]Kenya, South Africa, Uganda and Tanzania have integrated 
palliative care into healthcare policy. Uganda has mad oral morphine freely available to 
its patient’s population and it has passed law to allow prescription of morphine by nurses.
[7]The Ministry of Health in Malawi acknowledged palliative care as part of a minimum 
standard of care for all tertiary institutions.[8] The importance of palliative care in the 
African setting have been recognized by the World Health Organization (WHO). There 
are several palliative care initiative in Africa that have provided good quality palliative 
care in limited recourse setting.[3]The majority of successful palliative care initiatives 
are supported by international organizations in collaboration with governments and non-
governmental organization (NGOs) e.g. the WHO 5-country palliative care project. The 
Foundation for Hospices in Sub-Saharan Africa, has a grant support program operating 
in several African countries. The African Palliative Care Association (APCA) has a fast 
developing program of activities to promote development across the continent and 
supports governments and other local service providers to ensure the provision of 
opioids and other palliative care medications. The role of education and training has 
been essential in strengthening capacities to develop multidisciplinary palliative care 
programs. Efforts to develop in country training are underway in few African countries. 
The University of Cape Town offers Post Graduate Diploma/MPhil, in Palliative Medicine. 
Makerere University through its affiliated institution Hospice Africa Uganda in partnership 
with APCA offers a Bachelor’s Degree in Palliative Care. Nairobi Hospice in collaboration 
with Oxford Brookes University offers diploma in palliative care. The National Cancer 
Institute, Cairo offers Master degrees in pain management and palliative care has been 
incorporated in the curriculum of the oncology nursing program in the same institute. 
Palliative care in Africa is still at an early stage of development and faces many obstacles. 
A lot of progress has been made already, however much still remains to be done, 
particularly across sub-Saharan Africa. Many challenges cannot be corrected without 
governments and NGOs willing to effect changes and commit funds to research and 
training. References 1. Basu, A., B.N. Mittag-Leffler, and K. Miller, Palliative care in low- and 
medium-resource countries. Cancer J, 2013. 19(5): p. 410-3. 2. Spence, D., A. Merriman, 
and A. Binagwaho, Palliative care in Africa and the Caribbean. PLoS Med, 2004. 1(1): p. e5. 
3. Clark, D., et al., Hospice and palliative care development in Africa: a multi-method review 
of services and experiences. J Pain Symptom Manage, 2007. 33(6): p. 698-710. 4. Grant, 
L., et al., Palliative care in Africa since 2005: good progress, but much further to go. BMJ 
Support Palliat Care, 2011. 1(2): p. 118-22. 5. Ddungu, H., Palliative care: what approaches 
are suitable in developing countries? Br J Haematol, 2011. 154(6): p. 728-35. 6. Harding, 
R. and I.J. Higginson, Palliative care in sub-Saharan Africa. Lancet, 2005. 365(9475): 
p. 1971-7. 7. Ramsay, S., Leading the way in African home-based palliative care. Free oral 
morphine has allowed expansion of model home-based palliative care in Uganda. Lancet, 
2003. 362(9398): p. 1812-3. 8. Tapsfield, J.B. and M. Jane Bates, Hospital based palliative 
care in sub-Saharan Africa; a six month review from Malawi. BMC Palliat Care, 2011. 10: p. 12. 
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The major societies of Supportive and Palliative Care in Europe are the Multinational 
Association of Supportive Care in Cancer (MASCC), the European Society for 
Medical Oncology (ESMO) and the European Association for Palliative Care (EAPC). 
Supportive Care is defined by MASCC as: “Supportive Care in Cancer is the 
prevention and management of the adverse effects of cancer and its treatment. 
This includes management of physical and psychological symptoms and side effects 
across the continuum of the cancer experience from diagnosis through anticancer 
treatment to post-treatment care. Enhancing rehabilitation, secondary cancer 
prevention, survivorship and end of life care are integral to Supportive Care [1].” 
Palliative Care is defined by EAPC as: “Palliative Care is the active, total care of the 
patients whose disease is not responsive to curative treatment. Control of pain, of 
other symptoms, and of social, psychological and spiritual problems is paramount. 
the discussion about care goals at the time of diagnosis, during treatment, and at the time 
of recurrence. Shared decision-making about end-of-life care must be based on patient/
family caregiver beliefs, values, and preferences.4 Developing rapport with patients and 
starting the conversation about care goals is often difficult and time-consuming. Often, 
patients do not understand the difference between palliative care and hospice and may 
not want to participate in a palliative care program because of their concern that health 
care providers are “giving up” on them. In a survey of health care professionals, barriers 
to goals of care discussions with seriously ill hospitalized patients and families include: 
patients’ and family members’ difficulty accepting a poor prognosis and understanding 
limitations/complications of life-sustaining treatments, family member disagreement 
about care goals, and patient incapacity to make care decisions.5 Interventions to 
improve communication and shared decision making about plans and goals of care are 
key and must take into account cultural and spiritual preferences. Cultural and linguistic 
barriers increase disparities in providing palliative care for ethnic minorities. Patient and 
family cultural values have a major impact on care preferences at the end of life for some 
ethnic minorities and should be considered by the health care professional. Cultural, 
spiritual, and religious values often influence how palliative care and pain/symptom 
management are perceived and accepted. While nationwide averages of completed 
advance directives are low for all groups, patients of ethnic minority are less likely to 
have a living will, durable power of attorney, or a Do Not Resuscitate (DNR) order, are 
more likely to choose very aggressive care in the face of serious or incurable illness, and 
less likely to acknowledge their terminally ill status.6 Palliative care and hospice services 
are rarely accessed by non-Caucasians. In addition, expanding evidence suggests that 
adequate pain and symptom assessment and management is not achieved for many 
persons with late stage disease; pain occurs in approximately 80% of patients with 
life-threatening illness.7 Solano et al. found breathlessness and fatigue were present in 
>50% of patients with cancer and COPD.8 All of these barriers suggest that improving 
palliative care access may have benefit for patients and their family caregivers. However, 
tertiary palliative care cannot grow fast enough to meet the demand. Models of care 
that promote primary palliative care are required in outpatient, community, homecare, 
and rural settings to maintain the capacity for the ever-growing needs of patients 
and their family caregivers. Primary care physicians and nurses play important roles 
in delivering palliative care, and may in fact not have the knowledge and skills to do 
so effectively. Significant barriers to integrating palliative care include lack of access 
to palliative care resources to implement change, personnel constraints, inadequate 
basic knowledge about palliative care strategies and communication, and little training, 
skills, or certification in palliative care.11 It is imperative for health care professionals to 
improve their knowledge about palliative care, support the provision of early palliative 
care, and establish relationships with patients to understand values and preferences. Dr. 
Atul Gawande, in his recent book Being Mortal, suggests that patients be asked five key 
questions to open discussion about care goals.12 These questions include the following: 
1. What is the understanding of your current health and condition? 2. If your condition 
worsens, what are your goals? 3. What are your fears? 4. Are there any tradeoffs you 
are willing to make or not? 5. What would a good day be like? Additional suggestions and 
strategies to improve communication with patients and their family caregivers in the 
palliative care setting will be discussed in this presentation. 1. Ferris FD, Bruera E, Cherny 
N, et al. Palliative cancer care a decade later: accomplishments, the need, next steps 
-- from the American Society of Clinical Oncology. J Clin Oncol 2009;27:3052-8. 2. Temel 
JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-
small-cell lung cancer. N Engl J Med 2010;363:733-42. 3. Peppercorn JM, Smith TJ, Helft 
PR, et al. American society of clinical oncology statement: toward individualized care 
for patients with advanced cancer. J Clin Oncol 2011;29:755-60. 4. Curtis JR, White DB. 
Practical guidance for evidence-based ICU family conferences. Chest. 2008;134:835-
43. 5. You JJ, Downar J, Fowler RA, et al. Barriers to goals of care discussions 
with seriously ill hospitalized patients and their families: a multicenter survey of 
clinicians. JAMA Intern Med February 2, 2015;epub E1-8. 6. Smith AK, McCarthy EP, 
Paulk E, et al. Racial and ethnic differences in advance care planning among patients 
with cancer: impact of terminal illness acknowledgment, religiousness, and treatment 
preferences. J Clin Oncol2008;26:4131-7. 7. Kutner JS, Bryant LL, Beaty BL, Fairclough 
DL. Time course and characteristics of symptom distress and quality of life at the end 
of life. JPain Symptom Manage 2007;34:227-36. 8. Solano JP, Gomes B, Higginson IJ. A 
comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic 
obstructive pulmonary disease and renal disease. J Pain Sympt Manage 2006;31:58-69. 
9. Fink RM, Oman KS, Youngwerth J, Bryant L. A palliative care needs assessment of rural 
hospitals. J Pall Med 2013;16(6):638-644. 10. Gawande A. Being Mortal: medicine and 
what matter in the end. New York: Metropolitan Books, Henry Holt and Company, 2014. 
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Cancer has emerged as a major health problem in Africa.[1]Healthcare in Africa differ 
widely, countries in North Africa and the republic of South Africa have better health care 
services than those in sub Saharan Africa. In Africa particularly in sub-Saharan region, 
due to the limited access to cancer screening and early diagnosis, an estimated 80% of 
cancer patients are present with advanced stage. [2]Additionally, inadequate access to 
standard cancer therapies result in difficulty to achieve cure even for patients with early 
stage cancer. Despite the clear public health needs for multidisciplinary palliative care 
for millions of cancer patients, access to this option is limited in most African countries. 
Information regards palliative care in Africa is lacking.[3]It was estimated that only 5% 
of patients in need to palliative care receive it.[4]This is especially true in sub-Saharan 
Africa, where about 80% of cancer patients are likely to experience suffering in the 
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in men worldwide with the highest estimated age-standardized incidence rates in Central 
and Eastern Europe and Eastern Asia (>50.4 per 100,000); in women, the highest 
estimated rates are in Northern America (33.8) and Northern Europe (23.7). In United 
States, during 2005-2012, the proportion of heavy smokers who smoked ≥ 30 cigarettes 
per day declined significantly, from 12.6% to 7.0%. With the declining percentage of 
the population who smoke, lung cancer incidence and mortality have been decreasing 
among men in the past three decades, and only recently, has shown decrease among 
women. A similar trend has been observed in Olmsted County population, Minnesota 
(Figure). Meanwhile, former cigarette smokers remain at a high risk for lung cancer 
although at lower risk than they would have been had they continued smoking. As a 
consequence, more people with lung cancers are now identified in former smokers rather 
than in current smokers. Specifically, less than 18% of United States adults are current 
smokers and more than 30% are former smokers. Intriguingly, our recent report showed 
that approximately two thirds of newly diagnosed lung cancer patients would not have 
met the current USPSTF high-risk criteria for LDCT screening. Particularly, we found a 
24% offal in screening-eligibility (from 57% in 1984-1990 to 43% in 2005-2011) which 
exceeded the 17% decline in incidence in lung cancer (from 53 to 44/1000000) over the 
same time intervals. We have conducted further investigations to delineate the high-risk 
subpopulations based on evidence from two prospective lung cancer patient cohorts 
and a retrospective community cohort. Our goal was to improve the identification of 
individuals at high-risk for lung cancer by (1) demonstrating the chronological patterns 
of patients who would have been the beneficiaries or missed-outs under USPSTF criteria 
for lung cancer screening in two contrasting cohorts, and (2) provide strong evidence 
of a new subpopulation that should be added to the definition of high risk and the public 
health impact of this subgroup on smoking cessation effort. Two prospective cohorts 
are primary lung cancer patients diagnosed between 1997-2011 from referral patients 
(Hospital) and defined-community residents (Community); the retrospective cohort is 
the Olmsted County population (Minnesota, USA) followed for 28 years (1984-2011). 
Hospital and Community cohorts include 5988 and 850 patients, respectively; the 
Olmsted County population is approximately 140,000. Between 1997 and 2011, former 
smokers with 15-30 quit-years age 55-80 formed the largest subgroup not meeting 
current USPSTF screening criteria. This subgroup constituted 12% of the hospital 
cohort and 17% of community cohort of patients with lung cancer. Between 1984 and 
2011, using current screening criteria, the age- and sex-adjusted lung cancer incidence 
rates in Olmsted County decreased significantly from 1.5/1000 to 0.6/1000 person-
years; when adding former smoker cases with 15-30 quit-years to the high risk group, 
the incidence rate was doubled by 2011. Evidence from both Community and Hospital 
cohorts in this study suggest that former smokers with 30+ pack-years and 15-30 quit-
years of cigarettes remain at high risk and should be considered as eligible for lung 
cancer screening. These individuals may perceive the USPSTF’s requirement to stop 
screening after 15 years as an indication they are no longer at high risk for lung cancer or 
as a pass not to quit smoking. These results may impact smoking cessation and optimize 
the effectiveness of screening program, and demand more effective criteria to define 
high-risk for lung cancer. Individuals who are under 81 years, had 30 or more pack-year 
smoking history, and had quit for 15-30 years should also be considered as eligible for 
lung cancer screening.
 
Palliative Care is interdisciplinary in its approach and encompasses the patient, 
the family and the community in its scope. In a sense, palliative care is to offer the 
most basic concept of care – that of providing for the needs of the patient wherever 
he or she is cared for, either at home or in the hospital. Palliative care affirms 
life and regards dying as a normal process; it neither hastens nor postpones 
death. It sets out to preserve the best possible quality of life until death [2].” 
ESMO took a stand on Supportive and Palliative Care in 2003 as follows: “Supportive 
Care’ is defined as care that aims to optimize the comfort, function and social support of 
the patients and their family at all stages of the illness. This dimension of care emphasizes 
the oncologist’s role in optimizing quality of life for all patients, including those with 
potentially curative illness.” “Palliative Care’ is defined as care that aims to optimize 
the comfort, function and social support of the patients and their family when cure is 
not possible. This dimension of care emphasizes the special needs of patients whose 
illness is either unlikely to be cured or that is incurable. These needs include physical and 
psychological symptom control, education and optimization of community supports [3].” 
These definitions are summarized in the Figure. The definitions all respect the 
recent trend of early integration of Palliative Care in patients with advanced 
cancer. Two randomized studies showed a survival benefit [4] or an improvement 
in some quality of life parameters [5], whereas a recent randomized study was 
unable to demonstrate any benefit of early integration of Palliative Care [6]. 
Recently MASCC, ESMO and EAPC joint forces and completed two surveys to disclose 
the use of existing palliative care programs in Europe. The result of these surveys will 
be summarized [7, 8].
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As of 2014, use of low-dose computed tomography (LDCT) screening for lung cancer 
was recommended by the U.S. Preventive Services Task Force (USPSTF), i.e., to annually 
screen people aged 55-80 years of age who have smoked 30 or more pack-years of 
cigarettes and are either current smokers or have quit within 15 years recommend. 
From the perspective of epidemiology of lung cancer and smoking, the USPSTF criteria 
target precisely on the population at the highest risk: peak age range and the heaviest 
cumulative exposure to cigarette smoking. On the other hand, through closely following 
the dynamic trends of tobacco smoking and lung cancer incidence and mortality, 
updating and improving the eligibility criteria for lung cancer screening should be 
a continuing effort. Reported in 2015 from the Global Adult Tobacco Survey (GATS), 
current tobacco use prevalence ranges from 43% in Bangladesh to 6% in Panama and 
Nigeria. Based on a WHO 2015 report, lung cancer remains as the most common cancer 
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located, rapidly-growing nodules, but a few were misinterpreted by radiologists. The 
role of PET-CT in the workup algorithm was investigated on 378 COSMOS volunteers 
with indeterminate nodules (5). PET-CT was found highly sensitive for nodules 
detected at baseline, nodules ≥ 15 mm, and solid nodules. Sensitivity was lower 
for partially solid and nonsolid nodules, and those discovered after baseline, for 
which other methods, e.g. VDT, should be used. The Danish Lung Cancer Screening 
Trial investigated both PET-CT and VDT, finding that the best predictor of malignant 
nodules was PET-CT and VDT combined (6). NELSON trial investigators were the 
first to introduce VDT as main the component of the diagnostic algorithm (7). 
As regards overdiagnosis, in a retrospective analysis of 175 COSMOS patients 
VDT was suggested as a marker of aggressiveness that could be used to estimate 
overdiagnosis and tailor treatment [8]. We divided nodules into: fast-growing (VDT 
<400 days) days), slow-growing (VDT 400-599 days), and indolent (VDT >600 
days). Median VDT was significantly faster in new cancers than slow-growing and 
indolent cancers (52, 223 and 545 days, respectively). Median VDT (303 days) was 
significantly longer in adenocarcinomas than squamous cell carcinomas (77 days) 
and small cell cancers (70 days). The authors concluded that slow-growing nonsolid 
nodules, many of which are likely to be overdiagnosed, could be safely treated with 
minimally invasive (sublobar) surgery. If centrally located, stereotactic ablative 
body radiotherapy (SABR) should be considered and discussed with the patient. 
The recent paper of Yankelevitz et al. (9) focused on the frequency, treatment and 
prognosis of nonsolid nodules encountered the large I-ELCAP screening cohort. Nonsolid 
nodules were rare, being identified in 2392 (4.2%) of 57,496 baseline screenings, with 
new nonsolid nodules identified in 485 (0.7%) of 64,677 repeat screenings. All 84 lung 
cancers identified were stage I adenocarcinomas and survival was 100% a median of 
78 months (IQR, 45–122). after diagnosis. The authors concluded that nonsolid nodules 
of any size could be safely followed at 12-month intervals and that transition to part-
solid should prompt a pathologic diagnosis. The authors suggested the nonsolid nodules 
should be renamed ‘indolent lesions of epithelial origin,’ in part to counter the fear 
that the word cancer evokes; in part because they behave much like benign lesions. 
In the COSMOS study, nonsolid lesions constituted 17% of all cancers detected, probably 
more than in I-ELCAP (although an updated breakdown is not available). This may be because 
COSMOS investigators removed these nodules if they increased in size or were PET-CT positive. 
As regards the question of lymph node dissection for early lung cancers, 193 
consecutive patients with non-screening detected clinically N0 lung cancers, were 
studied (10). It emerged that 42/43 cases had negative PET-CT (usually SUVmax <2.0) 
or nodule ≤10 mm were pN0, suggesting that, for cancers with these characteristics, 
node dissection can be avoided because the risk of nodal involvement is minimal. 
To conclude, the results of the National Lung Screening Trial (1) shifted the debate from 
whether to how screening should be performed. Various diagnostic algorithms have been 
proposed, most with good results in terms of safety and number of resections for benign 
disease, however there is still room for improvement. The role of molecular markers, 
alone or in combination with VDT and PET positivity (FDG uptake), is under evaluation. 
Nonsolid nodules can be safely monitored at yearly intervals until the appearance of a 
solid component. Large scale implementation of screening in Europe is now a priority: 
although many investigators still have reservations, LDCT screening, with an appropriate 
diagnostic and surgical management protocol, is now good enough to save many lives 
with limited risks. 
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The National Lung Screening Trial (1) largely resolved the dispute as to whether low-dose 
computed tomography (LDCT) screening can reduce lung cancer mortality. However the 
trial was characterized by a high recall rate and high rate of benign disease at surgery, 
probably because a diagnostic and management protocol for indeterminate nodules was 
not in place. Screening has improved the stage distribution of lung cancer at diagnosis 
and greatly increased the cure rate (2). It has also increased numbers of overdiagnosed 
cancers and of potentially harmful diagnostic procedures carried out for benign disease. 
It is therefore critical to establish quality criteria for screening programs to reduce 
the risks of these occurrences. Recommendations from the surgeon team at 
the 2011 WCLC workshop, Amsterdam (3) were that:
(i) A formal diagnostic and surgical management protocol should be part of any screening 
program; surgeons should be involved drawing up protocols along with other members 
of the multidisciplinary team.
(ii) A false positive rate of less than 15% should be aimed at.
(iii) Screening should only be performed at centres with access to a full minimally invasive 
surgical program (VATS or robotic anatomical resection).
(iv) For pure ground-glass or partially-solid LDCT-detected lung cancers below 2 cm, 
anatomical segmentectomy is adequate treatment provided intraoperative frozen section 
examination shows that lymph nodes at hilar and mediastinal stations are negative.
The diagnostic algorithm of COSMOS (4) was non-invasive, with no routine CT-
guided transthoracic biopsy, and indication for surgery based on nodule size, 
volume doubling time (VDT), and SUV on PET-CT. After 5 years, only 14% of surgical 
biopsies were for benign disease, one of the lowest in the literature. Around half the 
biopsied benign nodules had a VDT generally considered to indicate malignancy, 
and the other half were PET positive. Thus addition always of reducing false 
positives are needed and molecular markers appear promising in this respect. 
The false negative rate is a good indicator of screening program quality. In COSMOS 
we defined false negatives as stage II-IV cancers present on a previous annual scan 
but not considered to merit further workup: 16 of the 190 cancers (8%) were false 
negatives, similar to the I-ELCAP figure of 9%. Most false negatives were centrally 
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SEGMENTECTOMY OF THE ANTERIOR SEGMENT OF THE RIGHT UPPER LOBE (from 
“Asamura’s Operative Thoracic Surgery”) 
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With the results of the National Lung Screening Trial (NLST) demonstrating improved 
overall survival with low-dose CT screening in high-risk patients,1 the management of 
screen-detected lung nodules has taken on increased clinical importance. In the NLST, 
low-dose CT scans showing any non-calcified mass or nodule were classified as ‘positive’, 
but with this definition, fewer than 4% of ‘positive’ results were ultimately shown to be lung 
cancer. Ongoing randomized trials of lung cancer screening use alternative definitions 
of a positive result, which may improve the specificity of CT screening. However, despite 
this high rate of false-positives, validated models are available to allow for accurate 
prediction of malignancy risk. One such model, developed from the Pan-Canadian Early 
Detection of Lung Cancer Study and validated, achieved excellent discrimination and 
calibration, with AUC values in excess of 0.90.2 The availability of such tools should 
substantially reduce the risk of patients undergoing unnecessary investigations or 
treatments for benign disease. For patients with a high probability of malignancy, surgical 
resection has been the historic treatment of choice. Surgical interventions provide a 
pathologic diagnosis and also allow for lymph node sampling, but can be associated 
with significant morbidity and mortality. Although surgical morbidity in the NLST was 
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THE oncological appropriateness of the limited, sublobar resection (segmentectomy 
or wide wedge resection) for lung cancer has been again discussed in the thoracic 
surgical community, although the previous randomized trial definitively showed the 
prognostic advantage of the lobectomy over sublobar, limited resection. Generally, 
the operative modes used for pulmonary parenchymal resection have been classified 
into pneumonectomy, bi-lobectomy, lobectomy, segmentectomy, and wedge resection 
according to the volume of the resected lung parenchyma. From a technical viewpoint, 
these can be divided into non-anatomic (wedge resection) and anatomic (all the others) 
resections. In anatomic resections, all vessels and bronchi are divided at the hilum to 
ensure the resection of the whole lung area related to the divided bronchus. The term, 
“limited resection”, is also used as opposed to “standard resection”, which is essentially 
at least lobectomy with hilar and mediastinal lymph node sampling/dissection as of 
now. Therefore, the present-day “limited” resection inevitably indicates “sublobar” 
resections. There are several important landmark articles in the surgical evolution for 
lung cancer. In 1930s, Churchill and Belsey originally introduced segmentectomy for the 
treatment of bronchiectasis of the lingular segment, and it was termed as “segmental 
pneumonectomy” [1]. In 1970’s, Jensik reported a 5-year survival rate at 56% and local 
recurrence rate at 10% after segmentectomy for T1 lung cancer. He suggested that 
anatomic segmentectomy could be effectively applied to small primary lung cancers 
when the surgical margins were sufficient [2]. After these, many non-randomized, case 
series came out, and suggested the prognostic equivalence between lobectomy and 
segmentectomy for T1 lung cancer. To definitively answer the question regarding the 
prognoses after lobectomy and limited resection, a prospective, randomized trial was 
conducted by the North American Lung Cancer Study Group (LCSG) [3]. Segmentectomy 
and wide wedge resection were compared with lobectomy for stage IA lung cancer with 
regard to the postoperative prognosis and pulmonary function. A three-fold increase 
in local recurrence rate and 30% increase in overall death rate were shown for limited 
resection, and therefore, this study solidified lobectomy as the procedure of choice for 
the treatment of T1N0 lung cancer. This is still the only completed, randomized trial that 
directly compared limited resection with lobectomy, and therefore, the gold standard 
for lung cancer still remains as lobectomy as of now. However, there has been a surge 
of the interest in the sublobar resection among thoracic surgeons recently, since many 
earlier, smaller cases are being found owing to the improved technology in CT image 
and the introduction of the CT screening programs. [4] Among the lesions that are 
specifically found in this context, the non-solid lesion that is referred to as ground glass 
opacity (GGO) is a newly established clinical entity that may be a candidate for limited 
pulmonary resection. The understandings of pathobiological nature of such earlier 
lesions have progressed [5]. New proposal for the classification of adenocarcinoma was 
also promulgated, in which the earlier forms of adenocarcinoma were newly defined as 
AIS (adenocarcinoma in situ) or MIA (minimally invasive adenocarcinoma) [6]. In the face 
of this situation, it is not surprising that questions have arisen as to whether it might be 
possible to manage smaller, earlier lung cancers by sublobar resections. Moreover, it 
has been more than 20 years since the LCSG randomized clinical trial was conducted in 
the 1980s. Given this situation, randomized clinical trials with peripheral lung cancers no 
more than 2 cm in diameter as the target lesions were begun in the United States (CALGB 
140503) and Japan (JCOG 0802) at almost the same time [7]. JCOG0802/WJOG4607L 
trial is a prospective, randomized, multi-institutional study which intends to compare the 
prognosis and postoperative pulmonary function between patients with non-small lung 
cancer 2 cm or less in diameter undergoing either lobectomy or segmentectomy. The 
target number of patient accrual is 1,100, and as of the end of June, 2015, accrual is over 
in full and the data maturation is awaited. The important fact is that the candidate lesions 
of this trial are supposed to be invasive adenocarcinomas pathologically with solid part in 
ground glass opacity (GGO) on the CT images. As a selection criterion, a consolidation/
tumor ratio has been employed as 25 to 100% to define invasive adenocarcinomas 
preoperatively. This study is coupled with JCOG0804/WJOG4507L trial, which deals 
with the non-invasive or minimally invasive adenocarcinomas (adenocarcinoma in situ, 
AIS/minimally invasive adenocarcinoma, MIA) with CT images as pure GGO with/without 
minimal solid part. They are treated with limited, sublobar resection (segmentectomy 
or wide wedge resection). This study is a prospective, but non-randomized, single-arm 
study because no death is expected for these tumors despite surgical modes. Target 
accrual is 330, and the registration was already closed, waiting for data maturation. The 
present-day selection of the surgical mode for lung cancer should be based upon the 
solid data which demonstrate the overt advantage over the standard mode of resection 
(lobectomy). We need another some years until getting the definitive conclusion as to the 
appropriateness of sublobar resection for early stage lung cancer. Until then, surgeons 
should be prudent in performing a sublobar resection as a radical resection for lung 
cancer.[8] 
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specificity of the risk models which use clinical variables alone. More importantly, the 
addition of these markers improves the correct assignment of risk in up to 25-30% of 
people participating in lung cancer screening trials. Other Molecular Biomarkers Other 
molecular markers for lung cancer currently under investigation are protein markers, 
antibody assays and expression (RNA) profiles.11-14 These types of assay are potentially 
subject to biological interference from smoking status (eg. current vs ex-smokers) or 
co-existing COPD, where drug therapies (eg. inhaled corticosteroids or antibiotics) and 
bacterial colonisation of the lung (eg. effects from the lung microbiome) are present. The 
“noise” from these co-existing conditions may cause confounding or mediating effects 
that reduce the predictive utility of the assay of interest. One of the more promising of 
these biological assays involves the analysis of exhaled volatile compounds from the lung 
which can now be measured with more accurate devices.14 These molecular assays are 
currently being validated in large prospective clinical trials. Biomarkers in CT screening – 
risk assessment While the utility of these assays in the context of CT screening remains 
to be established, they all have the potential to improve the current risk-benefit ratio of 
CT screening. First, this might involve identifying low risk individuals currently eligible for 
screening based on the age and pack year criteria (“NLST approach”) but who gain little 
benefit from screening. Alternatively, wider risk assessment would help identify those 
smokers who are at high risk despite not meeting the NLST criteria (“NCCN approach”). 
In this setting, markers related to a predisposition to COPD, such as airflow limitation 
based on spirometry, reduced DLCO (as a marker of emphysema and interstitial lung 
disease) or CT-based emphysema, are particularly relevant. Genetic (SNP) markers 
associated with an increased predisposition to COPD or lung cancer may also help in this 
regard.10 Second, expression-based markers may be helpful in distinguishing benign from 
malignant nodules. With time, greater refinement of these techniques for identifying and 
validating novel biomarkers will provide greater confidence in their use in conjunction with 
serial CT screening. This approach might augment existing risk models based on clinical 
parameters. However, these biomarkers are competing with serial CT -based volumetric 
analyses which appears on initial studies to considerably reduce the false positive rate 
(discriminate benign from malignant based on growth rate). These novel biomarkers 
would be combined with multivariate risk models to reduce the treatment of indolent 
nodules, reducing overdiagnosis and minimize harm. In a recent post-hoc analysis of 
the NLST-ACRIN data, we found that airflow limitation based on pre-bronchodilator 
spirometry is associated with little if any overdiagnosis. This finding is consistent with 
the results of others showing COPD to be associated with more aggressive lung cancer. 
Other biomarkers may have a similar utility. Biomarkers in CT screening – smoking 
cessation Smoking cessation is the only proven lifestyle modification that reduces the 
risk of lung cancer. Little thought is given to the use of biomarkers in smoking cessation. 
In a limited number of studies it has been shown that risk assessment tools have some 
contribution to make to smoking cessation.15 Inconsistency of findings with respect to the 
effects of lung function testing and CT nodule identification on quit rates means there is 
more work to be done here. The basic psychology of smoking suggests that challenging 
some smokers with personal biodata enhances their perception of smoking-related risks. 
In particular, showing a smoker they are at greater risk than the average smoker based 
on personal data increases their interest in quitting.15 This is believed to occur because 
personal biodata increases motivational tension and undermines the smoker’s denial 
which maintains their smoking habit. This aspect of CT screening programmes is not one 
that has received as much attention as it warrants. However CT screening programmes, 
with routine use of personalised risk appraisal, are uniquely positioned to reinforce 
existing public health strategies aimed at reducing smoking rates. Summary While there 
remains much to do to confirm the utility of biomarkers in the CT screening process , 
existing data suggests that significant gains may be made by their use in improving risk-
benefit appraisal of screening participants, better management of nodules and perhaps 
significant gains in reducing smoking rates among high risk smokers. 
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low,1 such results from specialized centers may not be widely generalizable. Population 
data have shown higher rates of complications than data from specialized centers, both 
in terms of complications for CT-guided biopsies, and also for surgical morbidity and 
mortality.3,4 Stereotactic ablative radiotherapy (SABR), also called stereotactic body 
radiation therapy (SBRT), is a non-invasive treatment often delivered in 1-8 fractions 
on an outpatient basis. For T1-T2N0 NSCLC, SABR achieves high-rates of local control, 
and with results comparable to surgery in many well-controlled studies. Randomized 
data, not specific to screen-detected lesions, suggests that SABR may achieve better 
overall survival than surgical resection.5 A major advantage of SABR appears to be a 
reduced risk of serious toxicity in high-risk patients: for example, a systematic review of 
outcomes for patients with T1-T2 NSCLC and severe COPD (GOLD III/IV) indicated a 30-
day mortality rate of 10% with surgical resection and 0% with SABR.6 Modeling studies 
comparing surgical resection and SABR suggest that as operative mortality rises, SABR 
is preferred. This presentation will discuss the relative merits and limitations in the use 
of SABR for screen-detected lung nodules, including evidence-based thresholds for 
treating without a definite pathologic diagnosis, issues pertaining to treatment delivery 
for small targets, toxicity of SABR for small lesions, and ongoing follow-up after SABR. 
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MS10.07 Biomarkers: Current Status and Future Direction Robert Young 
Faculty of Medical Health Sciences, University of Auckland, Auckland/New Zealand
The need for biomarkers Yearly low-dose computed tomography (CT) screening for lung 
cancer is now widely recommended in the United States.1 Published articles reviewing 
the benefits versus harms of lung cancer screening have highlighted the potential harms 
from radiation exposure, unnecessary invasive workup and overdiagnosis.2 While cost-
effectiveness analysis has suggested that CT screening for lung cancer is comparable to 
other existing cancer screening programs, this analysis makes a number of assumptions 
based on the NLST findings which may not translate to the wider community. These 
issues highlight the need for identifying biomarkers that may improve patient selection, 
maximise lung cancer detection, minimizing overdiagnosis and the treatment of indolent 
disease.2 The eligibility criteria for the NLST were specifically designed to maximize 
the number of cancers that could be identified during screening within a relatively 
high risk group. However, it has been shown that age and pack years alone have only 
limited utility in identifying those smokers at greatest risk.3-5 It was never intended that 
screening eligibility should be based solely on the NLST criteria. The first problem is the 
NLST screening criteria include low risk individuals for whom the risk of screening far 
outweighs the benefit.3-5 The second problem is that between 40-60% of lung cancer 
cases are currently ineligible for lung cancer screening due to restrictions on age 
and smoking history.6,7 The former group is estimated to represent about 30-40% of 
those currently eligible for screening based on the NLST and can be identified using 
multivariate risk models incorporating several clinical risk variables such as age, 
detailed smoking history, past diagnosis of COPD, BMI, occupation and ethnicity.4 Lung 
Function and related tests of COPD There have been several studies that show lung 
function testing adds considerable predictive utility to clinical multivariate models. This 
approach stratifies smokers with normal lung function (no airflow limitation and/or DLCO 
reduction) into a low risk group, where it has been shown their lung cancer incidence is 
only a quarter of that observed in those with COPD.8 Emphysema identified on CT has 
also been shown to identify high risk smokers for lung cancer where airflow limitation 
is absent.9 These studies confirm past epidemiology identifying that co-existing COPD, 
characterized by reductions in forced expiratory volume (and its ratio with forced vital 
capacity) are significant risk factors for lung cancer. Genetic Markers A limited number of 
studies have found that genetic markers, primarily single nucleotide polymorphic (SNP) 
variants, add to the predictive utility of clinically-based risk tests.10 These SNP markers 
reside in genes encoding several important proteins, including epithelial based receptors, 
involved in mediating smoking-related inflammation in the lungs.10 The value of identifying 
these genetic markers lies in their predictive utility to recognize high risk individuals long 
before the clinical manifestations of smoking damage (airflow limitation or emphysema) 
are clinically evident. The addition of SNP modestly increases the sensitivity and 
S108 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
molecularly targeted therapies together with technological advances in radiotherapy 
opens up for novel treatment strategies with potentially improved outcomes and less 
toxicity. This presentation will give an overview of randomized studies incorporating new 
approaches to combined modality therapy in stage III disease, including immune therapy 
with PD-1/PD-L1 inhibitors, inhibitors of EGFR and ALK as well as proton radiotherapy. 
Keywords: stage III, NSCLC, locally advanced, combined modality
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MS12.01 Biology of Cancer Stem Cells Neil Watkins The Kinghorn Cancer Centre, 
Garvan Institute of Medical Research, Darlinghurst/NSW/Australia
There is general agreement amongst biomedical researchers that stem cells exist 
in multicellular organisms. The most well characterized model of adult somatic stem 
cells is the bone marrow, in which serial transplantation in both immunocompetent 
and immunodeficient mice have clearly identified the hematopoietic stem cell (HSC). 
Using the same models, it is now generally accepted, even amongst cancer stem cell 
(CSC) sceptics, that most forms of myeloid leukemia are maintained by a self-renewing, 
transplantable HSC-like cell, even though the initial transformation event may have 
occurred in a committed progenitor. Given that nature tends to conserve processes 
across evolution, it is logical to hypothesize that a similar functional hierarchy exists 
in solid tumors. Over two decades, numerous papers have reported the presence of a 
functionally distinct, rare population of cells within solid tumors with stem-like properties 
based on the same criteria used to define the HSC and leukemic CSC. However, the 
idea that CSCs exist solid tumors remains controversial at best. The difficulties in 
reproducing results in highly complex models systems, and questions over the validity 
of CSC surface markers in solid tumors, have clearly contributed to these, often heated, 
arguments. If we assume for a moment that CSCs do not exist in solid tumors, they would 
constitute the only multicellular entity in nature without a hierarchical organisation based 
on self-renewal and differentiation. If this were true, then solid tumors would behave 
like colonies of bacteria or yeast, in which all cells were identical, where the capacity 
to self-renew in the face of an environmental challenge would be entirely determined 
by random genetic variants. In the setting of acquired resistance to targeted therapies, 
there is convincing evidence for such a “rare clone” hypothesis. For example, the 
source of acquired resistance to tyrosine kinase inhibitor (TKI) therapy in EGRF-mutant 
adenocarcinoma seems to be pre-existing clones that already possess a point mutation 
that confers resistance. But, can this genetic model explain other stemness phenotypes 
in non-small cell lung cancer (NSCLC)? In clinical terms, a pressing question is whether 
random genetic events can explain the rapid regeneration of NSCLC tumors after a long 
period of dormancy following curative surgery. Equally, can the “rare clone” hypothesis 
explain innate the innate chemoresistance of quiescent CSC-like NSCLC cells that have 
a greatly enhanced capacity for self-renewal. If the answer to either of questions is “not 
always”, then targeting CSCs based on function rather than genome remains a potential 
avenue for improving outcomes in NSCLC patients. The characterization of NSCLC CSCs 
is made difficult by the phenotypic and genomic heterogeneity of the disease, problems 
identifying robust surface markers, and in defining what experimental endpoints 
constitute CSC function. In addition, there is no general agreement on which markers 
are associated with CSC in NSCLC, although several studies suggest that the surface 
markers CD44 and CD133 can prospectively identify such cells. In therapeutic terms, 
elimination of CSCs in NSCLC would require such markers be reproducible and robust, 
but can also be therapeutically targeted in humans. An alternative approach is to target 
embryonic signaling pathways known to regulate self-renewal in development. This idea 
is the driving force behind clinical trials of Notch and Hedgehog inhibitors in several 
cancer types. Unfortunately, most of these clinical trials add the experimental agent 
along side standard-of-care chemotherapy rather than delivering the experimental agent 
following treatment in order to determine whether stem-cell targeting can “burn out” 
quiescent, undifferentiated residual disease. One promising candidate marker in NSCLC 
is ALDH1. In most published studies, expression of ALDH1 or ALDH1A correlates with 
reduced overall survival, consistent with the presence of enhanced regenerative capacity 
and innate chemoresistance in NSCLC. Moreover, experimental evidence supports the 
notion that expression of the ALDH1 protein, and its enzymatic activity, is associated 
with enhanced CSC functions in vitro and in vivo. Since secondary prevention studies in 
advanced NSCLC are impractical, it may be possible strengthen the case for targeting 
NSCLC, using ALDH1 as an example, using more practical preclinical and clinical 
approaches. Such an approach might be: 
1. Concentrate on one subgroup of NSCLC- for example KRAS mutant lung 
adenocarcinoma. 
2. Show that rare, single ALDH1+ cells give rise to tumors with the same ratio of ALDH1+ 
to ALDH1- cells as was seen in the parent tumor. 
3. Using single cell genomics, determine whether ALDH1+ and ALDH1- cells share the 
same genotype. 
4. In lung cancer patients treated with neoadjuvant chemotherapy, show that the 
percentage of ALDH1+ cells increases in the residual tumor removed at surgery. 
5. In lung cancer patients with recurrent disease following surgery, show that the 
recurrent tumor contains the same ratio of ALDH1+ to ALDH1- cells as was seen in the 
parent tumor. 
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MS11.02 Future Role of Surgery (Timing, Patient Selection, and New 
Techniques) Walter Weder Thoracic Surgery, University Hospital Zurich, Zurich/
Switzerland
The optimal management of locally advanced NSCLC is discussed controversially and 
depends from various aspects including the extent of N2 disease and/or T-stage as well 
as the patients risk profile and preference and the institutional experience. Therefore 
existing guidelines need a balanced modification during the tumorboard taking into 
account the different aspects relevant for the patient’s outcome and hence to define 
the best individualized treatment. Due to the lack of fully convincing randomized trials 
and the diversity of phase II studies and especially the heterogeneity of the study 
population, it is not surprising that the available evidence is interpreted differently 
and discussed controversially. Survival data may differ widely between studies and 
an explanation is often elusive. Patient selection is among other factors the key for 
differences in outcome. Unfortunately N2 disease is often imprecisely described. 
Several authors have proposed that N2 disease should be divided into subgroups. 
 
The question, whether N2 disease is resectable, cannot be answered easily in borderline 
situations since several co-founding factors play a role. The question includes at least 
four different aspects. The first aspect is resectability. The surgeon has to answer if the 
affected lymph nodes are completely removable. This question is a prerequisite and is 
typically answered by analysing images especially the CT or PET/CT by an experienced 
surgeon. The second and even more critical aspect relates to the question if local 
resection is useful for the patient since N2 disease may be the tip of an iceberg and 
indicate more than just locally advanced disease and rather a disease with systemic 
spread of tumor cells to other organs. The third aspect is the response rate of the tumor 
and mediastinal lymph nodes to neoadjuvant chemo- or chemo-radiotherapy. Finally the 
fourth consideration has to take into account the risk benefit ratio for the patient regarding 
the treatment. It is relevant for the decision making to evaluate to what risk the patient is 
exposed when a lobectomy or pneumonectomy is performed after neoadjuvant therapy. 
 
There are subgroups in stage IIIA (N2) which can be defined in which treatment 
recommendations are agreed among most oncologists, surgeons and radiotherapists. 
Microscopic N2 found unexpectedly during surgery and a radical resection of the tumor 
as well of the lymph nodes is possible and tolerated by the patient, surgery should 
be completed and adjuvant therapy is recommended. On the other hand in cases of 
bulky multilevel N2 at initial diagnosis and especially persistent after neoadjuvant 
therapy, surgery is not generally indicated since the patient will not experience a 
profit. The main controversy occurs in cases with initially diagnosed N2 disease at 
either a single or in some adjacent stations but surgically resectable. These patients 
are recommended to undergo neoadjuvant chemo- or chemo-radiotherapy followed 
by surgery most cases but direct surgery followed by adjuvant treatment is justified in 
single station N2 without extranodal disease. Definitive chemo-radiotherapy is reserved 
for those who are not completely resectable or with a high perioperative mortality. 
In general, these patients require a lobectomy with a complete mediastinal 
lymphadenectomy. In locally advanced stages, many surgeons still prefer to do these 
operations though a thoracotomy and in only a smaller percentage of patients can be 
operated minimal invasively by VATS. The invasiveness of the approach (VATS or open) is 
in any case of less importance than the completeness of the resection. Pneumonectomy 
should be avoided whenever possible and reconstructive techniques with bronchial-and 
or vascular reconstructions (sleeve resections) should be considered. These techniques 
can be done safely, even after induction chemo-or chemoradiotherapy. However, 
there are clear situation, when a pneumonectomy is necessary to achieve a complete 
resection and this should be considered, when the patient tolerates it functionally. 
Treatment of patients with locally advanced lung cancer is a challenge and requires 
the expertise of specialists from each discipline who respect the benefit and 
limitations of each individual technique in order to define the best individual treatment. 
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MS11.04 Overview of Current International Randomized Trials Simon Ekman 
Dept of Oncology, Karolinska University Hospital, Uppsala/Sweden
Overview Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease with 
regard to tumor extent, prognosis and treatment options. Surgery is indicated in some 
patients, but the majority of patients receive radiotherapy and chemotherapy alone. The 
standard of care for unresectable stage III NSCLC patients with a good performance status 
consists of concurrent chemoradiation. The chemotherapy regimen usually consists of 
a platinum doublet and radiation doses of at least 60 Gy is standard. The prognosis 
for these patients remains dismal with a median survival time of 15-22 months and the 
need for improved treatment approaches is urgent. The optimal choice of chemotherapy 
and radiation dose and the schedules for these have been under investigation but is 
still not clearly defined. Radiation dose escalation studies have not resulted in better 
outcomes and with potentially harmful effects. Clinical studies of targeted agents in 
unselected patient groups, including therapies against epidermal growth factor receptor 
(EGFR) and angiogenic factors, have not been successful. The recent advances in 
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combination, however with only gefitinib plus TPCA1 or gefitinib plus AZD0530, ALDH1A1 
mRNA was substantially increased in comparison with gefitinib alone (Figure). The western 
blot for the triple combination shows the inhibition of STAT3 Y705 phosphorylation as 
well as the phosphorylation of YAP (Ser397) and also from BMI1. We plan to confirm 
some of the data in clinical tumor samples to understand the contribution of IL6 and well 
established effectors-the SHP2-ERK, PI(3)K-Akt-mTORC1 and JAK-STAT3 modules and 
the interaction with YAP.
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MS12.04 Tumor-Propagating Cells in Non-Small Cell Lung Cancers Carla Kim 
Stem Cell Program, Boston Children’S Hospital, Boston/MA/United States of America
Our long-term goal is to elucidate the role of stem cells in lung homeostasis as a 
prerequisite to the development of therapeutic strategies that can be used to prevent or 
attenuate lung disease and lung cancer. Our previous experience isolating the first stem 
cell population from the adult murine lung, termedbronchioalveolar stem cells (BASCs), 
and our demonstration of a role for these cells in lung cancer serves as a platform 
to address these questions. We have recently developed three-dimensional co-culture 
and subcutaneous co-injection assays that allow us to quantitatively assess the identity 
and the differentiation potential of lung stem cells. This approach led us to uncover a 
cross-talk between lung endothelial cells and lung stem cells via a novel signaling axis 
involving Bmp4, NFATc1 and Tsp1;this pathway drives BASCs to differentiate into the 
alveolar epithelial cell lineage. Our work in the intersection of stem cell biology and 
lung disease has expanded into new insights for understanding metastasis and non-
small cell lung cancer (NSCLC). We previously showed the adenocarcinoma Kras/p53 
mutant mouse model contains Sca1+ tumor-propagating cells (TPCs), the cells that 
recapitulate the tumor by transplantation. We recently showed multiple lung tumor sub-
populations can give rise to metastatic disease, and that the Sca1+ CD24+ TPCs have 
the highest metastatic potential. We also showed the Hippo pathway mediators Yap/Taz 
are necessary andsufficient for lung cancer progression. Finally, in a new mouse model 
of lung squamous cancer, the second most common type of NSCLC, we identified a TPC 
population defined by the markers Sca1 and NGFR. These studies illustrate the utility of 
stem cell biology approaches to provide new avenues for lung cancer therapeutic targeting. 
Keywords: Cancer Stem Cells, mouse models, stem cells, KRAS
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MS13.01 Epigenomics James Herman Hematology/Oncology, University of Pittsburgh, 
Cancer Centre, Pittsburgh/PA/United States of America
DNA methylation changes in lung cancer: Defining functional events and use of cancer 
specific changes for early detection.
Epigenetic alterations in lung cancer represent early changes which are associated with 
tumor initiation and progression. Alterations in DNA methylation include the global loss 
of DNA methylation in non-promoter region and selective CpG island promoter region 
methylation leading to gene silencing. Previous studies have focused on individual 
loci identified through candidate gene approaches. However, recent improvements in 
technology allow the assessment of genome wide patterns of DNA methylation. The 
comprehensive genome wide analysis of molecular changes in cancer completed by The 
Cancer Genome Atlas (TCGA) includes determination of DNA methylation using the Illumina 
Infinium 450K array. Initial analyses have primarily focused upon defining methylation 
subtypes. However, this data can be used to determine novel cancer specific events 
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MS12.03 Where to Go from Here? Rafael Rosell1, Jordi Codony2, Imane Chaib3, 
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Biotech Sl, Barcelona/Spain, 5Medical Oncology, University of Verona, Verona/Italy, 6Medical 
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Lung cancer is a dismal disease, however, anticipated selective responses are observed 
in a subgroup of non-small cell lung cancer (NSCLC) patients where the disease is driven 
by epidermal growth factor receptor (EGFR) mutations. EGFR mutations occur in 15 – 
40% of lung adenocarcinomas, according to gender, smoking history and geographical 
region. Two types of EGFR mutations account for 90% of all lung adenocarcinoma-
associated EGFR mutations and are related to sensitivity to treatment with oral tyrosine 
kinase inhibitors (TKIs), such as gefitinib, afatinib or AZD9291: (i) small in-frame deletions 
in exon 19 that lead to elimination of an LREA motif in the protein (DEL) and (ii) a point 
mutation in exon 21 that substitutes an arginine for a leucine at position 858 in the protein 
(L858R). Lung cancer patients bearing EGFR mutations show radiographic responses 
to TKIs in 60 – 70% of cases. Although the majority of patients achieve a significant 
therapeutic benefit, almost all invariably progress in less than 1 year. Therefore there is 
an unmet medical need for novel therapies in order to avoid resistance to treatment. We 
have employed a wide array of approaches (MTT, western blot analysis, PCR, Aldefluor 
assay and mouse models) to demonstrate that the combination of gefitinib, afatinib or 
AZD9291 with compounds targeting signal transducer and activator of transcription 3 
(STAT3) can suppress the mechanisms of early adaptive resistance. STAT3 is a member 
of a family of proteins responsible for transmission of peptide hormone signals from the 
extracellular surface of the cells to the nucleus. STAT3 is a master regulator of several 
key hallmarks and enablers of cancer cells, including cell proliferation, resistance to 
apoptosis, metastasis, immune evasion, tumor angiogenesis, epithelial-mesenchymal 
transition, response to DNA damage and the Warburg effect. In addition STAT3 promotes 
an increase in the cell renewal of tumor-initiating cells or cancer stem cell subpopulation, 
mainly aldehyde dehydrogenase (ALDH). EGFR mutations cause receptor oligomerization 
and activation of intrinsic or receptor-associated tyrosine kinases, respectively. These 
activated kinases phosphorylate receptor tyrosine residues creating docking sites for 
recruitment of cytoplasmic STAT3. STAT3 docks to receptor phosphotyrosyl (pY) peptide 
sites through its Src-homology (SH2) domain which leads to its phosphorylation on Y705 
followed by STAT3 tail-to-tail homodimerization (SH2 domain of each monomer binds 
to the pY peptide domain of each partner). STAT3 homodimers accommodate in the 
nucleus, where they bind to specific STAT3 response elements in the promotor of target 
genes and regulate their transcription. EGFR mutations and tyrosine kinase-associated 
receptor interleukin-6 (IL-6) lead to the activation of STAT3 that is not obliterated by 
EGFR TKIs. Even more, 2 hours after starting gefitinib treatment there is an increase in 
STAT3 activation in EGFR mutant cell lines (P. Ma, Cancer Research, 2011). Moreover, 
following erlotinib treatment there is an enrichment of ALDH+ stem-like cells through 
EGFR-dependent activation of Notch3. We have tested several small molecules that 
target STAT3. The combination inhibits cell viability in several human EGFR mutant 
cells and blocks STAT3 activation. However, neither the combination of EGFR TKIs with 
TPCA1 (repurposed as a STAT3 inhibitor), nor the combination of gefitinib with AZD0530 
(a Src inhibitor) prevent the increment in the ALDH + cancer stem cell subpopulation. 
Therefore, we are exploring more in depth the crosstalk between EGFR and IL-6. As a 
whole, human EGFR mutant cell lines have increased levels of IL-6 which leads to STAT3 
hyper-activation. Nevertheless, recent evidence indicates that IL-6-Src can induce YAP 
activation and NOTCH signaling. The downstream effectors of YAP and NOTCH ligands 
CTGF and HES1, respectively, are being examined in clinical tumor samples. We have 
examined the combination of Src, YAP and NOTCH inhibitors in addition to the use of 
STAT3 inhibitors. The triple combination of gefitinib plus TPCA1 plus AZD0530 had great 
synergism with a very low combination index and also eliminated the ALDH+ population 
(Figure). Furthermore, the overexpression of ALDH1A1 was decreased with the triple 
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Colinge J, Bennett KL. Using iTRAQ combined with tandem affinity purification to enhance 
low-abundance proteins associated with somatically mutated EGFR core complexes in 
lung cancer. Journal of Proteome Research. 2011;10(1):182-90. Epub 2010/10/16. doi: 
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Division of Cancer Studies, Guy’s Hospital, King’s College London, London/United Kingdom
Study of genomics, epigenomics and proteomics may contribute to an understanding 
aetiology, prevention, early diagnosis, classification, treatment selection, and novel trial 
design in lung cancer. The clinical material available for analysis ranges from tumour biopsy 
to pleural fluid, bronchoalveolar lavage, saliva and even urine. The available techniques 
are in many cases sensitive (including PCR and mass spectrometry (MS)), and specificity 
can be optimised especially with reference to normal material such as germline DNA. The 
omic landscape of lung cancer has been extensively characterised (The Cancer Genome 
Atlas Research Network, 2014). This provides insight into disease biology via SNP/
exome/whole genome sequencing, CpG DNA methylation, mRNA sequencing and protein 
expression profiling. Epigenomics is a key component since promoter hypermethylation 
occurs an early event in lung tumourigenesis (Belinsky, S. et al. 2015), targeting tumour 
suppressor genes. Indeed epigenomics and genomics are intimately linked, with CpG 
methylation leading to base substitution through 5-methylcytosine deamination, and 
enhancing the effect of exogenous carcinogens. Although the contribution of smoking 
to lung cancer aetiology has long been recognised, genomics is now providing insight 
into somatic mutagenesis as the mechanism of this causal interaction, as well as 
into tumourigenesis in non-smokers. However, this wealth of genetic and epigenetic 
information requires further analysis to establish which of these events really drive the 
phenotype, and which can be biologically validated as targets for therapy. Both genetic 
and epigenetic targets for therapy of lung cancer have been identified, in the form of 
both activated oncogenes and loss of tumour suppressor gene function. In some cases 
tumour genotype proves valuable as a predictive biomarker for patient selection. Several 
current biomarker-directed trials (such as Lung-MAP and MATRIX) are seeking to identify 
further successful genotype/therapy pairings. Despite impressive response rates in 
genomically stratified populations, regulators seem still to require validation of omics-
driven treatment selection in a strategy-testing design, randomising to standard of care 
or personalised therapy. A further therapeutic application of genomics is characterisation 
of resistance mechanisms, an understanding of which has already led directly to next 
generation drugs in several drug classes including inhibitors of EGFR and ALK. It is 
genetic events that are at the origin of the hallmarks of cancer, but proteins, as the 
effectors of cellular processes, are key to a full understanding of the cancer phenotype. 
Some have argued that proteomic markers, as a surrogate for the genetic drivers, may 
be inferior to genomics. Certainly proteomic biomarkers are the less dynamic because 
their half life is measured in weeks, compared with a few hours for nucleic acids. Beyond 
the small number of actionable mutations already described in non-small cell lung cancer, 
the diagnostic, prognostic, and predictive potential of a large number of omic markers 
has been studied, and in most cases problems with reproducibility have limited their 
clinical impact. Indeed the utility of multi-gene predictive markers described to date, 
most likely to be of clinical value in therapy, is limited. An eight-peak MALDI-MS proteomic 
profile has been developed as a predictive tool (Taguchi, F. et al. 2007). Long suspected, 
the contribution of tumour heterogeneity to an analysis of tumour omics is now proven to 
be potentially problematic (Bedard, P. et al. 2013). The study of circulating genomic (eg 
circulating free DNA, cfDNA) and proteomic tumour markers provides an opportunity for 
integration of this heterogeneity. Nevertheless, further questions remain. For example, 
do primary and metastatic sites release similar amounts of DNA and protein into the 
circulation? However, potential advantages of these liquid biopsies are obvious, as 
they can be repeated over time without risk or inconvenience to the patient. Still to be 
fully clarified is the clinical utility of this approach. Possible applications include early 
discontinuation of toxic failing therapy, evaluation of an emerging resistance mechanism 
and selection of next therapy, and prognostication (for example, selection for adjuvant 
therapy). Earlier liquid biopsy methods required initial analysis of potential biomarkers in a 
tumour, to identify what to look for, followed by detection of this marker in blood samples. 
This approach requires personalisation for each patient. Newer techniques allow direct 
analysis, for example next generation sequencing of cfDNA. It is also possible to study the 
methylation status of cfDNA, so these liquid biopsies may in addition be relevant to the 
study of tumour epigenomics. cfDNA may be superior to circulating tumour cells (CTCs) 
as a biomarker since in some patients cfDNA but not CTC is detectable (Bettegowda, 
C. et al. 2014) The most prominent recent therapeutic advance in lung cancer is the 
validation of immunotherapy in the context of checkpoint inhibition. While this approach 
appears to target the tumour only indirectly, via host immunity, there is already good 
evidence that the genomic context of the target tumour is critically significant (Gubin, 
M. et al. 2015) The optimum strategy for selection of patients for clinical omic testing 
remains to be finalised. Should this be for all patients, from the time of diagnosis, or 
only after completion of standard care? And what material is ideal for testing (archival 
or contemporaneous biopsy, for example)? Guidelines on what, when and how to test 
are available (Lindeman, N. et al. 2013), but this advice quickly becomes out of date 
given the pace of change in the field. Further practical concerns include access to 
technology, turnaround time for testing, interpretation of molecular pathology results and 
bioinformatics, and clinical relevance. Fundamental questions arise about which changes 
are actionable, and the importance of any findings in the germline sequence (incidental 
or deleterious). Finally, quality control and regulation of omic technologies is demanding 
and not necessarily well served by existing approaches and infrastructure (Evans, B. et 
al. 2015), and these aspects must be developed alongside the emergence of these novel 
technologies. Progress in development of these techniques has been rapid, but maximum 
which are associated with transcriptional silencing to identify candidate driver epigenetic 
alterations. New promoter region DNA methylation changes leading to transcriptional 
silencing are found in multiple signaling pathways critical for lung cancer development. In 
addition, a search for common tumor specific DNA methylation provides new markers for 
early detection strategies. These novel biomarkers can be combined with novel methods 
developed with extremely sensitive assays for the detection of hypermethylated DNA 
sequences. By combining these more sensitive methods of detection with highly prevalent 
methylation changes in lung cancer, utrasensitive detection of tumor specific changes in 
DNA methylation in blood and sputum samples is possible. This molecular detection can 
complement CT screening to address the important issue of early detection of lung cancer. 
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MS13.02 Proteomics and Phosphoproteomics Eric Haura Thoracic Oncology, H. Lee 
Moffitt Cancer Center, Tampa/FL/United States of America
I will discuss opportunities and future directions in profiling lung cancer using mass 
spectrometry based proteomic technologies. This includes a proposal to perform deep 
integrated proteo-genomics studies on cancer subtypes to produce more complete 
views of the tumor architecture, allow contextual understanding of major drug targets, 
and discover new lung cancer subtypes. Alterations in the genomes of cancers ultimately 
get integrated and produce a cancer proteome that can be analyzed using modern state 
of the art mass spectrometry proteomic tools. For example, signaling pathways and 
networks involved in cancers are built using a ‘parts list’ of the cancer genome, such 
as through integrating mutated genes, genes altered through differential expression 
(i.e. copy number gain or loss), and through regulation by micro-RNA molecules. DNA 
sequencing-based atlases exist for major tumors allowing ‘part lists’ for cancers; however, 
these atlases lack integration with expressed proteomes and signaling architectures. By 
taking into account all these alterations in the cancer genome, cancer proteomics can 
annotate and prioritize proteins and pathways important for cancer growth and survival. 
Furthermore, microenvironmental influences, known to be important in drug response, 
are lacking from these DNA based studies. Proteomics can inform about active pathways 
driving cancers and lead to novel combination therapy approaches for targeting complex 
oncogenic networks. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is 
increasingly used to study cancer proteomes. This includes examining the ‘expressed 
proteome’ through shotgun proteomics, global signaling by annotating key post-
translational events (phosphorylation, acetylation, ubiquination) events in cancers or 
assembling protein-protein interaction data that yield network views of cancer. This allows 
unbiased and global views of signaling events in cancer thus offering complementary 
views of cancer biology that are not considered by sequencing of genes or gene 
expression. By integrating DNA-RNA-proteome-network type data, the co-existing driver 
processes instilled by the genome that either surround or act in parallel to drug targets 
can be mapped directly onto cancer molecular machines that drive cancer progression 
and response to therapy. Discovery proteomics has become a widely used tool in our 
laboratory. This approach provides an unbiased view of the components in a sample, 
supporting the testing of multiple hypotheses and generating new leads. I will discuss 
examples integrating complementary mass spectrometry approaches to build molecular 
snapshots of cancer proteomes, including phosphoproteomics in tumors related to drug 
resistance (1, 2), drug affinity selection of proteins and identification of drug targets 
using mass spectrometry (3-6), and protein-protein interaction mapping(7-9). Literature 
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MS14.02 Clinical Trials: Who Are the Proper Cohorts and How Do You Recruit 
Subjects? Stephen Lam Integrative Oncology, British Columbia Cancer Agency, 
Vancouver/Canada
Although chemoprevention as a means of reducing cancer incidence has been successful 
for basal cell carcinoma of skin, breast, and prostate cancer, after three decades of 
research, none of the phase III trials with agents such as Beta-carotene, retinol, 13-cis-
retinoic acid, alpha-tocopherol, N-acetylcysteine, acetylsalicylic acid, or selenium have 
demonstrated beneficial and reproducible results in preventing lung cancer, likely due to 
the complexity of genomic alterations in lung cancer (1). Intermediate endpoint biomarkers 
such as bronchial metaplasia or dysplasia have been used in Phase II trials (2). Studies on 
the natural history of pre-neoplastic lesions in the central airways showed that patients 
with high-grade dysplasia or carcinoma in-situ are more likely to develop invasive cancer 
at the same or another site in the lungs than those with low grade lesions. However, pre-
invasive bronchial lesions may be more of a marker of lung cancer risk because more 
cancers developed from a separate site in the same individual than progression from 
an initially biopsied dysplastic site and a significant proportion of the cancers are found 
by CT rather than by bronchoscopy (3,4). The advantage of using bronchial metaplasia/
dysplasia for phase II chemoprevention trials is that these lesions can be localized 
and biopsied using white light and autofluorescence bronchoscopy for histopathology 
confirmation. However, with a steady decline in the prevalence of centrally located 
squamous cell carcinomas and a shift to adenocarcinomas which are usually located in the 
peripheral lung beyond the range of sampling by standard flexible bronchoscopes, it has 
become increasingly difficult to enrol participants with bronchial dysplasia for clinical trial. 
With the implementation of low dose computed tomography for screening of lung cancer, 
alternative intermediate endpoint biomarkers, such as CT detected non-calcified lung 
nodules are being investigated for phase II lung cancer chemoprevention trials (5). The 
limitations of using CT-detected lung nodules as an intermediate endpoint are the lack 
of confirmation of the underlying pathology and variable growth behaviour of sub-solid 
nodules especially non-solid nodules (6,7). Without confirmation of the pathology (atypical 
adenomatous hyperplasia versus adenocarcinoma in-situ versus minimally invasive or 
invasive adenocarcinoma), when a nodule is first seen, volume doubling time measurement 
is meaningless to determine malignant behaviour. Endoscopic optical imaging tools such 
as combined auto-fluorescence-optical coherence tomography (8) are promising methods 
to localize and characterize small peripheral lung lesions for tissue or liquid biopsy for 
pathological diagnosis and molecular characterization (Example shown in Figure 1). 
The availability of accurate lung cancer risk prediction models such as the one developed 
by Tammemagi and co-workers (9 ) opens the possibility of using lung cancer as the 
endpoint for chemoprevention trials in high risk ever smokers instead of intermediate 
endpoint biomarkers to test chemopreventive agents that have sound biological basis. 
Prospective evaluation of a prototype PLCOm2012 lung cancer risk prediction model 
in the Pan-Canadian early Detection of Lung Cancer Study showed that a 3 years lung 
cancer risk of ≥ 2% can reliably identify a sufficient number of ever smokers who will 
develop lung cancer within 3 years to make it feasible to use lung cancer incidence 
as the endpoint for chemoprevention trials with a sample size of approximately 2500 
participants. The sample size can be significantly reduced by using a nodule malignancy 
risk prediction model (10). There is great potential to partner with lung cancer screening 
programs for developing and testing biologically rationalized agents for chemoprevention 
clinical trials within this framework, which may lead to their eventual implementation in 
screening programs to improve patient outcomes. Figure 1. Autofluorescence –Optical 
Coherence Tomography images of a CT-detected lung nodule showing the invasive and 
lepidic components of the adenocarcinoma confirmed by transbronchial lung biopsy.
utility to patients is still to be developed. Omics have made major contributions to the 
understanding of lung cancer biology, and to the identification of a growing spectrum 
of therapeutic targets, but more work remains to be done. References Bedard, P et al. 
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MS14.01 Preclinical Models: How Good Are They? Robert L. Keith Medicine, UC 
Denver/Denver VAMC, Denver/CO/United States of America
A commonly employed approach to understanding the pathogenesis of lung neoplasia 
is to use experimental animal models. The testing of potential chemopreventive 
(and chemotherapeutic) agents involves pre-clinical testing, and numerous animal 
models have been developed. In primary mouse lung tumor models, lung cancer 
develops through a predictable series of airway lesions that progress from normal 
epithelium to invasive cancer. Permanent genomic DNA alterations occur through 
either spontaneous, chemically, or environmentally-induced initiation events. The lung 
cancer chemoprevention field is increasingly reliant on animal studies as the results of 
negative, early, large scale human studies (for example, β-carotene) may have been 
predicted with extensive pre-clinical testing. Agents progressing to human trials now 
undergo extensive pre-clinical studies, and this review will focus on the commonly 
utilized models of adenocarcinoma (ADC) and squamous cell carcinoma(SCC).
ADC: Multiple, well-characterized models of murine adenocarcinoma are available in 
which pulmonary adenomas progress to adenocarcinomas. These progression models 
also allow for the study of pre-malignant airway lesions. The most commonly studied 
models include initiator-promoter carcinogenesis(1), mutant KRAS (2) or EGFR (3) and 
the use of complete carcinogens. Urethane, a component of cigarette smoke, is a 
complete carcinogen because it leads to tumor development without the need for other 
carcinogens or promoters(4). 4- (methylnitrosamino) -1- (3-pyridyl) -1-butanone (NNK) , 
another tobacco smoke carcinogen, is a chemically-induced model where the NNK is 
typically administered in drinking water or injected intraperitoneally. Tobacco smoke 
models also exist and they can reproducibly induce pulmonary adenocarcinomas, but 
they are fairly labor-intensive and do not result in robust tumor multiplicity(5). There 
are also multiple two-stage murine models of lung tumor promotion. Several of them 
use 3-methlycholanthrene (3-MCA), a polycyclic aromatic hydrocarbon, as the initiator 
at a low dose, followed by multiple doses of butylated hydroxytoluene (BHT). BHT is a 
well known antioxidant found in processed foods and packaging, however it is also an 
oxidant and well characterized promoter. In addition, genetically modified animal models, 
in which viral oncogenes or transforming ras mutants are selectively expressed in lung 
tissue, have been developed and extensively investigated. While there are differences 
between the human and murine respiratory tracts, the murine tumors derived from these 
models have many similarities to human adenocarcinoma, ranging from specific markers 
to gene expression patterns(6). SCC: Models of squamous cell lung cancer have also 
been developed, but they are much fewer in number. The most commonly utilized SCC 
model involves NTCU (N-nitroso-tris-chloroethylurea), which is applied topically and 
histopathological analysis of serial lung sections in this model revealed a range of lung 
pathology, including squamous-cell carcinoma, carcinoma in situ, and varying levels of 
bronchial dysplasia(7). Immunohistochemical studies on the premalignant lesions show 
staining that corresponds to analogous human lesions(8), and the NTCU model also 
induces dysplastic lesions that are similar to those found during bronchoscopy and can 
therefore be used to evaluate one proposed surrogate endpoint in pre-clinical studies 
(endobronchial dysplasia). Several positive murine chemoprevention studies examining 
ginseng, pomegranate fruit extract, and aerosolized budesonide +/- pioglitazone have 
also used NTCU (reviewed in (9)). Additional SCC models have been developed, the first 
consisting of a kinase dead IKKα knockin mouse (IkkαK44A/K44A, IkkαKA/KA) that develop 
spontaneous SCC and marked pulmonary inflammation(10). A recently described model 
involved biallelic inactivation of LKB1 and PTEN in mouse lung leads to SCC that expresses 
the squamous markers keratin 5, p63, and SOX2(11). Chemopreventive interventions 
have been assessed in many of the murine preclinical models. This includes (but is 
not limited to): inhaled and systemic glucocorticoids; myoinositol; overexpression of 
prostacyclin synthase; dietary administration of the prostacyclin agonist iloprost; PPARγ 
overexpression; dietary administration of pioglitazone; COX inhibitors; the VEGF inhibitor 
vandetanib; and the anti-estrogen fulvestrant. The effect of COX inhibitors on lung cancer 
prevention has also been tested in murine models. It is likely the chemoprevention world 
will take a cue from lung cancer therapeutics by determining the altered pathways in 
specific premalignant lesions and employing targeted (or ‘precision’) chemoprevention 
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occur as synchronous independent lesions of invasive cancer in resection specimens. 
However, a number of recent publications have begun to describe non-lesion associated 
biomarkers that can be correlated with radiographic features that appear to faithfully 
distinguish premalignant from invasive peripheral lung lesions. While AAH and AIS are 
considered to be precursors of adenocarcinomas derived from the terminal respiratory 
unit (TRU), a recently described premalignant lesion, mucous columnar cell change 
(MCCC), appears to be the precursor of a less common subset of adenocarcinomas 
derived from a region of the distal airways that is proximal to the TRU. This lesion has 
been reported to be present in up to 70% of the mucinous variant adenocarcinomas 
that are derived from these more central sites (2). This suggests that MCCC may be 
amenable to sampling at a pre-invasive stage by bronchoscopic means. In contrast, BD 
is detectable prior to development of invasive cancer by bronchoscopy but cannot be 
identified by radiographic examination. Higher rates of progression to invasive SCC and/
or carcinoma-in-situ for lesions with higher grades of atypia have been suggested in a 
number of studies and meta-analyses (3). We have assessed the relationship between 
persistence of BD and risk for development of invasive lung cancer employing a numeric 
scoring system (1=normal; 2-7=increasing levels of precursor atypia; 8=invasive 
cancer). These analyses have shown that higher histologic scores on follow-up biopsies 
at specific sites within the airway of individuals sampled over time are associated with 
higher baseline histologic score, the presence of papillary angiogenic change, and 
current smoking status (4). Multivariable analyses including these parameters show that 
sites in subjects that develop SCC have mean histologic scores on follow-up biopsy that 
are 1.55 higher than those in patient’s without development of invasive lung cancer. On 
a per subject basis, the frequency of SCC was significantly increased in subjects that 
showed multiple sites of BD at baseline that persisted as or progressed to high grade 
dysplasia (moderate dysplasia or worse, histology score > 5). A 33% increase in risk 
for development of SCC is associated with every 10% increase in percent of sites that 
persist/progress to HGD corresponding to an overall hazard ratio of 17.14 (CI 2.4, 123.3) 
for multifocal persistent BD. These findings lend support to the importance of a field 
effect in lung carcinogenesis and suggest a potential role for histologic demonstration 
of persistent field change as an indicator of risk for the development of lung SCC. A 
number of biomarkers have been studied to determine their relationship with outcomes 
in premalignant lung lesions. Direct analyses of AAH and AIS have shown that a significant 
number of these lesions harbor the activating EGFR driver mutations seen in invasive 
adenocarcinoma of the lung. The potential of these mutational events to act as predictors 
of progression is under investigation, and a case report has demonstrated response to 
EGFR inhibitors of radiographically established multifocal premalignant disease in which 
an EGFR mutation was demonstrated in biopsy tissue of one of the lesions (5). Interestingly, 
the tumors associated with MCCC show a higher proportion of KRAS mutations. Non-
lesional biomarkers of risk such as a recently reported assay measuring germline 
DNA repair activity that correlates decreased repair capability with increased risk for 
malignancy show promise for risk prediction (6). BDs, like SCC, demonstrate frequent 
genetic alterations in tumor suppressor genes and show characteristic associated 
alterations in gene methylation, loss of heterozygosity and gene copy number gains 
that have been associated with increased risk (7-10). In an analysis of a small series 
of cases in which sites with BD were observed to directly progress to invasive SCC, 
we have demonstrated frequent TP53 and some other mutations in precursor lesions. 
Furthermore, via pathway analysis of genes that we have found to be differentially 
expressed between persistent and regressive bronchial dysplasia, we have identified 
altered control of cell cycle, adhesion and immune activity (see abstract #3026) to be 
associated with persistence of BD. Overexpression of polo-like kinase 1 (PLK1) is the 
most prominent cell cycle control alteration associated with persistence and its role as a 
mediator of progression through the G2-M DNA damage checkpoint suggests a potential 
mechanism by which genomic instability can be promoted in high risk premalignant BD. 
PLK1 inhibitor treatment of primary cultures derived from sites of persistent BD causes 
an arrest of growth in S/G2 phase and induces apoptosis, neither of which occurs when 
PLK1 inhibitor is applied to primary cultures of normal bronchial epithelium. Histologic 
features and molecular biomarkers of premalignant lung lesions provide means by which 
risk can be assessed, appropriate targets for prevention can be identified and efficacy of 
preventive therapies can be measured. 
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MS14.03 Pathologic Biomarkers of Risk and Benefit of Treatment 
Daniel T. Merrick Department of Pathology, University of Colorado Anschutz Medical 
Campus, Aurora/CO/United States of America
Prevention of lung cancer could lead to a significant reduction in the mortality 
associated with this disease. Identification of individuals at high risk for the development 
of invasive lung cancer is critical to establishing efficient and effective screening 
and prevention programs. The presence of premalignant lesions including atypical 
adenomatous hyperplasia/adenocarcinoma-in-situ (AAH/AIS) and bronchial dysplasia 
(BD), which represent precursors of adenocarcinoma and squamous cell carcinoma 
(SCC) respectively, provide targets that can be studied by histologic, radiographic 
and molecular techniques to define biologic characteristics that are indicative of risk 
and potential cellular activities that can be targeted for prevention. The histologic 
features of premalignant lesions have been well described in published WHO defined 
classification systems (1). Accurate histologic assessment of precursor lesions of 
lung adenocarcinoma prior to development of invasive cancer is limited by sampling 
considerations. To establish a diagnosis of premalignant AAH or AIS, the whole lesion 
must be examined and size criteria and histologic confirmation of lack of invasion must 
be documented. Because resection is generally restricted to cases of invasive cancer, 
tissue from AAH or AIS prior to development of invasive adenocarcinoma are rare, and 
most analyses of these lesions are performed on lesions that are associated with or 
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Spira A et al. Airway epithelial gene expression in the diagnostic evaluation of smokers 
with suspect lung cancer. Nat Med 2007;13:361-6.
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MS15.01 NLST, USPSTF Recommendations - Is Screening Going to Happen in 
USA? James Mulshine Graduate College, Rush University, Chicago/IL/United States 
of America
In the wake of the demonstrated 20% mortality reduction benefit reported from the 
randomized National Lung Screening Trial (NLST), the United States Preventive Services 
Task Forces gave a “B” recommendation for low dose CT screening of for lung cancer in 
high risk populations (1). This favorable endorsement in turn led the Centers for Medicare 
and Medicaid Service to fully reimbursement the cost of providing this service by federal 
and commercial insurers for high risk smokers between the ages of 55-77 who have been 
smoking within the last 15 years. With these provisions, national lung cancer screening is 
now being implemented in the United States. The protocol and screening process used 
for the NLST was fixed at the time of study initiation in 2002 when 4-detector scanners 
were the default CT device and screening management was delivered based on the 
existing community standard (2). In the time since the NLST was conducted there have 
been a number of developments that have improved the process of lung cancer screening 
services (3). These innovations range from the introduction of more capable CT scanners, 
lower medical radiation scanning protocols, more effective and efficient diagnostic work 
up approaches, as well as improved and more tailored surgical approaches. The 
aggregate effect of all of these advances is that the cost efficiency of this process is also 
improving (4). Further improvements with clinical management may occur as the use of 
quantitative CT imaging allows for more consistent measurement of suspicious 
pulmonary nodules, as size criteria is emerging as a key determinant guiding invasive 
screening work-up (5). However implementing national CT screening to ensure delivery of 
high quality, best-practice early lung cancer detection in the target population of tobacco-
exposed individuals constitutes a profound challenge. Still the public health impact of 
tobacco-exposure is singularly lethal. In the United States alone over 438,000 annual 
deaths are related to tobacco-exposure with lung cancer being the most common cause 
of tobacco-related death approaching 30% of this total mortality burden. Advocacy 
groups have worked with academic medical centers as well as community hospitals to 
address this implementation challenge by creating a consortium of institutions that are 
conducting screening programs to systematically adopt best standard of screening 
practice for all components of clinical management (6). A critical aspect of the 
“Framework” process includes the expectation that participating institutions will 
prospectively acquire clinical follow-up information so that the outcomes of lung cancer 
screening efforts can be accessed and reported (6). This effort builds on previous 
models of cooperative research such as with using institutional feedback to accelerate 
learning curve in allowing new screening institutions to rapidly implement effective 
screening process. The best example to date of this approach with screening is the use 
of the recent I-ELCAP screening outcomes to evaluate the most favorable pulmonary 
nodule size to use as a threshold for a more invasive diagnostic work-up (7). Increasing 
the nodule size as the threshold for further diagnostic work-up markedly improves the 
efficiency of the screening management while reducing the rate of false positive work-
ups, cost and morbidity (7). An indispensible element in the national implementation of 
screening is the simultaneous provision of best practice smoking cessation services for 
those individuals that continue to smoke. Pyenson and co-workers have reported that 
routine integration of smoking cessation with the annual CT screening process can 
improve the cost utility ratio of quality adjusted life years by close to 40% (4). Indisputably 
implementing national annual CT screening in high risk populations is a significant societal 
cost. However there are attractive opportunities to leverage this new pattern of care to 
further benefit health outcomes in this at-risk cohort. For example, the annual CT visit 
provides a scaffolding to support more intensive research to define better smoking 
cessation measures. In asymptomatic tobacco-exposed individuals, a growing body of 
research suggests that the CT scan done to evaluate for early lung cancer also commonly 
finds individuals with evidence of asymptomatic COPD/emphysema or coronary artery 
disease (8, 9). These diseases along with lung cancer account for close to 70% of the 
excess mortality in heavily tobacco-exposed populations. Lung cancer screening will 
permit additional research opportunities in this tobacco-exposed cohort including 
catalyzing the development for more effective drugs to manage the early stage of lung 
cancer. With screening, the frequency of finding early stage lung cancer is greatly 
increased and focusing on these early stage patients could allow for much more rapid 
evaluation of new targeted therapeutic agents compared to the current setting. For the 
same reason, lung cancer screening will also find many more early asymptomatic COPD 
precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006; 66(6):3338-44. 
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MS14.04 Chemoprevention Clinical Trials: How Do We Move Forward? How Do 
We Identify Valid End Points? Eva Szabo Division of Cancer Prevention, National Cancer 
Institute, Bethesda/MD/United States of America
The ability to intervene in the process of carcinogenesis is predicated on an 
understanding of the pathways leading to invasive cancer and availability of targeted 
tools to abrogate the resulting processes. Thus, effective chemoprevention has been 
hampered by the evolving understanding of lung cancer as a heterogeneous set of 
malignancies arising from a multitude of diverse molecular deregulations. The simplistic 
view that early intervention (before the evolution of multiple complex mutational events 
that are characteristic of tobacco-related malignancies) is more likely to be effective than 
late intervention has been replaced by the realization that many complex abnormalities 
actually do occur early and we simply do not understand which individual abnormalities 
or combinations of abnormalities would derail the inevitable progression to invasive and 
metastatic cancer. To assess efficacy, well designed clinical trials need to have end 
points that are informative. For phase III trials, the ideal end point would be cancer-
related mortality so that cancer overdiagnosis does not cloud the issue. Realistically, 
cancer incidence is a more achievable and sufficiently informative end point. Phase II 
trials, however, depend on intermediate end points that are surrogates for cancer 
incidence, in a manner analogous to tumor shrinkage or progression-free survival being 
a surrogate for survival in phase II cancer treatment trials. Examples of end points 
that have been used in a variety of phase II chemoprevention trials are premalignant 
lesions, proliferative indices, and a variety of biomarkers of risk or malignant potential. 
It must be emphasized that to be useful, intermediate end points should be integrally 
involved in the process of carcinogenesis, differentially expressed in at-risk vs. normal 
epithelium, and modulated by effective interventions well above the level of spontaneous 
fluctuation (1). To date, no intermediate end point has been validated to replace lung 
cancer incidence, but such biomarkers can significantly inform drug development and 
decision-making for subsequent phase III trials. Nevertheless, the histologic evolution of 
squamous carcinogenesis, with progression from bronchial metaplasia through varying 
grades of dysplasia to carcinoma in situ is well described (2). This knowledge has allowed 
for clinical trials based on pre- and post-treatment assessment of effect of interventions 
on bronchial histology. However, the rate of progression of dysplasia to invasive cancer 
is variable even though high grade histologies are associated with higher rates of 
progression. Therefore, studies assessing dysplasia need to have placebo controls to 
correct for spontaneous and biopsy-induced regression. A recent trial of a prostacyclin 
analogue, iloprost, showed improvement in bronchial histology in former smokers after 6 
months of treatment (3). These results will be extended in a soon-to-open trial of inhaled 
iloprost in a similar population and will include analyses of potential molecular predictors 
of histologic progression. Ongoing efforts are focusing on understanding the process of 
carcinogenesis by profiling premalignant lesions, both in a cross-sectional manner with 
regard to lesions identified at time of lung cancer resection (4) and with longitudinal follow-
up. Understanding the natural history of premalignant lesions will help determine which 
ones progress, why they progress, and, therefore, which end points are likely to be most 
informative. An alternative way to approach the issue is to examine the at-risk epithelial 
field to identify biomarkers associated with progressive carcinogenesis. Gustafson et al. 
showed that the PI3K pathway is upregulated early during lung carcinogenesis and that an 
intervention with a drug, myo-inositol, that resulted in regression of bronchial dysplasia 
also inhibited PI3K activation in the histologically normal bronchial epithelium obtained 
by bronchial brushings (5). These data suggest that upregulated PI3K could potentially 
identify smokers at increased lung cancer risk and that pathway inhibition could serve as 
an end point for assessing treatment effect. This hypothesis is undergoing further testing 
in a recently finished phase II trial of myo-inositol in current and former smokers with 
dysplasia, where normal bronchial epithelium was collected and will be tested for PI3K 
activation pre- and post-treatment. Similarly, Spira et al. showed that gene expression 
classifiers from bronchial brushings of histologically normal epithelium obtained from 
individuals undergoing bronchoscopy for suspect lung cancer can aid in the diagnosis 
of lung cancer and can serve as lung cancer biomarkers (6,7). These classifiers have 
potential to be adapted to surrogate tissues further up in the aerodigestive tract, such 
as the nasal epithelium, and are being tested in chemoprevention ongoing clinical trials 
(8; NCT02123849). How do we move forward? A better understanding of the early 
carcinogenic processes and which processes are operative in individual persons is key 
to designing clinical trials that bring the prospect of precision medicine to lung cancer 
chemoprevention. The focus on a molecular understanding of premalignant lesions and 
the at-risk field is at the center of current efforts to identify informative end points for 
chemoprevention clinical trials. References
Szabo E. Phase II cancer prevention clinical trials. Semin Oncol 2010;37:359-66.
Saccomanno G et al. Development of carcinoma of the lung as reflected in exfoliated 
cells. Cancer 1974;33:256-70.
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(40.4%) substantially higher than in other trials: f.e. 3.8% in the NLST(2). Furthermore, our 
findings showed that the 2 year-probability of developing lung cancer for all included 
participants was 1.3% (1.2-1.5)(8). For screened participants without any nodules this 
probability (more than half of the included participants) was 0.4%, which suggests that a 
screening interval of at least two years might be safe to apply in these individuals. In all 
participants with CT-detected nodules, lung cancer probability was 2.5% (2.1-2.9) but 
individuals’ probabilities depended strongly on nodule volume, diameter and VDT. New 
data: the last screening round, which took place 2.5 years after the third round, showed 
46 screen-detected lung cancers, of which 58.7% were diagnosed at stage I and 23.8% 
at stage III/IV. More squamous-cell carcinomas (21.7% vs. 16.3%), small cell carcinomas 
(6.5% vs. 3.8%) and bronchioalveolar carcinomas (8.7% vs. 5.3%) were detected 
compared to the first three screening rounds. However, relative to the first three rounds 
the lung cancer detection rate was lower (0.80 vs 0.80-1.1) and lung cancer was detected 
at a more advanced stage (stage III/IV; 23.8% vs 8.1). Currently, we are working on the 
review of blinded medical files of the deceased participants to determine the cause of 
death, and we are collecting medical data of control arm participants.
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MS15.03 UKLS Impact of Utilization of Risk Assessment in Trial Selection 
John K. Field1, Anand Devaraj2, David R. Baldwin3, Stephen Duffy4 1Cancer Research 
Centre, University of Liverpool, Liverpool/United Kingdom, 2Royal Brompton & Harefield 
NHS Trust, London/United Kingdom, 3Nottingham University Hospitals, Nottingham/United 
Kingdom, 4Queen Mary University of London, London/United Kingdom
Future implementation of lung cancer screening programmes will require accurate 
identification of the population who will benefit the most, to ensure that the benefits 
outweigh the harms [1]. In the USA, the current criteria for Medicare reimbursement [2], 
for screening are: age 55 to 77, a smoking history of 30 pack-years or more and smoking 
within 14 years of entry [3]. However, an in-depth analysis of the NLST showed that there 
was marked variation in individual risk of lung cancer death, with some screened that had 
only a low chance of benefit: 20% of participants at lowest risk accounted for only 1% of 
prevented lung-cancer deaths). [4]Conversely, 88% of the prevented deaths were in the 
60% of participants that were at highest risk. The only risk prediction model so far utilised 
in the recruitment of participants into a CT Lung Cancer Screening RCT, is the LLPv2 risk 
model in the pilot UK lung cancer screening trial (UKLS) [5]. The Liverpool Lung Project 
(LLP) risk model was based on a case-control study [6]. The LLPv1 model utilised 
conditional logistic regression to develop a model based on factors that were significantly 
associated with lung cancer (smoking duration, prior diagnosis of pneumonia, 
occupational exposure to asbestos, prior diagnosis of cancer family history of lung 
cancer (early onset <60 years) and exposure to asbestosis [6]. The multivariable model 
was combined with age-standardised incidence data to estimate the absolute risk of 
developing lung cancer. The discrimination of the LLP was evaluated and demonstrated 
its predicted benefit for stratifying patients for CT screening by using data from three 
independent studies from Europe and North America [7]. The LLPv2 was used to select 
subjects with ≥ 5% risk of developing lung cancer in the next five years for UKLS [8]. This 
method may improve cost-effectiveness by limiting screening to high-risk individuals. The 
UKLS approached 247,354 individuals in the two pilot sites, 75,958 people (30.7%) 
responded positively to the screening invitation. Demographic factors associated with 
positive response were: higher socioeconomic status, age 56-70 years, and ex-smokers. 
Those from lower socioeconomic groups and current smokers were less likely to 
respond. 8,729 (11.5%) positive responders were calculated as high risk of lung cancer. 
patients and quantitative CT provides an economical biomarker to allow much more 
efficient COPD drug development research than is currently possible. Particular classes 
of drug targets such as immunomodulators could conceivably show benefit in arresting 
the progression of both early lung cancer and COPD. This time of initial US national 
screening dissemination is allowing a full national discussion not only about how to 
provide high quality lung cancer screening services, but also about how to thoughtfully 
leverage this newly reimbursed screening service to extend the utility of the thoracic 
imaging encounter and greatly accelerate progress with improving health outcomes in 
heavily tobacco-exposed populations. At the very least, evidence for one or more of 
these additional diseases on annual screening may heighten a smoker’s motivation to 
stop that habit. Other life style interventions such as diet modification and exercise are 
being successfully employed to manage the consequence of asymptomatic coronary 
calcification. Life style counseling could also emerge as integral part of the annual CT 
evaluation as these interventions can have markedly positive impact for a range of 
tobacco-dependent conditions. The emergence of lung cancer screening as a public 
health tool has evoked a lively global debate regarding its potential merits. While this 
healthy debate should continue, there are potentially unprecedented opportunities 
arising with this new approach to the lethality of chronic tobacco exposure that merit 
serious consideration. References: 1) Moyer VA. Screening for lung cancer: U.S. 
preventive services task force recommendation statement. Ann Intern Med. 2013 Dec 31. 
2) Aberle D, Adams A, Berg C et al. Reduced lung-cancer mortality with low-dose 
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D’Amico TA. Issues with implementing a high-quality lung cancer screening program. CA 
Cancer J Clin. 2014 Jun 27. 4) Villanti AC, Jiang Y, Abrams DB, Pyenson BS. A cost-utility 
analysis of lung cancer screening and the additional benefits of incorporating smoking 
cessation interventions. PLoS One. 2013 Aug 7; 8(8): e71379. PMCID: PMC3737088. 5) 
Mulshine JL1, Avila R, Yankelevitz D et al. Lung Cancer Workshop XI: Tobacco-Induced 
Disease: Advances in Policy, Early Detection and Management. J Thorac Oncol. 2015 
May;10(5):762-7. doi: 10.1097/JTO.0000000000000489. 6) Rights and expectations for 
excellence in lung cancer screening and continuum of care.[homepage on the Internet]. 
Available from: http://www.screenforlungcancer.org/national-framework/. 7) Henschke 
CI. Definition of a positive test result in computed tomography screening for lung cancer: 
A cohort study. Ann Intern Med. 2013; 158(4): 246-252. 8) Zulueta J, Wisnivesky J, 
Henschke C, et al. Emphysema scores predict death from COPD and lung 
cancer. Chest. 2012; 141(5): 1216-1223. 9) Htwe Y, Cham MD, Henschke CI, et al. 
Coronary artery calcification on low-dose computed tomography: comparison of 
Agatston and Ordinal Scores. Clin Imaging. 2015 Apr 18. pii: S0899-7071(15)00098-4. 
doi: 10.1016/j.clinimag.2015.04.006. [Epub ahead of print] 
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MS15.02 NELSON Emerging Data Harry De Koning, Uraujh Yousaf-Khan 
Public Health, Erasmus MC, Rotterdam/Netherlands
Background: lung cancer mortality is still the leading cause of cancer death worldwide(1). 
The majority of patients present with advanced disease and the current 5-year survival is 
only 15%. Despite treatment advances, there is little improvement of prognosis. As the 
American National Lung cancer Screening trial (NLST) showed that low-dose CT-scan 
(LDCT) screening can reduce lung cancer mortality in high risk subjects(2), the United 
States Preventive Task Force (USPTFS) recommends annual LDCT screening in adults 
who have a smoking history of at least 30 pack-years, and smoke now or have quit within 
the past 15 years and are between 55 and 80 years old(3). However, there are still some 
important challenges, f.e. high prevalence of false-positives, overdiagnosis and the 
optimal screening strategy . In Europe, the sufficiently powered Dutch-Belgian lung 
cancer screening trial (NELSON) is still ongoing. This trial is currently in the final phase of 
follow-up prior to definitive analysis and reporting. Results: the NELSON trial has been 
setup in 2003, in which subjects at high risk for lung cancer were selected from the 
general population(4). After informed consent, 15,791 participants were randomised (1:1) 
to the screen arm (n=7,900) or the control arm (n=7,891) (Figure 1). The screen arm 
participants received LDCT screening at four times: at baseline, after one year, after two 
years and after two and a half years, whereas the control arm participants received usual 
care (no screening). According to size and volume doubling time (VDT) of the nodules, 
three screen results were possible: negative (invitation for the next screening round), 
indeterminate (an invitation for a follow-up scan) or positive (referred to the pulmonologist 
because of suspected lung cancer). Main results of the first three screening rounds 
showed a favorable cancer stage distribution of the screen-detected lung cancers 
detected in the NELSON trial compared to the other trials and was more favorable 
(p<0.001) than in the NLST(5). More than half of the screen-detected lung cancers were 
adenocarcinomas (51.2%) and a large proportion was localized in the right upper lobe 
(45.0%). Women diagnosed with lung cancer were significantly younger (58.0 vs. 62.0 
years; p=0.03), had a lower BMI (23.8 vs 25.9;p=0.003) and were diagnosed at a more 
favorable cancer stage (p=0.028) than the men diagnosed with lung cancer. From the 
first screening round up to two years of follow-up after the third round scan, 34 
participants were diagnosed with an interval lung cancer(6, 7). Retrospectively, two-thirds 
of these interval cancers were visible on the last screening CT; detection errors, 
interpretation errors, and human errors were identified as the main causes of the failure 
in half of the interval cancers. Interval cancers were diagnosed at more advanced stages 
(p<0.001 ), and were more often small cell carcinoma (p=0.003) and less often 
adenocarcinomas (p=0.005) than screen-detected lung cancers. For the first three 
rounds combined, sensitivity was 84.6% (95% CI 79.6-89.2%), specificity was 98.6% 
(95% 98.5%-98.8%), positive predictive value was 40.4% (95% CI 35.9-44.7%), and 
negative predictive value was 99.8% (95% CI 99.8%-99.9%)(6). For the first screening 
round, the sensitivity was the same, but the specificity was higher in the NELSON trial 
relative to the NLST: 98.3% vs. 73.4%. The positive predictive value was in our trial 
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in smokers. Adenocarcinomas have increased worldwide in non-smokers, especially in 
Japan and other Asian countries, and a powerful lung cancer screening modality for 
non-smokers is also desired. In a recent Japanese cohort study, mortality reduction by 
thoracic CT screening was suggested even in non-smokers/smokers under 30 pack-
years (personal communication). Therefore, we are now conducting the JECS Study (The 
Japanese randomized trial for evaluating the Efficacy of low-dose thoracic CT Screening 
for lung cancer in non-smokers and smokers under 30 pack-years). Methods The aim of 
the JECS study is to assess the efficacy of lung cancer screening tests using low-dose 
thoracic CT once every five years, compared with chest roentgenography (XP), in people 
aged 50–64 with a smoking history under 30 pack-years. This study is a multi-regional 
prospective randomized controlled trial (RCT). The design of the RCT was described 
elsewhere (Jpn J Clin Oncol 42: 1219-21, 2012). Briefly, participants were recruited from 
people who ranged from 50-64 years old with smoking history under 30 pack-years, 
and underwent regular lung cancer screening using chest x-ray in the previous year (this 
latter requirement may be deleted after 2015). A letter for recruitment to participate in 
the trial was mailed to each citizen in the target municipalities, who was 50-64 years old 
with a smoking history under 30 pack-years. The letter explained the eligibility criteria, 
randomization, follow-up, possible benefit and harm including false-positive, radiation 
exposure and overdiagnosis. Several meetings were held for those who were interested 
in the trial for further explanation. People with a history of lung cancer or other malignant 
diseases as well as a history of thoracic CT screening were excluded. Appropriate written 
informed consent was completed by each participant who chose to take part in the trial. 
The participants were randomly assigned into one of 2 groups, a CT group and an XP 
group. The duration of this screening-follow-up period is 10 years. For the intervention 
arm, low-dose thoracic CT is provided for each participant in the first year and the sixth 
year. For the control arm, chest XP is provided for each participant in the first year. All of 
the participants are encouraged to receive annual routine lung cancer screening using 
chest XP in the other years. Thoracic CT findings were interpreted by two physicians, 
based upon the “Low-dose CT Lung Cancer Screening Guidelines for Pulmonary Nodules 
Management” established by the Japanese Society of CT Screening. A positive rate 
under 5% is preferred. The interpretation of chest XP findings is performed according 
to “The Manual of the Lung Cancer Screening” section in the “General rule for clinical 
and pathological record of lung cancer” published by the Japan Lung Cancer Society. 
The lung cancer incidence and mortality would be compared. The design of the trial 
was approved by the Institutional Review Board of the Kanazawa Medical University in 
2009, and was registered on the University Hospital Medical Information Network Clinical 
Trial Registration (UMIN-CTR), Japan in 2011 (registration number: UMIN000005909). 
The sample size, 17,500 subjects for each arm, is required to detect a 60% mortality 
reduction after 10 years. At the first step, 3,000 subjects are needed for evaluating QOL 
and value of contamination of the study. Results As of March 1, 2015, local governments 
of 20 municipalities in 7 prefectures in Japan permitted that we sent invitation letters for 
the JECS Study to residents. A letter for recruitment was mailed to each of 9,268 people 
who were 50-64 years old with a smoking history under 30 pack-years and underwent 
regular lung cancer screening in the previous year. Of them, 1,812 people (19.6%) sent 
us a reply letter and wanted to attend one of the meetings for further explanation. One 
thousand five hundred people actually attended one of the meetings. Finally 1,458 people 
participated in the JECS Study (15.7% of people who was invited and 97.2% of people who 
attended a meeting). Of them, 720 people were assigned to CT group and remaining 738 
people were assigned to XP group. The screening results of 48 of the 720 people who 
received low-dose thoracic CT screening (6.7%) were positive, whereas 20 of 738 people 
who underwent chest XP screening (2.7%) were positive. Until now, three lung cancer 
patients were diagnosed and 22 patients were under follow-up for the suspicion of having 
lung cancer in this whole cohort. Comments The results of the NLST demonstrated 
the efficacy of thoracic CT screening in smokers. However, the efficacy in non-smokers 
is still completely unknown. Therefore, we started to conduct a randomized trial, the 
JECS study, to evaluate the efficacy of low-dose thoracic CT screening for lung cancer 
in non-smokers/smokers under 30 pack-years. This is a first RCT in the world for not 
heavy-smokers. The preliminary results of this study indicated that 15.7% of the people 
who received the recruitment letter participated in the RCT. The compliance rate was 
high in comparison to that in the PLCO or the ITALUNG trial (0.3-7.2%). Over 97% of the 
1,500 people who attended a meeting participated in the RCT, which was extremely high. 
This indicated that the letter for recruitment was effective both for excluding ineligible 
subjects and for explaining the contents of the trial. The compliance in the preliminary 
results for this study was very high, and the above RCT appears to be feasible in Japan, 
if the sufficient budget is obtained. This study was supported in part by the Health and 
Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan. 
Keywords: Non-smokers, thoracic CT screening for lung cancer, efficacy, randomized 
controlled trial
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MS16.01 PARP Inhibitors and DNA Damage Lauren Byers Thoracic/Head & Neck 
Medical Oncology, UT MD Anderson Cancer Center, Houston/TX/United States of America
A leading cause of death in small cell lung cancer (SCLC) is the rapid emergence of drug 
resistance following an initial phase of chemotherapy and radiation sensitivity. Currently, 
response rates to existing second-line regimens (e.g., topotecan and other single-
agent chemotherapies) are less than 20%. Because of this overall poor response to 
subsequent therapy, average survival for relapsed disease ranges between 4-6 months. 
As such, there is a critical need for the development of novel, active therapies for SCLC. 
The high risk individuals were more often elderly, current smokers, of lower socioeconomic 
status and males (2.4x females). 4,055 were randomised into the UKLS. Forty two UKLS 
participants have been diagnosed with confirmed lung cancer, 34 of these were detected 
at baseline or three months, giving a baseline prevalence of 1.7% which is significantly 
higher than that reported by the NLST[9]or NELSON [10]trials. To date, 2.1% of all 
individuals screened have been diagnosed with lung cancer. 36/42 (85.7%) of the screen-
detected cancers were identified at stage 1 or 2. Of those with a confirmed cancer, 
17/42 (40.5%) were from the most deprived Index of Multiple Deprivation (IMD) quintile.
 
Figure 1: Percentage of UKLS positive responders (n=75,958) with an LLP risk 
of >5%, by individual year of age. The positive response rate increased steadily with 
higher socioeconomic status: 21.7% of individuals in the lowest (most deprived) IMD 
quintile gave a positive response compared with 39.7% in the highest quintile (p<0.001;) 
(Figure 2). The proportion of individuals with a high LLP risk score decreased with higher 
socioeconomic status; ranging from 18.2% in the most deprived quintile to 8.3% in 
the least deprived quintile (p<0.001;). LLP risk were offset by, the socio-demographic 
spectrum of the individuals attending the clinic, which was in proportion to that of the 
original approached sample. People recruited into the UKLS trial therefore spanned 
all IMD quintiles in roughly equal numbers, including a representative proportion from 
more deprived postcodes. However, in the high risk sub group of individuals invited for 
screening, there was a trend towards individuals of higher socioeconomic status being 
more likely to consent to participate in the trial.
  
Figure 2: Impact of socioeconomic status upon initial response rate (lower line), LLP 
risk (bars) and trial consent rate (upper line). The demographic and response data 
from the UKLS pilot trial enable specific recommendations to be made regarding 
the implementation of any future UK-wide lung LDCT screening programme. Such a 
programme would need to target those most at risk who may be least likely to take up offers 
of screening (i.e. the most deprived, current smokers, and the over 70s), and women. 
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MS15.04 Screening in Japan - The JECS Study Motoyasu Sagawa1, The Jecs Study 
Group2 1Thoracic Surgery, Kanazawa Medical University, Uchinada/Japan, 2Research Group, 
Uchinada/Japan
Background Lung cancer is the leading cause of cancer death in Japan as well as western 
countries. To decrease the lung cancer mortality, lung cancer screening using low-dose 
thoracic computed tomography (CT) may be a promising measure. Several randomized 
controlled trials (RCTs) are being conducted in the US and Europe to evaluate the efficacy 
of lung cancer CT screening, and one of those trials, National Lung Screening Trial (NLST), 
recently reported favorable results. However, the focus of all trials has been the efficacy 
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small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. 
2014 ASCO Annual Meeting; J Clin Oncol 32:5s, (suppl; abstr 7522) 2014. 
6. Owonikoko TK, Dahlberg SE, Khan SA, et al. A phase 1 safety study of veliparib 
combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial 
of the ECOG-ACRIN Cancer Research Group (E2511). Lung cancer 2015;89:66-70. 
7. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by Clinical PARP 
Inhibitors. Cancer research 2012;72:5588-99.  
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MS16.03 PI3K/AKT/mTOR Shigeki Umemura, Koichi Goto Department of Thoracic 
Oncology, National Cancer Center Hospital East, Kashiwa/Japan
Small cell lung cancer (SCLC) comprises approximately 15% of all lung cancers, and it is 
an exceptionally aggressive malignancy with a high proliferative index. Despite extensive 
basic and clinical research over the past 30 years, little progress has been made in 
treating this disease. A better understanding of the genomic changes in SCLC is essential 
to identify new therapeutic targets. However, a systematic genomic analysis of SCLC 
is difficult because this cancer subtype is rarely treated surgically, resulting in the lack 
of suitable tumor specimens for comprehensive analysis. Two reports regarding the 
comprehensive genomic analysis of SCLC have been published. These reports suggested 
that transcriptional deregulation might play a role in SCLC biology1,2. However, to date, 
attempts to develop targeted therapies toward these transcriptional deregulations have 
had limited success. Recently, we performed a comprehensive genomic analysis of 
51 surgical resected SCLCs and found a high penetrance of genetic alterations in the 
PI3K/AKT/mTOR pathway3. MYC family amplifications are known oncogenic drivers in 
SCLC. PI3K/AKT/mTOR pathway alterations and MYC family amplifications were mutually 
exclusive in this study (Figure 1). However, the information regarding therapeutically 
relevant genomic alterations in advanced non-surgical SCLC is not well developed; so 
we performed targeted sequencing from 90 advanced SCLC. We identified that the 
PI3K/AKT/mTOR pathway was frequently altered in advanced SCLC in the same way 
as surgically resected SCLC. In advanced SCLC, PI3K/AKT/mTOR pathway alterations 
and MYC family amplifications were also mutually exclusive. The genomic profile of 
advanced SCLC was almost similar to that of resectable SCLC. To further investigate 
whether the PI3K/AKT/mTOR pathway could be a feasible therapeutic target in SCLC, 
we performed the in vitro drug sensitivity test using PI3K/mTOR dual inhibitor: NVP-
BEZ235. NCI-H1048 cells harboring activating mutation in PIK3CA gene (H1047R), was 
the most sensitive to BEZ235, with IC50 value of 5.4 nM. Additionally, PIK3CA silencing 
induced a significant decrease in the proliferation of H1048 cells, suggesting that the 
proliferation of these cells was strongly dependent on the PI3K/AKT/mTOR pathway3. 
On the other hand, PTEN is a tumor suppressor gene working in PI3K/AKT/mTOR 
pathway. In murine model, Pten deletion accelerated SCLC by engineered deletion of 
two tumor suppressors (Rb and p53), suggesting that Pten was an important driver of 
tumor progression in SCLC4. Unlike other types of cancer, this is a unique phenomenon 
observed in SCLC, therefore targeting of PTEN signaling is reasonable in SCLC. There 
are many other reports which suggest that PI3K/AKT/mTOR pathway is the promising 
therapeutic target in SCLC. Although two specific inhibitors of mTORC1, everolimus 
and temsirolimus, have been tested against SCLC in a Phase II study, the antitumor 
activity was limited in unselected patients. To improve the response to these inhibitors, 
biomarker-based patient selection is first recommended. Secondly, the addition of PI3K 
inhibition might improve the response to specific inhibitors of mTORC1. The dual inhibition 
of PI3K and mTOR might be advantageous over the single inhibition of mTOR because 
of the suppression of the S6K feedback loop, which leads to the pathway reactivation. 
PF-05212384 is a novel potent dual inhibitor of PI3K and mTOR, which has demonstrated 
preliminary evidence of clinical activity in patients with solid malignancies5. However, dual 
inhibitor of PI3K and mTOR has not yet to be evaluated against SCLC in a phase II study. 
Thus, we planned the investigator initiated phase II study to investigate the efficacy of 
PF-05212384 in advanced recurrent SCLC patients harboring PI3K/AKT/mTOR pathway 
alteration. Key eligibility criteria include: advanced SCLC, harboring PI3K/AKT/mTOR 
pathway alteration, prior chemotherapy, aged ≥  20 years, and ECOG PS 0-2. The primary 
endpoint is objective response rate. Patients receive weekly intravenous dose of PF-
05212384 154 mg until disease progression. For screening SCLC patients harboring 
PI3K/AKT/mTOR pathway alteration, we use the multiplex next-generation sequencing 
tool enabling the analysis of about 150 genes in a single run. SCLC harboring PI3K/AKT/
mTOR pathway alteration is a “Rare Cancer”. Therefore, patient recruitment is performed 
using the nationwide lung cancer genomic screening program, LC-SCRUM-Japan. LC-
SCRUM-Japan is the largest molecular screening system in Japan. At the end of June 
2015, around 180 institutes in all prefectures of Japan are participating this screening 
program. The prospective genomic screening of SCLC will be started in July 2015. In 
conclusion, the SCLC genome possesses distinguishable genetic features in the PI3K/
AKT/mTOR pathway. Genetic alterations in the PI3K/AKT/mTOR pathway were noted as 
a top therapeutic priority in SCLC. Investigator initiated phase II study of PF-05212384 
in advanced recurrent SCLC patients harboring molecular alterations in PI3K/AKT/mTOR 
pathway is planned to be started in January 2016.
Drugs that target DNA damage response (DDR), including PARP inhibitors, have shown 
promising activity against SCLC in pre-clinical models and in early clinical trials. 
Previously, we performed proteomic profiling of a large panel of SCLC cell lines which 
led to the observation that PARP1, Chk1, and several other DNA repair proteins are 
expressed at high levels in SCLC1. PARP1 overexpression was confirmed in patient 
tumors at the protein level by immunohistochemistry and at the mRNA level. Based 
on this finding, several PARP inhibitors were tested in pre-clinical models of SCLC. 
Olaparib, rucaparib, and talazoparib (previously BMN-673) all demonstrated striking 
single agent activity in a majority of SCLC cell lines tested. Furthermore, the addition 
of a PARP inhibitor to standard chemotherapies (e.g., cisplatin, etoposide and/or 
topotecan) and radiation further potentiated their effect1,2. In animal models including 
xenografts and patient-derived xenografts (PDXs), talazoparib has demonstrated 
significant anti-tumor activity as a single agent, comparable or superior to cisplatin3,4. 
Following these observations, several clinical trials were initiated to investigate 
the effects of PARP inhibition in SCLC patients. The first two studies to complete 
enrollment investigated the use of PARP inhibitors in relapsed SCLC. In the first study, 
single-agent talazoparib (BMN-673) was tested in an expansion cohort of patients 
with platinum-sensitive SCLC relapse (NCT01286987). Preliminary data from this trial 
demonstrated 2/23 patients with RECIST confirmed partial responses and 3/23 with 
stable disease lasting more than 24 weeks (clinical benefit rate of 25%). More than half 
of patients treated had some tumor volume reduction as their best response5. In the 
second study, the oral alkylating drug temozolomide with or without veliparib (ABT-
888) was studied in 100 patients with sensitive or refractory relapse (NCT01638546). 
This trial recently completed enrollment and analysis of the results are ongoing. 
The use of PARP inhibitors in combination with chemotherapy builds upon prior pre-
clinical data in lung cancer and other malignancies supporting the notion that PARP 
inhibitors potentiate the effect of other DNA damaging therapies. Currently, there are two 
studies investigating the use of veliparib (ABT-888) in combination with standard frontline 
chemotherapy (NCT01642251 and NCT02289690). E2511 (NCT01642251) is a Phase I/
II trial of cisplatin, etoposide, and veliparib conducted through the ECOG-ACRIN Cancer 
Research Group in which treatment naïve SCLC patients receive the combination for up 
to 4 cycles. Published results from the Phase I portion support the safety and tolerability 
of the combination, with partial or complete responses observed in 5/7 evaluable 
patients6. More recently, another first-line study was initiated to investigate carboplatin in 
combination with etoposide and veliparib which will also address the question of veliparib 
maintenance (NCT02289690).
To date, the activity of PARP inhibitors are best established in cancers with mutations 
in BRCA1/2 and other DNA repair genes that result in synthetic lethality in the setting 
of PARP inhibition (which provides a second “hit” to the DNA repair machinery). In fact, 
olaparib monotherapy was FDA-approved last year for patients with advanced, BRCA-
mutated ovarian cancer who have received three or more lines of chemotherapy. 
This was based on a trial that demonstrated a response rate of 34% and a median 
duration of response or 7.9 months. Studies of other PARP inhibitors have also shown 
striking single-agent activity with this class of drugs in a mutation-selected population. 
However, in SCLC, the mechanism of action and identification of potential biomarkers 
of response to these drugs is an area of active investigation. Likely the universal loss 
of RB1, with resulting dependence on E2F1, plays a role, as may the PARP-trapping 
effects of several of these drugs which cause direct cytotoxicity7. Our group has 
demonstrated that expression levels of several DNA repair proteins – both individually 
and as a “DNA repair signature” – are associated with response in pre-clinical models 
of lung cancer3. However, further validation in the clinical setting is warranted. 
Additional DNA damage response (DDR) targets also show significant potential as 
therapeutic targets in SCLC. These include checkpoint kinases that are activated 
in response to DNA damage and facilitate S and G2 checkpoint arrest, such as Chk1 
(Checkpoint kinase 1), Wee1, and ATR (Ataxia Telangiectasia and Rad3 related). Similar 
to PARP1, in our previous work we demonstrated elevated expression of Chk1 in SCLC1. 
SCLC may be particularly susceptible to inhibitors of Chk1 and other checkpoint kinases 
due to the near universal loss of TP53 in these cancers which make them dependent on 
other checkpoint controls in the cell cycle. Several drugs targeting these DDR proteins 
have entered clinical trials. For example, based on pre-clinical data demonstrating the 
potentiation of topoisomerase inhibitors by ATR inhibition, a Phase I/II trial of topotecan 
with VX970 (an ATR kinase inhibitor) has recently been initiated for SCLC (NCT02487095). 
Ongoing trials of PARP inhibitors and other molecules targeting DDR will help us to 
understand the activity of these compounds in patients with SCLC. Important questions 
that require further investigation include the optimal combinations of these drugs 
with existing therapies or other targeted inhibitors, strategies to manage associated 
toxicities (especially combinations with overlapping hematologic toxicities), and further 
development of candidate predictive biomarkers.
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Cyclin Kinase Inhibitors Cyclin dependent kinases (CDK) belong to a family of serine/ 
threonine protein kinases that are associated with an activating cyclin regulatory subunit. 
CDKs are involved in the regulation of fundamental cellular processes such as cell division 
cycle and gene transcription. Cell-cycle CDKs 1, 2, 4, and 6 are required for the correct 
timing and order of the events of the cell-division cycle. CDK7 is a component of the CDK-
activating complex that contributes to the assembly of CDK1/cyclin B. In addition, CDK7 
functions as a transcriptional CDK, as well as CDKs 8 and 9, which have been shown to 
be involved in gene transcription via regulation of RNA polymerase II activity. Deregulated 
CDK activity results in loss of cell-cycle checkpoint function and increased expression 
of antiapoptotic proteins, which has been directly linked to the molecular pathology 
of cancer [5]. Roniciclib (BAY 1000394) is a CDK inhibitor with low nanomolar activity 
against cell-cycle CDKs and transcriptional CDKs. It was evaluated in cell line-derived and 
patient tumor derived SCLC xenograft models. The compound strongly reduced tumor 
growth with T/C values between 0.12 and 0.19 showing that roniciclib was similar or even 
more efficacious as compared with cisplatin (T/C values between 0.06 and 0.55) [6]. In 
vivo, studies showed that roniciclib has more than additive efficacy when combined with 
cisplatin and etoposide. This compound is currently under investigation in a double-blind, 
placebo controlled phase II CONCEPT-SCLC trial to assess the safety and efficacy of 
roniciclib in combination with etoposide and cisplatin or carboplatin as first line therapy 
in patients with extensive SCLC after results obtained in a multicenter phase I study that 
evaluated 25 pre-treated SCLC patients [7]. 
Aurora Kinase Inhibitors The aurora kinases (A, B, and C) are serine/threonine kinases 
that have a key role in mitosis; in particular, aurora kinase A is essential for centrosome 
function and maturation, spindle assembly, chromosome alignment, and mitotic entry. 
Aurora kinase A localizes to the centrosomes and spindle poles and recruits the cyclin 
B1–CDK1 complex. Inhibition of aurora kinase A leads to abnormal spindle formation, 
mitotic defects, and cell death. Overexpression or amplification of this enzyme has been 
noted across a range of different tumor types and is linked with tumor progression and 
poor prognosis. Thus, inhibition of aurora kinase A is a rational target for anticancer 
treatment [8]. Alisertib exhibits favorable pharmacokinetic parameters and displayed 
tumor growth inhibition [9]. In Phase I dose escalation studies with alisertib given orally 
on a twice daily schedule for seven consecutive days, the maximum tolerated dose was 
defined predominantly by the occurrence of grade 3 or grade 4 myelosuppression and 
stomatitis, consistent with the antiproliferative effects of Aurora A inhibition. In a phase 
II study, the small-cell lung cancer cohort (see figure 1), ten (21%; 95% CI 10–35) of 
48 patients had an objective response to alisertib; all responders achieved a partial 
response. Response-assessable patients with small- cell lung cancer received a median 
of 2,5 cycles (range 1−21) of alisertib, with a median time on treatment of 1,5 months 
(range 0,1−11,7, IQR 0,9–3,7). The median duration of response was 4,1months (95% CI 
3,1 not evaluable), median progression-free survival was 2,1 months (95% CI 1,4–3,4), 
and median time to progression was 2,6 months (95% CI 1,4–3,8). The adverse effects of 
alisertib were generally manageable and included anemia, fatigue, alopecia, and various 
gastrointestinal disorders, and consistent with those noted in earlier trials of alisertib. 
Neutropenia was the most frequent drug related grade 3–4 adverse event; however, 
febrile neutropenia was recorded much less frequently. The antitumor activity noted in 
the SCLC cohort in this study (objective response 21%) seems similar to that reported 
with the current standard of care, topotecan (objective response 7–24%) [3]. Although 
the initial signal of activity noted in both the chemotherapy sensitive relapse population 
and in patients with refractory and chemotherapy resistant relapse is encouraging, to 
achieve more meaningfully improved outcomes, combinations of alisertib with other 
anticancer drugs should be studied. A follow-up, randomized, global phase 2 trial of 
alisertib plus weekly paclitaxel versus placebo plus paclitaxel as second-line treatment 
for small cell lung cancer is currently enrolling. 
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Small cell lung cancer (SCLC), which accounts for 15 – 20% of all lung cancer cases, 
represents one of the most aggressive subtypes based on rapid growth and early 
metastasis. Only limited therapeutic progress has been achieved in the recent decades 
and despite multiple mutations no targeted therapy for SCLC has been available by 
now. Based on preclinical data that revealed a relevant correlation between the immune 
system and SCLC the exploration of immune modulating agents appears to be attractive. 
First signals coming from randomized phase II trials showed an enhanced activity 
for the combination of the anti cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody 
ipilimumab with chemotherapy compared to chemotherapy alone. This combination is 
now under investigation in a couple of extended randomised trials. Besides ipilimumab 
also antibodies inhibiting the axis of programmed cell death protein 1 (PD-1) and 
programmed cell death protein ligand 1 (PD-L1) like nivolumab or pembrolizumab have 
shown encouraging results either alone or in combination with ipilimumab in heavily 
pre-treated patients with advanced SCLC. Ongoin or planned randomised trials will 
validate these signals in various therapeutic lines. A confirmation of these attractive 
early outcomes would have an substantial clinical impact. In particular in SCLC 
identification of new potential biomarkers will become of great importance because 
the PDL-1 status might not be the optimal predictive marker in this tumor entity. 
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Introduction Small cell lung cancer (SCLC) represents approximately 13% of all lung 
cancer diagnoses and its incidence has reduced over the last 20 years, although the 
frequency is rising in women due to increased use of tobacco [1]. It is a highly malignant 
neuroendocrine tumor of the lung and treatment of SCLC remains challenging because 
of its rapid growth, early dissemination and development of drug resistance during the 
course of the disease [2]. Without treatment, SCLC has the most aggressive clinical 
course of any type of pulmonary tumor, with median survival from diagnosis of only 2 to 
4 months [2]. With current chemotherapy regimens survival is prolonged, however, the 
overall survival at 5 years is only 5% to 10% [2]. Topotecan [3] is currently the only drug 
licensed in Europe and the Unites States for second-line treatment of SCLC, having been 
shown in a phase III trial to lead to longer overall survival and better quality of life than with 
best supportive care. In advanced SCLC, prognosis after failure of first-line treatment is 
very poor. No new targeted agents have shown meaningful benefit in this disease and, 
therefore, an urgent need exists for new active agents [4]. 
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this study etirinotecan was administered at 145mg/m2 every 14 or 21 days, and the 21 
day dosing schedule was found to be better tolerated and selected for further study. A 
phase II study that plans to study the effect of etirinotecan dosed every 21 days on PFS 
in patients with relapsed SCLC is currently recruiting (NCT01876446). Another 
formulation of irinotecan, MM-398, which is a nanoliposomal encapsulated formulation 
that packs nearly 80,000 irinotecan molecules in a 100nm liposome, is also being 
actively investigated in pancreatic, gastrointestinal, and other solid tumors.14 Results 
from the NAPOLI-1 trial, a phase III study in which patients with metastatic pancreatic 
cancer who were previously treated with gemcitabine, were randomized to receive either 
single agent MM-398 at 120mg/m2 every 3 weeks or a combination of 5-fluorouracil 
(5FU), leucovorin (LV) and MM-398 at 80mg/m2, or 5-FU/LV alone, were recently 
presented.15 The primary objective of this study was OS and in the intention to treat 
analysis, this was significantly improved in the MM-398/5FU/LV combination arm 
compared to the 5FU/LV arm (median OS 6.1 months vs. 4.2 months, HR-0.57, 
p=0.0009). Although there is currently no clinical data regarding the efficacy or safety of 
these newer drugs in patients with SCLC, considering that taxanes, anthracyclines, and 
DNA topoisomerase inhibitors are each individually active in SCLC, and that newer agents 
such as these have shown some positive preliminary results in other cancers - there is 
hope and optimism that over the next few years we will witness substantial progress in 
the management of SCLC. Overall, the need for developing and implementing well-
designed biomarker driven clinical studies to investigate the role of these and other novel 
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MS17.01 Overview: Immunotherapy in Mesothelioma Anna K. Nowak School of 
Medicine and Pharmacology, University of Western Australia, Perth/WA/Australia
Immunotherapy has recently confirmed its place as an important treatment strategy for a 
number of solid tumors, including melanoma and non-small cell lung cancer. Checkpoint 
blockade, in particular, has emerged as an ‘off-the-shelf’ immunotherapy which does not 
rely on known tumor antigens, costly and time-consuming individualised preparation of 
autologous tumor, or viral vectors. This overview will cover the history of immunotherapy 
in mesothelioma, recent reported clinical trials, trials in progress, and current cutting 
edge research with the potential for translation. Although mesothelioma is not classically 
considered immunogenic, there is abundant evidence that it is recognised by the 
immune system. Earlier studies described the relationship between tumour infiltrating 
lymphocytes and prognosis, occasional spontaneous remissions are seen, and there 
have been reports of low rates of responsiveness to a range of immunotherapies 
over the past 30 years. There is also a body of work demonstrating impaired immune 
responsiveness in people with mesothelioma and an immunosuppressive intratumoral 
milieu. Specifically, NK cell activity is reduced, CD4+ lymphocyte numbers are reduced, 
and dendritic cell function is impaired (Cornwall S, unpublished data), amongst other 
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University School of Medicine, St Louis/United States of America
Small cell lung cancer (SCLC) accounts for nearly 15% of newly diagnosed lung 
cancers.1 With the advent of tyrosine kinase inhibitors, the last decade has witnessed 
remarkable improvements in the outcomes of patients with non-small cell lung cancer 
(NSCLC). However, outcomes in patients with SCLC continue to remain dismal. Currently 
approved targeted therapies have minimal role in the management of SCLC, since unlike 
NSCLC, targetable tyrosine kinase alterations are rarely witnessed in SCLC.2,3 Cytotoxic 
chemotherapy has therefore continued to remain the standard of care for SCLC. SCLC is 
usually very sensitive to first-line platinum based therapies.4 Nevertheless, these 
responses are seldom durable and majority of patients relapse within weeks to months 
of treatment completion. Relapsed SCLC is a tough disease to treat and barely responds 
to conventional therapies. There is hence is an urgent need to develop novel therapeutic 
strategies that are capable of improving survival in patients with SCLC - particularly those 
with relapsed disease. Several new chemotherapeutic agents are currently being 
developed and actively studied in various solid tumors. The objective of this article is to 
highlight some of these newer chemotherapies and discuss their potential relevance in 
the management of SCLC. Eribulin mesylate is a non-taxane halichondrin B analogue 
derived from the marine sponge Halichondria okadaic.5 Eribulin sequesters tubulin and 
inhibits mitotic spindle formation, leading to cell cycle arrest in G2-M and eventually cell 
death. Eribulin is currently FDA approved in the United States for the management of 
metastatic breast cancer in patients receiving prior treatment with at least two 
chemotherapy regimens, including an anthracycline and a taxane. In the phase III 
EMBRACE trial, as a part of which 762 women with breast cancer were randomized to 
receive eribulin or chemotherapy of the treating physician’s choice, overall survival (OS) 
was significantly improved with eribulin (13.1 vs. 10.6 months, HR 0.81 p=0.041).6 Eribulin 
as single agent and in combination with erlotinib were shown to be active and well 
tolerated in patients with NSCLC treated with prior platinum based therapies.7 In the 
study by Spira and colleauges, eribulin was dosed at 1.4mg/m2 on days 1 and 8 of a 21 
day cycle (similar to breast cancer dosing schedule) and in a second cohort of patients 
at 1.4 mg/m2 on days 1, 8 and 15 of a 28 day schedule.8 Among these, the 21 day dosing 
schedule was shown to be better tolerated and active with a median OS of 9.4 months in 
the second line setting for NSCLC. However, when used in combination with a second 
agent, the maximum tolerated dose (MTD) of eribulin was much lower. In a phase Ib/II 
study involving pretreated NSCLC patients, the MTD of eribulin was 0.9mg/m2, with 
500mg/m2 of pemetrexed, administered on day 1 of a 21 day cycle.9 Unfortunately, the 
combination was tolerable but showed no therapeutic benefit at this dose. Aldoxorubicin, 
formerly known as INNO-206, combines a molecular linker that allows doxorubicin to bind 
covalently to serum albumin upon intravenous administration.10 This formulation releases 
doxorubicin in the acidic tumor microenvironment. Aldoxorubicin is currently being 
actively investigated in the management of soft-tissue sarcomas and glioblastoma. In a 
phase Ib/II study by Chawla and colleagues, the MTD of aldoxorubicin was 350mg/m2 
administered every 21 days.11 The drug showed a partial response rate of 20% and stable 
disease rate of 40% in 25 patients with advanced chemotherapy refractory cancers, 
among which most patients (68%) had soft tissue sarcomas. Aldoxorubicin was 
considered to be safe and efficacious in these patients. Currently, aldoxorubicin is being 
studied as part of an ongoing randomized phase IIb trial in patients with relapsed/
refractory SCLC (NCT02200757). This study will compare progression free survival (PFS) 
between patients receiving aldoxorubicin at a dose of 230mg/m2 every 21 days, with 
those receiving topotecan. Irinotecan is a chemotherapeutic agent known to be active in 
SCLC. SN38 is the active metabolite of irinotecan, which through its inhibitory action on 
DNA topoisomerase I induces DNA breaks and inhibits repair. Etirinotecan pegol is a 
formulation designed to provide prolonged systemic exposure to SN38.12 In a phase I 
dose escalation study, 66 patients received etirinotecan on three different dosing 
schedules and 115mg/m2 administered on days 1, 8 and 15 of 21 day cycles was 
established as the MTD. Diarrhea was observed in 5 patients at the 115mg/m2 dose 
level, with one patient experiencing grade 3 or higher diarrhea. The cholinergic diarrhea 
that is seen with irinotecan was not observed with etirinotecan. The drug was also shown 
to induce partial responses in patients with various cancers including SCLC. Etirinotecan 
was also recently reported to be active in heavily pretreated ovarian cancer patients.13 In 
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Research, National Cancer Institute, Bethesda/MD/United States of America
Mesothelin is a tumor differentiation antigen that is highly expressed in several cancers, 
including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. 
The limited expression of mesothelin on normal human tissue and its high expression 
in many solid tumors make it an attractive candidate for cancer therapy. Several 
drugs targeting mesothelin, including immunotoxins (SS1P, RO6927005), a chimeric 
monoclonal antibody (Amatuximab), an antibody drug conjugate (Anetumab Ravtansine), 
and a tumor vaccine (CRS-207), are in various stages of development to treat patients 
with mesothelin-expressing tumors. The first anti-mesothelin therapeutic agent to enter 
the clinic was the immunotoxin SS1P and it demonstrated that mesothelin could be 
successfully exploited as a target for cancer therapy and has led to a broad interest in 
developing different approaches for mesothelin immunotherapy treatment of solid tumors 
including malignant mesothelioma. Immunotoxins are targeted anti-cancer therapeutics 
that kill cancer cells by inhibition of protein synthesis using a cytotoxic bacterial toxin 
payload. In a phase I clinical trial SS1P had limited anti-tumor activity because it was 
immunogenic and patients develop antibodies to the drug limiting treatment efficacy. 
However, we have recently shown that co-administration of SS1P with a lymphocyte 
depleting regimen of pentostatin and cyclophosphamide can delay anti-drug antibody 
formation, increasing the number of treatment cycles that patients can receive and 
resulting in durable responses in heavily pre-treated mesothelioma patients. In addition, a 
new generation of immunotoxin molecules with reduced immunogenicity and non-specific 
toxicity have been developed through protein engineering techniques. RO6927005 is 
a next generation anti-mesothelin PE-fusion protein that has been protein-engineered 
to maximally reduce its immunogenicity so that patients can receive multiple cycles of 
the drug. In pre-clinical studies RO6927005 has increased activity compared to SS1P 
against mesothelioma tumor cells directly obtained from patients as well as activity in 
mesothelioma tumor models either alone or in combination with chemotherapy. A phase I 
clinical trial of RO6927005 has just been initiated for patients with mesothelin expressing 
cancers including malignant mesothelioma. There are other antibody based therapeutics 
in advanced clinical development for treatment of malignant mesothelioma including 
amatuximab and anetumab ravtansine. In a phase II single arm trial of unresectable, 
chemotherapy naïve patients with pleural mesothelioma, amatuximab with pemetrexed 
and cisplatin was well tolerated with objective tumor response or stable disease rate of 
90% by independent radiologic review. Based on these results a registration front-line 
study of amatuximab with pemetrexed and cisplatin versus pemetrexed and cisplatin alone 
has been initiated for treatment of newly diagnosed patients with pleural mesothelioma. 
Anetumab Ravtansine (BAY 94-9343) is an antibody-drug conjugate in which a human 
anti-mesothelin monoclonal antibody is conjugated to the maytansinoid tublin inhibitor 
DM4. In preclinical studies it showed significant anti-tumor activity against mesothelioma 
cell lines as well as mesothelioma patient derived xenografts. Anetumab Ravtansine 
is currently being evaluated in patients with mesothelin expressing cancers who have 
failed standard therapies and represents a potential therapeutic option for treatment of 
patients with mesothelioma given the high and uniform expression of mesothelin in this 
tumor. Hopefully, these different approaches to exploit mesothelin for immunotherapy 
of malignant mesothelioma will result in new treatment options for these patients. 
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In recent years immunotherapy has become a new standard in the treatment of malignant 
diseases. Most clinical evaluated treatments like anti-PD1 aim to reactivate the cytotoxic 
T-cell response directed against the tumor (CTL-t ). A requirement for this treatment 
to be effective is the presence of CTL-t within the tumor as reviewed by us recently 
[Aerts, 2013]. CTL-t formation is dependent on a number of factors which are inhibited 
by tumor-derived factors and tumor-induced immune suppressive cells, precluding 
patients to respond to the PD-1 checkpoint blockade pathway. Knowing and bypassing 
these inhibition pathways of the tumor increases the number of responding patients. For 
instance, in melanoma it has been shown that combination treatment of anti-PD-1 and 
anti-CTLA-4 almost doubles the patients benefitting from checkpoint blockade inhibitors. 
 
However the number of inhibition pathways is diverse and also changeable according 
to the act – react principle. The blockade of one inhibitory pathway of the tumor may 
ultimately lead to the upregulation of another inhibitory pathway. This complex interplay 
inhibits the formation of new CTL-t and an exhaustion of the CTL-t present in the tumor. 
That is why cell based therapy, either with ex-vivo generated T-cells or stimulated dendritic 
cells (DC), precluding a number of inhibitory mechanisms in the patient is an alternative 
to increase the number of responding patients and thus the efficacy of immunotherapy. 
 
Mesothelioma is an aggressive neoplasm, with highly specific growth features 
making it a distinctive malignant tumor from other cancer types. One of the key 
immunological features in mesothelioma is the abundant immunosuppressive 
environment it is creating. There is a large infiltration of regulatory T-cells, 
immunosuppressive macrophages and myeloid derived suppressor cells (MDSC). 
Furthermore, the tumor milieu negatively influences immune activation for instance 
by the presence of hypoxic areas. , tumor metabolites (e.g. arachidonic acid), and 
suppressive cytokines and chemokines negatively influence the immune activation. 
 
changes. Regulatory T cells and inhibitory cytokines within the tumour may contribute to 
an immunosuppressive milieu [1]. The presence of CD8+ infiltration within the tumour is 
a predictor of more favourable outcomes [2]. More recently, mesothelioma, in particular 
sarcomatoid subtype, was shown to overexpress PD-L1 and to predict poor prognosis 
[3] Historically, response rates below 20% have been seen in clinical trials of systemic 
and intrapleural interferons, generally accompanied by high toxicity [4]. Similarly, other 
cytokines such as Interleukin-2 or GM-CSF have shown either poor response rates, low 
feasibility, or excessive toxicity [5]. Gene therapy approaches have similarly shown very 
low response rates and are technically demanding [6]. More recent trials have focussed 
on antigen-specific approaches using the known tumor antigens mesothelin and WT-1, 
and the use of checkpoint blockade. Immunological checkpoints are inbuilt mechanisms 
that negatively regulate the size and duration of an immune response, both during 
induction of the T cell response and during the effector phase of the response, in tumor 
tissue. Their normal function is to prevent excessive and ongoing T cell activation which 
may lead to overwhelming autoimmunity. Many tumors, including mesothelioma, express 
ligands for these checkpoint molecules, allowing tumors to negatively regulate the anti-
tumor immune response and thus evade elimination [3]. The expression of checkpoint 
molecules including Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) and PD-1 on T cells, 
and the expression of ligands such as PD-L1 and PD-L2 on tumors, has allowed the 
development of antibody blockade which can prevent downregulation of the anti-tumor 
response by inhibitory signals, hence ‘taking off the brakes’ and facilitating a more 
effective host response to tumor. CTLA4 is expressed on T cells after activation, and 
counter-regulates the T cell activation which normally occurs when the co-stimulatory 
receptor CD28 is engaged. Whilst ligation of CTLA4 normally restricts ongoing T cell 
co-stimulation and activation, abrogating anti-tumour immunity[7], CTLA4 blockade 
using monoclonal antibody inhibitors can allow the endogenous anti-tumour response to 
proceed unopposed. The first report of a clinical trial of this drug class in mesothelioma 
was published by Calabro and colleagues in 2013 [8], with results showing some 
similarities to the first trials of CTLA4 blocking antibodies in melanoma. Durable partial 
responses were seen in two patients, with a further seven of 29 patients experiencing 
prolonged stable disease. The disease control rate was 31%, median progression free 
survival was 6·1 months, and almost 40% of participants were alive at two years. The 
phenomenon of early progression followed by a lengthy partial response was seen in one 
patient. The authors noted that the progression free survival and two year survival results 
were better than expected for this population, and although partial responses were 
uncommon they were long lasting. This study provided the rationale for the subsequent 
testing of tremelimumab in a large randomised phase II study in mesothelioma which has 
recently completed recruitment (NCT01843374). A recent presentation at the American 
Association for Cancer Research (AACR) reported on results from the mesothelioma 
cohort enrolled in the KEYNOTE-028 study. This trial used PD1 axis blockade with 
pembrolizumab in patients with mesothelioma selected to express the PD-L1 ligand. Of 
25 patients treated, partial response was observed in 7 (28%) and stable disease in 12 
(48%), giving a disease control rate of 76% with a tolerable toxicity profile. Many of the 
responses seen were profound and durable[9], highlighting the enormous potential of 
this approach in mesothelioma. Finally, mesothelin is highly expressed on mesothelioma 
cells, predominantly of the epithelioid subtype. A number of methods of targeting 
mesothelin are under development and clinical testing. The anti-mesothelin immunotoxin 
SS1P has been administered together with lymphodepletion using cyclophosphamide 
and pentostatin. Major responses were observed in a subset of patients in a small 
clinical trial (n=10), notably with some reports of immune pseudoprogression before 
eventual treatment response. Other treatments using mesothelin as a target include 
CRS-207, a live attenuated listeria monocytogenes strain which expresses mesothelin, 
and MORAb-009, a monoclonal antibody that targets mesothelin. Immunotherapy in 
mesothelioma remains very immature. Results of PD1 and/or PD-L1 blockade in larger 
numbers of treated patients are needed, and phase III studies will be important to define 
any benefits. Combinations of checkpoint blockade have shown outstanding efficacy 
in other cancer types and must be tested in mesothelioma. Underpinning these trials 
must be the search for biomarkers of treatment efficacy. Technologies such as tumor 
sequencing also have the potential to identify neoantigens with immunological reactivity 
in individual patients, an approach that could lead to the development of personalised 
vaccines, potentially in combination with other immunotherapies. 
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about screening as well as the risk of lung cancer, in order to operate LD-CT screening 
effectively. GLCC poll in 2013 showed that in Australia and Great Britain current smokers 
are less aware of the symptoms of lung cancer than former smokers and people who 
have never smoked regularly. Even if screening system was developed, the risk of death 
due to lung cancer can not be reduced unless the people of high risk group do not visit to 
appropriate screening service that has been ensurring quality. In addition, Assessment 
of smoking and the provision of smoking cessation services must be part of any lung 
cancer screening program. Advocate movement based on research is urgently needed 
to develop approaches that will maximize cessation rates among smokers undergoing 
screening. Even more, it is required to enlightenment for smokers in cooperation with 
the international community by utilizing a variety of public relations means. In November 
2014, lung cancer awareness month, Japan Lung Cancer Society approved the Kyoto 
Declaration. This declaration has been included that the tackle in the prevention of lung 
cancer and development of effective treatment by alliance with lung cancer Society, lung 
cancer patient, government, people, medical personnel, advocacy organizations, and 
healthcare industry. While the evidence from the NLST supports the implementation of 
lung cancer screening for high-risk individuals via LDCT, the experience to date also must 
validates the prior recommendations around institutional approaches to lung cancer 
screening, including the need for the availability of multidisciplinary clinical teams. In order 
to advocate making responsible case, several ways should be developed like a “Shared 
Decision-Making” toolkit(s) by the Lung Association that would act as a “consumers’ 
guide” for those considering lung cancer screening. After examine such a tool, it is also 
one of the ideas to take advantage according to the circumstances of each country. 
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The development and release of scientific validation and national guidelines and 
recommendations for lung cancer screening over the past several years has resulted 
in a profound paradigm shift in clinical opinion and outcomes for those at high risk for 
lung cancer. No other cancer is poised to realize the scale and magnitude of benefit that 
is now being reported for the lung cancer community. Given the import and potential 
of this opportunity, it was evident that there was a lack of vigor and focus by public 
health leadership to move aggressively and to take the next steps to develop programs 
and guidance to ensure the safe, responsible and equitable implementation of lung 
cancer screening and to bring proper health messages to those at risk. Lung Cancer 
Alliance (LCA), a national non-profit cancer advocacy organization, recognized this 
absence and stepped in to bridge these gaps and create an environment to support the 
adoption of best practices and consumer safety measures, as well as public service 
messaging about screening risk and benefit. Immediately upon the scientific validation 
of the mortality benefit of lung cancer screening, LCA moved rapidly to convene a multi-
disciplinary team of health care professionals to devise a blueprint or framework to guide 
the responsible implementation of screening. The overarching goal embedded in this 
discussion was to ensure the public understood that they had right to know they could be 
risk for lung cancer and that they had a right to responsible care. This was particularly 
important after the National Cancer Institute (NCI) announced it was halting the National 
Lung Screening Trial (NLST) as the end point was reached proving at a minimum a 20% 
mortality benefit. And thus, the LCA National Framework for Excellence in Lung Cancer 
Screening and Continuum of Care was born in February 2012. Embedded within this 
National Framework are the following guiding principles and elements: 1. Increasing the 
public’s awareness about risk and their rights to responsible care, including educational 
resources and campaigns to spread this message; 2. Creating a framework of agreed 
upon best practices to guide the safe and responsible development of a screening center 
of excellence medical center network that then leveraged member resources to support 
each other; 3. Creating collaborations and relationships with other professional and 
advocacy societies and outreach to public and private payers to effect change at the 
policy level. Today, there are currently 350 hospitals within the LCA National Network 
of Screening Centers of Excellence who have committed to following certain best 
practice principles of care. Dozens of other medical centers continue to contact LCA for 
technical assistance and are in varying stages of program development. LCA launched 
an ad campaign in 2014 to raise risk awareness which received 90 million impressions 
through TV, print, and social media in 15 paid markets and about 20 PSA markets. In 
addition, LCA has helped successfully lead first-ever public health coalitions to advocate 
for coverage and other policy changes linking together diverse partnerships. This has 
included engaging the current screening centers of excellence in communication with the 
US Preventive Services Taskforce (USPSTF), Congress and other regulatory agencies, 
working with an alliance of stakeholders including ACR and STS to encourage swift action 
on the part of Centers for Medicare Medicaid Services (CMS) to ensure coverage for at-
risk seniors, and communicating with lawmakers and encouraging them to take oversight 
action to ensure public health strategies by our Health and Human Services (HHS) 
Departmental move forward as efficiently, effectively and equitably as possible. With the 
finalization of the USPSTF recommendation for lung cancer screening and coverage for 
Medicare beneficiaries, lung cancer screening is now a covered benefit for those at high 
risk, with no cost sharing, co-pays or deductibles. The LCA experience is an example of 
how an agile and responsive patient advocacy charity can provide critical institutional 
support and a national public health blueprint for the scale up of a new preventive service 
– that is patient focused and patient driven. By creating what in effect is a national pilot 
program for lung cancer screening, LCA proved that responsible screening and outreach 
could be reproduced in medical centers all across the country at the community level. 
And by working closely and directly with screening centers – we have established a 
deeper understanding of their needs which in turn has helped us tailor our continued 
outreach and support to better suit their needs. Our consumer-targeted awareness 
Some early phase studies showed a possible clinical effect of immunotherapy in 
mesothelioma. For instance, checkpoint inhibition with anti-CTLA-4 and anti PD-1 in 
a subgroup of patients showed some benefit which is now further evaluated in larger 
studies in second and further line treatment [Calabro 2013, NCT01843374 results 
pending, NCT02399371 amongst others] . Although it can be questioned whether that is 
the right setting to determine clinical benefit in placebo controlled trials. Anti mesothelin 
antibodies also did show clinical efficacy which is now investigated further [Hassan 2010]. 
 
Cell based therapy may increase efficacy of immunotherapy also in mesothelioma. 
The choice of the tumor associated antigens (TAA) to induce a CTL-t is critical, 
considering the diverse and changing repertoire of TAA. Genetically altered T-cells, 
directed against mesothelin or Wilms tumour-1 (WT-1) have been developed and 
are tested in the clinic [NCT02414269 amongst others]. Also DC therapy, being the 
most powerful initiator of an immune response, is also tested. An advantage of DC, 
apart from the induction of a natural CTL-t activation, is the ability to load the DC 
with a pluripotent antigen mixture. DC therapy with an autologous tumor cell lysate 
demonstrated promosing results [Hegmans 2010] and an allogeneic tumor cell 
lysate is now tested as tumor associated antigen source in the clinic [NCT2395679]. 
 
In the patient stimulation of DC seems an attractive option and has been investigated but 
may be hampered by the immunosuppressive environment created by the tumor [Powell, 
2006]. A new concept with in vivo activation of DC with mesothelin loaded listeria bacteria 
is now investigated in mesothelioma [NCT01675765]. DC treatment can also be optimized 
with the addition of different checkpoint activators or inhibitors [Lievense WCLC 2015] 
 
Apart from the immune activation strategies, investigations should focus on how to diminish 
the highly immunosuppressive effect of mesothelioma. Results of our trial on combination 
treatment with ex vivo matured DC loaded with autologous tumor cell lysate and regulatory T 
cell (Treg) depletion showed a reduction in circulation Treg [data submitted for publication]. 
 
We are in the field of a whole new changing treatment paradigm for mesothelioma. 
Immunotherapy will be one of the new treatment options. Much effort has to be invested 
to determine the optimal combination treatment for particular patients. Dendritic cell-
based therapy seems an attractive option to generate a more robust immune response 
that can serve as a backbone for combination treatment.
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MS18.02 Advocates Making a Responsible Case for High-Risk Screening 
Toshiyuki Sawa1, Kenji Eguchi2, Yoichi Nakanishi3, Kazuhiko Nakagawa4, Tetsuya 
Mitsudomi5 1Cancer Center, Gifu Municipal Hospital, Gifu/Japan, 2Teiky Univ School of Med, 
Tokyo/Japan, 3Kyushu University, Fukuoka/Japan, 4Medical Oncology, Kinki University Faculty 
of Medicine, Osaka-Sayama/Japan, 5Division of Thoracic Surgery, Department of Surgery, 
Kinki University Faculty of Medicine, Osaka-Sayama/Japan
Purpose: The purpose is to discuss how to advocate to make a Responsible Case for the 
Screening of lung cancer high risk group. Background and fact: Screening is looking for 
cancer at an early stage before a person has any symptoms. For the better screening, 
efficiency is determined as well as sensitivity and specificity. In these forty years, three 
screening tests have been studied to find if they decrease the risk of dying from lung 
cancer. Chest X-rays were evaluated at the earliest time in the lung cancer screening 
history while it is no longer recommended for screening.. Sputum cytology is a procedure 
in which a sample of sputum is viewed under a microscope to check for cancer cells, 
so it is required to good mucus that is coughed up from the lungs. Now, it is used as a 
non-invasive examination of a patient with a sputum symptoms rather than screening. 
Low-dose spiral CT (LDCT) scan is a special kind of x-ray that takes many pictures as 
you lie on a table that slides in and out of the machine. A computer then combines 
these pictures into a detailed picture of a slice of your body. In this procedure, low-dose 
radiation is used to make a series of very detailed pictures of areas inside the body with 
reduction of radiation exposure.. The National Lung Screening Trial (NLST) provided the 
first evidence that lung screening can reduce cancer deaths, when data from the study 
was published in 2011. The National Lung Screening Trial began in 2002 and enrolled 
more than 53,000 participants who were current or former heavy smokers, ages 55 
to 74. The trial randomly assigned people to receive lung screening either by low-dose 
helical CT scans or chest X-rays. The trial was sponsored by the National Cancer Institute, 
and the University of Michigan was one of 33 places across the country to take part. 
U-M enrolled 850 participants. The study found that screening individuals with low-dose 
CT scans could reduce lung cancer mortality by 20 percent compared to chest x-ray. 
Now, it is concluded that the only recommended screening test for lung cancer is LD-
CT, which result Medicare’s decision to cover lung cancer screening in US. However, 
the evidence at the present time in LD-CT screening is only one report from US, the 
results of additional studies from Europe (NELSON) and Japan (Sagawa team) is awaited. 
Discussion: To raise up the efficiency of screening, It is important who is suitable as 
subjects. According to “the Lung Cancer Screening Guidelines and Recommendations” 
by CDC, many organizations in US definite that lung cancer screening with LDCT is 
recommended for people of age 55 to 74 years with ≥  30 pack year smoking history, 
who either currently smoke or have quit within the past 15 years while some difference 
of subjects who are in relatively good health or age 55 to 80 years across organizations. 
However, major obstacles are lying that smokers are lack of awareness or information 
for risks and benefits with attention to the specifics of each person making a decision 
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advanced stage and normally receive aggressive treatments. It can be very difficult 
to cope with a diagnosis of lung cancer, both practically and emotionally, because the 
news can generate a wide range of emotions: fear, anxiety, anger, confusion, that could 
worsen the situation if patients are younger women because they often have to face 
challenges different than other patients. The worst are mothers of children or teenager, 
telling them the diagnosis is hard and traumatic, it means dealing with their emotions 
and reactions and helping them to face a daily routine affected by this event. Many feel 
unable to manage changes caused by lung cancer and this may create a state of distress 
that is increasingly recognized as a factor that can reduce the quality of life of patients. 
Moreover they feel hopeless, worried and sad about the uncertainty of their future and 
their children’s future. The disease and its treatments often may cause physical changes 
in the way they look, which is difficult to cope with and may affect the way women feel 
about themselves. Such body changes can diminish their self-esteem and change the 
way they relate to other people, especially family and friends. Disease progression, 
symptoms orside effects may force women to change the daily management of their 
family and house. The consequence is the inability to keep the pace of motherhood 
and to keep on doing things like they were used to do (for example working around 
the house), especially if children are young and energetic.These physical issues may 
also jeopardize their career and in many situations forcing them to quit job, increasing 
the frustration of losing their independence. Lung cancer may affect the dynamics of 
intimate relationships. This is connected to body image changes,in whichwomen may 
feelless attractive or desirable by their partner. Common symptoms of lung cancer, 
such as cough, fatigue or shortness of breath may affect their sexual life. Women with 
lung cancer have a number of unmet needs that require assistance. It is important to 
identify them efficiently and effectively so that patients can be provided with appropriate 
resources so they can find help. Physical needs are experienced by the majority of 
women, but emotional, psychological, social, spiritual, practical and informational needs 
are also present for some. Interventions must be developed to assist these women to 
cope with these needs and worldwide several gender focused educational and support 
programs have already been designed with this purpose. References:
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The Community Hospital Centers of Excellence (COE) seal and program is a paradigm 
shift in lung cancer care to greatly increase positive patient outcomes. This necessity 
is driven by the reality that the 5-year patient survival rate has remained unchanged 
and abysmally low at approximately 16% for 40+ years. 80% of lung cancer patients 
in the US receive treatment by a general oncologist at community hospitals, most 
often without disease-specific cancer doctors. Unfortunately, generalists lack access 
to the most up-to-date knowledge to specifically treat lung cancer, the world’s number 
one cancer killer that takes more lives annually than the other top five cancer killers 
combined. Because of the tremendous volume and pace of scientific discovery, it is 
impossible for community general oncologists to stay abreast of emerging treatment 
options, the complexities of each disease state (lung, breast, colon, etc) and practice-
changing clinical information. Due to this gap generalists cannot fully inform patients 
about all treatment options that exist, are expected and used every day by specialists at 
academic institutions where the enhanced standard of care includes molecular testing, 
campaigns have shape a culture of consciousness among the public which in turn have 
allowed us to better design educational materials. LCA is committed to continuing to 
build knowledge about the importance of screening among the at-risk public, healthcare 
providers, and policymakers alike. LCA is proud to have seized an important moment in 
time to have built a foundation for responsible care when people at risk for lung cancer 
needed it most.
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For a long period of time, lung cancer has been considered a malignancy affecting 
only men, but epidemiological data have shown a dramatic increase of the incidence 
among women and the gender gap has been narrowing steadily since the 1980s,mainly 
as a consequence of the huge spread of tobacco consumption during the past 60 
years. Although more men are diagnosed with lung cancer, incidence is leveling off or 
decreasing in men, but is increasing among women.Lung cancer is the leading cause of 
cancer death for women in the United Statesand other countries, with about 105,600 
new cases and 71,000 estimated deaths in 2015 for the female gender, whereas in 
European countries lung cancer is predicted to kill 87,500 women in 2015, but such 
predictions require caution. In Europe, for the first time in 2015 (unlike in the U.S. where it 
has been happening for some decades)lung cancer death rates in females are expected 
to overtake those of breast cancer. This trend is largely driven by women in the UK and 
Poland, confirming that the continuous increase in lung cancer mortality among women 
represents a challenge for cancer control. This disease is classified as a significant global 
women’s health issue. Unfortunately, women still lack awareness and knowledge about 
lung cancer, it is not considered a priority because most of them still believe that breast 
cancer is the number one cancer in women. They have misperceptions and in most 
cases they are not concerned because they are too young or are non-smokers. Gender 
differences in terms of susceptibility to carcinogens have been reported and several 
studies suggestthat women are more vulnerable to tobacco carcinogens than men, 
however this data remains controversial. Although smoking increases the risk of lung 
cancer dramatically, it’s not the only cause. Freedman et Al reported on a cohort of nearly 
500,000 individuals aged from 50 to 71 years, in which asignificant increase of cases 
occurred in women who never smoked, compared with male non-smokers. The rate of 
lung cancer in those who never smoked is higher for women in every population, counting 
approximately 20% of women who never smoked. The reason is unclear, but studies 
suggest that the hormonal status may be one potential explanation and researchers are 
devoting energies in this area to better understand the implication of gender differences 
in epidemiology, pathogenesis, prognosis and tumor response, considering that women 
have better survivalrates than men at any stage regardless of the type of lung cancer 
and the therapeutic approach. At the moment there are no gender-based approaches on 
diagnosis and treatment for lung cancer, but an improvement in understanding genetic, 
metabolic and hormonal factors could stimulate research towards further personalized 
gender-based investigations. Despite recent advances in treatment, lung cancer still 
remains a largely incurable disease with a physical impact upon women, as well as social, 
psychological, practical and emotional consequences. The diagnosis and subsequent 
treatments are traumatic events for patients and their loved ones. Serious disruptions in 
social and psychological aspects of their quality of life have been reported and younger 
women are most at risk. This type of cancer is normally associated with older people, 
where the disease is often diagnosed accidentally, while in young adults it is relatively 
rare, the incidence has been found to be around 1.2% to 6.2% (under 40 years), 5.3% 
(under than 45 years), and 13.4% (under 50 years),but previous reports have shown 
trends of increasing incidence rates of lung cancer among young patients. Unfortunately 
in this group this malignancy is more common in women, who are diagnosed at an 
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care, all populations affected by lung cancer--insured, uninsured, underserved, 
geographically disadvantaged--will benefit. COE will clearly be able to track outcomes 
and will define success through lives extended and in some cases, saved. By 
redesigning lung cancer patient health care delivery, COE provides an unprecedented 
coordination of care using technology and access to existing expertise/knowledge. 
Keywords: Multidisciplinary Care, Patient Survivablity, Improved Standard of Care, 
Access
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MS19.01 Nursing Challenges in Clinical Trials 
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Nackaerts1, Johan Vansteenkiste2 1Respiratory Oncology, University Hospital Ku Leuven, 
Leuven/Belgium, 2Respiratory Oncology Unit - Dept Pulmonology, University Hospital Ku 
Leuven, Leuven/Belgium
Background: The model of clinical trials in lung cancer has evolved quite dramatically 
over the past years. Expanded phase I trials in biomarker-driven populations are a new 
paradigm of accelerated drug approval. Enrolling patients in these clinical trials creates 
several new challenges. Clinical Research Nurses (CRNs) play an important role in 
recruitment, actual drug delivery, and monitoring of this whole process. Methods: Identify 
the different barriers to recruitment that CRNs face with these clinical trials. Barriers 
to participation can be patient-related, physician-related or tissue-related. Review of 
literature was the basis for the patient- and physician-related barriers. To identify the 
tissue barriers, we studied our own database. We also present practical tips to overcome 
these barriers out of own expertise in the field. Results: Patients’ barriers to participate 
in clinical trials include individual characteristics, practical issues, and attitudes. 
The most common barriers are the individual characteristics: cultural background, 
health literacy, ethnicity, and age. Lack of knowledge, insurance coverage, extra 
appointments, reimbursement, and patient ineligibility are typical practical barriers. 
Attitudinal barriers are reluctance to randomisation, fear for side effects, and efficacy 
concerns (e.g. allocation to placebo) (1-3). To overcome these barriers the trial should 
be explained clearly. Patient should be supported in what may be a difficult decision 
and should not be pressured to do so. Dedicated CRNs may help with monitoring the 
recruitment process, providing additional information, and obtaining informed consent 
(1). The process of informed consent is the optimal time to define clearly the terms 
of the clinical trial, and to explain the sometimes difficult to understand medical and 
legal terms in the informed consent document. Optimally, this should lead to good 
understanding by the patient of the potential benefits and risks (4). Main physicians’ 
barriers are lack of time due to competing priorities, insufficient staff and training to 
meet the ever increasing procedures from competent authorities or institutional review 
boards and finance departments, worry about the impact on the doctor-patient relation, 
concern for patients, and lack of reward and recognition. Lack of time is considered a 
major barrier. Doctors experience time pressure from their usual clinical practice and 
management duties. Recruitment, the consent process, and the follow up of clinical trials 
on top of that demand a large piece of extra time (1;4;5). Lack of support staff, for 
example CRNs, can also account for poor recruitment. A stable clinical research team is 
likely to be advantageous. CRNs should not only have expert clinical and well developed 
critical thinking skills, but be well acquainted with the complex scientific, regulatory, 
and ethical aspects of clinical research (6). Well trained and experienced CRNs truly 
are “PI-extensions”. By monitoring the clinical activity to find possible candidates for 
trials, they support the physician with recruitment, and later on with the follow-up of 
included patients. Over the last years, we saw a major progress in the treatment of 
advanced non-small cell lung cancer, largely due to new targeted agents, monoclonal 
antibodies, and immunomodulatory agents. Both in clinical practice, as well as in clinical 
trials, the availability of tissue for biomarker analysis – in order to make the best choice 
for the patient – is crucial. Tissue availability is a new important barrier to clinical 
trials, as we noted from our own experience (7). Moreover, central lab confirmation of 
an already known biomarker, is often requested before the patient is allowed to start 
therapy, leading to sometimes important delays. In our respiratory oncology trial unit, 
we analysed of our molecular database regarding this barrier (7). The mean waiting time 
between signing informed consent and receiving results of the biomarker analysis from 
the central laboratory turned out to be 25 calendar days! While delivering a tissue sample 
for central confirmation of molecular testing is crucial in biomarker-driven NSCLC trials, 
the mandatory waiting of patients to start therapy is to be discussed. Waiting times for 
central laboratory analysis not only lead to an important delay in treatment initiation, but 
even ineligibility for the trial(s) under consideration. Start of therapy based on a properly 
validated local test, with a posteriori central biomarker testing to guarantee the integrity 
of the trial, would be more rewarding for quite some patients (8). Conclusion:Recruitment 
in lung cancer clinical trials is a complex and vulnerable process with different types of 
barriers. Identifying such barriers can help clinical trial staff to develop strategies to 
optimize participation and cooperation. Well-trained CRNs have a unique knowledge and 
set of skills that allows them to make a significant contribution to the clinical research 
team. CRNs should follow the rapid change in clinical trials closely, so that they can be a 
guide for patients in their clinical trial journey. Moreover, they have an important role in 
minimising the patient barriers, give support in physician barriers, and facilitating tissue 
barriers. References (1) Ross S, Grant A, Counsell C et al. Barriers to participation in 
randomised controlled trials: A systematic review. J Clin Epidemiol 1999;52:1143-1156. 
(2) Manne S, Kashy D, Albrecht T et al. Attitudinal barriers to participation in oncology 
clinical trials: Factor analysis and correlates of barriers. Eur J Cancer Care 2015;24:28-
tumor board review, clinical trials, personalized/targeted treatment, multi-disciplinary 
care, etc. Health literacy of physicians and patients impacts survival. The lung cancer 
knowledge gap especially affects patients who have limited education, are low income, 
ethnic minorities, recent immigrants and non-native English speakers. Knowledge and 
access are the currency of success and the pathway for all patients/physicians to get 
the right information leading to the right treatment at the right time. Information is 
also key for patients and their families to act as their own advocates. EVERY PATIENT 
NEEDS TO KNOW EVERY OPTION. ALCF acknowledges this problem and provides an 
innovative, first-of-its-kind solution – Community Hospital Centers of Excellence (COE) – 
to give all patients 3600 care. Our solution provides community hospitals access to the 
same standard of care used at academic institutions to ensure that every physician and 
patient has access to and is educated about the newest, most effective diagnostic and 
therapeutic techniques, clinical resources, partners and people. Increasing lung cancer 
patient survival to the same high level as other cancers (breast/89.2%; prostate/98.9%) 
depends upon addressing disparities at the root – community hospitals – and to 
providing access to multi-institutional, collaborative, comprehensive care based on 
existing best practices. Equalizing access benefits all populations – insured, uninsured, 
underserved, geographically disadvantaged – fighting this disease. Physicians/hospitals 
in the COE national network commit to being fully informed partners with their patients in 
understanding, sharing and discussing treatment options. ALCF lung-specific community 
centers of excellence will be tracked by metrics to improve outcomes and reinforce 
ALCF’s belief that enhanced standard of care can extend survivability, improve quality 
of life, and some cases, save lives. ALCF, along with GE Healthcare and El Camino 
Hospital in California, has already shown success in its pilot program launched in 2012. 
Simultaneously, underlying research projects will be conducted to achieve milestones 
and increase discovery of treatment regimens for individualized therapy and survival 
acceleration through ALCF’s sister organization, the Addario Lung Cancer Medical 
Institute (ALCMI). At Centers of Excellence an on-site Patient Navigator oversees each 
patient’s care from the initial diagnosis. Care includes molecular testing for all patients 
to determine the unique genetic profile of the individual’s lung cancer. This knowledge will 
determine the best first-line treatment to achieve a positive outcome and will ensure that 
the right patient gets the right treatment at the right time. 
Community Hospital Centers of Excellence (COE) – Primary objectives are: 
• Provide lung cancer patient program participants with multi-disciplinary, multi-
institutional, collaborative, extensive, and comprehensive access to best care available. 
This “big picture” approach includes a Patient Navigator overseeing each patient’s care 
to include prospective tumor board review, molecular testing, targeted radiation therapy, 
and access to clinical trials, from a fully integrated team (oncologist, pulmonologist, 
radiologist, pathologist, immuno-oncologist, etc). 
• Establish and implement improved standard of care (SOC) at community hospitals 
nationwide by giving patients and physicians access to the SOC used at academic 
institutions. This standard will be measured through patient data tracking, follow-up and 
patient surveys, and benchmarked against national data and statistics. In addition, ALCF 
will actively support the adoption and scaling of its lung cancer “standard of care” model 
to apply across the cancer spectrum and to other diseases and disciplines, as applicable. 
• Improve progression free and overall survival rateand quality of life for patients. 
• Implement best practices with expected outcomes being a new patient-centric 
paradigm for lung cancer patient treatment with best practices managed and 
documented by ALCF and findings shared with ALCF key partners and prospective 
Community Hospital COE sites. Because outcomes/data are essential to determine 
program success, tracking and measurement of all COE patients will include:
• Method of Diagnosis
• Early Detection vs. Incidental Findings
• Diagnosis Date
• Lung Cancer Type
• Lung Cancer Stage at Diagnosis
• Molecular Testing - % of Patients Received
• Tumor Board Review
• 30 Day Survival
• Number of ER Visits
• 1 and 5 Year Survival (Progression Free and Overall)
• Clinical Trial Referral
• Quality of Life (i.e. Pulmonary Function, Neuropathy, Fatigue, Appetite etc)
• Patient Satisfaction Survey
• Line of Treatment
• Where Applicable:
• Dollars Lost/Impact on Community due to Early vs. Late Stage Diagnosis
• Business Impact on Hospital
During our pilot program’s first year (El Camino Hospital, Mtn View, CA) metrics have 
already shown a dramatically improved standard of care (diagnosis to treatment time 
improved from a national average of 40+ days to 14.5 days; 100% of patients have 
had molecular testing; 61% have had tumor board review vs. 15% pre-program; 26% 
diagnosed at stage 2b or below). In adopting this collaborative, integrated standard 
of care, each hospital must have capacity to enroll at least 200 patients yearly. 
At minimum, ALCF excpects 10,000 patients will be served by 2015 end thriough 
20 COEs. By equalizing physician/patient access to education and a standard of 
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followed by a triage discussion to help formulate treatment plans and referrals. 
Treatment plans must be clearly documented and communicated to the patient, family 
and team.[10] At an individual level, clinician should implement policy and procedures 
that support routine screening and access relevant training, support and supervision. 
Conclusion 
Lung cancer patients are among the most distressed and at risk cancer population. 
Evidence suggests that treating teams must take a person-centred approach to 
treatment including consideration of patients’ psychosocial needs. Routine screening 
allows practitioners and treating teams to appropriately consider psychosocial care and 
engage patients in intervention to minimize the potential negative impacts of untreated 
or poorly treated distress. 
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I am going to introduce the medical care for cancer and nursing for cancer in Japan. 
Starting from 1981, cancer claimed 1st place of the cause of death, and it currently 
account for approximately 30% of the cause of death. About 900,000 people are 
annually affected by the cancer. The per category death rate is in the order of lung 
cancer in 1st place, stomach cancer in 2nd place, and colorectal cancer in 3rd place. 
The per category affected subject rate is in the order of stomach cancer in 1st place, 
colorectal cancer in 2nd place, and lung cancer in 3rd place. As you can see from 
the above, cancer is a serious health problem for Japanese, and although Japan 
implemented countermeasure for cancer starting from the 60’s, “Cancer Control 
Act” was established in 2006, and “Basic Plan to Promote Cancer Control Program” 
was also setup to promote such Act. The purpose of the countermeasure is to do the 
following: 1.Reduce cancer death (Reduce age-adjusted mortality under 75 years, 
2.reduction of burden and improvement of quality of life among cancer patients and 
their families, 3.Buliding a society in which cancer patients can live peacefully. Based on 
such backdrop, the role of nurses are further increased. To enhance the specialization 
of nursing for cancer, “Japanese Society of Cancer Nursing” was established in 1987, 
and it is now celebrating its 30th anniversary. This establishment has been supporting 
activities such as education and research. Nurses with certification such as “Certified 
Cancer Nurse Specialist” that can be obtained with completion of master’s course at 
graduate school, and “Certified Nurse” that can be obtained with 600 hours of education 
for those with over 5 years of nurse experience are taking active role in the fields of 
Palliative Care, Cancer Chemotherapy Nursing, Cancer Pain Management Nursing, Breast 
Cancer Nursing, Radiation Therapy Nursing, etc. Such active role is making positive 
contribution toward the enhancement of specialization in the clinical field. A variety of 
issues surrounds the medical care for cancer such as being able to correspond to the 
advancement of medical technology, increase of cancer survivor, and aging of patients. 
There is much anticipation for the good use of specialization in the cancer-nursing for 
team medicine to support the life of patient and to respect the decision-making of 
patient. I would like to introduce these types of initiatives that are specific to the condition 
surrounding the nursing for cancer and enhancement of specialized nursing in Japan. 
Keywords: Oncology Nursing in Japan, Japanese Society of Cancer Nursing, Nurse 
Specialist, nurse education
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Australia
This paper discusses the prevalence of distress in the lung cancer population, reviews 
the benefits and barriers of screening and provides practical strategies to implement 
psychosocial screening. 
Background: Lung cancer is the leading cause of death by cancer for both men 
and women worldwide. Most lung cancers are diagnosed at advanced stage and 
approximately 15% of lung cancer patients will be alive five years post-diagnosis.
[1] Psychosocial distress is common for those experiencing cancer. The National 
Comprehensive Cancer Network (NCCN) defines psychosocial distress as ‘an unpleasant 
experience of an emotional, psychological, social or spiritual nature, that interferes 
with the ability to cope with cancer treatment, which extends along a continuum 
from common normal feelings of vulnerability, sadness and fear, to problems that are 
disabling such as true depression, anxiety, panic and feeling isolated or in a spiritual 
crisis’. The NCCN considers distress to be a treatable complication of cancer.[2] 
 
Lung cancer patients’ distress levels are among the highest of all cancer types with 
up to 60% of lung cancer patients experiencing clinical level of psychological distress 
compared with approximately 35% of patients with other cancer diagnoses.[3 4] 
These high levels of distress have been found to continue throughout the course of 
the illness. Prevalence of anxiety and depression in patients with lung cancer ranges 
from 20% to 50% [3 5] and patients with lung cancer have been identified as having 
one of the highest rates of suicide within the cancer population. [6] Distress has been 
associated with deterioration in quality of life, higher pain levels, increased fatigue, 
increased family burden and reduced adherence to medical treatments. Despite high 
levels of distress in this population, lung cancer patients also report experiencing a 
significantly higher mean number of unmet needs 15.6 (95% CI 12.1–19.1), compared 
to 10.9 (95% CI 10.0–11.8) in other cancer patients.[7] Psychosocial distress screening 
Distress screening is defined as “a brief method for prospectively identifying, triaging, 
and educating cancer patients and their families at risk for illness-related biopsychosocial 
complications that undermine the ability to fully benefit from medical care, the efficiency 
of the clinical encounter, patient satisfaction, and safety.”[2] Practice clinical guidelines 
recommend that all cancer patients undergo regular screening, with the American College 
of Surgeons (ACoS) Commission on Cancer (CoC) requiring cancer centers to implement 
screening programs for psychosocial distress as a new criterion for accreditation as 
of 2015. Without formal screening, distress may go unrecognized, clinicians could 
focus on the medical aspects of the illness and consider distress as a “normal” part 
of cancer and patients may not be offered effective biopsychosocial treatments to 
address distress. Without intervention for distress, the distress of lung cancer patients 
has been found to remain high, post six months of medical treatment.[8] Many tools 
exist for the screening of distress and these tools have undergone varying degrees 
of validation in the lung cancer patient group. The Distress Thermometer is the most 
popular of these tools and has been found to be both acceptable to patients with lung 
cancer and clinicians. In deciding which distress screening tool to employ, it is important 
that effective screening takes both disease (i.e. stage of illness, prognosis, side-effects, 
functional impairment) and demographic risk factors (i.e. age, isolation, past mental 
health history) into account, is easy to administer and sensitive to the identification of 
distress. Screening accompanied by discussion with lung cancer patients was found 
to be more effective than screening alone.[8] Overall, routine screening leads to 
improvements in communication with patient, families and staff, enhances psychosocial 
referrals improves symptom management and quality of life. However, some barriers 
may exist to the successful implementation of routine screening, including: a lack of 
knowledge about screening; a lack of training about how to manage distress; limited 
resources and time pressure; lack of institutional support; and a concern that screening 
may lead to ‘false positives’.[9] Implementing screening for distress recommendation 
The successful implementation of routing screening needs to be considered at the 
institutional, multidisciplinary team and individual clinician level. At an organizational 
level, screening and psychosocial care needs to be valued, prioritized and embedded 
in policy. Organizations need to ensure adequate psychosocial resources are available, 
staff are adequately trained and supported and that there is an ongoing evaluation of 
any psychosocial screening and referral process. At a multidisciplinary team level, the 
team needs to view psychosocial screening and treatment as part of routine care and 
distress needs to be assessed across the cancer trajectory, not just at a single point.
[10] Treating team members need to consistently inform patients and families that the 
management of distress is a central part of their medical care. Teams should use a 
validated and easy to use instrument to assess distress and all screening should be 
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the intervention or due to chemotherapy side effects. Conclusion This study contributes 
to the literature by taking into account patient perspectives of exercise interventions. The 
supervised intervention was undertaken safely by operable lung cancer patients initiated 
2 weeks after surgery. This select group of lung cancer patients experienced physical 
and emotional benefits and affirmed their social identity. This qualitative study indicates 
that exercise is beneficial for lung cancer patients in the postsurgical trajectory and 
especially for those who were physically active and motivated pre-illness. References 1. 
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MS19.05 Ethical Challenges in Conducting Clinical Research in Lung Cancer 
Angela M. Tod1, Peter Allmark2 1School of Nursing, Midwifery and Social Work, University 
of Manchester, Manchester/United Kingdom, 2Centre for Health and Social Care Research, 
Sheffield Hallam University, Sheffield/United Kingdom
Background This paper will reflect upon some of the ethical challenges in conducting 
clinical research into lung cancer and mesothelioma. Lung cancer care, treatment 
and research operate in a complex environment. Characteristics of lung cancer that 
contribute to this complexity are that, in comparison to other cancer sites, it has a limited 
evidence base, high mortality, late presentation, diagnosis at advanced stage, few 
curative treatments, complex trial designs and nihilistic attitudes regarding treatment 
and research. As a result, people delay reporting lung cancer symptoms because of 
fear, fatalism and poor knowledge of treatment.1 Such beliefs and attitudes may also 
influence decisions or prevent people from participating in research. When they are 
asked to participate, they are often in a situation of advanced illness with fear and/
or fatalism in their minds. As such, they may be desperate volunteers. 2 Desperate 
Volunteers An example of a study involving desperate volunteers might be a surgical 
intervention for mesothelioma, such as the procedures in Mesothelioma And Radical 
Surgery (MARS)Trial3 study or the new feasibility study of MARS 2. Treatment options in 
lung cancer and mesothelioma are increasing, but remain limited, especially regarding 
curative treatment. In mesothelioma, surgery will not be curative, but might be seen 
as the only palliative treatment that can make a substantial inroad into the disease 
pogression. Research treatments may therefore be seen as “the only treatment in town”. 
Both the multidisciplinary team and the patient may not see any other viable treatment. 
If the intervention is only available within research then research emerges as the only 
option. So what are the ethical challenges here? The ethical principle of voluntariness 
comes into play. Might recruitment into a trial be experienced as coercive – even if this 
is not the intention of the person recruiting? Is the experience of being approached about 
trial participation seen as coercive, or is it a decision in difficult circumstances? We 
need to ensure it is the later. It may be a decision taken under pressure, but needs to be 
made in a voluntary capacity. Other factors that will impact on levels of desperation, and 
the balance between coercion or decision, include whether the intervention is available 
outside the trial or not, and the trial design i.e. does it involve randomisation. Both these 
things will impact on someone’s readiness to participate in research and whether they 
will seek treatment outside of a trial. Finally it is necessary to consider whether the 
level of distress or desperation is impacting upon mental capacity.4 Trials for all As 
previously stated, the evidence base for lung cancer is limited when compared to other 
cancer sites. There is also a drive in the UK cancer and health research community to 
ensure all patients have a right to access any appropriate trial. In the historical context 
of lung cancer being the “poor relation” in terms of research activity, caution is required 
to avoid being over-zealous in putting this right. People have the right to have access to 
appropriate trials but this does not mean every patient should be on a trial. There are 
many reasons why people will not want to embark on the journey of being a research 
participant. This should be respected. There is a theoretical argument that an over-zealous 
“trails for all” approach could have two other impacts. First, it may lead a desperate 
volunteer to misinterpret or inflate what the trial may offer in terms of treatment, cure 
or symptom impact; second it may change perceptions of equipoise. Equipoise Clinical 
equipoise provides the ethical basis and justification for medical research which involves 
assigning or randomising patients to different treatment arms of a trial. The term was 
first used by Benjamin Freedman in 1987.5 If clinical equipoise exists there is genuine 
uncertainty over whether a treatment will be beneficial. It follows that it is reasonable 
for a clinician in equipoise to assign a patient to one arm or the other of a randomised 
trial. The challenge lies in deciding whether equipoise exists and whose interpretation it 
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MS19.04 The Importance of Pre- and Early Postoperative Rehabilitation in 
NSCLC Patient (Design and Rationale for the PROLUCA Study) 
Malene Missel1, Jesper H. Pedersen2, Maja S. Sommer3, Carsten Hendriksen4, 
Marianne Tewes5, Lis Adamsen6 1Dept. of Thoragic Surgery, University Hospital of 
Copenhagen, Copenhagen/Denmark, 2Dept. of Cardiothoracic Surgery, Copenhagen 
University Hospital, Copenhagen/Denmark, 3Copenhagen Centre for Cancer and Health, 
Municipality of Copenhagen, Copenhagen/Denmark, 4The Faculty of Health and Medical 
Sciences, University of Copenhagen, Copenhagen/Denmark, 5The Heart Centre, University 
of Copenhagen, Copenhagen/Denmark, 6The Faculty of Health and Medical Sciences and 
University Centre for Nursing and Care Research (UCSF), Copenhagen University Hospital, 
Copenhagen/Denmark
Background Exercise has been introduced to improve physical capacity (VO2peak and 
1RM) and quality of life and to reduce symptoms and side-effects of treatment in patients 
with cancer, mostly investigated in patients with breast cancer (1,2). Against this 
background a feasibility study was developed to investigate the safety and feasibility of 
a preoperative and postoperative exercise program in patients undergoing surgery for 
lung cancer (3). The study concluded that the preoperative exercise program was not 
feasible. However, initiation of exercise two weeks postoperatively for patients with 
NSCLC was safe and feasible. A randomized clinical trial (PROLUCA) was therefore 
developed to investigate the efficacy of a postoperative exercise intervention in a non-
hospital setting. Objectives The objective of the presented study was to explore 
operable lung cancer patient experiences with the postoperative exercise intervention 
from a longitudinal perspective according to patient motivation and patient perceived 
benefits and barriers of exercise. Methods This qualitative component formed part of the 
randomized control trial (PROLUCA) comparing the efficacy of early initiated postoperative 
exercise (initiated two weeks after surgery) with the effect of exercise initiated 14 weeks 
after surgery (usual care). NSCLC patients referred for surgery at the Department of 
Thoracic Surgery, Copenhagen University Hospital, were recruited for the exercise 
intervention. More details on the RCT study can be found in the published protocol by 
Sommer et al. (3). Nineteen patients enrolled in the exercise intervention two weeks post-
surgery participated in qualitative interviews at three time points; the day after surgery, 
7 weeks post-surgery and 4 months post-surgery. An analysis based on Ricoeur’s theory 
of interpretation was conducted in a phenomenological hermeneutical approach (4). 
Results The patient sample’s mean age was 63 years (range 48–75). Patients underwent 
video-assisted thoracoscopic surgery (VATS) with intent to cure. The majority (79 %) had 
comorbidities, including chronic obstructive pulmonary disease (26 %), cardiovascular 
disease (26 %) and hypertension (26%). Pre-illness physical activity levels of the patients 
showed that 47 % had not met the national recommendation for physical activity. Patients 
started exercising 15 days following surgery (median) (range 14–41 days). Delay was due 
to postoperative complications (pain, pneumothorax, pneumonia, atrial fibrillation, 
general discomfort). Eight participants dropped out of the intervention. Reasons for non-
adherence included chemotherapy side effects (nausea, fatigue) (n=3), other reasons 
(n=1), fractured arm (n=1), work (n=1), terminally ill husband (n=1) and death (n=1). The 
mean attendance rate for the 11 participants who completed the intervention was 82 % 
(range 58–100 %). No patients experienced severe adverse events (e.g. heart- or 
respiration stop) during or following exercise. The interview findings are organized into 
three themes reflecting the timespan related to the patients’ treatment trajectory: 1) 
Pre-intervention motivation for participation; 2) Benefits and barriers of the intervention; 
3) Overall experiences with the intervention. Motivation for participation included 
patients’ expectations of physical benefits and the security of having professionals 
present. Patients experienced physical and emotional benefits and affirmed their social 
identity, including improved breathing and increased well-being and energy level. Group 
training had social benefits and the patients experienced a sense of belonging. Exercising 
with others in a similar circumstance was meaningful to the patients and created a sense 
of community. Barriers were primarily related to side-effects of chemotherapy. The 
intervention put the patients on track to a healthier lifestyle regarding physical activity 
and smoking, and regaining vitality and energy increased the participants’ faith in the 
future. The patients were satisfied with the exercise intensity level, contents and variation 
and felt that after 12 weeks of two 60-min weekly sessions they had regained a good 
amount of strength and energy. Two of the eight patients who were undertaking adjuvant 
chemotherapy started training on completion of their treatment, while three other 
patients exercised while being treated. Discussion To our knowledge, this is the first 
study that addresses operable NSCLC patient perspectives on participating in an 
exercise intervention during the immediate post-surgical period and subsequent 
chemotherapy. The sample of the 19 patients included in the interview study appears to 
be a select group of operable lung cancer patients. So far it has not been possible to 
compare the interview sample with the larger sample of the trial and therefore not 
possible to discuss representativeness of the selected sample. However, when 
comparing the interview study sample with other operable lung cancer patients, it 
appears that the study patients are a little younger, better educated, have early stage 
disease, good performance status and are used to physical activity. Although this sample 
is comparable with other lung cancer exercise samples (5), this suggests social inequality 
related to the intervention’s design. This might also explain why the operable lung cancer 
patients consented to participate in the intervention and changed their behaviour—a 
finding that is not comparable with the general lung cancer population reported to have 
particularly low levels of physical activity during the post-treatment period (6) and with 
patients engaged in light physical activity (7). Despite the fact that the studied sample 
might be a select group, the diagnosis appears to represent “a teachable moment” as 
discussed by Demark-Wahnefried and colleagues (8), and the intervention seem to assist 
the patients by increasing their physical function and energy, their well-being and improve 
their social capital. Eleven of the patients completed the intervention with a mean 
attendance rate of 82 %, which is comparable with other exercise intervention studies 
(9). This result underscores the patients’ desire and ability to complete the intervention. 
Reasons for dropping out of the intervention were due to external conditions unrelated to 
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NHS England and Macmillan Cancer Support is aimed at entrenching NCSI findings and 
recommendations ensuring that those living with and beyond cancer get the care and 
support they require to lead as healthy and active a life as possible, for as long as possible. 
There are a number of key recommendations, including the introduction of an integrated 
package of interventions, “The Recovery Package”, which includes
• Structured Holistic Needs Assessment and Care Planning
• Treatment Summaries and Cancer Care reviews
• Patient education and support events (Health and Wellbeing Clinic)
• Advice about and access to schemes that support people to undertake physical 
activity and healthy weight management. 
The collaboration of multi-disciplinary working involved in such interventions will enable 
improved outcomes for cancer survivors, through creating a shared understanding 
between patient and professionals about the issues important to the individual patient, 
identifying any needs to be addressed in an appropriate and timely manner. It has been 
designed to complement the stratified care pathway (NHS Improvement 2012) which 
enables individualised follow-up care as a supported self-management programme, 
shared care or complex care. 
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MS20.01 Imaging for Surgical Treatment Decision and Planning 
Hans Hoffmann1, Claus P. Heussel2 1Thoracic Surgery, Thoraxklinik, University of 
Heidelberg, Heidelberg/Germany, 2Diagnostic Radiology, Thoraxklinik, University of 
Heidelberg, Heidelberg/Germany
When patients with early-stage non-small cell lung cancer (NSCLC) are accurately 
staged inappropriate surgery is avoided and on the other hand potentially curative 
surgical resection is not refused. The clinical algorithms using imaging studies for 
staging lung cancer patients with regard to surgical treatment decision and planning 
as recommended by current guidelines will be presented and discussed. Low-dose CT 
screening is now recommended for asymptomatic select patients who are at high risk for 
lung cancer and an increasing number of patients may come to clinical attention during 
screening. CT findings suggestive of malignancy in a patient with a solitary pulmonary 
nodule include larger lesion size, irregular or spiculated borders, upper lobe location, 
thick-walled cavitation, presence or development of a solid component within a ground 
glass lesion, and detection of growth by follow-up imaging. The general approach to 
patients suspected of having lung cancer begins with a thorough history and physical 
examination (1). Following that, essentially every patient suspected of having lung cancer 
should undergo a contrast-enhanced diagnostic CT scan of the chest. The diagnostic 
chest CT scan is an important first step, not only to help define the clinical diagnosis, but 
to structure the subsequent staging and diagnostic evaluation (1). In patients in whom 
lung cancer has been demonstrated, consideration must turn toward determining the 
extent of the disease to identify patients with stage IA, IB, IIA, and IIB disease who can 
benefit from surgical resection. **Extrathoracic (M) Staging** The purpose of extra 
thoracic imaging in NSCLC is to detect metastatic disease. Current literature continues 
to demonstrate that PET and PET-CT scans are superior to conventional staging tests 
(bone scan and abdominal CT scan) in terms of performance characteristics (1). Recent 
data confirm the superiority of the performance characteristics of PET and PET-CT scans 
compared with conventional scans in the evaluation of metastatic disease in key specific 
distant sites (1). Recommendation (1): In patients with a normal clinical evaluation and no 
suspicious extra thoracic abnormalities on chest CT being considered for curative-intent 
treatment, PET imaging (where available) is recommended to evaluate for metastases 
(except the brain) (Grade 1B). However, positive PET/CT scan findings for distant disease 
need pathologic or other radiologic confirmation (e.g., MRI of bone) (2). Brain MRI (to rule 
out asymptomatic brain metastases) is recommended for patients with stage II and higher 
(2). Patients with stage IB NSCLC are less likely to have brain metastases; therefore, 
brain MRI is only a category 2B recommendation in this setting (2).**Mediastinal Nodal 
is based upon. Usually the decision is made according to the best evidence.6 An ethical 
window of opportunity will exist within which it is justified to conduct a randomised trial. 
That is until evidence is generated to demonstrate whether an intervention is better than 
standard treatment or not. However, there is a value-based element to equipoise. As such 
equipoise may vary between researcher, clinician, and patient – and between different 
patients. For example, on the basis of best evidence it may be justified to randomise 
between a surgical intervention and standard care, as clinical equipoise is seen to exist. 
However, if standard treatment is NO treatment, will the patient view equipoise in the 
same way as the scientist? Implications The above challenges will apply in different ways 
to different patients and contexts. However This paper focuses on some key messages 
for clinical and research practice. These can be summarised as: · Information and 
consent: The process of providing participants with sufficient information, and obtaining 
informed consent, need to be actively managed in these complex situations. Sufficient 
time needs to be allowed in times of heightened emotion and a cooling off period is 
recommended in between information and consent. Also, consent should be approached 
in a staged or continuous manner, where willingness to continue participation in research 
is verified at different stages in the study. · Research designs: Where possible, patient 
preference trial designs should be considered.7,8 · Availability of research intervention 
outside of the trial: Consider the impact of this at the design stage. Is an agreement 
possible to cease delivery outside of a trial until evidence is generated? · Equipoise: 
Whose equipoise is the trial based on? It is necessary to consider patient/participant 
values as well as the judgements of the scientist and clinician. Patient experience: It 
is worth including a qualitative component in trials to understand what is going on for 
the participants, and trial staff, in terms of decisions to participate and be randomised, 
response to allocation, and experience of intervention. 1. Tod AM. Allmark P. Craven J. 
Diagnostic delay in lung cancer: a qualitative study. Journal of Advanced Nursing. 2008. 
61(3), 336-343 2. Allmark P (2006)  Should desperate volunteers be included in 
randomised controlled trials? JMedEth 32, 548-53 3. Treasure T, et al. Extra-pleural 
pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant 
pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery 
(MARS) randomised feasibility study. Lancet Oncol. 2011 Aug;12(8):763-72. doi: 
10.1016/S1470-2045(11)70149-8. Epub 2011 Jun 30. 4. Mental Capacity Act Code 
of Practice (2005) online Chapter 11 5. Freedman B (1987) Equipoise and the ethics 
of clinical research NEJM 317(3), 141-5 6. Kurzrock J, Stewart D (2014) Equipoise 
abandoned? Randomization and clinical trials. Ann Onc 24(10), 2471-74 7. Ismalia A, 
Walter S 2014 Review of designs for accommodating patients’ or physicians’ preferences 
in randomized controlled trials. In Montfort K van. et alDevelopments in Statistical Evaluation 
of Clinical Trials Sedgwick P (2013) What is a patient preference trial? BMJ 347:f5970 
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MS19.06 The Lung Cancer Patient - Addressing Issues of Survivorship 
Maria Guerin Thoracic, Aintree University Hospital, Liverpool/United Kingdom
An individual is considered a cancer survivor from the time of diagnosis, through the 
balance of his or her life (NCSI –Survivorship definitions 2004). In the UK Lung cancer 
survival has improved over the past two decades .In 1990 17% of male and female 
lung cancer patients were alive after one year compared with 29% of men and 33% 
of women diagnosed with lung cancer in 2010 . (The National Cancer Intelligence 
Network – public health England 2013).Such noticeable improvement in survival rates 
illustrates the improvements in Lung cancer care from diagnostics, treatments and 
configuration of cancer services. However variations and gaps in the delivery of lung 
cancer care nationally and internationally reinforce concerns around survivorship care. 
Lung cancer is a diagnosis associated with heavy disease burden and survivors may 
experience a myriad of concerns related to diagnosis and or treatment with high levels of 
physical and psychological distress affecting the quality of life for both patients and carer’s. 
Maguire et al (2012) reported that many people with a lung cancer diagnosis feel that 
supportive care needs are not being met, they have significantly more unmet supportive 
care needs compared to other cancer types. They are also less aware of supportive care 
elements available and have limited information to resources. (Steele and Fitch, 2008) 
The American Cancer Society (ACS)’s has set one of its 2015 goals for the 
nation as establishing “..Measurable improvement in the quality of life from 
the time of diagnosis and for the balance of life for all cancer survivors” 
Recent years have seen the growth of a new trends in medicine that are based entirely 
on data obtained from patients own assessment of their symptoms and ability to 
function “normally” Widely known in the cancer fields as a self-evaluation of health 
status or outcomes assessment. Such assessments were directed primarily towards 
patient evaluation and came to be known as health-related quality of life (HRQOL) in 
order to distinguish it from the quality of life of the general population. HRQOL refers to 
multidimensional assessments that include physical, psychological, social domains and 
also include other domains such as cognitive functioning, sexuality and spirituality. While 
single areas such as performance status or symptoms may be components of HRQOL 
they are, by themselves, insufficient to constitute a complete HRQOL assessment. 
In addition, the assessment of HRQOL does not usually include some other patient 
reported assessments, such as needs assessment and satisfaction with care. Thus, 
patient-reported outcomes (PROs) a more inclusive term, was proposed to include 
any data that may be reported directly by the patient without an intermediary such 
as a family member or a healthcare professional (Willke et al. 2004). The process of 
obtaining PRO data is commonly referred to as PRO measurement (PROM)s (Osoba 2011) 
The National cancer survivorship Initiative, (NCSI) launched in 2007, initially had limited 
evidence around the needs of cancer survivors. Taking action to improve outcomes 
(NCSI 2013)collected information on quality of life (QoL) through the use of PROMS 
and identified that many cancer survivors had unmet needs. Following on from the 
success of this National Cancer Survivorship Initiative, The Living With and Beyond 
Cancer (LWBC) Programme was set up in June 2014. This two year partnership between 
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RTOG 0235 was to assess post-treatment SUV for patients receiving radiotherapy as 
part of their treatment for stage III NSCLC, pre-treatment FDG-PET SUV (mean and 
max) were also assessed. While pre-treatment FDG-PET SUV did not predict outcomes, 
active research is assessing the delivery of differential dosing (via IMRT dose painting) 
based on variation in PET activity. Understanding the impact of tumor and organ motion 
during respiration is essential when utilizing highly conformal techniques in treating lung 
cancer. This is a key component of the simulation process and AAPM Task Group 76 
describes various options for tumor motion management in detail. Four-dimensional CT-
simulation 4D CT is accomplished by correlating the motion of an external surrogate 
device to the time signature of CT scans. Multiple scans are acquired during each 
phase of respiration and should provide sufficient motion detail to properly define the 
internal target volume (ITV). These phase calibrated images can then be processed into 
average or maximal intensity projections (MIP), or used directly as a cinema image of 
the tumor motion. In order to incorporate the extent of tumor motion from breathing 
during SBRT, contouring on the MIP, as opposed to helical or average intensity images, 
may be optimal. Tumor motion seen on the 4D CT is only representative of the motion 
at the time of simulation, so further assessment is needed to ensure this will be 
representative of tumor motion during the actual treatment. Real-time confirmation of 
tumor location during treatment, whether using the ITV method, respiratory gating, or 
tumor tracking may be provided by use of “cine” mode or fluoroscopy. Routine real-time 
imaging should be performed given the potential for variability in breathing and tumor 
motion over the treatment course. Image guided radiotherapy (IGRT), particularly KV 
cone-beam CT (CBCT) or MV – CT, is essential for ensuring accurate tumor targeting 
during radiotherapy. For example, image guidance capable of confirming the position of 
the target with each treatment was required for the RTOG 0236 trial.While the majority 
of clinical experience is based on 3D CBCT, 4D (respiration correlated) CBCT is now 
commercially available and reduces motion artifact and may have additional advantages 
over 3D CBCT in the treatment of lung tumors. IGRT also allows for routine assessment 
of tumor response and anatomic changes over time and facilitates implementation 
of adaptive radiotherapy approaches. Several experiences have detailed changes 
in tumor volume during the radiotherapy course and the (potential) impact of revising 
the radiotherapy plan during therapy. An ongoing prospective randomized phase II trial, 
RTOG 1106, is studying adaptive radiotherapy in stage III non-small cell lung cancer 
by incorporating changes in both functional and anatomic imaging. Repeat PET/CT and 
CT simulation in the midst of RT is performed for all patients on study with the “boost” 
volume in the experimental arm defined by the repeat PET/CT. The total dose for each 
patient in the experimental arm is dictated by the boost volume and predicted NTCP 
toxicity. The RTOG 1106 trial includes evaluation of 18F-fluoromisonidazole (FMiso) PET 
imaging, which may help identify areas of hypoxia, in a subset of patients. Magnetic 
resonance imaging (MRI) traditionally has been reserved for assessment of select lung 
tumors (potentially) invading soft tissue structures such as chest wall, mediastinum, lung 
apex in proximity to the brachial plexus (pancoast tumors), and lesions in proximity to the 
spinal cord. The recent development of a commercial hybrid radiotherapy /MRI unit may 
expand the role of MRI and permits IGRT (without the need for additional patient exposure 
to ionizing radiation) while also facilitating soft tisse tracking and adaptive radiotherapy. 
Keywords: Image Guidance, FDG-PET, Adaptive Therapy
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Introduction: Cancer cells express antigens that potentially differentiate them from 
normal cells. These are known to be numerous in lung cancer and characterized by a high 
mutational rate (7-11 mutations / MegaBase), especially in relation with smoking derived 
genetic instability, P53 mutations, and/or the presence of targetable mutations in 
adenocarcinoma. These tumor antigens should confer immunogenicity to lung cancer 
transformed cells. However, immune-editing occurs in most lung cancer along a three 
phases sequence: 1) Elimination, where transformed cells are destroyed by the immune 
system; 2) Equilibrium, equivalent to a functional state of dormancy in which tumor cells 
growth is controlled by adaptive immunity, a state characterized by typically dense 
lymphocytic infiltration rich in CD8 cytotoxic cells (E. Brambilla et al. JCO, under review); 
3) Escape from immune surveillance. PD-L1 in NSCLC is expressed on the membrane of 
tumor cells, and/or on immune infiltrating cells dendritic cells (DC), other antigen 
presenting cells (APC) and T lymphocytes. PD-1, the PDL1 receptor, is expressed on 
tumor infiltrating lymphocytes (TILS), mainly CD4 T cells, T regulatory (T-reg) and B, NK, 
monocytes and DC. Upon PD-L1 binding, PD-1 inhibits kinases involved in T cell activation. 
There are two mechanisms of expression of immune checkpoints on tumor cells and their 
immune stromal counterparts: oncogenic signaling, and response to inflammatory 
signals, both of which occur potentially in lung cancer. Tumor cells express multiple 
ligands and receptors and antitumor immune response can be enhanced by multi-level 
blockade of immune checkpoints. PD-1/PD-L1 engagement leads to HSP-2 phosphatase 
activity which dephosphorylates Pi3K and thus downregulate AKT. The necessary patient 
selection for immunotherapy has stressed the search for predictive biomarker of PD-1/
PD-L1 pathway inhibition. The cutoff for positivity on tumor cells1–3: The cutoff for 
positivity in and out of trials on tumor cells has never been assessed nor optimized or 
standardized. The percentage of PD-L1 membrane staining considered as the cutoff for 
positivity was from ≥ 1%, ≥ 5%, ≥ 10%, ≥ 50% and the intensity was or not defined and 
taking into account (any intensity, 1+, 2+, 3+, or a scale from 1 to 3+/H Score , or 
2+3+only). At least, most if not all reports considered only membrane staining on tumor 
(N) Staging** Mediastinal lymph node staging in NSCLC is particularly important, 
because in many cases, the nodal status actually determines whether there is surgically 
resectable disease. If the contrast-enhanced CT scan shows nodal mediastinal infiltration 
that encircles the vessels and airways, so that discrete lymph nodes can no longer be 
discerned or measured, non-resectable disease is evident and no further imaging studies 
are required to determine the exact N status (1). In patients with discrete mediastinal 
node enlargement further evaluation is recommended (1, 2). The NCCN Panel assessed 
studies that examined the sensitivity and specificity of chest CT scans for mediastinal 
lymph node staging. Depending on the clinical scenario, a sensitivity of 40% to 65% and 
a specificity of 45% to 90% were reported. PET/CT scans may be more sensitive than 
CT scans (2). However, in patients with discrete mediastinal node enlargement, the risks 
of false positive test results from either CT scanning and/or PET scanning are too high 
to rely on imaging alone to determine the mediastinal stage of the patient, and tissue 
confirmation is necessary (1). Transesophageal EUS-FNA and EBUS-TBNA have proven 
useful to stage patients or to diagnose mediastinal lesions; these techniques can be 
used instead of invasive staging procedures in select patients. When compared with CT 
and PET, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) 
has a high sensitivity and specificity for staging mediastinal and hilar lymph nodes in 
patients with lung cancer. In patients with positive nodes on CT or PET, EBUS-TNBA 
can be used to clarify the results. In patients with negative findings on EBUS-TNBA, 
conventional mediastinoscopy can be done to confirm the results. **Thoracic Tumor 
(T) Staging** The size of the tumor, its location and invasion of adjacent structures as 
reflected in the T status determines resectablity and - in cases with given resectablity - 
the extent of resection. In patients with T3 tumors or centrally located tumors that may 
necessitate a pneumonectomy, additional functional evaluation of the patient may be 
required to determine operability. Contrast-enhanced CT scan is the most commonly 
used imaging modality for T staging and can provide all the information needed. In select 
cases (e.g. Pancoast-Tumors) MRI may be useful to diagnose involvement of the brachial 
plexus and extension into the neural foramina and the spinal canal (3). Infiltration of the 
mediastinal great vessels, esophagus, trachea, and vertebral body is staged as T4 and 
usually defines unresectability. Findings on CT scan like obliteration of fat plane between 
the tumor and the mediastinum, circumference of contact between the tumor and the 
aorta, and the length of anatomical contact between the tumor and the mediastinum are 
not definitive signs for invasion. Both CT scan and MRI have similar diagnostic accuracy 
(56-89% for CT and 50-93% for MRI) in predicting mediastinal invasion, with no modality 
being considered to be distinctly superior (3).References: 1. Silvestri GA, et al. Methods 
for Staging Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd 
ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 
CHEST 2013; 143(5)(Suppl):e211S–e250S 2. NCCN Clinical Practice Guidelines in 
Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer, Version 7.2015, NCCN.org 
3. Nilendu C Purandare and Venkatesh Rangarajan.Imaging of lung cancer: Implications 
on staging and management. Indian J Radiol Imaging. 2015 Apr-Jun; 25(2): 109–120. 
Keywords: imaging studies in lung cancer, locoregional disease, NSCLC, lung cancer 
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This session reviews considerations of imaging for radiotherapy planning and delivery 
with particular focus on available completed and active prospective clinical research. 
State - of - the - art (intensive) treatment approaches, including definitive concurrent 
radiotherapy and chemotherapy for locally advanced lung cancer, and stereotactic 
body radiotherapy for treating early stage lung cancer, depend on the ability to 
precisely identify sites of gross tumor and surrounding critical normal structures. 
As such, the incorporation of optimal anatomic and functional imaging studies, both 
three-dimensional (3D) and four-dimensional (4D), in the radiation planning process 
has become increasing critical. Prospective trials initiated in the late 1990’s were the 
first studies assessing three-dimensional conformal radiotherapy based on computed 
tomography simulation. These trials directly assessed the ability to adequately dose 
3D targets and permitted implementation of tissue heterogeneity dose correction. The 
routine inclusion of mediastinal lymph node stations that were not pathologically enlarged 
was also questioned in the design of these studies, and while the initial prospective 
study from the University of North Carolina mandated elective nodal irradiation (ENI), 
subsequent studies performed by the RTOG and NCCTG did not include ENI. These single 
arm prospective studies suggested improved survival in stage III disease with delivery 
of high dose conventionally fractionated radiotherapy. Somewhat surprisingly, the 
landmark RTOG 0617 phase III trial did not confirm these results, but perhaps refinement 
of target volumes through improved imaging (and treatment planning/delivery) would 
lead to a different result. Functional imaging with FDG-PET (/CT) has had a profound 
overall impact on the staging and ultimate therapy for patients with lung cancer, and 
radiotherapy plans are frequently altered by including FDG-PET imaging data in addition 
to cross sectional imaging. Moreover, while the treatment volume may be increased, 
such as inclusion of PET avid mediastinal lymph nodes not enlarged on CT, the radiation 
target volume may also be reduced particularly in instances with atelectasis or tumor 
obstruction. Prospective studies in the US and Europe have prospectively assessed the 
impact of PET on radiotherapy planning. For example, RTOG 0515 reported that PET/
CT-derived tumor volumes were smaller than those derived by CT alone and that PET/
CT changed nodal GTV contours in most patients. Techniques to determine the gross 
target volume using PET images vary and include simple visualization and a variety of 
software / hardware based methods including automated solutions. This remains an 
area of active investigtion and an understanding of potential pitfalls of PET fusion with 
CT simulation is necessary in defining target volumes. Retrospective series suggest a 
correlation between the pre-treatment standardized uptake value (SUV) and survival in 
patients with non-small cell lung cancer. Though the primary objective of ACRIN 6668 / 
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Table 1: Prevalence of PD-L1 in NSCLC:
Percent tumor 
samples expressing 
PD-L1
Tumor surface expres-
sion cutoff for positivity
PD-L1 detection 
antibody Reference
49% 5% 28-8 Grosso et al. JCO, 2013
52% NR R&D B7-H1
Gatalica et al. Cancer 
Epidemiology biomark-
ers prevention, 2014
95% >10% 5H1 Dong et al. Nature Medicine, 2002
50% 11% MIH1 Konishi et al. CCR, 2004
21% (squamous only) >1% vs >5% vs H-score 5H1 Marti et al. JCO, 2014
60% 5% DAKO IHC Gettinger et al. JCO, 2014
50% 1% NR Sun et al. JCO, 2014
25% ≥ 50% NR Garon et al. NEJM, 2015
References: 1. Garon EB, et al. Pembrolizumab for the treatment of NSCLC. N 
Engl J Med. 2015;372(21):2018-2028. 2. Sorensen S, et al. PD-L1 expression and 
survival among advances NSCLC patients treated with chemotherapy. Ann Oncol. (25 
(Supplement 4)). 3. Soria J-C, et al. Clinical activity, safety and biomarkers of PD-L1 
blockade in NSCLC: Additional analyses from a clinical study of the engineered antibody 
MPDL3280A (anti-PDL1). 4. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive 
Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14(4):847-856. 5. Taube 
JM, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune 
microenvironment with response to anti-PD-1 therapy. CCR. 2014;20(19):5064-5074. 
6. Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody 
MPDL3280A in cancer patients. Nature. 2014;515(7528):563-567. 7. Soria J-C, et al. 
Immune checkpoint modulation for non-small cell lung cancer. CCR. 2015;21(10):2256-
2262. 8. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with 
advanced cancer. NEJM. 2012;366(26):2455-2465. 9. Kitazono S, et al. Reliability of 
Small Biopsy Samples Compared With Resected Specimens for the Determination of 
PD-L1 Expression in NSCLC. Clin Lung Cancer. 2015. 10. Rousseaux S, et al. Ectopic 
activation of germline and placental genes identifies aggressive metastasis-prone lung 
cancers. Sci Transl Med. 2013;5(186):186ra66. 11. Akbay EA, et al. Activation of the 
PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 
2013;3(12):1355-1363. 12. D’Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-
L1 expression in molecularly selected NSCLC patients. Br J Cancer. 2015;112(1):95-
102. 13. Chen N, et al. Upregulation of PD-L1 by EGFR Activation Mediates the Immune 
Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for 
NSCLC Patients with EGFR Mutation. J Thorac Oncol. 2015 14. Lin C, et al. Programmed 
Death-Ligand 1 Expression Predicts TKI Response and Better Prognosis in a Cohort of 
Patients With EGFR Mutation-Positive Lung Adenocarcinoma. Clin Lung Cancer. 2015. 
Keywords: PD-1/PD-L1 checkpoint, lung cancer, Immunohistochemistry, Biomarker 
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of America
Multiple genetic and epigenetic changes in several cancer types cause resistance 
to immune attack of tumors by inducing specific T cells tolerance and by expressing 
ligands that engage inhibitory receptors and block T cells activation, all resulting on 
T-cells anergy or exhaustion within the tumor microenvironment (1). In this process, 
programmed death 1 (PD-1) protein, a T-cell co-inhibitory receptor, and one of its ligands, 
PD-L1 (B7-H1 or CD274), play a pivotal role in the ability of tumor cells to evade the 
host’s immune system. Antibody-mediated blockade PD-1/PD-L1 induced durable tumor 
regression and prolonged disease stabilization in non-small cell carcinoma (NSCLC) (2). 
Although these studies have reported correlations between PD-L1 immunohistochemical 
(IHC) expression levels on NSCLC tumor cells and clinical responses to PD-1 and PD-L1 
inhibitors, there are patients with negative PD-L1 expression tumors who have showed 
similar responses than patients with positive expression. Recently, it has been shown that 
across multiple cancer types, including NSCLC, responses to anti-PD-L1 therapy were 
observed in patients with tumors expressing high levels of PD-L1, especially when PD-L1 
was expressed by tumor-associated infiltrating cells (TAICs). Altogether, these findings 
suggest that there are other factors in the tumor microenvironment, including tumor 
infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) that may drive 
responses to anti-PD-1/PD-L1 therapies, and be involved in lung cancer pathogenesis 
and progression. A number of studies have characterized the PD-L1 protein expression 
by immunohistochemistry (IHC) or immunofluorescence (IF) in all NSCLC stages using 
formalin-fixed and paraffin-embedded (FFPE) tumor tissues, and correlated those 
cells, although cytoplasmic staining was also considered with AQUA techniques. Stromal 
expression of PD-L1 on immune infiltrate (T cells, macrophages, DC) is also needed for 
scoring. Whereas DC and macrophages display a clear cytoplasmic membrane stain, this 
is not appreciated on lymphocytes. We have set up a study to assess a cutoff of positivity 
for prognosis analysis (1500 randomized early stage operable NSCLC patients with or 
without adjuvant cisplatin therapy after surgery) using E1L3N Cell Signaling antibody 
commercially available. We found that 20% of lung tumors cell expressed PD-L1 (≥ 20% 
intensity 2+3+), and 29% the immune stromal cells (T, macrophages, DC ) ≥ 10% intensity 
2+3+. PD-L1 positivity in both tumor and immune cells were seen in only 9% of NSCLC, 
20,7% were both negative . We double-check the scoring cells with Ming Tsao. The best 
concordance was for intensity 2+ /3+ (83%) although the intensity 1 was not reproducible 
( 40%) . There was no prognostic relevance of PD-L1 (tumor cells or stroma) in the control 
arm and pooled analysis, whatever cutoff by 10% increment or linear scoring was used. 
There was no statistical correlation between PDL1 expression (Tumor or Immune cells ) 
with clinicopathological criteria or histology . Only immune PD-L1 expression was 
correlated with a highly intense immune infiltrations (TILs ) ( P = 002 ). Not surprisingly, 
previous published evaluations of prognostic value were discordant likely because 
immune checkpoints modulators play both positive and negative roles in the immune 
inhibitory pathways with some redundancy, and patients series and assays were not 
comparable .The two meta-analyses with their numerous biases ( different antibodies, 
cutoffs, patient series composition in early and advanced stage, ethnicities and 
contribution of oncogene driven cancers, time of use of the initial resection sample or 
contemporary biopsy…) rendered their interpretation extremely problematic . Global 
result was favoring a poor prognosis of “PD-L1 positivity” on tumor cells. PD-L1 
expression as a predictive biomarker in cancer immunotherapy1,4–7: In the majority of 
phase I trials with four antibodies targeting the co-inhibitory receptor PD-1 or its primary 
ligand PD-L1 (Table 1), response rates appear higher in patients with increased tumor 
PD-L1 membrane expression by immunohistochemistry (IHC). However, different 
antibody assays, lack of standardization, different cutoff point to determine PD-L1 
positivity, the usual various pharmaceutic companies to recommend their companion 
test, and the small number of specimens available for testing, in addition with the 
variability of the intervals between biopsy and test, has surely hampered the conclusion 
and prevent consensus to be reached7,8. The most pertinent threshold was provided by 
Garon et al, with ≥ 50% of tumor cells PD-L1 positive to allow the highest response rate 
of 45% in pembrolizumab treated patients in the validation group1. In most trial series, 
biopsies or resected specimen were used restropectively although considerable 
difference between these samples occurs due to tumor heterogeneity. The reliability of 
small biopsy samples is questionned9. Indeed lung tumor heterogeneity is exemplary , 
and PD-L1 is typically heterogeneous in its distribution in the tumor bulk as is PD-L1 
positive immune cells . Multiple issues are yet addressed before PD-L1 is considered as 
a robust and definitive molecular predictor of efficacy. Various clones are currently being 
evaluated in and out of clinical trials (Ventana SP263, SP6242, Dako 28-8 and 22C3, Cell 
Signaling E1L3N). As for prognostic evaluations, thresholds of ≥ 1%, ≥ 5%, ≥ 10%, ≥ 50% 
or continuous H score have been used. In addition in a few trials, PD-L1 expression in TILs 
was predictive more than PD-L1 on tumor cells but the cutoff was not disclosed. IASLC 
pathology panel is leading a large multicentric reproducibility study ( Fred Hirsch )with 
lung pathologists of the IASLC Pathology Committee to address these 
questions. Alternative regulations of PD-1/PD-L1 pathway The ability of cancer cells to 
evade immunosurveillance results from the production of immunosuppressive 
chemokines by the tumor cells, loss of MHC antigen expression, a higher number of T-reg 
cells in the tumor microenvironment and inhibitory pathways referred to as immune 
checkpoints, which result in a link of inhibitory ligands to their receptors (CTLA4-PD-1, 
PD-L1/PD-L2-PD-1) are unfrequently upregulated in lung cancer. Moreover immune-
editing was associated with the illegitimate expression of tumor germ cell (testis /
placenta) antigens10, normally absent in normal tissue but testis and placenta, inducing a 
state of immune escape when aberrantly expressed in lung cancer correlating with highly 
and metastatic aggressive behavior. While patients with PD-L1 overexpression based on 
different assays, cutoff, tumor material, have more robust response to PD-L1 (67-100% 
ORR), PD-L1 negative NSCLC ranges from 0 to 15%, suggesting that PD-L1 IHC is not a 
clear and exclusive predictive biomarker. This is not surprising due to multiple regulations 
at the two clinically relevant immunologic synapses: the tumor-T cell interface, and the 
APC-T cell interface, both playing role in tumor control. In all cohorts, PD-L1 in tumor cells 
was observed with or without immune infiltration. TILs intense infiltration occurred in 10% 
of NSCLC across histology and was a statistically significant good prognosis factor 
although the oncogene driven adenocarcinomas lack immune infiltrate. EGFR pathway 
upregulates PD-L1 as well as PTEN loss11–14. In addition the 2 synapses are functionally 
affected by HLA loss (>50% of NSCLC), EGFR signaling, PTEN loss, the density of CD8 in 
infiltrate available for cytotoxicity and even more CD8 +/PD1+ exhausted cytotoxic T 
cells among TILs . The best predictive biomarker might not be simply binary . Biopsies 
may underevaluate the pertinent tumor-stroma interface , PD-L1 biologically relevant ( 
more than 1-10% of tumor cell ! ) has already taken place and destroyed the potentially 
reactive CD8 T cells. Indeed secondary biomarkers may drive the tumor in association or 
independently of PD-1/PD-L1 pathway. 
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identified in conjunction (i.e., complex/compound mutations in >15% of cases) with other 
less well-defined EGFR kinase domain mutations (such as E709X, L747X, S768X, R776X, 
T790M, A871G, among others); and these double mutations may affect some of the 
single mutant pattern of response to EGFR TKIs. In the absence of formal regulatory 
approval for G719X, exon 19 inserted and L861Q mutated lung adenocarcinomas (groups 
that comprise more than 5% of all EGFR mutated tumors), the use of EGFR TKIs is often 
provided as “off label therapy” with clinical management similar to EGFR-exon 19 deletions 
or EGFR-L858R mutated lung adenocarcinomas. How often EGFR-T790M emerges as a 
mechanism of resistance in these tumors is unclear. The third most common and most 
diverse group of EGFR mutations are EGFR exon 20 insertions mutations (up to 10% of all 
EGFR mutations), which usually occur near the end of the C-helix within the N-lobe of the 
kinase, after residue M766 up to amino-acid C775, but a small subset map to the middle 
of the C-helix affecting amino-acids E762 to Y764. Unlike the other aforementioned EGFR 
mutated lung adenocarcinomas, most tumors with EGFR exon 20 insertion mutations are 
insensitive (i.e., do not respond radiographically or clinically) to 1st and 2nd generation EGFR 
TKIs; with the exception of EGFR-A763_Y764insFQEA (identical to D761_E762insEAFQ 
and with structural homology similar to exon 21 single mutants by inducing a N-terminal 
shift in the C-helix while replacing the active site residue E762 of EGFR), where responses 
to 1st and 2nd generation EGFR TKIs arise. Preclinical models – that mirror clinical 
behavior – have convincingly demonstrated that Y764_V765insHH, M766_A767insAI, 
A767_V769dupASV, D770_N771insNPG, D770_N771insSVD and H773_V774insH are not 
inhibited by clinically-achievable doses of gefitinib, erlotinib or afatinib. The structure of 
D770_N771insNPG (a representative EGFR TKI-insensitive exon 20 mutation at the most 
common insertion position D770_N771) has disclosed the amino acids inserted lock the 
helix in its active position but don’t alter the kinase domain TKI biding pocket (i.e., these 
mutants lack a therapeutic window to TKIs when compared to wild-type). Therefore, 
EGFR exon 20 insertion mutations affecting amino-acids Y764 to V774 should be 
classified as non-sensitizing to EGFR TKIs and development of mutation-specific TKIs may 
be hampered by the lack of therapeutic window of the kinase domain when compared 
to wild-type EGFR. Most EGFR exon 20 insertion mutated lung adenocarcinomas – in 
lieu of innovative clinical trials – should be treated with evidence-based approaches for 
“oncogene negative” lung adenocarcinomas. In conclusion, EGFR mutations comprise 
a heterogeneous group of activating oncogene mutations that have become the most 
clinically-relevant “driver” oncogenes for the clinical care of lung adenocarcinomas. 
Keywords: L858R, EGFR-T790M, Exon 20 Insertion, exon 19 deletion
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Chromosomal rearrangements involving the ALK, ROS1, RET, and NTRK1 tyrosine kinases 
with several different gene fusion partners have been identified as therapeutically 
actionable genomic alterations in collectively up to 10% of non-small cell lung cancer 
(NSCLC) [1-4]. Notably, these kinase fusions have also been detected in several 
other epithelial, hematologic, neural, and mesenchymal malignancies, underscoring 
the importance of understanding fusion kinase biology in order to develop the most 
effective therapeutic strategies. In fact, numerous studies have now shown that tumors 
which harbor ALK, ROS1, RET, or NTRK1fusions exhibit a dependency on the activated 
tyrosine kinase for proliferation and survival. This dependency, or ‘oncogene addiction’, 
makes the cancer highly sensitive to small molecule tyrosine kinase inhibitors (TKIs). 
In particular, ALK serves as the paradigm for therapeutically targetable kinase fusions 
in NSCLC. Crizotinib was the first ALK TKI to be approved for treatment of patients 
with ALK fusion positive (ALK+) NSCLC. Several other ALK TKIs, including ceritinib, 
alectinib, X-396, brigatinib, ASP3026, and PF-06463922 are also being developed for 
the treatment of ALK+ malignancies. These ‘next-generation’ ALK TKIs typically have 
more on-target efficacy against the ALK kinase domain and are able to overcome some 
of the crizotinib resistance mutations which have been observed clinically. While much 
emphasis has been placed on the study of the tyrosine kinase portion of ALK, ROS1, RET, 
and NTRK1 fusions, less is known about the 5’ gene fusion partners. However, the biology 
of the 5’ gene fusion partner is essential for driving the expression and function of the 
kinase fusion. Numerous different 5’ gene partners have been identified for each of 
the kinase fusions in NSCLC (Table 1). For example, EML4 is the most common fusion 
partner for ALK in NSCLC; however, KIF5B, TFG, KLC1, PTPN3, STRN, and SQSTM1 have 
also been identified as ALK partner genes in this disease. To add to the complexity, 
more than 10 different EML4-ALK fusions have been detected in NSCLC, varying by 
the extent of the EML4 gene which is fused to ALK. Likewise, numerous gene fusion 
partners have been described for ROS1, RET, and NTRK1 fusions in lung cancer (Table 
1). Although the fusion partners can vary, they share three basic features. First, the 
promoter of the 5’ fusion partner dictates the expression of the fusion. Second, most 
fusion partners contribute an oligomerization domain, which can aid in auto-activation 
of the kinase [5]; although, this has not been verified for all fusion partners. The most 
common oligomerization domain found in the fusion partners is the coiled-coil domain. 
EML4-ALK homodimerizes by virtue of a coiled-coil domain in EML4. Disruption of this 
domain abrogates the ability of EML4-ALK to transform cells [5]. Furthermore, the extent 
of oligomerization may be important for transformation; some fusions dimerize, trimerize 
[6], or form tetramers [7]. Lastly, the 5’ gene fusion partner also determines subcellular 
localization of the fusion, and this can have significant effects on the interaction of the 
kinase fusion with other cellular proteins, influencing activation, signaling, function, 
and degradation of the fusion. For example, a thorough structural analysis of the most 
common EML4-ALK variants found in lung cancer revealed differences in the variant’s 
function, localization, and sensitivity to HSP90 inhibitors in clinical use [6]. Additionally, 
for some fusions, subcellular localization controls fusion activation, as is the case for 
findings with patient’s outcome, and in a limited number of cases with response to 
immunotherapy (3, 4). Those studies differ on the type of specimens (whole histology 
sections vs. tissue microarrays [TMAs]), the protein expression analysis (IHC vs. IF), 
and the quantification assessment (image analysis vs. microscope observation). Only 
few studies have attempted to correlate the expression of PD-L1 and TAICs, particularly 
TILs, using a limited number of IHC markers (e.g., CD8, CD45) (5). Up to date, there is 
no published study in which a comprehensive panel of immune markers, including PD-L1, 
has been performed attempting to develop a clinical relevant immuno-score system in 
surgically resected NSCLCs and explore their role as predictive markers of response 
to immunotherapy. We will present data on the characterization of TAICs in lung cancer 
tumor specimens using a large panel of markers (PD-L1, PD-1, CD3, CD4, CD8, CD45RO, 
CD57, Granzyme B, FOXP3, OX-40, and CD68) examined by both uniplex IHC and multiple 
immunofluorescence (IF) methodologies, and quantitated using image analysis systems 
(Aperio, Vectra and MultiOmyx). In surgically resected NSCLC tumor tissues the analysis 
was performed at both peri-tumoral and intra-tumoral compartments, and those data 
provided interesting data on the spatial distribution of TAICs and the expression of 
immune checkpoints in lung tumors. Our approach allowed us to devise an immuno-
score system for lung cancer tissue specimens using both surgically resected and small 
diagnostic biopsies (core needle biopsies, CNBs) that correlated with clinical, pathological 
and molecular features of tumors. References: 1. Mellman I, Coukos G, Dranoff G: 
Cancer immunotherapy comes of age. Nature 2011, 480:480-9. 2. Topalian SL, Hodi FS, 
Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman 
JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen 
L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, 
Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M: Safety, activity, and 
immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine 
2012, 366:2443-54. 3. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, 
Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, 
Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi 
FS: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer 
patients. Nature 2014, 515:563-7. 4. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, 
Chen L, Pardoll DM, Topalian SL, Anders RA: Association of PD-1, PD-1 Ligands, and Other 
Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. 
Clinical cancer research : an official journal of the American Association for Cancer 
Research 2014, 20:5064-74. 5. Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin 
J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL. Objective measurement and clinical 
significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. 2015 Feb 3;107(3). 
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MS22.01 EGFR Mutations (e.g., Exon 18 vs. 19 vs. 20 vs. 21) Daniel B. Costa 
Hematology/Oncology, Beth Israel Deaconess Medical Center/Harvard Medical School, 
Boston/MA/United States of America
The most common epidermal growth factor receptor (EGFR) mutations identified in lung 
adenocarcinomas – termed classic somatic EGFR kinase domain mutations – occur as 
small inframe deletion (indels) mutations within exon 19 (45% of EGFR mutations, the most 
common delE746_A750) or the exon 21 L858R (40% of EGFR mutations) point mutation. 
Tumors harboring these classic EGFR mutations become addicted to EGFR’s signaling 
cascades and are susceptible (i.e., have a favorable therapeutic window) to inhibition by 
ATP-mimetic reversible (1st generation) EGFR tyrosine kinase inhibitors (TKIs) and C797-
covalent (either wild-type specific [2nd generation] or mutation specific [3rd generation]) 
EGFR TKIs. EGFR-exon 19 deletions or EGFR-L858R are predictors of radiographic 
response and progression-free survival when gefitinib, erlotinib (1st generation) and 
afatinib (2nd generation) are used for patients with advanced lung adenocarcinomas. 
These anti-cancer compounds are approved by regulatory agencies and have 
revolutionized evidence-based care of advanced lung cancer. However, the palliative 
benefits of these drugs are limited by acquired mechanisms of tumor resistance, such 
as the gatekeeper EGFR-T790M mutation (which in turn can be inhibited by 3rd generation 
TKIs: mereletinib/AZD9291 and rociletinib. Both of these drugs are undergoing rapid 
development as palliative therapies for EGFR exon 19 deletion or L858R plus T790M 
mutated lung cancer and will soon be approved for evidence-based clinical care). The 
median survival of patients with EGFR-exon 19 deleted or EGFR-L858R mutated lung 
adenocarcinomas usually exceeds 24-36 months with a substantial portion of patients 
living for longer than 3 years when given sequential EGFR TKI therapy plus evidence-
based cytotoxic chemotherapy. Consistently, patients with EGFR exon 19 deletion 
mutated lung adenocarcinomas have improved outcomes on 1st and 2nd generations 
EGFR TKIs than those with L858R mutated tumors (for biological and clinical reasons 
that remain to be elucidated). Other EGFR mutations have also been linked in preclinical 
models and in patients with lung adenocarcinomas to sensitivity to 1st and 2nd generation 
EGFR inhibitors. These include exon 18 point mutations in position G719 (G719A, C or S 
[3% of EGFR mutations]), inframe exon 19 insertions (1% of EGFR mutations), the exon 
20 S768I mutation (<1% of EGFR mutations) and the exon 21 L861Q mutation (2% of 
EGFR mutations). Since most data for response to EGFR TKIs for these less frequent 
EGFR mutated lung adenocarcinomas comes from retrospective studies or single center 
experience; the true response rate, progression-free survival and overall survival of 
these tumors when given gefitinib, erlotinib, afatinib and 3rd generation EGFR TKIs is not 
clear. Interestingly, G719X, L858R and L861Q TKI-sensitive mutations can be commonly 
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MS22.04 KRAS - Are All KRAS Mutations the Same? Thomas E. Stinchcombe 
Hematology and Oncology, University of North Carolina, Chapel Hill/NC/United States 
of America
KRAS mutations are the most commonly detected mutation in non-small cell lung cancer 
(NSCLC). KRAS mutations encode proteins containing a single amino acid substitution 
and in NSCLC most mutations are in codons 12 and 13. KRAS mutant proteins are 
constitutively activated leading to stimulus independent activation of the RAF-MEK-
ERK pathway. KRAS mutations are associated with a history of tobacco use, and are 
more common in adenocarcinoma than in squamous histology. Patients with history of 
never smoking have a higher rate of transition mutations, but the biological and clinical 
significance is unknown.1KRAS mutations are mutually exclusive with EGFR mutations 
andALK and ROS1 rearrangements. The benefits of testing for KRAS mutations are 
to eliminate the need for further molecular testing and to enroll patients in trials 
investigating KRAS directed therapy. KRAS mutational status is predictive of benefit 
of anti-EGFR monoclonal antibodies in advanced colorectal cancer (CRC), and the 
benefit is restricted to patients with KRAS wild-type CRC. However, patients with 
metastatic CRC with KRAS G13D mutations have better prognosis and benefit from 
monoclonal antibodies demonstrating that the specific KRAS mutation may have clinical 
implications.2KRAS mutational status is not predictive of benefit of cetuximab in advanced 
NSCLC.3 The frequency and distribution of KRAS mutation subtype differs significantly 
among different cancer types. KRAS mutations can activate multiple downstream 
signaling pathways and activation of signaling pathways may be cancer-specific. The 
implication is that the success and failures of targeted agents against KRAS pathway 
in other cancers may not be relevant for the development of KRAS pathway targeting 
agents in NSCLC. A target therapy is not currently available for KRAS mutant NSCLC, 
and the recent focus has been on the development of MEK inhibitors. A randomized 
phase II trial of docetaxel alone or with selumetinib revealed that patients assigned to 
the selumetinib arm experienced a statistically significant higher objective response rate 
(ORR) (37% vs. 0%, p<0.0001) and longer progression-free survival (PFS) (hazard ratio 
of 0.58, 80% CI, 0.42-0.79, p=0.014; median 5.3 and 2.1 months respectively) and a 
numerically longer overall survival (OS) (HR of 0.80, 80% CI, 5.6 to 1.14, p=0.21; median 
9.4 and 5.2 months, respectively).4 A phase II trial compared trametinib to docetaxel 
in patients with KRAS mutant NSCLC. The ORR was same in the two treatment arms 
(12%), and the PFS similar (HR of 1.14; 95% CI, 0.75 to 1.75; p=0.5197).5,6 Trametinib 
was also investigated in two separate phase IB/II trials in combination with docetaxel 
or pemetrexed; patients with both KRAS mutant and wild-type NSCLC were enrolled. 
Patients with KRAS mutant and wild-type NSCLC had similar ORR and PFS raising the 
question if KRAS mutations are predictive of MEK inhibitor benefit. In a subset analysis 
of the trial of trametinib and docetaxel patients with KRAS G12C mutations (n=8) had 
an ORR of 40% and a disease control rate of 80%.7 This subset analysis is hypothesis 
generating and illustrates the need to collect the specific KRAS mutations in trials of 
novel agents. The prognostic and predictive value of KRAS mutations was investigated 
in a pooled analysis of resected patients enrolled in adjuvant chemotherapy trials.8 In 
the observation cohort no difference OS based KRAS mutational status or subtype was 
observed, and KRAS mutation status and mutation subtype was not prognostic. In the 
adjuvant chemotherapy cohort no significant OS benefit was observed among patients 
with KRAS wild-type and KRAS codon 12 mutant NSCLC; a detrimental effect of adjuvant 
chemotherapy on OS was observed among the 24 patients with KRAS codon 13 mutant 
NSCLC (HR of 5.78; 95% CI, 2.06-16.2; p<0.001; interaction p=0.002). This observation 
needs to be prospectively validated in a larger sample before being used to make decisions 
about the adjuvant chemotherapy. Preclinical data suggest that the presence or absence 
other mutations other thanKRAS may impact the efficacy of selumetinib.9KRAS mutations 
are frequently found in patients with a significant smoking history, and tobacco related 
NSCLC is associated high rate of mutations.10 Thus, the potential impact of concurrent 
mutations or molecular alterations should be considered in future investigations. 1. 
Dogan S, Shen R, Ang DC, et al: Molecular epidemiology of EGFR and KRAS mutations 
in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related 
KRAS-mutant cancers. Clin Cancer Res 18:6169-77, 2012 2. De Roock W, Jonker DJ, 
Di Nicolantonio F, et al: Association of KRAS p.G13D mutation with outcome in patients 
with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. 
JAMA 304:1812-20, 2010 3. O’Byrne KJ, Gatzemeier U, Bondarenko I, et al: Molecular 
biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 
3 FLEX study. Lancet Oncol 12:795-805, 2011 4. Janne PA, Shaw AT, Pereira JR, et 
al: Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: 
a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14:38-
47, 2013 5. Blumenschein GR, Smit EF, Planchard D, et al: MEK114653: A randomized, 
multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with 
docetaxel (D) in KRAS-mutant advanced non–small cell lung cancer (NSCLC). Journal 
of Clinical Oncology 31:abstract 8029, 2013 6. Kelly K, Mazieres J, Leighl NB, et al: 
Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed 
for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A 
phase I/Ib trial. Journal of Clinical Oncology 31:abstract 8027, 2013 7. Gandara DR, 
Hiret S, Blumenschein GR, et al: Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in 
combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell 
lung cancer (NSCLC): A phase I/Ib trial. Journal of Clinical Oncology 31:abstract 8028, 
2013 8. Shepherd FA, Domerg C, Hainaut P, et al: Pooled analysis of the prognostic 
and predictive effects of KRAS mutation status and KRAS mutation subtype in early-
stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin 
Oncol 31:2173-81, 2013 9. Chen Z, Cheng K, Walton Z, et al: A murine lung cancer 
co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483:613-
7, 2012 10. Lawrence MS, Stojanov P, Polak P, et al: Mutational heterogeneity in 
cancer and the search for new cancer-associated genes. Nature 499:214-8, 2013 
Keywords: kras mutation, MEK inhibitor, Targeted therapy, adjuvant chemotherapy
MSN-ALK which congregates at the plasma membrane [8]. While most ALK fusions 
appear pan-cytoplasmic, others like RANBP2-ALK (perinuclear) and NPM-ALK (nuclear, 
nucleolar, and cytoplasmic) have different localization, the effects of which have yet to 
be investigated [9]. Very little is known about how signaling downstream of an ALK fusion 
may differ from that of a ROS1 or RET fusion in lung cancer. In addition, how different 
gene fusion partners may affect downstream signaling from a specific kinase fusion 
also remains an open question. One provocative study of various ALK fusions found in 
anaplastic large cell lymphoma demonstrated that the fusions were differentially able 
to activate PI3K and JAK-STAT signaling [10]. Furthermore, the ability of the different 
ALK fusions to activate PI3K kinase activity correlated with the fusion’s transendothelial 
migration properties. Overall, this study supports the hypothesis that the specific fusion 
gene partner defines the activity, signaling specificity, and phenotypic properties of 
the kinase fusion. Notably, the most commonly employed clinical diagnostics used 
to detect kinase fusions, including immunohistochemistry (IHC) and fluorescence in 
situ hybridization (FISH), will not specify which fusion partner is present within a tumor. 
However, as more sophisticated next-generation sequencing technologies come to the 
forefront of clinical diagnostics, clinicians will not only know that a tyrosine kinase fusion 
is present, but also to which specific gene partner the kinase is fused At present, there is 
very little data, all retrospective, to address the question of how a different fusion partner 
may affect clinical outcomes and disease responsiveness to targeted therapies. This is 
largely because the trials have used methods, such as IHC and FISH, to define eligibility 
criteria. In-depth contextual studies in pre-clinical models of lung cancer and in clinical 
trials in patients with kinase fusion positive disease are lacking; however, further analysis 
of this issue will allow us to refine the treatment of fusion positive lung cancer on a 
more personalized level in order to more effectively inhibit tumor growth and understand 
potential therapeutic resistance mechanisms. References 1. Kwak, E.L., et al., Anaplastic 
lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 2010. 363(18): p. 
1693-703. 2. Shaw, A.T., et al., Crizotinib in ROS1-rearranged non-small-cell lung cancer. N 
Engl J Med, 2014. 371(21): p. 1963-71. 3. Drilon, A., et al., Response to Cabozantinib 
in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov, 2013. 3(6): 
p. 630-5. 4. Vaishnavi, A., et al., Oncogenic and drug-sensitive NTRK1 rearrangements in 
lung cancer. Nat Med, 2013. 19(11): p. 1469-72. 5. Soda, M., et al., Identification of the 
transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007. 448(7153): 
p. 561-6. 6. Richards, M.W., et al., Microtubule association of EML proteins and the EML4-ALK 
variant 3 oncoprotein require an N-terminal trimerization domain. Biochem J, 2015. 467(3): 
p. 529-36. 7. Zhao, X., et al., Structure of the Bcr-Abl oncoprotein oligomerization 
domain. Nat Struct Biol, 2002. 9(2): p. 117-20. 8. Tort, F., et al., Molecular characterization 
of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab 
Invest, 2001. 81(3): p. 419-26. 9. Chiarle, R., et al., The anaplastic lymphoma kinase in 
the pathogenesis of cancer. Nat Rev Cancer, 2008. 8(1): p. 11-23. 10. Armstrong, F., et 
al., Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion 
properties of NIH3T3 cells. Oncogene, 2004. 23(36): p. 6071-82.
Table 1: Spectrum of tyrosine kinase fusions detected to date in NSCLC
Kinase Gene Fusion partner
ALK EML4
KIF5B
KLC1
PTPN3
SQSTM1
STRN
TFG
NTRK1 CD74
MPRIP
ROS1 CCDC6
CD74
CLTC
EZR
FIG
GOPC
LIMA
LRIG3
MSN
SDC4
SLC34A2
TPM3
RET CCDC6
CUX1
KIAA1468
KIF5B
NCOA
TRIM33
 
Keywords: RET, ros1, NTRK1, ALK
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smokers. Int J Radiat Biol. 2015 May 13:1-24. 9.World Health Organization. Handbook on 
indoor radon. A public health perspective. WHO Geneva, Switzerland, 2009. 10. Axelsson 
G, Anderssson EM, Barregard L. Lung cancer risk from radon exposure in dwellings in 
Sweden: how many cases can be prevented if radon levels are lowered? Cancer Causes 
Control 2015; 26 (4): 541-7.
Geographic area Population Controls Cases Relative risk per 100 Bq/m3 (95% CI)
USA, Canada 7 studies 4 966 3 662 1.10 (0.99-1.26)
China 2 studies 1 995 1 050 1.13 (1.01-1.26)
Europe 13 studies 14 208 7 148 1.08 (1.03-1.16)
Table 1: Pooled analysis of case-control studies of indoor radon exposure, based on 
measured concentration radon (4-6).  
Keywords: radon, lung cancer, exposure, prevention
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MS23.02 Air Pollution-Outdoor; Biomass Smoke; Cooking Fuels Paolo Boffetta 
Tisch Cancer Institute, ICAHN School of Medicine at Mount Sinai, New York Ny/NY/United 
States of America
Indoor air pollution. Indoor air pollution is thought to be the main determinant of 
the elevated risk of lung cancer experienced by nonsmoking women living in several 
regions of China and other Asian countries. The evidence is stronger for coal burning 
in poorly ventilated houses, but also burning of wood and other solid fuels, as well as 
fumes from high-temperature cooking using unrefined vegetable oils such as rapeseed 
oil. A positive association between various indicators of indoor air pollution and lung 
cancer risk has also been reported in populations exposed to less extreme conditions 
than those encountered by some Chinese women, for example populations in Central 
and Eastern Europe and other regions. Overall, the evidence is stronger for studies of 
indoor pollution in population which used coal as main fuel. IARC has classified indoor 
emissions from household combustion of coal as established human carcinogen, and 
indoor emissions from household combustion of biomass fuel (primarily wood) as 
probable human carcinogen. Outdoor air pollution. There is abundant evidence that 
lung cancer rates are higher in cities than in rural settings.This pattern, however, might 
result from confounding by other factors, notably tobacco smoking, and occupational 
exposures, rather than from air pollution. Cohort and case-control studies are limited 
by difficulties in assessing past exposure to the relevant air pollutants. The exposure to 
air pollution has been assessed either on the basis of proxy indicators—for example, 
the number of inhabitants in the community of residence, residence near a major 
pollution source—or on the basis of actual data on pollutant levels. These data, however, 
reflect mainly present levels or levels in the recent past and refer to total suspended 
particulates, sulfur oxides, and nitrogen oxides, which are not likely to be the agents 
responsible for the carcinogenic effect, if any, of air pollution. Furthermore, the sources 
of data might cover quite a wide area, masking small-scale differences in exposure 
levels. The combined evidence suggests that urban air pollution might entail a small 
excess risk of lung cancer on the order of 50%, but residual confounding cannot be 
excluded. In four cohort studies, assessment of exposure to fine particles was based 
on environmental measurements. The results of these studies are suggestive of a small 
increase in risk among people classified as most highly exposed to air pollution. IARC 
recently classified outdoor air pollution as an established lung carcinogen in humans. 
Keywords: outdoor air pollution, indoor air pollution, cooking fumes, lung cancer
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MS23.03 Legalization of Marijuana: Implication for Lung Health James R. Jett 
Oncology, National Jewish Health, Denver/CO/United States of America
Marijuana is a mixture of dried, shredded leaves, flowers, stems, and seeds from the 
hemp plant, Cannabis Sativa. Cannabis is a genus of flowering plants that has psychoactive 
properties. The main active chemical is THC (delta-9-tetrahydrocannabinol). The 
psychoactive effects are primarily a state of relaxation and euphoria to some degree. 
Record of cannabis use dates back to the Chinese Emperor Shen Nung in 2727 BC. In 
the 1500s, Spaniards imported it into the Americas. The amount of THC in marijuana 
has been steadily increasing and is much stronger now than 30 years ago. The average 
THC levels have risen from less than 1% in the 1970s to 12% in 2012. (1,2) Uruguay is 
the first and only country to fully legalize marijuana, but a number of other countries 
are considering doing so. The Netherlands, especially Amsterdam, is well-known for its 
tolerance of marijuana use. Medical marijuana use is legal in 23 of the 50 states in the 
USA. The states of Colorado, Washington, Oregon, Alaska, and District of Columbia have 
legalized recreational marijuana use. A number of other states have decriminalized the 
use of marijuana and others are considering approval for recreational use. Most users 
smoke marijuana in hand-rolled cigarettes called joints, but it can also be smoked in blunts 
(cigars), bowls, pipes, bongs, or vaporizers. It is also available in oral forms for ingestion. 
This lecture will be limited to the health effects on the lungs of smoking marijuana. 
(2,3) Lung Effects: Marijuana smoke contains many of the same toxins and carcinogens 
as tobacco smoke. (4) In a systematic comparison of smoke from marijuana and tobacco 
cigarettes consumed under two sets of smoking conditions, there were qualitative 
similarities and some quantitative differences. Ammonia was 20-fold greater in marijuana. 
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MS23.01 Radon and Lung Cancer Boris Melloni Pulmonary Diseases and Thoracic 
Oncology, Universitary Hospital of Limoges, Limoges/France
Radon exposure is recognized as the second cause of lung cancer, after active cigarette 
smoking (1,2). Each year, 15 000 to 21 000 lung cancer deaths are estimated for the 
consequence of radon exposure in USA. In Europe, 18 000 deaths are attributable to 
radon, around 9 % of deaths from lung cancer. Atmospheric concentrations of natural 
radon gas vary importantly due to concentration of 226Ra and 232Th, present in soil of some 
geographic areas. Most of the radon in indoor spaces of houses and other dwellings is 
derived from the inert gas transfer from the soil or rock. Short-lived radioactive progeny 
from inhaled radon, polonium-214 and polonium-218 induce emission of alpha particles 
(2 protons and 2 neutrons) that directly damage DNA and can induce lung cancer. Radon 
progenies are inhaled either as free particles, or attached to airborne particles, as dust. 
The adverse effect of radon has been described since the fifteenth century in the Ore 
Mountains of Eastern Europe. As early as the 20th century, radon was identified a cause 
of lung cancer in miners in Eastern Europe. Large epidemiological studies on miners 
showed a link between lung cancer risk and radon exposure at high concentration. 
In 1988, International Agency for Research on Cancer (IARC) recognized radon, as a 
group 1 carcinogen, based on the results of epidemiological studies in uranium miners. 
The risk was correlated to radon exposure in eleven cohort studies in non-smoker and 
smoker miners, with a sub-multiplicative interaction between smoking and radon (3). 
In 1970s, it was recognized that the population could be exposed to radon in indoor 
environments, including home and dwellings. An association between the risk of lung 
cancer and residential radon concentration during the previous 30 years was outlined. 
Epidemiological case-control studies have reported clear evidence of a relation between 
lung cancer incidences in the general population and radon indoor exposure, at an average 
annual concentration above 200 Bq/m3 (4,5,6). A dose-response model is used without 
a threshold value, but this concept is matter of controversy for low dose To improve 
the statistical power, pooled case-control studies have been made in the USA, Europe 
and China, after variable adjustment for sex, smoking habits (Table 1). The combined 
estimation from the pooling studies showed an increase of 10% per 100 Bq/m3 (7). In 
the European pooled case-control studies, the estimated lung cancer risk, at 0, 100, and 
400 Bq/m3, was 25.8, 29.9, 42.3 for current smokers (15-24 cigarettes per day) versus 
1.0, 1.2, 1.6 for lifelong non-smokers (6). The relationship between active smoking and 
radon exposure seems to be synergic. The same relation is observed in patients with 
lung cancer exposed both to radon and environmental tobacco smoke (ETS). In Spain, 
a case control-study demonstrates that ETS exposure at home upgrades significantly 
the risk in individuals with radon exposure than 200 Bq/m3 (7). Concerning histological 
types of lung cancers observed, an excessive relative risk for small-cell lung cancer 
was first reported among the underground miners. In fact, all the histological types are 
present, most common being adenocarcinoma and squamous cell carcinomas. A recent 
study in Spain, in never-smoker cases exposed to radon, finds that the most frequent 
histology is adenocarcinoma, as now observed in non-smoker patients (8). The exact 
mechanism of lung cancer induced by alpha particles is not known. Alpha particles can 
cause DNA damage, chromosome aberrations, and generate reactive oxygen species. 
The results are a cell cycle modification, an up- and down-regulation of cytokines, and 
an increased potential for carcinogenesis. Despite these promising investigations on a 
mutation hotspot in one codon of the TP53 gene and in other regions, any molecular 
fingerprint of alpha particles has been identified in specific genes involved in lung cancer 
carcinogenesis. Reducing and controlling this natural radiation, the second cause of lung 
cancer, is paramount in the general population, especially in radon prone area. The WHO 
guideline has proposed a reference level of 100 Bq/m3 (2.7 pCi/L) to reduce the risk 
of lung cancer in the population (9). In the USA, the Environmental Protection Agency 
action level is 148 Bq/m3 (4 pCi/L) for the home. In Sweden, 35-40 % of lung cancer 
attributable to radon could be prevented if in all homes or dwellings radon concentrations 
over 100 Bq/m3 were lowered to 100 Bq/m3 (10). Buildings or houses with high radon 
concentration must be identified. New constructions should be “radon-proof”. Many 
strategies have been proposed to reduce indoor radon levels in the home. In conclusion, 
radon is the second leading cause of lung cancer among smokers and a major cause in 
non-smokers. Radon exposure must be identified in the population to reduce the level 
of exposure to individuals. Preventive measures are necessary for new homes in a high 
radon area. Smoking cessation is also important to reduce the risk of lung cancer from 
radon exposure. Bibliography 1. Samet JM, Avila-Tang E, Boffetta P, et al. Lung cancer 
in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 
2009;15(18):5626-45. 2. Tirmarche M, Harrison JD, Laurier D et al. ICPR, 2010. Lung 
cancer risk from radon and progeny and statement on radon. ICPR publications 115, Ann. 
ICPR 40(1). 3. Lubin JH, Boice JD, Edling JC et al. 1994. Radon and lung cancer risk: A 
joint analysis of 11 underground miner studies. Publication No. 96-3644. US National 
Institutes of Health, Bethesda, MD, USA. 4. Krewski D, Lubin JH, Zielenski JM at al. Radon 
and risk of lung cancer: a combined analysis of 7 North-American case-control studies. 
Epidemiology 2005;16:137-45. 5. Lubin JH, Wang ZY, Boice JD Jr et al. Risk of lung cancer 
and residential radon in China: pooled results of two studies. Int J Cancer 2004;109:132-
7. 6. Darby S, Hill D, Deo H et al. Residential radon and lung cancer-detailed results of a 
collaborative analysis of individual data on 7,148 persons with lung cancer and 14,208 
persons without lung cancer from 13 epidemiological studies in Europe. Scand J Work 
Environ Health 2006;32(suppl 1):1-83. 7. Torres-Duràn M, Ruano-Ravina A, Parente-
Lamelas I et al. Lung cancer in never smokers. A case-control study in a radon prone area 
(Galicia, Spain). Eur Respir J 2014;44(4):994-1001. 8. Torres-Duràn M, Ruano-Ravina 
A, Parente-Lamelas I et al. Residential radon and lung cancer characteristics in never 
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Eastern countries, waterpipe use has markedly increased in Europe and the US, and 
is especially popular among young people who frequently misperceive that the water 
filters out the harmful chemicals in the smoke. WP smoke contains many of the known 
toxicants and carcinogens found in cigarette smoke, including polycyclic aromatic 
hydrocarbons (PAHs), nicotine, TSNAs, volatile aldehydes and CO. Due to the burning 
charcoal, WP users are exposed to higher levels of CO, benzene and PAHs compared to 
cigarettes smokers. E-cigarettes, the most popular types of electronic nicotine delivery 
systems (ENDS), were developed in China in approximately 2003 and are increasingly 
popular in the US and Europe. ENDS heat an “e-liquid”, typically composed of nicotine, 
propylene glycol or glycerin, and flavorings into an aerosol that is inhaled by the user. 
The chemical constituents in ENDS aerosols are impacted by the device design, the 
e-liquid composition and user behaviors, and have not been adequately characterized. 
Carcinogenic and toxic compounds that have been detected in e-cigarette liquids and 
aerosols include TSNAs, formaldehyde, acetaldehyde, acrolein, PAHs and metals. 
However, in general, the amounts identified have been less than in cigarette smoke. The 
potential cytotoxicity and carcinogenicity of e-cigarette flavorings are being investigated. 
Keywords: Tobacco products, waterpipe, little cigars, electronic nicotine delivery 
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The global burden of lung cancer is significant and growing. In 2015, WHO reported that 
there were almost 1.7 million deaths from lung cancer and this number could increase 1.5 
times by 2030 (1).The cost associated with the management of lung cancer is significant 
and can be expected to increase dramatically. It has been estimated that the costs to 
manage lung cancer will increase in Canada by 80% from 2010 to 2030 but this may 
prove to be a gross underestimate because of new targeted and immuno-therapies (2). As 
smoking is the main cause of lung cancer, smoking cessation programs could improve not 
only the health of nations but also help to contain rising health care costs. In the face of the 
increasing global burden of lung cancer, it is instructive to consider the cost-effectiveness 
of lung cancer treatment in relation to smoking cessation programs. Cost effectiveness 
of lung cancer treatment options Treatment options for lung cancer depend on the stage 
and type of cancer. Recent advances in the treatment of metastatic non-small-cell lung 
cancer (NSCLC) have markedly increased the cost to health care systems and to patients 
themselves. When considering the implementation of new health care technologies, 
decision-makers consider the incremental cost of the new therapy (∆C) compared 
to the current standard in relation to the incremental benefit (∆E), usually 
expressed in life-years gained, to determine the incremental cost-
effectiveness ratio or ICER. The life-years gained may be adjusted 
for the quality of the life lived with the disease and its treatment producing an estimate 
of cost per quality-adjusted life year or QALY. The ICER is influenced by many factors 
including the choice of comparator (best supportive care vs a chemotherapy regimen), 
the time horizon of the analysis, the inclusion of the cost of managing early and late 
adverse events, amongst other factors. Not surprisingly, the major determinant of 
the ICER for most new drugs is the price of the drug and the magnitude of the clinical 
benefit. A review of economic evaluations of drugs used for advanced non-squamous 
NSCLC suggests that ICERs are progressively rising: the ICER for erlotinib as a 3rd line 
therapy was only $39,000/LY when compared to BSC (3). However, the ICER for 
pemetrexed used as a 1st line treatment in tumours with no known mutations was $142,500 
US dollars (2013) per QALY when compare to best supportive care (BSC) and $164,000 
per life year (LY) gained when compared to erlotinib (4).Estimates of the ICER for afatinib 
based on the pan-Canadian Oncology Drug Review (pCODR) ranged from $39,000 
to 211,000/QALY when compared to gefitinb reflecting the uncertainty in the clinical 
benefit in the absence of a head-to-head comparative trial (5). The ICER for crizotinib 
as first-line therapy in ALK +ve patients ranged from $173,570 (CDN) to $285,299, 
reflecting uncertainty in economic model assumptions related to the incremental benefit 
and the time horizon selected (5). ICERs above $100,000 per QALY are generally not 
considered “cost-effective” in Canada. The trend to higher ICERs could reverse with 
immune check point inhibitors given the potential for long term survival (much greater 
∆E) in some patients, although the incremental cost may be unacceptably high (6). 
However, it must be remembered that dollars spent on lung cancer treatments cannot 
be spent on something else and represent a lost opportunity cost no matter how cost-
effective the treatment appears. Value of smoking cessation programs Although 
some countries and American states have invested in public health programs to reduce 
smoking, globally there has been a low level of investment suggesting that there is 
resistance to investing in smoking cessation. This may be due to the perception that 
cessation interventions are ineffective, that smokers do not want to quit or that smoking 
cessation interventions are not cost effective (7). These commonly held perceptions 
are wrong. Smoking cessation (e.g., telephone counseling and pharmacological 
interventions) has been shown to improve health outcomes and survival. Most 
smokers in the general population, at least in North America, have made multiple quit 
attempts and express the desire to quit and cost-effectiveness estimates range from 
about $330 to $1500 US per life-year gained (7). A review of economic evaluations of 
smoking cessations programs shows that these programs are economically attractive 
and can even be cost-saving. For example, the American Cancer Society’s telephone 
counseling service nearly doubled a smoker’s odds of quitting and staying stopped 
for one year at a cost of approximately $1,500 per smoker (8).Nicotine Replacement 
Therapies (NRT) compared to self-help have an ICER of $1,500/QALY while varenicline was 
a dominant option compared to NRT. Also generally unrecognized are the health benefits 
to cancer patients, although these benefits have been well outlined in the 2014 U.S. 
Nitric oxide, hydrogen cyanide, and some aromatic amines were three to five times more 
than those in tobacco smoke. Selected polycyclic aromatic hydrocarbons were in lower 
concentration in marijuana. (4) Accurate studies on the health effects of marijuana use 
are difficult due to the illegal status of its use, variation in its use, and concomitant use 
of tobacco. (3,5) Bronchoscopic biopsies from subjects who smoke marijuana alone or 
marijuana and tobacco have been evaluated for histopathologic changes and molecular 
alterations. Smokers of marijuana alone reported symptoms of cough, sputum, wheeze, 
and acute episodes of bronchitis. (6) Histologic abnormalities were most frequent in 
smokers of both marijuana and tobacco. However, smokers of marijuana along did show 
changes of basal cell hyperplasia, inflammation, and squamous cell metaplasia in a large 
percentage of the 40 subjects examined. (6) Immunohistochemical analysis of bronchial 
biopsies from smokers of marijuana only demonstrated increased Ki-67 expression 
(cell proliferation marker) in 92% and increased EGFR expression in 57%. (7) Marijuana 
smoking does not appear to cause airflow obstruction. A study with 20 years of follow-up 
did not observe any significant change in pulmonary function. In a large cross section 
of US adults, cumulative life-time marijuana use up to 20 joint-years was not associated 
with airway obstruction. (8) There have been conflicting reports on the association of 
marijuana smoking and lung cancer. A 40-year cohort study from Sweden evaluated 
the baseline use of cannabis and cigarette smoking and the risk of lung cancer. They 
observed a strong dose-response relationship between tobacco use and lung cancer. 
They also reported a two-fold risk of lung cancer [HR 2.12 (95% CI 1.08-4.14)] in heavy 
cannabis smokers, even after adjustment for baseline tobacco use. (9) A major weakness 
of the study was reliance on only baseline self reporting of tobacco and cannabis use. No 
other data on use of these two agents was obtained throughout the 40 years of the study. 
A pooled analysis of six case-control studies from the US, Canada, United Kingdom, 
and New Zealand was performed to study the specific association between cannabis 
smoking and lung cancer. This included data on 2,159 lung cancers and 2,985 controls. 
(10) The odds ratio was 0.88 (95% CI 0.63-1.24) for individuals who smoked one or more 
joint-equivalents of cannabis per day and odds ratio of 0.94 for those who consumed at 
least 10 joint-years. The results from the pooled analysis provide little evidence for an 
increased risk of lung cancer among habitual long-term cannabis smokers. In summary, 
smoking marijuana causes airway inflammation and bronchitis, but to date there is no 
convincing data that it causes COPD or lung cancer. The level of the evidence is limited 
by the suboptimal quality of past studies. The current use and dose of inhaled marijuana 
is changing and therefore measurement of the pulmonary health effects are a moving 
target. References:
http://www.deamuseum.org/ccp/cannabis/history/html (last accessed June 30, 2015)
Volkow ND, et al. NEJM 2014; 370:2219-27
Tashkin DP. Annals ATS 2013; 10:239-47
Moir D, et al. Chem Res Toxicol 2008; 21:494-502
Howden ML, et al. Expert Rev Resp Med 2011; 5:87-92
Fligiel SH, et al. Chest 1997; 112:319-26
Barsky SH, et al. J Natl Cancer Inst 1998; 90:1198-1205
Kempker JA, et al. Annals ATS 2015; 12:135-41
Callaghan RC, et al. Cancer Causes Control 2013; 24:1811-1820
Zhang LR, et al. Int J Cancer 2015; 136:894-903
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The landscape of tobacco product use in the US is changing. Although cigarette smoking 
rates have declined in recent years, use of other tobacco products such as little cigars, 
waterpipe and electronic nicotine delivery systems (ENDS) is increasing. Background 
information about these “alternative” tobacco products, use trends, smoke or aerosol 
constituents and potential toxicities, especially those that may increase risk for lung 
cancer in users or bystanders, will be presented. Cigar consumption in the US increased 
from 6.2 billion cigars in 2000 to 13.3 billion in 2010 and is most common among young 
adults aged 18-24 years. This increased use has been attributed to use of little cigars and 
cigarillos, products that are less expensive alternatives to cigarettes in the US. “Small 
cigars” may be more likely to be smoked in similar fashion to cigarettes, especially by 
former cigarette smokers and dual users of cigarettes and cigars. Given that cigar 
smoke compared to cigarette smoke has higher concentrations of toxic and carcinogenic 
constituents (e.g., tobacco specific N-nitrosamines (TSNAs), carbon monoxide (CO), 
benzene), cigar users that inhale the smoke into the lungs may have greater risks for 
adverse health effects compared to cigarette smokers. Analysis of 25,000 participants 
from the US National Health and Nutrition Examination Survey (NHANES, 1999–2012) 
identified that current cigar/former cigarette smokers had significantly higher cotinine 
and 4- (methylnitrosamino) -1- (3-pyridyl) -1-butanol (NNAL) concentrations compared to 
cigar smokers with limited cigarette use, and NNAL concentrations were comparable 
between daily cigar and daily cigarettes smokers. Waterpipe (WP), also known as 
hookah, shisha and narghile, heat a mixture of tobacco, honey or molasses, and 
flavorings using charcoal. A centuries old style of smoking tobacco popular in Middle 
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were 10.2% (95% CI, 9.8% to 10.6%), 7.1% (CI, 6.7% to 7.4%), 5.1% (CI, 4.8% to 5.4%), 
and 4.0% (CI, 3.7% to 4.2%), respectively. Use of these alternative definitions would have 
reduced the work-up by 36%, 56%, 68%, and 75%, respectively. Concomitantly, lung 
cancer diagnostics would have been delayed by at most 9 months for 0%, 5.0% (CI, 1.1% 
to 9.0%), 5.9% (CI, 1.7 to 10.1%), and 6.7% (CI, 2.2% to 11.2%) of the cases of cancer, 
respectively. This type of analysis was also performed on the NLST data which using 
their 4 mm size cutoff had reported a 26.6% positive rate on baseline. The frequency of 
positive results using the definition of a positive result of any parenchymal, solid or part-
solid, noncalcified nodule of 5.0 mm or larger was 15.8%. Using alternative thresholds 
of 6.0, 7.0, 8.0, and 9.0 mm, the frequencies of positive results were 10.5% (2700 of 25 
813, 7.2% , 5.3% , and 4.1% , respectively, and the corresponding proportional reduction 
in additional CT scans would have been 33.8% , 54.7% , 66.6% , and 73.8% , respectively. 
Concomitantly, the proportion of lung cancer diagnoses determined within the first 12 
months would be delayed up to 9 months for 0.9% (two of 232), 2.6% (six of 232), 
6.0% (14 of 232), and 9.9% (23 of 232) of the patients, respectively. The use of the 6 
mm size threshold has now gained widespread acceptance in the context of screening 
having been endorsed by the NCCN, Lung-Rads and I-ELCAP. Nevertheless, it must still 
be recognized that the tradeoff is the delay in diagnosis of some small cancers for an 
additional nine months when the next annual screen would occur. While these cancers 
are unlikely to substantially change in size, the potential for progression is still present 
and this is the main consideration in balancing against the decrease in positive rate. 
While size does remain the dominant feature in defining a positive result in this high risk 
population, there are other approaches that consider additional features of the nodules 
that also have prognostic significance and may be useful in defining positive results. 
Keywords: nodule, false positive, CT screening
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MS24.02 Software for Density Calculation and Timing of Surgery in Subsolid 
Nodules Anthony Reeves, Yiting Xie School of Electrical and Computer Engineering, 
Cornell University, Ithaca/NY/United States of America
With the advent of lung cancer screening (LCS) with low-dose chest CT images, the 
attention for computer aided tools advances from proof of concept and validation studies 
to clinical utility. Computer aided image-based diagnosis tools (CAD) for LCS on the initial 
CT have a primary objective of improved decision making for follow up actions. There 
are four roles for CAD tools in this context: nodule detection, nodule characterization, 
nodule growth-rate measurement for malignancy status, and companion diagnostics. 
The special low-dose CT scan acquired as the primary test in LCS is of lower quality 
than a traditional clinical CT scan and, consequently, presents a higher challenge to 
computer analysis methods. Computer aided nodule detection systems address the 
critical screening task of identifying pulmonary nodules in low-dose CT images. These 
systems typically identify the location of nodule candidates in the CT images. In general, 
they detect small sphere like high intensity image regions that correspond to the 
most common and important finding in LCS. Their performance is related to size and 
most evaluations are focused on nodules of 4-5 mm or larger. For smaller nodules the 
false positive rate is much higher. The first of such systems received FDA approval in 
2004. There has been significant technology improvement since then with sensitivities 
in research systems higher than 90% reported in 2007 [1]. In 2012 Zhao et al [2] 
reported on a study using commercial software on 400 randomly selected cases from 
the NELSON study. They found that the CAD system could obtain 96.7% sensitivity on 
nodules greater than 50 mm3 (4.6 mm) with only 1.9 false positives per scan. In contrast, 
the double reading achieved 78.1% sensitivity. While the benefit of using computer 
detection for LCS has been clearly demonstrated and good commercial products are 
available, there has been little adoption of these methods in recent LCS studies. The 
second area in which the computer may by useful is in analyzing the images of pulmonary 
nodule candidates especially with respect to the critical issue of malignant or benign. The 
classical approach here is to generate some diagnostic features from the appearance 
of the nodule images and to perform classification from these to determine malignancy. 
A number of research studies have shown encouraging results; however, these studies 
have either used non-screening nodules and images, which have a vastly larger size and 
higher quality or did not separate out the contribution of nodule size, which is highly 
predictive of malignancy in LCS populations, from the other image features. A recent 
study [3] has shown that after compensating for size, for LCS CT images, the other image 
features provide only a moderate amount of additional information. This information is 
insufficient for a diagnosis by itself but may be used to refine follow up decisions. The 
measurement of nodule growth rate from two or more CT scans has been shown to be 
highly predictive of nodule malignancy status [4]. Since at least a second scan is required 
this method should be considered as a follow up procedure among other clinical follow 
up methods. The main barrier to clinical implementation of this method is that it requires 
the computing of the difference of the two CT scans, which is highly dependent on the 
geometric image quality of each scan. Unfortunately, there exists no agency or process 
by which this quality is monitored or measured on current scanners and without any 
scanner calibration imprecise results may occur. Correct use of this method requires 
careful attention to details. CT scans acquired for LCS also image other critical organs 
that are at risk for the screening population. Companion diagnostics refers to computer 
analysis for conditions other than lung cancer from the periodic LCS CT images. 
Conceptually, this is similar to a blood test where additional conditions may be evaluated 
from a single patient interaction. Therefore, the automatic risk factor assessment of 
these additional regions provides additional benefit without requiring additional imaging 
for the LCS population. Work in this area is still at an early stage. Research targets 
for automated evaluation reported in the literature include: lung (emphysema and 
COPD), cardiac (coronary artery calcium, aorta profile and calcium), breast (density 
assessment), and bone (vertebral body density evaluation). Computer aided methods 
will inevitably make major contributions to increasing the efficiency and benefit of LCS 
as they transition from research prototypes to clinical practice. More sophisticated 
Surgeon General’s Report on Smoking (9). Nonetheless, smoking cessation programs are 
rare in the oncology setting and information on the cost-effectiveness 
of smoking cessation in the oncology setting is limited. One study 
examined the cost-effectiveness of a pre-operative smoking cessation 
program for patients with early-stage NSCLC in the United States (10), 
and reported an ICER of $2,609/QALY and $2,703/LY at 5-years post-surgery. The 
cost-effectiveness of smoking cessation programs could be more dramatic over longer 
time horizons. Even though the benefits of smoking cessation programs on clinical 
outcomes have been reported, including the value for money of these programs, more 
evidence on the impact of smoking on outcomes for lung cancer patients receiving 
radiotherapy and systemic therapy is clearly needed. Discussion Faced with a global 
epidemic of lung cancer and a growing number of new but expensive drugs, recognition 
that smoking cessation programs are both effective and cost-effective should drive 
public policy.References 1. World Health Organization. Projections of mortality and 
burden of disease, 2002-2030. World Health Organization,; 2002 [cited 2015]; 
Available at:http:www.who.int/healthinfo/global_burden_disease/projections2002/
en/. 2. Hermus G, Stonebridge C, Goldfarb D, et al. Cost risk analysis for chronic lung 
disease in Canada: The Conference Board of Canada 3. Cromwell I, van der Hoek K, 
Taylor SCM, et al. Erlotinib or best supportive care for third-line treatment of advanced 
non-small-cell lung cancer: a real-world cost-effectiveness analysis. Lung Cancer 
2012;76(3):472-7 4. Matter-Walstra K, Joerger M, Kuhnel U, et al. Cost-effectiveness 
of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer 
from the perspective of the Swiss health care system. Value in health. 2012;15165-71 
5. Available at pcodr website . 6. Available at am.asco.org/aso-plenary-nivolumab-
ipilimumab-combination-effective-advanced-melanoma. 7. Parrott S, Godfrey C, 
Raw M, et al. Guidance for Commissioners on the cost-effectiveness of smoking 
cessation interventions. Thorax 1998; 53 (Suppl 5, Part 2): S2-S3 8. McAlister A, 
Rabius V, Geiger A, et al. Telephone assistance for smoking cessation: one year 
cost effectiveness estimations. Tobacco control. 2004;13(1):85-6. 9. The Health 
Consequences of Smoking - 50 Years of Progress. A report of the Surgeon General, 
2014. U.S Department of Health and Human Services, Office of the Surgeon General, 
Rockville, MD 10. Slatore CG, Au DH, Hollingworth W. Cost-effectiveness of a smoking 
cessation program implemented at the time of surgery for lung 
cancer. Journal of Thoracic Oncology. 2009;4(4):499-504. 
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MS24.01 Definition of Positive Cases and False Positives David F. Yankelevitz 
Radiology, Icahn School of Medicine, New York City/NY/United States of America
With the ever increasing acceptance of CT screening the need to now minimize harms 
becomes even greater. One of the harms which occurs with the greatest frequency are 
“false positives” as they can lead to unnecessary additional work up, sometimes invasive, 
added cost, and cause anxiety for the person being screened. The term “false positive” is 
somewhat confusing and is defined differently by different groups. In the computer aided 
diagnosis domain, it refers to a finding that does not represent a nodule and is mistakenly 
labelled by the computer to represent nodule. Most frequently this is a blood vessel. 
Thus, positive results are nodules (often described as actionable based on a size criteria) 
and false positives are findings not representing nodules. In the clinical domain, when 
interpreting a CT scan, a positive finding is something that meets a specified definition to 
be considered a positive result. A positive finding is not something that is inherent to the 
image but requires certain criteria to be met. Thus, a nodule by itself is not necessarily a 
positive finding, but must meet certain criteria to be considered positive. Typically it is a 
non-calcified nodule of a specific size. Thus, in the National Lung Screening Trial the cutoff 
was at 4 mm, while in I-ELCAP it was at 5 mm for non-calcified nodules. Given a positive 
result, the confusion now occurs in terms of whether the nodule actually turns out to be 
a cancer or not. Some prefer to call these cases “false positive” even though they are 
truly nodules and positive in the sense that they meet the definition of positive based on 
the CT criteria. Others merely refer to the rate at which positive results occur considering 
them all positive regardless of their final disposition with the view that imaging does not 
determine malignancy. Regardless of the linguistics and their potential for causing some 
confusion, the main concern is to limit the excess amount of work up on those cases 
which are not cancer. This can be accomplished primarily in two ways. First, to be certain 
that the population being screened is at high risk for cancer, and secondly, to identify 
those criteria most associated with cancer and use that in the definition of a positive 
result. By far, the most dominant of those criteria is size defined either volumetrically or 
by diameter. An important consideration when defining size cutoffs for positive results, 
is that the frequency of nodules decreases with increasing size, and the frequency 
of cancer increases with increasing size. Also, with increasing size of the cancer, the 
chance for cure decreases. The extent to which all this occurs is not fully known and has 
many additional considerations. As a start however, and especially in the era of increased 
scanner resolution, the frequency of positive results would approach 100% if the size 
criteria is made small enough and the overwhelming majority would be benign. One 
approach to determining an optimal size criteria is to perform a sensitivity analysis on 
a screening population balancing the positive rate against what might be considered an 
acceptable “miss” rate. Using the I-ELCAP database, the frequency of positive results in 
the baseline round using the 5 mm size cutoff for positive result (any parenchymal, solid 
or part-solid, noncalcified nodule ≥ 5.0 mm) was 16% (3396/21 136). When alternative 
threshold values of 6.0, 7.0, 8.0 and 9.0 mm were used, the frequencies of positive results 
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The possibility to combine metabolic profile with other biomarkers, such as circulating 
miRNAs [10], to identify indolent disease will require future investigations, to improve 
performance and reduce over-diagnosis of LDCT screening. 1 Aberle DR, Adams AM, Berg 
CD, et al. The National Lung Screening Trial Research Team (2011). Reduced lung-cancer 
mortality with low-dose computed tomographic screening. N Engl J Med 365:395-409. 
2 Aberle DR, DeMello S, Berg CD, et al. (2013) Results of the Two Incidence Screenings 
in the National Lung Screening Trial. N Engl J Med 369:920-31. 3 van Klaveren RJ, 
Oudkerk M, Prokop M, et al. (2009) Management of lung nodules detected by volume 
CT scanning. N Engl J Med 361:2221-9. 4 Kramer BS, Berg CD, Aberle DR, Prorok 
PC. Lung cancer screening with low-dose helical CT: results from the National Lung 
Screening Trial (NLST). J Med Screen. 2011;18:109-111. 5 M.K. Gould, C.C. Maclean, W.G. 
Kuschner, et a. l(2001). Owens, Accuracy of positron emission tomography for diagnosis 
of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285: 914–924. 6 Kim 
SK, Allen-Auerbach M, Goldin J, et al. (2007) Accuracy of PET/CT in characterization of 
solitary pulmonary lesions. J Nucl Med 48:214–220. 7 Pastorino U (2010) Lung Cancer 
Screening. British Journal of Cancer 102: 1681–1686 8 Veronesi G, Bellomi M, Veronesi 
U, et al. (2007) Role of positron emission tomography scanning in the management of 
lung nodules detected at baseline computed tomography screening. Ann Thorac Surg 
84:959-66 9 Pastorino U, Landoni C, Marchianò A, et al. (2009) Fluorodeoxyglucose 
(FDG) uptake measured by positron emission tomography (PET) and standardised 
uptake value (SUV) predicts long-term survival of CT screening-detected lung cancer 
in heavy smokers. J Thor Oncol 11:1352-6 10. Sozzi G, Boeri M, Rossi M, et al: Clinical 
utility of a plasma-based miRNA signature classifier within computed tomography 
lung cancer screening: A correlative MILD trial study. J Clin Oncol 32:768-773, 2014 
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Harvey I. Pass Department of Cardiothoracic Surgery, NYU Langone Medical Center, New 
York/NY/United States of America
The complexity of biomarker discovery is amplified by the multitude of platforms 
on which the biomarker is discovered (mutational sequencing, fluorescence in situ 
hybridization (FISH), single-nucleotide polymorphisms (SNPs), copy-number variation 
(CNV) of chromosomes, immunohistochemistry, epigenetics including methylation 
studies, or microRNA ), and by the material used (tissue, plasma, serum, urine, breath, 
sputum, effusion). The aim is to define these biomarkers in a way whereby their use is 
contingent on maximal accuracy, which depends on the ability of biomarker researchers 
to not only put forth markers with the greatest sensitivity and specificity, but also 
to be able to validate these biomarkers in a methodologic algorithm that will satisfy 
regulatory bodies including the Food and Drug Administration (FDA) in the United States 
as well as other agencies abroad. This lecture will concentrate on novel biomarkers 
for lung cancer being investigated by the Lung Group and industrial members of 
the Early Detection Research Network. These biomarkers include autoantibodies, 
MRM proteomics, micro and lncRNAs, SomaMers, and airway transcriptomics. 
Keywords: Genomics, proteomics, diagnosis, biomarker
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In my talk I will report a prospective surveillance program, longitudinally following 
patients with pre-invasive disease over a 10 year period. It is the largest study of its kind 
and demonstrates unexpectedly high rates of both local progression to invasive cancer 
of high grade lesions and the development of synchronous tumours elsewhere in the 
lung. Further I will show data identifying both gene expression and epigenetic signatures 
predicting progression of these lesions. These signatures may provide the biomarker 
strategy we require to identify those patients with lesions at high risk of progression 
and therefore requiring treatment. Lung cancer accounts for more deaths than breast, 
prostate and colon cancers combined. Over three quarters of lung cancer patients are 
diagnosed at a late stage when curative treatment is not possible. Initiatives are underway 
to detect lung cancer earlier. CT screening of high risk smokers or ex smokers is proven 
to save lives through increased detection of largely early stage adenocarcinomas (1, 
2). Meanwhile sputum cytometry and autofluorescence bronchoscopy of high risk 
individuals are under investigation as screening tools for the early detection of major 
airway squamous cell carcinomas in several studies. Squamous carcinogenesis is 
initiated by pre-invasive dysplastic lesions in the central airways and therefore lends 
itself to bronchoscopic evaluation. Bronchial dysplasia represents the earliest stages 
of what is traditionally thought to be a stepwise progression towards invasive disease 
commencing with squamous hyperplasia and metaplasia followed by mild, moderate, 
severe dysplasia (SD) and carcinoma-in-situ (CIS) with lesions possessing a greater 
mutational burden at each stage (WHO classification) (Figure 1). With progression of 
the lesion there are characteristic morphological changes and increasing cytological 
disarray. Initial changes affect only the basal epithelium, whilst ‘full thickness’ change 
is seen in the more advanced CIS. Once the basement membrane has been breached, 
invasive squamous cell carcinoma has developed.
computer algorithms and modern machine learning techniques will greatly improve 
CAD performance; however, such methods require very large training image datasets. 
Research studies to date typically involve 100 images examples or less; future algorithm 
development can greatly benefit by the millions of images that will be acquired with LCS 
practice. References [1] Enquobahrie A A, Reeves A P, Yankelevitz D F and Henschke C 
I, “Automated Detection of Small Pulmonary Nodules in Whole Lung CT Scans”, Acad 
Radiol, 14(5): 579-593, 2007. [2] Zhao Y, de Bock G H, Vliegenthart R, van Klaveren R J, 
Wang Y, Bogoni L, de Jong P A, Mali W P, van Ooijen P M A and Oudkerk M, “Performance 
of computer-aided detection of pulmonary nodules in low-dose CT: comparison with 
double reading by nodule volume”, Eur Radiol, 22(10): 2076-2084, 2012. [3] Reeves A 
P, Xie Y and Jirapatnakul A, “Automated pulmonary nodule CT image characterization in 
lung cancer screening”, IJCARS, doi: 10.1007/s11548-015-1245-7, 2015. [4] Reeves A P, 
“Measurement of Change in Size of Lung Nodules”. In Li Q, Nishikawa R M (ed) Computer-
Aided Detection and Diagnosis in Medical Imaging, Taylor & Francis, Chapter 11, 2015. 
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Effective screening programs should detect all cancers and reduce as much as possible 
the probability of false-positive results, not representing malignant disease. In lung 
cancer screening, false-positive low-dose computed tomography (LDCT) results are 
even more crucial than in other fields, because of the magnitude of risks and costs 
related to invasive diagnostic examinations, and the need of potentially harmful surgical 
procedures. Long-term follow-up of nodules ≤ 5 mm at baseline CT has proven that 
these nodules don’t require additional workup, but for non-calcified nodules between 5 
and 10 mm, surveillance of growth is mandatory to identify the relatively few malignant 
lesions. With the NLST diagnostic algorithm, based on diameter measurement, 24% of 
subjects had a positive LDCT but 96% of them proved to be false positives, with a positive 
predictive value (PPV) of only 3.6% at baseline, 2.4 first repeat and 5.2% at second repeat 
[1,2]. On the contrary, the diagnostic algorithm of Nelson trial, based on the automated 
assessment of 3D volumetry and doubling time, obtained a 36% PPV and a 99.9% 
negative predictive value (NPV) [3]. However, in the Nelson trial, where positron emission 
tomography (PET) was not included in the diagnostic algorithm, the frequency of invasive 
procedures for benign disease proved to be quite high (27%), and similar to the one 
observed in NLST trial (24%) [4]. Large meta-analyses have demonstrated the clinical 
value of PET in the differential diagnosis of undetermined pulmonary nodules detected by 
spiral CT, with a sensitivity rate of 96-97%, a specificity of 78-82% [5], and accuracy rate 
reaching 92% with the CT/PET fusion machine [6]. In 2000, our pilot study in Milan was 
the first screening protocol to include selective use of PET in the diagnostic algorhitm, 
thus showing that PET may be helpful in the management of CT detected nodules ≥  7 
mm. In the first five years of screening, PET was applied to only 1.4% of spiral CTs, with 
an overall sensitivity rate of 94%, specificity of 82%, and an accuracy rate of 88% [7,8]. 
In the Milan pilot trial, the cumulative frequency of surgical procedures for benign disease 
at 5 years was 15%. The MILD randomized trial has obtained similar results, in terms of 
frequency and diagnostic accuracy. From 2005 to 2015, a total of 113 PET were applied 
to 2376 individuals and 12,314 LDCTs, representing 4.8% of all screened individuals 
in 10 years, and 0.93% of all LDCTs. Excluding lung cancer cases, where PET would 
have been applied later for staging purposes, the true excess of PET examinations for 
screening purposes only reached a total 33 exams (1.4% of subjects, 0.3% of LDCTs). 
The sensitivity rate was 85%, specificity 80%, accuracy 83%, PPV 89% and NPV 74%. 
Of interest, only 3 patients underwent pulmonary resection for benign disease, out of 66 
surgical procedures (5%) performed in the MILD trial. Such a low benign resection rate, 
is not only due to selective use of PET, but also to the active surveillance programme 
applied to non-solid lesions in the MILD trial. Beyond differential diagnosis, PET may 
play a role in prediction of outcome, and identification of indolent lung cancer. We have 
demonstrated in a previous paper, based on 34 lung cancer patients from the first pilot 
trial, that PET-SUV value can accurately predict long term survival and identify individuals 
with 100% 5-year survival [9]. In the MILD trial we have confirmed the value of metabolic 
profile as a predictor of outcome. The following figure illustrates the 5-year survival of 95 
patients, from pilot and MILD trials.
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known to be critical for cell regulation, while high levels of ROS are toxic to cells. We 
found that airway basal stem cells have low levels of ROS at baseline, but injury results in 
an increase in ROS and this flux from low to higher levels of ROS mediates proliferation 
of the basal cells via signaling through ROS/Nrf2/Notch1. Perturbation of this pathway 
at the level of Nrf2 or Notch both in vitro and in vivo results in excessive proliferation of 
basal cells and the formation of premalignant lesions with hyperplasia and dysplasia of 
the repairing airway epithelium. Our results provide much needed information about the 
biology of airway epithelial repair, premalignant lesions and the molecular changes that 
occur during stepwise carcinogenesis of squamous cell lung cancer, and it highlights 
a novel approach for identifying some of the earliest molecular changes associated 
with initiation and progression of lung carcinogenesis within individual patients. 
Keywords: Premalignant lesions, airway basal stem cells, squamous lung cancer, 
transcriptomic changes
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The recently published Fourth Edition of the WHO Classification of Tumours of the 
Lung1 recognizes atypical adenomatous hyperplasia (AAH) and adenocarcinoma in situ 
(AIS) as pre-invasive or premalignant precursor lesions of invasive adenocarcinoma, 
which arises mostly in the periphery of the lung. In the previous (Third) Edition of WHO 
classification, AIS was classified as bronchiolo-alveolar carcinoma (BAC), one of the 
subtypes of malignant adenocarcinoma.2,3 Reclassification of AIS into the preinvasive 
category represents a conceptual confirmation of its role in multi-stage pathogenesis 
of peripheral lung adenocarcinoma.4-7 This is consistent with the histological hallmark of 
lack of invasion in AIS, and its association with 100% survival after surgical resection. 
The neoplastic nature of these lesions are supported at the molecular level with the 
identification of known genomic aberrations found in invasive lung adenocarcinoma.8,9 AIS 
is characterized histologically by the lepidic proliferation of neoplastic epithelium along 
pre-existing alveolar structures and lacking stromal, vascular or pleural invasion (Figure 
1). A majority of AIS is composed of non-mucinous neoplastic cells with Clara cell and/
or type-2 pneumocyte phenotype. Mucinous AIS is rare. By definition, AIS is limited to 
tumors that is ≤ 3 cm in greatest diameter and by TNM classification, is classified a 
Tis. AIS commonly shows varying degree of stromal thickening by fibrosis and chronic 
inflammatory cell infiltrate, with some cases showing focal or central area of fibrosis 
or scar. Around these areas, entrapment of the tumor cells within architecturally 
distorted and thickened alveolar septa give rise to morphological appearances of 
invasion. This remains one of the areas of diagnostic difficulty in distinguishing AIS 
from minimally invasive adenocarcinoma (MIA). However, limited data suggests that MIA 
is also associated with 100% curability by surgical resection. A majority of AAH are 
identified incidentally during microscopic examination of non-cancerous lung of surgically 
resected adenocarcinoma (Figure 2). The reported incidence in lung adenocarcinoma 
cases may reach up to 30%, and the reported number of lesion can reach up to 40/
case, depending on the extent of sampling. They are typically ≤ 5 mm, but size is not a 
diagnostic criteria for its diagnosis. Histologically it is characterized by slightly thickened 
alveolar septa that are lined by atypical appearing cuboidal to low columnar epithelial 
cells with gaps in between them. These cells have similar ultrastructural features as 
AIS cells, mainly those of type-2 pneumocyte and/or Clara cell. A spectrum of nuclear 
atypia may be observed but grading has not been recommended, as they have not 
been demonstrated as reproducible or correlated with neoplastic progression. AAH is 
considered a precursor of AIS, as they may harbor KRAS or EGFR mutations. In some 
cases, the histological distinction between AAH and AIS can be very challenging, even 
though both lesions are considered cured by surgical resection. Further deep genomic 
analyses of AAH and AIS can provide greater insights into the multistep molecular 
carcinogenesis of lung adenocarcinoma and potentially novel prevention strategies for 
this disease. References: 1. WHO Classification of Tumours of the Lung, Pleura, Thymus 
and Heart. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. IARC Press, Lyon, 
2015, page 46-50. 2. World Health Organization International Histological Classification 
of Tumours. Histological Typing of Lung and Pleural Tumours. Travis WD, Colby TV, 
Corrin B, Shimosato Y, Brambilla E. Springer Verlag, Berlin, Heidelberg, New York, 
1999, page 21-29. 3. WHO Classification of Tumours, Pathology and Genetics. Tumours 
of the Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E, Muller-Hermelink HK,, 
Harris CC. IARC Press: Lyon 2004, page 35-44, 73-75. 4. Miller RR, Nelems B, Evans 
KG, Muller NL, Ostrow DN. Glandular neoplasia of the lung. Cancer 1988;61:1009-
1015. 5. Kitamura H, Kameda Y, Ito T, Hayashi H. Atypical adenomatous hyperplasia 
of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am 
J Clin Pathol 1999;111:610-22. 6. Mori M, Rao SK, Popper HH, Cagle PT, Fraire AE. 
Atypical adenomatous hyperplasia of the lung: A probably forerunner in the development 
of adenocarcinoma of the lung. Mod Pathol 2001;14:72-84. 7. Chapman AD, Kerr KM. 
The association between atypical adenomatous hyperplasia and primary lung cancer. 
Br J Cancer 2000;83:632-36. 8. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, 
Offerhaus GJ, Slebos RJ. K-ras oncogene activation in atypical alveolar hyperplasias of 
the human lung. Cancer Res 1996;56:2224. 9. Sakamoto H, Shimizu J, Horio Y, Ueda 
R, Takahashi T, Mitsudomi T, Yatabe Y. Disproportionate representation of KRAS gene 
mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene 
mutation from preinvasive to invasive adenocarcinomas. J Pathol 2007;212:287-94. 
  
Our early findings, and those of others, have challenged this traditional stepwise model. 
With longitudinal follow up, few low grade dysplasia lesions (LGD: hyperplasia, metaplasia 
mild and moderate dysplasia) are seen to progress and largely remain indolent or often 
regress. High grade dysplasia lesions (HGD: SD and CIS) however, more frequently persist 
or progress to invasive disease. Bronchial dysplastic lesional destiny is unpredictable 
and despite research examining the genetic and epigenetic changes that occur, as yet no 
robust biomarker is able to determine which lesions will continue to progress to invasive 
disease. Low grade lesions rapidly progressing to cancer have been reported, and 
these rare lesions have been found to possess a high degree of chromosomal instability 
including DNA copy number alterations even at a metaplastic stage, seeming to confer 
a committed course to cancer development. It is likely that close analysis of these rare 
lesions and other high grade lesions that progress will lead to greater biological insight 
regarding key lung cancer driver mechanisms. Autofluorescence bronchoscopy (AFB) 
using blue-violet excitation light has made progress in facilitating not only the detection 
and delineation of extent of early stage invasive cancers in the airway but also the 
identification of precancerous central airway lesions that are generally missed on CT. 
AFB detection of precancerous lesions has been shown to have sensitivity exceeding 
that of white light bronchoscopy (WLB) alone. The sensitivity of combining AFB with WLB 
improves detection of bronchial premalignant and malignant lesions up to 96.8% versus 
76.3% for WLB alone, whilst corresponding negative predictive values are 97.2% versus 
83.1% (3). Treatment of precancerous lesions might be expected to lead to improved 
survival in those patients harboring them. However our lack of knowledge of the natural 
history of these lesions, the appearance of new lesions, the regular occurrence of 
separate lung primaries and the lack of interventional studies in this area leaves the role 
of early intervention (both surgical and local tissue sparing procedures) under dispute. 
Due to this poverty of knowledge, our strategy, in keeping with previously published 
studies, has been the surveillance of all grades of dysplasia. These include our own, initial 
observations that suggest a low rate of lesion progression but high synchronous invasive 
cancer occurrence (4, 5). This early experience indicates patients with preinvasive 
disease are at a globally high risk of developing lung cancer, although not necessarily 
from the lesion under observation and multiple lesions both centrally and peripherally 
commonly develop over time. Due to the shared risk factor of tobacco smoke exposure, 
patients often have significant respiratory and cardiovascular co-morbidity and radical 
treatment of preinvasive disease may lead to insufficient lung capacity to offer curative 
intervention to future invasive lung cancer. 1. NCCN Clinical Practise Guidelines in 
Oncology. Lung Cancer Screening. Version http://www.nccn.org/professionals/
physician_gls/pdf/lung_screening.pdf 2. National Lung Screening Trial Research Team, 
Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis 
C, Goldin J, Gohagan JK, Hillman B, Jaffe C, Kramer BS, Lynch D, Marcus PM, Schnall 
M, Sullivan DC, Sullivan D, Zylak CJ. The National Lung Screening Trial: overview and 
study design.Radiology. 2011 Jan;258(1):243-53. 3. Hanibuchi M, Yano S, Nishioka Y, 
Miyoshi T, Kondo K, Uehara H, Sone S. Autofluorescence bronchoscopy, a novel modality 
for the early detection of bronchial premalignant and malignant lesions. J Med Invest. 
2007 Aug;54(3-4):261-6. 4. George JP, Banerjee AK, Read CA, O’Sullivan C, Falzon M, 
Pezzella F, Nicholson AG, Shaw P, Laurent G, Rabbitts PH. Surveillance for the detection 
of early lung cancer in patients with bronchial dysplasia. Thorax. 2007 Jan;62(1):43-50. 
5 Auerbach O, Stout AP, Hammond EC, et al. Changes in bronchial epithelium in relation 
to cigarette smoking and in relation to lung cancer. N Engl J Med 1961;265:255–67.
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Epithelial cancers are thought to arise in a stepwise fashion from premalignant lesions and 
removal of premalignant lesions in epithelia such as colon and cervix has made a major 
improvement in survival in these cancers. However, premalignant lesions of the airway 
epithelium are poorly understood and it is not even known whether they represent a true 
premalignant state. This is in large part because of the heterogeneity of premalignant 
lesions of the airway and the fact that most of them will spontaneously resolve, even in 
high-risk patients. Premalignant lesions are thought to arise because of aberrant repair 
after injury but our understanding of the biology of normal repair after injury of the 
airways is limited and thus we do not know what the mechanisms are that drive aberrant 
repair and even less what the mechanisms are that drive the development of invasive 
non-small cell lung cancer. In order to increase our understanding of premalignant 
lesions of the airway, we laser-microdissected representative cell populations along 
the purported squamous cell lung cancer pathological continuum of patient-matched 
normal basal cells, premalignant lesions, and tumor cells. We obtained sufficient mRNA 
to perform high throughput RNA-sequencing. We discovered transcriptomic changes 
and identified genomic pathways altered with initiation and progression of SCC within 
individual patients. We used immunofluorescent staining to confirm gene expression 
changes in premalignant lesions and tumor cells, including increased expression of 
SLC2A1, CEACAM5, and PTBP3 at the protein level and increased activation of MYC via 
nuclear translocation. Cytoband enrichment analysis revealed coordinated loss and gain 
of expression in chromosome 3p and 3q regions, respectively, during carcinogenesis. 
We also identified several pathways that were upregulated in a stepwise fashion with 
progression of lesions. One of the pathways found to be upregulated with stepwise 
progression was redox regulation. Low levels of Reactive Oxygen Species (ROS) are 
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located in this region, we focused on the epithelial cell transforming sequence 2 (ECT2) 
oncogene, as ECT2 amplification was detected only in invasive adenocarcinoma, and not 
in in situ carcinoma. FISH and IHC analyses also detected amplification and overexpression 
of ECT2 in invasive adenocarcinoma (Fig 2), and this was correlated with both the Ki-67 
labeling index and mitotic index. In addition, it was associated with disease-free survival 
and overall survival of patients with lung adenocarcinoma. These results were verified 
using another set of early-stage adenocarcinomas resected at another hospital. 
Abnormality of the ECT2 gene occurs at a relatively early stage of lung adenocarcinogenesis 
and would be applicable as a new biomarker for prognostication of patients with lung 
adenocarcinoma.
 
Keywords: AIS, MIA, Stratifin, ECT2
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MS26.01 Genomic Alterations James Chih-Hsin Yang Graduate Institute of Oncology, 
National Taiwan University, Taipei/Taiwan
Genomic Alterations and Drug Targets in Small Cell Lung Cancer Over the past 15 
years, we have made a lot of advances in the treatment of non small cell lung cancer 
(NSCLC). However, the treatment paradigm for small cell lung cancer (SCLC) remains 
the same as 30 years ago, e.g., concurrent chemoradiotherapy for limited stage SCLC 
and chemotherapy for extensive stage SCLC. The successful introduction of epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of 
lung cancer patients has helped us understand the underlying genomic alterations in 
responding patients and the biology of tumor cells harboring EGFR mutations. In contrast 
to the successful story of EGFR TKIs in NSCLC treatment leading to the discovery of 
EGFR mutations in responding patients, the discovery of EML4-ALK fusion in NSCLC 
has led to the successful treatment of crizotinib in patients harboring this mutation. 
Crizotinib was designed to inhibit cMET but was developed successfully as an ALK 
inhibitor for those patients. Further genomic analysis of lung adenocarcinoma patients 
disclosed that some specific recurrent mutations in EGFR, HER2, KRAS, NRAS, BRAF, 
Figure 1. Adenocarcinoma in situ
 
Figure 2. Atypical Adenomatous Hyperplasia.
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Adenocarcinoma in situ (AIS) of the lung has an extremely favorable prognosis. However, 
early but invasive adenocarcinoma (eIA) sometimes has a fatal outcome. We examined 
epigenetical and genetic abnormalities of very early adenocarcinoma and compared 
them to early but advanced adenocarcinoma. We had previously compared the expression 
profiles of AIS with those of eIA showing lymph node metastasis or a fatal outcome, and 
found that stratifin (SFN, 14-3-3 sigma) was a differentially expressed gene related to cell 
proliferation. Here, we performed an in vivo study to clarify the role of SFN in progression 
of lung adenocarcinoma. Suppression of SFN expression in A549 (a human lung 
adenocarcinoma cell line) by siSFN significantly reduced cell proliferation activity and the 
S-phase subpopulation. In vivo, tumor development or metastasis to the lung was 
reduced in shSFN-transfected A549 cells. Moreover, we generated SFN-transgenic mice 
(Tg-SPC-SFN+/-) showing lung-specific expression of human SFN under the control of a 
tissue-specific enhancer, the SPC promoter. We found that Tg-SPC-SFN+/- mice developed 
lung tumors at a significantly higher rate than control mice after administration of 
chemical carcinogen, NNK (Fig 1). Interestingly, several Tg-SPC-SFN+/- mice developed 
tumors without NNK. These tumor cells showed high hSFN expression. These results 
suggest that SFN facilitates lung tumor development and progression. SFN appears to be 
a novel oncogene with potential as a therapeutic target. Next, gnetic abnormality in early-
stage lung adenocarcinoma was examined. Six in situ lung adenocarcinomas and nine 
small but invasive adenocarcinomas were examined by array-comparative genomic 
hybridization (array-CGH), and candidate genes of interest were screened. To examine 
gene abnormalities, 83 cases of various types of lung carcinoma were examined by 
quantitative real-time genomic PCR (qPCR) and immunohistochemistry (IHC). The results 
were then finally verified using another set of early-stage adenocarcinomas. Array-CGH 
demonstrated frequent amplification at chromosome 3q26, and among the 7 genes 
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(either C, L or N). Here, we also report our discovery of tumor-specific inactivation of 
the MYC-associated factor X gene, MAX, in about ten percent of small cell lung cancers 
(SCLC). This is mutually exclusive with alterations at MYC and BRG1. We also demonstrate 
that BRG1 regulates the expression of MAX through direct recruitment to the MAX 
promoter, and that depletion of BRG1 strongly hinders cell growth, specifically in MAX-
deficient cells, heralding a synthetic lethal interaction. Furthermore, MAX requires BRG1 
to activate neuroendocrine transcriptional programs and to up-regulate MYC-targets, 
such as glycolytic-related genes. Finally, we observed genetic inactivation of the MAX 
dimerization protein, MGA, in lung cancers with wild type components of the SWI/SNF or 
MYC pathways. Our results provide evidence that an aberrant SWI/SNF-MYC network is 
essential for lung cancer development. Altogether, the genetic observations coupled with 
the functional evidence demonstrate that an aberrant SWI/SNF-MYC network is essential 
for lung cancer development, and opens novel therapeutic possibilities for the treatment 
of SCLC patients with MAX-deficient tumors. In healthy adults and during embryonic 
development, the complex is involved in the control of cell differentiation and in the 
specification of different tissues. The effect of the SWI/SNF complex on some of these 
processes is, at least in part, related to its involvement in regulating hormone-responsive 
promoters. Components of the SWI/SNF complex bind to various nuclear receptors, 
such as those of estrogen, progesterone, androgen, glucocorticoids and retinoic acid, 
thereby adapting the gene expression programs to the demands of the cell environmental 
requirements. Retinoic acid (RA) and glucorticoids (GC) are well known modulators of cell 
differentiation, embryonic development and morphogenesis. Their role in promoting cell 
differentiation makes it possible to use GC and RA therapeutically to treat some types 
of cancers. GC are part of the curative treatment of acute lymphoblastic leukemia while 
RA is the therapeutic agent for some neuroblastomas and acute promyelocytic leukemia, 
which both carry the PML–RARa gene fusion. GC are also used as a co-medication in the 
therapy of solid tumors, because of their effectiveness in treating the malignancy, or 
due to their less severe side effects in cancer treatment, such as electrolyte imbalance, 
nausea and emesis. However, most solid tumors, including lung cancers, are refractory 
to GC- and RA-based therapies. Underlying some cases of refractoriness to GC and RA 
is a dysfunctional SWI/SNF complex, for example due to alterations at BRG1. On the 
other hand, compounds that modulate the structure of the chromatin are currently used 
to treat cancer. These include histone deacetylase (HDAC) inhibitors, in hematological 
malignancies and cutaneous T-cell lymphomas, and inhibitors of DNA methylation such 
as azacytidine for myelodysplasic syndrome. HDACs and DNA methylation inhibitors 
promote gene transcription by increasing DNA accessibility through the inhibition of 
histone deacetylation and DNA methylation, respectively. These drugs have been tested 
in lung cancer patients in two studies, in which they showed no major responses. However, 
in a phase I/II trial, the combination of the two inhibitors produced a median survival 
of the entire cohort that was significantly longer than those of the existing therapeutic 
options. Here, we aimed to determine whether there could be a therapeutic use for GC 
plus RA (GC/RA) in combination with the epigenetic drugs azacytidine and SAHA (A/S) for 
treating lung cancers carrying BRG1 inactivation or MYC amplification. We found that in 
vitro, GC/RA treatment reduced growth, triggered pro-differentiation gene expression 
signatures and downregulated MYC, in MYC-amplified but not in most BRG1-mutant lung 
cancer cells. The co-administration of A/S enhanced all these effects, accompanied by 
sustained reductions in genome-wide DNA methylation. In vivo, treatments with GC/
RA improved overall survival of mice implanted with MYC-amplified cells and reduced 
tumor-cell viability and cell proliferation. Thus, we propose that the combination of 
retinoids, corticoids and epigenetic treatments of lung tumors with MYC amplification 
constitute a strategy for therapeutic intervention in this otherwise incurable disease. 
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cMET, EML4-ALK, ROS1, RET fusions etc. were found in patients. However, each patient 
only harbored one mutation. Specific inhibitors are very effective in the treatment of 
lung adenocarcinoma patients harboring corresponding targeted mutations. Thus, 
driver mutation or oncogene addiction hypothesis was built through genomic analysis of 
lung adenocarcinoma patients and clinical observations of successful targeted therapy 
treatment. Several targeted therapies have been tested in a small scale of advanced 
stage SCLC patients. None of the studies showed any signal of anticancer activity in 
years. Thus, radiotherapy and chemotherapy remain the effective treatment for SCLC. 
Current technique allowed us to examine cancer genome in detail. The information can 
be used to predict clinical usage of certain targeted therapy. Genomic analysis of SCLC 
may open a door for us to understand the basic differences between NSCLC and SCLC 
and ponder the ineffectiveness of targeted therapy in SCLC. Genomic alterations of SCLC 
cells were first described in 1980s by observation of chromosome aberrations. Frequent 
deletion of 3p was first observed by Peng-Whang J et al. The most frequent reported 
genetic alterations in SCLC cells were inactivting mutations of TP53, RB1, PTEN, 
mutations in PIK3CA, EGFR and KRAS, amplification of myc family, EGFR and BCL2 as well 
as loss of RASSF1A, PTEN and FHIT. Those genomic alterations were examined through 
small series of samples and target gene examinations. Systemic approach to explore the 
multitude and magnitude of genomic alterations in SCLC was only possible with recent 
next generation sequencing technology and the application of bioinformatics to analyze 
the vast amount of data generated from the samples. Rudin et al. have collected 36 
primary human SCLC and normal tissue pairs and 17 matched SCLC and lymphoblastoid 
cell lines and examined the exome, transcriptome and copy number alterations. In 4 
primary tumors and 23 SCLC cell lines, the authors identified 22 significant mutated 
genes. In the exome of 42 SCLC tumor normal tissue pairs, they identified 26406 somatic 
mutations. 30% of them resulted in protein alterations. An average of 175 protein-
altering single nucleotide variants was calculated per patient. G-to-T transversions 
were the predominant mutation, followed by G-to-A and A-to-G transition mutations 
signify that these mutations were related to tobacco smoke carcinogens. In the whole 
genome analysis of one patient, 286 protein-altering changes were found. Frequent 
altered genes included genes encoding for kinases, G-protein-coupled receptors and 
chromatin-modifying proteins. The authors found that SOX2 mutation or amplification 
was frequently found in its series. SOX2 expression may play some crucial roles in 
SCLC cells, such as maintenance of pluripotency of stem cells property. In addition, 
the authors also discovered several non-recurrent fusion genes from RNA-seq data. 
The roles of these fusion proteins in SCLC are less well understood. But some of those 
fusion proteins seem to result in activating kinases. Peifer M et al. sequenced 29 SCLC 
exomes, 2 genomes and 15 transcriptomes. They discovered inactivation of TP53, RB1 
and recurrent mutations in CREBBP, EP300 and MLL genes. Additional findings included 
mutations in PTEN, SLIT2, EPHA7 and FGFR1 amplification. They concluded that histone 
modification is a major feature of SCLC. Both comprehensive genomic studies disclosed 
similar gene alterations such as TP53 and RB1 are the important signatures of SCLC 
genomic alterations. However, an individual analysis pointed out at different angles, for 
example, SOX2 or histone modification. The different results of two series reflected that 
only a limited number of samples were tested, interpatient heterogeneity may be huge 
and more genomic studies should be performed in the future. When major genomic 
alterations were compared among lung adenocarcinoma, squamous cell carcinoma and 
SCLC, alterations of TP53, CDKN2A, PIK3CA and PTEN were commonly found in all three 
types of lung cancer. FGFR1 and SOX2 alterations were found in SCLC and squamous cell 
carcinoma, whereas KEAP1 alterations was detected in both squamous cell carcinoma 
and adenocarcinoma. Recently, transformation from adenocarcinoma to SCLC was 
detected in a minority of patients with EGFR mutations who have received EGFR TKIs and 
developed resistance. Typical EGFR mutations can be found in untreated SCLC patients, 
especially in east Asian ethnic patients. Occasionally mixed SCLC and adenocarcinoma 
were described under light microscopy. Some of those patients harbor EGFR mutations. 
Unfortunately, EGFR TKI was usually not effective in the treatment of such patients, it 
suggested that alterations of the transcriptional factors contributed SCLC phenotype 
being more dominant and only chemotherapy was effective to control the progression 
of the disease. The heterogeneous nature of genomic alterations in SCLC suggested 
that targeted therapy may be difficult to be successful in SCLC treatment. None of the 
altered genes seems to be the dominant driver. On the other hand, RB1 and myc, genes 
altered easily that are not the good targets for current targeted therapy. Thus, genomic 
analysis of SCLC further indicated that the combination of targeted therapy may not 
be useful. It may have to combine targeted therapy and chemotherapy to obtain better 
anti-cancer activity. However, patient selection may be needed according to the genomic 
findings and pathway predictions. The hyper mutational genomic background was a 
good predictor for immune checkpoint inhibitor therapy. However, in a recent report in 
American Society of Clinical Oncology Meeting suggested that only a low response rate 
was noted in SCLC treated with immune checkpoint inhibitors. More genomic, immune 
studies and clinical trials are needed to advance the treatment of SCLC in the future. 
Keywords: SCLC, genomic, targeted therapy
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MS26.02 The MYC/MAX and the SWI/SNF Networks: Biological Understanding 
and Therapeutic Applications Montse Sanchez-Cespedes Epigenetics and Biology 
Program, Bellvitge Biomedical Research Institute, Barcelona/Spain
The SWI/SNF chromatin-remodeling complex modifies the structure of the chromatin 
by the ATP-dependent disruption of DNA–histone interactions at the nucleosomes 
to activate or repress gene expression. The widespread occurrence of alterations at 
genes encoding different components of the SWI/SNF complex reveals an important 
new feature that sustains cancer development and offers novel potential strategies for 
cancer therapeutics. We discovered that in lung cancer the SWI/SNF component, BRG1 
(also called SMARCA4), is genetically inactivated in about thirty per cent of non-small cell 
lung cancers (NSCLC), and that its inactivation occurs in a background of wild type MYC 
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MEK/ERK activity while MTOR inhibitors reduced the activity of TORC1 (p70S6K, S6) and 
TORC2 (AKT Ser473)-specific targets. In combination, FGFR TKIs and MTOR inhibitors 
simultaneously eliminated MEK/ERK and MTOR signaling. Xenografts generated from 
the FGFR1-dependent lung cancer cell lines, Colo699 and H1581, exhibited only modest 
sensitivity to monotherapy with the FGFR-specific TKI, AZD4547. However, consistent 
with the in vitro findings, combination treatment with AZD4547 and the MTOR inhibitor, 
AZD2014, afforded significantly greater tumor growth inhibition and prolonged survival. 
The data support the existence of a signaling network wherein unmutated FGFR1 drives 
the ERK pathway and distinct receptors under investigation activate the MTOR/AKT 
pathway to induce full transformation. Combining MTOR inhibitors with FGFR-specific TKIs 
may yield greater clinical efficacy in FGFR1-driven lung cancers.
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MS27.02 Incorporating Quality of Life & Palliative Care Measures in Clinical 
Trial Designs Raphael Catane1, Nathan Cherny2 1Oncology, Sheba Medical Center, Tel 
Hashomer/Israel, 2Oncology, Shaare Zedek Medical Center, Jerusalem/Israel
Evidence for clinical benefit from new treatment approaches is derived from phase 
III randomised clinical trials, which generate ostensibly unbiased data regarding the 
efficacy, benefit and safety of new therapeutic approaches. The potential benefits of a 
new treatment can be summarised as either living longer and/or living better, evaluated 
in clinical studies through the treatment effect on overall survival (OS) and/or quality of 
life (QoL), and their surrogates. In studies of interventions with curative intent in which 
mature survival data is not yet available disease-free survival (DFS), recurrence-free 
survival (RFS), event-free survival (EFS), distant disease free survival (DDFS), and time 
to recurrence (TTR), are used as surrogate measures. The validity of this approach, 
though not uncontroversial is well supported by data. In studies evaluating therapies 
in non-curative settings, progression-free survival (PFS), and time to progression (TTP) 
provide information about biological activity and may indicate benefit for some patients 
however they are not reliable surrogates for improved survival or QoL. Indeed in studies 
in which PFS benefit is observed, but because of subsequent treatments or crossover 
OS is not improved, QoL data is critical to evaluate the real meaning of the PFS. When 
QoL has been evaluated and there is either improvement or delayed deterioration this 
augments the significance of the PFS finding. Where is measured and PFS does not 
demonstrate improvement in QoL, this diminishes from the meaning of the PFS finding. 
QoL measurement has been widely adapted in the recent generation of lung cancer 
research and it has made a major contribution in verifying and amplifying the major 
clinical benefit conferred by Gefitinib, Afatanib and Crizotinib all of which were evaluated 
in PFS studies with crossover allowed. QoL has also been a critical primary outcome in an 
important study that demonstrated the QoL can be improved by initiating early palliative 
care for patients with metastatic lung cancer. 1. Fukuoka M, Wu Y-L, Thongprasert S et 
al. Biomarker analyses and final overall survival results from a phase III, randomized, 
open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected 
patients with advanced non–small-cell lung cancer in Asia (IPASS). Journal of Clinical 
Oncology 2011; 29: 2866-2874. 2. Mok TS, Wu Y-L, Thongprasert S et al. Gefitinib or 
carboplatin–paclitaxel in pulmonary adenocarcinoma. New Engl J Med 2009; 361: 947-
957. 3. Sequist LV, Yang JC-H, Yamamoto N et al. Phase III study of afatinib or cisplatin 
plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. 
Journal of Clinical Oncology 2013; 31: 3327-3334. 4. Yang JC-H, Hirsh V, Schuler M et al. 
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/
pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. 
Journal of Clinical Oncology 2013; 31: 3342-3350. 5. Shaw AT, Kim D-W, Nakagawa K 
et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New Engl 
J Med 2013; 368: 2385-2394. 6. Solomon BJ, Mok T, Kim DW et al. First-line crizotinib 
versus chemotherapy in ALK-positive lung cancer. The New England journal of medicine 
2014; 371: 2167-2177. 7. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for 
patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742. 
Keywords: palliative care, clinical trials, Quality-of-Life
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MS27.03 Patient Advocate Groups Driving Progress - Using the Evidence 
Craig Uthe (Independent Advocate), North Wales/PA/United States of America
Patient advocacy takes several forms, including that which strives to connect 
patients to medical research findings and promising trials to enable them to better 
understand and manage what they are experiencing and pursue promising newly-
emerging treatments in partnership with their oncologists. This short talk by online 
patient-to-patient advocate “CraiginPA” describes this role of advocate peers and 
advocacy groups, identifies some resources used by patients and supportive 
professionals/advocates who strive to understand or share newly emerging 
research, and gives examples of how advocates and advocate groups have used 
research evidence to push for more timely adoption into practice and standards. 
Keywords: patients using emerging research
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MS26.03 p53/Rb John Minna1, Alexander Augustyn2, Svetlana Earnest3, Patrick 
Dospoy1, Jane Johnson4, Melanie Cobb3 1Hamon Center for Therapeutic Oncology 
Research, University of Texas Southwestern Medical Center, Dallas/TX/United States 
of America, 2Hamon Center for Therapeutic Oncology Research, University of Texas 
Southwestern Medical Center, Dallas/United States of America, 3Department of 
Pharmacology, University of Texas Southwestern Medical Center, Dallas/TX/United States of 
America, 4Neuroscience, University of Texas Southwestern Medical Center, Dallas/TX/United 
States of America
ASCL1 is a lineage-specific transcription factor responsible during development for the 
formation of pulmonary neuroendocrine cells. ASCL1 is highly expressed in the majority 
of neuroendocrine lung tumors including small cell lung cancer (SCLC) and non-small cell 
lung cancer with neuroendocrine features (NSCLC-NE). Others have shown that SCLC 
survival depends on continued ASCL1 expression while we showed that ASCL1 is also 
required for the survival of NSCLC-NEs; that ASCL1 down-stream targets predict for 
poor survival in NSCLC patients; and that BCL2 is a therapeutically actionable ASCL1 
target gene (PNAS 2014;111(41):14788-93). Thus, we are trying to target ASCL1 and 
its “druggable” downstream genes by developing ASCL1 based ChIP-Seq datasets in 
SCLC and NSCLC-NE tumors. We have now discovered a way to reliably regulate ASCL1 
protein expression through “upstream” targeting. Phorbol 12-myristate 13-acetate 
(PMA) is an agonist of the MAPK pathway via specific activation of Protein Kinase C. 
Treatment of ASCL1(+) HCC1833 cells for 24 hours with nM quantities of PMA resulted 
in a robust down-regulation of ASCL1 mRNA and protein. Tumor cell death was apparent 
and apoptosis confirmed via induction of cleaved PARP. ASCL1 down-regulation was 
associated with activation of the MAPK pathway, measured by increased protein levels 
of phosphorylated ERK (pERK), and decreased ASCL1 mRNA expression was found 
to be at least partly due to mRNA degradation. These data indicate that activation of 
the MAPK pathway in high-grade neuroendocrine tumors has potential for therapeutic 
intervention and also provides a reason for the previously unexplained low levels of 
MAPK activation (pERK) in SCLC. Unexpectedly, we also found that siRNA mediated 
knockdown of ASCL1 resulted in activation of the MAPK pathway. In addition, pERK 
was significantly induced with ASCL1 knockdown even when we also knocked down 
MEK1 (MEK1 knockdown by itself completely eliminated pERK expression). The MAPK 
pathway depends on active phosphorylation/dephosphorylation and this is regulated 
in part by dual-specificity phosphatases (DUSPs). Using our ASCL1 ChIP-Seq data, we 
identified a conserved ASCL1 binding site in the promoter region of DUSP6. DUSP6 
mRNA was found to be dramatically elevated in ASCL1(+) lines HCC1833 and H889, 
while by contrast there was little or no DUSP6 expression in ASCL1(-) SCLC lines 
H82 and H526, and knockdown of ASCL1 resulted in a decrease of DUSP6 protein 
suggesting transcriptional regulation. This led us to try a DUSP6 allosteric inhibitor 
(E/Z-BCI, Sigma-Aldrich) which induced pERK, decreased ASCL1 protein expression, and 
inhibited soft agar colony forming ability of H889 SCLC cells. In conclusion: Our data 
indicate that the MAPK pathway regulates ASCL1 expression, where activation of pERK 
signaling is correlated with decreased ASCL1 mRNA and protein. In addition, ASCL1 
in turn, actively down-regulates the MAPK pathway. Our hypothesis is that high-grade 
neuroendocrine lung cancers down-regulate the MAPK pathway in order to maintain 
ASCL1 expression, which promotes cell survival and maintenance of the neuroendocrine 
lineage. This points to a double-negative feedback loop involving the MAPK pathway, 
ASCL1, and at least one DUSP. Targeting components of the MAPK pathway regulating 
ASCL1 expression is thus a new therapeutic avenue for high-grade neuroendocrine 
lung cancers. (Lung Cancer SPORE P50CA70907, NIH 1F30CA168264, CPRIT). 
Keywords: MAPK, NSLC-NE, SCLC, ASCL1
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MS26.04 FGFR1 Co-Activation Networks in Lung Cancer Lynn Heasley 
Craniofacial Biology, School of Dental Medicine, University of Colorado Anschutz Medical 
Campus, Aurora/CO/United States of America
FGFR1 is a therapeutic target under investigation in multiple solid tumors and clinical trials 
of FGFR-specific and selective tyrosine kinase inhibitors (TKIs) are underway. Our recent 
studies have demonstrated a role for unmutated FGFR1 as a driver in lung cancer cell lines 
of all histologies including small cell lung cancers (SCLCs), head and neck squamous cell 
carcinomas (HNSCCs) and mesotheliomas. Although potent in vitro growth suppression of 
lung cancer cell lines is observed in response to multikinase inhibitors such as ponatinib 
as well as FGFR-specific TKIs (AZD4547, BGJ398), the in vivo inhibitory effects of these 
drugs on xenografts propagated in immune deficient mice are more modest and short-
lived in our hands. Thus, while treatment with single FGFR TKIs represents a logical entry 
point to personalized therapy of cancers bearing over-expressed FGFR1, we hypothesize 
that intrinsic mechanisms involving rapid kinome reprogramming events limit the 
therapeutic efficacy of these TKIs. In fact, ample precedent exists to support the signaling 
of receptor tyrosine kinases (RTKs) within “co-activation networks” where multiple RTKs 
engage multiple signal pathways to bring about robust and flexible activation of signal 
cascades. We deployed RNAi-based functional genomic screens to identify protein 
kinases controlling the intrinsic sensitivity of FGFR1-dependent lung cancer and HNSCC 
cells to ponatinib, a multi-kinase FGFR-active inhibitor. Mammalian Target of Rapamycin 
(MTOR) was identified and validated as a synthetic lethal kinase with ponatinib in H157 
and H1299 cells. In other FGFR1-expressing cell lines (Colo699, H520 and H1703), 
MTOR was an essential protein kinase as evidenced by high sensitivity to MTOR-targeting 
shRNAs and pharmacological inhibitors. Despite wide ranging MTOR dependencies 
observed among the FGFR1-dependent cell lines, synergistic in vitro growth inhibition 
was a general observation when FGFR inhibitors where combined with pharmacological 
inhibitors of MTOR or AKT. At the molecular levels, FGFR inhibitors potently inhibited 
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• Provision of training for key Aboriginal Health Workers in culturally sensitive cancer 
support group facilitation and palliative care training.
In summary, the Let’s yarn about lung cancer project partners (Lung Foundation Australia 
and Hume Regional Integrated Cancer Services) developed a stronger collaborative 
relationships with the Aboriginal Health Workers and the local Aboriginal community, 
resulting in barriers to treatment and care being reduced. In turn, local cancer services 
have become more culturally aware, with health workers and community members 
feeling more comfortable accessing the local cancer services with their clients. 
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MS27.05 Supporting Lung Cancer Survivors – Living with and Beyond Lung 
Cancer Janet Freeman-Daily Lung Cancer Patient Advocacy, #LCSM Chat (LCSM = Lung 
Cancer Social Media), Federal Way/WA/United States of America
When I heard the words “lung cancer” at age 55, I could barely believe the diagnosis. 
The facts I found online were not encouraging. As we moved through the various staging 
procedures, my family and I experienced increasing levels of fear. Within sixteen months 
I had two chemo regimens, two radiation protocols, and two progressions. Fortunately, 
my online patient community informed me about mutation testing and the new ROS1 
translocation. My tumor tissue tested positive for ROS1, and I started taking crizotinib 
in a clinical trial in November 2012. I’ve had No Evidence of Disease for 30 months and 
counting. More new treatments have become available for lung cancer patients in the 
past four years than in the past four decades. Precision medicine, clinical trials, reliable 
online information sources, supportive online patient and caregiver communities, and 
care teams that engage in shared decision making have enabled me and many other 
metastatic lung cancer patients to beat the odds and live with metastatic lung cancer as 
a chronic illness instead of a death sentence. No therapy offers a permanent cure. We live 
from scan to scan. Yet we’re happy to be alive and have a relatively normal life for as long 
as it lasts. What are the keys to living with and beyond lung cancer? To live successfully 
with lung cancer, patients need access to appropriate and affordable treatment from 
compassionate, capable healthcare providers. We need those healthcare providers to 
stay current with treatment guidelines and use precision medicine best practices such 
as genomic sequencing to find effective treatments for our individual cancers. But we 
metastatic patients – who make up a majority of lung cancer patients -- need more than 
this. We need consultations with experts who have knowledge about our individual types 
of lung cancer. We need help accessing second opinions and clinical trials. We need 
plans for the next steps in case treatments aren’t effective. We need access to support 
services that improve our quality of life. Connecting stage IV patients to palliative care 
services early in the diagnosis and treatment process improves quality of life, gives us 
resources for dealing with treatment side effects and pain, and develops relationships 
which can help us and our family members consider our goals in pursuing further 
treatment. We need psychosocial supports for ourselves and loved ones to cope with 
depression and facilitate important conversations on difficult topics. After successful 
curative treatments, we need survivorship plans, and possibly rehab to deal with side 
effects. In addition to treatments, we need help to break through the shock of diagnosis, 
to become activated and engaged patients who participate in our own care--engaged 
patients tend to have better outcomes. We need people to dispel the stigma associated 
with lung cancer and treat us with respect and compassion regardless of our smoking 
history. After cancer forces us to realize how little control we truly have in life, we need 
to regain some sense of control. Choosing treatment options using a shared decision 
making process with our healthcare providers ensures our priorities and values are 
considered, and helps us understand the risks and benefits of each option. Connected 
health resources can help more lung cancer patients become engaged and participate 
in shared decision making. Trusted websites hosted by the NCI, cancer centers, medical 
societies, and advocacy organizations help inform us about our disease and our options. 
Patient success stories on personal blogs and social media offer us hope. Talking with 
other patients and caregivers who are sharing the same experiences lifts our spirits and 
helps us deal with side effects and losses. When both patients and healthcare providers 
embrace molecular and genomic testing, clinical trials as treatment options, online 
resources, connected patient and caregiver communities, and shared decision making, 
more lung cancer patients will successfully live with and through lung cancer. 
Barry MJ, Edgman-Levitan S. Shared Decision Making — The Pinnacle of Patient-Centered 
Care. N Engl J Med 2012; 366:780-781. DOI: 10.1056/NEJMp1109283. http://www.nejm.
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MS27.04 Let’s Yarn About Lung Cancer - An Indigenous Community Project in 
Regional Australia Kerrie Callaghan Lung Foundation Australia, Milton/QLD/Australia
Lung cancer is the leading cause of cancer death in Aboriginal and Torres Strait Islander 
people in Australia, with Indigenous Australians 70% more likely to die from lung cancer 
than non-Indigenous Australians. 
(1)Lung cancer is the most common cancer in Indigenous men and the second most 
common cancer in Indigenous women. In fact, the incidence and mortality rate of lung 
cancer is higher for Indigenous than for non-Indigenous Australians. (1)
 
 
Evidence indicates that Indigenous people experience poorer outcomes following a 
cancer diagnosis because this population has later presentation to healthcare and later 
diagnosis. 
 
In 2012, Lung Foundation Australia, a national non-government lung health organisation, 
in partnership with Hume Regional Integrated Cancer Services (Hume RICS) led a 
community engagement and cancer education program within the regional Indigenous 
community of Albury/Wodonga situated on the New South Wales and Victorian state 
borders.
At the time, Albury/ Wodonga had a population of 4,000 Aboriginal people and Hume RICS 
Cancer Support Nurse had only cared for three identified Aboriginal cancer patients in 
the last five years.
The Let’s yarn about lung cancer” project was a 2 year project that aimed to 
raise awareness and understanding of lung cancer risks and symptoms within 
the Indigenous community in Albury/Wodonga and to encourage those who have 
concerns about their lung health or the health of community members to take action. 
At the same time, the project team developed innovative and culturally sensitive ways 
to educate Aboriginal Health Workers and local community health providers in the early 
diagnosis, treatment and supportive care needs of local Aboriginal cancer patients and 
their families - with a focus on lung cancer.
A suite of culturally sensitive, evidence based patient resources were produced including:
• a lung cancer symptoms and risks community education DVD entitled “Let’s Yarn 
about lung cancer”
• 3 patient DVD stories around being proactive about potential symptoms, curative 
treatment away from “country” and life after treatment including a survivor story 
from highly respected Indigenous singer/songwriter, Archie Roach.
• an Aboriginal lung cancer awareness pin
Integral to the success of this project was the appointment of a local Aboriginal 
Project Officer who had strong relationships within the local Aboriginal and community 
health sector, was well respected in the local Aboriginal community and who 
ensured that culturally sensitivity was a key component of the project deliverables. 
National cancer control agency, Cancer Australia acknowledges that “there is no word meaning 
“cancer”, in most, if not all Indigenous Australian languages. Unlike many other illnesses, the 
concept of cancer is not embedded in the traditional Indigenous Australian story-telling”. (2) 
Prior to the “Let’s yarn about lung cancer” project, cancer was not a topic 
that was on the “radar” for local Aboriginal Health Workers or the Albury/
Wodonga Aboriginal community. Cancer was not openly discussed. 
Let’s yarn about lung cancer project deliverables and highlights included:
• Establishment of a dynamic project advisory group with strong representation 
from the local Indigenous health and community health services.
• Delivery of a series of culturally sensitive cancer education sessions on lung 
cancer, treatment options and palliative care services to local Aboriginal Health 
Workers within existing Chronic Health events.
• Local Aboriginal health workers attended interactive educational sessions at 
the local radiation, chemotherapy and palliative care units. These “walk-thru” 
visits provided an understanding of treatment options, referral pathways and the 
supportive care services available.
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MS28.04 Drug Development and Drug Approval Richard Gaynor Oncology Business 
Unit, Eli Lilly and Company, Indianapolis/IL/United States of America
Over the past decade, there have been rapid advances in cancer drug discovery 
and development. Much of this progress has resulted from a better understanding 
of the genetic changes in cancer and the development of agents that target the 
underlying biology of disease. In addition, an improved understanding of the immune 
system and cancer has resulted in the development of immune checkpoint inhibitors 
that have profound clinical activity in many tumors. Finally, the role of the tumor 
microenvironment in the regulation of tumor growth, metastatic spread, and modulation 
of the immune system is an area of intense investigation1. This enhanced understanding 
of the complex biology of cancer, and novel drugs against these new targets, have 
ushered in an exciting era in drug development leading to important new drug 
approvals2. 
 
An increasingly important aspect in both clinical development and drug approval is the 
incorporation of biomarkers and companion diagnostics to select patients more likely to 
benefit from specific therapies3. In lung cancer, the utilization of companion diagnostics 
has been key in the clinical development of TKIs directed at a variety of EGFR mutations 
and ALK alterations4,5,6. Other biomarker tests have been used to identify genes such 
as BRAF and ROS1 in order to develop clinical trials to test approved targeted agents 
with activity in patients with these molecular alterations7. Ongoing clinical studies 
exemplified by the Lung Master Protocol and NCI Match Protocol are utilizing biomarker 
panel strategies, including next generation sequencing (NGS), to identify patients 
with specific mutations in lung and other cancers respectively4. The use of NGS to 
characterize molecular alterations is also becoming more common to characterize 
patients’ tumors in both the academic and community settings. Immunohistochemistry 
assays continue to be a mainstay for understanding tumor biology and are also being 
utilized to quantitate markers such as PDL-1 expression in tumor immune cells in order 
to identify patients who are more likely to respond to immune checkpoint inhibitors8. In 
addition, analysis of biomarkers in liquid biopsies (e.g. plasma, spinal fluid) are being 
analyzed to provide supplemental information and/or to obviate the need for ongoing 
tumor biopsies during therapy9. 
 
Clinical development based on patient subset will increasingly be the norm, rather than 
the exception, in oncology. Rather than exclusively utilizing histology to screen patients 
for clinical trials, the use of basket trials to identify and treat patients of various 
histologies with agents targeted to similar molecular alterations is an approach which is 
increasingly being utilized10. In addition, retrospective analyses are being conducted to 
understand underlying molecular abnormalities of patients with exceptional responses 
to existing therapies and to use the information to design future clinical trials. 
 
One of the major challenges in clinical development is tumor heterogeneity and drug 
resistance. To prevent or overcome the development of drug resistance, combination 
therapies to target specific pathways are being explored. One such example is the use 
of BRAF and MEK inhibitors in the treatment of metastatic melanoma11. Many clinical 
studies in lung cancer are now incorporating mandatory tumor biopsies during the 
course of EGFR and ALK inhibitor therapy to identify evolving genetic changes in tumors 
during therapy in order to incorporate second and third generation TKIs. 
 
New mechanisms to facilitate the drug review and approval processes are underway12. 
One such mechanism is the Breakthrough Therapy (BT) Program. Breakthrough 
Therapy is intended to expedite the development and review of drugs for serious or 
life threatening conditions. Designation of a drug as a BT is based on preliminary 
clinical evidence that demonstrates that a new drug may have substantial improvement 
over available therapy and facilitates ongoing communication between the sponsor 
and the FDA to streamline the drug development process. Accelerated approval has 
been developed by the FDA for speeding the development and approval of promising 
therapies to treat serious disease that provides a meaningful therapeutic benefit over 
available therapy. Accelerated approval is based on an improvement in patient benefit 
utilizing surrogates of survival that are reasonably able to predict clinical benefit. The 
accelerated approval mechanism has been essential in facilitating new drug approvals 
of promising therapies. In addition, fast track designation is an FDA program intended 
to facilitate the development and expedite the review of drugs to treat serious 
medical conditions. This program allows sponsors to facilitate the review process 
for drug approval by having ongoing FDA interactions and utilizing a rolling review of 
submissions. 
 
Given the importance of biomarker-directed therapy, an additional critical component 
of the regulatory landscape is the review and approval of companion diagnostics at the 
same time as specific drug approvals. The drug-diagnostic co-development model is 
becoming increasingly common in oncology as biomarker-driven patient selection is 
required for many of the new targeted and immune therapies. Thus, an evolution in both 
the clinical development paradigm and the regulatory landscape is occurring based on 
the discovery and development of more effective, biomarker-directed targeted agents 
and novel immune checkpoint inhibitors. 
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Major advances in the understanding of molecular pathways that regulate tumor growth 
have led to development and FDA approval of new anticancer agents leading to improved 
survival in patients with certain cancer types. A common cancer like Non Small Cell Lung 
Cancer (NSCLC) is now subdivided in a number of molecularly defined subsets. Large 
randomized trials are not feasible anymore. This challenge to accrue to small subsets 
with availability of multiple drugs for each has led to novel trial design strategies like 
“Master Protocols” with multiple arms that are biomarker driven. Master Protocols are 
ideal if multiple molecular targets are known to drive tumor growth, if there is pre-clinical/
clinical evidence that these targets can be pharmacologically inhibited and if the drugs 
to be tested are available. These protocols provide consistency of drug development 
approach regardless of intended target, utilize resources (including patient resources) 
in an efficient manner and have potential of bringing safe and effective drugs to patients 
faster. On the other hand these trials are time and resource intense, and some trials 
with public/private partnership have added need of a high level coordination. Part of NCI 
precision medicine initiative has led to “Master Protocols” like Lung-MAP, ALCHEMIST and 
NCI-MATCH. The Lung-MAP trial is evaluating patients with squamous cell lung cancer 
who have progressed beyond at least one line of therapy. The study divides patients into 
multiple treatment arms based on the molecular profiles of their cancers testing efficacy 
of targeted drugs. Promising results in any arm can lead to testing the drugs in that 
treatment arm in more patients, with the goal of more rapid drug approvals in these small 
subsets of squamous cell lung cancer patients. ALCHEMIST is testing the benefits of 
molecularly targeted adjuvant (post-surgical) treatment of patients with early-stage lung 
adenocarcinomas whose tumors have either an EGFR gene mutation or an anaplastic 
lymphoma kinase (ALK) gene rearrangement. Depending on the genetic abnormality in a 
tumor, the patient will be randomized to receive the EGFR protein kinase inhibitor erlotinib 
or the ALK protein kinase inhibitor, crizotinib against a placebo. The Food and Drug 
Administration (FDA) has approved these molecularly targeted therapies for advanced 
lung adenocarcinoma in patients with the relevant genetic changes. It is expected that 
most patients with early lung adenocarcinoma who are screened will not be eligible for 
the therapeutic portion of this trial because their tumors will not have the necessary 
mutations. However, the tumor samples from these patients will be saved, and, if they 
relapse while on standard treatment, their tumors will be biopsied again and analyzed 
for insight into the progression of their disease and for potential therapeutic approaches 
suggested by this analysis. The NCI-MATCH trial will test a large number of agents in 
virtually any tumor type in which appropriate abnormalities are identified. This umbrella 
protocol will examine between 20 and 25 drugs, including those that have been FDA-
approved for the treatment of cancer at another tumor site or experimental agents that 
have shown activity against a known target at one or more tumor sites. If the response 
rate to a particular agent is high, the number of patients evaluated with that treatment 
would be expanded to further explore whether the targeted treatment represents a 
substantial advance over standard chemotherapy. If a tumor becomes resistant to the 
first test drug, it will be re-biopsied to see if another targeted therapy might be effective 
and to understand the basis for resistance to the initial treatment. By studying multiple 
agents at the same time, a higher proportion of patients will be eligible for the trial, and 
efficient progress can be made in the assessment of clinical benefit.
S140 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
6. Kwak EL, Bang Y-J, Camidge DR, et al. N Engl J Med. 2010; 18: 1693-1703. 
7. Camidge, DR., Pao, W., and Sequist, LV. Nature Rev. Clin. Onc. 2014; 11: 473-481. 
8. Carbognin, L., Pilotto, S., Milella, M., et al. PLOS ONE 2015; 10:1371 in press. 
9. Francis, G. and Stein, S. Int. J. Mol. Sci. 2015; 16: 14122-14142. 
10. Catenacci, DVT. Mol. Onc. 2015; 9: 967-996. 
11. Long, GV., Stroyakovskiy, D., Gogas, H., et al. NEJM 2014; 371: 1877-1888. 
12. Kesselheim, AS. and Darrow, JJ. Clin. Pharm. & Ther. 2015; 97: 29-36.
 
S141Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
phase 3 are to determine if there is a statistically signifi cant difference in OS and to 
determine if there is both a clinically meaningful and statistically signifi cant difference in 
IA-PFS. The conduct of Lung-MAP relies on close collaboration (a public-private 
partnership) among the NCI and NCTN (spearheaded by SWOG), the pharmaceutical 
industry, the Foundation for the NIH (FNIH), Friends of Cancer Research, advocates, and 
FDA. This Master Protocol will improve genomic screening of SCC patients for clinical 
trial entry, and improve time lines for drug-biomarker testing, allowing for inclusion of the 
maximum numbers of otherwise eligible patients. The clinical trial continues to be 
updated following science and alterations in the therapeutic landscape, with adaptations 
in design and incorporation of new agents against matched targets and the implementation 
of novel immunotherapy approaches for the unmatched arm.
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Lung-MAP, a “multi-drug, multi-study bio-marker driven squamous cell lung cancer clinical 
trial” [i] is, as the song says – a new day . . . a new life . . . and the old world is a new 
world.[ii] It represents an exciting and radical new paradigm for lung cancer research and 
with that a potential for new, life-saving treatment protocols for lung cancer. Lung-Map 
was borne of a National Cancer Institute (NCI) sponsored two-day workshop with the 
NCI Thoracic Steering Committee and the Federal Drug Administration (FDA) “to bring 
together leading academicians, clinicians, industry and government representatives to 
identify challenges and potential solutions in the clinical development of novel targeted 
therapies for lung cancer.”[iii] The objectives of the “workshop were to achieve initial 
consensus on a high priority biomarker-driven clinical trial designed to rapidly assess the 
activity of targeted agents and molecularly defi ned lung cancer subsets and to facilitate 
generations of data leading to approval of these new therapies.”[iv] The result of this 
workshop led to the development of an unprecedented public-private collaboration called 
the Lung-MAP Master protocol. Lung-MAP is a unique research model in several respects. 
First, it will study fi ve different experimental drugs at the same time for squamous cell 
lung cancer.[v] The approach stands in stark contrast to the long entrenched research 
approach whereby only one drug is tested and with that only those patients that might 
benefi t from the treatment are involved in the trial. Second, Lung-MAP researchers will 
examine the DNA from each participating volunteer patient’s lung tumor to identify the 
genetic alterations or mutations that are causing the tumor to grow. They will match 
these results with sub-studies testing related investigative treatments. [vi]
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The traditional obstacles to approval of oncologic therapeutic agents, especially 
targeted therapies that address a rare-biomarker defi ned group of patients are the 
long processes from initial drug discovery to clinical implementation, the diffi culties in 
recruitment for these clinical trials and high number of screen failures and the overall 
low rate of enrollment in clinical trials. The Lung Master Protocol (Lung-MAP, S1400) 
is a precedent-setting clinical trial designed to advance the effi cient development of 
targeted therapies for squamous cell cancer of the lung (SCCA). There are few new 
effective therapeutic options for patients with advanced lung SCCA. Immunotherapies, 
including nivolumab, have already shown clear benefi t for patients with SCCA in 2015 
leading to approval by the FDA which has been an unprecedented step forward for the 
treatment of patients, however we are still lacking predictive markers for these therapies 
that are reliably selecting patients more likely to benefi t. Lung-MAP (S1400) is aiming 
to identify biomarker-drug pairs that will lead to successful therapeutic outcomes and 
registration of new agents. It is a registration-intent master protocol that includes a 
screening component and clinical trial component; the clinical trial component includes 
multiple sub-studies which independently evaluate investigational therapies. The clinical 
trial component is designed to be modular such that new sub-studies can be added either 
as other sub-studies close or as new biomarker-drug pairs are identifi ed for testing in this 
patient population. Lung-MAP is utlilizing a broad NGS screening platform capitalizing on 
the expanding application of genomic sequencing in oncology that has through the Cancer 
Genome Atlas and other sequencing initiatives revealed targetable genetic aberrations 
including gene mutations, rearrangements, amplifi cations, and deletions, and creating an 
immense opportunity to implement personalized therapy with a high potential to improve 
patients outcomes. Immunotherapy has been integrated in the design of Lung-MAP from 
its launch in June of 2014. The original study design and structure is shown in the fi gure.
 
The modular design of the study has allowed for the fl exibility to adapt to the approval of 
nivolumab and the hault in further development of AMG102 (rilotumumab) with 
discontinuation of the corresponding sub-study by implementing timely modifi cations 
which include the following:1)Eligibility has changed from exclusively second line therapy 
to second-or more line therapy 2)Pre-screening, while patient receive fi rst line therapy 
has been added to boost accrual 3)the unmatched arm has been changed to a single (not 
randomized) arm study with the anti-PD-L1 agent MEDI-4736. Theses changes are 
refl ected in the fi gure. Each independently conducted and analyzed sub-study specifi es 
investigator-assessed progression-free survival (IA-PFS) and overall survival (OS) as the 
co-primary endpoints for the phase 3 primary objectives. The primary objectives for the 
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setting, in which its value is so modest as to be debatable. SQ NSCLC patients are 
presumed to be ALK and ROS-1 wild type and rarely candidates for therapies against 
these targets. Until very recently, therefore, SQ NSCLC has been characterized by the 
NSCLC treatments that are considered ineffective, prohibitively toxic, or of relatively 
marginal benefit. Several new management options, however, have emerged that are 
more directed to the SQ NSCLC population. Though the randomized phase III trial that 
let to approval of nab-paclitaxel in advanced NSCLC (6) was not specifically directed to 
patients with SQ NSCLC, the trial of carboplatin with either paclitaxel or nab-paclitaxel 
demonstrated a higher response rate in the nab-paclitaxel arm of 41% vs. 24% in favor 
of nab-paclitaxel. In the absence of other therapies that have shown enhanced efficacy 
in SQ NSCLC, nab-paclitaxel has an arguable role as first line therapy for SQ NSCLC, 
though there are no confirmatory trials or biomarker correlates to corroborate a special 
utility for nab-paclitaxel here. Another chemotherapy-based approach directed to SQ 
NSCLC is nedaplatin, a second generation platinum compound tested in a Japanese 
trial of 350 patients with chemotherapy-naïve advanced SQ NSCLC in which subjects 
were randomized to cisplatin/docetaxel or nedaplatin/docetaxel (docetaxel on each 
arm administered at the standard Japanese dose of 60 mg/m2 d1 every 21 days) (7). 
Median OS was >2 months longer with nedaplatin (13.6 vs. 11.4 months, HR 0.81, p 
= 0.037), and toxicity was relatively comparable between the two arms. Nedaplatin/
docetaxel combination may now be considered a new standard treatment for advanced 
SQ NSCLC in Japan, but the non-standard dosing of docetaxel for global populations 
and the recognition of potential differences in efficacy of regimens among different 
racial populations will likely limit broader use of nedaplatin until studies outside of Japan 
confirm superior efficacy. The SQUIRE trial of the monoclonal antibody against EGFR 
necitumumab trial in 1093 first line SQ NSCLC patients showed a modest OS benefit 
when this agent was added to cisplatin/gemcitabine, compared with chemotherapy 
alone (8). In absolute terms, however, the median OS benefit of only 1.6 months (11.5 
vs. 9.9 months), counterbalanced by greater toxicities and costs with the addition of 
necitumumab, has led to little enthusiasm for favoring the broader incorporation of this 
agent. Afatinib has been studied in the LUX-Lung-8 trial as an alternative to erlotinib in 
previously treated patients with SQ NSCLC (9). While the 1.1 month OS benefit and HR 
0.81 with afatanib reflect only marginal superiority to erlotinib, afatanib is now arguably 
the EGFR TKI of choice in this setting, pending FDA approval. However, with the value of 
erlotinib for SQ NSCLC considered so debatable in this setting, this may be interpreted as 
damning with faint praise. By far the greatest excitement for patients with advanced SQ 
NSCLC stemps from immune checkpoint inhibitor therapy, starting with the programmed 
cell death protein 1 (PD-1) inhibitor nivolumab, which was compared in the randomized 
Checkmate 017 trial to docetaxel as second line therapy in 272 chemotherapy-pretreated 
patients with advanced SQ NSCLC (10). Demonstrating a far superior median OS of 9.2 vs. 
6.0 months, HR 0.59 (p = 000025), a median duration of response not yet reached, and a 
far more favorable tolerability than docetaxel, nivolumab is now the clear, FDA-approved 
second line standard of care for SQ NSCLC. This trial also demonstrated no correlation of 
efficacy with nivolumab as a function of tumor expression of programmed death protein 
ligand-1 (PD-L1), supporting its use in an unselected SQ NSCLC population. As genomic 
testing becomes more readily available and incorporated into clinical practice, molecular 
markers relevant for patients with SQ NSCLC are likely to provide new targeted therapy 
opportunities to accompany those of immunotherapies and conventional chemotherapy 
for this large population still greatly needing new advances. 
References 1) Hirsch, JTO 2008 2) Scagliotti, JTO 2011 3) Cohen, Oncologist 2010 
4) Johnson, JCO 2004 5) Shepherd, NEJM 2005 6) Socinski, JCO 2012 7) Shukuya, 
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Recent advances in personalized medicine and associated companion diagnostic 
therapeutics have led to an increased utilization of genetic markers in oncology therapy 
selection. The rapid acceleration of biomarker driven therapy has been widely accepted into 
clinical guidelines based upon proven clinical utility and unprecedented patient outcomes. 
Despite these advances, utilization of molecular testing in community oncology practice 
has been more limited than in academic settings. The Levine Cancer Institute and Carolinas 
HealthCare System serve a wide variety of oncology patients in both academic and 
community settings using a multidisciplinary approach. During this session, a discussion 
of processes used for tissue acquisition and processing, pre-analytics, biomarker testing, 
and result reporting will be presented. Strategies that have been used in our system to 
eliminate common roadblocks in the testing process such as tissue stewardship will 
be discussed. A special emphasis will be given to the discussing the power and pitfalls 
of common biomarker testing techniques such as real-time PCR companion diagnostic 
testing, immunohistochemistry, FISH, and next-generation sequencing panels. During the 
presentation, a significant amount of time will be dedicated to a question and answer 
session so audience members can address community testing challenges from their 
local settings. Working to solve these challenges in the community setting will improve 
the oncology patient journey by increasing access to high quality biomarker testing. 
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Third, while not entirely unique but nonetheless significant, is Lung-MAP’s broad 
collaborative approach. Those participating in Lung-MAP include NCI, public and private 
research and advocacy organizations together with five pharmaceutical companies.[vii] 
The importance of this new paradigm for lung cancer research is graphically illustrated 
by the treatment and research options that have traditionally been offered to lung cancer 
patients. In 2000, the only treatments offered and/or available to lung cancer patients 
were the same platinum chemotherapies, radiation and surgery which had been used to 
treat lung cancer patients for the prior 30 years. Neither the course of time, nor repeated 
use of these treatment therapies, offered much hope for survival to lung cancer patients 
as evidenced by a stagnant 13% five-year survival rate, which has only recently increased 
to 17% five-year survival rate. The underpinning of Lung-MAP has its genesis, in part, in the 
completion in 2003 of the Human Genome Project (HGP) which led to The Cancer Genome 
Atlas (TCGA) in 2005. The completion of the HGP and the TCGA resulted in refreshing and 
hopefully effective new ways of looking at lung cancer. Before the advent of the HGP and 
the TCGA, lung cancer tumors were viewed as homogeneous. Now they are viewed as 
unique biological entities – more like snowflakes, with no two tumors alike. Following the 
TCGA, the first treatable genomic mutation –EGFR – was identified in 2003. The mutation 
is found in 10% of non-small cell lung cancer (NSCLC) patients. It was quickly followed by 
FDA approved treatments gefitinib and erlotinib. In 2007, EML4-ALK fusion was identified. 
It too was quickly followed by an FDA approved treatment – crizotinib. Following in this 
vein, Lung-MAP portends the identification of additional genomic mutations and with it, 
a chance for faster research results and more effective treatment of lung cancer. There 
are now at least 15 significant identified and hopefully targetable lung cancer genomic 
mutations. Three of these, EGFR, EML4-ALK and ROS1 have received FDA approved 
treatments. There are more in clinical trials. In 2015, the first immuno-oncologic therapy 
received FDA approval for squamous cell lung cancer with many more immuno-oncologic 
therapies in the clinical trial pipeline that are expected to be approved for not only NCSLC 
but also small cell lung cancer (SCLC). The core of Lung-MAP is “rapid assessment.” 
This fast pace of discovery will hopefully render archaic established models requiring 
10 to 15 years for development in clinical trials before receiving FDA approval. New 
approaches to clinical trial protocols such as Lung-MAP, are critical to keeping up with 
rapidly changing discoveries and changing the old order of research and development. 
Shortening the timeframe for translational research, from bench to bedside, in order to 
provide patients with the quickest and most effective benefit from these new therapies 
is critical and will save lives – especially for lung cancer patients. In order to continue to 
take advantage of this exciting period in the convergence of research and technology, it 
is equally imperative that we come together in a collaborative and open-sharing model 
that will deliver exciting, safe new therapies to patients as fast as possible and with that 
lead to a long overdue, exponential increase in the survival rate for lung cancer patients. 
[i] Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop 
on Strategies for Integrating Biomarkers in to Clinical Development of New Therapies for 
Lung Cancer Leading to the Inception of “Master Protocols” in Lung cancer. Shakun M. 
Malik, MD, Richard Pazdur, MD, Jeffrey S. Abrams, MD, Mark A. Socinski, MD, William 
T. Sause, MD, David H. Harpole Jr., MD, John J. Welch, MD, PhD, Edward L. Korn, 
PhD, Claudio Dansky Ullmann, MD, and Fred R. Hirsch, MD PhD Journal of Thoracic 
Oncology, Vol. 9, Number 10, October 2014, p. 1443. [ii] Feeling Good, Michael Bublé, 
2005 [iii] Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee at p. 
1443. [iv] Id. [v] Id. at 1443-1444 and www.lung-map.org/about - lung-map [vi] Id. [vii] Id. 
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In recent years, we have seen a new practical distinction made in terms of management 
recommendations for the histologic subtypes of non-small cell lung cancer (NSCLC). 
There is now a growing recognition of the biological relevance of the differences between 
major histologic subtypes, as clinical trials and distinct management algorithms emerge 
for the advanced squamous (SQ) NSCLC population. Though differences in the clinical 
behavior of SQ vs. non-squamous (NSQ) NSCLC have been recognized for decades (1), 
the first functional distinction emerged with the recognition of different results for SQ 
and NSQ populations in multiple trials of pemetrexed that together demonstrated that the 
efficacy of this agent was limited to patients with NSQ histology (2), ultimately leading 
to a change in the label of pemetrexed, previously approved for all NSCLC patients as 
second line therapy, to being indicated for NSQ patients only (3). Development of the 
anti-angiogenic agent bevacizumab was also limited to patients with NSQ histology after 
a post-hoc analysis of results in a phase II trial of carboplatin/paclitaxel with either of 
two dose levels of bevacizumab or placebo demonstrated a high risk of life-threatening 
or fatal pulmonary hemorrhage among patients with SQ histology (4). Subsequent 
development and clinical use of bevaicizumab in advanced NSCLC has been limited to 
NSQ histology. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
(TKIs) are another class of anticancer therapy that are more effective in NSQ than 
SQ NSCLC (5). Though patients with SQ NSCLC were included in early, pivotal trials 
in molecularly unselected populations that revealed a modest overall survival (OS) 
benefit with erlotinib, molecular selection of patients with an activating EGFR mutation 
has shown that high response rates (RR) and prolonged benefit with EGFR TKIs is 
overwhelmingly in patients with an activating EGFR mutation, so rare in SQ NSCLC that 
routine testing for it is not recommended. ALK and ROS-1 rearrangements are similarly 
rare in SQ NSCLC, with routine for these markers in SQ NSCLC not recommended. 
Patients with SQ NSCLC remain candidates for erlotinib in the maintenance or salvage 
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Dyspnea (or the subjective experience of breathlessness) has a prevalence of about 
50% in people with any cancer (not just lung cancer), and moderate to severe dyspnea 
is present in 28% of terminally ill cancer patients. Up to 60% of patients with lung 
cancer can experience dyspnea. Typically dyspnea experience will be of moderate level 
intensity, distressing and interfere with activities of daily living. Managing dyspnea is 
often challenging and should include an assessment to identify first and treat reversible 
causes. The following table shows such causes and possible treatment (Cancer Care 
Ontario, 2010).
Treatable causes of dyspnea Treatment Options
RESPIRATORY SYSTEM Chronic 
obstructive pulmonary disease 
(COPD) Large airway obstruction 
Pleural effusion Pneumonia 
Pulmonary emboli CARDIOVAS-
CULAR SYSTEM Angina pectoris 
Atrial fibrillation Congestive Heart 
Failure Pericardial effusion Supe-
rior vena cava obstruction OTHER 
SYSTEMS Anemia Severe Ascites
Inhaled bronchodilators; inhaled or systemic 
corticosteroids Radiotherapy; systemic cortico-
steroids; stenting; heliox; nebulized epinephrine 
Drain; if recurrent - sclerosing agents; indwelling 
catheter Antibiotics Anti-coagulation; inferior 
vena cava filter Optimize conventional medica-
tions Medications for ventricular rate control 
Optimize conventional medications Drain; if re-
current - sclerosing agents; pericardial window; 
indwelling catheter Corticosteroids; radiothera-
py; stenting Red blood cell transfusion Drain; if 
recurrent- indwelling catheter
Pharmacological options, beyond treating the underlying cause, include systemic opioids 
(but not nebulized opioids), and occasionally benzodiazepines for managing dyspnea-
related anxiety. Systematic reviews and meta-analyses (ie. Ben-Aharon et al, 2012) have 
shown the following:
• Systemic opioids (Oral and parenteral routes) Effective
• Nebulised opioids Not effective (nebulized hydromorphone very effective in 1 small 
trial)
• Supplemental Oxygen (non-hypoxic patients) Not recommended
• Supplemental Oxygen (hypoxic patients) Recommended
• Nebulised furosemide Insufficient evidence but probably ineffective
• Nebulised lidocaine Not recommended
• Benzodiazepines Not recommended for managing dyspnea, but can be used to treat 
related anxiety
• Systemic corticosteroids No comparative data available
• Phenothiazines No comparative data available. To consider if other interventions 
have failed in severe dyspnea
• Morphine combined with midazolam More effective than either option alone. 
Contradictory evidence
The session will provide more data supporting the above statements. Non-pharmacological 
interventions may include diaphragmatic breathing exercises, positioning, education 
or supportive counseling. The session will also focus on recent findings from a new 
intervention to manage the symptom cluster of respiratory distress (breathlessness-
cough-fatigue) and the results of a new study testing the effects of resistance inspiratory 
muscle training (Yorke et al, in press; Molassiotis et al, 2015). In relation to the newly 
developed complex psycho-educational and self-management interventions in 101 
patients with lung cancer, results suggest improvements in managing dyspnea over the 
3 months of the follow-up. In the last study to be presented, using resistance inspiratory 
muscle training (IMT) through a breathing device in 46 patients with lung cancer, results 
suggest a clinically meaningful improvement for those patients using the device for 3 
months. The session will look at the symptom clusters around breathlessness and also 
cough management as this is impacting dyspnea too. Finally, the research gaps in the 
field will be highlighted. 
References: Cancer Care Ontario (2010). Symptom Management Guide-to-Practice: 
Dyspnea. file:///C:/Users/hkpuadmin/Downloads/Dyspnea%20(Full)%20(2).pdf Ben-
Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. (2012). Interventions for alleviating cancer-
related dyspnea: a systematic review and meta-analysis. Acta Oncol.; 51(8):996-1008. 
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Bronchoscopy dates back to the late 18th century where rigid illuminating tubes were 
used to examine the tracheobronchial tree. With the introduction of the fiberoptic 
bronchoscope, bronchoscopy has revolutionized the practice of pulmonary medicine. 
In lung cancer, due to advances in real-time imaging and catheter based techniques, 
bronchoscopy remains pivotal not only in diagnosis and staging, it also allows therapeutic 
intervention for airway restoration in patients with central airway obstruction, and 
treatment of early detected central airway cancers. For peripheral lung nodules that are 
beyond the visibility of the bronchoscope, computed tomography (CT) guided, navigational 
methods, and endobronchial ultrasonography (EBUS) facilitate accurate targeting. Since 
bronchoscopy allows access to the lung, it enables researchers to better understand 
lung carcinogenesis, discover biomarkers for early detection and prognostication as 
well as assess tumor response to targeted therapy by in-vivo microdynamic imaging. 
Pleuroscopy provides the physician a window to the pleural space by enabling biopsy of 
the parietal pleura under direct visual guidance in the evaluation of effusions of unknown 
etiology, guided chest tube placement, and talc pleurodesis as palliation of malignant 
pleural effusions. Cancer related pleural effusions occur as a result of direct tumor 
invasion, tumor emboli to the visceral pleura with secondary seeding of the parietal 
pleura, hematogenous spread, or via lymphatic involvement. Elastin staining and careful 
examination for invasion beyond the elastic layer of the visceral pleura should be carried out 
for lung cancer resections, as visceral pleural invasion is regarded as an important stage-
defining feature in the absence of nodal involvement. Metastatic spread of lung cancer 
to the pleura adversely affects survival, and in the recent TNM staging of lung cancer, 
presence of pleural metastasis is defined as M1a (from T4), representing a corresponding 
change from stage IIIB to stage IV. It is rare to find resectable lung cancer in the setting of 
an exudative pleural effusion, despite negative cytologic examination. Thus, pleuroscopy 
can establish operative eligibility by determining if the pleural effusion is paramalignant or 
due to metastases. If pleural metastases are found, and therefore confirming inoperable 
disease, talc poudrage can be performed at the same setting. This has been shown to 
be more effective in preventing recurrence than intrapleural instillation of a sclerosant. 
 
Keywords: interventional pulmonology pleuroscopy lung cancer
SESSION MTE 06:  
SURVIVORSHIP AFTER COMBINED MODALITY THERAPY 
(IMAGING, SALVAGE THERAPY)  
MONDAY, SEPTEMBER 07, 2015
MTE06.01 Curative Radiotherapy for Local or Locoregional Disease Yasushi 
Nagata Radiation Oncology, Hiroshima University, Graduate School of Medical Sciences, 
Hiroshima/Japan
Radiation and chemotherapy are usually combined in the treatment of locally advanced 
lung cancer. Therefore, survivorship after chemoradiotherapy is important. The most 
frequent pattern of failure is distant metastases, followed by lymph nodal failure and 
local failure. Periodical examination by CT and/or FDG-PET as imaging method is 
important. However, its optimal frequency and timing are still unknown. Palliative 
radiotherapy is indicated for several metastases. Stereotactic radiosurgery (SRS) is 
usually indicated for single or multiple brain metastases less than 4 in number. Whole 
brain radiotherapy is indicated for multiple brain metastases. Single or fractionated 
radiotherapy is indicated for bone metastases in combination with Zoledronic acid 
Hudrates. Strontium-90 can be indicated for multiple bone metastases when tumor has 
its uptake. Stereotactic body radiotherapy (SBRT) is a technique, introduced in the late 
1990s. SBRT is a method of using single 10-20Gy of high dose and hypofractionated 
radiotherapy. Recently, many papers have been published on its clinical results, 
especially in early stage lung cancer. SBRT can also be used for lung metastases. 
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that serve vulnerable populations who consume tobacco (to be presented at IASLC). 
 
Keywords: Tobacco Control, Cancer Patients and Smoking Cessation, Tobacco 
Cessation
TOBACCO CONTROL: WHAT DO THE EXPERTS DO?  
MONDAY, SEPTEMBER 07, 2015 - 07:00-08:00
MTE08.02 Tobacco Control: What Do the Experts Do? Emily Stone Thoracic 
Medicine, St Vincent’s Hospital, Sydney/NSW/Australia
Better understanding of tobacco control assists clinicians with individual patient care and 
with opposition to an industry with resources and motivation to undermine health policy. 
Modern tobacco control is anchored in the WHO Framework Convention on Tobacco 
Control1 which advocates effective policies including plain packaging legislation, 
widespread smoking bans and control of advertising. Tobacco control policies, despite 
apparent simplicity, are complex to implement and vulnerable to attack. The tobacco 
industry anticipates and undermines much policy change. To match this, tobacco 
control needs to be sophisticated, robust and anticipate the tobacco industry. Article 
5.3 of the FCTC calls for protection of tobacco control against attack. Clinicians may 
improve smoking cessation with an understanding of current tobacco control. Many 
tobacco control strategies are effective, particularly tobacco taxes, plain packaging and 
smoking bans2. Tobacco taxes can have a rapid, demonstrable and predictable effect 
on smoking rates, both over time and in comparisons between countries3,4 5. Taxes have 
recently been increased in China6. Tobacco taxation can be complex and multilayered, 
with different tax structures having varying impact on the price of cigarettes and 
therefore smoking rates4. Plain packaging, now in place in Australia, the UK and Ireland, 
has emerging effects on smoking rates and attitudes to smoking7. Smoking bans can 
have a marked effect on smoking rates2. Keeping tobacco “out-of-sight” has had an 
impact; recent Australian data (where post-plain packaging smoking rates have fallen by 
almost 3%8) show discernible changes in cigarette pack display and active smoking at 
outdoor venues9.Tobacco control strategies are complex to implement. Local strategies, 
while relatively straightforward conceptually, can be vulnerable to opposition from the 
tobacco industry. The globalization of the tobacco epidemic, with internationalization 
of tobacco companies, makes the effects of trade liberalisation, trade agreements and 
foreign investment very influential on tobacco control and regulation10. Strategies which 
appear to be locally driven, such as smoking bans, advertising bans and modifications in 
packaging can suffer from intervention at a global level, such as challenges to Australia’s 
plain packaging legislation, a domestic health policy challenged by Phillip Morris Asia 
to the High Court of Australia11. The tobacco industry uses complex strategies to 
oppose tobacco control. The industry anticipates legislation and exploits international 
legal processes to oppose health policy implementation, as exemplified by Ukraine’s 
incongruous opposition to Australia’s introduction of plain packaging, now abandoned12. 
Trade agreements may facilitate this sort of legal exploitation; the planned TPPA, an 
agreement under negotiation between 12 Pacific Rim countries including the USA and 
Australia, includes investor state dispute settlement (ISDS) provisions that assist foreign 
investment to oppose policy that adversely affects their interests10. The tobacco industry 
can be difficult to separate from the modern economy, with wide infiltration of financial 
systems such as superannuation13 and governments compromised by ownership of 
tobacco industries as in China14 and Vietnam15. Tobacco control strategies require 
thought, tenacity, political will and flair to match the efforts of an industry powerfully 
motivated towards profit. Clinicians may benefit from understanding tobacco control. 
Tobacco cessation, a component of which is prevention of uptake, can be understood 
in this context. Tobacco tax increases have been shown to predict quitline use which 
gives clinicians an opportunity to intensify tobacco cessation treatment16. The FCTC 
divides tobacco control into reduction of demand (tobacco cessation) and reduction in 
supply. Reduction in demand results most clearly from tobacco cessation, addressing 
nicotine dependence and habit. Reduction in supply can have an impact on demand 
too, with evidence that advertising bans, smoking bans and plain packaging change 
the attitudes of smokers17. Placing tobacco cessation in the context of tobacco control 
may give the smoker and the physician more control and may enhance quit rates 
and reduce uptake. Tobacco control is much more complex than it first appears. The 
context of the WHO FCTC is the best basis on which build an understanding of the 
modern paradigm of control. Local strategies are essential to reduce demand. Global 
control strategies are pivotal in reducing supply. Individual cessation strategies, 
particularly the duration and intensity of the treatment of nicotine addiction may 
be more successfully implemented with an understanding of tobacco control. 
 
References: 1. WHO | WHO Framework Convention on Tobacco Control.WHO at <http://
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cigarette prices under different tax structures: findings from the International Tobacco 
Control Policy Evaluation (ITC) Project. Tob. Control 23, i23–i29 (2014). 5. Hill, S., Amos, 
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Introduction Cancer mortality continues to decline in the US and the number of cancer 
survivors continues to rise, currently estimated at 14.5 million in 2014 and predicted 
to reach 19 million by 2024 (ACS and NCI). The percent of adult cancer survivors 
who are current smokers has not changed dramatically over the past 10 years, and is 
comparable to the general population, except in the youngest age group, 18-44, where it 
is significantly higher (2000-2010 NHIS). The 2014 Report of the Surgeon General, “The 
Health Consequences of Smoking - 50 Years of Progress,” cited 20,830,000 premature 
deaths caused by smoking and exposure to secondhand smoke (1965-2014). Smoking–
related cancers accounted for 6,587,000 and lung cancers caused by exposure to 
secondhand smoke accounted for 263,000. Between 2005 and 2009, over 480,000 
US deaths annually were attributable to cigarette smoking. Lung cancer accounted for 
almost 138,000 (29%). In 2015, the estimate is 158,040 lung cancer deaths – 86,380 
(28%) in men and 71,660 (26%) in women, still the leading cause of cancer death in 
the US. The 2014 SGR concluded that there is a causal relationship between cigarette 
smoking and adverse health outcomes, and that quitting smoking improves the prognosis 
of cancer patients. In cancer patients and survivors, a causal relationship was concluded 
between smoking and all-cause mortality, cancer-specific mortality, and increased 
risk for second primary cancers known to be caused by smoking. The relationship is 
considered suggestive but not causal between cigarette smoking and risk of recurrence, 
poorer response to treatment and increased treatment-related toxicity. Among chronic 
disease populations (NHIS 2006 vs 2012), 15.2% of lung cancer survivors continue to 
smoke, compared to 20.9% in 2006. Among other smoking-related cancers, 33.8% 
of survivors continue to smoke, compared to 38.8% in 2006. Among persons with 
no chronic disease, the comparable percents of current smokers were 16.6% in 2012 
and 19.3% in 2006. These elevated rates of current smoking among chronic disease 
survivors are truly alarming. Clearly, the need for tobacco cessation intervention is great 
among cancer patients and survivors. Addiction to cigarette smoking (and all tobacco 
use) is challenging to treat in both healthy individuals and in those with serious diseases. 
Nearly 70% of smokers say they want to quit, and nicotine dependence is considered 
a chronic relapsing disorder. Negative affect, particularly symptoms of depression or 
negative mood, is strongly related to higher smoking prevalence and relapse rates. MD 
Anderson’s Tobacco Treatment Program (TTP) In response to the great need to assist 
cancer patients and survivors in their efforts to stop using tobacco, in 2006 the Tobacco 
Treatment Program was established at MD Anderson, underwritten by funds from the 
State of Texas settlement with the tobacco industry. The program continues to be funded 
from that source, at no cost to participants. The Mission of the TTP is to implement a 
comprehensive tobacco-cessation and relapse prevention program for all MD Anderson 
patients and employees (including family members). The program is led by three faculty 
Directors, members of the Department of Behavioral Science: Paul Cinciripini, Ph.D., 
Program Director; Janice Blalock, Ph.D., Assistant Director; and Maher Karam-Hage, MD, 
Associate Medical Director. The program is staffed by a counseling team, a medical 
team, a data team and a number of research and administrative staff. The TTP provides 
a range of treatment options that become progressive more intense, to match the needs 
of each participant. Multiple options for service delivery include: Self-help educational 
packet and follow-up call; Motivational intervention, education and follow-up call; 
Telephone counseling only; and Comprehensive, individualized counseling involving in-
person counseling and both in-person and telephone follow-up. This component includes 
pharmacotherapy and the assessment and treatment of psychiatric co-morbid disorders. 
In 2012, MD Anderson began automatic referral to the TTP of all patients who currently 
smoke or recently quit smoking for proactive assistance. The number of referrals/day 
more than quadrupled, from ~10/day to between 40-50/day (2012-2014 data). Recently, 
there has been an expansion of service to the Regional Care Centers via a Telemedicine 
Platform. In FY 14, 4,613 patients had a motivational interaction with program staff, 
including 3,639 current smokers and 974 recent quitters. The three top clinic sources 
were GU (16.8%), Head & Neck (14.6%) and Thoracic (14.3%). The data below are based 
on the subset of patients who participated in the “in-person” option. 
In terms of demographics: Ethnicity – 75.3% non-Hispanic white; 12.9% black/
African-American; 6.9% Hispanic; and 4.9% other; Gender – 52.0% female and 48.0% 
male; Location – 56.1% Houston Metro area; Mean age – 55.7 years; Mean number 
of cigarettes smoked/day – 15.1; number of years smoked – 32.7. Psychiatric co-
morbidity – 12% alcohol abuse, 13% major depression, 11% other depression, 13% 
anxiety, and 8% panic disorder; 61% no psychiatric disorder. Between 2006 and 2013, 
a cohort of 3404 individuals reached the 9 month time point since completing their 
initial individual consultation with TTP providers. Self-reported 7 day point prevalence 
abstinence information was determined for two analyses - Intent–To-Treat (ITT, all 
patients, excluding deceased) and Respondent-Only (RO, only those patients who 
responded to follow-up). Response rates for the RO analysis were high – 89% at 3 
months, 83% at 6 months, and 76% at 9 months). The RO analysis was undertaken 
because patients cannot be reached at follow-up for reasons other than relapse to 
smoking, including illness, successful cessation, and other personal concerns. The 
ITT analysis utilized the traditional conservative approach of representing missing data 
as smoking. The 7 day point prevalence abstinence rates for ITT and RO analyses, at 
follow-up, were: 3 months – ITT 41.1%, RO 46.0% 6 months – ITT 39.1%, RO 47.2% 9 
months – ITT 35.1%, RO 46.2% These data compare favorably with those of smoking 
cessation studies in the general population, using both pharmacotherapy and counseling. 
In conclusion, the MD Anderson Cancer Center seeks to reduce tobacco use and its 
adverse consequences in its own patient and employee population and in a set of new 
initiatives to extend its expertise throughout the Texas university system and institutions 
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9.5). Both topotecan and temsirolimus failed to show clinical benefit as consolidation 
or maintenance therapy following frontline doublet chemotherapy.9 However, sunitinib 
as a maintenance therapy was associated with improved PFS in SCLC-ED. The CALGB 
30504 trial was a randomized phase II study that enrolled patients without progression 
to placebo or sunitinib. Ninety-five patients were randomly assigned; 10 patients did 
not receive maintenance therapy (five on each arm). The median PFS was 2.1 months 
for placebo and 3.7 months for sunitinib (HR, 1.62; 70% CI, 1.27 to 2.08; 95% CI, 1.02 
to 2.60; one-sided P = .02). Median overall survival from random assignment was 6.9 
months for placebo and 9.0 months for sunitinib (HR, 1.28; 95% CI, 0.79 to 2.10; P = 
0.16). A phase III study to confirm this positive finding is currently in planning.10 Salvage 
Therapy: The poor outcome associated with SCLC is due primarily to the refractoriness 
of relapsed disease to salvage therapy.11 Although a number of agents have shown 
activity in relapsed SCLC including irinotecan, paclitaxel, bendamustine, etoposide and 
gemcitabine, topotecan remains the only approved agent for the treatment of relapsed 
SCLC in Western countries. Amrubicin showed positive efficacy and is an approved 
agent in Japan for relapsed SCLC. However, it failed to demonstrate superior efficacy 
over topotecan in a randomized phase III study conducted in the West. A total of 637 
patients were randomized to amrubicin or topotecan. The median PFS was 4.1 vs. 3.5 
months (HR, 0.802; P = .018); median OS was 7.5 months vs. 7.8 months (HR: 0.880; 
P = .170); with amrubicin and topotecan respectively.12 Immune checkpoint inhibitors 
targeting PD-1 signaling (nivolumab; pembrolizumab) and CTLA4 pathways (ipilimumab) 
are currently being evaluated in relapsed SCLC. Initial reports showed encouraging 
activity of this class of therapeutic agents with superior efficacy noted with combination 
therapy over single agent and potential enrichment for patients likely to benefit with 
the use of PD-L1 expression as a predictive biomarker.13, 14 Perspectives on the future: 
E2511 is an ongoing phase II study exploring whether the addition of a PARP inhibitor to 
platinum doublet will result in improved clinical outcome. There is preclinical support and 
biological rationale to expect that PARP inhibitor therapy will enhance the efficacy of DNA-
damage inducing chemotherapy regimen. The study completed accrual in the 2nd quarter 
of 2015 and results are awaited. The genomics of SCLC is significantly understudied 
in comparison to the non-small cell lung cancer and other cancer types. Recent works 
using state of the art genomic assays confirmed previously known frequent alterations 
in RB, TP53 and Myc family genes.15, 16 These works also identified hitherto unknown 
driver alterations in other genes such as the SOX family of genes. Advancement in the 
management of SCLC in the coming years is most likely to emanate from the integration 
of immunecheckpoint blockade into standard treatment paradigm for SCLC as well as 
through successful exploitation of the frequent genetic and epigenetic alterations that 
characterize this disease for targeted therapeutics. 
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Chemotherapy is the bedrock of advanced SCLC management. Platinum-based 
chemotherapy is the most widely employed regimen in the frontline setting.1 Systemic 
therapy is administered for SCLC in different settings including frontline, maintenance and 
salvage settings. Frontline Therapy: The clinical efficacy of frontline chemotherapy does 
not significantly differ based on the choice of partner chemotherapy employed along 
with platinum particularly in non-Japanese patients. The limited impact of the established 
frontline chemotherapy regimen is highlighted by the fact that lass than 25% of patients 
with extensive stage SCLC survive past 2 years. Nonetheless, population-based analysis 
of real-world patient outcome showed survival benefit of chemotherapy whereas the 
outcome for untreated patients has not improved in the last 20 years.2 Attempts to 
improve on treatment efficacy through intensification of chemotherapy regimens have 
met with uniform failure with heightened toxicity and no significant survival benefit. 
Incorporation of targeted biologic agents showed some promise in the preclinical and 
clinical settings. The addition of antiangiogenic agent to standard platinum-based doublet 
showed a non significant but positive trend towards improved survival. The SALUTE trial 
enrolled and randomly assigned 52 patients to receive standard platinum-doublet along 
with bevacizumab or placebo.3 The median PFS and RR were higher in the bevacizumab 
group (5.5 vs. 4.4 months; hazard ratio [HR], 0.53; 95% CI, 0.32 to 0.86) and 58% 
(95% CI, 43% to 71%) vs. 48% (95% CI, 34% to 62%). The median overall survival (OS) 
was no different (HR of 1.16; 95% CI, 0.66 to 2.04).3 E3501 study also evaluated the 
benefit of antiangiogenic therapy in a 63-patient single arm study treated with cisplatin, 
etoposide and bevacizumab.4 The response rate was 63.5%, median PFS of 4.7 months 
and OS was 10.9 months. Patients who had high baseline VCAM had a higher risk of 
progression or death compared with those who had low baseline VCAM levels. Using a 
different partner chemotherapy of carboplatin, irinotecan and bevacizumab, Spigel et al. 
reported an ORR of 84% (95% CI 71-93%), median TTP of 9.13 months (95% CI 7.36-9.46 
months) and median OS of 12.1 months.5 Identification of a reliable predictive biomarker 
would be critical for this management strategy to proceed beyond the completed phase 
II trials. Similarly, the E1508 study combined inhibitors of the hedgehog developmental 
pathway (vismodegib; GDC0049) and insulin-like growth factor receptor (cixutumumab; 
IMCA12) with platinum-doublet chemotherapy and compared the clinical outcome to 
platinum-doublet only. There was no improvement in median PFS (4.7, 4.4, 4.6 months) 
or OS (9.4, 9.8, 10.1 months).6 The combination of ipilimumab, an immune checkpoint 
inhibitor targeting CTLA4, with platinum doublet chemotherapy was very promising as 
a frontline regimen in SCLC especially when administered in a phased schedule.7 The 
study randomized 130 patients with chemotherapy-naïve SCLC-ED in a 1: 1: 1 ratio 
to receive paclitaxel/carboplatin with placebo (control), ipilimumab concurrent with 
paclitaxel/carboplatin or phased ipilimumab following induction paclitaxel/carboplatin. 
Phased ipilimumab improved irPFS versus control [HR =0.64; P=0.03] with median irPFS 
of 6.4 vs. 5.3 months and median OS of 12.9, vs. 9.9 months. This promising result 
provided the rationale for a phase III study of this regimen in newly diagnosed SCLC-ED. 
Maintenance or Consolidation Therapy: The strategy of maintenance or consolidation 
therapy has been systematically evaluated in SCLC-ED following completion of frontline 
doublet chemotherapy. Topotecan was investigated as a maintenance therapy in E7593 
study, a phase III trial that randomized patients with stable or responding disease 
following induction doublet chemotherapy to observation or four cycles of topotecan. 
A total of 223 were randomized to observation (n-111) or topotecan (n = 112). The 
PFS associated with consolidation topotecan was 3.6 months v 2.3 months (P <.001) 
for observation but without any significant difference in OS between the observation 
and topotecan arms (8.9 months v 9.3 months; P =.43).8 Similarly, E1500 evaluated 
temsirolimus as maintenance therapy following frontline therapy of SCLC-ED. The 
study enrolled 87 patients with either stable or responding disease following induction 
platinum-doublet to receive temsirolimus (25mg or 250mg) every week until disease 
progression. The median and 1-year PFS were 2.2 months (95% CI: 1.8, 2.9) and 
4.7% (95% CI: 0.2%, 9.2%), respectively. The median OS was 8 months (95% CI: 6.5, 
S146 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
SESSION MTE 10:  
SUBSOLID NODULES: WHAT THE CLINICIANS NEED TO 
KNOW / CLINICAL WORKUP OF CT DETECTED NODULES  
MONDAY, SEPTEMBER 07, 2015
MTE10.01 Subsolid Nodules: What the Clinicians Need to Know Kavita Garg 
Radiology, University of Colorado, Denver/CO/United States of America
Subsolid is a relatively new descriptor for a pulmonary nodule. Subsolid nodules include 
nonsolid or ground glass nodules (GGN) or part-solid nodules (PSN). Pure Ground-Glass 
Nodule (synonym: nonsolid nodule) is a focal area of increased lung attenuation within 
which the margins of any normal structures, e.g., vessels or airways remain outlined. 
Solid Nodule is a focal area of increased attenuation of such density that normal 
structures are completely obscured. Part-solid Nodule (synonym: semisolid nodule) 
is a focal nodular opacity containing both solid and ground-glass components. Their 
relative slow growth and indolent behavior compared to the typical speculated solid 
nodule has been recognized over time suggesting the possibility of overdiagnosis. 
Subsolid pulmonary nodules representing the adenocarcinoma spectrum represent 
the majority of screening CT detected lung cancers, and the behavior of these lesions 
seem to differ significantly from their clinically detected counterparts, although the data 
regarding the natural history of these lesions is limited. Because nodule size and growth 
are strong predictors for malignancy, the accurate assessment of size at baseline and 
growth on follow up CT is important in diagnostic work up of indeterminate nodules. 
Nodule growth can be quantified using either diameter or volume. Recently automated 
volumetric measurements have been suggested because malignant nodules may grow 
asymmetrically, and therefore, their growth may remain unnoticed with manual diameter 
measurements alone. Furthermore manual 2D measurements of small nodules have 
modest repeatability. It is important to differentiate part-solid nodules from pure ground-
glass because a solid component typically represents invasion. Part-Solid nodules 
(PSN) had much higher malignancy rate (62.5 %) than GGN (19%) or solid nodules 
(7%) in a recent study (1). Given advances in imaging and molecular pathology, a new 
Classification of Lung Adenocarcinoma was proposed by the International Association 
for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 
in 2011 (2). The 2011 classification addressed three important weaknesses in the 
previous classification. First, it eliminated the term bronchioloalveolar carcinoma (BAC). 
Second, it added new terminologies of carcinoma-in-situ (CIS), and minimally invasive 
adenocarcinoma (MIA) to recognize that minimal invasion (< 5mm) had nearly similar 
clinical outcome as noninvasive nodules. Third, it replaced the terminology of mixed 
subtype of adenocarcinoma. The widespread availability of MDCT and abundance of 
new information obtained especially from low-dose CT lung cancer screening programs, 
have increased our understanding of the types and management of small peripheral 
lung nodules encountered in daily clinical practice, in particular, the importance and 
prevalence of subsolid pulmonary nodules (atypical adenomatous hyperplasia (AAH), 
ground glass nodules (GGN) and part-solid nodules). Thin-section CT has emerged 
as a new biomarker for lung adenocarcinoma subtypes. Finding a subsolid nodule is 
expected to increase as screening CT become more prevalent after CMS approval. The 
approval of CT as a screening tool for lung cancer was based primarily on National Lung 
Screening Trial (NLST) results. The NLST recently found that Low Dose Helical Computed 
Tomography (LDCT) reduces lung cancer specific mortality by 20% relative to chest x-ray 
screening in a cohort at high risk of lung cancer (3). Despite the decrease in lung cancer 
mortality by CT screening in the NLST, significant concerns remain regarding its high 
false positive rate, overdiagnosis, cost effectiveness and concerns related to radiation 
burden from repeat CT screens. Radiation dose saving is especially important in patients 
with lung nodules because of the frequent follow up examinations. There is a trade-of 
between early detection of lung cancer vs unnecessary work-up of indeterminate nodules 
resulting in many side effects including anxiety, radiation exposure from CT follow-up to 
assess for growth, cost and morbidity and mortality related to biopsy or resection of a 
benign nodule. This is a significant issue as there is high false positive rate greater than 
95% reported in many screening CT studies (95% of 39% positive screen (3 rounds) were 
false positive and 24% underwent surgery for benign nodule and 73% nonsurgical biopsy 
revealed benign findings in NLST. It is expected that false positive rate would decrease by 
50% using more accurate phenotyping of a nodule using the lung CT reporting and data 
system (Lung-RADS) appropriately (4). One of the major changes proposed in Lung-RADS 
is the size threshold for positive screen, from 4 mm in NLST to 6 mm for solid nodules 
and 20 mm for nonsolid nodules. Smaller nodules will continue annual screening with 
low-dose CT (LDCT) in 12 months. Nodules larger than 6 mm and smaller than 8 mm 
will get follow-up LDCT in 6 months and nodules between the sizes of 8-15 mm will get 3 
month LDCT and PET/CT may be used when there is larger than 8 mm solid component. 
Tissue sampling would be used primarily for larger than 15 mm solid nodules or PET 
positive nodules with larger than 8 mm solid component. False positive rate would still 
be likely not acceptable for an individual using this approach. There is need for more 
accurate nodule assessment and risk stratification as given our current understanding 
that genetic make-up of a nodule is the ultimate determinant of clinical outcome (5). 
Further improvements in stage discrimination and management of lung nodules could 
be expected in the future, as more robust data related to texture analyses of tumors, 
their genetic profiles and impact of those on clinical outcome becomes available (6-
8). Simple measuring the tumor size with one-dimensional (Response Evaluation Criteria 
in Solid Tumors (or RECIST) long-axis measurements do not reflect the complexity of 
tumor morphology or behavior. Also, it may not be predictive of therapeutic benefit. In 
contrast, the emerging field of radiomics is a high-throughput process in which a large 
number of shape, edge, and texture imaging features are extracted, quantified, and 
stored in databases in an objective, reproducible, and mineable form. Once transformed 
into a quantifiable form, radiologic tumor properties can be linked to underlying genetic 
alterations and to medical outcomes. Marked heterogeneity in genetic properties of 
different cells in the same tumor is typical and reflects ongoing intratumoral evolution. 
Clinical imaging is well suited to measure temporal and spatial heterogeneity. Subjective 
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Lung Cancer is the leading cause of cancer-related death[1]. Small-cell lung cancer 
accounts for about 15-20% of lung cancer[2]. Although SCLC is chemosensitive, majority 
of SCLC patients develop disease progression soon after the first line therapy and 
need 2nd line therapy. However, over the past decades, most studies have failed and 
there is no substantial progress in second-line therapy for SCLC[3]. Topotecan remains 
2nd line therapy for SCLC patients with sensitive relapse. 1. Targeted therapy Almost 
all of the studies focused on the molecular targeted therapy for second-line treatment 
of SCLC were failed. However, in a recent randomized phase II trial (CALGB 30504) of 
chemotherapy with or without maintenance sunitinib for untreated extensive-stage SCLC, 
the primary end point [progression-free survival (PFS)] was met for maintenance sunitinib 
than placebo [median PFS: 3.7 vs 2.1 months; hazard ratio (HR), 1.62; 95% confidence 
interval (CI), 1.02 to 2.60; P = 0.02]. Overall survival (OS) in maintenance group was also 
better than in placebo (median OS: 9.0 vs 6.9 months; HR, 1.28; 95% CI, 0.79 to 2.10; P 
= 0.16). This result suggested that maintenance sunitinib was safe and improved PFS in 
extensive-stage SCLC[4]. 2. Topotecan Single-agent chemotherapy such as topotecan, 
paclitaxel, docetaxel, irinotecan, gemcitabine, ifosfamide, vinorelbine and temozolomide 
have been studied in 2nd line therapy of SCLC. But single agent topotecan is the only 
second-line therapy approved by the U.S. Food and Drug Administration for the treatment 
of relapsed SCLC. Both oral and intravenious topotecan could significantly improve PFS 
and OS compared with placebo. Compared with cyclophosphamide, doxorubicin, and 
vincristine (CAV) regimen in relapsed SCLC patients (n = 211), topotecan produced 
comparable efficacy but poorer quality of life [5]. Toxicity of topotecan could not be 
tolerated in many patients. 3. Amrubicin Anthracyclines, including doxorubicin, liposomal 
doxorubicin, epirubicin, mitoxantrone, have been studied in 2nd line therapy of SCLC. 
Tumor response rate ranged from 0% to 20%. Amrubicin, a third-generation anthracycline 
and potent topoisomerase II inhibitor, has shown promising activity in SCLC. In ACT-1 trial, 
amrubicin failed to improve OS compared with topotecan but an improvement in OS was 
noted in patients with refractory disease treated with amrubicin[6]. 4. Immunotherapy 
Monoclonal antibodies again immune checkpoint inhibitors including ipilimumab, 
nivolumab and pembrolizumab have been approved as therapy of some solid tumors 
including melanoma, non-small cell lung cancer (NSCLC), and also studied in SCLC. 
In the phase Ib KEYNOTE-028 study, SCLC patients who were failure of or inability to 
receive standard therapy with PD-L1 positivity received pembrolizumab 10 mg/kg, the 
overall survival rate (ORR) was 35% and safety profiles were consistent with previous 
studies[7]. Another two trials to explore the efficacy of combination of pembrozulimab 
and chemotherap/ radiotherapy for extensive-stage SCLC are ongoing (NCT02359019 
and NCT02402920). Ipilimumab is a fully human IgG1 cytotoxic T-lymphocyte associated 
antigen 4 (CTLA-4) monoclonal antibody[8]. In the phase I/II CheckMate-032 study, SCLC 
patients with progressive disease after > 1 prior line of therapy received nivolumab + 
ipilimumab or nivolumab monotherapy. The combination or monotherapy showed activity 
and durable response in SCLC patients who progressed after > 1 prior line of therapy and 
safety profile was consistent with other tumor types. Unlike NSCLC, second-line therapy 
has a little progress in SCLC. Second-line treatment for SCLC should be based on the 
time of recurrence, the reaction and toxicity of first-line chemotherapy, and performance 
status (PS). A patient’s response to first-line treatment and the duration of the 
subsequent progression-free period influences the likelihood that a patient will respond 
to second-line chemotherapy[9]. Tumors that are refractory to first-line chemotherapy or 
relapse within 60 to 90 days are considered chemoresistant. Tumors whose response 
to first-line therapy exceeds 60 to 90 days are considered to be chemosensitive and 
the recommended second-line therapy is the single agent chemotherapy. Topotecan is 
the optimal choice. Patients in whom response to first-line therapy is maintained for 
longer than 180 days are likely to benefit from retreatment with prior etoposide/platinum 
chemotherapy[10]. Immunotherapy in SCLC is widely studied now. 
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strongly advised that such patients be seen at tertiary centers for optimal management, 
especially surgery.
MEDIASTINAL TUMORS INCLUDING THYMIC TUMORS, LYMPHOMA, GERM-CELL TUMORS: BIOLO-
GY, DIAGNOSIS AND TREATMENT  
MONDAY, SEPTEMBER 07, 2015 - 07:00-08:00
MTE11.02 Mediastinal Tumors Including Thymic Tumors, Lymphoma, Germ-
Cell Tumors: Biology, Diagnosis and Treatment Gregory J. Riely Medicine, Memorial 
Sloan Kettering, New York/NY/United States of America
While rare tumors overall, thymic tumors are one of the most common malignancies 
of the anterior mediastinum. The histology of these tumors is typically described 
using the WHO classification, which includes type A, AB, B, and type C tumors. This 
histologic classification system can help to determine prognosis when combined with 
stage. While there are multiple categories within this classification system, perhaps 
the most clinically relevant differentiation is between thymoma and thymic carcinoma 
(type C). Although there is great heterogeneity in prognosis for patients with thymic 
tumors in general, typically, patients with thymic carcinoma have a somewhat more 
rapid course of disease them those with thymoma. There are two dominant staging 
systems in use for description of patients with thymic tumors: the Masaoka staging 
system and the TNM staging system. The Masaoka staging system is probably the most 
widely used and centers around the primary tumor’s degree of invasion into the capsule 
(completely encapsulated tumors are stage I, while tumors with trans-capsular invasion 
or invasion into surrounding fatty tissue are stage II) or surrounding tissues (tumors 
with macroscopic invasion into neighboring organs are stage III). Notably, the Masaoka 
staging system differentiates stage IV thymic tumors into stage IV A, which is metastatic 
disease involving the pleura only and stage IV B, where patients have hematologic or 
lymphatic dissemination (including regional and local lymph nodes). One of the hallmarks 
of thymic tumors, is paraneoplastic syndromes. The most common paraneoplastic 
syndrome in patients with thymoma is myasthenia gravis. In patients newly diagnosed 
with myasthenia gravis, approximately 10-15% will have a thymoma. Conversely, 
approximately half of patients with thymoma develop myasthenia gravis. It is important 
to be aware of the diagnosis of myasthenia gravis prior to surgical resection. Multiple 
other paraneoplastic syndromes have been described in patients with thymoma including 
pure red cell aplasia, hypogammaglobulinemia, Good’s syndrome, and neuromyotonia. 
Notably, paraneoplastic syndrome such as these are distinctly uncommon in patients 
with thymic carcinoma. The treatment of patients with early stage thymoma is primarily 
surgical. For patients with a clinical diagnosis of an anterior mediastinal mass that is 
suggestive of thymoma or thymic carcinoma, if the tumor is small, it may be reasonable 
to resect the tumor rather than perform a biopsy prior to surgery. In patients with more 
locally advanced disease or where the diagnosis is uncertain, it is appropriate to perform 
a needle biopsy prior to surgery or other therapy. In general, patients with stage I and 
II disease are best managed with surgery alone. Given the critical nature of complete 
surgical resection for long-term outcomes, those patients with more locally advanced 
disease may benefit from induction chemotherapy prior to surgical resection. The most 
common chemotherapy regimens used for preoperative chemotherapy include platinum/
taxane combinations, cisplatin and etoposide, and the 3 drug combination of cisplatin, 
doxorubicin, and cyclophosphamide. None of these regimens has been prospectively 
compared. For patients in whom surgical resection is not feasible, radiation therapy may 
be appropriate. For patients with recurrent or metastatic disease that is not amenable 
to surgical resection, systemic therapy is appropriate. Chemotherapy regimens similar 
to what is described for preoperative therapy are widely used. For those patients with 
thymoma, anthracycline-based combinations seem to have the highest response rates 
as initial therapy. For those patients with thymic carcinoma, there is supportive data 
for the use of platinum/taxane combinations as preferred initial therapy. At the time 
of progressive disease after first line therapy, multiple drugs have been explored, 
however as in first-line therapy, there are no randomized prospective trials to determine 
the optimal regimen. For those patients with octreotide-avid disease, administration of 
octreotide in combination with prednisone has been found to be useful. Data supporting 
the efficacy of a number of drugs has been reported. More recent data support the use 
of pemetrexed, everolimus, sunitinib (for thymic carcinoma), as well as cixutumumab, an 
anti-IGF 1R antibody. Given the rarity of this tumor and the multidisciplinary nature of care 
required for patients with thymic carcinomas or thymoma, referral to a multidisciplinary 
team with experience in management of patients with thymic tumors is appropriate.
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The mediastinum is customarily divided into an anterior, middle (visceral) and posterior 
(bilateral paravertebral) compartment. Studies encompassing large series of patients 
indicate that more than half of the mediastinal masses arise in the anterior compartment 
(54-59%), up to 20% in the middle compartment, and 25% in the paravertebral (posterior) 
compartment. The general approach to a patient with a mediastinal mass include a 
thorough history and clinical examination. The type of a mediastinal tumor largely depends 
on the age of the patient and the presence of associated symptoms and/or paraneoplastic 
conditions. The most common symptoms are nonspecific and include cough, dyspnea, 
chest pain, arrhythmias, dysphagia, pleural effusion or, in more aggressive forms, 
superior vena cava (SVC) syndrome. Some tumor markers may be helpful in some forms 
imaging descriptors of cancers are inadequate to capture this heterogeneity and must 
be replaced by quantitative metrics that enable statistical comparisons between features 
describing intratumoral heterogeneity and clinical outcomes and molecular properties. 
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The advancements in CT imaging have allowed for faster and higher resolution 
imaging of the thorax. Unfortunately, this had led to an increase in purposely and 
incidentally detected nodules of which the etiology is uncertain. The management 
of these nodules is based on multiple factors, but primarily based on risk factors 
of the patient. Broad categories of risk include nodules detected in patients 
incidentally, in patients being evaluated for thoracic disease, in people undergoing 
lung cancer screening and in patients being evaluated and treated for a malignancy. 
Current recommendations for management of these patients will be reviewed. 
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Mediastinal germ cell tumors represent 2% of all germ cell tumors. The anterior 
mediastinum is the site of origin. There is never a clinical situation where a patient 
has a primary tumor in the testis with spread to the anterior mediastinum, as typical 
nodal spread goes to the ipsilateral retroperitoneal lymph nodes and subsequently to 
the posterior mediastinal. The most common mediastinal germ cell tumor is mature 
teratoma. These patients will have a normal hCG and AFP and routinely be cured with 
surgical resection alone. Mediastinal seminomas are all good-risk disease unless there is 
spread to liver, bone, or brain. Patients with mediastinal seminomas might have a slight 
elevation of hCG, but would never have an elevation of serum alphafetoprotein. In the 
past, they were treated with radiation therapy, but now they are treated with standard 
chemotherapy, usually BEP x 3 unless the patient is over age 50. Despite the size of the 
tumor, the expected cure rate is 90-100%. Primary mediastinal non-seminomatous germ 
cell tumor reflects a much worse prognosis and regardless of the size of the tumor or 
amplitude of tumor marker, they are all categorized as advanced disease. These tumors 
represent a real challenge for the multi-disciplinary team consisting of medical oncology 
and thoracic surgery. The cure rate is only 40-50% and if cure is not possible with first-
line therapy, subsequent cures with any form of non-surgical salvage chemotherapy, 
including high dose chemotherapy, is very low. We prefer etoposide (VP-16) + ifosfamide 
+ cisplatin (VIP) for 4 cycles in preference to BEP x 4. A prior phase III study in advanced 
germ cell tumors of any category revealed similarity in cure rates with these 2 regimens. 
Because these patients will usually require extensive thoracic resections, we prefer 
to avoid the 12 weeks of bleomycin. The ability to cure these complicated patients is 
dependent upon the diagnostic skill of pathologists, the clinical acumen of medical 
oncologists, but especially the skill and experience of thoracic surgical oncologists. It is 
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Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related death 
worldwide, with a median survival that rarely exceeds 10–12 months in unselected 
patients with metastatic disease treated with conventional chemotherapy. In the last 
decade, identification of key genetic events driving tumor growth and metastatic 
spread led to the concept of oncogene-addiction. According to this model, the inhibition 
of certain molecular drivers by targeted agents could be effective in reducing tumor 
burden and improving patient survival. Several molecular alterations have been 
described in NSCLC, particularly in adenocarcinomas, especially, but not exclusively, 
in the never/ former smoker population. The most notable examples are the epidermal 
growth factor receptor (EGFR) activating mutations, mainly represented by deletion in 
exon 19 or the L858R substitution in exon 21, and the echinoderm microtubule protein 
like-4/anaplastic lymphoma kinase (EML4-ALK) translocation. Although only 12–15% of 
NSCLC tumors areEGFR mutated or ALK-rearrangement-positive, this translates into a 
considerable number of patients affected worldwide. In metastatic NSCLC, presence 
of EGFR activating mutations confers a more favorable prognosis and strongly predicts 
for sensitivity to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or 
afatinib. Indeed, nine large randomized trials comparing an EGFR-TKI versus standard 
platinum based chemotherapy have clearly demonstrated the superiority of the target 
agent in prolonging progression-free survival (PFS), improving response rate (RR) along 
with a more favorable safety profile. Similarly, in presence of EML4-ALK translocation, the 
ALK inhibitor crizotinib produces higher RR and longer PFS when compared to standard 
chemotherapy, both in first and second line setting. Unfortunately, no patient with 
metastatic oncogene-addicted NSCLC can achieve a definitive cure and after a median 
time of 8–12 months, all patients eventually develop acquired resistance to targeted 
therapy. So far, several studies of tumor samples obtained at the time of treatment 
failure have identified different potential mechanisms responsible for acquired resistance 
to targeted agents. In the majority of cases resistance is the consequence of a biological 
event occurring in the target (target-dependent acquired resistance), whereas in other 
cases acquired resistance is the consequence of the activation of other pathways 
(target-independent acquired resistance). As for EGFR mutant NSCLCs the emergence 
of the secondary T790M mutation in the tyrosine kinase domain of EGFR account for 
up to 60% of erlotinib or gefitinib failure, investigations have focused on the potential 
efficacy of a new class of drugs that could irreversibly inhibit T790M clones, with 
reduced activity against wild-type EGFR. This new class of agents includes several 
new drugs under clinical development, with rociletinib and AZD9291 to-date being the 
most promising. A large phase I-II study evaluated the efficacy of rociletinib in patients 
with EGFR mutations who progressed during previous treatment with an EGFR inhibitor. 
In patients with centrally confirmed T790M-positive tumors, RR was approximately 60% 
with a median PFS that exceeded 1 year. However, also patients whose tumors were 
T790M-negative gained some benefits from rociletinib with a RR of 29% and median 
PFS of approximately 6 months. In a phase I trial conducted in patients who failed first- 
or second-generation EGFR-TKI, AZD9291 produced a RR of 50%. Importantly, RR was 
61% in patients harboring a T790M mutation, whereas in T790M-negative cases RR 
was 21% with a median PFS of only 3 months. Results of ongoing trials with rociletinib 
and AZD9291 will better clarify the role of third generation EGFR-TKIs in the treatment 
algorithm of EGFR mutant NSCLC. Similarly, for the vast majority of ALK positive 
NSCLCs, resistance is mediated by an ALK dominant mechanism, such as mutations 
in the kinase domain of ALK gene or ALK fusion gene amplification. So far, a number of 
mutations have been identified and they seem to confer different sensitivities to second-
generation ALK inhibitors. In addition, there are an increasing number of patients for 
which disease progression occurs only in the central nervous system (CNS), supporting 
the hypothesis of an inadequate CNS drug penetration. Several novel and more potent 
second-generation ALK inhibitors are currently under investigations in clinical trials. 
Among them, ceritinib and alectinib gained the FDA breakthrough therapy designation 
for ALK-positive NSCLC due to the encouraging results that emerged from a phase 
I-II trials. Beyond EGFR mutations and ALK translocation, novel biomarkers have been 
linked with adenocarcinoma histology, including ROS1fusion gene, MET amplification or 
mutations, BRAF and HER2 mutations, for which many targeted drugs are currently under 
investigation. ROS1 rearrangements and MET amplification represent two additional 
molecular aberrations candidate as predictors for crizotinib sensitivity. Indeed, results 
from expansion cohorts of the PROFILE 1001 phase I suggested the potential efficacy of 
crizotinib in lung cancer patients with ROS1 translocation or MET amplification. Another 
promising target is BRAF mutation, a rare event occurring in 1% to 3% of adenocarcinoma 
patients, including those with a history of smoking. Recently, combination of the BRAF 
inhibitor dabrafenib with the MEK inhibitor trametinib emerged as a suitable strategy in 
patients with BRAF mutant NSCLC. Dual BRAF/MEK axis inhibition translated into a RR of 
63% with an acceptable toxicity profile. In conclusion, targeted agents are rapidly changing 
the natural history of NSCLC, with several new agents entering onto clinical practice. In 
the next few years, the major challenge will be to define the optimal sequence of targeted 
agents as well as their combination with novel strategies including immunotherapy. 
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(germ cell tumors). Chest radiography and CT scan can image the mass and can allocate 
it to one of the mediastinal compartments. The CT characteristics may somehow guide 
the clinician to a differential diagnosis and to the nature (benign or malignant) of the 
mass. In selected cases MRI may be useful to assess the relationship with the vascular 
structures and the heart. PET or integrated PET-CT have a role to define the activity 
of the tumor and the correct stage. Biopsy of the mass, either through a fine-needle 
aspiration (FNA) or core biopsy is indicated in case the imaging is not diagnostic. Very 
often, a surgical biopsy through an anterior mediastinotomy (Chamberlain procedure), 
mediastinoscopy or VATS is needed to provide sufficient tissue to the pathologist for a 
correct diagnosis. A brief description of the histologic types and the diagnostic workup 
for the most common mediastinal tumors in the three compartments will be presented. 
In conclusion, diagnostic workup of mediastinal masses include a careful medical history 
(age, duration and type of symptoms); imaging definition with CT scan is essential to 
precisely determine the mediastinal compartment, and cyto-histological confirmation 
is required in case of undetermined lesions. Differential diagnosis is crucial to provide 
optimal treatment.
Anterior mediastinal tumors. They represent more than half of the mediastinal masses 
at any age. The most common types are thymic tumors (35%), lymphomas (25%), 
intrathoracic thyroid tumors (15%), germ cell tumors (20%, malignant 10% - teratomas 
10%), other tumors (5%). According to age groups, in adults (> 40 years) thymic tumors 
are the most common type in men and women. Thyroid tumors are the second most 
common type in elderly patients. In adolescent/young adults (<40 years) lymphomas 
are the most common type (either Hodgkin or non-Hodgkin), while thymic tumors are 
the second most common in young adults, and germ cell (teratoma) in adolescents. 
Finally, in children (<10 years) a similar prevalence of thymic tumors, teratomas, and 
lymphomas is observed. The diagnosis of an anterior mediastinal mass is based on the 
duration and type of symptoms. Thymomas, thyroid goitres and teratomas are usually 
asymptomatic or indolent, Hodgkin lymphoma and seminomas are associated with an 
intermediate duration of symptoms, while non-seminomatous germ cell tumors (NSGCT) 
and lymphoblastic lymphomas have a rapid onset of severe symptoms (SVC syndrome is 
frequent in these patients). High alpha-feto protein (AFP) or beta-HCG levels are diagnostic 
of NSGCT, and high lactate dehydrogenase (LDH) suggest a diagnosis of lymphoma; the 
association of Myasthenia Gravis secures the diagnosis of thymoma. Cyto-histological 
diagnosis is indicated in undetermined forms, usually to differentiate lymphoma from 
thymic tumors for optimal subsequent treatment. The average sensitivity of needle 
biopsy (either FNA or core biopsy) in the diagnosis of lymphoma is around 50%, and in 
most cases a surgical biopsy is needed in suspected cases. Mediastinotomy is preferred 
to mediastinoscopy (which reaches the middle-visceral mediastinal compartment). 
Video-assisted thoracic surgery (VATS) is also a reliable technique, particularly in case of 
associated pleural effusion.
Middle mediastinal tumors. The vast majority of middle (visceral) mediastinal masses 
are benign. Half of these are cysts (bronchogenic, esophageal duplication cysts). 
The remaining masses are most often from lymphnodes and can be either malignant 
(lymphadenopathy from lung cancer, lymphomas), or inflammatory/granulomatous 
(tuberculosis, sarcoidosis). A small percentage of these lesion (<10%) are miscellaneous 
(Castleman disease, paraganglioma, intrathoracic thyroid mass). Diagnosis is usually 
easily accomplished with CT scan, which reveals the liquid component of the cyst. MRI 
is required in undetermined solid lesions. Cyto-histologic diagnosis (FNA/core biopsy 
or mediastinoscopy/VATS) is sometimes required for undetermined adenopathy for the 
differential diagnosis between lymphoma and solid tumors. Almost all the benign lesions 
are asymptomatic or associated with mild nonspecific symptoms (cough, arrhythmias). 
In the malignant lesions most symptoms result from the underlying disease (lymphoma, 
lung cancer).
Paravertebral mediastinal tumors. Almost all the tumors in the paravertebral 
compartment arise from the nervous structures (nerves and ganglia). The prevalence 
of the different types is different in adults and children/adolescents. In adults almost 
90% of the masses are benign, including schwannoma (50%), ganglioneuroma (20%) 
and neurofibroma (15-20%). The little percentage of malignant neurofibrosarcomas are 
part of a familial neurofibromatosis. In these patients the clinical presentation includes 
severe symptoms (pleural effusion, chest pain, dyspnea) and a large tumor (> 10 cm.). 
Benign paravertebral masses without symptoms can be observed over time if there is 
no spinal extension. Diagnosis is quite easy using CT scan. Intraspinal extension can be 
documented with MRI. Resection is indicated in symptomatic forms or in case of intraspinal 
extension. Patients with familial neurofibromatosis and paravertebral mediastinal mass 
should receive surgery due to the demonstrated high rate of malignant shift. In children 
less than 4 years of age paravertebral masses are in high percentages malignant 
neuroblastomas or ganglioneuroblastomas (virtually 100%l in children < 1 year). The 
percentage of malignant forms decreases with increasing age. In neuroblastomas, serum 
levels of vanillylmandelic acid (VMA) and metanephrine are almost always elevated and 
therefore diagnostic.
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Lung cancer represents the major causes of cancer death in the industrialized countries. 
Non-small cell lung cancer (NSCLC) accounts for nearly 80% of all lung cancer cases. 
While in the early stages I and II surgery has been accepted as the major curative 
therapy, most of patients with NSCLC and major airway and vascular obstruction have 
an IIIB disease and rarely can be cured by local treatment modalities like surgery or 
radiotherapy alone. T4 tumors may include the mediastinal organs such as the vena 
cava, pulmonary artery, thoracic aorta, left atrium, carina and trachea. However the 
extend of the disease is usually made by radiological methods as computed tomography 
(CT), magnetic resonance imaging (MRT) or fusioned positron emission tomography 
and CT-scan (PET-CT) and the correlation between radiologic and pathologic findings 
is very low. Combined resection of the lung and major vessels or central airways for 
lung cancer remains challenging in terms of technical aspects and prognosis, because 
the local advanced disease comprises different subgroups with distinguishable clinical 
problems and necessary treatment decisions. In the surgical treatment of lung cancer 
invading the superior vena cava (SVC), the pattern of invasion was considered to be 
a significant prognostic factor. Patients who underwent partial SVC resection had a 
significantly higher probability of survival and there was a trend towards later recurrence 
in patients who had induction treatment. Also survival of patients with N2 disease was 
significantly worse than those with localized N0/N1 nodal status (1). For combined 
resection of thoracic aorta and primary lung cancer only studies with small number 
of cases are reported. The most patients received an adventitia resection or a patch 
graft repair of the defect in the aortic wall. For a smaller group total replacement of 
the descending aorta with an artificial vessel was reported, recent report indicated the 
placement of endoluminal prosthesis 1-3 weeks before surgery. Operative deaths occur 
in 0-24%, the 5 year survival ranged between 17% and 50%. Survival was only depended 
on mediastinal nodal involvement (2). Direct invasion of the left atrium (LA) has generally 
a significantly worse prognosis than patients with great vessels invasion. Patients who 
undergo LA resection have higher mortality and morbidity rates compared with those 
who had pneumonectomy alone. Median survival rate is 10 months, the 5-yearsurvival 
14-16%. Palliative incomplete resection of T4 disease has not shown any survival benefit 
(3). Patients with localized invasion of the carina or/and distal trachea may be able to be 
completely resected despite their T4 classification. Extraluminal extension of the tumor 
found in CT-scan was associated with unresectability. In general, patients benefit from 
surgery, when a radical resection and systematic lymph node dissection can be achieved 
with low morbidity and mortality (4). For inoperable patients, palliative treatment with 
laser desobliteration, stent implantation or photodynamic therapy can be added to the 
standard chemoradiotherapy. Surgery in the treatment of lung cancer invading the great 
vessels, LA and major airways may improve survival only in selected patients. Induction 
treatment and new drugs may increase the number of potential candidates for surgery 
and improve survival. Preoperative every possible effort should be made to achieve 
an adequate evaluation of N-status. Complete resection is important and patient’s 
functional status must be compatible with the extent of resection and reconstruction. 
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Thymic malignancies represent a heterogeneous group of rare thoracic cancers [1, 2]. 
The histopathological classification distinguishes thymomas from thymic carcinomas. 
Thymomas are further subdivided into different types (so-called A, AB, B1, B2, and B3) 
based upon the atypia of tumor cells, the relative proportion of the associated non-tumoral 
lymphocytic component, and resemblance to the normal thymic architecture [3]. Thymic 
carcinomas are similar to their extra-thymic counterpart, the most frequent subtype being 
squamous cell carcinoma. The diagnosis of any thymic epithelial tumour relies on making 
the differential diagnosis with other anterior mediastinal tumours and non-malignant 
thymic lesions. Thymic epithelial tumours are routinely staged according to the Masaoka-
Koga staging system, which is correlated with overall survival. Masaoka-Koga staging is 
a surgical pathology system that is assessable only after surgical resection of the tumour 
[4]. Recently, the International Association for the Study of Lung Cancer (IASLC) Staging 
Prognostic Factors Committee, together with the International Thymic Malignancy Interest 
Group (ITMIG), proposed a Tumour-Node-Metastasis (TNM)-based staging system for 
thymic malignancies, based on overall survival analyses of a retrospective international 
database of more than 10,000 cases [5]. The TNM-based approach has the advantage 
of being more appropriate both for thymoma and thymic carcinomas, which present with 
a higher propensity towards nodal and distant metastatic invasion. The management of 
thymic epithelial tumours is a paradigm of multidisciplinary collaboration. Systematic 
immunological check-up is recommended when a diagnosis of thymic epithelial tumour 
is suspected, including complete blood cells count with reticulocytes and serum protein 
electrophoresis, as well as anti-acetylcholine receptor and antinuclear antibodies tests. 
This is to make the diagnosis of the most frequent immune disorders associated with 
thymoma, the most frequent being myasthenia gravis, that may impact any therapeutic 
intervention, including surgery, radiotherapy, and chemotherapy. The treatment strategy 
is based on the resectability of the tumour [6]. The assessment of resectability is mostly 
based on the surgeon’s expertise; it is recommended to discuss indications for surgery 
in a multidisciplinary tumour board setting. The new TNM staging may even better help 
to formalize resectability: T1-3 level of invasion refers to structures amenable to surgical 
resection, when T4 level of invasion includes unresectable structures. If complete 
resection is deemed to be achievable upfront, as it is the case in Masaoka-Koga stage I/
II and some stage III tumours, surgery represents the first step of the treatment, possibly 
followed by postoperative radiotherapy, and for carcinomas, chemotherapy. Standard 
approach is median sternotomy; minimally-invasive surgery is an option for presumed 
stage I and possibly stage II tumours in the hands of appropriately-trained thoracic 
surgeons. Current practices for postoperative radiotherapy are highly variable and there 
is paucity of prospective, multicentre evidence. The global trend over the past years has 
been towards a less frequent use of postoperative radiotherapy in thymoma, and to keep 
it in reserve for high-risk cases. This is based on recent reports from large databases, as 
well as pooled analyses of retrospective studies, indicating: 
1) the absence of survival benefit after radiotherapy in stage I thymoma, or after R0/1 
resection of stage II-III thymoma; 
2) a similar rate of recurrence in patients who received postoperative radiotherapy or not 
after complete resection of thymoma; and 
3) a recurrence-free and overall survival benefit with postoperative radiotherapy after 
resection of thymic carcinoma.
If complete resection is deemed not to be achievable upfront on the basis of imaging 
studies, as it is frequently the case in Masaoka-Koga stage III/IVA tumours, a biopsy 
should be taken, followed by primary/induction chemotherapy as part of a curative-
intent sequential strategy that integrates subsequent surgery or radiotherapy. Patients 
not eligible for local treatment receive palliative chemotherapy only. Cisplatin-based 
combination regimens should be administered; combinations of cisplatin, adriamycin 
and cyclophosphamide, and cisplatin and etoposide, are the recommended options [7]. 
Primary chemoradiotherapy with platin and etoposide is an option for thymic carcinomas. 
Innovative options may include KIT sequencing in the setting of potential access to 
specific inhibitors, particularly clinical trials; sunitinib may represent an off-label option 
as second-line treatment for thymic carcinomas, independently from KIT status, through 
antiangiogenic effects [8]. mTOR is emerging as a potential target in thymic epithelial 
tumours, following tumour responses observed in phase I-II trials. Ongoing trials are 
assessing immune checkpoint inhibitors for refractory thymic carcinoma. No prospective 
data are available to build recommendations about post-treatment oncological follow-up 
of patients. Follow-up may be continued for 10-15 years given the possible occurrence 
of late recurrences. Clinicians should be aware of the possible late onset of new 
autoimmune disorders. 
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Approximately 30-40% of patients with advanced lung cancer develop bone metastases, 
but as the newer therapies are extending survival, the chance of developing bone 
metastases increases. Bone metastases cause skeletal-related events (SREs) such as 
pathologic fractures, spinal cord compression, radiation therapy or surgery to bone, 
or hypercalcemia – all of which can have debilitating consequences (including pain) 
affecting patients’ health-related quality of life (HR-QOL) and performance status (PS)1. 
Bone metastases are the most common cause of cancer-associated pain in patients with 
advanced malignancies2. Poor PS prevents the patients from receiving further lines of 
treatments available today. SREs are associated with increased economic costs. In one 
clinical trial, the median time to first SRE was only 5 months3. Early detection of bone 
metastases can prevent SREs and avoid inappropriate implementation of major surgery 
or chemoradiation therapy. With the new generation bisphosphonate zoledronic acid or 
denosumab (anti-RANKL activity), one can reduce the number of patients who experience 
SREs, decrease the annual incidence of SREs, and delay the median time-to-first SRE3. 
These agents are effective even after the onset of SREs. They are well tolerated, with 
manageable side effects. The biochemical markers of bone metabolism especially 
N-telopeptide of type I collagen (NTX) and bone specific alkaline phosphatase (BALP) 
can be both prognostic and predictive markers for the patients with bone metastases 
from NSCLC4-6. Anticancer activity of zoledronic acid and denosumab further supports 
their use as soon as bone metastases are diagnosed in patients with non-small cell 
lung cancer (NSCLC). Further trials will inform us about the efficacy of these agents for 
prevention of bone metastases and even about possible effects on visceral metastases, 
with a significant impact on overall survival7, 8. These trials will be discussed, as well as 
the explanation for the longer survival on the bone-targeted agents. The new targeted 
agents which are being investigated will be mentioned too9, 10. 
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With the improvement of treatment efficacy, quality of life and sexual functioning 
after cancer treatment have become very important. Sexual well-being may be 
altered by both the diagnosis and the treatment of cancer. This in turn can have 
a deleterious impact on quality of life. Sexual dysfunction in cancer patients may 
result from biological, psychological and social factors (1). Biological factors such as 
anatomic alterations (rectum or penile amputation), physiological changes (hormonal 
status) and secondary effect of medical intervention may preclude normal sexual 
functioning even when sex desire is intact. Side effects of chemotherapy such as 
nausea, vomiting, fatigue, hair loss can result in adverse effects on sexuality together 
with disfiguring surgery (mastectomy, colostomy). Negative emotional states such 
as anxiety, depression, anger may also disrupt sexual activity (1). Disturbances 
of body image can contribute to the development of sexual dysfunction as well. 
Radiotherapy and radical prostatectomy are the most effective treatments for prostate 
cancer. Erectile dysfunction is reported in 6-80% after external-beam radiotherapy 
and 2-61% after brachytherapy. Erectile dysfunction after surgery is reported in 40-
70% after nerve-sparing techniques and 100% in non-nerve-sparing techniques, and it 
occurs immediately after surgery. Ejaculation problems and libido decrease occur in 
up to 80%. Vascular, neurogenic and psychogenic factors are all important etiologic 
factors (1-3). Similar data are reported after treatment of bladder and colorectal cancer 
in males. Testicular cancer affects young men in their fertile and sexually active life. 
Retrograde ejaculation, erectile dysfunction, loss of libido, decreased orgasm and body 
image impairment are often reported after treatment (1,4). Surgery and radiotherapy 
for gynaecological cancer can alter vaginal sensation and may cause stenosis 
leading to painful penetration (1,3,5). These treatments lead to ovarian suppression, 
with vaginal discharge, dryness, dyspareunia and a loss of sexual interest. Only 50% 
of the females is still sexually active after cancer treatment (1). There is often fear of 
pain and of urine or faeces incontinence during sexual activity. Similar complaints are 
reported after treatment of colo-rectal and anal cancer in women. There is no data 
on the effects of treatment for lung cancer on sexual functioning. Though it is to be 
expected that these patients, both males and females, can report sexual dysfunction 
as a result of chemotherapy, social and psychological factors (distress, depression). 
For several reasons sexual counseling has not become a routine part of oncology care in 
most hospitals (6). There is a time constraint: in busy oncology clinics, where the outpatient 
visit is focused on addressing prognosis and treatment, physicians do not have time to 
assess quality of life. Another barrier is the discomfort physicians, and patients, have to 
discuss sexuality. The great majority of oncology professionals are scared to address 
sexuality and the great majority of sexological professionals are scared by cancer (7). 
Sexual counseling should be routinely provided in an oncology clinic having a health care 
professional (physician, or oncology nurse specialist) to evaluate and discuss quality of 
life matters, including sexual dysfunction, and possible treatments. In most cases patients 
do not require extensive medical or psychological treatments, but they need information 
about the impact of cancer treatment on sexuality (6). Patients, and partners, are often 
uninformed about the anatomy of sexual organs, therefore they have to be counseled 
on the effects that treatment has on the sexual organs. Several questionnaires are 
available to evaluate sexual functioning in both males and females (1). Recently a specific 
questionnaire on sexual functioning after treatment of cancer has been developed in 
the USA, but has not been validated yet in other countries (8). The 3rd International 
Consultation on Sexual Medicine appointed for the first time in 2009 a Committee on 
chronic illness (including cancer) and sexual medicine. The recommendations of that 
committee are very useful in helping to develop research programs in oncology and 
sexual medicine (9). Sexual dysfunction is often unrecognized, underestimated and 
untreated. Cancer affects quantity and quality of life. The challenge for physicians and 
other health care professionals is to address both components with compassion (7). 
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Introduction The neuroendocrine tumours of the lung are all malignant lesions, unified 
by a common characteristic of neuroendocrine differentiation, but diverse in terms of 
histological features, clinical presentation, aetiology and biology. In the new World Health 
Organisation classification of lung tumours, published in 2015, the four major types of 
neuroendocrine tumour (small cell carcinoma, large cell neuroendocrine carcinoma, 
carcinoid tumour and atypical carcinoid tumour) are now included under a single heading 
of neuroendocrine tumours. 
Small cell carcinoma (SCLC) SCLC is a high-grade malignant epithelial tumour 
comprising relatively small cells with scanty cytoplasm, fusiform to round nuclei, finely 
disperse granular chromatin, inconspicuous nucleoli and prominent nuclear moulding. 
Mitoses, apoptosis and extensive necrosis are typical. Tumours characteristically 
have neuroendocrine granules visible on electron microscopy and most cases express 
neuroendocrine markers by immunohistochemistry. An organoid architecture with 
rosettes and trabeculae is uncommon, but SCLC samples are often small, precluding 
identification. SCLC may be seen combined with other non-small cell carcinoma (NSCLC) 
subtypes (Combined small cell carcinoma). Here, SCLC has priority, regardless of the 
relative proportion of the tumour that is SCLC. SCLC accounts for between 10-15% 
of cases diagnosed and is strongly associated with tobacco smoking. The typical 
presentation of SCLC is stage IV metastatic disease with rapid progression. Radiologically 
a large central mass with contiguous, bulky hilar nodes is typical and mediastinal invasion 
is usually evident. The vast majority of SCLC present. Production of hormonal peptides 
accounts for several paraneoplastic complications. Ectopic hormones (or hormone-like 
peptides) such as ADH or ACTH, and peptides native to the pulmonary neuroendocrine 
cells (calcitonin and gastrin-releasing peptide) may be produced. 
Large cell neuroendocrine carcinoma (LCNEC) Another high grade neuroendocrine 
carcinoma, characterized by morphological neuroendocrine features (rosettes, 
trabeculae, peripheral nuclear palisading). Cells are relatively large, cytoplasm 
abundant/eosinophilic, and nuclei show coarse chromatin and nucleoli. Nodular tumour, 
a fine vascular stroma, cribriform architecture and central comedo necrosis are 
common. Mitoses are abundant (always >10 per 2mm2: rarely <30 and averages 75). 
Combined tumours, with SCLC or, more often NSCLC, when adenocarcinoma is the most 
frequent accompaniment, are not unusual. LCNEC should demonstrate neuroendocrine 
differentiation by immunohistochemistry [NCAM/CD56 (~100%), Chromogranin (80-
85%), synaptophysin (50-60%). At least 50% express TTF1. Usually at least two stains 
are positive. There is a similar, strong association between LCNEC and tobacco smoking. 
These are relatively rare tumours, accounting for about 4% of resected cases but true 
prevalence across all stages, is not clear. Presentation and radiological appearances 
are no different from other NSCLC cases of similar stage; the vast majority of LCNEC 
are diagnosed in surgical resections. They are more often peripheral than centrally 
located tumours. The bulky nodal/mediastinal disease common in SCLC, is uncommon in 
LCNEC but there may be selection and diagnostic bias driving this observation. Hormonal 
production and paraneoplastic syndromes are rare in LCNEC, another difference with 
SCLC. 
Carcinoid tumour Carcinoid tumours are malignant tumours, divided into typical carcinoid 
(TC) where there is no evidence of necrosis and mitoses number less than 2 per 2mm2 of 
tumour. Atypical carcinoid tumours (AC) may show punctate necrosis and/or exhibit 2 or 
more, but <10 mitoses per 2mm2. Otherwise, the lesions are very similar histologically 
- small regular cells, variable cytoplasm, bland round to oval nuclei. Architecture is 
usually insular, trabecular but rosettes or glands occur. Spindle cell carcinoids occur 
mostly in thee lung periphery; insular/trabecular lesions are characteristically central. 
Strong neuroendocrine markers expression is expected. Proliferation markers such 
as Ki67 mirror, to some extent, the mitotic rate, may aid distinction from high grade 
neuroendocrine tumours in crushed samples but are not reliable or recommended for 
distinguishing TC from AC. These are rare tumours, accounting for 4-6% of primary 
lung ‘cancers’; atypical carcinoid account for around 10% of all lung carcinoids. Typical 
carcinoids may show lymph node spread in 10% cases, distant metastases are rare. 
In AC, distant metastases are not unusual. Syndromes related to peptides (Cushing’s, 
Acromegaly) or secretion of 5-HT (carcinoid syndrome) are very rare. 
Neuroendocrine tumour development and Genetics Precursor lesions are not described 
for the high grade lesions and the strong link with smoking and the common combination 
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Outcomes for the majority of cancer prevention trials overall have been disappointing 
at best. Lung cancer remains the leading cause of cancer-related mortality worldwide, 
causing an estimated 156,000 deaths in the United States for 2013. Most lung cancers 
(>60%) are diagnosed at an advanced stage, with associated 5-year survival of less 
than 15%. Efforts in early diagnosis and cancer prevention remain crucial to reverse 
the impact of this deadly disease. For this session, I will be joined by Dr. Eva Szabo 
and Dr. Avi Spira to review perspectives on the past, present, and future of lung cancer 
chemoprevention trials. We will review a number of current concepts and important 
themes in lung cancer chemoprevention, including: 1. Genomic alterations in pre-
malignant lesions for both lung adenocarcinoma and squamous cell carcinoma. 2. 
Patient stratification for applying chemoprevention. 3. Novel agents. 4. Strategies for 
individualized or precision chemoprevention. 5. Trial designs for rapid and efficient testing 
of chemoprevention hypotheses. 6. Priorities for further study. To reduce the mortality 
rate of lung cancer, and to prevent cancer initiation, progression and development, 
new techniques and approaches to cancer prevention must be developed. We will 
present both data and opinion regarding promising leads, routes to evaluation, and a 
vision for research priorities to advance the science of lung cancer chemoprevention. 
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(1). This session will describe the evolution of the nicotine delivery market, especially 
with the explosive growth of vaporized nicotine products (referred to throughout this 
application as VNPs which includes e-cigarettes, also referred to here as ENDS – 
Electronic Nicotine Delivery Systems, pressurized aerosol nicotine products, and heat 
no-burn tobacco products), which may represent a new paradigm for tobacco control 
by ostensibly offering smokers an opportunity to obtain nicotine in ways that do not 
cause the extreme risks for such a broad spectrum of smoking-caused diseases that 
make tobacco smoke the leading cause of premature death in high-income nations (2-
4). The rapidly growing demand for VNPs seen in many countries suggests that these 
products are already having an impact on cigarette consumption today (5-6). Despite this 
unpromising history of harm reduction products, VNPs, of which e-cigarettes are the best 
know, represent a new generation of alternatives that show some promise for eventually 
displacing cigarettes and possibly offering real harm reduction (7). This presentation will 
provide an overview of e-cigarettes and other VNP products, will present data on who is 
using these products, whether the products can help smokers quit, and discuss safety 
concerns (8-9). Finally, the presentation will also provide some practical advice on how 
to talk to your patients about e-cigarettes (10). 
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addition, achaete-scute homolog 1 (ASCL1), a transcription factor required for proper 
development of pulmonary NE cells (2), is pivotal for the survival of a majority of SCLCs 
and as well as NSCLC with NE features (4). Accordingly, ASCL1 is a lineage-specific 
oncogene for SCLCs. Efforts to identify relevant pathways regulated by this gene as well 
as others that might provide molecular targets for treatments are ongoing on several 
fronts. 
Tools for Investigation: Because SCLC is routinely diagnosed mainly using small 
bronchial biopsies or needle aspiration cytology specimens prior to cytotoxic chemo- 
and radiotherapies there has been a chronic shortage of suitable material for molecular 
and biological research. Fortunately, there are many well characterized human SCLC cell 
lines available that quite accurately recapitulate both molecular and histopathological 
features of the primary tumors. More recently, a range of genetically engineered mouse 
models have been generated based on the conditional ablation of both Rb and p53 tumor 
suppressor genes with select other genetic alterations (5). In vivo models provide 
important material to investigate sequential evolution of SCLC including metastases, 
molecular profiling and preclinical studies (6). 
Summary and Conclusions: SCLC is a neuroendocrine (NE) carcinoma with dismal 
prognosis and no substantial improvements in therapies for several decades. While the 
identification of effective therapies remains a major challenge, advances in understanding 
the biology, improved molecular techniques and sophisticated animal models have 
opened up novel avenues for the development of targeted therapies. 
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Introduction: Lung cancer is highly curable if detected at an early stage. Screening 
with low dose CT (LDCT) has been shown to reduce lung cancer mortality, but largely 
detects peripheral tumours. Due to limitation of resolution, LDCT currently cannot detect 
early pre-invasive central lung cancers. Evaluation of the central bronchial tree remains 
important in populations where central squamous carcinoma remains a significant 
contributor to lung cancer incidence or in patients at high risk of developing synchronous 
or metachronous squamous cell cancers. 
Imaging Technology: The imaging modality most commonly used for evaluation of the 
central airways is white light flexible bronchoscopy (WLB). The ability of routine white light 
examination to detect small pre-invasive central lung cancer remains limited. A number of 
technological advances and development of alternative in vivo optical imaging modalities 
improve the detection and evaluation of central pre-invasive lesions. These techniques 
include high magnification WLB, autofluorescence imaging (AFB), narrow band imaging 
(NBI), optical coherence tomography (OCT), confocal microendoscopy/endocystoscopy 
and raman spectroscopy (RS). 
Management: There are multiple tools available to be used with a flexible bronchoscopic 
approach to treat pre-invasive central lung cancers once detected. These include 
endobronchial electrocautery, argon plasma coagulation, cryotherapy, photodynamic 
therapy, brachytherapy and laser therapy. Therapeutic outcomes are dependent on 
multiple factors but curative rates of >85-90% are achievable. Patients are at risk of 
recurrence or the development of metachronous lesions and require close surveillance.
Summary: The detection of early central lung cancers often requires more sophisticated 
tools than conventional white light bronchoscopy. The multimodality utilisation of different 
technologies will enable the rapid detection and diagnosis of early curable central lung 
cancers in selected high-risk populations. There are multiple tools available for curative 
treatment of early central lung cancers. 
with NSCLC elements makes it likely that origins at least, are from the same cell populations 
that give rise to other NSCLC. Both central and peripheral lung epithelial compartments 
are capable of neuroendocrine differentiation, possibly in part driven by transcription 
factor ASCL1. It is also notable that a proportion of EGFR-mutated adenocarcinomas 
recur as SCLC after initial response to EGFR tyrosine kinase inhibitors. Carcinoid tumours 
probably also derive from the same epithelia, but via different mechanisms. Carcinoid 
and SCLC or NSCLC effectively never co-exist in the same lesion and carcinoids are 
not associated with tobacco smoking. Rarely carcinoids are associated with MEN type 
1 syndrome, and sporadic cases may show MEN1 mutations. A rare disease called 
diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is associated 
with spindle-cell carcinoid tumours, often multiple, and is considered a rare carcinoid 
precursor lesion. There are evolving data which show that SCLC in particular, has 
patterns of very frequent mutations and epigenetic changes (gene hypermethylation) 
reflecting tobacco carcinogenesis. SCLC and LCNEC share many features in their 
genetic profile and inactivating mutations of both RB and TP53 are characteristic. 
SCLC shares many of the characteristic deletions or losses of tumour suppressor 
genes seen in squamous cell carcinoma, especially in 3p loci. SCLC and LCNEC show 
many alterations in genes involved in cell cycle regulation. In LCNEC, some genes such 
as TTF1, CDKN2, STK11and KEAP1 may be altered, akin to that seen in some squamous 
cell or adenocarcinomas, again, and reminiscent of the post-EGFR TKI recurrence 
scenario, raising the possibility of origin through divergent differentiation within ‘NSCLC 
precursors’. Carcinoid tumour genomics are entirely different, less well studied, and as 
expected, do not show a ‘tobacco signature’. As well as MEN1 mutations, alteration of 
genes of the methylation complex and chromatin remodelling genes are not infrequent. 
Carcinoid tumours are NOT precursor lesions for, and do not evolve into, SCLC or LCNEC. 
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Introduction: Small cell lung cancer (SCLC) is the most common and most virulent 
neuroendocrine (NE) carcinoma. For pathological and therapeutic reasons human lung 
cancers are traditionally divided into non-SCLCs (NSCLCs) and SCLCs which currently 
account for 10 – 15% of all lung cancers. While prognosis for all lung cancers is poor, it 
is dismal for SCLC with less than 5% for patients surviving for five years. As molecular 
characterization of NSCLCs is quickly taking hold in guiding personalized care of cancer 
patients, the approach to SCLC is still based on principles developed decades ago. There 
has been practically no improvement in survival for past thirty years. Following the 2013 
congressional mandate demanding concentrated research focus on such recalcitrant 
cancers as SCLC and pancreatic cancer it will hopefully be changing. 
Epidemiology and Histology: SCLC is strongly associated with smoking history and 
commonly found both in women and men at their sixties. It is mostly a centrally located 
submucosal mass in major airways although peripheral tumors have been reported. 
At the time of diagnosis, most SCLCs have already metastasized. There are no known 
premalignant lesions. Histologically the tumors are characterized by sheets of poorly 
differentiated cells with finely granular chromatin pattern and inconspicuous nuclei, and 
scanty cytoplasm among other features. Mitoses (>10 per high power field), areas of 
necrosis and ‘Azzopardi effect’ are consistent with aggressive nature and high DNA 
content of the tumor. When SCLC is associated with any of the histologic types of NSCLC, 
it is called combined SCLC (1). 
Neuroendocrine (NE) Features and the Cell of Origin: Ultrastructurally SCLC is 
characterized by the presence of scattered dense core vesicles, a hall mark of endocrine 
differentiation. Functionally the cells reveal a variety of NE properties such as uptake 
and synthesis of bioactive amines, hormones and neuropeptides, the presence of neural 
receptors such as nicotinic acetylcholine receptors, antigens and ion channels with the 
neuron-like ability to conduct electric currents. Consequently, SCLCs may be associated 
with ectopic hormone secretion or paraneoplastic syndromes. In addition, airway 
epithelium harbors a rare cell type with similar properties that is only visible using special 
techniques such as electron microscopy or immunohistochemistry and called pulmonary 
NE cells (2). In normal lung they occur as solitary cells or innervated clusters called 
neuroepithelial bodies or NEBs. It has been commonly believed that the pulmonary NE 
cell is the precursor of SCLC although there has been no direct evidence. Recent studies 
applying sophisticated tracing techniques in transgenic mice support the hypothesis 
while still leaving open the question what happens in human lung (3). 
Spectrum of Neuroendocrine (NE) Differentiation in Lung Cancers: SCLC is the 
prototype of pulmonary NE cancers but up a third of all lung cancers may reveal a 
degree of NE differentiation. They range from well differentiated carcinoids and atypical 
carcinoids to less well differentiated SCLCs and large cell NE carcinomas (LCNECs) and 
finally to 10% of NSCLCs that show focal NE differentiation (NSCLC-NEs). Notably the 
cancers are molecularly, histogenetically, morphologically distinct entities and should be 
distinguished from SCLCs. Clinically SCLCs and LCNECs are high-grade NE tumors while 
NSCLC-NEs appear to be a more controversial entity. 
Molecular Pathology: SCLC presents a complex genomic landscape with a high number 
of mutations due to the toxic impact of tobacco smoke. The field is rapidly evolving. 
However, both Rb and p53 are almost invariably inactivated in SCLCs. Rb is altered in 
many human NE cancers regardless of the tissue of origin, while p53 mutations are 
common in NSCLCs. In contrast, SCLCs lack Ras mutations which are typical of many 
NSCLCs. Moreover, SCLCs may show overexpression or amplification of MYC genes. In 
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reciprocal ratios among 24 miRNAs by comparing samples collected before (n=20) 
and at the time (n=19) of LDCT disease detection to those of 27 control samples 
belonging to the INT-IEO trial [7]. These signatures were initially validated in a subset 
of 88 samples collected from 22 patients and 54 controls enrolled in the MILD trial 
[8]. Three years later, the same group developed a miRNA signature classifier (MSC), 
containing the 24 miRNAs previously identified, and tested its performance in enlarged 
validation set composed of 85 patients and 1000 controls belonging to the MILD trial 
[9]. The results of this study showed that the combination of MSC and LDCT reduced 
LDCT false-positive rate from 19.4% to 3.7% and that the MSC risk groups were 
significantly associated with survival. In addition, MSC was high sensitive (87%) and 
specific (81%) and its predictive value was confirmed by time-dependency analysis. 
Bianchi et al. identified a 34 miRNA signature in serum samples from 59 patients enrolled 
in the COSMOS trial compared to 69 disease free individuals divided in training and testing 
sets. Globally, the test showed an AUC of 89% in the testing set, and it was also able to 
rule out cancer in 79% of benign lung nodules. In addition, the 34 miRNA signature did not 
discriminate benign or malignant breast nodules, emphasizing the specificity of the test 
for lung cancer. Finally, the test did not classify pre-disease plasma samples, thus limiting 
the capability of the test to predict the development of the disease. Very recently, the same 
group refined their signature to 13 miRNAs which was validated in an independent set 
of 1008 subjects enrolled in the COSMOS trial [10]. Interestingly, this signature displays 
overlap of five miRNAs with the MSC signature (38.5%), an encouraging finding given the 
well known difficulty in validating expression signatures in different studies and given 
the differences in samples collection between these two studies (i.e. plasma vs serum). 
More recently, taking advantage of two screening programs with a total follow up of 
23,967 person-years and a median time follow-up of 5.9 years, we analyzed the 
prognostic value of MSC in 84 in lung cancer patients identified in LDCT screening 
programs. In addition, to test the ability of the plasma MSC to monitor the disease 
status and recurrence during follow up, the MSC test was employed to analyze 86 
longitudinally-collected plasma samples obtained from patients before and after surgical 
resection of primary lung tumors with a follow up time up to 4.1 years. We demonstrated 
that the three MSC risk groups were associated with significant differences in overall 
survival for the 84 subjects examined, also when adjusting for tumor stage. Moreover, 
the MSC risk level significantly decreased in subjects who remained disease free 
whereas in all relapsing patients increase of the MSC risk level was observed at 
the time of detection of a second primary tumor or of metastatic progression. 
The results presented highlight the clinical usefulness of circulating miRNAs as 
diagnostic, prognostic and monitoring tool in lung cancer. 
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Improvements in clinical management of lung cancer have been modest over the last 
20 years, with an overall 5-year survival rate just above 10% in Europe and 16% in the 
United States. Treatment failure is mainly due to the presence of metastatic disease at 
diagnosis, occurring in 70% of all patients whereas in patients resected in stage IA the 
5-year survival rate is higher than 70% [1]. Detection of lung cancer at an early stage 
offers the real potential to reduce mortality with new chances of cure. The outcomes of 
the National Lung Cancer Screening Trial (NLST) have highlighted favorable prospects 
for lung cancer low-dose CT screening (LDCT) but the cost benefit profile of screening 
is still matter of debate in the scientific community [2]. In particular, the high false 
positive rates of LDCT lead to multiple screening rounds, repeated radiation exposure, 
the use of invasive diagnostic follow–up procedures with associated morbidity as well 
as increased time and costs. In addition, LDCT screening showed a limited impact on 
the more aggressive lung cancers, achieving an overall mortality reduction of only 20%. 
Several studies have reported blood-based biomarkers for early detection of lung cancer 
but so far only few of them have proven useful in lung cancer clinical practice. Beside 
technical issues related to difficulties in protocol standardization and lack of large scale 
validation in clinical trials, genetic and biological tumor heterogeneity has likely limited 
the successful identification of tumor-specific markers. A ground-breaking way to identify 
novel and more reliable biomarkers is searching for candidates by looking not only at the 
tumor itself but also at the interplay between the tumor and the host with the aim to identify 
very early changes related to the biological reactivity of the host to a developing cancer. 
In this respect, epigenetic markers, above all circulating microRNAs (miRNAs), could 
represent ideal candidates since they act as extracellular messengers of biological signals 
derived from the cross-talk between the tumor and its surrounding microenvironment. 
MiRNA are short non-coding RNA emerged as critical regulators of gene expression 
playing a key role in physiological and pathological mechanism. Blood circulating miRNAs 
were also reported to be promising biomarkers for cancer detection and prognosis 
[3]. MiRNAs are released into the bloodstream by different mechanisms such as passive 
leakage of cellular miRNAs from broken cells or active secretion through microvesicles or 
protein complexes by several cell subtypes [4].Although LDCT is currently the standard 
of care for early lung cancer detection, it results in a general over diagnosis of indolent 
nodules, thus increasing unnecessary confirmatory diagnostic procedures. Non-invasive 
circulating miRNA assays could overcome most of these problems by exploiting the synergy 
between the molecular and imaging tests to reduce the number of the false positives. 
Two groups, in 2011, identified specific plasma and serum miRNA signatures comparing 
samples from patients and disease free individuals collected in three independent 
LDCT screening trials [5;6]. Our group reported four signatures composed by 
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The clinical benefits of biomarker-driven targeted cancer therapy are clear in many 
tumor types, particularly in lung adenocarcinoma. At this time, use of targeted agents is 
predicated on access to tumor tissue; in lung cancer patients this tissue is often limited in 
quantity, a product of minimally invasive procedures using narrow-gauge biopsy needles 
intended to reduce complications. Current clinical practice has forced pathology labs 
to revisit approaches to tissue handling, diagnosis, and molecular platform selection. 
Coordinated efforts are critical to optimizing the handling of small biopsies, from the time 
of request, to the actual procedure, to receipt in the pathology lab. Ideally, the requesting 
physician clearly communicates the need for genomic studies to both the operator, who 
may consider the need/feasibility of multiple biopsies, and pathologist, who may perform 
rapid on site evaluation. Interventional techniques designed to improve the chances of 
obtaining material amenable to molecular diagnostics should be implemented whenever 
possible, including combined core biopsy and fine needle aspiration,1and preferential 
sampling of soft tissue components of bony metastases when possible, in order to avoid 
the need for specimen decalcification. In the future, in vivo microscopy may be used 
to guide the biopsy location.2 Routine histology practices, such as cutting slides from 
a paraffin block in an iterative fashion only after a pathologist’s review, often requires 
“refacing” to optimize the plane of section and can waste valuable tumor tissue. The need 
for genomics studies should be clearly indicated to the receiving pathology laboratory, 
thereby facilitating histology protocols designed to conserve tissue. Such protocols may 
include embedding each tissue core in an individual block, delivering “up-front” unstained 
sections for use in immunohistochemistry and molecular studies, and/or triaging slides 
to a dedicated molecular diagnostics workflow. As an example, from a single 18-gauge 
core needle biopsy containing 30% tumor, 15-20 unstained slides can typically generate 
enough material to perform a diagnostic workup, immunohistochemistry and/or FISH for 
ALK and ROS1 rearrangements, and adequate DNA for hybrid capture next generation 
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Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor issued from the 
mesothelial surface of the pleural space. A previous exposure to asbestos is the main 
risk factor of mesothelioma. Clinical signs are most of time late and unspecific. Chest 
CT-scan, a key imaging procedure, usually shows pleural effusion ±pleural thickening. 
PET-CT may help to differentiate MPM from pleural benign tumors, as well for distal tumor 
staging. But PET-CT is not recommended for the diagnosis of MPM, as well as soluble 
biomarkers, including mesothelin. A diagnosis of MPM based on pleural biopsies best 
obtained by thoracoscopy is recommended with compulsory immunohistochemistry 
(1, 2). The treatment of MPM is so far quite deceptive with median overall survival 
(OS) around 12 months, and relies mostly on chemotherapy and best supportive care 
(BSC). To date, only first line chemotherapy by cisplatin/carboplatin+pemetrexed 
is recommended by all guidelines for patients fitted for chemotherapy (3). The 
optimal duration of first line chemotherapy is unknown but a maximum of 6 cycles is 
recommended. There is no evidence supporting a maintenance treatment including 
by pemetrexed. Therapeutic options beyond first line treatment are presently highly 
limited despite nearly half of patients are clinically fitted for. According to guidelines, 
pemetrexed alone may be proposed again if patients did have tumor progression at least 
3 to 6 months after stopping chemotherapy (1, 2). Other options exhibited deceptive 
response rates (4). Therefore, it is recommended in the other cases to propose patients 
to join clinical trials. Pathogenesis of MPM includes overexpression of growth factors 
(VEGF…), many genetic and epigenetic alterations and/or mutations of malignant cells 
(p16 INK4A/CDKN2A, BAP-1, NF-2…) responsible for cell proliferation and resistance to 
apoptosis, pleural inflammation and local immunosuppression induced by the tumor and 
favoring its growth. These elements provide the rationale for many targeted therapies 
and immunotherapy. But so far, very few drugs exhibited sufficient value to deserve 
further trials. Thus, first trials assessing anti-angiogenic drugs in MPM did not support 
their use in this cancer despite the key role of VEGF. A phase II trial of bevacizumab 
(anti-VEGF antibodies) combined with cisplatin+gemcitabine was negative (5). But other 
phase II trials evaluating bevacizumab with cisplatin+pemetrexed were promising with 
PFS of 6.9, 7.9 and 9.2 months, and DCR of 40, 57 and 88%, respectively. Therefore a 
phase III randomized (1:1) trial (« MAPS ») recruited 448 unresectable MPM patients to 
test cisplatin+pemetrexed with (arm B) or without (arm A) bevacizumab (6). Arm B non-
progressive patients received bevacizumab maintenance until progression or toxicity. 
Median OS was significantly longer in the B arm: 18.8 [95%CI: 15.9-22.6] vs. 16.1 
months [14.0-17.9] in the A arm, (adj.HR= 0.76, p=0.012). Thus bevacizumab addition 
to pemetrexed+cisplatin provided a significantly longer survival in MPM patients with 
acceptable toxicity, making this triplet a new treatment paradigm for this cancer. Pro-
apoptotic agents such as proteasome inhibitors (bortezomib) or histones deacetylases 
inhibitors (HDACi) were also assessed with discordant results. In 2nd/3rd line treatment, 
vorinostat (HDACi) failed to show any significant OS gain versus placebo in a large phase 
III trial (7). Focal adhesion kinase (FAK) is a tyrosine kinase with multiple roles in tumor 
growth and resistance to chemotherapy. FAK is overexpressed with increasing activity 
in many human cancers, associated to a low tumor expression of the Merlin molecule, a 
potential predictive biomarker of FAK inhibitors. An inhibition of FAK may induce tumor 
cells apoptosis, reduce cancer stem cells, and modulate the activity of NF-2, frequently 
mutated in MPM. Thus, a trial is currently assessing FAK inhibitors (VS-6063/Defactinib) 
as maintenance treatment after 1rst line chemotherapy by platinum+pemetrexed. Phase 
I-II trials assessed antibodies targeting mesothelin, a mesothelial cell surface molecule 
overexpressed in (epithelioïd) MPM, alone or combined with Listeria toxin, showing 
promising results (8). Other innovative techniques including gene therapy, cellular 
therapy or oncovirotherapy, are also currently evaluated with first promising results. But, 
as in melanoma or in lung cancers, checkpoint inhibitors represent presently the most 
exciting tool. First results with anti-CTLA4 Ab (tremelimumab) were recently published: 
the main goal (RR) was not achieved but several prolonged response or stable disease 
were observed, justifying a larger phase II trial (n=564), assessing tremelimumab versus 
placebo in 2nd/3rd line treatment of MPM. Early data of a phase Ib basket trial with anti-
PD-1 (Pembrolizumab) in the same setting found promising RR of 28% and DCR of 76% 
in PD-L1 positive MPM (2015 AACR meeting). Other trials with checkpoint inhibitors are 
underway. To date, the place of radiotherapy is limited in MPM, mostly with palliative intent 
(1). Prophylactic irradiation of chest scars and drains is highly discussed. A definitive 
answer on this controversial indication is hoped with a current randomized UK trial. 
Adjuvant radiotherapy is not validated yet as well. Limitations due to technical reasons 
and toxicities may be answered in the future by new modalities of radiotherapy such as 
IMRT. Multimodal treatment of MPM patients, whatever the surgery is (i.e. extrapleural 
pneumonectomy (EPP) or pleurectomy/decortication (P/D)) is not recommended outside 
clinical trials (1). Recent trials, even the highly controversial “MARS” trial, and meta-
analysis undeniably plead for stopping EPP and to continue P/D only in clinical trials to find 
the best multimodal treatment for potentially resecable MPM patients, fitted for surgery 
(9). Additional intrapleural treatments (chemotherapy, photodynamic therapy (PDT) 
or immunotherapy) seem needed to improve significantly the post-surgery outcome, 
mostly as now targeted therapies such as bevacizumab may increase median OS close 
to 19 months in patients less selected than surgical patients! Thus, Friedberg and al 
found exciting OS over 31 months in patients treated by multimodal treatment including 
extensive P/D and intrapleural PDT (10). In conclusion, many research studies presently 
assess the value of targeted therapies and biomarkers, opening new perspectives in 
the management of MPM. Remaining questions are how to target the best patients for 
each drug or technique, and how to combine the different current and future therapeutic 
tools in MPM. But real hopes seem close now for our patients after a long dark age. 
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cell lung cancer patients beyond chemotherapy. Recently several new agents have been 
studied in squamous cell lung cancer patients and promising results have been observed, 
with some of the trial results leading to drug approval for NSCLC patients in general and 
squamous cell lung cancer patients in particular. The recent advances in drug therapy 
can be categorized according to drug type into cytotoxic chemotherapy agents, immune 
checkpoint inhibitors and molecularly targeted agents. Nab paclitaxel, an albumin bound 
formulation of paclitaxel combined with carboplatin was compared with the standard 
combination of the carboplatin and paclitaxel in advanced NSCLC patients (1). The nab 
paclitaxel combination showed a significant improvement in response rate in squamous 
cell patients (41% vs. 24%), p < 0.001). This improvement in response rate was 
associated with a modest but statistically non-significant improvement in progression 
free survival (PFS) and overall survival. These results, have led to the approval of this 
combination for the management of advanced NSCLC patients and this combination is 
preferentially considered in squamous cell patients. The immune check point inhibitors 
have generated most excitement in recent years. In a randomized trial, Checkmate 017, 
the anti-PD-1 drug nivolumab was compared with docetaxel in patients with progressive 
squamous cell lung cancer and demonstrated both PFS (HR-0.62) and survival (HR-0.59) 
improvement (2). Toxicities in general were less in patients who received nivolumab 
and immune related toxicities were not common. In this trial PD-L1 expression did not 
correlate with benefit from nivolumab. Ipilimumab, an anti-CTLA4 antibody, has also been 
evaluated in squamous cell lung cancer patients. In a randomized phase II trial phased in 
ipilimumab with chemotherapy demonstrated superior outcomes compared to advanced 
NSCLC patients receiving chemotherapy alone (3). Retrospective analysis suggested 
greater benefit in squamous cell patients. Based on these results, a randomized study 
evaluating ipilimumab with chemotherapy in advanced squamous cell patients as front 
line therapy was initiated and has completed accrual (NCT01285609). Drugs targeting 
EGFR (Epidermal Growth Factor Receptor) have been studied in squamous cell lung 
cancer patients. Though EGFR-tyrosine kinase mutations are extremely uncommon in 
squamous cell lung cancer patients EGFR amplification has been observed in 7-10% of 
the patients and EGFR is expressed in a high proportion of squamous cell lung cancers. 
Necitumumab, a recombinant human EGFR antibody combined with chemotherapy 
cisplatin and gemcitabine demonstrated a modest survival advantage (HR- 0.84, p = 
0.01) compared to chemotherapy alone (4). Afatinib, an irreversible EGFR tyrosine kinase 
inhibitor demonstrated superior survival compared to erlotinib in patients with recurrent 
squamous cell lung cancer following front line therapy (HR-0.81, p = 0.007) (5). The modest 
benefit observed suggests that EGFR targeting drugs are useful only in a proportion of 
squamous cell lung cancer patients and a biomarker to identify patients that benefit from 
these drugs could be valuable in the future use of these drugs. Another drug that showed 
clinical benefit in squamous cell lung cancer patients, along with other NSCLC patients 
is ramucirumab, a VEGFR2 receptor directed monoclonal antibody. In the REVEL study 
NSCLC patients with progressive disease following front therapy were randomized to 
docetaxel with or without ramucirumab (6). The combination demonstrated a superior 
survival compared to single agent docetaxel (HR-0.86, p = 0.023). Benefits were seen 
across all histologies, including squamous cell lung cancer. Several drugs targeting other 
signaling pathways, specifically PI3K and FGFR, are currently undergoing evaluation. 
Results to date in patients with tumors that have these specific molecular alterations 
have shown only modest benefit or no benefit at all. The reasons for these results are 
unclear. Ongoing clinical trials will determine the potential benefit for targeting these 
pathways. A major effort in analyzing targeted drugs based on molecular alteration in the 
patient’s tumor is ongoing with the LUNG MAP study, led by Southwest Oncology Group 
(SWOG) with participation from all the US Oncology Cooperative Groups. In conclusion, 
after a period of no advances for the treatment of squamous cell lung cancer patients, 
several drugs recently have shown clinical benefit and several others are currently being 
evaluated. It is clear that therapy of advanced squamous cell lung cancer patients has 
evolved beyond cytotoxic chemotherapy and will provide greater clinical benefit. 
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sequencing.3With careful histology embedding and sectioning, material will still remain 
in the block for future studies. International guidelines have recognized the centrality of 
molecular testing to the clinical management of lung cancer patients and have responded 
with recommendations for judicious use of immunohistochemical studies in pathology 
workups and introduced new diagnostic categories intended to eliminate ambiguous 
classifications, particularly for small biopsy specimens.4These guidelines advise against 
use of the term “non small cell lung carcinoma” whenever possible and recommend 
use of TTF-1 and p63 or p40 immunohistochemical stains as first line markers for 
distinguishing between adenocarcinoma and squamous cell carcinoma.5 Simultaneous 
evaluation of fine needle aspirates and core biopsies with an optimized IHC protocol may 
significantly reduce rates of the NSCLC diagnosis and generate additional “testable” 
material.6 In institutions that use touch imprints for rapid evaluation of core needle 
biopsies, careful specimen handling is required to maintain tumor cell adequacy in the 
needle biopsy specimen.7 When cytology material is available for testing, cell blocks 
are preferred because a physical record of the sample can be retained in the form 
of a stained glass slide.4 However, in many circumstances the most cellular material 
is in the form of a smear; these preps can generate abundant and high quality DNA 
and so should be considered for use in molecular testing, particularly if the slide can 
be scanned and a digital image archived. Validation of alternative specimens such as 
cytology smears for FISH can provide additional tissue for in situ assays when core 
needle or cell block specimens are inadequate.8 In the molecular diagnostics lab, a 
plethora of testing platforms are available, many of which are evolving to accept low 
DNA inputs. Many targeted amplicon-sequencing based assays can accept as little as 
10ng of input DNA, whereas hybrid capture approaches typically require around 50ng or 
more for targeted sequencing panels and whole exome sequencing. However, in today’s 
practice, it is rare that a single test can provide comprehensive analysis of all the desired 
targets; indeed, confirmation of individual events detected by sequencing by FISH or 
immunohistochemistry may be needed. Therefore, an interdisciplinary effort to optimize 
tumor sampling and conserve tissue is required to ensure successful and comprehensive 
molecular profiling of lung tumors. 
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Management of patients with advanced Non-Small Cell Lung Cancer (NSCLC) in recent 
years has been approached based on defining the histologic subtype and identifying 
actionable genetic alterations in the tumor. Many of the recent developments in the 
management of advanced NSCLC are applicable only to non-squamous NSCLC patients. 
Cytotoxic chemotherapy has remained the primary systemic therapy for squamous cell 
lung cancer patients. Despite a decline in the incidence in some parts of the world, 
squamous cell lung cancer as a single entity remains one of the major causes of cancer 
related mortality worldwide. Therefore there is a need to advance therapy of squamous 
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screening. A multidisciplinary tumor/nodule board can help share the decision making, 
cross fertilize, and facilitate care for those who need treatment. 
1. Aberle DR, Adams AM, Berg CD, et al. National Lung Screening Trial Research Team. 
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl 
J Med 2011;365: 395–409. 
2. Moyer VA. Screening for lung cancer: U.S. Preventive services task force 
recommendation statement. Ann Intern Med 2014;160:330-338. 
3. Centers for Medicare & Medicaid Services. Decision memo for screening for lung 
cancer with low dose computed tomography (ldct) (cag-00439n) 2015. Available from: 
http://www.cms.gov/medicare-coverage-database/details/nca-decision-memoaspx?N
CAId=274&NcaName=Screening+for+Lung+Cancer+with+Low+Dose+Computed+T
omography+(LDCT)&MEDCACId=68&IsPopup=y&bc=AAAAAAAAAgAAAA%3d%3d&. 
4. Mazzone P, Powell CA, Arenberg D et al. Components necessary for high-quality lung 
cancer screening: American College of Chest Physicians and American Thoracic Society 
Policy Statement. Chest. 2015;147:295-303. 
5. Wiener RS, Gould MK, Arenberg D, et al. Official American Thoracic Society / American 
College of Chest Physicians Policy Statement: Implementation of Lung Cancer Screening 
Programs with Low-Dose Computed Tomography in Clinical Practice. Am J Respir Crit 
Care Med. 2015; in press. 
6. National Comprehensive Cancer Network. Nccn clinical practice guidelines in oncology 
(nccn guidelines) - lung cancer screening, version 1.2015. 2014. Available from: http://
www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf. 
7. Jaklitsch MT, Jacobson FL, Austin JH, et al. The american association for thoracic 
surgery guidelines for lung cancer screening using low-dose computed tomography 
scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 
2012;144:33-38. 
8. American Academy of Family Physicians Policy Statement available from: http://www.
aafp.org/patient-care/clinical-recommendations/all/lung-cancer.html 
9. Kazerooni EA, Austin JH, Black WC, et al. Acr-str practice parameter for the 
performance and reporting of lung cancer screening thoracic computed tomography 
(CT): 2014 (resolution 4). J Thorac Imaging 2014;29:310-316. 
10. Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer 
screening. N Engl J Med 2013;368:728-736.
Keywords: CT screening, lung cancer, multidiciplinary program
SESSION MTE 27:  
MODERN APPROACHES TO RADIOTHERAPY IN  
STAGE III DISEASE  
WEDNESDAY, SEPTEMBER 09, 2015
MTE27.01 Modern Approaches to Radiotherapy in Stage III Disease Maria 
Werner-Wasik Radiation Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson 
University, Philadelphia/PA/United States of America
Thoracic radiation therapy (RT) has been historically the first definitive therapy for Stage 
III non-small cell lung cancer (NSCLC), achieving median survival time (MST) of 10 months 
(mo). Adding chemotherapy extended MST to 13.8 mo (induction chemotherapy) or 17-
20 mo. (concurrent chemotherapy) in randomized trials which used two-dimensional (2D) 
RT. Most recently, large randomized clinical trials for PET-staged patients treated with 
modern thoracic RT reported MST of 28.7 mo. (1). The reasons for such impressive 
survival improvement over last two decades are not fully understood and are likely 
multifactorial, including universal FDG-PET staging on presentation (therefore removing 
unsuspected Stage IV patients); progress in thoracic RT (precise target definition with 
CT simulation; widespread 3D RT or Intensity Modulated RT[IMRT], allowing volumetric 
rather than point radiation dose prescribing; heterogeneity correction accounting 
for different density of air vs. soft tissue; increased understanding of normal tissue 
tolerance, such as spinal cord, allowing relative sparing of lung parenchyma; image-
guided RT minimizing normal tissue margins and “missed targets” etc.); widespread 
use of low-dose well-tolerated outpatient chemotherapy regimens; improved supportive 
care; effectiveness of second- and third-line systemic therapy etc. In a population study 
of >5,000 SEER-Medicare patients with NSCLC, wider adoption of CT simulation for 
thoracic RT planning was associated with improved overall survival (2). Local control rate 
was 70% at 2 years in the large cooperative group Phase III randomized trial (RTOG 0617) 
in the 60 Gy standard arms, defined as lack of tumor progression within the irradiated 
field. Most patients succumb to distant metastases which continue to be the leading 
cause of death of patients with lung cancer. Since death from distant metastases and 
local failure constitute competing risks, the likely incidence of local failure may be higher 
if longer overall survivals are achieved. The optimal RT dose allowing improved local 
control has not been fully established and the current recommendation is to use 60 Gy 
in daily 2 Gy fractions, with concurrent chemotherapy in fit patients. RT dose escalation 
to 74 Gy was associated with worse MST when compared to 60 Gy in a randomized trial 
(20.3 vs. 28.7 mo., respectively) (RTOG 0617). While the reasons for such worse survival 
are not clear, the possibilities include higher RT heart doses in the 74 Gy arm, greater 
number of deaths in the high-dose group, extended duration of radiation therapy to 7.5 
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The National Lung Screening Trial results provided convincing evidence to the US 
Preventive services Task Force (USPSTF) to give a B recommendation (same as 
mammography) to screening high-risk individuals with low-dose CT (LDCT) in 2013.1,2 In 
response in 2015 the Center for Medicare and Medicaid services (CMS) determined 
payment for screening those age 55 to 77 with the same smoking requirements.3 So 
how is the medical community supposed to implement screening? At this point it appears 
easier to come up with the questions than the answers and it is unclear if there will be 
additional large randomized studies to guide the process. Programs will have similar 
elements with yet with features reflective of local needs and resources. In the US 
much of this process is being dictated by CMS and the American College of Radiology 
(ACR) which will maintain the registry through which reimbursement by CMS has been 
approved. As of July, this registry has not been set up and reimbursement by CMS is 
promised but not being done. As the NLST is the only randomized control trial to show 
benefit, whether international adoption occurs remains to be seen. Policy statements 
are available to help identify the key components and implementation strategies for a 
CT screening program.4,5 A multidisciplinary committee that meets regularly consisting 
of pulmonology, radiology, primary care, thoracic surgery, interventional radiology, and 
medical and radiation oncology is important to facilitate LDCT screening, and evaluation 
and treatment of screening results. The inclusion of each of these disciplines helps 
to assure the patient has a complete complement of options regarding diagnosis and 
treatment and also limits the implementation of screening to systems with the needed 
expertise available. Having dedicated secretarial and administrative support is as 
important to a program’s success. 
Who to screen? The simplest answer is to screen those for whom benefit has been 
shown, namely those fitting the NLST criteria: age 55-74 with a 30 pk-year history of 
smoking and either current smokers or those who have quit within 15 years.1 But it 
should be more complicated that as there are many patients at equivalent or higher 
risk who don’t fit the NLST criteria. There are several guidelines published and they all 
differ. USPSTF recommends ages 55 to 80 (and is so mandated within the Affordable 
Care Act), CMS is reimbursing for those age 55 to 77 (in medicare or medicaid), the 
National Comprehensive Care Network (NCCN) additionally recommends screening for 
those age > 50 with a 20 pack-year history and one additional risk factor such as COPD, 
family history of lung cancer, occupational exposure to carcinogens, and significant 
radon exposure.6 Similarly the American Association of Thoracic Surgery recommends 
screening for those ages 55-79 within the NSLT smoking criteria as well as those > age 
50 with a > 20 pk-year history and a cumulative risk of > 5% over 5 years.7 At present 
the American Academy of Family Physicians recommends against LDCT screening.8 Our 
program is recommending screening based on risk rather than reimbursement and, as a 
consequence, in additional to those who meet USPSTF criteria, recommends screening 
to those who have equivalent or higher risk using the PLCO2012 model.
9 Exclusion criteria 
should be similar between programs and based on the NLST.1 
Shared Decision Making. The USPSTF recommendation includes a shared decision 
making process (not recommended for breast cancer screening); this is also mandated 
by CMS as an identifiable visit with specific components: eligibility, absence of signs or 
symptoms of lung cancer, benefits and harms of screening, follow-up diagnostic testing, 
over-diagnosis, false positive rate, radiation exposure; importance of adherence to 
annual screening, impact of comorbidities, willingness to undergo treatment; and the 
importance cigarette smoking abstinence or cessation.3 We mandate tobacco cessation 
counseling for current smokers prior to screening in an attempt to make clear that 
cessation is more lifesaving than screening. In the NLST there were 16 deaths within 60 
days of an invasive procedure and only 10 of those had cancer; patients need to know 
process of screening can be fatal.1 
Radiology, results and Data collection. The ACR and Society of Thoracic Radiology 
have identified specifications for a LDCT and the registry requires that those technical 
parameters be met.10 A structured reporting system is desired yet unfortunately the ACR 
registry requires that LungRADS be used which is not consistent with evidence based 
guidelines, is ambiguous, and is not aimed at patient communication. 
Nodule Evaluation. An optimal nodule evaluation algorhythm is yet to be determined, 
and since patient preference is to be weighed, no one fit will size all. Doing the CT scan is 
the easy part; follow-up is imperative - a dedicated registry is mandatory in this regard. 
Many raise concerns about the false positives of CT screening; within the NLST (positive 
defined as > 4mm) false positives were 96%. The 4 mm nodule has a likelihood of lung 
cancer of less than 1%. Should we call it a positive with that probability? The reality is that 
the vast majority of nodules found by CT screening need no additional evaluation other 
than CT follow-up – most with the next annual scan. We are recommending PET or biopsy 
(depending on the circumstances) only for nodules 1cm or greater and that eliminates 
immediate evaluation for 95% of the participants. But we don’t call a 6 mm nodule 
negative; it exists and needs follow-up – a key is to provide accurate information to the 
patient and their provider as to the likelihood of malignancy. Our program is responsible 
for the evaluation and followup of findings in a desire to favorably the tip the balance of 
benefit versus harms. People don’t die from false positives, but they can die from their 
evaluation. Nodule evaluation should be done by those who do it every day; we don’t 
feel this is appropriate for the primary provider and perhaps why the AAFP rejects LDCT 
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The cancer anorexia-cachexia syndrome (CACS) is a significant clinical problem, 
affecting upwards of half of all patients with cancer, and causing at least 20% of deaths in 
the general cancer population. An international expert consensus grouprecently defined 
cancer anorexia-cachexia as “a multifactorial syndrome characterized by an ongoing 
loss of skeletal mass (with or without loss of fat mass) that cannot be fully reversed by 
conventional nutritional support and leads to progressive functional impairment” [1]. Its 
impact is particularly significant in lung cancers, where it is present in 60% of patients at 
diagnosis; in all stages of NSCLCa patients, 5 kg of weight loss reduced survival rates 
by more than 40%. Systemic inflammation, reduced food intake and altered metabolism 
contribute to loss of muscle mass and body weight reduction [2,3]. CACS is associated 
with fatigue and a reduction in physical functioning, quality of life (QoL), tolerance 
and response to anticancer therapy, and survival [1,4,5,6]. The condition is further 
compounded by its under-recognition, with CACS often present even in the absence of 
weight loss and at times obscured by obesity [5]. CACS may be preceded by muscle loss 
and may be exacerbated by anticancer therapies. It is the final common pathway in people 
with advanced cancer leading to death unless some other process supervenes. The most 
prominent feature of CACS is its nonresponsiveness to existing treatment approaches, 
which have included unsuccessful use of nutritional supplements, appetite stimulants, 
5-hydroxytryptamine-3 (5-HT3) antagonists and cyclooxygenase-2 (COX-2) inhibitors 
[2]. American guidelines are aimed at the delivery of optimal nutrition management 
[7], with those of organizations such as the National Comprehensive Cancer Network 
lacking specific guidance on pharmacologic treatments [8]. The European Palliative Care 
Research Collaborative (EPCRC) offers clinical guidance on drug treatments for cancer 
cachexia [9], but is limited in available advice due to the lack of widely effective and 
safe agents. There is a vast unmet medical need for this debilitating syndrome. While 
CACS continues to be an issue that impacts many cancer patients, headway is being 
made in the development of drugs that can significantly improve quality of life. Some 
investigational agents have shown potential in completed Phase II or III studies of patients 
with CACS. During this session we will review recent clinical trial evidence for these 
agents. Other developmental headway is being made in rapid identification of people 
at risk for CACS and/or requiring treatment, and point of care clinical decision support 
to optimize treatment approach. The use of aggregating clinical, biological and patient-
reported data and development of specific predictive models are leading to personalized 
symptom control. In totality, the industry is making progress in the treatment of CACS, 
and there continues to be vast opportunity to further improve in the future. 
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weeks, and uncertainty about true causes of death (1). Nevertheless, efforts toward 
RT dose intensification continue, with particular attention given to the shortening of 
the overall treatment time through hypofractionation (for example, in the RTOG 1106 a 
mid-treatment PET-adapted hypofractionated RT boost is applied to the residual tumor 
volumes during a total duration of 30 RT fractions )(NCT01507428). While the proportion 
of patients with Stage III NSCLC receiving IMRT has been increasing as compared to 3D 
RT (3% in 2002 vs. 26.8% in 2009)(3), the superiority of IMRT has not been convincingly 
demonstrated. Among patients receiving potentially curative treatment, there was no 
difference in overall survival (propensity adjusted HR .99, p = 0.83) or number of hospital 
days in the 90 days following radiation start, as demonstrated by the SEER-Medicare 
analysis of over 7,000 patients.The technology currently being investigated involves 
proton therapy, which has been shown in treatment-planning comparisons to deliver 
high-dose, highly conformal radiation to targets while minimizing damage to surrounding 
normal tissues. In particular, the subclinical cardiovascular toxicity suspected to be 
detrimental in the RTOG 0617 trial, which might have accounted for worse survival in 
the high-dose arms, may be mitigated with protons due to their physical property of a 
sharp distal dose edge. Long term results from a prospective single institution study 
of 134 patients receiving concurrent proton thoracic RT (median dose: 74 Gy) and 
chemotherapy (4) demonstrated the MST of 40 mo. for Stage II NSCLC patients and 30 
mo. for Stage III patients, and a local + marginal failure-free rate of approximately 50% at 
5 years. Grade 2 radiation pneumonitis was reported in 29 (22%) patients and Grade 3, 
in 2(1.5%). An ongoing study, the NRG Oncology/RTOG 1308, is a phase III trial exploiting 
the potential of protons compared with photons to escalate radiation dose to 70 Gy while 
applying strict dose volume constraints to adjacent normal tissues (NCT01993810). In 
summary, while numerous advances in thoracic RT for Stage III NSCLC were introduced 
over the last 20 years, local tumor control and overall survival need refinement and no 
single RT technology/RT dose and fractionation have been identified as the most optimal 
approach.
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It has been 10 years since we first understood about the importance of targeted therapies 
in lung cancer. This group of medications is now part of our everyday clinical care for 
patients with lung cancer who harbour an EGFR or ALK mutation. Mechanisms of action 
and the associated toxicities of targeted therapies, such as tyrosine kinase inhibitors 
(TKI), differ from chemotherapy. Whilst these medications tend to be better tolerated in 
patients, they still carry a number of associated side effects which require intervention and 
management. Amongst these are acneform rash, paronychia, diarrhoea, nausea, raised 
liver functions, interstitial lung disease, loss of appetite, neuropathy, vision problems, 
and fatigue. With many lung patients on multiple medications due to comorbidities at 
presentation there should also be consideration of drug interactions with the CYP450 
pathway utilised to metabolise many medications. This session will explore traditional and 
more novel approaches to supporting patients on TKI medications, patient resources, and 
the role nurses play in ensuring compliance and improved outcomes for lung cancer patients. 
Keywords: EGFR mutation, ALK mutation, Targeted therapy
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Lung cancer screening with computed tomography has demonstrated a significant 
reduction in mortality (1) leading to the recommendation for annual low-dose CT (LDCT) 
screening for lung cancer for adults between 55 and 80 years old who are at high risk 
for lung cancer because of their age and extensive smoking history. In addition to lung 
cancer screening having public health benefit for early detection of lung cancer, lung 
cancer screening programs may also represent a “teachable moment” for reaching 
smokers and promoting cessation through the delivery of evidence-based tobacco 
cessation treatment (2). Since the advent of lung cancer screening programs, there has 
been much interest in the impact of lung cancer screening on smoking behaviors. Ostroff 
and colleagues (3) first published the observation that 25% of current smokers seeking 
lung cancer screening reported smoking cessation one-year following enrollment in a 
lung cancer screening program Since then, several observational studies have reported 
cessation rates ranging from 6.6% to 42% following enrollment in lung cancer screening 
programs (4-11). However, a more recent systematic review of clinical trials and 
cohort studies examining smoking behaviors among individuals undergoing LDCT for 
lung cancer screening concluded that lung cancer screening per se does not change 
smoking behaviors leading to the conclusion that further research is needed to develop 
and evaluate cost-effective models for delivery of tobacco treatment in lung cancer 
screening protocols (12). A recent survey of lung cancer screening sites examined 
the organizational priority, practice patterns and perceived barriers associated with 
tobacco treatment (13). To facilitate the integration of tobacco treatment within lung 
cancer screening programs, a greater understanding of the barriers associated with 
implementation is needed. Thus, the presentation objectives are to: 1) Establish the 
rationale for integration of tobacco dependence treatment in lung cancer screening 
programs; 2) Examine patterns and predictors of smoking cessation among lung cancer 
screening program enrollees; 3) Examine current organizational priority, practice 
patterns and perceived barriers associated with tobacco treatment delivery; 4) Review 
opportunities and challenges of integrating tobacco dependence in lung cancer screening 
protocols. This presentation will provide a blueprint for developing and implementing 
evidence-based tobacco treatment services within the context of lung cancer screening 
program. 
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An international consensus group has defined cancer cachexia as “a multifactorial 
syndrome defined by an ongoing loss of skeletal muscle mass (with or without fat mass) 
that cannot be fully reversed by conventional nutritional support and leads to progressive 
functional impairment”.1 Fifty percent of patients with lung cancer have muscle wasting 
at diagnosis and this muscle loss increases throughout their disease course. Metabolic 
changes associated with cachexia lead to decreased protein stores, altered metabolism, 
and impaired immunity which clinically can be associated with anorexia and fatigue, 
weakness, and decreased physical performance. Cancer patients with muscle wasting 
are less able to tolerate chemotherapy, have worse treatment outcomes, loss of 
independence and overall shorter survival. Effective prevention and treatment strategies 
are needed. Although muscle wasting is central to the process of cachexia, our clinical 
diagnostic criteria are largely based on weight. Standard definitions for cancer cachexia 
include either weight loss > 5% of body weight or a body mass index (BMI) of < 20 
kg/m2 with 2% weight loss. More exact measurements of muscle and muscle wasting 
can be made through imaging techniques assessing lean body mass (LBM). Dexascan 
has been used to evaluate LBM, but is not routinely used in clinical practice currently. 
A very promising technique involves the use of standard computerized tomography 
in conjunction with a software program which accurately delineates skeletal muscle 
from adipose tissue, with excellent correlation with other techniques.2 Application of 
this technique to a large population of patients with advanced lung and GI cancer has 
demonstrated a high prevalence of muscle wasting (sarcopenia) in patients with a 
BMI <20, but also documents a prevalence of sarcopenia of 40-60% in patients with 
normal BMI. At least 20% of patients with an elevated BMI also have muscle wasting 
(sarcopenic obesity). Studies in this population with sarcopenia regardless of baseline 
weight have shown increased toxicity of chemotherapy treatments, shorter time to tumor 
progression and decreased overall survival. Despite the frequency and severity of cancer 
cachexia, broad based accepted clinical practice guidelines are limited. The European 
Palliative Care Research Collaborative consensus recommendations3 include enteral 
nutritional therapy, nutritional counseling, physical therapy, and psychotherapeutic 
interventions for quality of life benefit. However, specific pharmacologic therapies, to 
date, have had little established benefit. For example, Megesterol stimulates appetite 
and weight gain in some patients, but without an increase in muscle mass, and has 
significant toxicity regarding venous thromboembolic events. The most effective 
strategy would be effective anticancer therapy. However, in advanced cancer where our 
treatments may only be partially effective or ineffective, toxicities are frequent and add 
to the overall wasting syndrome. Improved biologic understanding of muscle wasting 
has led to new therapeutic approaches that are under development. One category of 
agents interferes with biologic signaling and cytokines that may lead to muscle atrophy, 
including myostatin/activan inhibitors, anti-TNFa and anti-IL6 agents, among others. 
Several of these agents are in early phase clinical trials. A second approach has been 
to target pathways that directly stimulate hypertrophy of muscle. Two of these agents 
have been studied in phase 3 trials in advanced lung cancer patients, enobosarm and 
anamorelin. Enobosarm, a selective androgen receptor modulator, has been developed 
to have direct action on muscle, but without androgenic effects on prostate or 
virilization. Phase 2 trials have shown a clear increase in LBM and physical function, 
leading to two randomized phase 3 trials in patients with advanced lung cancer receiving 
chemotherapy. These studies have shown a clear impact on improvement in LBM in both 
trials, but an inconsistent effect on function as measured by stair climb power between 
the 2 studies.4 As predicted by the mechanism of action, no change in appetite or body 
weight was noted. A second approach for muscle hypertrophy is Anamorelin, a ghrelin 
receptor agonist. Ghrelin stimulates appetite, increase in body weight and body mass and 
metabolism. Randomized phase 3 trials of Anamorelin in advanced lung cancer patients 
have demonstrated an increase in body weight, along with LBM, but no improvement in 
functional assessment as measured by hand grip strength.5 Quality of life improvements 
have also been seen in the study population with Anamorelin. Clinical trial results of both 
enobosarm and Anamorelin will be reviewed and compared in more detail, as well as 
potential implications for future development of these and other agents, leading to more 
effective therapeutic interventions for patients with cancer cachexia in the future. 
References
Ferron K, et al. Lancet Oncol. 12:485-495, 2011.
Prado C, et al. Lancet Oncol. 9:629, 2008.
European Palliative Care Research Collaborative, 2011, www.epcrc.org.
Crawford, J. J Clin Oncol 32:5s, 2014 (suppl; abstr 9618).
Temel J, Abernethy A, et al. ASCO Proceedings, Abstract 9500, 2015.
 
Keywords: Cachexia, sarcopenia, Enobosarm, Anamorelin
S159Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
3. Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, et al. Timing of chest 
radiotherapy in patients with limited stage small cell lung cancer: A systematic review 
and meta-analysis of randomised controlled trials. Cancer Treat Rev 2007: 33: 461–473 
4. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day 
of chemotherapy and the last day of chest radiation is the most important predictor of 
survival in limited-disease small-cell lung cancer. J Clin Oncol 2006;24:1057-63. 
5. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic 
radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and 
etoposide. N Engl J Med 1999;340:265-71. 
6. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients 
with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation 
Overview Collaborative Group. N Engl J Med 1999;341:476-84. 
7. Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose 
prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer 
in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 
22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 
2009;10:467-74. The author declares no relevant conflict of interest. 
Keywords: small cell lung cancer, Radiotherapy, combined modality treatment
SESSION MTE 33:  
(DEBATE ON) PROGNOSTIC BIOMARKERS IN  
MESOTHELIOMA  
WEDNESDAY, SEPTEMBER 09, 2015
MTE33.02 (Debate on) Prognostic Biomarkers in Mesothelioma Bruce W.S. 
Robinson1, Jeanette Creaney2, Ian M. Dick2 1National Centre for Asbestos Related 
Diseases, University of Western Australia, Perth/WA/Australia, 2National Centre for Asbestos 
Related Diseases, University of Western Australia, Perth/Australia
Prognosis for mesothelioma is bleak; median survival for the cohort is generally less 
than 12 months. However individual patients have been known to survive for many years. 
From the CARET study 5 year survival rates of 9% have been reported. Our own data 
shows 5 year survival at less than 5%. The most frequent question of newly diagnosed 
mesothelioma patients relates to their prognosis. Clinical and laboratory prognostic 
variables proposed nearly two decades ago from consortium data from the European 
Organisation for Research and Treatment of Cancer (EORTC) (Curran et al, 1998) and 
the Cancer and Leukaemia Group B (CALGB) (Herndon et al, 1998) have been validated. 
Prognostic variables including performance status (PS), age, gender, tumour histology, 
white blood cell count (WCC), haemoglobin (Hb) level, and the presence or absence of 
chest pain and weight loss are taken into account when giving the patient their prognosis. 
Clearly, besides tumour histology and possibly the laboratory variables, most relate to 
the overall health and fitness of the individual. Non-subjectively determined biomarkers 
have been proposed as an independent means of providing prognostic information. 
And indeed several markers have been shown in a research setting to reflect prognosis 
however few of these studies have taken into account the known clinical prognostic 
factors. The prognostic value of serum concentrations of soluble mesothelin, the most 
well studied mesothelioma biomarker, have been inconsistent between studies. Data is 
compromised by study cohort characteristics, as tumours of sarcomatoid histology tend 
to have low mesothelin levels and poor survival. Our own data suggests that mesothelin 
levels in patients with epithelioid tumours are reflective of tumour burden as assessed 
by chest x-ray, CT or PET scans, which itself is an indicator of survival. Several other 
serological biomarkers have been reported to have prognostic value, including aquaporin 
1 and osteopontin. In addition there has been extensive work on inflammation-based 
prognostic indices, including the neutrophil to lymphocyte ratio as well as serum albumin 
levels. Another useful source of prognostic biomarkers is tumour associated antigens. We 
have shown that serum immunoreactivity to the ATP synthase protein ATP5B is positively 
correlated with prognosis, and have unpublished data showing a similar significant 
positive association of immunoreactivity to RAB38, a previously described melanoma 
associated tumour antigen. In addition to blood based biomarkers, in mesothelioma it 
is also possible to examine soluble biomarkers in the pleural effusion. There is evidence 
that pleural effusion concentrations of hyaluronic acid and of fibulin-3 may provide 
independent prognostic data. In the case of hyaluronic acid, higher concentration of this 
biomarker is associated with a better prognosis. Fibulin-3 has the potential to be a useful 
prognostic marker because its interpretation is not confounded by lower concentrations 
associated with a sarcomatoid histopathology; rather sarcomatoid effusions have 
higher concentrations of this marker and it has been shown to be markedly superior to 
effusion mesothelin as a prognostic marker. Other prognostic effusion biomarkers that 
have been identified are syndecan-1 and osteopontin. Recently, several novel pleural 
effusion based biomarkers have been reported from discovery studies; these include 
galectin-1, aldo-keto reductase and apoliproptein C-1. Of these high effusion levels of 
galectin-1 and aldo-keto reductase were associated with a relatively poor prognosis 
whereas high effusion levels apoliproptein C-1 were associated with improved prognosis. 
It is important to realize that these findings remain un-validated in other patient cohorts. 
These biomarkers that have been identified as having prognostic value were generally 
not initially investigated as prognostic markers, rather they have been studied for this 
purpose after their identification as potential diagnostic markers. Typically their initial 
identification has not been thoroughly investigated in independent cohorts of patients, 
nor have they been systematically investigated together to determine the degree to 
which they are independent of each other as prognostic markers. It is possible that 
more suitable markers could be identified that were initially investigated as prognostic 
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SCLC constitutes about 15% of all lung cancers and occurs almost exclusively in 
smokers. Clinical features of SCLC include rapid growth and the early development of 
metastases. The vast majority of SCLC patients present with either locally advanced or 
metastatic disease. Owing to high metastatic potential of SCLC, a careful mediastinum 
staging, along with brain, bone and abdomen imaging, is indicated to identify patients 
amenable to curative approaches. Traditionally, SCLC patients have been divided into 
limited stage (LS), defined as tumor confined to the ipsilateral hemithorax and regional 
nodes, and extensive stage disease, defined as tumor beyond these boundaries. In 
2007, the International Association for the Study of Lung Cancer (IASLC) recommended 
TNM staging for SCLC similarly to NSCLC, and this change was incorporated in 2010 
into the AJCC/UICC 7th edition. Chemotherapy remains the mainstay of treatment 
in all SCLC patients. The current standard of care for LS-SCLC patients includes 4 
cycles of chemotherapy consisting of cisplatin and etoposide. Carpoplatin can be 
substituted to cisplatin if contraindicated or in patients with poor tolerance to cisplatin. 
In LS-SCLC patients chemotherapy should be accompanied by thoracic radiotherapy. 
The metaanalysis of randomized studies comparing chemotherapy with or without 
radiotherapy showed apparently increased local tumor control and increased overall 
survival in favor of combined treatment (relative risk of death 0.86 [95% CI, 0.78 to 
0.94; p=0.001], corresponding to a an absolute benefit of 5.4% at 3 years), at the 
expense of slightly increased early toxicity.1 Radiotherapy concurrent to chemotherapy 
is preferred to sequential approach, despite higher incidence of severe pneumonitis and 
oesophagitis.2 Early introduction of radiotherapy (with 1 or 2 cycle of chemotherapy) may 
increase treatment outcome.3 A critical factor in chemoradiation for LS-SCLC is a short 
time from to the start of any therapy to the end of radiotherapy.4 The optimal dose of 
radiotherapy for patients with LS-SCLC remains a matter of debate. Hyperfractionated 
radiotherapy including 45 Gy in 3 weeks (1.5 Gy twice daily) has been shown to be 
superior to 45 Gy in 5 weeks (1.8 Gy daily),5 and is currently used as an alternative to 
standard regimens (60-70 Gy, 2 Gy daily). The volume of thoracic radiotherapy should 
be defined based on CT or (whenever possible) PET/CT scan, obtained within 4 weeks 
before treatment, and on CT scan obtained in the therapeutic position at the time of 
radiotherapy planning. The target to be irradiated should include all gross disease 
present at the time of radiation planning (postchemotherapy volume), and all nodal 
regions involved at the time of initial diagnosis (prechemotherapy volume). The use of 
traditional larger fields including also elective nodal sites is currently not recommended. 
With more effective therapy of LS-SCLC and a decreased risk of a thoracic relapse, 
the brain has emerged as one of the main sites of relapse, with a cumulative incidence 
at 2 years higher than 50%. Owing to limited penetration of cytotoxic drugs through 
the blood-brain barrier, the brain is considered a pharmacologic sanctuary site. This 
observation led to the development of prophylactic cranial irradiation (PCI) aiming at 
prevention of clinically overt brain metastases. Several randomized trials showed that 
PCI in patients who achieved a complete remission with chemotherapy significantly 
decreases the incidence of brain metastasis. The metaanalysis of these studies also 
demonstrated a small but significant overall survival improvement with PCI (the relative 
risk of death in the PCI vs. non-PCI group was 0.84 [95% CI: 0.73–0.97, p=0.01]), 
corresponding to a 5.4% increase in the rate of survival at 3 years.6Based on these 
results, PCI is currently recommended as a routine part of management in LS-SCLC 
patients who achieve a response to initial therapy. The dose of PCI has long been a matter 
of debate. Results of the randomized study comparing a standard (25 Gy in 10 fractions) 
vs. higher dose (36 Gy in 18 fractions) of PCI in LS-SCLC showed no significant difference 
in the 2-year incidence of brain metastases between two groups, and a lower overall 
survival in the higher-dose group.7 In consequence, 25 Gy in 10 fractions remains the 
standard of care in LS-SCLC. In summary, current management in patients with LD-SCLC 
and good performance status includes the combination of cisplatin and etoposide, along 
with early thoracic radiotherapy (45 Gy in 3 weeks, 2 fractions daily, or 60-70 Gy in 6-7 
weeks, one fraction daily), followed by PCI (25 Gy in 10 fractions) in those who achieved 
response to initial chemotherapy. 
References 
1. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for 
small-cell lung cancer. N Engl J Med 1992;327:1618-24. 
2. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus 
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markers. An example of this would be the identification of proteins that were under or 
over expressed in pleural effusions from patients with longer survival compared to those 
with a shorter survival time using proteomics discovery methods. This underscores 
the importance of prospective collection of biological samples with scrupulous 
recording of clinical details for future evaluation of markers as they are discovered. 
 
Keywords: Mesothelioma, Biomarkers, Prognosis, mesothelin
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tumor (3). Among all patients undergoing surgery, 94% were able to undergo an R0 
resection. Patients with pathologic complete response had a marked advantage in five 
year overall survival (median survival not reached for complete responders versus 30 
months for those with residual disease). Overall survival of the entire cohort was 44%, 
but was 54% after complete resection. Similar results were found in a multi-institutional 
trial from Japan (JCOG 9806), in which 21% of patients experienced a complete 
pathologic response following neoadjuvant therapy with mitomycin, vindesine, and 
cisplatin and concurrent radiation of 45 Gy (4). Among surgical patients, 89% underwent 
an R0 resection. Overall five-year survival for the cohort exceeded 50%, with survival of 
complete responders again especially favorable. The successful adoption of neoadjuvant 
therapy followed by surgery for Pancoast tumors raised the question of whether a similar 
induction strategy should be used in patients with other T3 chest wall tumors outside of 
the superior sulcus. Previous reports have suggested that prognostic factors for survival 
in patients with chest wall tumors include lymph node status and depth of chest wall 
invasion, but also completeness of surgical resection and completion of chemotherapy 
(5,6). It seems logical that neoadjuvant chemotherapy or chemoradiation may facilitate 
an R0 resection and that such therapy may be better tolerated preoperatively in patients 
undergoing potentially morbid chest wall resections. Along those lines, a prospective 
phase II study of trimodality therapy was performed in Japan (CJLSG 0801) for patients 
with T3N0 or T3N1 NSCLC involving the chest wall (7). Fifty-one patients were entered 
into the study, among whom 49 (96%) completed neoadjuvant cisplatin and vinorelbine 
with concurrent radiation (40 Gy) and among whom 44 (92%) underwent complete 
resection. Similar to prospective studies in NSCLC patients with superior sulcus tumors, 
in resected tumors there was a high rate of complete pathological response (25%) and of 
only minimal residual disease (65%). Treatment was relatively safe. However, one patient 
did die during neoadjuvant therapy secondary to infection following neutropenia and 
seven additional patients (16%) experienced grade 4 toxicity. Despite this, 86% of 
patients completed the induction regimen. Among the 29 patients (66%) who went on to 
surgery, 5 patients experiencing major complications and there was 1 postoperative 
mortality. Although median follow up was only 16 months, the 2-year overall and 
progression-free survival rates were excellent at 85% and 71% respectively. While the 
results of CJLSG 0801 perhaps make a compelling argument to treat chest wall tumors 
with neoadjuvant therapy prior to resection, several caveats must be considered. From 
previous studies, it would seem that nodal disease is the strongest indicator of the need 
for systemic therapy. However, previously reported rates of nodal disease for chest wall 
tumors are generally only between 20-40% (5). The rate of nodal disease reported in a 
recently published review of a Japanese registry of chest wall tumors was only 27% (8). 
These patients without nodal disease will not clearly benefit from systemic therapy. 
Furthermore, as opposed to Pancoast tumors, the rate of complete resection of chest 
wall tumors outside the superior sulcus is high even without neoadjuvant therapy, 88% in 
the Japanese registry study (8). This ability to obtain an R0 resection calls into question 
the need to include radiation therapy in the preoperative treatment regimen for most 
cT3N0 patients, given the potential added morbidity. In conclusion, it would seem most 
reasonable to utilize neoadjuvant therapy in chest wall tumors with clinical N1 nodal 
disease. These patients are designated as stage IIIA and need chemotherapy as part of 
their treatment regimen. Neoadjuvant therapy prior to surgery makes sense, although 
care should be taken to avoid complications that may prevent surgical resection. For 
T3N0 patients, the treatment algorithm is less clear. Conceptually, large bulky tumors in 
which it is expected that difficulty in obtaining negative margins surgically would seem to 
be good candidates for chemotherapy and radiation preoperatively. Further studies need 
to explicitly compare neoadjuvant versus adjuvant chemotherapy for T3N0 chest wall 
tumors and need to better evaluate whether there is any beneficial role of radiation in this 
challenging group of NSCLC patients. 1. Kozower BD, Larner JM, Detterbeck FC, Jones 
DR. Special treatment issues in non-small cell lung cancer, diagnosis and management of 
lung cancer 3rded: American College of of Chest Physicians evidence-based clinical 
practice guidelines. Chest 2013;143(5):e3696S-e399S. 2. Rami-Porta R, Bolejack V, 
Crowley J et al. Proposals for the Revisions of the T descriptors in the forthcoming eight 
edition of the TNM classification for lung cancer. J Thorac Oncol 2015;10:990-1003. 3. 
Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for 
superior sulcus non-small-cell lung carcinomas: long term results of Southwest Oncology 
Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007;25:313-318. 4. Kunitoh H, 
Kato H, Tsuboi M, et al. Phase II trial of preoperative chemoradiotherapy followed by 
surgical resection in patients with superior sulcus non-small-cell lung cancers: report of 
Japan Clinical Oncology Group Trial 9806. J Clin Oncol 2008;26:644-649. 5. Riquet M, 
Arame A, Le Pimpec Barthes F. Non-small cell lung cancer invading the chest wall. Thorac 
Surg Clin 2010;20:519-527. 6. Lee CY, Syun CS, Lee JG, et al. The prognostic factors of 
resected non-small cell lung cancer with chest wall invasion. World J Surg Onc 2012;10:9. 
7. Kawaguchi K, Yokoi K, Niwa H, et al. Trimodality therapy for lung cancer with chest wall 
invasion: initial results of a phase II study. Ann Thorac Surg 2014;98:1184-91. 8. 
Kawaguchi K, Miyaoka E, Asamura H, et al. Modern surgical results of lung cancer 
involving neighboring structures: a retrospective analysis of 531 pT3 cases in a Japanese 
Lung Cancer Resistry Study. J Thorac Cardiovasc Surg 2012;144:431-7. 
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GR01.03 T4 Lung Tumors According to the New Classification - What Is the Role 
of Surgery? Daniel Boffa Thoracic Surgery, Yale University, New Haven/CT/United States 
of America
Surgical resection offers the best chance of cure for most patients with localized non-
small lung cancer (NSCLC). However, the risk-benefit deliberation for surgery becomes 
less clear in patients with more locally advanced tumors (T4), because the procedures 
are typically more dangerous (higher risk) and the patient’s prognosis is worse (benefit 
less clear). That being said, surgery remains a curative option for a significant proportion 
of patients with T4 tumors. In order to minimize risk and maximize benefit, surgeons 
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GR01.01 The Role of Localized Therapy in Lung Cancer Invading the Great 
Vessels David Harpole Surgery and Pathology, Duke University, Durham/NC/United States 
of America
Usually NSCLC tumors that have invaded the central/mediastinal vascular structures 
are considered unresectable, and staged as T4 locally-advanced NSCLC and are treated 
with concurrent platinum-based chemotherapy and thoracic radiation with curative 
intent (60+Gy). However, subsets of good functional status patients with limited 
involvement (clinically node-negative; T4N0) have been selectively treated with surgical 
resection before or after additional therapy. This has been most commonly employed 
for tumor invasion at the base of one of the pulmonary veins with extension into the 
proximal left atrium or for right upper lobe tumors with segmental involvement of the 
superior vena cava. Smaller series exist for resection of lung tumors having primary 
extension into the cardiac chambers and aortic arch. There are no prospective trials, 
only manuscripts that detail decades-long retrospective single institution series. This 
presentation will review the literature and surgical approaches to NSCLC involving the 
great vessel with and without circulatory support. Surgical management of lung cancer 
invading the aorta or the superior vena cava. Misthos P, Papagiannakis G, Kokotsakis J, 
Lazopoulos G, Skouteli E, Lioulias A. Lung Cancer. 2007 May;56(2):223-7. Epub 2007 
Jan 16. Extended resection of the left atrium, great vessels, or both for lung cancer. 
Tsuchiya R, Asamura H, Kondo H, Goya T, Naruke T. Ann Thorac Surg. 1994;57(4):960-
5 Results of superior vena cava resection for lung cancer. Analysis of prognostic 
factors. Spaggiari L, Magdeleinat P, Kondo H, Thomas P, Leon ME, Rollet G, Regnard 
JF, Tsuchiya R, Pastorino U. Lung Cancer. 2004 Jun;44(3):339-46. 15 years single 
center experience with surgical resection of the superior vena cava for non-small cell 
lung cancer. Shargall Y, de Perrot M, Keshavjee S, Darling G, Ginsberg R, Johnston M, 
Pierre A, Waddell TK. Lung Cancer. 2004:357-63 Superior vena cava resection for lung 
and mediastinal malignancies: a single-center experience with 70 cases. Spaggiari L, 
Leo F, Veronesi G, Solli P, Galetta D, Tatani B, Petrella F, Radice D. Ann Thorac Surg. 
2007 Jan;83(1):223-9; discussion 229-30 Left atrial resection for T4 lung cancer 
without cardiopulmonary bypass: technical aspects and outcomes. Galvaing G, Tardy 
MM, Cassagnes L, Da Costa V, Chadeyras JB, Naamee A, Bailly P, Filaire E, Pereira B, 
Filaire M. Ann Thorac Surg. 2014 May;97(5):1708-13 Results of primary surgery with T4 
non-small cell lung cancer during a 25-year period in a single center: the benefit is worth 
the risk. Yildizeli B, Dartevelle PG, Fadel E, Mussot S, Chapelier A. Ann Thorac Surg. 2008 
Oct;86(4):1065-75; Twelve-year experience with left atrial resection in the treatment of 
non-small cell lung cancer. Ratto GB, Costa R, Vassallo G, Alloisio A, Maineri P, Bruzzi 
P. Ann Thorac Surg. 2004 Jul;78(1):234-7. Review. Survival after extended resection 
for mediastinal advanced lung cancer: lessons learned on 167 consecutive cases. 
Spaggiari L, Tessitore A, Casiraghi M, Guarize J, Solli P, Borri A, Gasparri R Petrella F, 
Maisonneuve P, Galetta D. Ann Thorac Surg. 2013;95(5):1717-25 Superior vena caval 
resection in lung cancer. Lee DS, Flores RM. Thorac Surg Clin. 2014 Nov;24(4):441-7 
Keywords: Great Vessel Invasion of lung cancer, Surgical resection, locally advanced 
lung cancer, T4 lung cancer
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GR01.02 Should All Lung Tumors Invading the Chest Wall Be Treated Like 
Pancoast Tumors? Brendon Stiles Division on Cardiothoracic Surgery, New York 
Presbyterian Hospital, Weill Cornell Medical College, New York/NY/United States of America
Chest wall involvement is rare in patients with non-small cell lung cancer (NSCLC), 
occurring in <8% of patients (1). Invasion of the chest wall accords a T3 designation in 
both the 7th and in the newly proposed 8th edition TNM staging systems (2). The overall 
five-year survival for patients with clinically staged T3N0 NSCLC is approximately 45% 
(2). With clinically suspected nodal disease, even limited to N1 stations, survival is 
markedly worse. While cT3N2 NSCLC patients are designated stage IIIA and typically 
given neoadjuvant therapy, optimal treatment protocols are less clear for cT3N0 or even 
for cT3N1 patients with chest wall tumors, despite the fact that cT3N1 patients are also 
classified stage IIIA. An en bloc surgical resection of the involved lung and of the chest 
wall with or without adjuvant therapy has historically been the treatment algorithm of 
choice for these patients. Little data exists to determine whether neoadjuvant 
chemotherapy or chemoradiation might be beneficial in this setting. In contrast, the 
preferred treatment algorithm for a unique subset of chest wall tumors, Pancoast tumors, 
has been clearly defined (1). These T3 or T4 superior sulcus tumors arise in the apex of 
the lung and invade the chest wall at the level of the first rib or above, often with 
involvement of the brachial plexus, subclavian vessels, or spine. For these patients with 
clinical T3-4N0-1 disease, two carefully conducted prospective, multi-institutional trials 
demonstrated that induction chemoradiation therapy was associated with high rates of 
pathological response, improved resectability, and increased survival over historical 
controls (3,4). In the Southwest Oncology Group Trial 9416 (Intergroup Trial 0160), 
following neoadjuvant cisplatin and etoposide with concurrent radiation (45 Gy), 61% of 
patients had either a pathologic complete response or minimal microscopic residual 
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There was no mortality at 90 days, 43% experienced some complication, including 
1 ARDS and I BPF. Median post op survival was 9 months, mean 2 year survival was 
49%.(2) Bauman in 2008 reported on 24 patients in 8 years who underwent salvage 
resection after RT, mean dose of 64 Gy (59 to 70), 22 had received concurrent chemo. 
The interval from completion of RT to surgery ranged from 5 to 94 weeks (median 21). 
Most underwent lobectomies but 10 were pneumonectomies, including 4 right sided. 
19/24 had stump coverage, 16 by omentopexy. Median OR time was 5.5 hours. There 
was one post op death due to ARDS, 58% experienced some complications, no BPF. 
80% of specimen had viable tumor, 2 had R1 resections, 11/24 had N1-2. Median f-up 
was 29 months, median OS was 30 months, 43 months if PET information/changes 
led to salvage resection. The estimated 3 year survival was 47%: 2 patients had were 
found to have brain metastases within 2 months of the salvage resection, neither had 
had brain imaging in the re-evaluation leading to salvage surgery.(3) Personal opinion 
(4): the preoperative evaluation of such candidates should always include fresh CT 
PET, brain MRI and PFTs including a DCO as well as a quantitative perfusion scan as 
the possibilities of pneumonectomy are not insignificant in this population. Smoking 
cessation is mandatory. The location of the tumor at presentation also matters: it may 
be technically much more difficult to perform a lobectomy for centrally radiated lesions. 
Though not the topic at hand, in my experience, the technical challenges to salvage 
after SABR pale in comparison as usually the hilar structures are relatively intact after 
SABR. These surgeries can be challenging and I would encourage that one obtain as 
much information as possible upfront before going to resection. This includes that one 
attempt to obtain histological confirmation of viable cancer before undertaking these 
surgeries. We now know that after RT, particularly after SABR, the PET information may 
be falsely positive. Along the same lines, I will get EBUS sampling of the mediastinal and 
hilar lymph nodes before resection. If negative, I will add mediastinoscopy evaluation 
even in those who had mediastinoscopy at presentation. (5) Intraoperatively, you need 
to communicate with anesthesia that these patients do not tolerate excess IV fluid well 
at all as a result of having had their mediastinum radiated. We prepare/ harvest the 
intercostal muscle bundle at entry. Early circumferential control of the proximal PA and 
PVs early on is also favored… just in case. Intrapericardial access to the PVs often helps 
when the hilum is fibrosed, in such instances, open division of the lobar bronchus will 
often help accessing the lobar PA branches, particularly with the RUL. We cover all of 
our stumps with the prepared intercostal bundle. Post-operatively, IV fluid restriction 
remains a priority. Patients whose left hilar dissection was difficult are kept fasting until 
the left recurrent nerve function is evaluated or judged to be intact. Any concern prompts 
immediate laryngoscopic evaluation and temporary medialization of any suspicious “lazy” 
vocal cord follows. The literature on the topic is sparse and all retrospective but we can 
conclude from its review that: in experienced hands, such resections can be performed 
safely with acceptable morbidity, such resections, particularly if one is attempting to 
perform less than a pneumonectomy can be technically challenging and that selection 
of the patients who may benefit the most from such surgery is not easy. References:
Yang CJ, Meyerhoff RR, Stephens SJ, et al. Long-Term Outcomes of Lobectomy for Non-
Small Cell Lung Cancer After Definitive Radiation Treatment. Ann Thorac Surg 2015; 
99:1914–20
Kuzmik GA, Detterbeck FC, Decker RH, et al. Pulmonary resections following prior 
definitive chemoradiation therapy are associated with acceptable survival Eur J Card-
Thorac Surg 44 (2013) e66–e70
Bauman JE, Mulligan MS, Martins RG, et al. Salvage Lung Resection After Definitive 
Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgicaland Oncologic OutcomesAnn 
Thorac Surg 2008;86:1632–9
Page B, Blitz M, Louie BE, et al. Pulmonary Resection of NSCLC can be performed safely 
following definitive chemoradiotherapy. Oral presentation 13th World Conference on Lung 
Cancer, San Francisco, CA August 1st 2009, J Thorac Oncol. 4(9) Supplement 1:S301, 
September 2009
Louie BE, Kapur S, Farivar AS, et al. Safety and Utility of Mediastinoscopy in Non-Small 
Cell Lung Cancer in a Complex Mediastinum, Ann Thorac Surgery 92(1): 278-83, 2011
Keywords: definitive chemoradiation therapy, salvage surgery, lung cancer
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GR02.01 Case 1: A 70 Year Old with a Biphasic Stage I MPM Harvey I. Pass 
Department of Cardiothoracic Surgery, NYU Langone Medical Center, New York/NY/United 
States of America
A 70 year old retired insulator presented to the emergency room with progressive 
shortness of breath limiting his ability to complete his daily 5 mile runs. Physical 
examination reveals minimal breath sounds and dullness to percussion on the right 
side. The patient denies chest pain or weight loss. There is no history of cardiac 
disease and he is a never smoker. Family history reveals a brother with cured uveal 
melanoma. Chest radiography reveals a completely opacified right hemithorax. WBC is 
7000, platelet count 245,000, and his HgB is 13.2 gms. A thoracentesis reveals 3.5 
liters of serosanguinous fluid, and post thoracentesis radiograph reveals complete 
expansion. Fluid is sent for culture and cytology, and the patient is discharged to home 
with a 2 day supply analgesics. The culture report at 5 days reveals no growth and the 
should select patients with 1) T4 tumors that can be removed safely, 2) T4 tumors that 
can be completely removed (R0) and 3) patients that are less likely to experience early 
systemic failure. The group of T4 NSCLC tumors that have historically been amenable 
to safe surgical resection include those that invade the spine, trachea, esophagus 
great vessels, and atrium. The 7th edition of the lung cancer stage classification system 
expanded the T4 designation to include tumors that involve a nodule in a separate 
ipsilateral pulmonary lobe. The recently released proposal for the 8th edition of the lung 
cancer stage classification system has moved tumors greater than 7cm in maximum 
diameter and tumors that invade the diaphragm to the T4 category. We have previously 
stated that changes in staging nomenclature should NOT be taken as justification for 
changing the way a patient is treated (because the revision only considers prognosis 
without any regard to treatment). However, these additional members of the T4 staging 
group pose the same risk-benefit conundrum that the others members pose and are 
discussed. Global health should be assessed as this is a critical component to the 
surgical risk calculation for patients. This typically includes an assessment of comorbid 
condition severity, pulmonary function testing, exercise testing and cardiopulmonary 
stress testing in patients at risk for cardiac disease. Strategies for safe removal of T4 
tumors typically center around preparation for the unexpected. The supporting services 
should be alerted to not only the planned elements of the case but also possible needs 
in the event of a more extensive resection. The anesthesia team should be prepared 
to deal with abrupt bleeding (e.g. appropriate intravenous access that is located away 
from vessels that are likely to be clamped), the need for alternate ventilation strategies 
(e.g. jet ventilation). Any surgical specialty that could support an extended resection 
(e.g. spine service) should be alerted to the possibility. Surgeons should adjust their 
surgical approach to not only address what is apparent, but possible occult involvement 
of neighboring structures. Incisions should be placed in a way that allows the surgeon the 
flexibility to extend the planned resection. If possible, entrance should preserve tissues 
that can be used to treat surgical complications (e.g. preserving muscle for later use as 
a muscle flap). The exposure should allow for proximal and distal control of neighboring 
vessels, the use of cross table ventilation and the urgent use of cardiopulmonary bypass. 
Complete resection (removing all gross and microscopic disease) is of paramount 
importance, as the survival of patients is severely compromised by a positive surgical 
margin. While positive margins are an unfortunate reality to cancer surgery, every 
effort should be made to estimate the likelihood that a negative surgical margin can be 
obtained. At times this involves an exploratory phase of the resection (occasionally a 
minimally invasive approach to start) in order to assess the extent of local involvement 
(because imaging is notoriously inaccurate for determining the extent of local invasion). 
Finally the multi-disciplinary team must attempt to select patients that are less likely to 
develop early systemic failure, as these patients will not benefit from resection. This is 
of course not knowable with any degree of certainty but an estimate is helpful. Patients 
should undergo a thorough staging evaluation (brain imaging, PET scanning). While 
not an absolute contraindication for surgical resection, surgeons should be cognizant 
of other staging parameters that further compromise the patient’s potential for long-
term survival. Most notably this would include the patient’s mediastinal lymph node 
status. The presence of mediastinal lymph node metastases (N2) is a further indication 
of the patient’s risk for systemic failure, and is an overall poor prognosticator. While 
prognosis does not alone define treatment, the patient’s overall prognosis should be 
considered when attempting to justify surgical risk (which is typically increased for 
T4 tumor resection). For this reason, it is recommended that surgeons refrain from 
resecting of T4 tumors associated with N2 disease as their default approach, and rather 
develop a strategy that attempts to allow patients to declare their potential for early 
failure. One strategy would be to offer the patient curative-intent nonsurgical therapy 
(chemoradiation) and observe the patient for a “local only” recurrence. In conclusion, 
surgical resection of T4 tumors is reasonable and effective in highly selected NSCLC 
patients. The onus is on surgeons and multidisciplinary care teams to attempt to 
identify the patients most likely to benefit and least likely to be harmed by surgery. 
Keywords: NSCLC, T4, surgery
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GR01.04 Salvage Surgery After Chemoradiotherapy Eric Vallieres Thoracic 
Surgery, Swedish Cancer Institute, Seattle/WA/United States of America
After definitive CRT, approximately 25-30% of patients with stage III disease will fail at 
their primary site while the regional and systemic fields are under control. As a result, 
the question of whether some of these patients may potentially benefit from salvage 
resection of their primary site is often brought up at multidisciplinary tumor boards. The 
largest published series is from Duke who reported earlier this year on 31 patients in 17 
years who underwent lobectomy after definitive radiation therapy (RT), 29 of whom had 
also received concurrent chemotherapy. Median dose of RT was 60Gy, ranging from 40 
to more than 70. The median interval in between completion of the RT and the lobectomy 
was 18 weeks, ranging from 8 to 111. The majority of these resections were done open 
though, to their credit, 6 were done VATS without conversion. There was no operative 
mortality and 48% patients experienced some complications, only a third of these being 
major. There were no post op bronchopleural fistulae (BPF) despite only a third of patients 
having their stumps covered: 30/31 achieved an R0 resection, 19/31 had viable tumor 
in the specimen as histological confirmation of recurrence / persistent disease was not 
mandated before resection. Median follow-up (f-up) was 26 months and the median OS 
was 60 months: 20 months if persistent tumor was present in the resected specimen. 
For the patients who went to salvage resection for recurrent disease (n=3: DFIs being 
240, 300 and 700 days) the OS was 9 months, significantly less than the 26 months of 
those who had persistent disease after RT. The 5 y survival was 31%, 0 if N1-2 disease 
was present at resection or if salvage was done for relapse, but very small numbers… 
(1) In 2013, the Yale group reported on 14 patients in 6 years who underwent salvage 
resection for biopsy proven persistent/ recurrent T disease after definitive CRT. Most 
underwent lobectomies (9), 2 pneumonectomies. 36% underwent stump coverage. 
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GR02.04a Addressing the Needs of the Mesothelioma Patient Who Has 
Exhausted Treatment Options: Palliation and Support for Family and Patient 
Helen Clayson1, Liz Darlison2, Mary Hesdorffer3 1Centre for the Social History of Health 
and Healthcare, Glasgow Caledonian University and University of Strathclyde, Glasgow/
United Kingdom, 2Mesothelioma UK, University Hospitals of Leicester NHS Trust, Leicester/
United Kingdom, 3Non Profit, Mesothelioma Applied Research Foundation, Annapolis/United 
States of America
The care of people with end-stage mesothelioma is complex due to the interplay of 
severe physical symptoms, intense psychological distress, and social factors related to 
mesothelioma being a fatal occupational disease. In comparison with people suffering 
from lung cancer, patients with mesothelioma experience more pain and greater negative 
impact on role and functioning and insomnia (1). Patients and family members should 
expect effective management of symptoms, support during the continuum of the illness 
and a rapid response to crisis. The high symptom burden experienced by patients with 
mesothelioma in the last year of life is shown in the table below (2):
Pleural mesothelioma: Symptoms in the last year of life
Breathlessness 96% Social 16%
Pain 91% Nausea 14%
Cough 41% Fatigue 13%
Weight loss 41% Dysphagia 11%
Anxiety 31% Psychiatric 10%
Anorexia (loss of appetite) 25% Constipation 8%
Depression 19% Ascites 8%
Sweating 18% Vomiting 5%
Emotional disturbance 16% Painful metastasis 5%
 
Patients with incurable disease deserve and need to receive clear information and to 
share in the decision-making about each stage of their cancer journey. Once oncological 
treatments are exhausted, healthcare professionals hold the responsibility for helping 
patients and their families shift their expectation from “cure” to palliation of symptoms. 
A care plan for a good death needs to be sensitively eased into the clinical discussions, 
taking into account each individual patient’s preferences (3). In rare diseases such as 
mesothelioma a feeling of isolation tends to overwhelm the patient and their family. Unlike 
most cancers mesothelioma has an explained occupational and/or environmental cause. 
In many cases understanding that the fatal illness was caused by asbestos exposure due 
to neglect of health and safety precautions at work can lead to blame, anger, depression 
and inability to cope. The complicated processes concerning claims for welfare benefits 
and civil compensation litigation often exacerbate this psychological distress. Meeting 
the care needs of patients and their families in this situation requires a compassionate 
and specialised multi-disciplinary approach. Expert timely supportive and palliative care 
can address the burdens associated with advanced disease and guide the patient and 
family in accepting and planning for a good death. Transition to focus care on the family 
during the grief process completes the cycle in the care of the mesothelioma patient 
and family. Panel discussion will include the following areas: · Advanced education 
and the expanded role of a nursing team solely focused on mesothelioma (4). · The 
roles and availability of on-line, in person and telephone support groups · The need 
for early referral into palliative, supportive and hospice care References 1. Nowak AK, 
Stockler MR, Byrne MJ (2004) Assessing quality of life during chemotherapy for pleural 
mesothelioma: feasibility, validity, and results of using the European Organization for 
Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer 
Module. J Clin Oncol. Aug 1;22 (15):3172-80. 2. Clayson H (2007) Thesis: The Experience 
of Mesothelioma in Northern England. University of Sheffield. Available online at etheses.
whiterose.ac.uk/1775/ 3. Pass HI, Hesdorfer M, Lake SE, Lake SA. (2012) 100 Questions 
and Answers about Mesothelioma. Third Edition 4. Moore S, Darlison L (2011) Improving 
the nursing care of patients with mesothelioma. Nurs Stand May 25-31;25(38):35-8 
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cytology reveals atypical mesothelial hyperpplasia. Two months after his thoracentesis 
he returns to see his PCP with similar complaints of shortness of breath with exertion 
without chest pain. 1. What is the proper further management of this patient? 2. 
What is unusual about his family history, and what are the possible implications? 
Keywords: effusion, asbestos, Mesothelioma, biphasic
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Malignant Pleural Mesothelioma: A patient with unresectable disease It is generally 
accepted that only a minority of patient are candidates for combined modality treatment. 
Surgery or radiation alone is not able to achieve a complete pathological control of the 
tumor. Therefore most patients have to be considered for a systemic treatment. Since 
the nineties of last century only a slow progress has been achieved with the advent of 
chemotherapy. Single agents were tried but failed to achieve durable responses and did 
not achieve response rates over 20%. It was until the beginning of the current century 
that a standard therapy was defined using platin and an anti-folate. The response rate 
was 30-35% and the median survival increased from 9 to 13 months. Unfortunately 
80% of the patients succumbed to the disease in the 2 years after chemotherapy. The 
new approaches that are currently available can be grossly divided into a maintenance; 
immunological and signal-pathway approach. For the case presented to our tumor board 
it is the challenge to decide which treatment is the most successful with acceptable 
toxicity. The choice of treatment strongly depends on the patients’ characteristics since 
cure is not very realistic. The standard of treatment consists of the administration of 
4-6 courses of (cis)platin with pemetrexed given every 3 weeks. MPM is well known 
to respond slowly to chemotherapy and ongoing responses can be seen even after 6 
courses of therapy. This has lead to the idea of maintenance therapy. In line with the 
results in NSCLC one can choose to continue with single agent pemetrexed but to date no 
randomized study has addressed this issue. Switch maintenance is currently under study 
with different drugs. The most mature phase III study is with bevacizumab (MAPS study), 
which showed an improvement in survival in the combination arm. This randomized study 
showed a very high survival in the control arm of 16 months. The addition of bevacizumab 
increased the OS to 18.8 months with statistical significance. The full data have not yet 
been presented and selection of the very best patients might account for this success. 
An ongoing randomized phase II study with defactinib tests the effect in a maintenance 
setting. The drug inhibits the Focal Adhesion Kinase pathway, rendering cells susceptible 
for apoptosis and it reduces the stem cells after chemotherapy. The results are expected 
in 2016. Since the disease recurs within 1 year, often second line therapy is offered. In 
table 1 a summary of different approaches is presented. Besides different chemotherapy 
regimens, inhibition of signal transduction pathways or immunotherapy has been tested. 
Until now no chemotherapeutic agent or oral TKI has been identified as promising 
agent. Immunotherapy however, is now one of the new and perhaps most promising 
developments of this decade. In this particular anti-PD-1 monoclonal antibodies and 
antibody drug conjugates have shown interesting results in phase I setting. There are a 
few issues to be resolved in the near future:
• How to select the best drug for each patient.
• How to compare study results in patients with different pathology/biological 
characteristics
With a relatively small number of patients per year we must not embark blindly in to 
large phase 3 studies. We must try to personalize the treatment by increasing our TR 
efforts. Pre- and post-treatment biopsies can help to identify promising drugs at an early 
stage. Pre-treatment cell cultures can help to improve the selection of patients who might 
be good responders to certain chemical compounds. And finally we must improve our 
collaboration between centers to offer optimal service to our patients. Table 1
Agent group line Recommended Agents LoE Remark
Chemotherapy 1 cis/pem I Standard since 2003 (1)
2 pem; vin II pem showed improved PFS (2)
Maintenance 1 bev I Reported at ASCO 2015 (3)
TKI 2 none - Many tested; no conclusive results
Immunotherapy 2 Immunotoxins III Phase I study of pseudomonas toxin (4)
a-CTL4; a-PD1 III
Trametinib now tested in maintenance set-
ting in phase III; pembrolizumab showed 
promising results in phase I (5)
cis: cisplatin; pem: pemetrexed; vin: vinorelbine; bev: bevacizumab; a-CTL4: anti 
cytotoxic lymphocyte 4; a-PD1: anti-programmed death; LoE: level of evidence; 
PFS: progression free survival Selected references 1.Vogelzang NJ, Rusthoven JJ, 
Symanowski J, et al. J Clin Oncol 2003;21:2636–44 2, Jassem J, Ramlau R, Santoro A, et 
al. J Clin Oncol 2008;26:1698-1704 3. Zalcman et al. pASCO 2015 4. Hassan R, Miller AC, 
Sharon E et al. Sci Transl Medicine. 2013;5(208):208ra147. 5. Alley E et al. pAACR 2015 
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extensive-stage small cell lung cancer. Radiother Oncol 2012;102:234–238. 9. Slotman 
BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage 
small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015;385:36–42. 
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Since the 1960’s, SCLC has been recognized as a distinct lung cancer subtype with 
unique sensitivity to chemotherapy and radiotherapy. Indeed SCLC and NSCLC are 
generally discussed as separate topics. After 50 years of investigation, it may be useful 
to recognize similarities as well as differences in therapeutic principles for systemic 
therapy. For metastatic disease, palliative first-line systemic therapy for SCLC and 
NSCLC patients without a drugable driver mutation is a platinum-based two drug 
chemotherapy combination. For SCLC, platinum and etoposide has generally prevailed as 
standard although platinum plus irinotecan is widely used in Asia. The platinum doublet 
used for first-line chemotherapy for NSCLC has had a more complex evolution with many 
variations, however, the evidence for improved survival with modern platinum doublets 
can be questioned, even for non-squamous cancers.(1) In both pathologic types, single 
agents or dose attenuation with first-line therapy result in inferior outcomes. Three and 
four drug chemotherapy regimens are not better than two drug regimens. Dose-dense 
and high dose cytotoxic regimens do not generate superior survival results. Non-platinum 
regimens are not superior to platinum-based two drug combinations. Four to six cycles 
of first-line therapy is sufficient for most patients. Maintenance chemotherapy is not 
recommended for SCLC whereas it is an option for NSCLC that confers a survival 
advantage if patients fail to receive second-line therapy. Second-line treatment for both 
types of lung cancer is single agent chemotherapy and the survival benefit is worthwhile 
but modest. Topoisomerase-1 inhibitors have been extensively investigated and used in 
SCLC. Docetaxel is standard second-line therapy for squamous cancers whereas 
docetaxel and pemetrexed have equal efficacy in second-line chemotherapy of non-
squamous cancers. For both types of lung cancer, second-line chemotherapy is usually 
unrewarding for cases progressing on first-line chemotherapy or relapsing within less 
than three months as these tumors have demonstrated chemotherapy resistant biology 
with response rates of about 10%. Tumors that are sensitive to first-line chemotherapy 
with a long time to progression are somewhat more tractable with second-line therapy. 
Third line chemotherapy is not evidenced-based for either SCLC or NSCLC, but may be a 
reasonable option in selected patients that have responded to second-line treatment. The 
survival outcome for metastatic SCLC and metastatic NSCLC (without EGFR or ALK 
mutations) is similar with a median survival of 11-12 months and a two-year survival of 
5-10%. Although the initial response rate of SCLC of 60-70% is about double that of 
NSCLC, the median time for chemotherapy resistant clones to cause a fatal outcome is 
about the same for both diseases. Without doubt, the natural history of metastatic lung 
cancer unrestrained by any chemotherapy is worse for SCLC than NSCLC. With respect 
to trials of SCLC with new chemotherapy agents, it is important to recognize themes of 
investigation that have been unrewarding. Generally speaking, analogues of active drugs 
have failed to show evidence of improved survival compared to the parent compounds. 
This has been shown for alkylating agents, platinum compounds, vinca alkaloids, 
epipodophylotoxins, and anthracyclines. Moreover, randomized trials have demonstrated 
statistically significantly inferior survival outcomes for two novel analogues when 
compared to regimens considered to be standard-of-care. The folate antagonist 
pemetrexed was studied in a phase III trial of first-line chemotherapy. The GALES (Global 
Analysis of Pemetrexed in SCLC Extensive Stage) randomized pemetrexed/ cisplatin 
versus etoposide/ cisplatin.(2) Accrual was terminated early by the data safety and 
monitoring committee. Survival was inferior in the pemetrexed-platinum arm (median 
survival 8.1 months) compared to 10.6 months for etoposide-cisplatin (p <0.01). Time to 
progression (TTP) and response rates (RR) were worse as well. The inferior result was not 
explained by thymidylate synthase expression or other folate pathway biomarkers.(3) 
Pemetrexed is simply a bad drug for treatment of SCLC. Similarly, the taxane analogue 
cabizitaxel was tested in the second-line setting against topotecan.(4) Cabizitaxel was 
signifantly inferior to topotecan for RR, TTP and survival. This result stands as another 
example of analogue investigation failure and makes one wonder about the use of any 
taxane in SCLC. The discovery of treatable molecular targets in adenocarcinomas with 
approved drugs is a conspicuous difference in systemic therapy of NSCLC compared to 
SCLC. No molecular targets that can be treated with drugs with proven efficacy have as 
yet been approved for SCLC.(5) This is not due to a lack of trying. A large number of 
molecular targeted agents have already been studied in SCLC without a signal of 
sufficient activity to continue development.(6) The roster includes pathways suggested 
by analysis of the SCLC genome but numerous other molecular targeted drugs of interest 
in other cancers were also tested. Drugs with better efficacy may be identified by more 
extensive SCLC genome analysis,(5) but there is no escaping the fact that results 
reported to date have been disappointing. Data from genome analysis have shown a 
bewildering array of abnormalities in this tobacco hyper-mutated tumor. Like squamous 
carcinomas, the SCLC molecular battlefield is bleak and complex with little opportunity 
for even temporary respite by identification of mutually exclusive oncogenic drivers. An 
intriguing possibility is that the numerous mutations in SCLC may be an asset for 
immunotherapy studies. Checkpoint inhibition has already been demonstrated superior 
to standard of care in second-line therapy of both squamous (8) and non-squamous 
NSCLC.(9) At ASCO 2015, two phase II studies of immunotherapy in previously treated 
SCLC were presented and the results are provocative. Nivolumab produced a RR of 18% 
and nivolumab plus ipilumimab had a RR of 17% in a population unselected for PD-L1 
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The incidence of lung cancer has been declining since the advent of tobacco cessation 
efforts, and screening has improved 5-year overall survival rates among smokers to 
some extent. Nevertheless, about 13% of lung cancers are of the small cell subtype 
(SCLC), and many such cases present as extensive disease. Outcomes for patients 
with extensive SCLC remain poor, with median times to progression of 4–6 months, 
median survival times of 7–11 months, and 2-year survival rates of <5%.1 Chemotherapy 
has been the cornerstone of treatment, with the current standard being 4–6 cycles of 
platinum-based chemotherapy. Other approaches involving other chemotherapeutic 
agents, molecular targeted drugs, or maintenance chemotherapy have not led to 
improvement. A notable exception, however, is prophylactic cranial irradiation (PCI) for 
patients who experience a complete response after induction chemotherapy. PCI has 
been shown to eliminate the progressive increase in the risk of brain metastasis that 
accompanies extended survival in patients with SCLC, and in that context is important 
for maximizing the probability for cure for such patients.2 Indeed, PCI has led to extended 
survival among patients with limited-stage SCLC and some patients with extensive SCLC. 
A randomized phase III trial of patients with extensive SCLC reported by Slotman et 
al.3 showed that PCI reduced the incidence of symptomatic brain metastases (15% 
versus 40% in a no-PCI control group) and increased the 1-year overall survival (OS) rate 
from 13% to 27%. However, a benefit of PCI for patients with extensive SCLC has not 
been noted consistently. A multicenter trial from Japan (UMIN000001755, reported in 
abstract form at ASCO 2014) 4 was terminated early because the futility boundary was 
crossed for OS. That study indicated that receipt of PCI after response to chemotherapy 
for extensive SCLC reduced the risk of developing brain metastases but had a negative 
effect on OS (median OS time 10.1 months for PCI vs. 15.1 months for observation, 
HR=1.38, 95% CI 0.95-2.01, stratified log-rank test P=0.091). Differences between that 
study and the phase III trial reported by Slotman included the use of magnetic resonance 
imaging to rule out brain involvement at enrollment, use of only platinum-based doublet 
chemotherapy, and use of a single PCI schedule (25 Gy in 10 fractions). Another 
multicenter study involving PCI, RTOG 0937, was also closed early for crossing a survival 
futility boundary. Further, although the Japanese study showed no difference between 
the PCI vs. observation groups in terms of incidence of grade >2 adverse events, a 
disproportionate distribution of grade 4 and 5 events in RTOG 0937 between groups (PCI 
with or without consolidative extracranial irradiation) also contributed to the early closure 
of that trial. In addition to PCI, thoracic radiation therapy can improve local control and 
extend survival for patients with limited-stage disease and possibly for some patients 
with extensive disease. Controlling intrathoracic tumors remains problematic in SCLC, 
as such disease remains after induction chemotherapy in most patients and progresses 
in nearly all patients within the first year after diagnosis. Evidence of benefit for patients 
with extensive disease includes a single-institution trial of patients with a complete 
response to induction chemotherapy at distant disease sites, and a complete or partial 
local response, who received additional low-dose chemotherapy with or without thoracic 
radiotherapy; that study showed significant improvements in local control and survival 
after thoracic radiotherapy.5 Other evidence of benefit comes from two retrospective 
analyses,6,7 one non-randomised phase II trial,8 and a recent phase III multicenter trial of 
thoracic radiotherapy with PCI for patients with extensive SCLC that had responded to 
chemotherapy.9 The latter study involved 247 patients who received thoracic radiation 
and PCI and 248 who received PCI only after responding to chemotherapy. Although OS 
at 1 year was no different between groups (33% [95% confidence interval {CI} 27–39] 
thoracic vs. 28% [95% CI 22–34] control), a secondary analysis showed that the 2-year 
OS rate was better (13% [95% CI 9–19] vs. 3% [95% CI 2–8], P=0.004) and progression 
was less likely in the group that received thoracic radiotherapy (hazard ratio 0.73, 95% 
CI 0.61–0.87, P=0.001). These findings, in combination with low rates of severe toxic 
effects (no grade 5; grade 3-4 in 26 thoracic and 18 control patients), led the authors to 
recommend that thoracic radiotherapy be considered, in addition to PCI, for all patients 
with extensive SCLC who respond to chemotherapy. References 1. Govindan R, Page 
N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United 
States over the last 30 years: analysis of the Surveillance, Epidemiology, and End Results 
database. J Clin Oncol 2006;24:4539–44. 2. Komaki R, Cox JD, Whitson W. Risk of 
brain metastasis from small cell carcinoma of the lung related to length of survival and 
prophylactic irradiation. Cancer Treat Rep 1981;65(9-10):811-814. 3. Slotman B, Faivre-
Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. 
N Engl J Med 2007;357:664–672. 4. Seto T, Takahashi T, Yamanaka T, et al. Prophylactic 
cranial irradiation has a detrimental effect on the overall survival of patients with extensive 
disease small cell lung cancer: results of a Japanese randomized phase III trial (abstract). 
J Clin Oncol 2014;32:5s (suppl; abstr 7503). 5. Jeremic B, Shibamoto Y, Nikolic N, et al. 
Role of radiation therapy in the combined-modality treatment of patients with extensive 
disease small-cell lung cancer: a randomized study. J Clin Oncol 1999;17:2092–2099. 
6. Giuliani ME, Atallah S, Sun A, et al. Clinical outcomes of extensive stage small cell 
lung carcinoma patients treated with consolidative thoracic radiotherapy. Clin Lung 
Cancer 2011; 12: 375–379. 7. Zhu H, Zhou Z, Wang Y, et al. Thoracic radiation therapy 
improves the overall survival of patients with extensive-stage small cell lung cancer 
with distant metastasis. Cancer 2011; 117: 5423–5431. 8. Yee D, Butts C, Reiman 
A, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for 
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Thymic epithelial tumors (TETs) are rare malignanices of the thymic epitehlial cells. 
Recent research has identified recurrent mutations in these tumors, using NextGen 
sequencing (Petrini et al. Nature Gen 2014; Wang et al Sci. Rep. 2015). GTF2i, a general 
transcription factor has been found to have a high frequency of a unique mutation in 
over 70% of type A and AB, whereas this mutation decreases in frequency in thymic 
carcinomas. Mutation in GTF2i may represent an oncogenic event in TETs. Common 
recurrent mutations in known cancer genes have been found more frequently in thymic 
carcinomas, where the number of mutations is higher than in more indolent forms of 
TETs. In particular genes involved in epigenetic regulation have been found recurrently 
mutated. Presence of P53 mutations was also found to be related to poorer survival, as 
well as the number of recurrent mutations. The implications of molecular characterization 
of TETs on treatment are still relatively small, but they represent a first step toeards more 
targeted treatments. Chemotherapy remains the standard treatment for first line therapy 
of patients with un-resectable disease, or as neoadjuvant therapy in large tumors before 
surgery or radiation. The more commonly employed regimes still are represented by 
the PAC regimen, PE regimen and more recently carbo-taxol. Targeted therapies have 
been studied in unselected patients and of all of those tested in properly conducted 
phase II studies, sunitinib appears to be the most effective in thymic carcinoma (25% 
response rate; Thomas et al. Lancet Oncol 2015). A phase II of pembrolizumab is actively 
accruing in patients with thymic carcinomas, where PDL-1 expression is relatively high. 
Keywords: Thymoma, biology, GTF2i, chemotherapy
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Thymic Epithelial Tumors (TET) comprised of thymoma (T) and thymic carcinoma (TC) are 
rare cancers with an incidence of 1.7 and 1.3 per million per year in Europe[i] and the 
US[ii], respectively. Five-year overall survival (OS) varies significantly sitting at > 80% for 
T compared with ~40% for TC[iii],[iv]. Surgery remains the treatment of choice for 
operable TET, whereas chemotherapy is standard of care for metastatic or inoperable / 
recurrent disease. The response rate (RR) of TET to current chemotherapy agents differs 
by histological features: T responds better to first-line platinum based chemotherapy 
than TC (69% vs. 41%)[v]. No standard treatments are available for advanced TET after 
failure of first-line platinum-based chemotherapy, although single agents are generally 
used with modest benefit. For example pemetrexed, has been associated with a 17% 
partial response (PR) rate in T and 10% of PR in TC, with a median progression free 
survival (PFS) of 13.8 months and 6.5 months, respectively[vi]. Other drugs have recently 
been tested in second-line with promising results. In a phase II trial which recruited 14 T 
and 19 TC patients, amrubicin (a topoisomerase II inhibitor) was administered at 35 mg/
m2 IV days 1-3 on a 21-day cycle, producing an 18% RR (n=6, all PR: 29% in T and 11% in 
TC) without unexpected toxicity or cardiotoxicity[vii]. Another phase II trial investigated 
the combination of capecitabine plus gemcitabine in 30 pretreated TET patients (22 T 
and 8 TC). Overall RR was 40% (3 CR and 8 PR, with 3 PR in TC 3), PFS for T and TC was 
11 months and 6 months, respectively and median OS was 16 months[viii]. In octreoscan 
positive patients with TET, somatostatin analogs with or without prednisone have also 
been shown to be effective as maintenance or as second-line treatment[ix],[x]. Given the 
poor survival of advanced TET, especially TC, there is a clear need for new treatment 
options. However, the molecular pathogenesis of TET is poorly understood at present. 
Profiled somatic genetic variations in 78 advanced-TET[xi] cases showed higher a 
incidence of somatic non-synonymous mutations in TC compared to T (62% vs. 13%; 
p<0.0001). TP53 was the most frequently mutated gene (overall in TET was 17% and 
especially in TC, 26%) and was associated with poorer OS (p<0.0001). Moreover, genes 
invovlved with histone modification (e.g. BAP1), chromatin remodelling, DNA methylation 
genes and c-KIT were also frequently mutated in advanced TCs. Although the presence of 
activating mutations is low in TET, the SPECTA-lung trial (NCT02214134) will allow 
analysis of more than 360 genes in patients with thoracic tumors, including T and TC. In 
this EORTC/ETOP umbrella study, eighteen European centres will allocate patients to 
different treatment arms based on the molecular characteristics of their disease, 
suggesting that basket trials allow the study of the genetics of less common 
positivity.(10) In patients selected for PD-L1 positivity, pembrolizumab produced 
responses in 35%.(11) Although data is preliminary, some responses in these 
immunotherapy studies may be long-lasting. . The therapeutic principles of systemic 
therapy of SCLC and NSCLC may be converging again with immunotherapy becoming the 
most exciting advance in both histologic types. References (1) Murray N. Reality check 
for pemetrexed and maintenance therapy in advanced non-small-cell lung cancer. J Clin 
Oncol 2014 Feb 10;32(5):482-483. (2) Socinski MA, Smit EF, Lorigan P, Konduri K, Reck 
M, Szczesna A, et al. Phase III Study of Pemetrexed Plus Carboplatin Compared With 
Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-
Cell Lung Cancer. J Clin Oncol 2009 October 1;27(28):4787-4792. (3) Smit EF, Socinski 
MA, Mullaney BP, Myrand SP, Scagliotti GV, Lorigan P, et al. Biomarker analysis in a phase 
III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients 
with extensive-stage small-cell lung cancer. Ann Oncol 2012 Jul;23(7):1723-1729. (4) 
Evans TL, Kim J, Shepherd FA, Syrigos KN, Udud K, Chubenko V, et al. Cabazitaxel (Cbz) 
versus topotecan in patients (pts) with small cell lung cancer (SCLC) that has progressed 
during or after first-line treatment with platinum-based chemotherapy: A randomized 
phase II study. ASCO Meeting Abstracts 2013 June 17;31(15_suppl):TPS7609. (5) Rudin 
CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive 
genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. 
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Radiation Oncology, MD Anderson Cancer Center, Houston/TX/United States of America
Indications and techniques for radiation therapy for thymic malignancies have evolved 
over the past decade. The primary indication for radiation has historically been 
mediastinal radiation in the adjuvant setting (postoperative radiation therapy, PORT). 
The recommendations for PORT vary by stage. As increased evidence suggests 
high local control rates with surgery alone in Masaoka-Koga stage I-II disease, there 
is a general consensus that in early stages PORT can be omitted. Several studies 
have demonstrated that local control rates after surgery alone in stage I disease are 
excellent, and thus there is no indication for PORT in this setting1-3. In contrast, for stage 
III disease, many studies have shown increased rates of local failure after surgery alone, 
and with an improvement in outcomes with PORT3-5. Indeed, common approaches in 
stage III disease include neoadjuvant chemotherapy, followed by surgery, and then 
PORT, based on institutional results that demonstrate high levels of disease control 
with this approach6-8, and neoadjuvant chemoradiation followed by surgery9. Similar to 
other thoracic malignancies, the advent of advanced radiation techniques has allowed 
for increased sparing of mediastinal structures such as the heart, great vessels, and 
lung. This reduction in dose may ultimately lead to lower side effects, thus enhancing 
the quality of life for survivors of this malignancy. It is recommended that all patients 
undergo computed tomography-based simulation and radiation treatment with conformal 
techniques, to minimize dose to the surrounding structures such as the lungs, heart, 
and underlying vasculature. If possible, motion management should be performed 
during treatment planning to encompass the extent of respiratory motion. The radiation 
treatment field should encompass the preoperative extent of disease, including regions 
of surgical clips. Radiation oncologists should consult the surgeon in the design of their 
field to ensure that high-risk operative regions are included. Elective nodal radiation is not 
indicated, based on studies showing that there are minimal to no recurrences in elective 
nodes after mediastinal radiation. In addition to PORT to the mediastinal bed, as patterns 
of failure analyses have demonstrated a propensity for pleural failure, there has been 
interest in utilizing more extensive radiation fields (e.g. hemithoracic radiation therapy), 
either as prophylaxis or when pleural recurrence occurs10. Given the lack of strong 
evidence supporting this approach, it is recommended that this treatment primarily be 
performed in the context of a clinical trial. At this time, there is not an established role 
for radiation in stage IV disease, and studies assessing this technique using modern 
radiation modalities are ongoing. 
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GR04.01 Case of a Patient with EGFR Mutation Positive Disease and Two 
Small Brain Metastases Corinne Faivre-Finn Department of Clinical Oncology, Univ. of 
Manchester and the Christie NHS Foundation Trust, Manchester/United Kingdom
Non-small-cell lung cancer (NSCLC) is the leading cause of brain metastases. The 
development of brain metastases in this group of patients represents an important 
public health issue, as 20-40% of NSCLC patients present with or will develop brain 
metastasis during the course of their treatment. The prognosis of NSCLC patients with 
brain metastases is generally extremely poor and brain metastases have a major impact 
on quality of life. The incidence of brain metastases has been increasing over time as 
a consequence of better neuroimaging modalities and also prolonged survival in the 
locally advanced and metastatic setting with improved therapies. This is particularly 
relevant in the group of patients with somatic aberrations within driver oncogenes, 
such as epidermal growth factor receptor (EGFR) as targeted therapy using tyrosine 
kinase inhibitors (TKIs) are producing high response rates and progression free survival. 
Patients with EGFR mutations therefore represent a population at higher risk of brain 
metastases than the overall NSCLC population, with a risk of developing intra-cranial 
disease as the first site of progression in approximately 20-30%, and a lifetime risk 
>50%. Of note, brain metastases in this group of patients present more and more in 
the context of well controlled systemic disease and are more likely to be treatable than 
in the historic paradigm where brain metastases developed in concert with progressive 
multi-organ metastatic disease. Furthermore, there is a suggestion that the prognosis 
of EGFR mutated patients and brain metastases is better compared to wild type . In the 
context of stable thoracic and systemic disease treatment options for oligometastatic 
brain disease include; surgery, stereotactic radiotherapy, whole brain radiotherapy, and 
systemic treatments. Surgery can play an important role in patients with brain metastases 
and particularly patients with mass effect from a large symptomatic lesion. Randomised 
controlled trials with single brain metastases have demonstrated that the addition of 
surgery to WBRT improves survival. Stereotactic radiosurgery (SRS) is increasingly used 
as the sole treatment rather than as a ‘booster therapy’ in addition to WBRT to improve local 
control. Typically, SRS is reserved for patients with controlled extracranial disease and 
life expectancy >6 months, 1 to 4 brain metastases less than 3cm in maximum diameter. 
Treatment with EGFR TKIs is generally considered in patients with EGFR mutations 
but the evidence to support the optimal sequencing with local therapies is limited. 
 
In my talk I will discuss the following points: 
• Risk of developing brain metastases in EGFR mutated NSCLC 
• Prognostic factors (including EGFR mutation) 
• The role of local treatment (SRS, WBRT and neurosurgery) 
• The role of prophylactic cranial irradiation 
• The role of systemic treatment 
• Future directions
Keywords: brain metastases, EGFR mutation
malignancies[xii]. Despite data demonstrating EGFR and KIT overexpression in 
TET, EGFR and c-KIT mutations are rare, reported at 2%-10% and 9%, respectively[xiii]. 
This low percentage could explain the lack of RR observed in phase II studies evaluating 
Gefitinib, Erlotinib plus bevacizumab, and Glivec. In a recent retrospective analysis of 48 
TC and thymic neuroendocrine tumors, the probability to finding c-KIT mutations was 
higher in CD117-positive thymic squamous cell carcinoma with poorly-differentiation and 
co-expression of CD5 and p63 in the absence of neuroendocrine markers (6 out of 23, 
26%)[xiv], suggesting that a subgroup of TC might respond to c-KIT inhibitors. Recently 
SRC inhibitors (AZD0530) reported no RR in a phase II trial[xv]. Angiogenesis is another 
relevant pathway in TET. VEGF-A, -C, -D and VEGFR-1,-2,-3- are all overexpressed in high 
risk T and TC[xvi]. Sunitinib is an oral tyrosine kinase inhibitor (TKI) of VEGFR, KIT, and 
PDGFR. In a single arm phase 2 trial of sunitinib (50 mg/day for 4 weeks on, 2 weeks off) 
after at least one previous line of chemotherapy, a PR was reported in 26% of TC and 6% 
in T, with a mPFS of 7.2 months and 8.5 months, respectively. Main adverse events (AE) 
reported were lymphocytopenia, fatigue, and oral mucositis[xvii]. Although response 
was mainly limited to TC, sunitinib demonstrated an unprecedented activity for a targeted 
agent so far. Other antiangiogenic compounds that could be of value include Lucitanib, a 
selective TKI of FGFR1-3, VEGFR1-3, and PDGFR α/β. Efficacy data in 15 patients will be 
reported for this drug at the WCLC 2015. Insulin-like growth factor-1 receptor (IGF-1R) 
over-expression has been reported in 86% of TC and 43% of T[xviii], and carries poor 
prognosis. In a recent phase II trial of 49 patients with recurrent TET (37 T and 12 TC), 
single agent cixutumumab (a fully human IgG1 monoclonal antibody anti-IGF-1R, 
20 mg/kg every 3 weeks), reported clinical activity only in T (14% PR, 28% SD, TTP 9 
months and OS 27.5 months). No activity was recorded in the TC cohort (42% SD, TTP 
1.7 months and OS 8.4 months). The most common toxicity in both groups was 
hypoglycemia (10%). Of note, 9 patients with T experienced autoimmune disorders[xix]. 
A phase II trial, Belinostat (PXD101, a pan-histone deacetylase inhibitor, 1g/m2 on days 
1 through 5 in a 3-week schedule) among 41 patients (25 T and 16 TC) has reported only 
modest activity, with an 8% RR in T and no responses observed in TC. However, based on 
the duration of response and disease stabilization (median TTP and OS were 5.8 and 19.1 
months, respectively), additional testing of belinostat in this disease may be 
warranted[xx]. Milciclib (PHA-848125AC) is an inhibitor of cyclin-dependent kinase2/
cyclin A and SRC family members. Milciclib (150 mg/d 7 days on / 7 days off, 2-week 
cycles) has been evaluated in a phase II trial with 43 patients (26 TC and 9 B3-T). Out of 
30 patients, 14 cases (46.7%) reached the primary end point and were PFS at 3 months, 
including PR. Five cases of SD lived longer than 1 year. The median PFS was 8.2 months 
and median OS has not been yet reached. The toxicity profile appeared favourable with 
nausea, asthenia and neutropenia (8.3%) reported as the most common severe AEs[xxi]. 
The mTOR inhibitor everolimus (10 mg/d) has been tested in a phase II trial in 50 patients 
with advanced or recurrent T (n=30) or TC (n=19) previously treated with cisplatin-
containing chemotherapy. Preliminary data among the 43 evaluable patients showed a 
disease control rate (DCR) of 86% (1 CR, 10 PR, 32 SD) that was beyond the pre-specified 
endpoint of 40% DCR. The median PFS was 11.3 months (T not reached vs. 5.5 months 
in TC), and median OS was 18.6 months for TC and not reached for T. Few severe AEs 
were reported (asthenia, dyspnoea, neutropenia and hyperglycemia)[xxii]. Blockade of 
the immune checkpoint programmed death receptor ligand-1 (PD-L1)/PD-1 pathway has 
clinical activity in many tumors types. In a cohort of 139 TET, retrospective PDL-1 
expression by IHC with the E1L3N antibody has been reported in 70% of TC and 23% of 
T, respectively. PDL-1 expression was not a significant prognostic factor in multivariable 
analysis[xxiii], although in other reported cohorts overexpression of PD-L1 was 
associated with worse prognosis [xxv, xxiv]. These results generally support 
immunotherapeutic strategies in TET (NCT02364076). At present, antiangiogenics, 
mTOR and CDK inhibitors, are the most promising drugs in TET treatment. Consensus on 
meaningful end-points, and knowledge of predictive biomarkers are challenges in this 
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System (USRDS) Annual Report for patients receiving hemodialysis for end-stage renal 
disease, describes 3-year survival as 52%, and 61% for patients receiving peritoneal 
dialysis. The risk of death is particularly high in the first year of hemodialysis, with rates 
reported up to 25%. The Canadian Organ Replacement Register Annual Report describes 
a 5-year survival for patients on dialysis of approximately 43% (www.cihi.ca/corr ). For 
patients with end-stage heart failure, the 1-year survival is approximately 50% 8, which is 
not dramatically different to patients with stage 4 NSCLC receiving 1st line chemotherapy. 
The prognosis of patients with liver cirrhosis is variable, depending on severity, etiology 
and the presence or absence of complications. The MELD score (Model for End-Stage 
Liver Disease) is used to assess the severity of chronic liver disease 9, as an alternative 
to the Child-Pugh scoring system. Salpeter et al reported patients with decompensated 
liver failure (the presence of complications of cirrhosis) may have a median survival <6 
months if associated with high MELD scores. An understanding of competing morbidities 
therefore clearly plays an important role in understanding the role systemic therapy 
plays in lung cancer. In assessing the need for adjuvant chemotherapy in patients with 
early stage disease, for patients with organ failure it is highly likely that any benefit from 
chemotherapy (approximately 5%) will be outweighed by the competing risks of the 
comorbid condition. After assessing patients with lung cancer, in the multi-disciplinary 
context and taking into account the issues discussed, the decision may still be to proceed 
with therapy. This should be on the understanding of the relative lack of data, and then a 
choice of regimen based on an understanding of the drug metabolism, with appropriate 
dose adjustments after dialogue with an oncology pharmacist. Table 1 outlines common 
lung cancer drugs and their route of elimination, and recommendations on use in renal 
or hepatic impairment. For patients receiving dialysis, there is variation in advice as to 
timing of administration relative to dialysis. This information and tabular information is 
taken from product monographs and selected references 10,11. Data on efficacy for these 
drugs in these scenarios is largely limited to case reports. In conclusion, lung cancer 
patients with organ failure represent a population excluded from clinical trials and with 
a limited evidence base. The competing morbidity and mortality significantly mitigate 
against potential benefits from anti-cancer systemic therapy. The newer generations of 
targeted therapies and immunotherapies may be easier to deliver, but again limited data 
exists. Clinicians should discuss these cases in a multi-disciplinary environment, and 
early intervention from palliative care specialists may be particularly appropriate.
Drug Elimination Liver Renal
Cisplatin Renal N/A ↓ depending on CrCl
Caboplatin Renal N/A Calvert Formula
Docetaxel Liver Adjust N/A
Pemetrexed Renal Caution in severe dysfunction avoid if CrCl <45
Paclitaxel Liver Adjust N/A
Gemcitabine Urine (inactive) Adjust by Bilirubin Caution
Vinorelbine Liver Adjust by Bilirubin N/A
Gefitinib Liver Caution Caution if CrCl <20
Erlotinib Liver Caution N/A
Afatinib Liver Caution Caution if CrCl <30
Crizotinib Liver Adjust Caution if CrCl <30
Ceritnib Liver Adjust Caution if CrCl <30
Bevacizumab Reticulo-endothelial system Not involved Not involved
Nivolumab Biochemical degra-dation
No effect in mild 
impairment
no effect if 
CrCl>/=15
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for advanced non-small cell lung cancer (NSCLC): Investigating disparities between 
patients who are treated versus those who are not. J Clin Oncol 33, 2015 2. Al-Baimani 
K, Jonker H, Zhang T, et al: Are clinical trial eligibility criteria an accurate reflection 
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Leptomeningeal disease is a severe neurologic complication that can be seen in up to 5% 
of patients with cancer and it is more commonly seen in patients with lymphoma, breast 
cancer, melanoma and lung cancer. It usually presents in approximately 70% patients 
with metastatic and progressive disease but may also be the first manifestation of cancer 
in 10% of cases. With improved diagnostic methods and longer survival of patients with 
advanced stage non-small cell lung cancer (NSCLC), the incidence of leptomeningeal 
disease has increased. The diagnosis of leptomeningeal disease is usually established by 
cytological examination of the cerebrospinal fluid (CSF) or by characteristic changes seen 
on gadolinium enhanced magnetic resonance imaging (MRI). Furthermore MRI provides 
anatomic information that may be useful in identifying sites for local radiotherapy 
treatment. Prognosis is generally poor, especially in patients with poor performance 
status, multiple, serious or major neurological deficits, bulky CNS disease, and CSF 
block. Factors associated with a better prognosis include good performance status, 
absence of major neurological deficits, minimal systemic disease, absence of CSF block 
and the availability of reasonable systemic therapies. Management principles include 
early diagnosis and achieving systemic control with the aim of preserving or improving 
neurological status, improving quality of life and prolonging survival, taking into account 
the burden of systemic disease, intracranial metastasis and the expected prognosis. 
Currently there is no standard treatment for leptomeningeal disease in patients with 
NSCLC and options include intra-thecal chemotherapy, systemic chemotherapy, 
molecular targeted therapy, and radiotherapy. Although the benefit of intra-thecal 
chemotherapy has not been proven in randomized controlled studies, it is commonly used 
as it provides local therapy with minimum systemic toxicity and high drug concentrations 
can be achieved. It has been noted that intra-thecal chemotherapy is ineffective for bulky 
meningeal disease as intra-CSF agents can only penetrate 2-3mm into such lesions. 
Retrospective studies in patients with NSCLC harboring sensitizing mutations in the 
epidermal growth factor receptor (EGFR) gene or rearrangement in anaplastic lymphoma 
kinase (ALK) gene suggest EGFR or ALK tyrosine kinase inhibitors is an attractive 
treatment option. Radiotherapy is used to in the treatment of bulky disease and in patients 
with CSF flow abnormalities. Radiotherapy is also indicated in symptomatic sites and 
also in the treatment of cauda equine syndrome and cranial neuropathies. Craniospinal 
irradiation is rarely administered, as it is associated with significant systemic toxicities 
and leucoencephalopathy. Several case examples will be presented and the clinical 
presentation, diagnostic assessment and management will be discussed. The role of 
molecular targeted agents such as the EGFR and ALK tyrosine kinase inhibitors will also 
be reviewed. The development of novel systemic agents especially molecular targeted 
agents with improved CNS penetration and anti-tumor activity is urgently required. 
 
Keywords: intra-thecal chemotherapy, leptomeningeal disease, Tyrosine kinase 
inhibitors
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For patients with lung cancer, choices of systemic therapy are informed by clinical 
research. These guide the patient and clinician as to the gold standard options when 
facing their disease. However many patients seen day to day in the clinic are not eligible 
for clinical trials due to one factor or another, and therefore the applicability of standard of 
care options has a less solid evidence base. In a recent analysis of 528 newly diagnosed 
stage 4 NSCLC patients seen in consultation by medical oncologists, only 55% received 
systemic treatment 1. Further, when simple and limited generic clinical trial inclusion 
criteria were applied to these patients, only 27% would have been ‘trial eligible’ 2. In 
a review of selected recent practice changing chemotherapy, targeted therapy and 
immunotherapy trials, patients with significant renal impairment, hepatic impairment or 
cardiac impairment would have been excluded 3-6. Therefore how should clinicians and 
patients approach making decisions about systemic therapy in the presence of organ 
failure, given the lack of available evidence? This abstract seeks to provide guidance on a 
reasonable approach to patients with lung cancer and organ failure. These issues should 
be discussed in a multi-disciplinary format, with specific interaction with specialists 
related to the particular organ failure (nephrology, hepatology, cardiology etc.), in 
addition to a specialist oncology pharmacist if the decision is made to proceed with 
therapy. Patients should be fully informed regarding relative benefits and harms from 
therapy, the consequences of declining therapy, and that proceeding with treatment will 
almost certainly not be based on level one evidence. Consideration should be given to 
early palliative care specialist input, and advance care planning. Understanding the cause 
and prognosis of the organ failure is self-evidently important. This abstract restricts 
discussion to patients with pre-existing organ failure, rather than organ failure secondary 
to the malignancy. In a recent review of clinical indicators of 6-month mortality in advanced 
non-cancer illnesses, Salpeter and colleagues evaluated heart failure, dementia, geriatric 
failure-to-thrive syndrome, hepatic cirrhosis, chronic obstructive pulmonary disease and 
end-stage renal disease. This list represented approximately 70% of the non-cancer 
diagnoses on admission to hospice 7. Clearly not all patients with these conditions die 
within 6 months, and the authors identified common and disease specific prognostic 
indicators, including poor PS, malnutrition, comorbid illness and organ dysfunction. In 
the cancer clinic, the clinician must understand the natural course of the organ failure 
pathology. For patients with liver, kidney or heart failure who may be waiting for organ 
transplantation, the diagnosis of lung cancer makes them ineligible for the transplant 
program. Regarding prognosis of advanced organ failure, the United States Renal Data 
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Over the last years stereotactic radiotherapy (SRT) has emerged as an alternative 
treatment to surgical resection for treatment of localized, early-stage non-small cell lung 
cancer (NSCLC). Precise delivery of high-dose radiotherapy has become possible to 
eradicate the primary tumor (1). SRT has mainly been applied for functionally inoperable 
patients with severe cardiopulmonary morbidity. Recently, the question has emerged 
whether SRT is also a valid oncological treatment in technically and functionally operable 
patients. At the present time, no randomized studies are available directly comparing 
SRT and surgical resection with systematic lymph node dissection. Several trials were 
initiated but they were closed prematurely due to poor accrual. SRT is certainly emerging 
as a valid therapeutic option. However, from a thoracic surgical point of view several 
concerns remain when applying SRT to operable early-stage NSCLC: precise pathology 
is not obtained in all cases, no precise information is available on locoregional lymph 
node involvement making it difficult to recommend adjuvant chemotherapy in specific 
cases, and in general, different criteria are applied when comparing results of surgery 
and SRT. This applies specifically to the definition of local recurrence which gives rise 
to a potential comparison bias and limits the accuracy of long-term evaluation (2, 3). 
Moreover, thoracic surgeons are more and more confronted with “salvage surgery” after 
previous radiotherapy when no other therapeutic options are available (4). Technically, 
these resections can be very challenging. As no high-grade evidence is available, different 
opinions prevail in present-day literature. In a pooled analysis of two randomised trials 
comparing SRT with lobectomy for stage I NSCLC that closed prematurely due to poor 
accrual, the authors concluded that SRT could be an option for treating operable stage 
I NSCLC. However, as the authors indicate themselves, because of small patient sample 
size and short follow-up time, further randomized studies should be performed before 
more definite recommendations can be made (5). In contrast, in a recent propensity 
score analysis 41 patients who underwent video-assisted (VATS) lobectomy were 
matched with 41 patients treated with SRT for stage I NSCLC (6). Significant differences 
were found in overall survival, cause-specific survival, recurrence-free survival, local 
and distant control favoring VATS lobectomy. Conclusion of this study was that VATS 
lobectomy may offer a significantly better long-term outcome than SRT in potentially 
operable patients with biopsy-proven clinical stage I NSCLC. In another propensity score 
analysis long-term survival was compared between SRT and sublobar resection for stage 
I NSCLC in patients at high risk for lobectomy (7). In 53 matched pairs the difference in 
overall survival was not significant and the cumulative incidence of cause-specific death 
was comparable between both groups. Conclusion of this study was that SRT can be 
an alternative treatment option tosublobar resection for patients who cannot tolerate 
lobectomy because of medical comorbidities. In June 2015 the “Comité de l’Evolution des 
Pratiques en Oncologie (CEPO) from Québec, Canada published its recommendations 
regarding the use of SRT (8). For medically operable patients with T1-2N0M0 NSCLC 
surgery remains the standard treatment due to the lack of scientifically valid comparative 
data. For medically inoperable patients with T1-2N0M0 NSCLC or medically operable 
patients who refuse surgery, SRT should be preferred to external beam radiotherapy, 
a biological equivalent dose (BED) of at least 100 Gy should be administered, and the 
choice of using SRT should be discussed within a tumor board. Radiotherapy should not be 
considered for patients whose life expectancy is very limited because of comorbidities. 
In conclusion, surgical resection remains the treatment of choice for patients with early-
stage NSCLC who are functionally operable. After discussion within a multidisciplinary 
tumor board SRT may be considered for functionally compromised patients who cannot 
tolerate lobectomy. Further evidence is needed requiring cooperation between radiation 
oncologists and thoracic surgeons when designing comparative trials with strict inclusion 
criteria and precise definitions of endpoints. In this way a scientifically valid comparison 
between SRT and surgical treatment is provided. References 1. Louie AV, Palma DA, 
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Stereotactic ablative radiotherapy (SBRT, or SABR) is the guideline-recommended 
treatment for a peripheral stage I non-small cell lung cancer in patients who are unfit for 
surgery, or those who decline surgery. In patients fit to undergo surgery, no phase three 
randomized trial comparing the two modalities has been completed to date. However, 
comparative effectiveness research suggests that a similar disease-free survival and 
loco-regional control can be achieved with the two modalities [Louie AV 2015a]. At 
present, the only available prospective randomized data available in operable NSCLC 
reveals a 3 year rate of freedom from local recurrence of 96% (95% CI 89–100) in 
patients treated using SBRT, compared with 100% (95% CI 100–100) for patients in the 
surgery group (log-rank p=0.44) [Chang J, 2015]. With a number of new randomized 
clinical trials now in preparation, it is useful to understand the main reasons for a 
reluctance to believe that 2 treatment modalities are comparable. The poorer overall 
survival reported in the SBRT literature led to the suggestion that early deaths may be 
due to poor disease control and/or unrecognized toxicity. However, patients treated in 
early studies of SBRT often had multiple comorbidities, a factor which also decreases 
survival in surgical patients. For example, data from the Danish Cancer registry on 
resected patients reported a 5-year overall survival of 38% (95% confidence interval 
23-53%) for pT1 and Charlson comorbidity score 3+, versus a 5-year overall survival 
of 69% (CI 62-75%) for pT1 and no comorbidity [Luchtenborg M, 2012]. An externally 
validated prognostic validation tool consisting of a recursive partitioning analysis 
(RPA) and nomogram, the Amsterdam prognostic model (APM), has been developed 
for overall survival after SBRT [Louie AV, 2015b]. While the nomogram retained strong 
performance across surgical and SBRT external validation datasets, RPA performance 
was poor in surgical patients, suggesting again that two distinct patient populations are 
now being treated with these local modalities. It has been argued that the identification 
of nodal metastases during surgery, followed by adjuvant chemotherapy, can lead to 
superior survival with surgery, as occult nodal metastases may be missed in patients 
who undergo SBRT after PET-CT staging. However, even recent surgical publications 
indicate that guideline-specified nodal staging is not being performed in a significant 
number of patients, but that this difference was not detrimental. Danish Cancer Registry 
data revealed that nodal upstaging for clinical stage I NSCLC was lower after VATS than 
after open lobectomy, but also that that the extent of nodal harvest did not influence 
overall survival [Licht PB, 2013]. The IELCAP investigators reported on outcomes in 347 
patients, where of the patients undergoing sub-lobar resection and lobectomy, more than 
40% and approximately one quarter, respectively, did not even have a single mediastinal 
lymph node biopsied [Altorki NK, 2014]. We previously argued that the benefits of surgical 
nodal harvest are modest at best in this patient population. The lack of clear benefit for a 
nodal dissection, particularly in patient groups with a stage I NSCLC at increased risk of 
postoperative complications will limit the benefits of primary surgery. This is not a totally 
unexpected finding as recent studies have shown that more extensive nodal surgery was 
not beneficial in malignancies of the breast, esophagus and stage III melanomas with 
micrometastasis to the sentinel nodes. Cost-effectiveness analyses have consistently 
demonstrated that SBRT is cost-effective when compared to sublobar resection 
[reviewed in Louie AV, 2015]. Survivors of both surgery and SBRT are at risk of a second 
primary lung cancer, at a rate varying from 3-6% per person year [Lou F, 2013; Verstegen 
N, in press]. Lung cancer deaths predominate in the first 5 years after treatment, after 
which the relative contribution of cardiovascular and COPD causes of death increases 
[Janssen-Heijnen M, 2015]. It has been argued previously that “to expose patients to 
a hypofractionated SABR without mature evidence of absence of its toxicity would be 
hazardous” [van Schil P, 2013]. As long-term follow-up data after SABR is now available 
[Verstegen N, 2015], and as SABR has clearly fewer post-treatment complications than 
a surgical resection [Chang J, 2015], it is only appropriate to discuss all these findings 
with patients in the context of shared decision-making. Much of the recent debate has 
focused on pathological staging and techniques. However, there is growing awareness of 
the importance of ‘value in healthcare’. Both patients and their insurers increasingly wish 
to know what their life will be like after treatment, if they will return to work, and if their 
symptoms will improve [http://www.ichom.org/]. In the near future, patient reported 
outcome measures (PROMs) are likely to take a complimentary role in decisions about 
the choice of local therapy for stage I NSCLC, as high-quality data from randomized 
clinical trials are awaited. References Louie AV. Management of early-stage non-small 
cell lung cancer using stereotactic ablative radiotherapy: Controversies, insights, and 
changing horizons. Radiotherapy and Oncology 2015;114:138-47. Chang JY. Stereotactic 
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With the dramatic clinical benefit that can be observed using tyrosine kinase inhibitors 
(TKIs) of the epidermal growth factor receptor (EGFR) in patients with non-small cell lung 
cancer (NSCLC) harbouring activating mutations in EGFR, there has understandably been 
a focus on the use of these agents in this subset of NSCLC. However, EGFR mutation 
positive NSCLC represents only approximately 10 – 15 % of all non-squamous NSCLC 
in non-East Asian patients, and a substantial proportion of East Asian patients do not 
harbour this mutation. Thus, world-wide, the vast majority of those with NSCLC are 
so-called “wild-type” for EGFR. For these patients, it is clear from randomized clinical 
trials that the treatment of choice in the first-line metastatic setting is platinum-doublet 
chemotherapy. Increasing data suggest that chemotherapy may be preferred in the 
second-line setting. Is there any role for the use of EGFR TKIs in the wild-type population? 
Randomized data in which an EGFR TKI is compared to placebo in both the maintenance 
and refractory settings suggest that there may be. NCIC Clinical Trials Group study BR21 
[1] which randomized 731 unselected patients to either erlotinib or matching placebo, 
was designed and conducted prior to the discovery of activating mutations. Patients 
had received 1 (50 %) or > 2 (50 %) lines of prior therapy; > 90 % had received a 
platinum-doublet. An improvement in median survival (6.7 versus 4.7 months [HR 0.70, 
p < 0.001]) was also associated with a quality of life benefit. This benefit was consistent 
across subgroups, including in the 50 % of patients with non-adenocarcinoma histology. 
In a separate analysis of ever-smokers with squamous histology, patients highly unlikely 
to harbour an EGFR mutation, the magnitude of survival benefit was the same as in the 
overall study population (median 5.6 versus 3.5 months [HR 0.66, p=0.009])[2]. The 
SATURN trial [3] randomized 889 patients who had not progressed after 4 cycles of 
platinum-doublet chemotherapy to either erlotinib or placebo. While of debatable clinical 
relevance, there was a statistically significant one month prolongation of median survival 
with the use of erlotinib (HR 0.81, p=0.009). A similar effect was observed in the 44 % of 
patients with known EGFR wild-type status (HR 0.77, p=0.02). In a pre-planned subgroup 
analysis [4], a greater magnitude of benefit was observed in those patients whose best 
response to induction chemotherapy was stable disease (median overall survival 11.9 
versus 9.6 months [HR 0.72, p=0.002]), with a similar effect noted in those patients with 
squamous histology (HR 0.67, p=0.01), and those known to be EGFR wild-type (HR 0.65, 
p=0.004). Maintenance erlotinib has been shown to not negatively impact quality of life 
[5], and when used in those with stable disease, to be cost effective [6]. Meta-analyses 
of placebo-controlled trials of EGFR TKIs in the maintenance setting have confirmed 
a modest progression-free survival benefit in squamous [7] and known wild-type [8] 
patients. Multiple trials have compared an EGFR TKI to either docetaxel or pemetrexed in 
the second-line setting. The TAILOR trial [9], the only trial to prospectively determine and 
enrol only wild-type patients, showed a clear PFS advantage to docetaxel, and a trend 
towards improved overall survival. However several other trials that enrolled patients 
who were unselected with regard to EGFR status had a substantial number of wild type 
patients, and none of these trials demonstrated a difference in overall survival in wild-
type patients between an EGFR TKI and chemotherapy. While these were retrospective 
analyses on only a subset of enrolled patients with available tissue, wild-type patient 
numbers in many trials approached (and in one exceeded) the number of patients 
enrolled to TAILOR. Further, unlike other trials, TAILOR prohibited crossover, which may 
have impacted survival results, particularly for patients with squamous carcinoma in 
the erlotinib arm. Taken together these trials suggest that a treatment strategy that 
includes both chemotherapy and an EGFR TKI sequentially, irrespective of order, will 
lead to a similar length of survival provided patients receive both lines of therapy. In 
platinum-pretreated patients who are fit it is likely preferred to use chemotherapy and 
then at progression move on to an EGFR TKI, as the chance of patients receiving both 
treatments is higher. Additional data to suggest that EGFR TKIs may have activity in 
wild-type patients comes from several small, randomized phase II trials comparing 
second-line chemotherapy with the same chemotherapy with intercalated EGFR TKIs. 
These studies have shown prolonged PFS in patients treated with the combination. What 
these trials demonstrate is that EGFR TKIs appear to have a modest treatment effect 
in EGFR wild-type patients. In these days of targeted therapies leading to substantial 
treatment effects in a variety of tumours with oncogenic drivers, is this magnitude of 
benefit sufficient? In lung cancer, many other treatments have been adopted for a similar 
magnitude of benefit. Although objective response rates to EGFR TKIs are low in wild-
type patients, they are also low to standard cytotoxic chemotherapies beyond first-line, 
and it seems possible that there is a larger proportion of patients with stabilization of 
disease and / or slowing of progression that is clinically relevant. Not all oncologists 
or patients will feel that a trial is warranted, but an EGFR TKI is a reasonable choice as 
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Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative 
radiotherapy (SABR), has been rapidly adapted as a standard treatment for inoperable 
early stage non-small cell lung cancer (NSCLC).1 Due to the potential risks of biopsy 
and the ability to evaluate and characterize pulmonary nodules on CT and 18FDG-PET, 
centers have had differing standards of whether to treat patients without a pathologic 
diagnosis. In other diseases, there are well established protocols for treating without a 
pathologic diagnosis. For example, ten years ago, a diagnostic algorithm was developed 
and subsequently validated for the diagnosis of hepatocellular carcinoma based on 
imaging. 2 If a screened patient has a liver lesion is greater than 2 cm, shows arterial 
hypervascularity and venous washout, it is considered diagnostic. Two of the main 
techniques for establishing pathologic diagnosis for lung tumors are bronchoscopy and 
transthoracic needle biopsy (TTNB). Since solitary pulmonary nodules are frequently in 
the periphery, TTNB is the more frequently used method of diagnosis. Pneumothorax is 
a common complication of TTNB with rates varying in the literature from 9 – 54% with an 
average of around 20%.3 Approximately 5% of patients undergoing TTNB require chest 
tube placement. In surgical series, the observed rate of surgical resection of non-malignant 
nodules ranges from 9 to 40%. Even programs with prospective CT-screening cohorts 
and nodule management protocols such as the International Early Lung Cancer Action 
Program report benign disease in 11% of resected patients. 4 Centers that have a relatively 
high proportion of treated patients with only a clinical diagnosis typically use criteria such 
as a new or growing lesion that is avid on 18FDG-PET. Additionally, the probability of 
malignancy of a specific pulmonary nodule can be estimated based on statistical work of 
Swensen, et al. and Herder, et al. 5,6 The are numerous on-line calculators that incorporate 
these equations for evaluation of an individual patient. The VU University Medical Center 
in Amsterdam analyzed their results in patients who underwent SABR on whether they 
had a pathologic diagnosis. 7 In their prospective database of 591 patients, 35% had a 
pathologic diagnosis (biopsy proven) and 65% were diagnosed clinically. In a comparison 
of the two groups, the patients with a pathologic diagnosis had significantly larger tumor 
diameters and higher predicted FEV1 values. There was no significant difference seen in 
overall survival, local control regional or distant recurrences. In a retrospective analysis 
of 94 lesions (86 patients) treated with SBRT at the Cleveland Clinic, 35% of patients 
did not have tissue diagnosis. 8 They reported no difference in overall survival between 
these patients and those with pathologic confirmation. A prospective Phase II trial of 
SBRT from the Nordic Cancer Union was reported by Baumann, et al. 9 Nineteen (33%) 
of the 57 patients on the trial did not have pathologic confirmation of malignancy and 
only 14 of those 19 had 18FDG-PET to help establish the diagnosis. Similar to the VU 
experience, patients with a pathologic diagnosis tended to have larger tumors. They 
reported no difference in progression-free, overall or cancer-specific survival between 
the subgroup with pathological confirmation and the whole patient group. The toxicity of 
lung SBRT is well established. In the VU experience reported above, they report Grade 3 
or worse radiation pneumonitis in 3% of patients. Other complications include rib fracture 
and chest wall pain. As expected, there is no difference in toxicity between patients 
with or without pathologic diagnosis. There clearly is a role for SBRT in patients with 
radiographic-only confirmation of early stage NSCLC. In the centers where treatment 
of these patients is common practice, there is no evidence of differences in outcomes, 
nor excess toxicity. But the appropriate threshold for treatment of non-biopsied lung 
nodules is still unknown. Radiation oncologists need further input from our colleagues 
in diagnostic radiology, thoracic surgery and pulmonary medicine to develop specific 
guidelines on patients where biopsy could, and perhaps should, be avoided. This is 
especially true in countries where the potential of medical liability is relatively high since 
it is inevitable that some patients who actually do not have cancer will be treated with 
aggressive radiation therapy. References 1. Palma D, Senan S. Stereotactic radiation 
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or radiotherapy. Another point to consider is that metastases in SCLC, often are multiple 
with limited options for high dose (stereotactic) radiotherapy, in contrast to NSCLC. Use 
of radiotherapy techniques that reduce doses to the hippocampus [7], as well as the use 
of Alzheimer drugs drugs such as memantine and donezepil [8] may further mitigate the 
effect of PCI. The effectiveness and safety of these approaches remains to be be evaluated 
in prospective clinical trials. Second, it has been questioned whether PCI will continue 
to show a beneficial effect if a brain MRI is repeated after completion of chemotherapy, 
in order to eliminate some subclinical metastases. This is discussion intensified after 
the presentation of a Japanese study in 2014 [9]. In the study, MRI brain was not only 
performed after chemotherapy, but also at regular intervals during the follow-up. Any 
brain metastases detected were treated with radiotherapy or radiosurgery. The study 
was designed as a superiority study for PCI, with overall survival as primary endpoint, but 
closed early due to futility. The likelihood of finding a survival benefit of PCI was less than 
0,1%, but the discussion was fueled by the incorrect and misleading title using the word 
‘detrimental’. Due to slow accrual, the Japanese study enrolled 160 patients entered from 
40 centers in 4 years, thereby suggesting that patient selection may have played a roll. 
The publication of this analysis is awaited with interest. In order to address this topic from 
another angle, we have re-analyzed the effect of PCI on brain metastases and survival 
in a previous EORTC PCI study, after excluding patients who either died or developed 
brain metastases in the first 8 weeks after randomization, as such patients may have 
had asymptomatic brain metastases, visible if an MRI would have been performed. Even 
after exclusion of these patients, the EORTC PCI trial found a significant effect on brain 
metastases (HR 0.40; p<0.001) and overall survival (HR0.74; p=0.035) [unpublished 
data]. Conclusion In conclusion, PCI should remain standard of care in SCLC patients 
who have responded to chemotherapy. The pros and cons of PCI should be individually 
weighted and discussed with the patient. Some promising new techniques undergoing 
evaluation now may reduce the side-effects of PCI. References 1. Aupérin A, Arriagada 
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PC03.03 Is There a Role for Radiation in Oligometastatic Disease? - Pro 
Cecile Le Pechoux Radiation Oncology, Gustave Roussy, Villejuif/France
Fewer than 20% of all lung cancers are small cell lung carcinomas (SCLCs). As SCLC is an 
aggressive tumor because of its high and early risk of dissemination, most patients (60-
70%) have metastatic disease at diagnosis. Given the high propensity of SCLC for early 
metastatic dissemination, chemotherapy has been and still is the cornerstone of treatment 
based on etoposide and platinum, but SCLC is also very sensitive to radiotherapy. Median 
survival for patients with non-metastatic disease for whom the standard treatment is 
combined chemotherapy and thoracic radiotherapy, as well as prophylactic cranial 
irradiation (PCI), is currently 15–20 months, with 20–40% surviving to 2 years, and 25% 
surviving at 5 years in the best series. For metastatic patients, median survival is 8–13 
months and 2 year survival is around 5%. Recent advances in SCLC management derive 
mostly from a better integration of chemotherapy and radiotherapy. So patients with a 
limited number of metastases in number and location may have an intermediate outcome; 
and local treatment of both the primary tumor as well as oligometastatic disease could be 
discussed. Such an approach is supported by the fact that many patients in early studies 
that established the role of thoracic radiation therapy in limited disease would now be 
considered as having metastatic disease. The percentage of such metastatic patients 
seems to have increased partly because of stage migration with the more frequent use 
of PET scan and brain MRI. Thus there is a category of patients with oligometastatic 
disease for whom local treatment may be envisaged. The oligometastatic status was 
first described by Hellman and Weichselbaum as an intermediate clinical state between 
locoregionally confined and widespread cancer in 1995. There has been strong interest 
lately in this subgroup of non-small cell lung cancer oligometastatic patients, with the 
development of stereotactic ablative radiotherapy. Until recently, there were few data 
last-line therapy when the option is no further treatment, or as maintenance treatment 
in patients with squamous histology following a best response of stable disease to 
induction platinum-based chemotherapy. EGFR “wild-type” is a heterogeneous, not 
homogeneous, population, and as with any therapy, only a subgroup of patients will 
benefit from treatment. However a consistent reproducible biomarker for benefit in 
the wild-type subgroup has not yet been discovered. EGFR protein expression, gene 
copy number, Kras status and serum proteomics have all been evaluated with at times 
conflicting results, due to limited samples and the retrospective nature of the analyses. 
The development of rash may be a pharmacodynamic predictor of greater efficacy [10]. 
Additional work is required to determine which wild-type patients may derive benefit from 
an EGFR TKI, to avoid needless toxicity and improve cost-effectiveness. References 1. 
Shepherd et al. N Engl J Med 353: 123-132, 2005 2. Clark et al. Clin Lung Cancer 7:389-
394, 2006 3. Cappuzzo et al. Lancet Oncol 11:521-529, 2010 4. Coudert et al. Ann Oncol 
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PC02.04 Whole Exome Sequencing vs. Selected Testing (e.g., ALK and EGFR) 
- Con Yasushi Yatabe Dept of Pathology and Molecular Diagnostics, Aichi Cancer Center, 
Nagoya/Japan
Great advantages of next generation sequencing have been published so far, and many 
new genetic alterations were found with whole genome sequencing. Targeted sequencing 
using next generation sequencing technique can analyze FFPE small biopsy specimens, 
but may be equivalent or less than the current selected testing, such as EGFR and ALK 
testing. Although the targeted sequencing can actually analyze multiple genes, most 
diagnostic panels include the genes that are frequently altered in cancer generally, thus 
practically useful genes are limited in terms of lung cancer, such as EGFR, ALK, ROS1, and 
RET. In contrast, whole exome sequencing is potentially useful, as it can comprehensively 
examine mRNA expression on tumor cells. In general, mRNA in clinical samples well 
represents tumor genetic status even with significant dilution with the normal cells, 
which are less active in transcription. However, it is difficult to preserve high quality RNA 
with clinical samples, and it is unclear that the whole exome sequencing is constantly 
clinically applicable for small biopsy specimens. Furthermore, there are some cases 
that show discrepant results between DNA and RNA based assays. As EGFR transcript 
is suppressed in SCLC, EGFR mutation cannot be detected with the exome sequencing 
in SCLC transformed as a resistant mechanism to EGFR-TKI treatment. On the other 
hand, current selected testing for EGFR and ALK has been confirmed with clinical trials 
and are adjusted to clinical demands, e.g., short turnaround time and high sensitivity. 
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Netherlands
Background Brain metastases are an important clinical problem in patients with small 
cell lung cancer (SCLC), with 20% of patients having them at diagnosis and about 80% 
at autopsy. In patients with LS-SCLC, prophylactic cranial irradiation (PCI) significantly 
reduces the risk of brain metastases, and it improves survival [1]. A meta-analysis showed 
a survival benefit of almost 6% at 3 years with PCI (21 vs 15%). A subsequent international 
multi-center study comparing higher and lower dose PCI found no improvement in 
outcomes with higher doses [2]. Consequently, a dose of 25 Gy in 10 fractions remains 
the standard dose for PCI. Since the risk of brain metastases is even higher in patients with 
ES-SCLC, PCI has also been investigated in these patients.A randomized EORTC study 
showed that PCI both reduced the risk of brain metastases and improved overall survival 
[3]. Survival at 1 year was 27% for the patients who received PCI compared to 13% for 
the controls. Interestingly, patients who received PCI were more likely to receive 2nd or 
3rd line chemotherapy with subsequent disease progression (68 vs45%), presumably 
because they remained fitter without brain metastases. PCI was well tolerated in the 
effect on quality of life was small and transient [4]. The beneficial effect of of PCI was 
underscored in the recent CREST trial, where the risk of brain metastases was less than 
5% [5]. Controversies surrounding the use of PCI Firstly, PCI can have a negative 
effect on cognition [6], with important risk factors being advanced age, pre-existing 
cerebrovascular problems, diabetes and the use of anti-epileptics. It should however be 
appreciated that brain metastases by themselves also have an important negative effect 
on cognition and quality of life. Moreover, SCLC patients may have impaired cognitive 
functioning in comparison with healthy controls, independent of the use of chemotherapy 
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supporting the role of radiation therapy in metastatic small cell lung cancer, except PCI. 
As there are few therapeutic options in second line, local treatment approaches have 
been evaluated in extensive disease. Prophylactic cranial irradiation is now part of the 
standard treatment in responders and more recently a phase III trial has shown that 
consolidation thoracic radiotherapy could improve outcome. The 2-year survival rate was 
13% in the investigational arm versus 3% in the control arm where patients had 4-6 cycles 
of chemotherapy and PCI [Auperin, 1999; Slotman 2007; Slotman, 2015]. A randomized 
phase II trial (RTOG 0937) went further in the local approach of metastatic disease after 
systemic chemotherapy and really addressed the issue of oligometastatic disease [Gore, 
RTOG 0937]. It compared PCI to PCI and consolidative radiation therapy not only to the 
primary intrathoracic disease but also to residual extracranial metastatic lesions (1-4 
extracranial metastases who achieve a CR/PR following chemotherapy). The trial has 
included 96 patients and has closed recently after a planned protocol interim analysis. 
Results are eagerly awaited. Even if there are studies supporting the role of radiotherapy 
in metastatic SCLC, new strategies are needed for this category of patients. There are 
promising preclinical data showing a strong synergy between radiotherapy and immune 
treatments. Such approaches are starting to be explored in SCLC in prospective studies. 
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